<SEC-DOCUMENT>0001193125-16-718500.txt : 20160923
<SEC-HEADER>0001193125-16-718500.hdr.sgml : 20160923
<ACCEPTANCE-DATETIME>20160923164307
ACCESSION NUMBER:		0001193125-16-718500
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		32
FILED AS OF DATE:		20160923
DATE AS OF CHANGE:		20160923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211714
		FILM NUMBER:		161900266

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d16439d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4) <BR> Registration No. 333-211714<BR><BR> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>6,000,000 Shares </B></P>
<P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g80t23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Shares </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This is the initial
public offering of AC Immune SA. No public market has previously existed for our common shares. We are offering 6,000,000 of our common shares in this offering. The initial public offering price is $11.00 per common share. Our common shares have
been approved for listing on the NASDAQ Global Market under the symbol &#147;ACIU.&#148; </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined
under the federal securities laws and, as such, will be subject to reduced public company reporting requirements. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company&#148; and &#147;&#151;Implications of Being a
Foreign Private Issuer.&#148; </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:ARIAL"><B>Investing in our common shares involves a high degree of risk. See &#147;<A HREF="#rom16439_4">Risk
Factors</A>&#148; beginning on page 12. </B></P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:57.30pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Price to Public</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Underwriting&nbsp;Discounts</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:92.00pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and&nbsp;Commissions(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Proceeds,&nbsp;Before</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:67.90pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Expenses to Us</B></P></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Common Share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$11.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$0.77</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$10.23</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$66,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$4,620,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">$61,380,000</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; for additional information regarding total underwriter compensation. </TD></TR></TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
have granted the underwriters an option for a period of 30 days from the date of this prospectus to purchase an additional 900,000 common shares from us to cover over-allotments. </P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain of our existing shareholders have
agreed to purchase an aggregate of 1.9 million of the common shares being offered in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any common shares purchased by these investors
as they will on any other common shares sold to the public in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Delivery of the common shares is expected to be made on or about
September&nbsp;28, 2016. </P> <P STYLE="font-size:14pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Credit&nbsp;Suisse</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Leerink Partners</B></TD></TR>
</TABLE> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The date of this prospectus is September&nbsp;22, 2016 </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_1">Prospectus Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_2">The Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_3">Summary Historical and Other Financial Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_5">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_6">Market and Industry Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_8">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_11">Exchange Rates</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_12">Selected Financial and Other Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_13">Management&#146;s Discussion and Analysis of Financial Condition and Results
 of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_14">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_15">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_16">Principal Shareholder</A>s</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_17">Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_18">Description of Share Capital and Articles of Association</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_19">Comparison of Swiss Law and Delaware Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_20">Common Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_21">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_22">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_23">Expenses of the Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_24">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_25">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">194</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_26">Enforcement of Judgments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_27">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom16439_28">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is located in Ecublens, Switzerland. Moreover, a number
of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United
States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon
the federal and state securities laws of the United States. See &#147;Enforcement of Judgments&#148; for additional information. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless
otherwise indicated or the context otherwise requires, all references in this prospectus to &#147;AC Immune,&#148; the &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;ours,&#148; &#147;us&#148; or similar terms refer to AC Immune SA.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We own various trademark registrations and applications, and unregistered trademarks, including Morphomer&#153;, SupraAntigen&#153; and our
corporate logo. All other trade names, trademarks and service marks of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other companies appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We
do not intend to use or display other companies&#146; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our financial statements are presented in Swiss Francs and in accordance with IFRS as issued by the IASB. None of the financial statements
were prepared in accordance with generally accepted accounting principles in the United States. The terms &#147;dollar,&#148; &#147;USD&#148; or &#147;$&#148; refer to U.S. dollars and the term &#147;Swiss Franc&#148; and &#147;CHF&#148; refer to
the legal currency of Switzerland, unless otherwise indicated. Unless otherwise indicated, certain Swiss Franc amounts and certain U.S. dollar amounts have been translated into U.S. dollars and Swiss Francs, respectively, at a rate of USD 1.0235 to
CHF 1.00, the official exchange rate quoted as of September 9, 2016 by the U.S. Federal Reserve Bank. Such Swiss Franc and U.S. dollar amounts are not necessarily indicative of the amounts of U.S. dollars and Swiss Francs, respectively, that could
actually have been purchased upon exchange of the other currency at the dates indicated or any other date, and such translated amounts have been provided solely for the convenience of the reader. We have made rounding adjustments to some of the
figures included in this prospectus. Accordingly, any numerical discrepancies in any table between totals and sums of the amounts listed are due to rounding. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the
underwriters have not authorized anyone to provide any information other than that contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we may have referred you. We and the underwriters take no
responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor
the underwriters are making an offer to sell the common shares in any jurisdiction where the offer or sale is not permitted. This offering is being made in the United States and elsewhere solely on the basis of the information contained in this
prospectus. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of the common shares. Our
business, financial condition, results of operations and prospects may have changed since the date on the front cover of this prospectus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We are
incorporated as a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland, and a majority of our outstanding securities are owned by non-U.S. residents. Under the rules of the U.S. Securities and Exchange
Commission, or SEC, we are currently eligible for treatment as a &#147;foreign private issuer.&#148; As a foreign private issuer, we will not be required to file periodic reports and financial statements with the SEC as frequently or as promptly as
domestic registrants whose securities are registered under the Securities Exchange Act of 1934, as amended, or the Exchange Act.<I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEALER PROSPECTUS DELIVERY OBLIGATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through and including October 17, 2016, all dealers that effect transactions in our common stock, whether or not participating in this
offering, may be required to deliver a prospectus. This is in addition to the dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to unsold allotments or subscriptions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information contained elsewhere in this prospectus. This summary may not contain all the information that may be
important to you, and we urge you to read this entire prospectus carefully, including the &#147;Risk Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
sections and our financial statements, including the notes thereto, included elsewhere in this prospectus, before deciding to invest in our common shares. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding.
Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and
alpha-synuclein. We believe that our large and diverse pipeline of seven therapeutic candidates, including four clinical-stage candidates and three diagnostic candidates, has the potential to drive a paradigm shift in the treatment of a broad
spectrum of neurodegenerative and other diseases related to protein misfolding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is currently an absence of reliable, early-stage
diagnosis and disease-modifying treatments for widely prevalent neurodegenerative and other diseases associated with protein misfolding. AD is the most common form of dementia, with an estimated worldwide patient population of 47&nbsp;million in
2015, which is expected to grow to 75&nbsp;million by 2030 and 132&nbsp;million by 2050 according to the World Alzheimer Report 2015. AD is typically diagnosed by neurologists and psychiatrists through a series of cognitive and functioning tests
once symptoms are clinically present, resulting in diagnosis at later stages of the disease after irreversible loss of neurons has already occurred. Currently approved AD treatments include medications that only treat the symptoms of the disease,
with limited clinical benefit. PD, the second most common neurodegenerative disease worldwide, affects an estimated 7 to 10&nbsp;million people. In PD, the use of symptomatic treatments, such as levodopa, is associated with the loss of control of
motor functions in approximately 50% of patients who have taken the drug for 5 years or longer. There remains a significant unmet medical need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow
the progress of neurodegenerative diseases. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram below summarizes the status of our research and development programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g10y79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody
that we developed using our proprietary SupraAntigen<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> platform. Crenezumab commenced Phase 3 clinical studies in the first quarter of 2016 and we believe it has the potential to become a
best-in-class disease-modifying treatment for AD. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab for the treatment of AD under a collaboration agreement with us, pursuant to which it is responsible for the
clinical development of crenezumab, including the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Under our collaboration agreement, we are eligible to receive
payments from Genentech totaling up to approximately $340 million, as well as sales royalties. Crenezumab has received Fast Track designation from the FDA. The Fast Track program is intended to expedite or facilitate the process for reviewing new
drugs that are designed to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs, as further described under &#147;Business&#151;Government Regulation and Our Regulatory Department&#151;Product
Approval Process.&#148; In 2012, crenezumab was independently selected by the National Institute of Health, the Banner Alzheimer&#146;s Institute and Genentech for use in the first-ever AD prevention study, which serves as the cornerstone of the
global Alzheimer&#146;s Prevention Initiative. While crenezumab did not meet its co-primary endpoints in its Phase 2 studies, the data showed promising signals of activity in patients with a milder stage of the disease. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, crenezumab has the potential to treat the underlying cause of the disease and intervene at an earlier stage of AD progression,
prior to irreversible neuronal damage. We believe that crenezumab is ideally positioned to be at the forefront of disease-modifying and preventive medicine. We believe key advantages of crenezumab include: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Unique mechanism of action:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recognizes and binds to multiple forms of misfolded Abeta, a protein commonly associated with AD. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Helps to protect against neurotoxicity due to high affinity for the multiple forms of misfolded Abeta. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Promotes disaggregation of existing Abeta aggregates and disrupts their assembly to prevent amyloid plaque formation, which is associated with AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clears misfolded Abeta from the brain while limiting inflammation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Signal of activity in milder AD patients in Phase 2 studies:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the proof-of-concept Phase 2 studies of crenezumab, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ABBY cognition study: although the study did not meet its co-primary endpoints, which were assessments using the ADAS-cog and CDR-Sum of boxes, the sample size was not expected to have adequate power to detect a modest
but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase&nbsp;2 studies in AD). Instead, consistent trends across different endpoints and dose dependency are
considered indicators of a response in this learning phase of development, with confirmation then sought in Phase&nbsp;3. The results showed trends favoring crenezumab in the milder patient population. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">BLAZE biomarker study: the high-dose crenezumab arm showed a consistent trend of reduced Abeta accumulation in the brain over time and a significant increase of Abeta in the cerebrospinal fluid, which suggests that
Abeta is being removed from the brain when patients are treated with crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unique mechanism of action linked to the reduced ability to cause inflammation-related vasogenic edema, which is an accumulation of fluid in the brain that can lead to headaches, loss of coordination and disorientation.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical data showed a very low incidence of vasogenic edema. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1 study is ongoing to study crenezumab at higher doses to potentially increase the efficacy signal. This study has helped define the design of the Phase 3 clinical study. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of our other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through
active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. In January 2016, we announced that,
together with the University of California, San Diego and with support from the LuMind Foundation, we commenced a Phase&nbsp;1 clinical study for ACI-24 in patients with Down syndrome. Down syndrome patients are a population that is at high risk for
AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that we are developing under a collaboration agreement with Janssen Pharmaceuticals, Inc., a Johnson&nbsp;&amp; Johnson Company. We and Janssen are co-developing ACI-35 through
the ongoing Phase 1b clinical study, which we expect to be completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect
Phase 2 clinical studies to begin in 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a passive anti-tau monoclonal antibody candidate is being
developed under a collaboration agreement with Genentech. The Phase 1 clinical study in patients with AD and healthy volunteers commenced in the second quarter of 2016, with results expected in the first half of 2017. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical evidence suggests that early detection of neurodegenerative diseases is critical to
enhancing the effectiveness of both symptomatic and disease-modifying therapies. As such, we are using our Morphomer&#153; platform to develop complementary diagnostic products such as positron emission tomography, or PET, ligands, which are tracers
that can directly measure misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our tau PET imaging agent is currently in a First-in-Man study (a clinical study in which a medical procedure, previously developed and assessed through <I>in vitro</I> or animal testing or through mathematical
modelling, is tested on human subjects for the first time) and being developed under a collaboration agreement with Piramal Imaging. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins, such as PD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2016, we entered into a non-exclusive collaboration with Biogen International GmbH to develop PET imaging diagnostics for neurodegenerative diseases resulting from the misfolding of alpha-synuclein proteins and
TDP-43, which is a protein that has been recently linked to neurodegeneration in diseases including AD, PD and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig&#146;s disease). </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Platform Technologies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These
platforms are our engines for generating novel molecules that are designed to bind to their targets with high affinity and conformational specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins.
All of our product candidates and our development programs have been derived from our proprietary platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurodegenerative diseases,
such as AD and PD, as well as other neuro-orphan diseases, such as progressive supranuclear palsy, amyotrophic lateral sclerosis, and Huntington&#146;s disease, are all associated with pathologies that involve misfolded proteins. Research has shown
that misfolded proteins are unable to carry out their normal functions and aggregate to form certain types of deposits that damage brain tissue. Our SupraAntigen and Morphomer platforms seek to produce conformationally specific molecules in order to
prevent or disrupt the formation of misfolded proteins. We believe that our proprietary platforms also have the potential to generate additional molecules for indications that relate to protein misfolding outside of neurodegenerative diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is to become a
global leader in the treatment of neurodegenerative diseases by developing therapies and complementary diagnostics that target neurodegenerative diseases with significant unmet medical need using our proprietary SupraAntigen and Morphomer technology
platforms. Key elements of our strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Advance, in partnership or alone, our product candidates crenezumab, ACI-24 and ACI-35, and our diagnostic candidates through clinical development to regulatory approval and potential commercialization.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Expand into other neurodegenerative and neuro-orphan diseases. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Accelerate the advancement of our diagnostic portfolio. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Leverage the duality of our therapeutic and diagnostic approaches to become the leader in personalized treatment of neurodegenerative diseases. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Strategically collaborate or selectively partner for the development and commercialization of product candidates. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to implement our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk
Factors&#148; immediately following this prospectus summary. These risks include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The success of our and our collaboration partners&#146; clinical studies, and our and their ability to obtain regulatory approval and to commercialize crenezumab, ACI-24, ACI-35 and our anti-tau antibody candidate.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our direct reliance on our collaboration partners&#146; efforts to obtain regulatory and marketing approvals for and to manufacture, sell and market certain of our product candidates, including crenezumab, ACI-35 and
our anti-tau antibodies, in order to derive revenue from these product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The failure of crenezumab to achieve success in Phase 3 clinical studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Morphomer and SupraAntigen proprietary technology platforms and their success in building additional product candidates for our pipeline. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to maintain our current strategic relationships with our collaboration partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Failure to protect our, and not infringe on third parties&#146;, intellectual property rights throughout the world. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA&#146;s and applicable foreign regulatory authorities&#146; acceptance of data from studies we conduct in the future. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our foreign private issuer status, the loss of which would require us to comply with the domestic reporting regime of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and cause us to incur
significant legal, accounting and other expenses. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies incorporated in the United States. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our failure to maintain an effective system of internal control over financial reporting, given the material weakness identified in connection with the audit of our financial statements as of and for the year ended
December 31, 2014. This material weakness continued to exist as of December 31, 2015 and as at June 30, 2016. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company and Other
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated as a Swiss limited liability company (<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute;
limit&eacute;e</I>) on February&nbsp;13, 2003 and transformed into a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August&nbsp;25, 2003. Our principal executive offices are located at EPFL Innovation
Park, Building B, 1015 Lausanne, Switzerland and our telephone number is +41 21 345 91 21. Our website is <I>www.acimmune.com</I>. Our website and the information contained therein or connected thereto are not incorporated into this prospectus or
the registration statement of which it forms a part. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These provisions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to have only two years of audited financial statements in addition to any required interim financial statements and correspondingly reduced disclosure in the Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations disclosure in the registration statement of which this prospectus forms a part; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Section&nbsp;404 of the Sarbanes-Oxley Act of 2002; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to the extent that we no longer qualify as a foreign private issuer, (i)&nbsp;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (ii)&nbsp;exemptions from
the requirements of holding a non-binding advisory vote on executive compensation, including golden parachute compensation. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would
cease to be an emerging growth company upon the earliest to occur of (i)&nbsp;the last day of the fiscal year in which we have more than $1.0 billion in annual revenue; (ii)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at
least $700 million of equity securities held by non-affiliates; (iii)&nbsp;the issuance, in any three-year period, by our company of more than $1.0 billion in non-convertible debt securities; or (iv)&nbsp;the last day of the fiscal year ending after
the fifth anniversary of this offering. We may choose to take advantage of some but not all of these reduced burdens. For example, Section&nbsp;107 of the JOBS Act provides that an emerging growth company can use the extended transition period
provided in Section&nbsp;7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. However, given that we currently report and expect to continue to report under
International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or IASB, we have irrevocably elected not to avail ourselves of this extended transition period and, as a result, we will adopt new or
revised accounting standards on the relevant dates on which adoption of such standards is required by the IASB. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being a Foreign
Private Issuer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also considered a &#147;foreign private issuer.&#148; Accordingly, upon consummation of this offering, we will
report under the Exchange Act as a non-U.S. company with foreign private issuer status. This means that, even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act we will
be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on Form 10-Q containing unaudited financial and other specified information, or current
reports on Form 8-K, upon the occurrence of specified significant events. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although as a foreign private issuer we will not
be required to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act, we intend to report our results of operations voluntarily on a
quarterly basis. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may take advantage of these exemptions until such time as we are no longer a foreign
private issuer. We would cease to be a foreign private issuer at such time as more than 50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances applies: (i)&nbsp;the majority of our executive
officers or directors are U.S. citizens or residents, (ii)&nbsp;more than 50% of our assets are located in the United States or (iii)&nbsp;our business is administered principally in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In this prospectus, we have taken advantage of certain of the reduced reporting requirements as a result of being an emerging growth company
and a foreign private issuer. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Tau Antibody Phase 1 Milestone Payment</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, Genentech, our collaboration partner, informed us that the first patient has been dosed in a Phase&nbsp;1 clinical study for
Alzheimer&#146;s disease with an anti-tau monoclonal antibody, making us eligible to receive a milestone payment of CHF 14 million, which we received in July 2016 (the &#147;Anti-Tau Antibody Phase 1 Milestone Payment&#148;). For more information on
our collaboration agreement with Genentech, see &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Strategic Collaborations and Licensing Agreements&#151;Anti-Tau Antibodies&#151;Collaboration with
Genentech&#148; and &#147;Business&#151;License Agreements and Collaborations&#151;Genentech.&#148; </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_2"></A>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights information presented in greater detail elsewhere in this prospectus. This summary is not complete and does not
contain all the information you should consider before investing in our common shares. You should carefully read this entire prospectus before investing in our common shares including &#147;Risk Factors&#148; and our financial statements. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares offered by us </P></TD>
<TD>6,000,000 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common shares to be outstanding immediately after this offering </P></TD>
<TD>55,396,042 shares. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Over-allotment option </P></TD>
<TD>We have granted the underwriters the option to purchase up to an additional 900,000 common shares from us within 30 days of the date of this prospectus to cover over-allotments, if any. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $57.8&nbsp;million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We intend to use the net proceeds from
this offering together with cash and cash equivalents on hand (including the Anti-Tau Antibody Phase 1 Milestone Payment) to further the development of our therapeutic product candidates under collaboration agreements (ACI-35 and anti-tau
antibodies), advance our other clinical and pre-clinical programs, and for research and development of other indications and initiatives that are complementary to our existing and planned research activities. See &#147;Use of Proceeds&#148; for a
more complete description of the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider before deciding to invest in our common shares. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">NASDAQ symbol </P></TD>
<TD>&#147;ACIU.&#148; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of our common shares to be outstanding after this offering is based on 10,819,000
common shares outstanding as at August 31, 2016 and 38,577,042 additional common shares issuable upon the conversion of all of our preferred shares on a one-for-one basis upon the closing of this offering, but excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,196,250 of our common shares issuable upon the exercise of vested and unvested options outstanding under our existing equity incentive plans at a weighted-average exercise price of CHF 0.14548 per common share; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,300,000 of our common shares issued to Credit Suisse AG, Zurich on May&nbsp;25, 2016 (the &#147;CS AG Share Issuance&#148;), as described in Note&nbsp;7 (Other current liabilities) of our unaudited interim condensed
financial statements as of and for the six months ended June 30, 2016 and June 30, 2015 included elsewhere in this prospectus. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, all information contained in this prospectus assumes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no issuance of any common shares reserved for future issuance under our new omnibus equity incentive plan or exercise of the options outstanding under our existing equity incentive plans, each as described in the
immediately preceding paragraph; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of all of our preferred shares (including the preferred shares issued in the Series E Private Placement Extension) into common shares on a one-for-one basis upon the closing of this offering and the
filing and effectiveness of our amended and restated articles of association, resulting in a total of 49,396,042 common shares outstanding, and additional authorized share capital of 16,047,500 common shares at the closing of this offering.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, unless otherwise indicated, all information in this prospectus excludes the issuance of 5,300,000 of our
common shares to Credit Suisse AG, Zurich in the CS AG Share Issuance, as described in Note 7 (Other current liabilities) of our unaudited interim condensed financial statements as of and for the six months ended June 30, 2016 and June 30, 2015
included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing shareholders have agreed to purchase an aggregate of 1.9 million of the
common shares being offered in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any common shares purchased by these investors as they will on any other common shares sold to the
public in this offering. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_3"></A>SUMMARY HISTORICAL AND OTHER FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary historical financial information should be read in conjunction with &#147;Selected Financial and Other
Information,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements, including the notes thereto, included elsewhere in this prospectus. Our historical results are
not necessarily indicative of the results that may be expected in the future and results of interim periods are not necessarily indicative of results for the entire year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The summary income statement data and balance sheet data for and as of the years ended December&nbsp;31, 2015 and 2014 are derived from our
audited financial statements included elsewhere in this prospectus. The financial data as at June&nbsp;30, 2016 and for the six months ended June&nbsp;30, 2016 and 2015 have been derived from our unaudited interim financial statements included
elsewhere in this prospectus. The unaudited interim financial statements have been prepared on the same basis as our audited financial statements and include all normal recurring adjustments that we consider necessary for a fair statement of our
financial position and operating results as of the dates and for the periods presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain our books and records in, and our
audited financial statements and unaudited condensed interim financial statements are prepared and presented in accordance with IFRS in, CHF. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in CHF &#146;000 except for share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income Statement Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income/(loss)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income/(loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp; </TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income/(loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share in CHF
(basic)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share in CHF (fully
diluted)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings per share basic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,209,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,725,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,412,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,684,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings per share fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,101,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,845,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,043,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,552,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes preferred shares outstanding as of the dates indicated, and these preferred shares will be converted on a one-for-one basis upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Earnings per share calculations do not give effect to the CS AG Share Issuance. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at June 30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;Adjusted<SUP STYLE="font-size:85%; vertical-align:top"></SUP><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>(in CHF &#145;000)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">As adjusted balance sheet data gives effect to (i) our issuance and sale of 6,000,000 common shares in this offering, at the initial public offering price of $11.00&nbsp;per common share, after deducting underwriting
discounts and commissions and estimated offering expenses payable by us and (ii) our receipt in July 2016 of the Anti-Tau Antibody Phase 1 Milestone Payment described under &#147;Prospectus Summary&#151;Anti-Tau Antibody Phase 1 Milestone
Payment.&#148; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>You should carefully consider the risks and uncertainties described below and the other information in this prospectus before making an
investment in our common shares. Our business, financial condition or results of operations could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our common shares could decline and you could
lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#147;Cautionary Statement Regarding Forward-Looking Statements.&#148; Our actual results could differ materially
and adversely from those anticipated in these forward-looking statements as a result of certain factors. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend heavily on the success of crenezumab, and, to a lesser extent, ACI-24, ACI-35 and our anti-tau antibody candidate, all of which
are in clinical development. If our clinical studies are unsuccessful, we or our collaboration partner do not obtain regulatory approval or we are unable to commercialize crenezumab, ACI-24 for AD and ACI-35, or we experience significant delays in
doing so, our business, financial condition and results of operations will be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no
products approved for sale and have invested a significant portion of our efforts and financial resources in the development of crenezumab, ACI-24, ACI-35 and our anti-tau antibody candidate, all of which are in clinical development. Our ability to
generate product revenues, which we do not expect will occur for at least the next several years, if ever, will depend heavily on successful clinical development, obtaining regulatory approval and eventual commercialization of these product
candidates. We currently generate no revenues from sales of any drugs, and we may never be able to develop or commercialize a marketable drug. The success of our current and future product candidates will depend on several factors, including the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing clinical studies that demonstrate the efficacy and safety of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receiving marketing approvals from applicable regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establishing commercial manufacturing capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching commercial sales, marketing and distribution operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates by patients, the medical community and third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a continued acceptable safety profile following approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competing effectively with other therapies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">qualifying for, obtaining, maintaining, enforcing and defending our intellectual property rights and claims and not infringing on third parties&#146; intellectual property rights. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our collaboration partner do not achieve one or more of these factors in a timely manner or at all, we could experience significant
delays or an inability to successfully commercialize our current or future product candidates, which would materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Results of early clinical studies may not be predictive of future study results. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Positive or timely results from preclinical or early stage studies do not ensure positive or timely results in late stage clinical studies or
product approval by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or comparable foreign regulatory authorities. Products that show positive preclinical or early clinical results may not show sufficient
safety or efficacy in later stage clinical studies and therefore may fail to obtain regulatory approvals. For example, our collaboration partner Genentech may fail to achieve success in Phase 3 clinical studies of crenezumab. In addition,
preclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that believed their product candidates performed satisfactorily in preclinical and clinical studies have nonetheless failed to obtain
marketing approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
for the product candidates. The FDA, the EMA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether regulatory
approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical studies of our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA or any other
regulatory authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different studies
of the same product candidate due to numerous factors, including changes in study procedures set forth in protocols, differences in the size and type of the patient populations, adherence to the dosing regimen and other study protocols and the rate
of dropout among clinical study participants. In the case of our late stage clinical product candidates, results may differ in general on the basis of the larger number of clinical study sites and additional countries and languages involved in Phase
3 clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies are, or will be, based on patient reported outcomes, some of which are or will be captured daily by
study participants with electronic diaries. We have no assurance and cannot rely on past experience that the high frequency of questioning is not influencing the measured outcome. In addition, low compliance with daily reporting requirements may
impact the studies&#146; validity or statistical power. We cannot assure you that any Phase 2, Phase 3 or other clinical studies that either we or our collaboration partners may conduct will demonstrate consistent or adequate efficacy and safety to
obtain regulatory approval to market our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we or our collaboration partners are required to conduct additional
clinical studies or other testing of any of our current or future product candidates that we or our collaboration partners develop beyond the studies and testing that we or our collaboration partners contemplate, if we or our collaboration partners
are unable to successfully complete clinical studies of our product candidates or other testing, if the results of these studies or tests are unfavorable or are only modestly favorable or if there are safety concerns associated with our current or
future product candidates, we may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be delayed in obtaining marketing approval for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not obtain marketing approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval for indications or patient populations that are not as broad as intended or desired; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain approval with labeling that includes significant use or distribution restrictions or significant safety warnings, including boxed warnings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be subject to additional post-marketing testing or other requirements; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">remove the product from the market after obtaining marketing approval. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product
development costs will also increase if we experience delays in testing or marketing approvals and we may be required to obtain additional funds to complete clinical studies. We cannot assure you that our clinical studies will begin as planned or be
completed on schedule, if at all, or that we will not need to restructure our studies after they have begun. Significant clinical study delays also could shorten any periods during which we may have the exclusive right to commercialize our product
candidates or allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates, which may harm our business and results of operations. In addition,
some of the factors that cause, or lead to, clinical study delays may ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Additional competitors could enter the market with generic versions of our products, which may result in a material decline in sales of
affected products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a
pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generic copy of an approved innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit a new drug application, or NDA, under section 505(b)(2) that references the FDA&#146;s
prior approval of the innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. Hatch-Waxman also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in
some circumstances, FDA filing and reviewing) of an ANDA or 505(b)(2) NDA. These include, subject to certain exceptions, the period during which an FDA-approved drug is subject to orphan drug exclusivity. In addition to the benefits of regulatory
exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#147;Approved Drug Products with Therapeutic
Equivalence Evaluations,&#148; known as the &#147;Orange Book.&#148; If there are patents listed in the Orange Book, a generic or 505(b)(2) applicant that seeks to market its product before expiration of the patents must include in the ANDA what is
known as a &#147;Paragraph IV certification,&#148; challenging the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the innovator, too, and if within 45 days
of receiving notice the innovator sues to protect its patents, approval of the ANDA is stayed for 30 months, or as lengthened or shortened by the court. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accordingly, if crenezumab, ACI-24, ACI-35 and our anti-tau antibody candidate are approved, competitors could file ANDAs for generic versions
of crenezumab, ACI-24 and ACI-35, or 505(b)(2)&nbsp;NDAs that reference crenezumab, ACI-24, ACI-35 or our anti-tau antibody candidate, respectively. If there are patents listed for crenezumab, ACI-24 and ACI-35 in the Orange Book, those ANDAs and
505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the ANDA applicant does or does not intend to challenge the patent. We cannot predict whether any patents issuing from our pending patent
applications will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents, or the outcome of any such suit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license.
Moreover, if any patents that are granted and listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent litigation, the affected product could immediately face generic competition and its sales would
likely decline rapidly and materially. Should sales decline, we may have to write off a portion or all of the intangible assets associated with the affected product and our results of operations and cash flows could be materially and adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>One of our collaboration partners is evaluating a product candidate in the same indication as our lead product candidate
crenezumab. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our collaboration partner Genentech is a subsidiary of Roche, which is evaluating gantenerumab, a product candidate
for the same indication as our lead product candidate crenezumab. Our collaboration agreement with Genentech for crenezumab provides Genentech with control over, and responsibility for, the clinical development process, including obtaining
regulatory and marketing approvals, manufacturing costs and sales and marketing costs. In addition, the collaboration agreement provides that Genentech may terminate the agreement at any time by providing three months&#146; notice to us. As a
result, Roche may choose to devote more time and resources to advancing gantenerumab instead of crenezumab, which could render crenezumab non-competitive and limit or make it more difficult for us to achieve or maintain profitability with
crenezumab. Should this occur, our business, financial condition and results of operations could be materially impacted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The successful commercialization of our product candidates will depend in part on the
extent to which governmental authorities and health insurers establish adequate coverage and reimbursement levels and pricing policies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The successful commercialization of our product candidates will depend, in part, on the extent to which coverage and reimbursement for our
products will be available from government and health administration authorities, private health insurers and other third-party payors. To manage healthcare costs, many governments and third-party payors increasingly scrutinize the pricing of new
technologies and require greater levels of evidence of favorable clinical outcomes and cost-effectiveness before extending coverage. In light of such challenges to prices and increasing levels of evidence of the benefits and clinical outcomes of new
technologies, we cannot be sure that coverage will be available for any of our current or future product candidates that we commercialize and, if available, that the reimbursement rates will be adequate. If we are unable to obtain adequate levels of
coverage and reimbursement for our product candidates, their marketability will be negatively and materially impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third party payors
may deny coverage and reimbursement status altogether of a given drug product, or cover the product but may also establish prices at levels that are too low to enable us to realize an appropriate return on our investment in product development.
Because the rules and regulations regarding coverage and reimbursement change frequently, in some cases at short notice, even when there is favorable coverage and reimbursement, future changes may occur that adversely impact the favorable status.
Further, the net reimbursement for drug products may be subject to additional reductions if there are changes to laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unavailability or inadequacy of third-party coverage and reimbursement could have a material adverse effect on the market acceptance of
our product candidates and the future revenues we may expect to receive from those products. In addition, we are unable to predict what additional legislation or regulation relating to the healthcare industry or third-party coverage and
reimbursement may be enacted in the future, or what effect such legislation or regulation would have on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our products
may not gain market acceptance, in which case we may not be able to generate product revenues, which will materially adversely affect our business, financial condition and results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if the FDA, the EMA or other regulatory authority approves the marketing of any product candidates that we develop, physicians, healthcare
providers, patients or the medical community may not accept or use them. Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If any of
our current or future product candidates does not achieve an adequate level of acceptance, we may not generate significant product revenues or any profits from operations. The degree of market acceptance of our product candidates that are approved
for commercial sale will depend on a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how clinicians and potential patients perceive our novel products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of market introduction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and clinical profile of competing products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to provide acceptable evidence of safety and efficacy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of any side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effectiveness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient diagnostics and screening infrastructure in each market; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third-party payors, both public and private; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other potential advantages over alternative treatment methods. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates fail
to gain market acceptance, this will have a material adverse impact on our ability to generate revenues to provide a satisfactory, or any, return on our investments. Even if some products achieve market acceptance, the market may prove not to be
large enough to allow us to generate significant revenues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the potential market opportunity of our product candidates is
difficult to precisely estimate. Our estimates of the potential market opportunity are predicated on several key assumptions such as industry knowledge and publications, third-party research reports and other surveys. These assumptions involve the
exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions could not have been assessed by an independent source in every detail. If any of the assumptions proves to be
inaccurate, then the actual market for our product candidates could be smaller than our estimates of the potential market opportunity. If the actual market for our product candidates is smaller than we expect, or if any approved products fail to
achieve an adequate level of acceptance by physicians, health care payors and patients, our product revenue may be limited and it may be more difficult for us to achieve or maintain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We depend on enrollment of patients in our clinical studies for our product candidates. If we are unable to enroll patients in our
clinical studies, our research and development efforts could be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful and timely completion of
clinical studies will require that we enroll a sufficient number of patient candidates. Studies may be subject to delays as a result of patient enrollment taking longer than anticipated or patient withdrawal. Patient enrollment depends on many
factors, including the size and nature of the patient population, eligibility criteria for the study, the proximity of patients to clinical sites, the design of the clinical protocol, the availability of competing clinical studies, the availability
of new drugs approved for the indication the clinical study is investigating, and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug being studied in relation to other available therapies. In the Phase 3
clinical studies of crenezumab, our collaboration partner Genentech will seek to enroll patients in the early stages of AD and it may be unable to successfully identify an adequate number of eligible patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific target population of patients and therapeutic time windows may make it difficult for us to enroll enough patients to complete our
clinical studies in a timely and cost-effective manner. Delays in the completion of any clinical study of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially
jeopardize our ability to commence product sales and generate revenue. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial of regulatory
approval of our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If serious adverse, undesirable or unacceptable side effects are identified during the
development of our product candidates or following approval, if any, we may need to abandon our development of such product candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative
consequences following marketing approval, if any. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are associated with serious adverse, undesirable or
unacceptable side effects, we may need to abandon their development or limit development to certain uses or sub-populations in which such side effects are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that initially showed promise in preclinical or early stage testing have later been found to cause side effects that restricted their use and prevented further development of the compound for
larger indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has not disclosed detailed information about serious adverse events associated with crenezumab either
publicly or to us. However, at the 2014 Alzheimer&#146;s Association International Conference, it was reported that in the combined Phase 2 study populations, serious adverse events occurred at similar rates in patients treated with crenezumab
(16.5%) and in patients given a placebo (11.9%). In addition, adverse events identified in the clinical studies of crenezumab initiated to date have included inflammation of the throat and nasal passages, urinary tract infections and upper
respiratory infections. In addition, five serious adverse events were observed in three patients during clinical studies of ACI-35, although we believe that these serious adverse events were not related to the treatment. Acute pyelonephritis, or
kidney infection, and dizziness were observed in one patient and sick sinus syndrome was reported for a second patient, and these were labeled as possibly related due to the close timing proximity with the last administration of ACI-35. In the third
patient, urosepsis, or blood poisoning, and pyelonephritis were described and classified as unlikely related to the drug. A relationship between these serious adverse effects and ACI-35 cannot be ruled out, however. Non-drug related serious adverse
effects observed during clinical studies of ACI-24 were acute chest pain, death due to Alzheimer&#146;s disease or myocardial infarction (heart attack), colonic cancer, wound infections and pneumonia. Occurrence of serious procedure- or
treatment-related side effects could impede clinical study enrollment and receipt of marketing approval from the FDA, the EMA and comparable foreign regulatory authorities. Adverse events could also adversely affect physician or patient acceptance
of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally if one or more of our product candidates receives marketing approval, and we or others later
identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may withdraw approvals of such product and require us to take any approved products off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered, conduct additional studies or change the labeling of the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations in how we promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we could be sued and held liable for harm caused to patients; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation and physician or patient acceptance of our products may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these
events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We operate in highly competitive and rapidly changing industries, which may result in others discovering, developing or commercializing
competing products before or more successfully than we do. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceutical and pharmaceutical industries are highly
competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to discover, develop and obtain marketing approval for new and innovative products on a cost-effective basis and to market them
successfully. In doing so, we face and will continue to face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies, academic institutions, government agencies and other private and public research institutions in Europe, the United States and other jurisdictions. Many of our potential competitors,
alone or with their strategic partners, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory
approvals of treatments and the commercialization of those treatments. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we
may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to
enter the market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our key competitor product candidates are (i)&nbsp;aducanumab (Biogen), solanezumab (Eli Lilly),
gantenerumab (Roche) and bapineuzumab (Elan, Pfizer and Johnson&nbsp;&amp; Johnson) for crenezumab; (ii)&nbsp;CAD-106 (Novartis) and ABvac 40 (Araclon Biotech) for ACI-24; and (iii)&nbsp;AADVAC1 (Axon Neurosciences) for ACI-35, as described under
&#147;Business&#151;Competition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The highly competitive nature of and rapid technological changes in the biotechnology and
pharmaceutical industries could render our product candidates or our technology obsolete or non-competitive. Our competitors may, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and commercialize products that are safer, more effective, less expensive, or more convenient or easier to administer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain quicker regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish superior intellectual property and proprietary positions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have access to more manufacturing capacity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implement more effective approaches to sales and marketing; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">form more advantageous strategic alliances. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of these occur, our business,
financial condition and results of operations could be materially adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to
use and expand our Morphomer and SupraAntigen proprietary technology platforms to build additional product candidates for our pipeline. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our Morphomer and SupraAntigen proprietary technology platforms to create unique drug
therapies for conformational diseases, such as AD, and progress these product candidates through clinical development. Although our research and development efforts to date have resulted in a pipeline of product candidates, we may not be able to
develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipelines, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being
shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to
commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect the price of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to economic, political, regulatory and other risks associated with
international operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. We and a number of
our suppliers and collaborative and clinical study relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular non-U.S. economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals in non-U.S. countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with non-U.S. laws and regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. currency exchange rates and currency controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing international operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future
viability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We began our operations in 2003. Our operations to date have been limited to financing and staffing our company,
developing our technology and developing crenezumab and our other product candidates. We have not yet demonstrated an ability successfully to complete a large-scale, pivotal clinical study, obtain marketing approval, manufacture a commercial scale
product or conduct sales and marketing activities necessary for successful product commercialization. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a history of successfully
developing and commercializing pharmaceutical products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Business interruptions could delay us in the process of developing our
product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Loss of our laboratory facilities through fire or other causes could have an adverse effect on our ability to
continue to conduct our business. We currently have insurance coverage to compensate us for such business interruptions; however, such coverage may prove insufficient to fully compensate us for the damage to our business resulting from any
significant property or casualty loss to our facilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our future growth and ability to compete depends on retaining our key personnel and
recruiting additional qualified personnel. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success depends upon the continued contributions of our key management, scientific
and technical personnel, many of whom have substantial experience with or been instrumental for us and our projects. Members of our key management include Dr.&nbsp;Andrea Pfeifer, our Chief Executive Officer; Dr.&nbsp;Andreas Muhs, our Chief
Scientific Officer; George Pavey, our Chief Financial Officer; and Jean-Fabien Monin, our Chief Administrative Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The loss of our
key managers and senior scientists could delay our research and development activities. Laws and regulations on executive compensation, including legislation in our home country, Switzerland, may restrict our ability to attract, motivate and retain
the required level of qualified personnel. In Switzerland, new legislation affecting public companies has been passed that, among other things, (i)&nbsp;imposes an annual binding shareholders&#146; &#147;say on pay&#148; vote with respect to the
compensation of executive management, including executive officers and the board of directors; (ii)&nbsp;prohibits severance, advances, transaction premiums and similar payments to executive officers and directors; and (iii)&nbsp;requires companies
to specify various compensation-related matters in their articles of association, thus requiring them to be approved by a shareholders&#146; vote. In addition, the competition for qualified personnel in the biopharmaceutical and pharmaceutical field
is intense, and our future success depends upon our ability to attract, retain and motivate highly-skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private
research institutions and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement business strategy, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We expect to expand our development, and regulatory capabilities, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to experience growth in the number of our employees and the scope of our operations.
To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited
financial resources, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and
business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may become exposed to costly and damaging liability claims, either when testing our product candidates in the clinic or at the
commercial stage; and our product liability insurance may not cover all damages from such claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to potential
product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. Currently we have no products that have been approved for commercial sale; however, our
current and future use of product candidates in clinical studies, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers,
pharmaceutical companies or others selling such products. Any claims against us, regardless of their merit, could be difficult and costly to defend and could materially adversely affect the market for our product candidates or any prospects for
commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the clinical study process is designed to identify and assess potential side
effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical studies or after approval of the product candidate,
we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We purchase liability insurance in connection with the clinical studies that we undertake in
amounts that we consider to be consistent with industry norms. It is possible that our liabilities could exceed our insurance coverage. We intend to expand our insurance coverage to include the sale of commercial products if we obtain marketing
approval for any of our product candidates. However, we may not be able to maintain insurance coverage at a reasonable cost or obtain insurance coverage that will be adequate to satisfy any liability that may arise. If a successful product liability
claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should any of the events described above occur, this could have a material adverse effect on our business, financial condition and results of
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to obtain orphan drug designation for certain of our product candidates. Orphan drug designation may not
ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity for such product candidates, we may be subject to earlier competition and our potential revenue will be reduced.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or
condition, defined as a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered
from sales in the United States. In the European Union, the EMA&#146;s Committee for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the diagnosis, prevention, or
treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment of a
life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or
biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant benefit to those affected by the condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards
clinical study costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may
not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the
manufacturer is unable to assure sufficient product quantity. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction of fees or fee waivers and ten years of market exclusivity following drug or
biological product approval. This period may be reduced to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to obtain orphan drug designation for any of our product candidates, and even if we do, we may not be the first to
obtain marketing approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug designation for a product, that exclusivity may not effectively
protect the product from competition because different drugs with different active moieties can be approved for the same condition. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug
any advantage in the regulatory review or approval process. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Due to our limited resources and access to capital, we must prioritize development of
certain product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited resources and access to capital to fund our operations, we must decide which
product candidates to pursue and the amount of resources to allocate to each. As such, we are currently primarily focused on the development of ACI-24 and ACI-35 for the treatment of AD. Our decisions concerning the allocation of research,
collaboration, management and financial resources toward particular compounds, product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources away from better opportunities. Similarly,
our potential decisions to delay, terminate or collaborate with third parties in respect of certain product development programs may also prove not to be optimal and could cause us to miss valuable opportunities. If we make incorrect determinations
regarding the market potential of our product candidates or misread trends in the biopharmaceutical industry, in particular for neurological disorders, our business, financial condition and results of operations could be materially adversely
affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our research and development activities could be affected or delayed as a result of possible restrictions on animal
testing. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain laws and regulations require us to test our product candidates on animals before initiating clinical studies in
humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in
these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted, delayed or become more expensive. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our information technology systems could face serious disruptions that could adversely affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our information technology and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to
the internet, face the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology and other internal infrastructure systems could cause interruptions in our collaborations
with our partners and delays in our research and development work. The loss of product development or clinical study data could result in delays in our regulatory approval efforts and significantly increase our costs. To the extent that any
disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our development programs and the development of
our product candidates could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have never commercialized a product candidate before and may lack the necessary
expertise, personnel and resources to successfully commercialize our products on our own or together with suitable partners. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for our product candidates, we will have to develop our own sales, marketing and supply
organization or outsource these activities to a third party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that may affect our ability to commercialize our product candidates
on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our drug candidates and other unforeseen costs associated with
creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective
sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach
or sustain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Relationships with Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to maintain our current strategic relationships with Genentech, Janssen, Piramal and other of our current or future strategic
partners, our business, commercialization prospects and financial condition may be materially adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have two
partnerships with Genentech. In 2006, we granted Genentech an exclusive, worldwide license for crenezumab. In 2012, we entered into a second partnership to commercialize our anti-tau antibodies for use as immunotherapies. We partner with Janssen to
develop and commercialize therapeutic anti-tau vaccines for the treatment of AD and potentially other tauopathies. We also have a diagnostic partnership with Piramal Imaging for a compound from our Morphomer chemical library that binds pathogenic
tau for use as a positron emission tomography, or PET, tracer. Genentech has the right to terminate its agreements with us at any time and for any reason upon providing us with a certain notice period. After a specified amount of time, Janssen and
Piramal will also each have the right to terminate their agreements with us for any reason upon providing us with a certain notice period. If Genentech, Janssen, Piramal or other of our current or future strategic partners terminates its agreement
with us at any time, it could delay or prevent development of our product candidates and materially harm our business, financial condition, commercialization prospects and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Good relationships with Genentech, Janssen, Piramal and other of our current or future strategic partners are important for our business
prospects. If our relationships with Genentech, Janssen, Piramal or other of our current or future strategic partners were to deteriorate substantially or Genentech, Janssen, Piramal or other of our current or future strategic partners were to
challenge our use of their intellectual property or our calculations of the payments we owe under our agreements, our business, financial condition, commercialization prospects and results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lastly, our collaboration agreement with Genentech for crenezumab provides Genentech with control over, and responsibility for, the clinical
development process, including obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. Our other existing collaboration agreements provide our collaboration partners with similar control over the clinical
development process and future collaboration agreements may also relinquish development control to our partners. Genentech or our other current or future collaboration partners may separately pursue competing products, therapeutic approaches or
technologies to develop treatments for the diseases targeted by us or our collaborative efforts. Even if our partners continue their contributions to the collaborative agreements to which we are a party, they may nevertheless determine not to
actively pursue the development or commercialization of any resulting products. Our partners may also fail to perform their obligations under the collaboration agreements or may be slow in performing their obligations. Any of these circumstances
could result in a material adverse impact on our business, financial condition, commercialization prospectus or results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may seek to form additional strategic alliances in the future with respect to our product candidates, and if we do not realize the
benefits of such alliances, our business, financial condition, commercialization prospects and results of operations may be materially adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product development programs and the potential commercialization of our product candidates will require substantial additional cash to fund
expenses and may require expertise, such as sales and marketing expertise, which we do not currently possess. Therefore, in addition to our relationships with Genentech, Janssen and Piramal, we may decide to enter into strategic alliances, or create
joint ventures or collaborations with pharmaceutical or biopharmaceutical companies for the further development and potential commercialization of those and other of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face significant competition in seeking appropriate collaborators. Collaborations are complex and time-consuming to negotiate and document.
Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market. We may
also be restricted under existing and future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaboration agreements from entering into strategic partnerships or collaboration agreements on certain terms with other potential collaborators. We may not be able to negotiate collaborations
on acceptable terms, or at all, for any of our existing or future product candidates and programs because the potential partner may consider that our research and development pipeline is insufficiently developed to justify a collaborative effort, or
that our product candidates and programs do not have the requisite potential to demonstrate safety and efficacy in the target population. If we are unsuccessful in establishing and maintaining a collaboration with respect to a particular product
candidate, we may have to curtail the development of that product candidate, reduce the scope of or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of our
sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense for which we have not budgeted. If we elect to increase our expenditures to fund development or
commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we will not be able to bring our product candidates to market and
generate product revenue. Even if we are successful in establishing a new strategic partnership or entering into a collaboration agreement, we cannot be certain that, following such a strategic transaction or license, we will be able to progress the
development and commercialization of the applicable product candidates as envisaged, or that we will achieve the revenues that would justify such transaction, and we could be subject to the following risks, each of which may materially harm our
business, commercialization prospects and financial condition: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not be able to control the amount and timing of resources that the collaboration partner devotes to the product development program; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the collaboration partner may experience financial difficulties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to grant or otherwise relinquish important rights such as marketing, distribution and intellectual property rights; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaboration partner could move forward with a competing product developed either independently or in collaboration with third parties, including our competitors; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business combinations or significant changes in a collaboration partner&#146;s business strategy may adversely affect our willingness to complete our obligations under any arrangement. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We rely on third parties to conduct our nonclinical and clinical studies and perform other tasks for us. If these third parties do not
successfully carry out their contractual duties, meet expected deadlines, or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially
harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third-party clinical research organizations, or CROs, to monitor and
manage data for our ongoing nonclinical and clinical programs, including the clinical studies of our product candidates. We rely on these parties for execution of our nonclinical and clinical studies and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory
responsibilities. We and our CROs and other vendors are required to comply with current good manufacturing practices, or cGMP, current good clinical practice, or cGCP, and Good Laboratory Practice, or GLP, which are regulations and guidelines
enforced by the FDA, the Competent Authorities of the Member States of the European Union and comparable foreign regulatory authorities for all of our product candidates in nonclinical and clinical development. Regulatory authorities enforce these
regulations through periodic inspections of study sponsors, principal investigators, study sites and other contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, the data generated in our nonclinical and
clinical studies may be deemed unreliable and the EMA, FDA, other regulatory authorities may require us to perform additional nonclinical and clinical studies before approving our marketing applications. We cannot assure you that upon inspection by
a given regulatory authority, such regulatory authority will determine that all of our clinical studies comply with cGCP regulations. In addition, our clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
studies must be conducted with products produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical studies, which would delay the regulatory
approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our relationships with these third-party CROs terminates, we may not be able to enter into arrangements with
alternative CROs or do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and
resources to our on-going nonclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the data they obtain
is compromised due to the failure to adhere to our protocols, regulatory requirements, or for other reasons, our clinical studies may be extended, delayed, or terminated and we may not be able to obtain regulatory approval for or successfully
commercialize our product candidates. CROs may also generate higher costs than anticipated. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase, and our ability to
generate revenue could be delayed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switching or adding additional CROs involves additional cost and requires management time and focus.
In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we carefully manage our relationships with
our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on third-party suppliers and other third parties for production of our product candidates and our dependence on these
third parties may impair the advancement of our research and development programs and the development of our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently rely on and expect to continue to rely on third parties, for the manufacturing and supply of chemical compounds for the clinical
studies of our current and future product candidates. For the foreseeable future, we expect to continue to rely on such third parties for the manufacture of any of our product candidates on a clinical or commercial scale, if any of our product
candidates receives regulatory approval. Reliance on third-party providers may expose us to different risks than if we were to manufacture product candidates ourselves. The facilities used by our contract manufacturers to manufacture our product
candidates must be approved by the FDA or other regulatory authorities pursuant to inspections that will be conducted after we submit our NDA or comparable marketing application to the FDA or other regulatory authority. We do not have control over a
supplier&#146;s or manufacturer&#146;s compliance with these laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. If our contract manufacturers cannot
successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition,
we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the
manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our
product candidates, if approved. Any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacturing of our product candidates or that obtained
approvals could be revoked, which would adversely affect our business and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party providers may breach agreements they
have with us because of factors beyond our control. Contract manufacturers often encounter difficulties involving production yields, quality control and quality assurance, as well as shortages of qualified personnel. They may also terminate or
refuse to renew their agreements because of their own financial difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for us. If we were unable to find adequate replacement or another acceptable solution
in time, our clinical studies could be delayed or our commercial activities could be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the fact that we are dependent on our suppliers and other third parties for the
manufacture, storage and distribution of our product candidates means that we are subject to the risk that our product candidates and, if approved, commercial products may have manufacturing defects that we have limited ability to prevent or
control. The sale of products containing such defects could result in recalls or regulatory enforcement action that could adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Growth in the costs and expenses of components or raw materials may also adversely influence our business, financial condition and results of
operations. Supply sources could be interrupted from time to time and, if interrupted, we cannot be certain that supplies could be resumed (whether in part or in whole) within a reasonable timeframe and at an acceptable cost or at all. Our current
and anticipated future dependence upon others for the manufacturing of our current and future product candidates may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely
and competitive basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our collaboration arrangements with our strategic partners may make us an attractive target for potential
acquisitions under certain circumstances. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under certain circumstances, due to the structure of our collaboration arrangements with
our strategic partners, our strategic partners may prefer to acquire us rather than paying the milestone payments or royalties under the collaboration arrangements, which may bring additional uncertainties to our business development and prospects.
For example, under our collaboration arrangements with Genentech and Janssen, we may become entitled to substantial milestone payments and royalties. As a result, rather than paying the milestone payments or royalties, Genentech or Janssen, or one
of their affiliates including Roche or Johnson&nbsp;&amp; Johnson, may choose to acquire us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not have sufficient patent terms to effectively protect our products and business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Although
various extensions or adjustments may be available, such as adjustments based on certain delays caused by the United States Patent and Trademark Office, or the USPTO, the life of a patent, and the protection it affords, is limited. Given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned, co-owned and licensed
patent portfolios may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage. Even if patents covering our product candidates are
obtained and unchallenged, once the patent life has expired for a product, we may be open to competition from generic medications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While
patent term extensions under the Hatch-Waxman Act, in the United States and under supplementary protection certificates in Europe may be available to extend the patent exclusivity term for our products, we cannot provide any assurances that any such
patent term extension will be obtained and, if so, for how long. The Hatch-Waxman Act permits a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot
extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it or a method for manufacturing it may be
extended. However, we may not be granted any extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to
expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension
or the term of any such extension is less than we request, such result could have a material adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We or our licensing or collaboration partners may become subject to intellectual
property-related litigation or other proceedings to protect or enforce our patents or the patents of our licensors or collaborators, any of which could be expensive, time consuming, and unsuccessful, and may ultimately result in our loss of
ownership of intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe our patents or the patents of our licensors or collaborators. To
counter such infringement, we may be required to file claims against those competitors, which can be expensive and time-consuming. If we or one of our licensing or collaboration partners were to initiate legal proceedings against a third party to
enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable, or that we infringe the defendant&#146;s patents. In patent litigation in the
United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness,
obviousness-type double patenting, lack of written description, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO,
or made a misleading statement, during prosecution. In addition, third parties may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post
grant review<I>, inter partes </I>review, interference and derivation proceedings as well as equivalent proceedings in foreign jurisdictions. The outcome following legal assertions of invalidity and unenforceability is unpredictable. Such
proceedings or patent litigations could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates or otherwise provide any competitive advantage. With respect to the
validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing or collaboration partners were unaware during prosecution. A court may also refuse to stop a third
party from using the technology in question on the grounds that our patents do not cover that technology. An adverse result in any proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly, which could have
a material adverse effect on our business and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interference proceedings provoked by third parties or brought by us or
declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors or collaborators. An unfavorable outcome could require us or our licensing or collaboration
partners to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be materially harmed if the prevailing party does not offer us or our licensing or collaboration partners a license on
commercially reasonable terms or at all. If we or our licensing or collaboration partners are unsuccessful in any interference proceedings, we may lose our ownership of intellectual property or our patents may be narrowed or invalidated. There can
be no assurance as to the outcome of the interference and opposition proceedings, and any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our defense of litigation, interference proceedings or other intellectual property-related proceedings may fail and, even if successful, may
result in substantial costs and distract our management and other employees from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and could substantially reduce the funds necessary to
continue our clinical studies, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market. We may not be able to prevent, alone or
with our licensing or collaboration partners, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that
some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, decisions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we or our licensing or collaboration partners are unable to obtain and maintain
effective patent rights for our technologies, product candidates or any future product candidates, or if the scope of the patent rights obtained is not sufficiently broad, our competitors could develop and commercialize products and technology
similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to
our technologies and product candidates. Our success depends in large part on our and our licensing or collaboration partners&#146; ability to obtain and maintain patent and other intellectual property protection in the United States and in other
countries with respect to our proprietary technologies and product candidates. In particular, Genentech or our other licensing or collaboration partners may be dependent on a license with a third party for the development and commercialization of
crenezumab or our other product candidates. If such license is terminated, Genentech or such other licensing or collaboration partners may be required to cease development and commercialization of crenezumab or our other product candidates, any of
which could have a material adverse effect on our business, financial condition, results of operations or prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sought to
protect our proprietary position by filing patent applications in the United States and abroad related to any of our novel technologies and products that are important to our business. This process is expensive, time consuming, and complex, and we
may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost, in a timely manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our or our licensing or
collaboration partners&#146; research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or
to maintain the patents, covering technology that we license to or from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual
questions for which legal principles remain unsolved. As a result, the inventorship, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. The pending or future patent applications that we own,
co-own or in-license may fail to issue, fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries, or fail to effectively prevent others from commercializing competitive
technologies and product candidates. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be aware of all third-party intellectual property rights potentially relating to our technologies or product candidates.
Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions remain confidential for a period of time after filing, and some remain so until
issued. Therefore, we cannot be certain that we were the first to file any patent application related to our product candidates or technologies, or whether we were the first to make the inventions claimed in our owned or co-owned patents or pending
patent applications, nor can we know whether those from whom we license patents were the first to make the inventions claimed or were the first to file. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can
invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or
scope, which may result in such patents being narrowed, found unenforceable or invalidated, which could allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability
to manufacture or commercialize products without infringing third party patent rights. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our
product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
candidates, prevent others from designing around our claims or provide us with a competitive advantage. Any of these outcomes could impair our ability to prevent competition from third parties,
which may have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims challenging the inventorship of our patents
and other intellectual property. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be subject to claims that former employees, collaborators or other third parties have an
interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates.
Litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may
lose valuable intellectual property rights, such as exclusive ownership of, or the right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against
such claims, litigation could result in substantial costs and be a distraction to management and other employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Patent policy and
rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, thereby impairing our ability to protect our technologies and products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs
surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming the other requirements for patentability are met, in the United States prior to March&nbsp;15, 2013, the first to make the claimed
invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March&nbsp;15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on
September&nbsp;16, 2011, the United States has moved to a first-to-file system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to
the patent on an invention regardless of whether a third party was the first to invent the invention. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect
patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including
reexamination proceedings, <I>inter partes </I>review, post-grant review and derivation proceedings. The effects of these changes on the operation of our business are currently unclear as, among other reasons, the USPTO must still implement various
regulations and courts must interpret these changes. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued
patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain
circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S.
Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our
intellectual property in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to maintain effective proprietary rights for our technologies, product
candidates or any future product candidates, we may not be able to compete effectively in our markets. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the
protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not
covered by patents. However, trade secrets can be difficult to protect and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. Because we rely on our advisors, employees and third-party
contractors and consultants to research and develop and to manufacture our product candidates, we must, at times, share our intellectual property with them. We seek to protect our intellectual property and other proprietary technology in part by
entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, contractors, consultants, licensing and collaboration partners, and other
third parties. These agreements typically limit the rights of these third parties to use or disclose our confidential information, including our intellectual property and trade secrets. These agreements also typically restrict the ability of third
parties to publish data potentially relating to our intellectual property, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with in the future may expect to be
granted rights to publish data arising out of such collaboration, provided that we may have the right to be notified in advance and given the opportunity to delay publication for a limited time period in order for us to secure patent protection of
intellectual property rights arising from the collaboration, in addition to the opportunity to remove confidential or trade secret information from any such publication. In the future, we may also conduct joint research and development programs that
may require us to share intellectual property under the terms of our research and development or similar agreements. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade
secrets or other confidential information or proprietary technology and processes or that such agreements will not be breached or that our trade secrets or other confidential information will not otherwise be disclosed. Despite the contractual
provisions employed when working with these advisors, employees and third party contractors and consultants, the need to share intellectual property and other confidential information increases the risk that such confidential information becomes
known by our competitors, are inadvertently incorporated into the product development of others or are disclosed or used in violation of these agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and
physical and electronic security of our information technology systems. Despite our efforts to protect our intellectual property, our competitors may discover our trade secrets through breach of our agreements with third parties, where we may not
have adequate remedies for any breach, independent development or publication of information by any of our licensing or collaboration partners. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have
insufficient recourse against third parties for misappropriating such trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business.
Moreover, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent such competitor or other third party from using that technology or information to
compete with us. A competitor&#146;s or other third party&#146;s discovery of our intellectual property would impair our competitive position and have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the
United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the intellectual property related to our
technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on a patent and patent application are due to be paid
to the USPTO and foreign patent agencies in several stages over the lifetime </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the patent and patent application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar
provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements and we are also dependent on our licensors or collaboration partners to take the necessary action to
comply with these requirements with respect to certain of our intellectual property. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in
which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a
patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors
might be able to enter the market, which would have a material adverse effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The patent protection and patent
prosecution for some of our product candidates is dependent on third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we normally seek to obtain the right to
control prosecution, maintenance and enforcement of the patents relating to our product candidates, there may be times when the filing and prosecution activities for patents relating to our product candidates are controlled by our licensors or
collaboration partners. If any of our current or future licensing or collaboration partners fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by
payment of all applicable fees for patents covering our product candidates, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates may
be adversely affected and we may not be able to prevent competitors from making, using, and selling competing products. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to
and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with the obligations in our intellectual property agreements, including those under which we license intellectual
property and other rights to or from third parties, or otherwise experience disruptions to our business relationships with our licensees, our licensors and partners, we could lose intellectual property rights that are important to our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a party to a number of intellectual property license and co-ownership agreements that are important to our business and
expect to enter into additional such agreements in the future. Under certain circumstances, the royalties payable to us under these agreements are subject to certain reductions, which may have a materially adverse effect on our business, financial
condition, results of operations and prospects. In addition, our existing agreements impose, and we expect that future agreements will impose, various diligence, commercialization, milestone payment, royalty and other obligations on us. If we fail
to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be required to make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminate the
license, in which event we would not be able to develop or market products covered by the license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Licensing of intellectual property is
of critical importance to our business and involves complex legal, business, and scientific issues. Disputes may arise regarding intellectual property subject to a licensing or co-ownership agreement, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which our technology and processes infringe or otherwise violate intellectual property of the licensor, the licensee or partner that is not subject to the agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sublicensing of patent and other rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the diligence, development and commercialization obligations under the agreement and what activities satisfy those obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors or collaboration partners and us; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the priority of invention of patented technology. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property and
other rights that we have licensed or co-own prevent or impair our ability to maintain our current licensing or exclusivity arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain provisions in the agreements under which we currently license intellectual property or technology to and from third
parties may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology,
increase what we believe to be our financial or other obligations under the relevant agreement, or decrease the third party&#146;s financial or other obligations under the relevant agreement, any of which could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in obtaining or maintaining necessary
rights to our product candidates through acquisitions and in-licenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our programs may in the future require the use of
proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, maintain or use these proprietary rights. In addition, our product candidates may require specific formulations to
work effectively and efficiently and the rights to these formulations may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties
that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire
third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization
capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an
appropriate return on our investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our
preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the
collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other
parties, potentially blocking our ability to pursue our applicable product candidate or program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to successfully obtain
a license to third-party intellectual property rights necessary for the development of a product candidate or program, we may have to abandon development of that product candidate or program and our business and financial condition could suffer.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Third-party claims of intellectual property infringement may expose us to substantial liability or prevent or delay our development
and commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends on our ability and the ability of our licensees or collaborators to
develop, manufacture, market and sell our product candidates and use our proprietary technology without infringing, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misappropriating, or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and
complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product
candidates and technology, including patent infringement lawsuits, interferences, oppositions, reexamination proceedings, <I>inter partes </I>review, derivation proceedings and post grant review before the USPTO and corresponding foreign patent
offices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields
in which we are developing product candidates. For example, we are aware of third party patents that may be construed to cover one or more of our product candidates. If these patents are asserted against us or our licensing or collaboration partners
and either we or our licensing or collaboration partners are found to infringe any of these patents, and are unsuccessful in demonstrating that such patents are invalid or unenforceable, then we and our licensing or collaboration partners could be
required to pay substantial monetary damages or cease further development or commercialization of one or more of our product candidates. There may also be other third-party patents or patent applications with claims to materials, formulations,
methods of manufacture, or methods of treatment related to the use or manufacture of our product candidates and technology. Although we generally conduct a freedom to operate search and review with respect to our product candidates, we cannot
guarantee that our search and review is complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our
product candidates or use of our technology. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition,
third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third parties may
assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party
patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize our product candidates or technologies covered by the asserted third party patents. If we are found to infringe a third
party&#146;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to
obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and it
could require us to make substantial payments to the licensor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may also obtain injunctive or other
equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a
substantial diversion of management and employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful
infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Any of the foregoing could have a material and adverse
effect on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, claims that we have misappropriated the
confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. There could also be public announcements of the results of hearings, motions,
decisions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of our competitors may have substantially greater resources and more mature and developed
intellectual property portfolios than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on
extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of
infringement of the patent rights of third parties. The uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential
information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ and utilize the services of individuals who were previously employed or provided services to universities or other biotechnology or
pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us,
we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our
employee&#146;s, consultant&#146;s or independent contractor&#146;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages,
we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management
and other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, while it is our policy to require our employees, consultants and independent contractors who may be
involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops
intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that
they may bring against us, to determine the ownership of what we regard as our intellectual property. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect
our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all
countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property rights to the same extent as the laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or
importing products made using our inventions in and into the United States or other jurisdictions. In the ordinary course of prosecution and maintenance activities, we determine whether to seek patent protection outside the U.S. and in which
countries. This also applies to patents we have acquired or in-licensed from third parties. In some cases, we, or our predecessors in interest or licensors of patents within our portfolio, have sought patent protection in a limited number of
countries for patents covering our product candidates. Competitors may use our technologies in jurisdictions where we have not obtained or are unable to adequately enforce patent protection to develop their own products and further, may export
otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not
be effective or sufficient to prevent them from competing, which would have a material adverse effect on our business and financial positions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to
stop the infringement, misappropriation or other violations of our intellectual property and proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and
divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims
against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial
Condition and Capital Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage company and have a history of operating losses. We anticipate that we
will continue to incur losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company. Since 2003, while we
have received upfront and milestone payments from our collaboration partners and certain other revenue, we have also incurred significant operating losses. For example, we incurred net losses (defined as net loss attributable to owners of the
company) of CHF 11.2&nbsp;million for the year ended December&nbsp;31, 2013. In addition, we had accumulated losses of CHF&nbsp;33.8 million as of June&nbsp;30, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our losses have resulted principally from research and development expenses and from general business and administrative expenses. We expect
to continue to incur significant operating losses in the future as we continue our research and development efforts for our current and future product candidates and seek to obtain regulatory approval and commercialization of such product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have financed our operations through private placements of preferred securities, in addition to upfront and
milestone payments from our collaboration partners and certain other revenue. We have no products approved for commercialization and have never generated any revenues from product sales. Biopharmaceutical product development is a highly speculative
undertaking and involves a substantial degree of risk. It may be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a product candidate approved for commercialization and we begin to generate
revenue or royalties from product sales. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>While we have generated revenues from upfront and milestone payments related to our
collaboration agreements, we have never generated any revenue from product sales and may never be profitable. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While we have
generated revenue from upfront and milestone payments related to our collaboration agreements, we have no products approved for commercialization and have never generated any revenue product sales. Our ability to generate revenue and achieve
profitability depends on our ability to successfully complete the development of, and obtain the marketing approvals necessary to commercialize, one or more of our product candidates. We do not anticipate generating revenue from product sales unless
and until we or our collaboration partners obtain regulatory approval for, and commercialize, our product candidates. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited
to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completing research and clinical development of our product candidates, including us or our collaboration partners, as the case may be, successfully completing a Phase 3 clinical study of crenezumab, a Phase 1/2a
clinical study of ACI-24 for AD, a Phase&nbsp;1 clinical study of ACI-24 in Down syndrome, a Phase 1b clinical study of ACI-35 and a Phase&nbsp;1 clinical study of our anti-tau antibody; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining marketing approvals for our product candidates, including crenezumab, ACI-24 for AD, ACI-35 or our anti-tau antibody, for which we complete clinical studies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developing a sustainable and scalable manufacturing process for any approved product candidates and maintaining supply and manufacturing relationships with third parties that can conduct the process and provide adequate
(in amount and quality) products to support clinical development and the market demand for our product candidates, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">launching and commercializing product candidates for which we obtain marketing approval, either directly or with a collaborator or distributor; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining market acceptance of our product candidates as viable treatment options; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">addressing any competing technological and market developments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, assessing, acquiring and/or developing new product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negotiating favorable terms in any collaboration, licensing, or other similar arrangements into which we may enter; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining, protecting, and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attracting, hiring and retaining qualified personnel. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if one or more of the product
candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Because of the numerous risks and uncertainties with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Our expenses could increase beyond expectations if we are required by the FDA, the EMA, or other
regulatory agencies, domestic or foreign, to change our manufacturing processes, or to perform clinical, nonclinical, or other types of studies in addition to those that we currently anticipate. In cases where we are successful in obtaining
regulatory approvals to market one or more of our product candidates, our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to
obtain coverage and reimbursement at any price, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is
narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved. Accordingly, we may not be profitable
in the future from the sale of any approved products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may be unable to develop and commercialize any of our current or future product
candidates and, even if we do, may not achieve profitability in the future. Even if we do achieve profitability in the future, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to be profitable in
the future would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if this offering is successful, we expect that we will need substantial additional funding before we can expect to become
profitable from sales of our products. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts. </I></B></P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently advancing our product candidates through clinical development, either together with a collaboration partner (crenezumab,
ACI-35 and our anti-tau antibody) or independently (ACI-24 for AD and Down syndrome). We expect our research and development expenses to continue to increase in connection with our ongoing activities, particularly as we and/or our collaboration
partners continue our ongoing studies and initiate new studies of crenezumab, ACI-24 for AD, ACI-35 and our anti-tau antibody and initiate preclinical and clinical development of our other product candidates. As of June 30, 2016, we had cash and
cash equivalents of CHF 82.4&nbsp;million. We currently believe that our existing capital resources, not including potential milestone payments and the proceeds we receive from this offering, but including the proceeds we received from the Series E
Private Placement Extension, will be sufficient to meet our projected operating requirements for at least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
through the fourth quarter of fiscal year 2017. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our capital resources sooner than we currently expect.
Our future funding requirements will depend on many factors, including but not limited to: </P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, rate of progress, results and cost of our pre-clinical and clinical studies and other related activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing clinical supplies and establishing commercial supplies of our existing product candidates and any other products we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost, timing, and outcomes of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost and timing of establishing sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and timing of any collaborative, licensing, and other arrangements that we may establish in the future, as well as our existing such arrangements, including any required milestone and royalty payments
thereunder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the emergence of competing technologies or other adverse market developments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential cost and timing of managing and protecting our portfolio of intellectual property. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that we will require additional capital to commercialize our product candidates. If we receive regulatory approval for our current
and future product candidates, and if we have not already licensed such product candidate to a collaboration partner and choose to commercialize such product candidate independently, we expect to incur significant commercialization expenses related
to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize. We also expect to incur additional costs associated with operating as a public company following this offering. Additional funds may not be
available on a timely basis, on favorable terms, or at all, and such funds, if raised, may not be sufficient to enable us to continue to implement our long-term business strategy. If we are not able to raise capital when needed, we could be forced
to delay, reduce or eliminate our product development programs or commercialization efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause
dilution to our shareholders, restrict our operations or require us to relinquish rights to our intellectual property or future revenue streams. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity
offerings, debt financings, grants and license and development agreements in connection with collaborations. We do not have any committed external source of funds. In the event we need to seek additional funds, we may raise additional capital
through the sale of equity, convertible debt or other securities. In such an event, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder
of our common shares. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or proposing dividends to
our shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing
arrangements with third parties, we may have to grant or otherwise relinquish valuable rights to our intellectual property or future revenue streams. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce
or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to use tax loss carryforwards in Switzerland may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December 31, 2015, we reported tax loss carryforwards from financial years 2007 until 2014 for purposes of Swiss corporate income tax in
the aggregate amount of CHF 29.1 million that could be available to offset future taxable income. If not used, these tax losses will expire seven years after the year in which they were incurred. Due to our limited income, there is a high risk that
the tax loss carryforwards will expire partly or entirely and cannot be used to offset future taxable income thereafter for Swiss corporate income tax purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Exchange rate fluctuations or abandonment of the euro currency may materially affect our
results of operations and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our existing agreements, we receive a significant amount of payments in USD,
Swiss Francs and euro. As a result, changes and fluctuations in currency exchange rates between the Swiss Franc and other currencies, especially the USD and euro could have a materially adverse effect on our operating results. Since our reporting
currency is the Swiss Franc, financial line items are converted into Swiss Francs at the applicable exchange rates. We also expect that in the future, a significant portion of our revenues and expenses will be denominated in Swiss Franc, USD and
euro. Therefore, unfavorable developments in the value of the Swiss Franc as compared to the euro or any other currency could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Regulatory Environment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We cannot give any assurance that any of our product candidates will receive regulatory approval, which is necessary before they can be
commercialized. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future success is dependent on our ability to successfully develop, obtain regulatory approval for, and then
successfully commercialize one or more product candidates. We currently have one product candidate that has completed Phase 2 clinical studies. Enrollment in Phase 3 clinical studies of crenezumab initiated by our collaboration partner Genentech
started in the first quarter of 2016. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA, EMA or comparable foreign regulatory authorities, and we may never receive such
regulatory approval for any of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that any of our product candidates will be successful in
clinical studies or receive regulatory approval. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical program may not be sufficiently broad or representative to assure safety in the full population for which we seek approval; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical or clinical studies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the data collected from clinical studies of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be unable to demonstrate to the FDA, EMA or comparable foreign regulatory authorities that a product candidate&#146;s risk-benefit ratio for its proposed indication is acceptable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA, EMA or other regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications, or facilities of third-party manufacturers with which we contract for clinical and
commercial supplies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We generally plan to seek regulatory approval to commercialize our product candidates in the United States, the European Union and in
additional foreign countries where we have commercial rights. To obtain regulatory approval in other countries, we must comply with numerous and varying regulatory requirements of such other countries regarding safety, efficacy, chemistry,
manufacturing and controls, clinical studies, commercial sales, pricing, and distribution of our product candidates. Even if we are successful in obtaining approval in one </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
jurisdiction, we cannot ensure that we will obtain approval in any other jurisdictions. Failure to obtain marketing authorization for our product candidates will result in our being unable to
market and sell such products, which would materially adversely affect our business, financial conditional and results of operation. If we fail to obtain approval in any jurisdiction, the geographic market for our product candidates could be
limited. Similarly, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Clinical drug development involves a lengthy and expensive process with uncertain timelines and uncertain outcomes. If clinical studies
of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals, and therefore be unable to commercialize our product candidates on a timely basis or at all. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To obtain the requisite regulatory approvals to market and sell any of our product candidates, we must demonstrate through extensive
preclinical and clinical studies that our products are safe and effective in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical study
process. The results of preclinical and early clinical studies of our product candidates may not be predictive of the results of later-stage clinical studies. For example, the positive results generated to date in clinical studies for our product
candidates do not ensure that later clinical studies will demonstrate similar results. Product candidates in later stages of clinical studies may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and initial clinical studies. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical studies due to lack of efficacy or adverse safety profiles, notwithstanding promising results in
earlier studies. Our future clinical study results may not be successful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies must be conducted in accordance with FDA, EMA
and comparable foreign regulatory authorities&#146; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and Institutional Review Boards, or IRBs, at the medical institutions where the clinical
studies are conducted. In addition, clinical studies must be conducted with supplies of our product candidates produced under cGMP and other requirements. We depend on medical institutions and CROs, to conduct our clinical studies in compliance with
cGCP standards. To the extent the CROs fail to enroll participants for our clinical studies, fail to conduct the study to cGCP standards or are delayed for a significant time in the execution of studies, including achieving full enrollment, we may
be affected by increased costs, program delays or both, which may harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, neither we nor our collaboration partners
have completed all clinical studies required for the approval of any of our product candidates. Crenezumab has completed Phase 2 clinical testing, ACI-24 for AD is in a combined Phase 1/2a clinical study, ACI-24 for Down syndrome in a Phase 1
clinical study, ACI-35 is in Phase 1b clinical studies and our anti-tau antibody in a Phase 1 clinical study. The development of our other product candidates is less advanced and studies have not yet started. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The completion of clinical studies for our clinical product candidates may be delayed, suspended or terminated as a result of many factors,
including but not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the delay or refusal of regulators or IRBs to authorize us to commence a clinical study at a prospective study site or changes in regulatory requirements, policies and guidelines; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays or failure to reach agreement on acceptable terms with prospective CROs and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and
study sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in patient enrollment and variability in the number and types of patients available for clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative or inconclusive results, which may require us to conduct additional preclinical or clinical studies or to abandon projects that we expected to be promising; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safety or tolerability concerns, which could cause us to suspend or terminate a study if we find that the participants are being exposed to unacceptable health risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulators or IRBs requiring that we or our investigators suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements or safety concerns, among others;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lower than anticipated retention rates of patients and volunteers in clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our CROs or clinical study sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays relating to adding new clinical study sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in maintaining contact with patients after treatment, resulting in incomplete data; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in establishing the appropriate dosage levels; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the quality or stability of the product candidate falling below acceptable standards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to produce or obtain sufficient quantities of the product candidate to complete clinical studies; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exceeding budgeted costs due to difficulty in accurately predicting costs associated with clinical studies. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delays in completing our clinical studies will increase our costs, slow our product candidate development and approval process and
jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the
commencement or completion of clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain and maintain approval for our drug candidates from one jurisdiction, we may never obtain approval for our drug
candidates in other jurisdictions, which would limit our market opportunities and adversely affect our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of our
approved drugs will be subject to U.S. and non-U.S. regulatory requirements governing clinical studies and regulatory approval, and we plan to seek regulatory approval to commercialize our drug candidates in the United States, the EEA, and other
countries. Clinical studies conducted in one country may not be accepted by regulatory authorities in other countries and regulatory approval in one country does not ensure approval in any other country, while a failure or delay in obtaining
regulatory approval in one country may have a negative effect on the regulatory approval process in others. For example, approval in the United States by the FDA does not ensure approval by the regulatory authorities in other countries or
jurisdictions, and similarly approval by a non-U.S. regulatory authority, such as the EMA, does not ensure approval by regulatory authorities in other countries, including by the FDA. However, the failure to obtain approval in one jurisdiction may
have a negative impact on our ability to obtain approval elsewhere. Approval processes and regulatory requirements vary among countries and can involve additional drug testing and validation and additional administrative review periods. Even if a
drug is approved, the FDA or EMA, as the case may be, may limit the indications for which the drug may be marketed, require extensive warnings on the drug labeling or require expensive and time-consuming clinical studies or reporting as conditions
of approval. In many countries outside the United States, a drug candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for a drug is also subject to
approval. Regulatory authorities in other countries also have their own requirements for approval of drug candidates with which we must comply prior to marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in those countries. Obtaining non-U.S. regulatory approvals and compliance with such non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and could
delay or prevent the introduction of our current and any future drugs, in certain countries. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in
international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our drug candidates will be unrealized. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Even if our product candidates obtain regulatory approval, we will be subject to ongoing obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory
requirements or experience unanticipated problems with our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If marketing authorization is obtained for any of our product
candidates, the product will remain subject to continual regulatory review and therefore authorization could be subsequently withdrawn or restricted. Any regulatory approvals that we receive for our product candidates may also be subject to
limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical studies and surveillance to monitor
the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to ongoing regulatory obligations and oversight by regulatory
authorities, including with respect to the manufacturing processes, labeling, packing, distribution, adverse event reporting, storage, advertising and marketing restrictions, and recordkeeping and, potentially, other post-marketing obligations, all
of which may result in significant expense and limit our ability to commercialize such products. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with
cGMPs and cGCPs for any clinical studies that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or
manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these events occurs,
our ability to sell such product may be impaired, and we may incur substantial additional expense to comply with regulatory requirements, which could materially adversely affect our business, financial condition and results of operations. The
FDA&#146;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain
profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have conducted and may in the future conduct clinical studies for our drug candidates outside the United States,
and the FDA and applicable foreign regulatory authorities may not accept data from such studies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have conducted and may in the
future choose to conduct one or more of our clinical studies outside the United States, including in Germany, Austria, Denmark, Sweden and Finland. The acceptance of study data from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical studies conducted outside the United States or another jurisdiction by the FDA or applicable foreign regulatory authority may be subject to certain conditions. In cases where data from
foreign clinical studies are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless the following are true: the data are applicable to the United
States population and United States medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers
such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#146;s clinical study requirements, including sufficient size of patient populations and
statistical powering, must be met. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be
no assurance that the FDA or any applicable foreign regulatory authority will accept data from studies conducted outside of the United States or the applicable jurisdiction. If the FDA or any applicable foreign regulatory authority does not accept
such data, it would result in the need for additional studies, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our drugs or drug candidates not receiving approval or clearance for
commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Enacted and future legislation may increase the difficulty and cost for us to
obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States
and the European Union, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system. These changes could prevent or delay marketing approval of our product candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United
States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the Medicare Modernization Act, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug
purchases by the elderly and introduced a new reimbursement methodology based on average sale prices for physician-administered drugs. In addition, this legislation provided authority for limiting the number of drugs that will be covered in any
therapeutic class. Cost-reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for any approved products. While the Medicare Modernization Act applies only to drug benefits for Medicare
beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the Medicare Modernization Act may result in a similar
reduction in payments from private payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">More recently, in March 2010, President Obama signed into law the Patient Protection and
Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the Health Care Reform Law, a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending,
enhance remedies against fraud and abuse, add new transparency requirements for health care and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Health Care Reform Law,
among other things, increased rebates a manufacturer must pay to the Medicaid program, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused,
instilled, implanted or injected, established a new Medicare Part D coverage gap discount program, in which manufacturers must provide 50% point-of-sale discounts on products covered under Part D and implemented payment system reforms including a
national pilot program on payment bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Further, the new law imposed a
significant annual fee on companies that manufacture or import branded prescription drug products. Substantial new provisions affecting compliance were enacted, which may affect our business practices with health care practitioners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, other legislative changes have also been proposed and adopted in the United States
since the Health Care Reform Law was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a
targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate
reductions to Medicare payments to providers of 2%&nbsp;per fiscal year, which went into effect on April&nbsp;1, 2013. On January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other
things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to
five years. These new laws may result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, proposed new clinical study regulations will centralize clinical study approval, which eliminates redundancy, but in
some cases this may extend timelines for clinical study approvals due to potentially longer wait times. Proposals to require specific consents for use of data in research, among other measures, may increase the costs and timelines for our product
development efforts. Austerity measures in certain European nations may also affect the prices we are able to seek if our products are approved, as discussed below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both in the United States and in the European Union, legislative and regulatory proposals have been made to expand post-approval requirements
and restrict sales and promotional activities for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the regulations, guidance or interpretations will be changed, or what the impact of such
changes on the marketing approvals of our product candidates, if any, may be. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We could be subject to liabilities under
environmental, health and safety laws or regulations, or fines, penalties or other sanctions, if we fail to comply with such laws or regulations or otherwise incur costs that could have a material adverse effect on the success of our business.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws, regulations, and permitting requirements, including those
governing laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials,
including chemicals and biological materials and produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials
or wastes either at our sites or at third party disposal sites. In the event of such contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs
associated with civil or criminal fines and penalties. Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other
work-related injuries, this insurance may not provide adequate coverage against potential liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur
substantial costs in order to comply with current or future environmental, health and safety laws, regulations or permitting requirements. Such laws, regulations and requirements are becoming increasingly more stringent and may impair our research,
development or production efforts. Failure to comply with these laws, regulations and permitting requirements also may result in substantial fines, penalties or other sanctions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our relationships with customers and payors will be subject to applicable anti-kickback,
fraud and abuse and other healthcare laws and regulations, which, if violated, could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual damages, reputational harm and diminished profits and
future earnings. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Healthcare providers, physicians and others play a primary role in the recommendation and prescription of any
products for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, primarily in the United States, that may
constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable healthcare laws and regulations, include the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to
induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under U.S. government healthcare programs such as Medicare and Medicaid; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S.
government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program or making false statements relating
to healthcare matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and
transmission of individually identifiable health information; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transparency requirements under the Health Care Reform Law require manufacturers of drugs, devices, biologics and medical supplies to report to the U.S. Department of Health and Human Services information related to
payments and other transfers of value made by such manufacturers to physicians and teaching hospitals, and ownership and investment interests held by physicians or their immediate family members; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">analogous laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental
third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal
government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the U.S. federal
Anti-Kickback Statute, it is possible that some of our future business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has strengthened these laws. For example, the Health
Care Reform Law, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it.
Moreover, the Health Care Reform Law provides that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the False
Claims Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Efforts to ensure that our business arrangements with third parties will comply with applicable
healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative
penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other providers or entities with whom we expect
to do business with are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Risks from the improper conduct of employees, agents, contractors, or collaborators could adversely affect our reputation and our
business, prospects, operating results, and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot ensure that our compliance controls, policies, and
procedures will in every instance protect us from acts committed by our employees, agents, contractors, or collaborators that would violate the laws or regulations of the jurisdictions in which we operate, including, without limitation, healthcare,
employment, foreign corrupt practices, environmental, competition, and patient privacy and other privacy laws and regulations. Such improper actions could subject us to civil or criminal investigations, and monetary and injunctive penalties, and
could adversely impact our ability to conduct business, operating results, and reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud
or other misconduct. Misconduct by employees could include intentional failures to comply with FDA or EMA regulations, to provide accurate information to the FDA or the EMA or intentional failures to report financial information or data accurately
or to disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious harm to our reputation. We will
adopt a code of conduct in connection with this offering, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or
unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Our business activities may be subject to the Foreign Corrupt Practices Act, or FCPA, and similar anti-bribery and anti-corruption laws.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other
countries in which we operate, including the U.K. Bribery Act. The FCPA generally prohibits offering, promising, giving, or authorizing others to give anything of value, either directly or indirectly, to a non-U.S. government official in order to
influence official action, or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an
adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of non-U.S. governments. Additionally, in many other countries, the health
care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the FCPA.
Recently the Securities and Exchange Commission, or SEC, and Department of Justice have increased their FCPA enforcement activities with respect to pharmaceutical companies. There is no certainty that all of our employees, agents, contractors, or
collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions
against us, our officers, or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
implementation of compliance programs, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more
countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, and financial condition. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to this Offering and our Common Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common shares may be volatile and may fluctuate due to factors beyond our control. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The share prices of publicly traded emerging biopharmaceutical and drug discovery and development companies have been highly volatile and are
likely to remain highly volatile in the future. The market price of our common shares may fluctuate significantly due to a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">positive or negative results of testing and clinical studies by us, strategic partners, or competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">technological innovations or commercial product introductions by us or competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in government regulations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning proprietary rights, including patents and litigation matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern relating to the commercial value or safety of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financing or other corporate transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of research reports or comments by securities or industry analysts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions in the pharmaceutical industry or in the economy as a whole; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">other events and factors beyond our control. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the stock market in general has
recently experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of individual companies. Broad market and industry factors may materially affect the market price of
companies&#146; stock, including ours, regardless of actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>There was no public market for our common shares
prior to this offering, and an active market in our common shares may not develop in which investors can resell our common shares. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering there was no public market for our common shares. We cannot predict the extent to which an active market for our common
shares will develop or be sustained after this offering, or how the development of such a market might affect the market price for our common shares. The initial public offering price of our common shares in this offering was agreed among us and the
underwriters based on a number of factors, including market conditions in effect at the time of this offering, which may not be indicative of the price at which our common shares will trade following completion of this offering. Investors may not be
able to sell their common shares at or above the initial public offering price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Certain of our existing shareholders will continue
to be able to exercise significant control over us, and your interests may conflict with the interests of our existing shareholders. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of this offering, our existing shareholders are expected to own approximately 89.2% of our common shares (or approximately
87.7% if the underwriters exercise their over-allotment option in full), excluding any shares purchased by any such holders in this offering. Depending on the level of attendance at our general meetings of shareholders, these shareholders may be in
a position to determine the outcome of decisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
taken at any such general meeting. To the extent that the interests of these shareholders may differ from the interests of the company&#146;s other shareholders, the latter may be disadvantaged
by any action that these shareholders may seek to pursue. Among other consequences, this concentration of ownership may have the effect of delaying or preventing a change in control and might therefore negatively affect the market price of our
common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Future sales, or the possibility of future sales, of a substantial number of our common shares could adversely
affect the price of our common shares. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future sales of a substantial number of our common shares, or the perception that such
sales will occur, could cause a decline in the market price of our common shares. Following the completion of this offering, we will have 55,396,042 common shares outstanding based on 10,819,000 common shares outstanding as of August&nbsp;31, 2016
and 38,577,042 additional common shares issuable upon the conversion of all of our outstanding preferred shares into common shares, excluding 5,300,000 of our common shares issued to Credit Suisse AG, Zurich in the CS AG Share Issuance. This
includes the common shares in this offering, which may be resold in the public market immediately upon the closing of this offering without restriction, unless purchased by our affiliates. Approximately 64.2% of the common shares outstanding are
expected to be held by affiliates (assuming no exercise of the underwriters&#146; over-allotment option). All of these common shares will be subject to the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. If,
after the end of such lock-up agreements, these shareholders sell substantial amounts of common shares in the public market, or the market perceives that such sales may occur, the market price of our common shares and our ability to raise capital
through an issue of equity securities in the future could be adversely affected. We also entered into a registration rights agreement in connection with the Series E Private Placement with certain investors in the Series E Private Placement pursuant
to which we agreed under certain circumstances to file a registration statement to register the resale of the common shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such common shares. In
addition, following the completion of this offering, we intend to cease any new grants under our existing equity incentive plans and to adopt a new omnibus equity incentive plan under which we would have the discretion to grant a broad range of
equity-based awards to eligible participants. We intend to register all common shares that we may issue under this equity compensation plan. Once we register these common shares, they can be freely sold in the public market upon issuance, subject to
volume limitations applicable to affiliates and the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. If a large number of our common shares or securities convertible into our common shares are sold in the
public market after they become eligible for sale, the sales could reduce the trading price of our common shares and impede our ability to raise future capital. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If you purchase common shares in this offering, you will suffer immediate dilution of your investment. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial public offering price of our common shares is substantially higher than the as adjusted net tangible book value per common share.
Therefore, if you purchase common shares in this offering, you will pay a price per common share that substantially exceeds our as adjusted net tangible book value per common share after this offering. To the extent outstanding options are
exercised, you will incur further dilution. You will experience immediate dilution of CHF&nbsp;6.76 ($6.92) per common share, representing the difference between our as adjusted net tangible book value per common share after giving effect to this
offering and the initial public offering price. In addition, purchasers of common shares in this offering will have contributed approximately 31.2% of the aggregate price paid by all purchasers of common shares issued by us but will own only
approximately 10.8% of our common shares outstanding after this offering. See &#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use
them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could
spend the proceeds in ways that do not improve our results of operations or enhance the value of our common shares. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse
effect on our business, cause the price of our common shares to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses
value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We do not expect to pay dividends in the foreseeable future. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not paid any dividends since our incorporation. Even if future operations lead to significant levels of distributable profits, we
currently intend that any earnings will be reinvested in our business and that dividends will not be paid until we have an established revenue stream to support continuing dividends. The proposal to pay future dividends to shareholders will in
addition effectively be at the discretion of our board of directors after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future
dividends is subject to certain limitation pursuant to Swiss law or by our articles of association. See &#147;Description of Share Capital and Articles of Association.&#148; Accordingly, investors cannot rely on dividend income from our common
shares and any returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are a Swiss corporation. The rights of our shareholders may be different from the rights of shareholders in companies governed by the
laws of U.S. jurisdictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Swiss corporation. Our corporate affairs are governed by our articles of association and by
the laws governing companies, including listed companies, incorporated in Switzerland. The rights of our shareholders and the responsibilities of members of our board of directors may be different from the rights and obligations of shareholders and
directors of companies governed by the laws of U.S. jurisdictions. In the performance of its duties, our board of directors is required by Swiss law to consider the interests of our company, our shareholders, our employees and other stakeholders, in
all cases with due observation of the principles of reasonableness and fairness. It is possible that some of these parties will have interests that are different from, or in addition to, your interests as a shareholder. Swiss corporate law limits
the ability of our shareholders to challenge resolutions made or other actions taken by our board of directors in court. Our shareholders generally are not permitted to file a suit to reverse a decision or an action taken by our board of directors
but are instead only permitted to seek damages for breaches of fiduciary duty. As a matter of Swiss law, shareholder claims against a member of our board of directors for breach of fiduciary duty would have to be brought in Lausanne, Switzerland, or
where the relevant member of our board of directors is domiciled. In addition, under Swiss law, any claims by our shareholders against us must be brought exclusively in Lausanne, Switzerland. See &#147;Description of Share Capital and Articles of
Association&#148; and &#147;Comparison of Delaware Law and Swiss Law.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>The implementation of the authorized share capital
increase may be blocked. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This offering is based upon and subject to a resolution regarding the authorized share capital increase
that was approved by the shareholders at the shareholders&#146; meeting held on October 21, 2015, which requires registration with the commercial register of the Canton of Vaud. On May 27, 2016, the commercial register of the Canton of Vaud approved
an increase in our authorized share capital of 5,300,000 common shares, all of which were issued to Credit Suisse AG, Zurich. See Note&nbsp;7 (Other current liabilities) of our unaudited interim condensed financial statements as of and for the six
months ended June&nbsp;30, 2016 and June&nbsp;30, 2015 included elsewhere in this prospectus. Any registration of a capital increase over and above these 5,300,000 common shares in the commercial register of the Canton of Vaud may be blocked by a
shareholder and, therefore, prevent or delay the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our common shares are issued under the laws of Switzerland, which may not protect investors
in a similar fashion afforded by incorporation in a U.S. state. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland. A further summary
of applicable Swiss company law is contained in this prospectus, see &#147;Description of Share Capital and Articles of Association&#148; and &#147;Comparison of Delaware Law and Swiss Law.&#148; However, there can be no assurance that Swiss law
will not change in the future or that it will serve to protect investors in a similar fashion afforded under corporate law principles in the U.S., which could adversely affect the rights of investors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our status as a Swiss corporation may limit our flexibility with respect to certain aspects of capital management and may cause us to be
unable to make distributions without subjecting our shareholders to Swiss withholding tax. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law allows our shareholders to
authorize share capital that can be issued by the board of directors without additional shareholder approval. This authorization is limited to 50% of the existing registered share capital and must be renewed by the shareholders every two years.
Additionally, subject to specified exceptions, Swiss law grants pre-emptive subscription rights to existing shareholders to subscribe to any new issuance of shares. Swiss law also does not provide as much flexibility in the various terms that can
attach to different classes of shares as the laws of some other jurisdictions. Swiss law also reserves for approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For
example, dividends must be approved by shareholders. These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided substantial benefits to our
shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, a Swiss corporation may pay dividends only if the corporation has sufficient distributable profits from
previous fiscal years, or if the corporation has distributable reserves, each as evidenced by its audited statutory balance sheet. Freely distributable reserves are generally booked either as &#147;free reserves&#148; or as &#147;capital
contributions&#148; (<I>apports de capital</I>, contributions received from shareholders) in the &#147;reserve from capital contributions.&#148; Distributions may be made out of issued share capital&#151;the aggregate nominal value of a
company&#146;s issued shares&#151;only by way of a capital reduction. Upon completion of this offering, we expect the Company to have CHF 152.5 million of qualifying capital contributions and CHF 1,107,921 of registered share capital (consisting of
55,396,042 common shares each with a nominal value of CHF 0.02 and no preferred shares) on its audited statutory balance sheet. The number of common shares referred to in the preceding sentence includes the number of shares to be issued in this
offering from the 5,300,000 common shares issued in the CS AG Share Issuance. We expect the aggregate of these amounts (less the minimum issued share capital and legal reserve of together CHF 150,000) to represent the amount available for future
dividends or capital reductions on a Swiss withholding tax-free basis. We will not be able to pay dividends or make other distributions to shareholders on a Swiss withholding tax-free basis in excess of that amount unless the Company increases its
share capital or its reserves from capital contributions. We would also be able to pay dividends out of distributable profits or freely distributable reserves but such dividends would be subject to Swiss withholding taxes. There can be no assurance
that we will have sufficient distributable profits, free reserves, reserves from capital contributions or registered share capital to pay a dividend or effect a capital reduction, that our shareholders will approve dividends or capital reductions
proposed by us, or that we will be able to meet the other legal requirements for dividend payments or distributions as a result of capital reductions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, Swiss withholding tax of 35% is due on dividends and similar distributions to our shareholders, regardless of the place of
residency of the shareholder, unless the distribution is made to shareholders out of (i)&nbsp;a reduction of nominal value or (ii)&nbsp;assuming certain conditions are met, qualifying capital contributions accumulated on or after January&nbsp;1,
1997. A U.S. holder that qualifies for benefits under the Convention between the United States of America and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, which we refer to as the &#147;U.S.-Swiss
Treaty,&#148; may apply for a refund of the tax withheld in excess of the 15% treaty rate (or in excess of the 5% reduced treaty rate for qualifying corporate shareholders with at least 10% participation in our voting stock, or for a full refund in
the case of qualified pension funds). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
There can be no assurance that we will have sufficient qualifying capital contributions to pay dividends free from Swiss withholding tax, or that Swiss withholding rules will not be changed in
the future. In addition, we cannot provide assurance that the current Swiss law with respect to distributions out of qualifying capital contributions will not be changed or that a change in Swiss law will not adversely affect us or our shareholders,
in particular as a result of distributions out of qualifying capital contributions becoming subject to additional corporate law or other restrictions. There are currently motions pending in the Swiss Parliament that purport to limit the distribution
of qualifying capital contributions. In addition, over the long term, the amount of par value available to us for nominal value reductions or qualifying capital contributions available to us to pay out as distributions is limited. If we are unable
to make a distribution through a reduction in nominal value or out of qualifying capital contributions, we may not be able to make distributions without subjecting our shareholders to Swiss withholding taxes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under present Swiss tax laws, repurchases of shares for the purposes of cancellation are treated as a partial liquidation subject to 35% Swiss
withholding tax on the difference between the repurchase price and the nominal value except, since January&nbsp;1, 2011, to the extent attributable to qualifying capital contributions (<I>apports de capital</I>) if any, and to the extent that, the
repurchase of shares is out of retained earnings or other taxable reserves. No partial liquidation treatment applies and no withholding tax is triggered if the shares are not repurchased for cancellation but held by the Company as treasury shares.
However, should Company not resell such treasury shares within six years, the withholding tax becomes due at the end of the six year period. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>U.S. shareholders may not be able to obtain judgments or enforce civil liabilities against us or our executive officers or members of
our board of directors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is located in
Ecublens, near Lausanne, Switzerland. Moreover, a number of our directors and executive officers and a number of directors of each of our subsidiaries are not residents of the United States, and all or a substantial portion of the assets of such
persons are located outside the United States. As a result, it may not be possible for investors to effect service of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts,
including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original
actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely
upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss Federal Act on Private International Law. This statute provides that the application of provisions of non-Swiss law by the
courts in Switzerland shall be precluded if the result is incompatible with Swiss public policy. Also, certain mandatory provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switzerland and the United States do not have a treaty providing for reciprocal recognition and enforcement of judgments in civil and
commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set forth in the Swiss Federal Act on Private International Law. This statute provides in principle
that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment of such non-Swiss court has become final and non-appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment does not contravene Swiss public policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in
Switzerland. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our status as a Swiss corporation means that our shareholders enjoy certain rights that may
limit our flexibility to raise capital, issue dividends and otherwise manage ongoing capital needs. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law reserves for
approval by shareholders certain corporate actions over which a board of directors would have authority in some other jurisdictions. For example, the payment of dividends and cancellation of treasury shares must be approved by shareholders. Swiss
law also requires that our shareholders themselves resolve to, or authorize our board of directors to, increase our share capital. While our shareholders may authorize share capital that can be issued by our board of directors without additional
shareholder approval, Swiss law limits this authorization to 50% of the issued share capital at the time of the authorization. The authorization, furthermore, has a limited duration of up to two years and must be renewed by the shareholders from
time to time thereafter in order to be available for raising capital. Additionally, subject to specified exceptions, including exceptions explicitly described in our articles of association, Swiss law grants pre-emptive subscription rights to
existing shareholders to subscribe for new issuances of shares. Swiss law also does not provide as much flexibility in the various rights and regulations that can attach to different categories of shares as do the laws of some other jurisdictions.
These Swiss law requirements relating to our capital management may limit our flexibility, and situations may arise where greater flexibility would have provided benefits to our shareholders. See &#147;Description of Share Capital and Articles of
Association&#148; and &#147;Comparison of Delaware Law and Swiss Law.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss law restricts our ability to pay dividends.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The proposal to pay future dividends to shareholders will effectively be at the discretion of our board of directors and subject
to approval by, in their discretion, our shareholders after taking into account various factors including our business prospects, cash requirements, financial performance and new product development. In addition, payment of future dividends is
subject to certain limitation pursuant to Swiss law or by our articles of association. See &#147;Description of Share Capital and Articles of Association.&#148; Accordingly, investors cannot rely on dividend income from our common shares and any
returns on an investment in our common shares will likely depend entirely upon any future appreciation in the price of our common shares. Dividends paid on our common shares are subject to Swiss federal withholding tax, except if paid out of
reserves from capital contributions (&#147;<I>apports de capital</I>&#148;). See &#147;Taxation&#151;Swiss Tax Considerations&#148; for a summary of certain Swiss tax consequences regarding dividends distributed to holders of our common shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We will be a foreign private issuer and, as a result, we will not be subject to U.S. proxy rules and will be subject to Exchange Act
reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon
consummation of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under the Exchange Act and although we are subject to Swiss laws and
regulations with regard to such matters and intend to furnish quarterly financial information to the SEC, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including (i)&nbsp;the
sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; (ii)&nbsp;the sections of the Exchange Act requiring insiders to file public reports of their
stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and (iii)&nbsp;the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing
unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events. In addition, foreign private issuers are not required to file their annual report on Form 20-F until four
months after the end of each financial year, while U.S. domestic issuers that are accelerated filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers are also exempt from
the Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private
issuers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a foreign private issuer and as permitted by the listing requirements of NASDAQ, we will
rely on certain home country governance practices rather than the corporate governance requirements of NASDAQ. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be a
foreign private issuer as of the effective date of this registration statement. As a result, in accordance with NASDAQ Listing Rule 5615(a)(3), we will comply with home country governance requirements and certain exemptions thereunder rather than
complying with certain of the corporate governance requirements of NASDAQ. Swiss law does not require that a majority of our board of directors consist of independent directors. Our board of directors therefore may include fewer independent
directors than would be required if we were subject to NASDAQ Listing Rule 5605(b)(1). In addition, we will not be subject to NASDAQ Listing Rule 5605(b)(2), which requires that independent directors must regularly have scheduled meetings at which
only independent directors are present. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although Swiss law also requires that we adopt a compensation committee, we will follow home
country requirements with respect to such committee and our compensation, nomination and governance committee will also be tasked with certain director nomination and governance responsibilities as described under &#147;Management&#151;Committees of
the Board of Directors.&#148; As a result, our practice will vary from the requirements of NASDAQ Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees, and
from the independent director oversight of director nominations requirements of NASDAQ Listing Rule 5605(e). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in accordance
with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements generally applicable to general meetings of shareholders. Our practice thus varies from the requirement of NASDAQ Listing Rule
5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting stock. Our articles of association provide for an independent proxy holder
elected by our shareholders, who may represent our shareholders at a general meeting of shareholders, and we must provide shareholders with an agenda and other relevant documents for the general meeting of shareholders. However, Swiss law does not
have a regulatory regime for the solicitation of proxies and company solicitation of proxies is prohibited for public companies in Switzerland, thus our practice will vary from the requirement of NASDAQ Listing Rule 5620(b), which sets forth certain
requirements regarding the solicitation of proxies. In addition, we have opted out of shareholder approval requirements for the issuance of securities in connection with certain events such as the acquisition of stock or assets of another company,
the establishment of or amendments to equity-based compensation plans for employees, a change of control of us and certain private placements. To this extent, our practice varies from the requirements of NASDAQ Listing Rule 5635, which generally
requires an issuer to obtain shareholder approval for the issuance of securities in connection with such events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For an overview of our
corporate governance principles, see &#147;Description of Share Capital and Articles of Association.&#148; As a result of the above, you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We may lose our foreign private issuer status, which would then require us to comply with the Exchange Act&#146;s domestic
reporting regime and cause us to incur significant legal, accounting and other expenses. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a foreign private issuer and
therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. We may no longer be a foreign private issuer as of June&nbsp;30, 2017 (the end of
our second fiscal quarter in the fiscal year after this offering), which would require us to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers as of January&nbsp;1,
2018. In order to maintain our current status as a foreign private issuer, either (a)&nbsp;a majority of our common shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our
executive officers or directors may not be United States citizens or residents, (ii)&nbsp;more than 50 percent of our assets cannot be located in the United States and (iii)&nbsp;our business must be administered principally outside the United
States. If we lost this status, we would be required to comply with the Exchange Act reporting and other requirements applicable </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in
accordance with various SEC and stock exchange rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher
than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We
also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to
accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company,&#148; and we cannot be certain if the reduced reporting requirements applicable to
&#147;emerging growth companies&#148; will make our common shares less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company,&#148; as defined in the Jumpstart our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an &#147;emerging growth company,&#148; we may take advantage of exemptions from various reporting requirements that are
applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, exemptions from the
requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. As an &#147;emerging growth company&#148; in our initial registration statement we are
required to report only two years of financial results and selected financial data compared to three and five years, respectively, for comparable data reported by other public companies. We could be an &#147;emerging growth company&#148; for up to
five years, although circumstances could cause us to lose that status earlier, including if the market value of our common shares held by non-affiliates exceeds $700 million as of any June&nbsp;30 (the end of our second fiscal quarter) before that
time, in which case we would no longer be an &#147;emerging growth company&#148; as of the following December&nbsp;31 (our fiscal year end). We cannot predict if investors will find our common shares less attractive because we may rely on these
exemptions. If some investors find our common shares less attractive as a result, there may be a less active trading market for our common shares and the price of our common shares may be more volatile. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>As a result of being a public company we will incur additional costs and we may not manage to comply with our internal control
procedures and corporate governance structures. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur additional legal, insurance, accounting and
other expenses that we did not incur as a private company. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls and disclosure controls and procedures and bear all of the internal and external
costs of preparing and distributing periodic public reports in compliance with our obligation under the securities laws. However, if our efforts to comply with evolving laws, regulations and standards differ from the activities intended by
regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us. This could have a material adverse impact on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>In connection with the audit of our financial statements as at and for the year ended December 31, 2014, we and our independent
registered public accounting firm identified a material weakness in our internal control over financial reporting. This material weakness continued to exist as at December 31, 2015 and as at June 30, 2016. If we fail to maintain an effective system
of internal control over financial reporting, we may be unable to accurately report our financial results or prevent fraud, and investor confidence in our company and the market price of our shares may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, we have been a private company with limited accounting personnel and other resources with which to address our internal
control over financial reporting. Further, our reporting obligations as a public company will continue to place a significant strain on our management, operational and financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resources and systems for the foreseeable future. In connection with our preparation and the audit of our financial statements as of and for the year ended December 31, 2014, we and our
independent registered public accounting firm identified a material weakness as defined under the Exchange Act and by the U.S. Public Company Accounting Oversight Board, or PCAOB, in our internal control over financial reporting, and this material
weakness was not remediated as of December&nbsp;31, 2015 nor as at June 30, 2016. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a
material misstatement of the company&#146;s annual financial statements will not be prevented or detected on a timely basis. The material weakness identified relates specifically to the accounting for and disclosure of non-routine and complex
accounting transactions and the related internal controls and processes supporting these areas. In light of the material weakness that was identified, we believe it is possible that, had we performed a formal assessment of our internal control over
financial reporting or had our independent registered public accounting firm performed an audit of our internal control over financial reporting in accordance with PCAOB standards, additional control deficiencies may have been identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once public, we will be subject to reporting obligations under U.S. securities laws and the Sarbanes-Oxley Act of 2002. Section 404 of the
Sarbanes-Oxley Act will require that we include a report from management on the effectiveness of our internal control over financial reporting in our annual report on Form 20-F beginning with our annual report for the fiscal year ending December 31,
2017. If we fail to remediate the material weakness identified above, our management may conclude that our internal control over financial reporting is not effective. This conclusion could adversely impact the market price of our shares due to a
loss of investor confidence in the reliability of our reporting processes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have begun taking measures and plan to continue to take
measures to remediate this material weakness. However, the implementation of these measures may not fully address this material weakness in our internal control over financial reporting, and therefore we would not be able to conclude that it has
been fully remedied. Our failure to correct this material weakness or our failure to discover and address any other control deficiencies could result in inaccuracies in our financial statements and could also impair our ability to comply with
applicable financial reporting requirements and make related regulatory filings on a timely basis. As a result, our business, financial condition, results of operations and prospects, as well as the trading price of our shares, may be materially and
adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If in the future we fail to maintain an effective system of internal control over financial reporting, we may
not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common shares.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with
adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. As
discussed above, in connection with the audit of our financial statements as and for the year ended December&nbsp;31, 2014, we identified a material weakness in our internal control over financial reporting, which was not remediated as at
December&nbsp;31, 2015 nor as at June&nbsp;30, 2016. In addition, any testing by us conducted in connection with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, or any subsequent testing by our independent registered public accounting firm, may
reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or
improvement. Inferior internal controls could also subject us to regulatory scrutiny and sanctions, impair our ability to raise revenue and cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to disclose changes made in our internal controls and procedures and our
management will be required to assess the effectiveness of these controls annually. However, for as long as we are an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;emerging growth company&#148; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over
financial reporting pursuant to Section&nbsp;404. We could be an &#147;emerging growth company&#148; for up to five years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#146;s
assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price
of our common shares and our trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common shares will depend in part on the
research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no or too few securities or industry analysts commence
coverage of our company, the trading price for our common shares would likely be negatively affected. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common shares or publish
inaccurate or unfavorable research about our business, the price of our common shares would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our common shares could
decrease, which might cause the price of our common shares and trading volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Although we believe that we were not a
&#147;passive foreign investment company,&#148; or PFIC, for U.S. federal income tax purposes in 2015 and we do not expect to be a PFIC in the immediately foreseeable future, if we were a PFIC U.S. shareholders may be subject to adverse U.S. federal
income tax consequences. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Internal Revenue Code of 1986, as amended, or the Code, we will be a PFIC for any taxable year
in which, after the application of certain look-through rules with respect to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of passive income or (ii)&nbsp;50% or more of the average quarterly value of our assets consists of
assets that produce, or are held for the production of, passive income. Passive income generally includes dividends, interest, certain non-active rents and royalties, and capital gains. Based on our business plan and certain estimates and
projections, including as to the relative values of our assets, we do not believe that we were a PFIC for our 2015 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there can be no assurance that the IRS
will agree with our conclusion. In addition, whether we will be a PFIC in 2016 or any future years is uncertain because, among other things, (i)&nbsp;we currently own, and will own after the completion of this offering, a substantial amount of
passive assets, including cash, and (ii)&nbsp;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time. Accordingly, there can be no assurance
that we will not be a PFIC for any taxable year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are a PFIC for any taxable year during which a U.S. investor holds common shares,
we generally would continue to be treated as a PFIC with respect to that U.S. investor for all succeeding years during which the U.S. investor holds common shares, even if we ceased to meet the threshold requirements for PFIC status. Such a U.S.
investor may be subject to adverse U.S. federal income tax consequences, including (i)&nbsp;the treatment of all or a portion of any gain on disposition as ordinary income, (ii)&nbsp;the application of a deferred interest charge on such gain and the
receipt of certain dividends and (iii)&nbsp;compliance with certain reporting requirements. We do not intend to provide the information that would enable investors to take a qualified electing fund election that could mitigate the adverse U.S.
federal income tax consequences should we be classified as a PFIC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For further discussion, see &#147;Taxation&#151;Material U.S. Federal
Income Tax Considerations for U.S. Holders.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_5"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains statements that constitute forward-looking statements. All statements other than statements of historical facts
contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, product pipeline, ongoing and planned clinical studies, including those of our collaboration
partners, regulatory approvals, research and development costs, timing and likelihood of success, as well as plans and objectives of management for future operations are forward-looking statements. Many of the forward-looking statements contained in
this prospectus can be identified by the use of forward-looking words such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;should,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;estimate,&#148;
&#147;will&#148; and &#147;potential,&#148; among others. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements appear in a number of places in this prospectus and
include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management&#146;s beliefs and assumptions and on information currently available to our management. Such
statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to of various factors, including, but not limited to, those identified under the
section entitled &#147;Risk Factors&#148; in this prospectus. These risks and uncertainties include factors relating to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The success of our and our collaboration partners&#146; clinical studies, and our and their ability to obtain regulatory approval and to commercialize crenezumab, ACI-24 for AD and ACI-35; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The ability of our competitors to discover, develop or commercialize competing products before or more successfully than we do; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Morphomer and SupraAntigen proprietary technology platforms and their success in building additional product candidates for our pipeline; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The identification of serious adverse, undesirable or unacceptable side effects related to our product candidates; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to maintain our current strategic relationships with our collaboration partners; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Failure to protect our, and not infringe on third parties&#146;, intellectual property rights throughout the world; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our ability to raise capital when needed in order to continue our product development programs or commercialization efforts; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA&#146;s and applicable foreign regulatory authorities&#146; acceptance of data from studies we conduct outside the United States in the future; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our foreign private issuer status, the loss of which would require us to comply with the Exchange Act&#146;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our incorporation in Switzerland, the laws of which govern our corporate affairs and may differ from those applicable to companies incorporated in the United States; and </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The other risk factors discussed under &#147;Risk Factors.&#148; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements speak only as of the date of this prospectus and are subject to
a number of risks, uncertainties and assumptions described under the sections in this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and
elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these
forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law,
we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. The forward-looking statements contained in this prospectus
are excluded from the safe harbor protection provided by the Private Securities Litigation Reform Act of 1995 and Section&nbsp;27A of the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_6"></A>MARKET AND INDUSTRY DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains industry, market and competitive position data that are based on industry publications and studies conducted by third
parties as well as our own internal estimates and research. These industry publications and third-party studies generally state that the information that they contain has been obtained from sources believed to be reliable, although they do not
guarantee the accuracy or completeness of such information. While we believe that each of these publications, third-party studies and our internal research is reliable and that the definition of our market and industry is appropriate, you are
cautioned not to give undue weight to this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds from the sale of 6,000,000 common shares by us in this offering will be approximately $57.8 million, after
deducting the underwriting discount and estimated offering expenses payable by us. In addition, we received gross proceeds of CHF&nbsp;14 million in July&nbsp;2016 from Genentech related to our collaboration on the
<FONT STYLE="white-space:nowrap">anti-tau</FONT> antibody program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are undertaking this offering in order to access the public capital
markets and to increase our liquidity. At June&nbsp;30, 2016, after taking into consideration the CHF&nbsp;14 million milestone payment from Genentech related to the anti-tau antibody program, we would have had cash and cash equivalents of
CHF&nbsp;96.4&nbsp;million. We intend to use the net proceeds of this offering over the next three years together with our existing cash and cash equivalents as follows:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $5.0&nbsp;million to fund our share of the costs for the further development of our therapeutic product candidates (other than ACI-35) and diagnostics product candidates under collaboration agreements
(anti-tau antibodies and the tau PET tracers), excluding our collaboration agreement with Biogen, over the next three years, of which approximately $4.0 million will be spent on therapeutic product candidates and of which approximately $1.0 million
will be spent on diagnostic product candidates, and we expect these expenditures will take the tau PET tracers into Phase&nbsp;2 and the anti-tau antibody program into Phase 2; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $10.0 million to fund our share of the costs for the further development of ACI-35, our tau vaccine under collaboration with Janssen, and we expect these expenditures will take ACI-35 into Phase 2;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $65.0&nbsp;million for the further development of ACI-24 for AD through the remainder of the Phase 1/2a study and the Phase 2b study and for our ongoing Phase 1 study and a portion of the proposed Phase 2
study of ACI-24 for Down syndrome; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $25.0 million for funding our PD-focused programs, including further pre-clinical development, the completion of Phase 1 studies and commencement of Phase 2 studies for our alpha-synuclein diagnostic
product candidate as well as further pre-clinical development and the commencement of a Phase 1 clinical study of Morphomer alpha-synuclein, our alpha-synuclein morphomer product candidate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $20.0&nbsp;million for the further development of non-AD and non-PD programs, including our morphomer tau and glaucoma program for which we intend to commence a Phase 1 study; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $10.0&nbsp;million for new research and development initiatives that are complementary to our existing and planned research initiatives (with the intent to advance these new initiatives through the
discovery phase); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder for general corporate purposes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, due to the uncertainties inherent in
the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering that may be used for the above purposes. The amount and timing of our actual expenditures will depend upon numerous
factors, including the results of our research and development efforts, the timing and success of our ongoing preclinical and clinical studies or preclinical and clinical studies we may commence in the future and the timing of regulatory
submissions. As a result, our management will have broad discretion over the use of the net proceeds from this offering, and investors will be relying on our judgment regarding the application of the net proceeds. In addition, we might decide to
postpone or not pursue certain preclinical activities or clinical studies if the net proceeds from this offering and our other sources of cash are less than expected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the use of the proceeds from this offering, we intend to invest the net proceeds in
interest-bearing, investment-grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. and Swiss governments. We are likely to convert a substantial amount of the proceeds into CHF shortly after the closing of this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings, if any,
to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>Under Swiss law, any dividend must be proposed by our board of directors and approved by our shareholders. In addition, our auditors
must confirm that the dividend proposal of our board of directors conforms to Swiss statutory law and our articles of association. A Swiss corporation may pay dividends only if it has sufficient distributable profits brought forward from the
previous business years (&#147;<I>report des b&eacute;n&eacute;fices</I>&#148;) or if it has distributable reserves (&#147;<I>r&eacute;serves &agrave; libre disposition</I>&#148;), each as evidenced by its audited standalone statutory balance sheet
prepared pursuant to Swiss law and after allocations to reserves required by Swiss law and its articles of association have been deducted. Distributable reserves are generally booked either as &#147;free reserves&#148; (&#147;<I>r&eacute;serves
libres</I>&#148;) or as &#147;reserve from capital contributions&#148; (&#147;<I>apports de capital</I>&#148;). Distributions out of nominal share capital, which is the aggregate nominal value of a corporation&#146;s issued shares, may be made only
by way of a share capital reduction. See &#147;Description of Share Capital and Articles of Association.&#148;<I> </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth our cash and cash equivalents and our total capitalization (defined as the sum of total debt and
shareholders&#146; equity) as of June&nbsp;30, 2016 derived from our unaudited interim financial statements prepared in accordance with IFRS: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an actual basis; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as adjusted basis to reflect: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(i) the conversion of all shares of our preferred stock
outstanding as of June&nbsp;30, 2016 into an aggregate of 38,577,042 common shares; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ii) the filing and effectiveness of our amended and
restated articles of association; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iii) our receipt in July 2016 of the Anti-Tau Antibody Phase 1 Milestone Payment described under
&#147;Prospectus Summary&#151;Anti-Tau Antibody Phase 1 Milestone Payment&#148;; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(iv) the exercise of options into a total of 4,500
common shares between July 1, 2016 and August&nbsp;31, 2016; and </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on an as further adjusted basis to further reflect the receipt of the estimated net proceeds from the sale of 6,000,000 common shares by us in this offering, after deducting the underwriting discount and estimated
expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this table in conjunction with our audited financial statements included in this
prospectus as well as &#147;Use of Proceeds,&#148; &#147;Selected Financial and Other Information&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements included
elsewhere in this prospectus. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at June 30, 2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As<BR>Further<BR>Adjusted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands)</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">82,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">96,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">155,423</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Common shares nominal value CHF 0.02&nbsp;per share, 10,814,500&nbsp;shares issued and
outstanding, actual; 65,443,542 shares authorized, 49,396,042&nbsp;shares issued and outstanding, as adjusted; and 65,443,542 shares authorized, 55,396,042 shares issued and outstanding, as further adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">216</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">988</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">1,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Preferred shares nominal value CHF 0.02&nbsp;per share, 38,577,042 authorized preferred shares,
38,577,042 preferred shares issued and outstanding, actual; no shares authorized or issued and outstanding, as adjusted or as further adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">772</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Accumulated (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(33,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(33,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">(33,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">90,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">90,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">147,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">90,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">90,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">147,026</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of common shares in the table above excludes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,196,250 of our common shares issuable upon the exercise of vested and unvested options outstanding under our existing equity incentive plans as at August&nbsp;31, 2016 at an exercise price of CHF 0.14548 per common
share; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,300,000 of our common shares issued to Credit Suisse AG, Zurich in the CS AG Share Issuance, as described in Note 7 (Other current liabilities) of our unaudited interim condensed financial statements as at and for the
six months ended June&nbsp;30, 2016 and June&nbsp;30, 2015 included elsewhere in this prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_10"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common shares, your interest will be diluted to the extent of the difference between the initial public offering price
per share and the as adjusted net tangible book value per share of our common shares immediately after this offering and our preferred shares that will convert into our common shares on a one-for-one basis upon the completion of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net tangible book value is determined by dividing our total tangible assets less our total liabilities by the number of our common shares
outstanding. Our historical net tangible book value as of June&nbsp;30, 2016 was $92.7 (CHF&nbsp;90.5) million, or $8.57 (CHF&nbsp;8.37), per common share (on a fully diluted basis). Our as adjusted net tangible book value as at June&nbsp;30, 2016,
before giving effect to this offering was $92.7 (CHF&nbsp;90.5) million, or $1.88&nbsp;(CHF&nbsp;1.83) per common share, based on the total number of our common shares outstanding as at June&nbsp;30, 2016, after giving effect to (i)&nbsp;the
conversion of all preferred stock outstanding as of June&nbsp;30, 2016 into an aggregate of 38,577,042 common shares, (ii)&nbsp;our receipt in July 2016 of the Anti-Tau Antibody Phase&nbsp;1 Milestone Payment described under &#147;Prospectus
Summary&#151;Anti-Tau Antibody Phase&nbsp;1 Milestone Payment&#148; and (iii)&nbsp;the exercise of options into a total of 4,500 common shares between July&nbsp;1, 2016 and August&nbsp;31, 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors represents the difference between the amount per share paid by purchasers of common shares in this
offering and the as further adjusted net tangible book value per common share immediately after completion of this offering. After giving effect to the sale of 6,000,000 common shares in this offering, after deducting the underwriting discount and
estimated expenses payable by us, our as further adjusted net tangible book value as at June&nbsp;30, 2016 would have been $150.5 (CHF&nbsp;147.0) million, or $2.72 (CHF&nbsp;2.65) per share. This represents an immediate increase in as adjusted net
tangible book value of $9.64 (CHF 9.41) per share to existing shareholders and an immediate dilution of $6.92 (CHF&nbsp;6.76) per share to investors participating in this offering, as illustrated in the following table: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Historical net tangible book value per share at June&nbsp;30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As adjusted net tangible book value per share at June&nbsp;30, 2016, before giving effect to this
offering but giving effect to the adjustments described in the second immediately preceding paragraph</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in as adjusted net tangible book value per share attributable to new investors purchasing
shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">As further adjusted net tangible book value per share after giving effect to
this<BR>offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents, on an as further adjusted basis described above, the difference between the
existing shareholders as at June&nbsp;30, 2016 and the purchasers of shares in this offering with respect to the number of shares purchased from us, the total consideration paid, which includes net proceeds received from the issuance of common and
preferred stock and cash received from the exercise of stock options. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration<BR>(USD &#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;Consideration<BR>(CHF &#146;000)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average<BR>Price&nbsp;per<BR>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(USD)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(CHF)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,396,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">127,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,483</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,396,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The calculations above are based on 49,396,042 shares outstanding as at June&nbsp;30, 2016 after
giving effect to (i)&nbsp;the conversion of all preferred stock outstanding as of June 30, 2016 into an aggregate of 38,577,042&nbsp;common shares, (ii)&nbsp;our receipt in July 2016 of the Anti-Tau Antibody Phase 1 Milestone Payment described under
&#147;Prospectus Summary&#151;Anti-Tau Antibody Phase 1 Milestone Payment&#148; and (iii)&nbsp;the exercise of options into a total of 4,500 common shares between July 1, 2016 and August 31, 2016, and exclude 2,196,250 of our common shares issuable
upon the exercise of vested and unvested options outstanding under our existing equity incentive plans at an exercise price of CHF 0.14548&nbsp;per common share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After giving effect to the sale of shares in this offering by us, if the underwriters exercise in full their option to purchase additional
shares from us, our existing shareholders would own approximately 87.7% and our new investors would own approximately 12.3% of the total number of common shares outstanding after this offering, excluding any shares purchased by any existing holders
in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any outstanding options are exercised, new options are issued under our stock-based compensation
plans or we issue additional common shares in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_11"></A>EXCHANGE RATES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, for the periods indicated, the high, low, average and period-end exchange rates for the purchase of U.S.
dollars expressed in CHF per U.S. dollar. The average rate is calculated by using the average of the U.S. Federal Reserve Bank&#146;s reported exchange rates on each day during a monthly period and on the last day of each month during an annual
period. On September 9, 2016, the exchange rate as reported by the U.S. Federal Reserve Bank was CHF&nbsp;1.0235 to $1.00. In this prospectus, translations from CHF to U.S. dollars were made at this rate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Period-end</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Average&nbsp;for<BR>Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(CHF per U.S. dollar)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Years Ended December 31:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8949</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8904</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9814</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.8488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Months Ended:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">January 29, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9972</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">February 29, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9920</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">April 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9536</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">May 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9916</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9777</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9541</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9934</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">June 30, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9792</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9695</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9566</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9902</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">July 31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9690</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9830</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9690</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9936</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">August 31, 2016 </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9830</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9711</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9576</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">0.9838</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September 30, 2016 (through September 9, 2016)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_12"></A>SELECTED FINANCIAL AND OTHER INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following tables summarize our financial data as of the dates and for the periods indicated. The financial data for the years ended
December&nbsp;31, 2015 and 2014 have been derived from our audited financial statements, which have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting Standards Board, or
IASB, and audited in accordance with the standards of the U.S. Public Company Accounting Oversight Board, and included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial data as at June&nbsp;30, 2016 and for the six months ended June&nbsp;30, 2016 and 2015 have been derived from our unaudited
interim condensed financial statements included elsewhere in this prospectus. The unaudited interim condensed financial statements have been prepared on the same basis as our audited financial statements and include all normal recurring adjustments
that we consider necessary for a fair statement of our financial position and operating results as of the dates and for the periods presented. We maintain our books and records in, and our financial statements are prepared and presented in, Swiss
Francs, our presentation currency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our historical results are not necessarily indicative of the results that may be expected in the
future. Our interim financial results for the periods presented are not necessarily indicative of results for a full year or for any subsequent interim period. The following summary financial data should be read in conjunction with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Comprehensive Income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in CHF &#145;000 except for share<BR>and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,624</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,717</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result&#151;net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) before tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income / (loss) for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share in CHF (basic)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share in CHF (fully
diluted)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings per share&nbsp;basic<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,209,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,725,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,412,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,684,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute earnings per share fully&nbsp;diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,101,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,845,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,043,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,552,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes common shares and preferred shares outstanding as of the dates indicated adjusted for the 250-for-1 stock split effected on October 23, 2015, and these preferred shares will be converted on a one-for-one basis
upon the closing of this offering, but does not give effect to the CS AG Share Issuance, as described in Note&nbsp;7 (Other current liabilities) of our unaudited interim condensed financial statements as at and for the six months ended June&nbsp;30,
2016 and June&nbsp;30, 2015 included elsewhere in this prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>As at</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">90,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total equity and liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_13"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion of our financial condition and results of operations should be read in conjunction with &#147;Selected Financial
and Other Information,&#148; and our financial statements included elsewhere in this prospectus. We present our financial statements in Swiss Francs and in accordance with International Financial Reporting Standards, or IFRS, as issued by the
International Accounting Standards Board, or IASB. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The statements in this discussion regarding industry outlook, our strategy, our
expectations regarding our future performance, liquidity and capital resources and other non-historical statements are forward-looking statements. These forward-looking statements are subject to numerous risks and uncertainties, including, but not
limited to, the risks and uncertainties described in &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in this prospectus. Our actual results may differ materially from those contained in or implied
by any forward-looking statements. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel,
proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we
developed using our proprietary SupraAntigen platform. Crenezumab commenced Phase&nbsp;3 clinical studies in the first quarter of 2016 and we believe it has the potential to become a best-in-class disease-modifying treatment for Alzheimer&#146;s
disease, or AD. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab for the treatment of AD under a collaboration agreement with us, pursuant to which it is responsible for the clinical development of
crenezumab, including the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of our other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through
active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate currently in a Phase 1/2a study. We expect to complete this study and announce top line results in the second half of 2016. ACI-24 is also being studied in a
Phase&nbsp;1 clinical study in patients with Down syndrome, a population that is at high risk for AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that we are developing under a collaboration agreement with Janssen. We and Janssen are co-developing ACI-35 through the ongoing Phase 1b clinical study, which we expect to be
completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect Phase 2 clinical studies to begin in 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a passive anti-tau monoclonal antibody candidate is being developed under a collaboration agreement with Genentech. The Phase 1
clinical study in patients with AD and healthy volunteers commenced in the second quarter of 2016, with results expected in the first half of 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also using our Morphomer platform to develop complementary diagnostic products such as positron emission tomography, or PET, ligands,
which are tracers that can directly measure misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific
small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These platforms are our engines for generating novel molecules that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
designed to bind to their targets with high affinity and conformational specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins. All of our
product candidates and our development programs have been derived from our proprietary platforms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have primarily financed our
operations through private placements of preferred securities, in addition to upfront and milestone payments from our collaboration partners. We have no products approved for commercialization and have never generated any revenues from product
sales. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. It may be several years, if ever, before we or our collaboration partners complete pivotal clinical studies and have a
product candidate approved for commercialization and we begin to generate revenue and royalties from product sales. Since our inception, while we have received upfront and milestone payments from our collaboration partners and certain other revenue.
We have also incurred significant operating losses and had accumulated losses of CHF 33.8&nbsp;million as of June&nbsp;30, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic
Collaborations and Licensing Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, we have entered into strategic collaboration agreements with a range of
partners covering a number of our product candidates. We entered into a strategic collaboration with Genentech in November 2006 (as amended in May 2015) regarding the development, manufacture and commercialization of crenezumab, and we refer to this
agreement as the 2006 Genentech agreement. In June 2012, we entered into an additional strategic collaboration agreement with Genentech regarding the development, manufacture and commercialization of our anti-tau antibodies, and we refer to this
agreement as the 2012 Genentech agreement. We expect to capitalize on Genentech&#146;s drug development and regulatory expertise and commercial capabilities to bring our partnered therapeutic products to market. In May 2014, we entered into a
collaboration agreement with Piramal Imaging, a leader in imaging agents, covering our tau PET Imaging tracer. In December 2014, we entered into a strategic collaboration agreement with Janssen regarding the development, manufacture and
commercialization of ACI-35, an anti-tau vaccine. We expect to capitalize on Janssen and Johnson&nbsp;&amp; Johnson&#146;s extensive regulatory expertise and experience in developing, manufacturing and, if approved, commercializing vaccines to bring
ACI-35 to market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we entered into a non-exclusive collaboration with Biogen covering our alpha-synuclein PET imaging
tracer and future initiatives targeted at TDP-43 PET imaging tracers, which is a protein that has been recently linked to neurodegeneration in diseases including AD, PD and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig&#146;s
disease). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab&#151;Collaboration with Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2006 Genentech agreement, we may become entitled to receive upfront and milestone payments totaling up to approximately $340 million,
excluding royalties. We received an upfront payment of $25&nbsp;million in 2006 and are entitled to various milestone payments based on the achievement of specified development and commercialization milestones. To date, we have received payments
totaling $65 million from Genentech, including the $25 million upfront payment and milestone payments totaling $40 million for crenezumab entering into Phase 1, Phase 2 and Phase 3 clinical studies. Under the 2006 Genentech agreement, we are
entitled to various regulatory and marketing approval milestone payments. If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the U.S.
and Europe. These percentage rates range from net high single digits to the mid-teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2006 Genentech agreement also provides for a
second indication for which we would be eligible to receive clinical milestone payments payable upon commencement of each of Phase 2 and 3 of clinical development as well as regulatory and marketing milestone payments similar to those applicable to
crenezumab. If this second indication receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes at the same rates applicable to crenezumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Tau Antibodies&#151;Collaboration with Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the 2012 Genentech agreement, we are entitled to receive upfront and milestone payments in excess of CHF 400&nbsp;million, excluding
royalties. We received an upfront payment of CHF 17&nbsp;million in 2012 and are entitled to various milestone payments based on the achievement of specified clinical, regulatory and commercialization milestones. To date, we have received payments
totaling CHF 45&nbsp;million from Genentech including a milestone payment of CHF 14 million upon the commencement of the Phase 1 clinical study, which we received in July 2016. In addition to milestones, we will be eligible to receive royalties on
sales at a percentage rate ranging from the mid-single digits to low double digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The 2012 Genentech agreement also provides for a
second indication for which we would be eligible to receive clinical milestone payments payable upon commencement of each of Phase 2 and 3 of clinical development as well as regulatory and marketing milestone payments. If this second indication
receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes at the same rates applicable to the lead indication. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tau PET Imaging Tracer&#151;Collaboration with Piramal Imaging </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our agreement with Piramal Imaging covering our anti-tau PET imaging agent, we received an upfront payment of &#128;0.5&nbsp;million in
May 2014 and are entitled to various clinical milestone payments totaling up to &#128;7&nbsp;million based on the achievement of specified development milestones. In addition, we are entitled to further regulatory and sales-based milestones totaling
&#128;150 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35&#151;Collaboration with Janssen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the collaboration agreement with Janssen regarding the development of ACI-35, we may become entitled to receive upfront and milestone
payments totaling up to CHF 500&nbsp;million, plus royalties on sales at a percentage rate ranging from low double digits to mid-teens. To date, we have received an upfront payment of CHF 25.9 million, a research contribution of CHF 1.5&nbsp;million
and a CHF&nbsp;4.9 million clinical milestone payment. The total future payments that we would be entitled to under the agreement for clinical milestones amounts to CHF 77.1&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Alpha-synuclein and TDP-43 PET Imaging Tracers&#151;Collaboration with Biogen </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we entered into a non-exclusive research and development agreement with Biogen covering the research and early clinical
development of our alpha-synuclein PET Tracer program for Parkinson&#146;s disease and other synucleinopathies, and a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to
neurodegeneration in diseases such as amyotrophic lateral sclerosis. Under the agreement, we are entitled to a technology access fee and will receive funding from Biogen towards FTE and research and development activities on both PET imaging
programs. We will retain all intellectual property rights to any PET product developed for further commercialization. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Grants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2011, we were included in a research study focused on Huntington&#146;s disease as part of the 7<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Framework Program of the European Union under the Marie Currie Actions program. This research study was coordinated by the University of T&uuml;bingen and ran over a 3-year period between September
2011 and September 2014. We recognized revenues from this grant on a straight-line basis over the study period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2015, we were
awarded a grant from the Michael J. Fox Parkinson&#146;s Foundation for the further research and development of an alpha-synuclein diagnostic imaging agent. Under the terms of the grant, we retain all rights, results and intellectual property
relating to the program. The grant covers research and development work over a 1.5-year period. We recognize revenues from this grant on a straight line basis over the life of the grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2016, we were awarded a grant from the LuMind Research Down Syndrome Foundation to
support our <FONT STYLE="white-space:nowrap">ACI-24</FONT> Phase&nbsp;1 clinical study in patients with Down Syndrome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our stage
of development, we have not generated any revenue from product sales. Our revenue to date has been derived primarily from four separate collaboration agreements on some of our product candidates in various stages of pre-clinical and clinical
developments and a number of research grants we have secured. For collaborations established on programs in pre-clinical stage, we recognize revenue from upfront payments under our collaboration agreements ratably over the term of our estimated
period of performance under each agreement. For collaboration agreements on product candidates that are (i)&nbsp;in clinical development, (ii)&nbsp;where the upfront payment reflects a payment for past investments we have made in the development of
the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and (iii)&nbsp;where there is no further performance commitment, we recognize the fair value of the upfront payment at the time of
entering into the collaboration agreement. For collaboration agreements with product candidates in clinical development but where the conditions described in clauses (ii)&nbsp;and (iii)&nbsp;above are not met, we recognize the upfront payments
ratably over the term of our estimated period of performance under each agreement. For all of our collaboration agreements, in addition to receiving upfront payments, we are entitled to milestone and other contingent payments upon achieving
pre-defined objectives. Revenue from milestones, if they are non-refundable and deemed substantive, are recognized upon successful accomplishment of the milestones. To the extent that non-substantive milestones are achieved and we have remaining
performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
revenues have experienced significant fluctuations over the past three years as a result of securing new collaboration agreements, the timing of milestone achievement and the size of each milestone payment. We expect that any revenue we generate
from our two collaboration agreements with Genentech, our collaboration agreements with each of Janssen and Piramal Imaging, research and development grants, and any future collaboration partners will fluctuate from year to year as a result of the
timing and amount of milestones and other payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses comprise direct research costs, including the use of CROs, consultants and experts hired to assist on our
research and development activities, consumables used for research and development purposes, employment compensation for our research and development, intellectual property, regulatory affairs, quality control and manufacturing personnel, as well as
expenses related to regulatory affairs and quality control. Our research and development costs include the costs associated with our recurrent maintenance costs associated with our portfolio of intellectual property including patents. In addition,
research and development expenditures include the depreciation of fixed assets used in research and development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The largest component of
our total operating expenses has historically been, and will continue to be, our investment in research and development activities, including the clinical development of our product candidates. Historically, research and development expenses have
represented over 80% of our total annual operating costs. Research and development expenses represent costs incurred to conduct research, such as the discovery and development of our product candidates, as well as development of new product
candidates from our SupraAntigen and Morphomer platforms as well as the development of product candidates pursuant to our collaboration agreements with Genentech, Janssen and Piramal Imaging. We recognize all research and development costs as they
are incurred. Clinical study costs, contract manufacturing and other development costs incurred by third parties are expensed as the contracted work is performed. At present, our research activities comprise five major areas: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AD therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Non-AD therapies that are not neuro-orphans therapies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Neuro-orphan disease therapies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Diagnostics; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">New discovery projects. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the limited financial resources of the Company, we have
historically allocated over 70% of our research and development budget to AD therapies. We expect our research and development expenses to increase substantially in the future and expect to fund a broader number of projects. Specifically, the
planned capital raising will impact our research strategy in four key ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">we expect to undertake later-stage research and development of our product candidates and, if approved, to take some of those product candidates into commercialization; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">we will allocate more funding to existing programs to advance the development of these programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">we will increase our research and development efforts on non-AD indications including neuro-orphans; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">we will initiate a number of new research initiatives that are complementary to our existing and planned research initiatives. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, research initiatives targeting AD will continue to be the primary focus of our research efforts. However, other indications
including PD, selected neuro-orphans and diagnostics are likely to consume an increasing share of the total research and development expenditures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below provides a breakdown of our research and development costs, including direct research and development costs and manufacturing
costs related to research and development, by major development program for the periods covered by this &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; section. These research and development
costs exclude employment costs, regulatory, quality assurance and intellectual property costs. With the exception of ACI-35, research costs that are subject to collaboration agreements typically have a limited amount research expenses since our
partners bear most or all of the research and development costs. We have shown below our research and development costs associated with advancing ACI-35, the tau vaccine candidate that is being developed jointly with Janssen, since pursuant to our
agreement we are required to provide significant research support for this program until the end of 2016. Our research and development costs for ACI-24 for AD and Down syndrome are expected to increase significantly in the coming years as we fund
Phase 2b and Phase 1 clinical studies for ACI-24 in AD and ACI-24 in Down syndrome, respectively. Research and development costs for our alpha-synuclein PET tracer diagnostics program and other new discovery areas are also likely to rise
substantially in the coming years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Detailed Research and Development Expenditures by Major Development Program </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months<BR>Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended </B><br><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in&nbsp;CHF&nbsp;thousands) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" COLSPAN="10" ALIGN="center"><B>(in&nbsp;CHF&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Programs subject to collaboration agreements(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(317</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACI-35</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,222</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ACI-24 (for AD and Down syndrome)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(423</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PD (therapeutics and diagnostics)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">757</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New discovery programs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,254</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes research and development expenditures for crenezumab, anti-tau antibodies and tau PET imaging tracer. Does not include research and development expenditures for ACI-35. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses include personnel costs, expenses for outside professional services, and all other allocated expenses.
Personnel costs consist of salaries, cash bonuses, benefits and share-based compensation. Outside professional services consist of legal, accounting and audit services, IT and other consulting fees. Allocated expenses consist of rent expense related
to our office and research and development facility. We expect to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, and those of any national
securities exchange on which our securities are then traded (including the NASDAQ on which we intend to list our common shares in connection with this offering), additional insurance expenses, investor relations activities and other administrative
and professional services. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial expenses are bank fees associated with charges levied by banks on foreign payments and foreign exchange transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income consists of interest received from banks on our cash balances. Other financial income relates principally to gains that we
have made historically on foreign currency transactions, which arise from the fact that some of our collaboration agreements such as the collaboration agreements with Janssen and Piramal Imaging are in currencies other than Swiss Francs, and
selected purchases, which we effect in foreign currencies. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Taxation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to corporate taxation in Switzerland. In 2005, the Canton of Vaud granted us a ten-year tax holiday for all income and capital
taxes on a communal and cantonal level commencing in fiscal 2005 and valid through to 2014. In 2005, under a ruling created by the Swiss Federal Government to encourage the creation of new enterprises, we were granted a tax holiday of nine years
from inception. Both tax holidays expired on December&nbsp;31, 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also entitled under Swiss laws to carry forward any losses
incurred for a period of seven years and can offset our losses carried forward against future taxes. As of December 31, 2015, we had tax loss carryforwards totaling CHF 29.1&nbsp;million. There is no certainty that we will make sufficient profits to
avail ourselves of these tax loss carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The corporate tax rate in the Canton of Vaud where we are domiciled is currently 22.5%.
The Canton does from time to time, amend the level of taxation levied on corporations and there is no certainty that the tax rate currently in effect will not change in the future. At present, there are discussions on lowering the corporate tax rate
in the Canton of Vaud to below 15% by 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Value Added Tax, or VAT, is charged on all qualifying goods and services by VAT-registered
businesses. An amount of 8.0% of the value of the goods or services is added to all sales invoices and is payable to the Swiss tax authorities. Similarly, VAT paid on purchase invoices is reclaimable from the Swiss tax authorities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the First Six Months Ended June&nbsp;30, 2016 and June&nbsp;30, 2015 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
summarizes our revenues during the six months ended June&nbsp;30, 2016 and 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six<BR>Months&nbsp;Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B></B><I></I><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">20,451</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues rose to CHF 20.5&nbsp;million for the six months ended June&nbsp;30, 2016 from CHF
14.4&nbsp;million for the six months ended June&nbsp;30, 2015, an increase of CHF 6.1 million. The increase in revenues was principally attributable to an increase in collaboration revenues. Specifically, in the first half of 2016, pursuant to the
collaboration agreement with Janssen for ACI-35, we received a payment of CHF 1.5&nbsp;million in January 2016 to cover part of our research costs associated with this program and a CHF 4.9&nbsp;million milestone payment. In addition, in June we
recognized revenues of CHF 14.0&nbsp;million related to achieving a clinical milestone in our collaboration on the anti-tau antibody program with Genentech. The CHF 4.9&nbsp;million and CHF 14.0&nbsp;million milestone payments are non-refundable and
there is no further performance obligation and, as a result, we recognized the amounts as revenues. As there is a performance obligation to the end of the Phase 1b clinical study which we expect will be completed in late 2016, we are recognizing the
revenues related to the Janssen CHF 1.5&nbsp;million research contribution on a straight line basis through December&nbsp;31, 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses during the six months ended
June&nbsp;30, 2016 and 2015: </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six</B><br><B>Months Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,011</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,597</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,271</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">11,018</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses increased to CHF
11.0&nbsp;million for the six months ended June&nbsp;30, 2016 from CHF 7.2&nbsp;million for the six months ended June&nbsp;30, 2015, an increase of CHF 3.8 million. The significant increase in research and development costs is attributable to three
key factors: (i)&nbsp;increased expenditures on direct research and development costs totaling CHF 3.2&nbsp;million due principally to increased expenditures on ACI-35, ACI-24 and our new discovery programs, (ii)&nbsp;increased expenditures on
manufacturing and quality assurance and increased regulatory costs, and (iii)&nbsp;greater wage expenses due to additional headcount in our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
research and development team. Pursuant to our collaboration agreement with Janssen for ACI-35, we committed to spend a total of CHF 13.8&nbsp;million over a two-year period starting in January
2015 to help bring ACI-35 to the end of the Phase 1b clinical trial. Because the scope of the Phase 1b clinical trial was not agreed to until mid 2015, we spent less than CHF 1.3 million, excluding wages, on research and development activities
related to ACI-35 in the first half of 2015. In contrast, in the six months period ended June&nbsp;30, 2016, research and development expenses totalled CHF 2.5&nbsp;million, excluding wages. Similarly, during the first quarter of 2016, we spent CHF
1.9&nbsp;million on the ACI-24 programs, as compared to CHF 0.6&nbsp;million for the first six months ended June&nbsp;30, 2015 while more than doubling the outlay on R&amp;D expenditures on new discovery programs from CHF 0.4&nbsp;million in the
first half of 2015 to CHF&nbsp;1.1&nbsp;million in the first half of 2016. As we are in the process of transitioning from an early stage development company to a more mature company, we are having to make substantial investments to upgrade and
improve our manufacturing infrastructure. As a result, in the six month period ended June&nbsp;30, 2016 we spent over CHF&nbsp;2.0&nbsp;million on manufacturing related initiatives, as compared to the CHF 0.8&nbsp;million we spend in the six months
period ended June&nbsp;30, 2015. We have added a total of nine employees to our research and development team which has resulted in our wages and share based compensation attributable to research and development staff rising to CHF 3.3&nbsp;million
for the first six months of 2016 from CHF 3.0&nbsp;million for the same period in 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses during the six months ended June&nbsp;30, 2016 and 2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six<BR>Months<BR>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,689</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">756</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,750</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the six months ended June&nbsp;30, 2016 our general and administrative expenses totaled CHF
2.8&nbsp;million, up CHF 1.0&nbsp;million from the CHF 1.7&nbsp;million we incurred during the six months ended June&nbsp;30, 2015. The increase is due primarily with increased wage costs and information technology costs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our financial income and expenses during the six months ended June&nbsp;30, 2016 and 2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months<BR>Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense and bank fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gain / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial (expense) / income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial income amounted to CHF 0.1&nbsp;million for the six months period ended June&nbsp;30, 2016
compared with net financial income of CHF 0.2&nbsp;million for the six months period ended June&nbsp;30, 2015. The principal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
difference in the net financial result is attributable to (i)&nbsp;fees payable on the CS AG Share Issuance and (ii)&nbsp;the net impact of foreign exchange movements on our financial assets and
payables owed by us during the reporting periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comparison of the Years Ended December&nbsp;31, 2015 and 2014 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table
summarizes our revenues during the years ended December&nbsp;31, 2015 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Total revenues rose to CHF 39.1&nbsp;million for the year ended December&nbsp;31, 2015 from CHF
30.3&nbsp;million for the year ended December&nbsp;31, 2014, an increase of CHF 8.8 million. The increase was principally due to collaboration and license revenues rising to CHF 38.8&nbsp;million for the year ended December&nbsp;31, 2015 from CHF
30.2&nbsp;million for the year ended December&nbsp;31, 2014. In 2015, we recognized revenue from two collaboration agreements, including a $25 million milestone payment related to our collaboration with Genentech for crenezumab and a CHF
14&nbsp;million milestone payment associated with the Genentech collaboration agreement for our anti-tau antibody. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development
Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our research and development expenses during the years ended December&nbsp;31, 2015 and
2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation. </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development expenses rose to CHF
17.0&nbsp;million for the year ended December&nbsp;31, 2015 from CHF 16.1&nbsp;million, an increase of CHF 0.9&nbsp;million, as compared to year ended December&nbsp;31, 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2015 our research and development operating costs increased by CHF 0.5&nbsp;million to CHF
10.5&nbsp;million due principally to the increase in expenditures related to ACI-35 which we are developing jointly with Janssen. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
salaries and related costs related to our research and development activities rose by CHF 0.5&nbsp;million to CHF 6.3&nbsp;million for the year ended December&nbsp;31, 2015 from CHF 5.8&nbsp;million for the year ended December&nbsp;31, 2014. The
increase is due to an average increase in the base compensation of 1.4% and the addition of two scientists to our research and development team. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share based compensation related to our research and development employees rose to CHF
0.4&nbsp;million for the year ended December&nbsp;31, 2015 from CHF 0.2&nbsp;million for the year ended December&nbsp;31, 2014. The increase is primarily due to the fact that the company valuation used as the basis for expensing share based
compensation was nearly doubled during 2015 compared to 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our general and administrative expenses during the years ended December&nbsp;31, 2015 and 2014: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Salaries and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses for the year ended December&nbsp;31, 2015 were CHF 3.4&nbsp;million which
is in line with the CHF 3.4&nbsp;million for the year ended December&nbsp;31, 2014. It should be noted that CHF 2.2&nbsp;million of costs associated with the preparations for becoming a public company in the United States were not expensed in the
year ended December&nbsp;31, 2015 but rather were accrued and carried forward into 2016 and appear under prepaid expenses on our balance sheet for the year ended December&nbsp;31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financial Income and Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
following table summarizes our financial income and expenses during the years ended December&nbsp;31, 2015 and 2014: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense and bank fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net foreign exchange gain / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total financial (expense) / income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,619</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net financial income increased to CHF 1.6&nbsp;million for the year ended December&nbsp;31, 2015 from CHF
27&nbsp;thousand for the year ended December&nbsp;31, 2014. The increase was driven primarily by gains related to foreign exchange rates on our cash balances in US dollars as well as an increase in the interest income due to significantly higher
cash balances on hand during the year in 2015 as compared to 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our operations have been financed primarily by proceeds from the collaboration and license agreements we have with a number of partners,
including Genentech, Janssen and Piramal Imaging, research grants awarded to us and net proceeds from the issuance of preferred shares. At June&nbsp;30, 2016, we had cash and cash equivalents of CHF 82.4&nbsp;million. At June&nbsp;30, 2016, after
giving effect to the CHF 14&nbsp;million milestone payment from Genentech for the anti-tau antibody program, we would have had cash and cash equivalents of CHF 96.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of capital are, and we expect will continue to be, research and development
expenses, compensation and related expenses, and other operating expenses including rent. Cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and
accrued expenses. We expect to incur substantial expenses in connection with a number of our product candidates in various stages of clinical development including co-funding ACI-35 to the end of the ongoing Phase 1b clinical study, material
increases in spending on ACI-24 in AD to fund a Phase 2b study, ACI-24 in Down syndrome, our PET imaging candidates focused on alpha-synuclein and TDP-43 which we are developing together with Biogen and a number of research initiatives focused on
neurodegenerative orphan diseases other than AD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to continue to fund our operating and capital funding needs through proceeds
received from collaboration and licensing agreements and through equity or other forms of financing. We may also consider entering into additional collaboration agreements and selectively partnering for clinical development and commercialization.
The sale of additional equity would result in additional dilution to our shareholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash Flows </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of the First Six Months Ended June&nbsp;30, 2016 and 2015 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,202</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,302</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities was CHF 7.2&nbsp;million for the six months ended June&nbsp;30, 2016 compared with net cash generated in
operating activities of CHF 16.1&nbsp;million for the six months ended June&nbsp;30, 2015. The significant change in cash used in operating activities in the first six months of 2016 was due to (i)&nbsp;our outstanding receivables balances growing
substantially in the first half of 2016 due to the notification in late June by Genentech that the anti-tau antibody program had moved into Phase&nbsp;1 clinical studies triggering a CHF 14&nbsp;million milestone payment while receivables declined
sharply during the same period in 2015 due to the receipt of the CHF 25.9 million upfront payment from Janssen related to the collaboration agreement on ACI-35 which was partially offset by the addition of a CHF 14 million receivable from Genentech
related to the ED-GO milestone payment, (ii)&nbsp;our prepaid expense balances rising from CHF 0.4&nbsp;million to CHF 1.8 million between June&nbsp;30, 2015 and June&nbsp;30, 2016 while (iii)&nbsp;the amount of deferred revenues rose by
CHF&nbsp;2.1 million between June&nbsp;30, 2015 and June&nbsp;30, 2016 and (iv)&nbsp;the change in accounts payable positively impacted our cash position between June&nbsp;30, 2015 and June&nbsp;30, 2016 by CHF 0.9&nbsp;million. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in
investing activities rose to CHF 0.3&nbsp;million for the six months ended June&nbsp;30, 2016 compared with net cash used in investing activities of CHF 0.1&nbsp;million in the six months ended June&nbsp;30, 2015 due to increased capital
expenditures to strengthen our manufacturing and research infrastructure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was CHF 13.2&nbsp;million for the six months ended June&nbsp;30, 2016 compared with net cash from
investing activities of CHF 6&nbsp;thousand for the six months ended June&nbsp;30, 2015. The increase is principally due to the completion of the Series E Extension (CHF 13.3 million) in April 2016, proceeds from the issuance of shares related to
option exercises (CHF&nbsp;0.2&nbsp;million) and proceeds from issuance of shares under the CS AG Share issuance (CHF 0.1 million). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comparison of
the Years Ended December&nbsp;31, 2015 and 2014 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in CHF thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(131</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(113</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,778</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,572</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The net cash provided by operating activities rose to CHF 44.1&nbsp;million for the year ended December&nbsp;31, 2015 from net cash used by
operating activities of CHF 17.6&nbsp;million for the year ended December&nbsp;31, 2014. The significant improvement is driven by three key factors: (i)&nbsp;a significant change in our current receivables which amounted to CHF 0.3&nbsp;million for
the year ended December&nbsp;31, 2015 compared with CHF 25.9&nbsp;million for the year ended December&nbsp;31, 2014 driven by the receipt of the upfront payment from Janssen related to our collaboration on ACI-35, (ii)&nbsp;we generated a net income
of CHF 20.3&nbsp;million for the year ended December&nbsp;31, 2015 compared with net income of CHF 10.7&nbsp;million for the year ended December&nbsp;31, 2014 and (iii)&nbsp;a reduction in the amount deferred revenue which declined to CHF
0.2&nbsp;million for the year ended December&nbsp;31, 2015 from CHF 3.7&nbsp;million for the year ended December&nbsp;31, 2014. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing activities
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was CHF 0.2&nbsp;million for the year ended December&nbsp;31, 2015, compared with CHF
0.1&nbsp;million for the year ended December&nbsp;31, 2014. The CHF 0.1&nbsp;million increase was due to a slight increase in investments in fixed assets in the laboratory. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Financing activities </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided
by financing activities was CHF 27.8&nbsp;million for the year ended December&nbsp;31, 2015, compared to CHF 9.8&nbsp;million for the year ended December&nbsp;31, 2014. The increase was driven primarily by the $30 million Series E Private Placement
which we completed in October 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Operating Capital Requirements and Plan of Operations </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not expect to generate revenues from royalties based on product sales unless and until our partners obtain regulatory approval of and
commercialize our current or any future product candidates. As of June&nbsp;30, 2016 we had cash balances totaling CHF 82.4&nbsp;million. The increase relative to December&nbsp;31, 2015 is due to the proceeds we received from the Series&nbsp;E
Extension in April 2016, partially offset by a significant rise in total operating expenses driven by CHF 3.8&nbsp;million spent on research and development. There can be no certainty as to the exact timing, or in fact whether any future milestone
payments will ever be made given that these </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
milestone payments are contingent on clear milestones being reached. Accordingly, assuming we do not receive potential milestone payments and based upon our currently contemplated research and
development strategy and expenditures and assuming our receipt of the net proceeds from this offering in the amount of $57.8, we believe that our existing capital resources (including the proceeds we received from Genentech, as described below under
&#147;&#151;Anti-Tau Antibody Phase 1 Milestone Payment&#148;) will be sufficient to meet our projected operating requirements up to the fourth quarter of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to generate losses for the foreseeable future, and these losses could increase as we continue product development and if we
successfully achieve regulatory approvals for our product candidates and begin to commercialize any approved products. We are subject to all the risks pertinent to the development of new products, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may harm our business. Upon closing of this offering, we expect to incur additional costs associated with operating a public company and we anticipate that we will need substantial
additional funding in connection with our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we need to raise additional capital to fund our operations and
complete our ongoing and planned clinical studies, funding may not be available to us on acceptable terms, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding
requirements will depend on many factors, including but not limited to the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The scope, rate of progress, results and cost of our pre-clinical and clinical studies and other related activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The cost of manufacturing clinical supplies and establishing commercial supplies of our product candidates and any other products we may develop; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The cost, timing and outcomes of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The costs and timing of establishing sales, marketing and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The terms and timing of any collaborative, licensing and other arrangements that we may establish, including any required milestone and royalty payments thereunder; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The emergence of competing technologies or other adverse market developments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The potential cost and timing of managing and protecting our portfolio of intellectual property. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Internal
Control over Financial Reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In preparing our financial statements as of and for the years ended December 31, 2014 and
December&nbsp;31, 2015 and reviewing our interim financial statements as of June&nbsp;30, 2016, a material weakness in our internal control over financial reporting was identified, as defined in the SEC guidelines for public companies. The material
weakness identified relates specifically to the accounting for and disclosure of non-routine and complex accounting transactions and the related internal controls and processes supporting these areas. As a result, there is a reasonable possibility
that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are in the
process of implementing improvements and remedial measures in response to these assessments and recommendations, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assembling a team from our finance department to be responsible for the preparation of financial statements under U.S. Securities laws, including hiring additional qualified personnel as necessary; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">organizing regular training sessions on IFRS for our finance department in the form of workshops, seminars and newsletters as well as requiring our finance personnel to participate in annual in-house or public IFRS
training courses; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">setting up an internal audit department to review our internal control processes, policies and procedures to ensure compliance with the Sarbanes-Oxley Act. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we have been implementing these measures, the implementation of these measures has not fully remediated the material weakness and
they may not fully address this material weakness in our internal control over financial reporting, and we therefore may not be able to conclude that it has been fully remedied. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue Recognition </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
historically generated revenues from funds received under collaboration and license agreements as well as research grants. Revenues from research activities made under collaboration arrangements are recognized when there is persuasive evidence that
an arrangement exists, services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Since our inception, we have entered into strategic collaboration agreements with a range of partners covering a number
of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For collaborations established on programs in pre-clinical stage, we recognize revenue from upfront payments
under our collaboration agreements ratably over the term of our estimated period of performance under each agreement. For collaboration agreements on product candidates that are (i)&nbsp;in clinical development, (ii)&nbsp;where the upfront payment
reflects a payment for past investments we have made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and (iii)&nbsp;where there is no further performance
commitment, we recognize the fair value of the upfront payment at the time of entering into the collaboration agreement. For collaboration agreements with product candidates in clinical development but where the conditions described in clauses
(ii)&nbsp;and (iii)&nbsp;are not met, we recognize the upfront payments ratably over the term of our estimated period of performance under each agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record amounts received prior to satisfying the above revenue recognition criteria as deferred revenue until all applicable revenue
recognition criteria are met. Deferred revenue represents the portion of research or license payments received that have not been earned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Milestones are considered substantive if all of the following conditions are met: (i)&nbsp;the milestone is non-refundable,
(ii)&nbsp;achievement of the milestone was not reasonably assured at the inception of the arrangement, (iii)&nbsp;substantive effort is involved to achieve the milestone and (iv)&nbsp;the amount of the milestone appears reasonable in relation to the
effort expended, and the other milestones in the arrangement and the related risk associated with the achievement of the milestone and any ongoing research and development or other services are priced at fair value. Such payments that are contingent
upon achievement of a substantive milestone are recognized entirely as revenues in the period in which the milestone is achieved. To the extent that <FONT STYLE="white-space:nowrap">non-substantive</FONT> milestones are achieved and we have
remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. If there are no remaining performance obligations, we recognize the revenue in the period it is earned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grants provide funding for certain types of expenditures in connection with research and development activities over a contractually-defined
period. Revenue related to grants is recognized in the period during which the related costs are incurred and the related services are rendered, provided that the applicable performance obligations under the grants have been met. We intend to
continue to evaluate pursuing additional grant opportunities on a case-by-case basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record accrued expenses for estimated costs of our research and development activities conducted by third party service providers, which
include amongst others the conduct of preclinical studies and clinical studies and contract manufacturing activities. We record accrued expenses for estimated costs of our research and development activities based upon the estimated amount of
services provided but not yet invoiced, and we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
include these costs in accrued liabilities on the balance sheets and within research and development expenses in the statement of operations and comprehensive income. These costs are a
significant component of our research and development expenses. We record accrued expenses for these costs based on the estimated amount of work completed in accordance with agreements established with these third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the amount of work completed through discussions with our project leaders and external service providers as to the progress or
stage of completion of the services and the agreed-upon fee to be paid for such services. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued
estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed, the number of patients enrolled and the rate of patient enrollment may
vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party
service providers. To date, there have been no material differences from our accrued expenses to actual expenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Share-Based Compensation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in
exchange for the grant of options and shares is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting
conditions. Non-market vesting conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are
expected to become exercisable. It recognizes the impact of the revision of original estimates, if any, in the income statement, and a corresponding adjustment to equity over the remaining vesting period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We recorded share-based compensation expense related to options granted of CHF 0.5&nbsp;million and CHF 0.2&nbsp;million in each of the years
ended December&nbsp;31, 2015 and 2014, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Term </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The expected term represents the period that share-based awards are expected to be outstanding. We used the simplified method to determine the
expected term, which is calculated as the mid-point between the vesting date and the end of the contractual term of the options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Volatility
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since we are not yet a public company and do not have any trading history for our common shares, the expected volatility was estimated
based on the average historical volatilities of common shares of comparable publicly traded entities over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on similar geographic location,
similar size, and similar stage in the life cycle or area of specialty. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Risk-Free Interest Rate </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The risk-free
rate is based on long dated Swiss government zero coupon bond issues in effect at the time of the grant for periods corresponding with the expected term of the option. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expected Dividends </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never paid
dividends on our common shares and have no plans to pay dividends on our common shares. Therefore, we used an expected dividend yield of zero percent. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to Black-Scholes assumptions, we estimate our forfeiture rate based on our actual
forfeitures and continue to evaluate the adequacy of the forfeiture rate based on the actual forfeiture experience, analysis of employee turnover behavior and other factors. The impact from any forfeiture rate adjustment would be recognized in full
in the period of adjustment, and if the actual number of future forfeitures differs from our estimates, we might be required to record adjustments to share-based compensation in future periods. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, for all periods prior to this offering, the fair value of the common shares underlying our share-based awards was estimated on
each grant date by our management and approved by our board of directors. In order to determine the fair value of our common shares underlying option grants, our board of directors considered, among other things, the breadth of our product candidate
portfolio, the stages of development of our various product candidates and major changes to stage of development, the progress and additions to our collaboration agreements, risks inherent in our activities, the lack of liquidity of our companies
securities and the valuations and sentiment toward biotech companies. Given the absence of a public trading market for our common shares, our board of directors exercised reasonable judgment and considered a number of objective and subjective
factors to determine the best estimate of the fair value of our common shares, including our stage of development, progress of our research and development efforts, the strength of our balance sheets and capital base, equity market conditions
affecting comparable public companies and the lack of liquidity marketability of our common shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of 2015 Option Plan </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We grant options at the outset of the award period with the options vesting over a four year period. In line with IFRS accounting principles
for option awards, we are using the graded methodology to expense the fair value of the awards on a straight line basis over the four year vesting period of the options. Specifically, the accounting rules require us to recognize that four separate
options with four separate option periods were issued. Consequently, in year one, we need to expense (i)&nbsp;the fair value of the awards issued in the first year, (ii)&nbsp;one half of the fair value of the awards to be issued in year two,
(iii)&nbsp;one third of the value of the awards to be issued in year three and (iv)&nbsp;one quarter of the fair value of the options issued to be in year four. The result in the change in the way we expense options means that we are recognizing a
larger expense in years one and two (relative to the traditional straight line expensing method) while recognizing a smaller expense in years three and four (relative to the traditional straight line expensing method). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Plan A Stock Option Plan </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
2015, we amended the Plan A stock option plan that we developed in 2004. Two key amendments were made to the program: (i)&nbsp;the duration of the stock option plan was increased by two years from 10.5 to 12.5 years and (ii)&nbsp;the split adjusted
strike price of the option was reduced from CHF 0.93188 per share to a split adjusted strike price of CHF 0.14548 per share. The lengthening of the plan&#146;s term and lowering of the strike price was effected to bring the plan in line with our
other plans, and resulted in a material increase in the value of the options to the option holders and required us to recognize the impact of the transfer in value on our accounts in the first half of 2015. The impact of the amendment of the Plan A
stock option plan totaled CHF 0.4 million. There are no further expenses that we need to recognize in the future associated with this plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Acceleration of Options </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The original
terms of our Stock Option Plan of 2005 (Plan C) contained a provision that would result in the automatic acceleration of all unvested options upon the consummation of an initial public offering.&nbsp;Pursuant to a board resolution on October 13,
2015 the Stock Option Plan of 2005 was amended and the automatic acceleration feature was removed.&nbsp;Instead, employees (excluding executive officers and board members) have the right, but not the obligation, to have their unvested options
accelerated such that they vest immediately.&nbsp;A total of 1,250 options could be accelerated upon completion of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
board of directors has the authority to accelerate the vesting of all outstanding unvested options granted to employees prior to July 2014, in the event of an initial public offering. Pursuant to a board decision on September 18, 2015, if we
successfully complete this offering, the board will accelerate 76,000 options which were granted to directors and executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Other Commitments</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have been a tenant at our current location in the EPFL Innovation Park since shortly after our inception in 2003. We have entered into
long-term rental lease agreements with respect to these facilities. However, our lease agreements are structured such that we can exit these lease agreements without penalty provided we give the owner of our premises sufficient notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subsequent Event </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Tau Antibody Phase 1
Milestone Payment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2016, Genentech, our collaboration partner informed us that the first patient has been dosed in a
Phase&nbsp;1 clinical study for Alzheimer&#146;s disease with an anti-tau monoclonal antibody, making us eligible to receive a milestone payment of CHF 14.0 million, which we received in July 2016. For more information on our collaboration agreement
with Genentech, see &#147;&#151;Strategic Collaborations and Licensing Agreements&#151;Anti-Tau Antibodies&#151;Collaboration with Genentech&#148; and &#147;Business&#151;License Agreements and Collaborations&#151;Genentech.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
have any material off-balance sheet arrangements or commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Quantitative and Qualitative Disclosures about Market Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market risk arises from our exposure to fluctuation in interest rates and currency exchange rates. We are exposed to market risks in the
ordinary course of our business, which are principally limited to foreign currency exchange rate fluctuations and to a lesser degree, interest rate fluctuations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As at June&nbsp;30, 2016 we had cash and cash equivalents of CHF 82.4&nbsp;million, which consisted exclusively of bank deposits. Such
interest-earning instruments carry a degree of interest rate risk. However, historical fluctuations of interest income have not been significant and have been principally impacted by the change in our cash balances as opposed to changes in interest
rates received on the cash balances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not been exposed nor do we anticipate being exposed to material risks due to changes in
interest rates. A hypothetical 10% change in interest rates during any of the periods presented would not have had a material impact on our financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a number of collaboration agreements where the upfront payments, milestone payments and future royalty payments are not denominated in
Swiss Francs, our reporting currency. Furthermore, many of our research and development activities are subcontracted including to parties outside of Switzerland and we purchase materials from suppliers outside of Switzerland. As a result, we are
exposed to foreign exchange risk. Approximately 40% of our total costs are incurred in currencies other than the Swiss Franc. Due to the size of some of the income received from collaboration agreements but also the high percentage of our costs
indirectly being in foreign currencies, a hypothetical 10% change in exchange rates relative to the Swiss Franc could have a material impact on our financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_14"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage
biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding.
Misfolded proteins are generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and
alpha-synuclein. We believe that our large and diverse pipeline of seven therapeutic candidates and three diagnostic candidates has the potential to drive a paradigm shift in the treatment of a broad spectrum of neurodegenerative and other diseases
related to protein misfolding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta
antibody that we developed using our SupraAntigen&#153; platform. Crenezumab commenced Phase 3 clinical studies in the first quarter of 2016. Genentech, Inc., a wholly owned subsidiary of Roche, or Genentech, is advancing crenezumab under a
collaboration agreement with us for the treatment of AD, a progressive neurodegenerative disease that affected an estimated 9.0&nbsp;million people in the United States, the United Kingdom, Western Europe, Japan, China and India in 2013. Under this
collaboration agreement, Genentech is responsible for the clinical development of crenezumab, including the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs and sales and marketing costs. We believe
our collaboration with Genentech validates our technology and crenezumab&#146;s potential to become a best-in-class disease-modifying treatment for AD. We are eligible to receive up to $340 million in total payments from Genentech, as well as sales
royalties. Crenezumab has received Fast Track designation from the U.S. Food and Drug Administration, or FDA. The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that are designed to treat a serious or
life-threatening condition and demonstrate the potential to address unmet medical needs, as further described under &#147;&#151;Government Regulation and Our Regulatory Department&#151;Product Approval Process.&#148; In 2012, crenezumab was
independently selected by the National Institute of Health, or NIH, the Banner Alzheimer&#146;s Institute and Genentech for use in the first-ever AD prevention study, which serves as the cornerstone of the global Alzheimer&#146;s Prevention
Initiative. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If approved, crenezumab has the potential to treat the underlying cause of the disease and intervene at an earlier stage of
AD progression, prior to irreversible neuronal damage. We believe that crenezumab is ideally positioned to be at the forefront of disease-modifying and preventive medicine. We believe the key advantages of crenezumab include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Unique mechanism of action:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Recognizes and binds to multiple forms of misfolded Abeta, a protein commonly associated with AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Helps to protect against neurotoxicity due to high affinity for the multiple forms of misfolded Abeta. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Promotes disaggregation of existing Abeta aggregates and disrupts their assembly to prevent amyloid plaque formation, which is associated with AD. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Clears misfolded Abeta from the brain while limiting inflammation. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Signal of activity in milder AD patients in Phase 2 studies:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ABBY cognition study: although the study did not meet its co-primary endpoints, which were assessments under the
ADAS-cog and CDR-Sum of boxes, the sample size was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in
Phase&nbsp;2 studies </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
in AD). Instead, consistent trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of development, with confirmation then sought in
Phase 3. The results showed trends favoring crenezumab in the milder patient population. Notably, in an exploratory analysis, the high-dose crenezumab arm showed a non-significant slowing of cognition in the overall and mildly demented populations,
which was statistically significant (p=0.036) with a 35% slowing of the rate of cognitive decline measured by the ADAS-cog Scale over 73 weeks in patients with the non-pre-specified milder cognitive impairment (Mini-Mental State Examination score,
or MMSE, of 22-26). The MMSE is a widely used test of overall cognitive function, which assesses memory, orientation and ability to perform simple tasks. Scores range from 0 (worst) to 30 (best) with a score of 0-11 indicating severe dementia, a
score of 12-19 indicating moderate dementia and a score of 20-26 indicating mild dementia. Statistical significance is an indicator of the likelihood of an observed effect being due to the study drug rather than due to chance. The &#147;p&#148;
value is the probability of an event occurring by chance alone. When the p value is less than 5% (0.05) the results are considered to be statistically significant. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">BLAZE biomarker study: the high-dose crenezumab arm showed a consistent trend of reduced Abeta accumulation in the brain over time and a significant increase in cerebrospinal fluid, or CSF, which suggests that Abeta is
being removed from the brain when patients are treated with crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B><B></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Unique mechanism of action linked to the reduced ability to cause inflammation-related vasogenic edema, an accumulation of fluid in the brain that can lead to headaches, loss of coordination and disorientation.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 clinical data showed a very low incidence of vasogenic edema. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A Phase 1 study is ongoing to study crenezumab at higher doses to potentially increase the efficacy signal. This study has helped define the design of the Phase 3 clinical study. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Two of our other clinical product candidates, ACI-24 and ACI-35, are being developed using our SupraAntigen platform and target AD through
active immunization, where the immune system is stimulated to make its own antibodies against pathological proteins: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-24 is our wholly-owned anti-Abeta vaccine candidate that is T-cell independent, meaning it can generate an antibody response in the absence of T-cells. This product candidate is currently in a Phase 1/2a clinical
study to evaluate safety, tolerability, immunogenicity and biomarker endpoints in patients with mild to moderate AD in Europe. We expect to complete our Phase 1/2a clinical study of ACI-24 and announce top line results in the second half of 2016.
ACI-24 is also being studied in a Phase 1 clinical study in patients with Down syndrome, a population which is at high risk for AD, and we expect to present the data from this study in 2018. A protocol amendment for the Phase 1b study of <FONT
STYLE="white-space:nowrap">ACI-24</FONT> was submitted to the FDA in September 2015. Phase 1 and 2 studies are also currently ongoing in Finland, Sweden and Denmark. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ACI-35 is an anti-tau vaccine candidate that is T-cell independent. We are developing ACI-35 under a collaboration agreement with Janssen, which we entered into in December 2014. A Phase 1b clinical study to evaluate
the safety, tolerability and immunogenicity of ACI-35 in patients with mild to moderate AD is ongoing in Finland and the United Kingdom. We and Janssen are co-developing <FONT STYLE="white-space:nowrap">ACI-35</FONT> through this ongoing Phase 1b
clinical study, which we expect to be completed in the fourth quarter of 2016. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. We expect Phase 2 clinical
studies to begin in 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, our passive anti-tau monoclonal antibody candidate is being developed under a
collaboration agreement with Genentech, which we entered into in June 2012. The anti-tau antibody candidate is a humanized monoclonal antibody that is believed to bind specifically to tau. A Phase&nbsp;1 clinical study conducted by Genentech will
evaluate the safety, tolerability and pharmacokinetics in patients with mild to moderate Alzheimer&#146;s disease and healthy volunteers. The Phase 1 clinical study commenced in the second quarter of 2016, with results expected in the first half of
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical evidence suggests that early detection of neurodegenerative diseases is critical to enhancing the effectiveness of both
symptomatic and disease-modifying therapies. As such, we are using our Morphomer&#153; platform to develop complementary diagnostic product candidates such as positron emission tomography, or PET, ligands which are tracers that can directly measure
misfolded tau and alpha-synuclein in the brain, to enable early and reliable disease diagnoses: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our tau PET imaging agent is currently in a First-in-Man study (a clinical study in which a medical procedure, previously developed and assessed through <I>in vitro</I> or animal testing or through mathematical
modelling, is tested on human subjects for the first time) and being developed under a collaboration agreement with Piramal Imaging. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins, such as PD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In April 2016, we entered into a non-exclusive collaboration with Biogen to develop PET imaging diagnostics for neurodegenerative diseases resulting from the misfolding of alpha-synuclein proteins and TDP-43, which is a
protein that has been recently linked to neurodegeneration in diseases including AD, PD and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig&#146;s disease). We expect to commence a Phase 1 clinical study of our alpha-synuclein PET
imaging agent in 2017. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific
biologics) and Morphomer (conformation-specific small molecules), to discover, design and develop medicines and diagnostics to target misfolded proteins. These platforms are our engines for generating novel molecules that are designed to bind to
their targets with high affinity and conformational specificity, meaning they are enabled to differentiate between misfolded proteins and normally-folded proteins. All of our product candidates and our development programs have been derived from our
proprietary platforms. Neurodegenerative diseases, such as AD and PD as well as other neuro-orphan diseases, such as progressive supranuclear palsy, amyotrophic lateral sclerosis, or ALS, and Huntington&#146;s disease, are all associated with
pathologies that involve misfolded proteins. Research has shown that misfolded proteins are unable to carry out their normal functions and aggregate to form certain types of deposits such as Abeta plaques or tau tangles that damage brain tissue. Our
SupraAntigen and Morphomer platforms seek to produce conformationally specific molecules in order to prevent or disrupt the formation of misfolded proteins. We believe that our proprietary platforms also have the potential to generate additional
molecules for indications that relate to protein misfolding outside of neurodegenerative diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram below summarizes the status of our research and development programs. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g10y79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neurodegenerative diseases and other diseases associated with protein misfolding are prevalent, but there is
currently an absence of reliable, early-stage diagnosis and disease-modifying treatments for these diseases. The growth in the number of people with neurodegenerative diseases has been significant as evidenced by the prevalence of people affected by
AD and PD, two of the most common neurodegenerative diseases. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">AD is the most common form of dementia, which affects an estimated worldwide patient population of 47&nbsp;million in 2015, and is expected to grow to 75&nbsp;million by 2030 and 132&nbsp;million by 2050, according to
the World Alzheimer Report 2015. The estimated aggregate cost of prevention and treatments in the United States was $172 billion in 2010 and is estimated by Alzheimer&#146;s Disease International, or ADI, to grow to $408 billion in 2030 and $1,078
billion in 2050. ADI estimated that the cost of prevention and treatments in the United States could be reduced from over a trillion dollars to $631 billion in 2050 if the onset of AD could be delayed by five years in the patient population. In
addition, at autopsy, AD has been reported in 80% of people with Down syndrome over age 40 and 100% over age 60. Down syndrome affects approximately one in 1,000 live births worldwide. </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">AD is typically diagnosed by neurologists and psychiatrists through a series of cognitive and functioning tests once symptoms are clinically
present, resulting in diagnosis at later stages of the disease after irreversible loss of neurons has already occurred. Currently approved AD treatments include medications that only treat the symptoms of the disease. The clinical benefit derived
from these symptomatic treatments is typically incomplete. Only between 40 and 70 percent of patients with AD benefit from taking symptomatic treatments and the symptoms improve for 6 to 12 months in most cases. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Therapeutic development for AD is increasingly focused on treating early stages of the disease to delay or prevent progression and to preserve
the maximum amount of cognitive function before irreversible neuronal damage occurs. Most clinical studies now target mild stages of the disease, increasing the need for accurate diagnosis that is independent of potentially subjective and otherwise
sub-optimal cognitive metrics. Diagnostics therefore have a crucial role in selecting more uniform and stage-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
specific clinical study subjects, tracking patient progress and results, managing patients receiving treatment and ultimately diagnosing the disease at its earliest stage for immediate treatment.
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">PD, the second most common neurodegenerative disease worldwide, affects an estimated 7 to 10&nbsp;million people. In PD, the use of symptomatic treatments, such as levodopa, is associated with the loss of control of
motor functions in approximately 50% of patients who have taken the drug for 5 years or longer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There remains a significant
unmet medical need for reliable and accurate diagnostics to enable early diagnosis and disease-modifying treatments that slow the progress of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have assembled an outstanding management team with relevant scientific, clinical and regulatory expertise. Our scientific founders,
Dr.&nbsp;Jean-Marie Lehn, Dr.&nbsp;Claude Nicolau, Dr.&nbsp;Roscoe Brady and Dr.&nbsp;Fred van Leuven, are regarded as pioneers in their respective scientific domains, including in the study of AD. Our co-founder and Chief Executive Officer,
Dr.&nbsp;Andrea Pfeifer, a pharmacologist with a Ph.D. in cancer research and former National Institute of Health researcher, has a 30 year track record in product innovation and implementation and was formerly head of Nestl&eacute; Global Research
and the co-founder of Nestl&eacute; Venture Fund. Our Chief Scientific Officer, Dr.&nbsp;Andreas Muhs, has more than 20 years of experience in various aspects of discovery research and drug development, including working on multiple drug development
programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Strategy </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our goal is
to become a global leader in the treatment of neurodegenerative diseases by developing therapies and complementary diagnostics that target neurodegenerative diseases with significant unmet medical need using our proprietary SupraAntigen and
Morphomer technology platforms. Key elements of our strategy are to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Advance our product candidates, in partnership or alone, through clinical development to regulatory approval and potential commercialization. </B> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Crenezumab</I></B><I>.</I> Our collaboration partner, Genentech, will advance crenezumab through Phase 3 clinical studies and seek regulatory approval. We believe that crenezumab&#146;s efficacy, coupled with its
safety profile, has the potential to become a best-in-class disease-modifying treatment for AD. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-24</I></B><I>. </I>We will continue to advance ACI-24, both through completion of an ongoing Phase 1/2a clinical study to evaluate the safety, tolerability, immunogenicity and biomarker endpoints in patients
with mild to moderate AD and, if the Phase 1/2a results are favorable, through a Phase 2/3 clinical study in patients with Down syndrome. We expect top line results from our Phase 1/2a clinical study in the second half of 2016. Our Phase 1 clinical
study of ACI-24 in patients with Down syndrome is intended to assess safety and started in December 2015. We own the global rights to ACI-24 and we intend to continue to develop ACI-24 in-house as a therapeutic candidate. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-35</I></B>. We will continue to advance ACI-35 through Phase 1b clinical studies in collaboration with Janssen. If the Phase 1b results are favorable, Janssen will advance ACI-35 through the additional
clinical development stages in collaboration with us. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Anti-tau antibody</I></B>.<B><I></I></B><I> </I>Our collaboration partner, Genentech, is advancing an anti-tau antibody candidate through a Phase 1 clinical study. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diagnostic candidates</I></B>. In addition to the above product candidates, we will continue to develop our complementary diagnostic product candidates and to advance these through clinical development, either
independently or with collaboration partners. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Expand into other neurodegenerative and neuro-orphan diseases.</B> We intend to leverage our proprietary technology platforms to develop product candidates that share the same disease targets as misfolded Abeta, tau
and alpha-synuclein proteins, which are the key features in the pathology of many </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
neurodegenerative diseases. We plan to pursue selected neuro-orphan indications, such as PSP and Huntington&#146;s disease, as well as tau-related orphan diseases, such as frontotemporal dementia
and corticobasal degeneration. Pursuing neuro-orphan indications may enable us to obtain a streamlined regulatory approval pathway and favorable reimbursement treatment of any approved product. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Accelerate the advancement of our diagnostic portfolio.</B> We are also developing a complementary diagnostic portfolio. We currently have three diagnostics candidates in our pipeline that we developed using our
Morphomer and SupraAntigen platforms. Our tau PET imaging agent is currently undergoing First-in-Man studies and we intend to work with our partner, Piramal Imaging, to advance this product candidate through the clinical development process. We are
also developing PET imaging diagnostics for diseases resulting from the misfolding of alpha-synuclein proteins. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Leverage the duality of our therapeutic and diagnostic approaches to become the leader in personalized treatment of neurodegenerative diseases.</B> Personalized medicine involves the development of diagnostics,
therapies and treatment procedures best suited for an individual patient, taking into consideration the stage of the disease, as well as genetic and environmental factors. The biggest limitation in neurodegenerative disease management is the lack of
appropriate biomarkers and reliable diagnostics for early disease detection and the absence of approved disease-modifying therapies. We believe that the future treatment paradigm for neurodegenerative diseases will likely involve early disease
diagnosis and combination therapy, leveraging both symptomatic and disease-modifying treatments, with different disease-modifying treatments used at various points in the progression of the disease. We believe that our multi-pronged approach to
neurodegenerative disease diagnosis and treatment may result in the generation of individualized treatment options for patients and improve clinical outcomes. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Strategically collaborate or selectively partner for the development and commercialization of product candidates.</B> Historically, we have relied on collaboration agreements with leading pharmaceutical companies to
leverage their scientific, development, manufacturing and commercialization expertise and other resources in order to accelerate the development of our product candidates. To date, we have entered into collaboration agreements with leading global
pharmaceutical companies, including two collaborations with Genentech and one with Janssen, a Johnson&nbsp;&amp; Johnson company. We believe that these partnerships validate our core strategy of discovering safe and efficacious therapies using our
proprietary platforms and advancing them through the various stages of regulatory approval. In the future, for any approved products targeting large markets, we may selectively partner with leading companies that we believe can contribute
manufacturing and marketing expertise, geographic reach and other resources and know-how that can enhance the value of these approved products. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Approach to Treating Diseases Related to Protein Misfolding </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Protein folding and unfolding are important ways of regulating the protein&#146;s biological activity and cellular location. Misfolding of
proteins occurs due to a breakdown of cellular quality control systems, and is a common feature of many neurodegenerative diseases. Research has shown that misfolded proteins are not only unable to carry out their normal functions, but also
aggregate to form deposits in the brain that eventually lead to neuronal damage and cell death. The progression of neurodegenerative diseases, such as AD and PD, is linked to the misfolded conformations of proteins, such as Abeta, tau and
alpha-synuclein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g24u20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows how, in today&#146;s understanding, misfolded proteins play a key role in the
pathology of neurodegenerative diseases. Typically, protein misfolding occurs during cellular stress, which can be triggered by many different causes, including oxidation and a lack of growth factors. A cascade of molecular events begins with the
misfolding of single proteins within a cell that then continue to aggregate to ultimately form plaques and tangles. These misfolded proteins are then exported and spread to healthy cells nearby, causing normal proteins to misfold in a process known
as seeding. This process eventually leads to cell death in various areas of the brain and is linked to a decline in cognitive function. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Challenges
in targeting misfolded proteins </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The central challenge in targeting misfolded proteins for therapeutic effect is a product&#146;s
ability to differentiate, or conformationally select, between a misfolded protein and a normally-folded protein. This ability to conformationally select for the misfolded protein prevents the therapeutic candidate from interfering with the function
of the normally-folded protein, thereby reducing the risk of side effects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Benefits of our approach </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key aspect of both our SupraAntigen and Morphomer technology platforms is conformational specificity, which we believe is central to the
development of effective therapeutics for neurodegenerative diseases. Our SupraAntigen platform targets misfolded proteins through antigens displayed on the surface of liposomes which mimic the targeted pathological form of the protein. In a
complementary approach, our Morphomer platform uses small molecular weight compounds to target the aggregation and seeding process, which prevents the misfolded proteins from aggregating inside the cell and the formation of new misfolded proteins in
healthy neighboring cells through a seeding mechanism. Small molecules derived from our Morphomer platform, which we refer to as Morphomers, also promote disaggregation of already formed pathological protein aggregates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g34u48.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows how we believe our therapies aim to intervene in the key pathology steps involved
in neurodegenerative diseases: (1)&nbsp;prevent misfolding; (2)&nbsp;promote disaggregation; (3)&nbsp;inhibit spreading; and (4)&nbsp;prevent seeding in healthy cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current Treatment Paradigm for Neurodegenerative Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Current diagnostic and treatment paradigms for neurodegenerative diseases are suboptimal. Diagnosis typically takes the form of observation of
cognitive, functional and behavioral impairment and other symptoms of the diseases, which are generally only apparent after irreversible neuronal damage has already occurred. These symptoms are treated with medicines capable of providing cognitive
benefit and functional improvement but fail to affect the progression of the disease. For AD, there are currently four approved therapies, all of which only provide modest efficacy in treating the symptoms of AD, while having significant side effect
risks, and fail to address the progression of the disease. Despite these shortcomings, marketed therapies, such as Eisai and Pfizer&#146;s Aricept, have achieved peak annual global sales of approximately $4&nbsp;billion prior to loss of exclusivity.
Similarly, in the treatment of PD, the current standard of care is intended only to alleviate physical symptoms. In both AD and PD, there are no approved disease-modifying treatments that slow or stop the course of disease progression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Modifying the progression of the disease requires targeting the underlying biological processes that drive disease progression. Unfortunately,
these processes evolve over the course of many years prior to manifestation of symptoms and a high percentage of neurons may be lost prior to clinical manifestation. Many of the failed clinical studies for disease-modifying treatments targeted
patients with moderate stages of the disease, when irreversible neuronal damage and death had already occurred. This had led to the conclusion that early intervention is necessary to slow the disease progression and that disease-modifying therapies
should be studied in patients with milder stages of the disease. As a result of this, in recent years, there has been a movement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
towards early intervention in clinical development. Early intervention, however, requires accurate disease detection prior to physical manifestation of symptoms, using new and sophisticated
technologies that are superior to the subjective rating scales currently used to assess patients. Thus, new diagnostic technologies are critical to the clinical development process of disease-modifying therapies and ultimately better disease
management of patients with neurodegenerative diseases. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Opportunity for AC Immune in Neurodegenerative Diseases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to change the way that neurodegenerative diseases are treated by combining reliable diagnostic tools that facilitate intervening at
earlier stages of the disease with therapies that treat the underlying disease process, as shown in the diagram below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g82t66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our lead product candidate, crenezumab, is ideally positioned to be at the forefront of
disease-modifying and preventative medicine due to its demonstrated efficacy in milder AD subjects and favorable safety profile. Unlike the current standard of care, crenezumab seeks to modify the course of AD by intervening at an earlier stage of
the disease progression prior to irreversible neuronal damage. Beyond AD, we believe that we can leverage our proprietary platforms to generate additional molecules that treat the causes of other neurodegenerative and neuro-orphan diseases, such as
PSP, ALS and Huntington&#146;s disease. We believe that the future treatment paradigm for neurodegenerative diseases will involve different disease-modifying treatments used at various points in the progression of the disease. One such combination
may be passive immunization targeting Abeta, such as crenezumab together with anti-tau antibodies or immunotherapies and small molecules targeting Abeta or tau. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that we are a leader in discovering new PET imaging agents to improve the timing and accuracy of diagnoses in neurodegenerative
diseases. We have three diagnostic candidates in our pipeline that were developed through our Morphomer and SupraAntigen platforms and that target Abeta, tau and alpha-synuclein. We believe our tau-PET imaging program has received external
validation through our partnership with Piramal Imaging, a leader in imaging agents. We are also developing an Abeta and tau <I>in&nbsp;vitro</I> diagnostic agent for AD and an alpha-synuclein PET imaging agent for PD. We believe that our diagnostic
product candidate pipeline will complement our disease-modifying treatment product candidate pipeline, with the ultimate goal of reshaping the clinical course and treatment of neurodegenerative diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Proprietary Technology Platforms </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development program is based on our two unique proprietary technology platforms: our SupraAntigen platform, which is our
biological and immunological platform, and our Morphomer platform, which is our small molecule, chemical platform. These platforms are designed to generate antibodies and small molecules, respectively, which selectively bind to misfolded proteins
which are common in a broad range of neurodegenerative diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen platform generates humanized monoclonal antibodies and
vaccines for use as passive and active immunotherapies that are highly specific for pathological, or misfolded, forms of Abeta and tau typically found in AD and certain other neurodegenerative diseases. In addition to the high target specificity,
the generated antibodies clear the misfolded proteins from the brain without generating inflammation. This characteristic was clinically confirmed in the Phase 2 clinical studies of crenezumab, where a favorable safety profile was demonstrated.
Similarly, <FONT STYLE="white-space:nowrap">ACI-35</FONT> and <FONT STYLE="white-space:nowrap">ACI-24</FONT> have been well tolerated in their respective Phase&nbsp;1b and 1/2a clinical studies. Our diagnostic portfolio is also an important part of
our strategy, as PET and molecular diagnostics should enable earlier diagnosis of neurodegeneration than current approaches that are based on clinical symptoms, a result that we believe will result in better clinical outcomes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research has shown that misfolded proteins are not only unable to carry out their normal functions but that they also aggregate to form
deposits commonly known as plaques and tangles that damage neuronal tissue and lead to cell death. Our SupraAntigen and Morphomer platforms seek to produce conformationally specific molecules, which are molecules that are able to differentiate
between misfolded proteins and normally-folded proteins, and target misfolded proteins with minimal side effects on normally-folded proteins. We believe that our platforms can also generate compounds in indications related to protein misfolding
outside of neurodegenerative disease, such as in glaucoma where aggregated Abeta peptides and tau proteins have been shown to cause damage to the optic nerve. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our platforms address two key issues in the development of drugs against diseases of protein misfolding: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The body does not make antibodies against misfolded proteins because, although pathogenic, they are still recognized as &#147;self-proteins&#148; and do not trigger an immune response. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The difference between a normal protein and a pathological protein is only related to a conformational change in protein structure making drug specificity difficult to achieve. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g31v36.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above shows the process by which conformationally-specific molecules break down the
aggregation of misfolded proteins. We expect that antibodies and Morphomers should prevent or disrupt the formation of insoluble plaques and stabilize soluble non-pathological proteins. </P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g81p33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SupraAntigen platform was created by our scientific founders Dr.&nbsp;Claude Nicolau in collaboration
with Dr.&nbsp;Fred Van Leuven. This technology generates conformation-sensitive antibodies and is used by us to create product candidates for both passive and active immunization. Passive immunization involves the application of therapeutic
antibodies, whereas active immunization stimulates the human body to make its own antibodies against pathological proteins, as shown in the diagram above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SupraAntigen Platform: Active Immunization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product approach is based on the ability of antigens attached to liposomes to elicit the immune system to produce antibodies against
self-proteins. The liposome is constructed of cholesterol, phospholipids and monophospholipid-A as an adjuvant. The liposome can accommodate antigens, or peptides, of different lengths that are chemically modified with palmitic acids to
&#147;anchor&#148; them in the liposomal membrane. The interaction between the charged liposome surface and the peptides force the peptide into the pathological conformation that mimics the targeted misfolded proteins. The diagram below shows the
vaccine construct which is used as a basis for ACI-24 and ACI-35 vaccine candidates. ACI-24 and ACI-35 are vaccine candidates developed using our SupraAntigen platform for active immunization. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g87q91.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>SupraAntigen Platform: Passive Immunization </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen platform can also be used to develop passive immunization product candidates. The antibodies are created by injecting the
SupraAntigen constructs in mice and by selecting the antibodies for their ability to break up aggregated fibers. The antibodies eliminate protein aggregates such as plaques and tangles by changing the equilibrium from the insoluble pathological to
the soluble fibers which are depleted by the antibodies. Both crenezumab and the anti-tau antibodies were derived from this platform. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer
Platform </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Morphomer platform represents a highly promising technology to identify and develop therapeutic small molecules for
the treatment of diseases resulting from misfolded proteins. This proprietary platform enables us to generate small molecules that bind to their target and break up neurotoxic protein aggregates. As of June&nbsp;30, 2016, the Morphomer library
consisted of more than 2,900 compounds. Our key platform assets have been validated for selective binding to Abeta, tau and alpha-synuclein through <I>in vitro</I> efficacy studies and have a validated mechanism of action through reproducible <I>in
vivo</I> efficacy for Abeta, tau and alpha-synuclein. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g41y22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The figure above shows a Morphomer blocking amyloid growth. Only one end of aggregated amyloid fibers
grows, and these molecules are designed to inhibit that growing end as shown in the above diagram. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Most molecules involved in
neurodegenerative diseases follow the same overall disease development and aggregation process, including Abeta in AD, alpha-synuclein in PD and huntingtin in Huntington&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The key advantages of our Morphomer platform include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">High specificity for the targeted misfolded protein; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">One Morphomer can inhibit multiple protein units in oligomers and fibers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Early inhibition of aggregation and seeding. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Morphomer platform was developed through a collaboration of our scientific founders Dr.
Jean-Marie Lehn, a recipient of the Nobel Prize in chemistry, and Dr. Claude Nicolau, a former Harvard Medical School professor, and our board member Dr. Detlev Riesner. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our AD Programs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab is a humanized, conformation-specific monoclonal antibody that targets the misfolded version of Abeta and has a broad binding
profile. Crenezumab was developed using our proprietary SupraAntigen platform. In 2006, we licensed crenezumab to Genentech and a company with a long history of developing and commercializing innovative biologics. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Abeta is produced by the breakdown of a larger protein called amyloid precursor protein, or APP. The Abeta fragment containing 42 amino acids,
or Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, is believed to be associated with the highest toxicity of the Abeta fragments. Misfolded Abeta subunits combine to form oligomers and fibrils that are found in amyloid
plaques. Data resulting from preclinical and clinical studies show that crenezumab binds with high affinity to amino acids 12&#150;24 of Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, as well as multiple forms of Abeta,
including monomers, oligomers, and fibrils, which reduces Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB> induced cytotoxicity. Furthermore, these data indicate that crenezumab enhances the uptake of neurotoxic Abeta oligomers
by microglial cells, the resident immune cells of the brain, which normally respond to neuronal damage and remove the damaged cells for subsequent disposal and clearance from the brain. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A challenge with agents acting to remove Abeta is the potential to induce inflammation leading to vasogenic edema, which is accumulation of
fluid in the brain that can lead to headaches, loss of coordination and disorientation. The fluid can be seen clearly on MRI scans and is referred to as Amyloid Related Imaging Abnormality-Edema, or ARIA-E. Crenezumab is engineered on an IgG4
backbone, which was selected because IgG4 antibodies are associated with a greatly reduced risk of causing inflammation. As a result, crenezumab&#146;s IgG4 structure activates microglial cells to clear Abeta without producing inflammation and
associated vasogenic edema, as demonstrated in the Phase 2 clinical studies. In contrast, ARIA-E and other inflammation-related side effects have been observed in other antibodies with an IgG1 backbone. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Abeta1-42 oligomers</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Reduces Abeta 1-42 oligomer toxicity</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g16439g68g01.jpg" ALT="LOGO">
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Abeta 1-42 oligomers + MABT</B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g16439g55x10.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MABT is equivalent to crenezumab, mMABT is the</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">parental murine version of crenezumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g16439g93d53.jpg" ALT="LOGO">
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Reduces microglia inflammatory
activation</B></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">


<IMG SRC="g16439g79m98.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The figure above shows that crenezumab promotes Abeta oligomer engulfment by microglia without inflammatory activation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We believe crenezumab may have the following important competitive advantages relative to other drugs targeting Abeta in
development<I>: </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Unique mechanism of action:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab recognizes and binds to multiple forms of Abeta, including monomeric, oligomeric and fibrillar Abeta that are found in amyloid plaques. In contrast, certain other antibodies in development such as solanezumab
and aducanumab have only been shown in studies to recognize a subset of Abeta forms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Due to its high affinity to the multiple forms of Abeta, crenezumab also protects against oligomer-induced neurotoxicity. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Linked to its unique epitope, crenezumab has been shown to promote disaggregation of existing Abeta aggregates and disrupt their assembly to prevent amyloid plaque formation. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab has been designed with an IgG4 backbone to reduce effector function on microglia and to clear Abeta from the brain while limiting inflammation. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g19n26.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Signal of activity in milder AD patients (MMSE 22-26):</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the proof-of-concept Phase 2 studies of crenezumab, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD (MMSE 22-26). </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the ABBY cognition study there was a statistically significant 35% reduction in the rate of cognitive decline in the non-pre-specified milder AD patient population (MMSE 22-26) for the high-dose arm.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the BLAZE biomarker study, the high-dose arm showed a consistent trend of reduced Abeta accumulation in the brain over time, as shown in two independent exploratory analyses of florbetapir-PET data. In addition, it
has been shown that crenezumab has the ability to enhance the removal of these proteins from the brain as evidenced by a significant increase in CSF Abeta, confirming target engagement by crenezumab. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Favorable safety profile allowing for potentially higher dosing:</I></B> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2 data from ABBY and BLAZE studies suggested that there were no imbalances in overall rate of Adverse Events, or AEs, and overall rate of AEs was not dose-related, with only one case of asymptomatic ARIA-E (0.4%
in ABBY, 0.3% on active pooled) in crenezumab patients. AEs also included inflammation of the throat and nasal passages, urinary tract infections and upper respiratory infections. However, no patients in the studies experienced serious adverse
events that we believe were related to the administration of crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Crenezumab is a member of the IgG4 isotype subclass of antibodies. This isotype was selected because IgG4 antibodies are associated with a greatly reduced ability to cause inflammation. By contrast, all other antibody
products currently in development that target Abeta are of the IgG1 isotype subclass, which is associated with a higher incidence of inflammation-related ARIA-E. Dose limiting toxicities are a major risk for failure of competing antibody products.
Potential safety at high doses is a key product feature of crenezumab. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Due to its favorable safety profile, there is an ongoing Phase 1 study in which crenezumab is currently being studied at higher doses to potentially increase its efficacy signal. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table below sets forth the relative incidence of ARIA-E of crenezumab and other competitive
product candidates. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g14o09.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">10 mg/kg dose cohort </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">6 mg/kg dose cohort </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Reduced effector function </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">**</TD>
<TD ALIGN="left" VALIGN="top">Full effector function </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2 Studies </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 2 Study Design Overview </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab has been studied in two Phase 2 clinical studies, the ABBY proof-of-concept study and the BLAZE biomarker study. These two studies
enrolled a total of 522 patients. The purpose of these studies was to investigate whether crenezumab could delay cognitive and functional decline and reduce the accumulation of brain amyloid in patients with mild to moderate AD. The sample size of
the studies was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent
trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of development, with confirmation then sought in Phase 3. Both studies had two active arms: a low dose arm receiving 300mg
subcutaneous injection, which is an injection administered beneath the skin, every two weeks and a higher dose arm receiving 15mg/kg intravenously every four weeks. The primary analysis was conducted at 73 weeks, after 68 weeks of treatment. Safety
and tolerability measures included repeated MRI scans to assess for the development of Amyloid Related Imaging Abnormalities, both vasogenic edema and hemorrhages. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>ABBY Study Design </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
ABBY study was a randomized, double-blind, parallel group, placebo-controlled study to evaluate the safety and efficacy of crenezumab in patients with mild to moderate AD, with an MMSE score at screening of 18-26 points. 444 patients were enrolled
into the study including 13 patients who were included in a safety run-in cohort to support the use of the 15 mg/kg intravenous dose, which had not been tested in Phase 1. Since these patients received active medication after the second infusion and
were then no longer blinded, they were included in the safety, but not the primary efficacy, analysis. The remaining 431 patients were randomized separately to receive crenezumab, either subcutaneously at a dose of 300 mg every two weeks (low dose)
or intravenously at a dose of 15 mg/kg once every 4 weeks (high-dose), with a 2:1 active:placebo ratio in each dose group. In the subcutaneous injection dose arm, 122 patients received crenezumab and 62 patients received placebo. In the intravenous
dose arm, 163 patients received crenezumab and 84 patients received placebo. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Co-primary endpoints were cognition assessed using the Alzheimer Disease Assessment
Scale-Cognitive Subscale, or ADAS-cog 12 scale, and global function assessed by the Clinical Dementia Rating-Sum of Boxes (CDR-Sum of boxes). Secondary endpoints such as the MMSE score and Digit Symbol Substitution Test, or DSST, were also included
in the study. ADAS-cog is a widely used scale in clinical studies that measures a patient&#146;s performance on tests of memory and other areas of cognition, especially orientation, praxis and language. Scores range from 0 (best) to 70 (worst). The
ADAS-cog 12 score includes an additional item of delayed recall, leading to a highest possible score of 80 points. On average, the score of patients with mild to moderate AD increases by 5 to 8 points per year. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CDR-Sum of boxes is an assessment of &#147;global&#148; (overall) function of the patient in daily life. The patient&#146;s performance in
the six domains of memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care are assessed through interviews with the patient and caregiver. Each domain is scored from 0 (best) to 3 (worst) based on the
level of impairment. The scores for the six domains are then summed up and the resulting score or &#147;sum of boxes&#148; ranges from 0 to 18, with a higher score indicating greater impairment. </P>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DSST is a classic paper and pencil test used to assess a patient&#146;s processing speed in the so-called digit symbol substitution test
during which the patient is asked to insert a symbol in place of a digit according to a scheme as quickly as possible over a set period of time. The DSST measures the number of correct symbols the patient inserts within the allowed time, i.e. 90 or
120 seconds. A higher score demonstrates better performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY Study Disposition </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g08h09.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>ABBY Study Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ABBY study, a positive trend in cognition was observed with a greater effect on cognition in patients with a milder stage of AD (MMSE
22-26), although the study did not meet its co-primary endpoints in mild-to-moderate AD (MMSE 18-26) patients. There was no significant change in cognition in patients who received low-dose subcutaneous crenezumab. Results of an exploratory analysis
of the high-dose intravenous arm demonstrated that patients with the mildest cognitive impairment at screening (MMSE 22-26) showed a statistically significant 35% slowing of the rate of cognitive decline over 73 weeks. The effect became greater over
time, as shown by the increasing separation of the crenezumab (solid line) and placebo (dashed line) curves in the diagram below. The milder group was not pre-specified, meaning the group of milder AD patients was not identified before commencing
the Phase 2 clinical studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY High Dose Arm: Change in ADAS-Cog 12 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g61l28.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g01b26.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">An exploratory subanalysis in a non-pre-specified subgroup of patients with milder symptoms <FONT
STYLE="white-space:nowrap">(MMSE&nbsp;22-26)</FONT> showed a 35.4% reduction in cognitive decline. The sample size of the study was not expected to have adequate power to detect a modest but clinically significant difference between active
medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across different endpoints and dose dependency are considered indicators of a response in this learning phase of
development, with confirmation then sought in Phase&nbsp;3. In the pre-specified subgroup analysis in patients with mild AD (MMSE 20-26), treatment with high-dose intravenous crenezumab led to a 23.8% reduction in cognitive decline. In patients with
mild-to-moderate AD (MMSE 18-26) treated with high-dose intravenous crenezumab, there was a 16.8% reduction in cognitive decline. Effect sizes and p-values for exploratory analyses were not adjusted for multiplicity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ABBY High Dose Arm: Change in DSST </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g73o56.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g84j07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ABBY high-dose arm result for DSST was significant in the milder patient sub-group (MMSE
22-26). The mild and milder patients that were given crenezumab intravenously showed no further cognitive deterioration between 12 and 18 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ABBY study, patients in the high-dose crenezumab arm showed less decline on the measure of global function, CDR-Sum of boxes, as
compared to placebo. In mild-to-moderate AD (MMSE 18-26), a non-significant 3.1% reduction in global functional decline was observed. In the pre-specified subgroup analysis in patients with mild AD (MMSE 20-26), treatment with high-dose intravenous
crenezumab did not show reduction in global functional decline (1.0% reduction; p=0.96). An exploratory analysis in two cohorts of patients with milder symptoms showed a 19.6% (MMSE 22-26) and 45% (MMSE 24-26) reduction in global functional decline.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g92q71.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Greater relative reductions were observed in the crenezumab arm compared with placebo in the CDR subdomains
Memory, Orientation, Judgment &amp; Problem Solving and Home &amp; Hobbies in progressively milder patients. Treatment effects were less consistent in progressively milder patients for the CDR subdomains Community Affairs and Personal Care. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g98s75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#068;</FONT> CDR subdomains=difference in change from baseline to Week 73 in CDR
subdomain scores between treatment and control groups. Diamonds represent LS mean change from baseline at Week 73, error bars 95% present CI. Positive values indicate less decline in crenezumab group. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the overall results were not statistically significant, it should be noted that the sample size of the study was not expected to have
adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Instead, consistent trends across different endpoints and
timepoints and dose dependency are considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indicators of a response in this learning phase of development, with confirmation then sought in Phase&nbsp;3. Trends favoring crenezumab were not observed in the activities of daily living scale
(ADCS-ADL) although the study was significantly underpowered for this type of assessment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The BLAZE study was a randomized, double-blind, parallel-group, placebo-controlled study to evaluate the effects of crenezumab on brain amyloid
burden as assessed by amyloid PET imaging and other biomarker endpoints in patients with mild to moderate AD. The primary endpoint was to measure the change in brain amyloid load using florbetapir-PET. The terms brain amyloid burden and brain
amyloid load refer to the total amount of amyloid deposited in the brain. Each of these typically increases over time in an AD patient. Other endpoints included changes from baseline in other biomarkers (CSF, volumetric MRI), cognition (ADAS-cog12),
global function (CDR-Sum of boxes), and activities of daily living (ADCS-ADL). Enrollment required florbetapir-PET positive scans, or patients who were amyloid positive. Ninety-one patients were included in the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE Study Disposition </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g50q80.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Results </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary end point of change in brain amyloid load by florbetapir-PET was not met, but the study was not powered to detect statistically
significant results. When assessing the amyloid load, the amount of amyloid in a region of the brain is determined by comparing the amount of an amyloid tracer to that found in a region with little or no amyloid, such as the cerebellum or the white
matter, usually in the cortex. Recent studies have shown that the variability from scan to scan in the same patient over time is much higher when using the cerebellum than with the white matter, making the white matter a more powerful point of
comparison for use in longitudinal studies. The higher variability of the cerebellum may be due to difficulties in exact positioning between scans and higher background levels. Taking this into account, the exploratory analyses of the BLAZE amyloid
PET results using white matter reference region were conducted independently by two laboratories, the Banner Alzheimer&#146;s Institute and MNI Laboratories. The analyses produced analogous results where a trend in the reduction of Abeta
accumulation was observed in the high-dose arm. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g10m11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BLAZE biomarker study high-dose intravenous cohort showed a consistent trend of reduced Abeta
accumulation in the brain over time shown by two independent exploratory analyses of florbetapir-PET data. Using white matter rather than cerebellum as the key reference region in the brain is generally considered a more robust method of showing
treatment effects of AD therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the BLAZE study, patients also showed a statistically significant increase in CSF Abeta<SUB
STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, which we believe confirms target engagement by crenezumab. Similar results were observed in the ABBY study where CSF was assessed in 49 patients. These results suggest that Abeta is being
eliminated from the brain when treated with crenezumab. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE High Dose Arm: Crenezumab Increases CSF Total Abeta Relative to Placebo </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g08u57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>BLAZE Study Results: Effects on Cognition and Global Function </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A similar and consistent pattern of response was observed in the BLAZE study with slowing of loss of cognition compared to placebo observed at
the high-dose intravenous crenezumab arm, and having the most effect in patients with more mild MMSE scores. There was no significant cognitive change in patients who received low-dose subcutaneous crenezumab. Importantly, the sample size of the
study was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). BLAZE study results suggest
that Abeta is being eliminated from the brain as patients showed a statistically significant increase in CSF Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1&#150;42</SUB>, which confirms target engagement by crenezumab. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BLAZE High Dose Arm: Change in ADAS-Cog 12 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g47w32.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The BLAZE high-dose arm showed increasing separation over time of the curves of decline on
ADAS-Cog 12 for placebo (dashed line) and intravenous crenezumab (solid line) in the mild subgroup of patients (MMSE 20-26). In a post-hoc analysis of a group of patients with mild AD (MMSE 20-26) treated with high-dose intravenous crenezumab, there
was a 52.0% reduction in cognitive decline (p=0.29). In patients with mild-to-moderate AD (MMSE 18-26) treated with high-dose intravenous crenezumab, there was a 10.3% reduction in cognitive decline (p=0.84). Importantly, the sample size of the
study was not expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). Effect sizes and <FONT
STYLE="white-space:nowrap">p-values</FONT> were not adjusted for multiplicity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the BLAZE study, patients in the high-dose crenezumab
arm showed less cognitive decline on the measure of global function, CDR-Sum of boxes, as compared to placebo. In mild-to-moderate AD (MMSE 18-26), a 7.4% reduction in global functional decline (p=0.84) was observed. In a post-hoc analysis in
patients with mild AD (MMSE 20-26), treatment with high-dose intravenous crenezumab resulted in a 41.5% reduction in global functional decline (p=0.44). Although the results were not statistically significant, the sample size of the study was not
expected to have adequate power to detect a modest but clinically significant difference between active medication and placebo at the 5% significance level (as is commonly the case in Phase 2 studies in AD). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Safety Data from ABBY and BLAZE Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Crenezumab demonstrated favorable safety and tolerability in Phase 2 clinical studies even at high doses. Crenezumab&#146;s safety profile is
especially reflected in a low incidence of ARIA-E (0.3%) in Phase 2 clinical studies. ARIA-E was observed in only one patient who received high-dose intravenous crenezumab in the ABBY study. No case of ARIA-E was reported in the placebo arm or the
BLAZE study. Favorable pharmacokinetic properties coupled with a favorable safety and tolerability profile enables crenezumab to penetrate the brain more readily at therapeutically relevant doses. Since dose limiting toxicities are a potential
reason for the failure of other antibodies to demonstrate efficacy, crenuzamab&#146;s potential safety at high doses is a key distinguishing product feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There was no imbalance in the overall rate of AEs. AEs were observed in 91.3% of patients treated with crenezumab versus 90.3% of patients who
received placebo. AEs were generally mild-to-moderate and transient. AEs did not appear to be related to crenezumab exposure. Five deaths occurred during ABBY and BLAZE, all in patients who received crenezumab during the randomized
placebo-controlled period (1.4% of the crenezumab-treated population). The overall rate of deaths is consistent with the background rate of death in the elderly AD population. There was no consistent pattern for the cause of death and none were
considered by the investigators to be related to crenezumab. It was reported that 3.2% of crenezumab-treated patients developed pneumonia versus 0.6% in placebo-treated patients in ABBY and BLAZE, but the rate of pneumonia cases in
crenezumab-treated patients is consistent with the expected rate in the elderly population (2.5%&#150;4.4%) and no drug-related mechanism for pneumonia was identified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech has not disclosed detailed information about serious adverse events associated with crenezumab either publicly or to us. However, at
the 2014 Alzheimer&#146;s Association International Conference, it was reported that in the combined Phase 2 study populations, serious adverse events occurred at similar rates in patients treated with crenezumab (16.5%) and in patients given a
placebo (11.9%). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Phase 1 Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To explore safety at higher doses, crenezumab is currently being tested in a Phase 1 clinical study conducted in the United States. This
randomized, placebo-controlled, double-blind, four parallel-arm study will evaluate the safety and tolerability of at least two doses of intravenous crenezumab in up to 72 patients with mild to moderate AD (MMSE 18-28) between the ages of 50 to 90.
An optional open-label extension stage will be offered to patients after completion of the double-blind stage of the study. This study is expected to be completed in May 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2 AD Prevention Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2012, crenezumab was independently selected from among twenty five product candidates for use in the first-ever AD prevention study. The
study, a $100 million collaboration between the NIH, Banner Alzheimer&#146;s Institute and Genentech, is the cornerstone of the global Alzheimer&#146;s Prevention Initiative. Crenezumab is being administered pre-symptomatically to 300 members of an
extended Colombian family, of which 200 members carry a mutation that causes early-onset AD. Family members usually develop symptoms before the age of 45. The five-year study has cognitive endpoints. An interim analysis is expected in 2017, but the
data and results of that analysis may not be made public given patient sensitivity. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Ongoing Phase 3 Study (CREAD Study)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech entered Phase 3 clinical development of crenezumab in the first quarter of 2016. The CREAD Study is ongoing. This
randomized, double-blind, placebo-controlled, parallel group Phase 3 study will enroll about 750 participants with prodromal or mild AD at the age of 50-85 years. A high dose of crenezumab (dose not disclosed) is administered intravenously once
every 4 weeks for 100 weeks. Primary outcome measure is change from baseline to week 105 in Clinical Dementia Rating - Sum of Boxes (CDR-SB) score. Final data collection date for primary outcome measures is expected by August 2020, with study
completion by July 2021. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 is a vaccine candidate that is in a combined Phase 1/2a clinical study for AD. ACI-24 was developed utilizing our SupraAntigen platform,
and is designed to stimulate a patient&#146;s immune system to produce antibodies that specifically target the misfolded Abeta conformer to prevent plaque accumulation and to enhance plaque clearance. Pre-clinical data demonstrated significant
activity in plaque reduction and memory restoration. ACI-24 has a favorable safety profile, characterized by a lack of observed local inflammation and a mechanism of action independent of inflammatory T-cells. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1/2a Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To be considered a Phase 1/2a study, a study or part of it must include as a primary goal the assessment of efficacy in a patient population,
assessed using either clinical endpoints or biomarkers. This is in contrast to a Phase&nbsp;1 study where the primary goal typically includes safety and pharmacokinetic or pharmacodynamic measures. The ACI-24 study is an adaptive design study where,
after completion of a first step assessment of safety and immunogenicity at different doses, the study may be expanded to assess the efficacy at the best dose in a Phase 2a-type design. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Phase 1 part of the combined Phase 1/2a study is currently ongoing. The efficacy, tolerability and immunogenicity of ACI-24 are being
tested in mild to moderate AD patients with four different doses. It is a randomized, placebo controlled, double blind study. The different doses are tested via an ascending dose design in four consecutive cohorts with 12 patients each (9 on active,
3 on placebo treatment). ACI-24 is administered by subcutaneous injection with multiple injections per cohort. Each dose cohort is followed by a two-year treatment-free safety follow-up period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The treatment of the first three cohorts has been completed. The treatment of the fourth cohort is ongoing. To date, ACI-24 has shown a
favorable safety profile and has been well tolerated. None of the observed serious adverse events were considered related to the administration of ACI-24. The Phase 2a study of the combined Phase 1/2a study will focus on safety, tolerability and
efficacy and will be conducted after all data of Phase 1 are available. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical results showed that ACI-24 induced a rapid and significant anti-Abeta antibody response in a T-cell independent manner, which is
linked to a more favorable safety profile. The antibody response following treatment with ACI-24 reduced the Abeta brain burden and restored the memory capacity in double-transgenic AD mice. Anti-Abeta antibodies induced by ACI-24 preferentially
bind to both pathologically aggregated Abeta species such as oligomers and fibrils. Relative to other anti-Abeta vaccines currently or previously in clinical development ACI-24 has shown differentiation in pre-clinical studies on the basis of
mechanism of action, safety and efficacy. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g57z32.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in the diagram above, immunization of an AD mouse model with ACI-24 led to a significant decrease
of insoluble, plaque-related (black bars) and soluble (grey bars) oligomeric Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1-40</SUB> and Abeta<SUB STYLE="font-size:85%; vertical-align:bottom">1-42</SUB>. This target engagement was
accompanied by the significant improvement of cognitive memory capacity in the novel object recognition test, or ORT. In contrast, immunization with ACI-01, the vaccine candidate which did not present the antigen in its pathological conformation,
did not result in any restoration of memory. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 in Down Syndrome </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Individuals with Down syndrome have an extra copy of chromosome 21 where the gene for APP resides. These individuals have a rate of AD that is
three to five times that of the general population and develop the disease at a much younger age. At autopsy, AD has been reported in 80% of people with Down syndrome over age 40 and 100% over age 60. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 is a vaccine candidate against the pathological form of Abeta in plaques of AD patients. It contains a palmitic-acid Abeta peptide
corresponding to amino acids 1-15 of the Abeta molecule anchored in liposomes and adopts the conformation of the pathological Abeta conformers found in plaques. ACI-24 has a novel mode of action whereby antibody production is induced through direct
B-cell (antibody producing cell) activation that is independent of T-helper cells. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An IND to study the disease-modifying properties of ACI-24 for the prevention of cognitive
decline with Down syndrome was filed and cleared by the FDA. ACI-24 commenced the Phase 1 clinical study for Down syndrome at the end of 2015 after the authorization of the amended protocol. The study is supported by a substantial NIH grant and
other grants from the LuMind Research Down Syndrome Foundation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g11d65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagram above, based on work published by AC Immune in collaboration with Dr.&nbsp;Mobley of University
of California, San Diego in March 2016, shows in a Down syndrome mouse model (Ts65Dn) a 20% significant improvement of the memory&nbsp;(left) and a 27% reduction of Abeta in the brain following vaccination with ACI-DS-01, the mouse equivalent of
ACI-24 (right). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-35 is a vaccine candidate directed against another key component of the pathology of AD: phosphorylated tau proteins, or p-tau, found in
tau tangles. ACI-35 is designed to stimulate a patient&#146;s immune system to produce antibodies against the misfolded and phosphorylated pathogenic conformers of tau protein that aggregate to create the neurofibrillary tangles that characterize
AD. ACI-35 is the first vaccine candidate against phosphorylated pathological tau in clinical studies, and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In 2015, we entered into a partnership with Janssen
Pharmaceuticals, a subsidiary of Johnson&nbsp;&amp; Johnson, for the clinical development of ACI-35 beyond Phase 1b. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The dendrites and
axons, or nerve endings, of the neurons contain an elaborate series of thin tubes, or microtubules, which serve to support them and transport nutrients down to the nerve endings. Tau proteins are a key component of these microtubules, and, hence,
are known as microtubule associated proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In AD, tau protein is misfolded, becomes hyperphosphorylated and aggregates into neurotoxic
oligomers that ultimately form neurofibrillary tangles within neurons. The degree of tau pathology correlates strongly with the degree of cognitive loss in AD. Approaches to reducing the level of abnormal tau proteins and slowing their build-up in
the brain are considered important targets for new AD therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We developed ACI-35 using our SupraAntigen technology. In pre-clinical
testing, the vaccine candidate induced an antibody response that was highly specific to misfolded and phosphorylated tau. This antibody response resulted in a reduction of phosphorylated misfolded tau and an improvement in cognitive clinical
parameters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1b Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Phase 1b Study Design </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Safety, tolerability and immunogenicity of ACI-35 are being tested in an ongoing Phase 1b study in mild to moderate AD patients. It is a
randomized, placebo controlled double blind study, where ACI-35 is administered via subcutaneous injection. Different doses and dosing schedules are being investigated in an ascending dose design. Multiple injections of ACI-35 are administered per
cohort for active or placebo treatment in a three-to-one ratio. To date, ACI-35 has been generally safe and well tolerated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-clinical Study </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In research and pre-clinical studies, ACI-35 demonstrated: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A high and specific anti-p-tau IgG antibody response in wild-type mice, tau transgenic mice and primates (cynomolgus and rhesus monkeys); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The induction of highly specific antibodies that are able to recognize p-tau over non-phosphorylated tau peptide and yield a 30-100 fold higher titer for p-tau over non-phosphorylated tau; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A favorable safety profile by showing that multiple doses in mice and monkeys induced strong antibody responses that were well tolerated and not associated with organ toxicity. The main adverse events were local
reactions observed at the injection site and were consistent with a normal granulomatous inflammatory reaction after subcutaneous injection of a foreign body; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No observable toxicity at the highest dose used in cynomolgus monkeys or mice; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">No cross-reactivity to any human tissue with the antibodies induced in monkeys by ACI-35 immunization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-35 generated antibodies that are phosphor-specific for the full-length p-tau protein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g64u74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The left graph shows that the ACI-35 vaccination raised highly-specific antibodies against phosphorylated
tau protein in both transgenic and wild type mice. On the other hand, the right graph shows that a classical vaccine, composed of a p-tau peptide adsorbed to aluminum phosphate, raised antibody responses that do not discriminate between
phosphorylated tau and non-phosphorylated tau protein in both wild type and tau transgenic mice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anti-Tau Antibody </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our anti-tau monoclonal antibody program generated humanized monoclonal antibodies for use as passive immunotherapies that are highly specific
for pathological forms of tau found in AD brains and other tauopathies. Results from studies conducted in pre-clinical development demonstrate a significant reduction in pathological tau with reduced effector function, meaning decreased ability to
affect the function of tau, as well as improvement of long-term spatial memory. A lead development candidate has been selected, and Genentech, our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
collaboration partner for the anti-tau antibody program, announced the commencement of a Phase 1 clinical study in July 2016. The Phase 1 clinical study will test the safety, tolerability and
pharmacokinetics of various dosing regimens of the anti-tau antibody in patients with mild to moderate AD as well as in healthy volunteers. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pre-clinical and Discovery Stage Therapeutic Programs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Using our SupraAntigen and Morphomer platforms, we have generated additional discovery and pre-clinical stage molecules targeting
neurodegenerative diseases, and diagnostics targeting both Abeta and tau. We currently have four therapeutic product candidates and two diagnostic product candidates in various stages of pre-clinical development. A number of our therapeutic product
candidates in pre-clinical development are focused on indications outside of AD and evidence our expansion strategy. Based on the data we have received to date, we believe that our technology platforms can be applied to misfolded proteins across a
broad range of indications. The table below lists our three pre-clinical product candidates, the platform from which each candidate stems and the lead indication being pursued: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.10pt; font-size:8pt; font-family:Times New Roman"><B>Product Candidate</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Target</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Lead Indication</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Partner</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Platform</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer tau</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">tau</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">AD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer abeta</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Abeta</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Glaucoma</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Morphomer alpha-synuclein</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">alpha-synuclein</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">PD</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">N/A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Morphomer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Anti-tau Morphomers:</I></B> Anti-tau Morphomers are small molecule compounds designed to inhibit tau
aggregation with the aim of interacting with the beta sheet conformation present in misfolded aggregated tau protein. Our anti-tau Morphomers show a significant inhibition of full length tau aggregation, size-reduction and solubilization of full
length tau aggregates and intracellular target engagement by reduction of cellular, aggregated and phosphorylated tau. Importantly, research data show that our compounds reduce cytotoxicity induced by tau. These data were further confirmed by the
reduction of misfolded tau in the brain and memory improvement in a tau disease mouse model. This molecule is expected to enter Phase 1 clinical studies in 2017 or&nbsp;2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer abeta:</I></B> Our Morphomer abeta product candidate is a small molecule that inhibits and disrupts Abeta propagation and
aggregation, and is currently being evaluated for the treatment of glaucoma, where its anti-Abeta properties represent a novel mechanism of action for that disease. In pre-clinical testing, Morphomer abeta demonstrated a strong ability to protect
the eyes of rats exposed to increased ocular pressure and chronic ocular hypertension which are clinical features of glaucoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>Morphomer alpha-synuclein:</I></B> Our Morphomer alpha-synuclein product candidate is a small molecule that reduces the cytotoxicity of
alpha-synuclein aggregates by a decrease in their beta sheet content. In pre-clinical studies, Morphomer alpha-synuclein significantly reduced <I>in vivo</I> the formation of alpha-synuclein pathological structures accompanied by improvement of a
neuronal marker relevant to PD. Ongoing activities are focused on increasing potency and pharmacokinetic properties and preparing compounds for pre-clinical development activities. In a mouse model of tauopathies, our lead compounds show improvement
of learning and memory deficit and reduce brain atrophy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Diagnostics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Scientists increasingly believe that early detection of neurodegenerative diseases is critical to enhancing the effectiveness of both
symptomatic and disease-modifying therapies. As a result, therapeutic development for AD increasingly focuses on treating early stage disease to delay or prevent progression and to preserve the maximum amount of cognitive function before it is
irreversibly lost. Most clinical studies now target mild stages of the disease increasing the need for accurate diagnosis that is independent of potentially subjective cognitive metrics. At least one study estimates that as many as one-third of
patients in previous AD studies did not in fact have AD. Accurate and early diagnosis of AD is thus a substantial unmet market need, and diagnostic products will have a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
key role in generating a new treatment paradigm, including by selecting more uniform and stage-specific clinical study subjects, tracking patient progress and results, managing patients receiving
treatment, and ultimately diagnosing disease at its earliest stage for immediate treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing two diagnostic product
candidates using our Morphomer technology platform. These product candidates are PET ligands, that are tracers that can be used to target tau and alpha-synuclein aggregates. In May 2014, we established a licensing collaboration for our tau-PET
imaging program with Piramal Imaging. Our tau-PET imaging agent is currently in a First-in-Man clinical study. Piramal Imaging is expecting to advance this program into Phase 1 clinical development in 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our PET tracers are designed to bind specifically to tau tangles and have demonstrated their ability to cross the blood-brain barrier. The
severity of cognitive impairment in AD patients is correlated with the presence of tau protein tangles, leading us to believe that an imaging agent for tau is equally important. Our tau-PET tracers are more selective for tau than Abeta when compared
to current published tau-PET agents in development and can be readily radiolabelled. While PET imaging has improved the diagnosis of AD by targeting Abeta, tau imaging will further enhance the diagnosis of early AD. To date, there are no approved
tau tracers. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g55g60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The diagrams above show that our lead tau-PET imaging compound has high selectivity and can identify tau
aggregates as early as stage one of the six stages of the Braak scale, which is the pre-symptomatic stage (as indicated with arrows in the far left diagram), and have a favorable uptake in the brain (right diagram). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">AD diagnostics are a major market opportunity that will be driven by the growth in the aging population and the testing and availability of
disease-modifying drugs. We believe a best-in-class tau tracer has the potential to achieve a substantial market share in this large and growing market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alongside our AD diagnostics activities, we have a program targeting PET imaging agents for alpha-synuclein, an important protein involved in
PD, and which progressively accumulates in structures in the PD brain. Scientists believe that the misfolding of alpha-synuclein is central to the neurodegenerative process of PD, as well as a number of other disorders, collectively called
synucleinopathies, such as Lewy Body Dementia and Multiple System Atrophy, making it a priority target for drug development. We have identified molecules from our Morphomer library that stain selectively alpha-synuclein pathological structures in
human PD brain sections. Ongoing work to optimize the potency, selectivity and pharmacokinetics of these tracers is being funded by the Michael J. Fox Foundation for Parkinson&#146;s Research and Biogen under the non-exclusive research and
development agreement signed in April 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently there are no imaging products in the market that target alpha-synuclein. This provides
us with a unique opportunity to become the market leader in alpha-synuclein PET imaging. We believe the ability to image alpha-synuclein deposits in the brain will enable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The diagnosis of PD at much earlier premotor stages than is now possible, thereby enabling early therapeutic intervention and corresponding better patient outcomes; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The use of alpha-synuclein as a surrogate marker in clinical studies of novel therapeutic regimens designed to slow or halt progression of PD; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The diagnosis of sub-populations of PD and other synucleinopathies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These applications of
alpha-synuclein PET imaging agents have the potential to fundamentally change the approach of treating PD and other similar diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
PD market size is estimated to grow from $3.6 billion in 2012 to approximately $5.3 billion in 2022. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements and Collaborations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our SupraAntigen and Morphomer platforms have generated large numbers of clinical assets that address diseases related to protein misfolding,
such as AD, PD and Down syndrome. Select key assets in the product pipeline have been licensed for upfront payments, milestones and royalties to help offset the cost of our research and internal product development. Discussions with other companies
are ongoing. We have signed a number of licensing agreements with leading pharmaceutical companies to assist and accelerate the development of our product pipeline, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Genentech signed in November 2006 (and amended in May 2015) for crenezumab for AD, under which we may become eligible to receive payments totaling up to approximately $340 million,
excluding royalties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Genentech signed in June 2012 for anti-tau antibodies for AD, under which we may become eligible to receive payments totaling up to $418 million, excluding royalties.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Janssen signed in December 2014 for therapeutic anti-tau vaccines for AD, and potentially other tauopathies, under which we may become eligible to receive payments totaling up to CHF
500&nbsp;million, excluding royalties. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A worldwide licensing agreement with Piramal Imaging signed in May 2014 for small molecule tau ligands for use as PET tracers under which we may become eligible to receive payments totaling up to &#128;157&nbsp;million,
excluding royalties. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Genentech </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have two partnership agreements with Genentech, a company with a reputation for scientific excellence and a history of bringing innovative
protein therapeutics to market. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Crenezumab Collaboration Agreement of 2006 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We signed our first agreement with Genentech in November 2006 and amended the agreement in May 2015. This is an exclusive, worldwide licensing
agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta. The agreement provides for a second therapeutic product based on the same intellectual property and anti-Abeta antibody compound, as well as an anti-Abeta
diagnostic product. Genentech commenced Phase 3 clinical studies for crenezumab in the first quarter of 2016. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the agreement with Genentech, we may become eligible to receive payments totaling up to
approximately $340 million, excluding royalties. The agreement includes upfront and milestone payments. In addition, we will receive royalties on sales. The structure of the collaboration agreement is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> are payable upon commencement of each of Phase 1 and 2 of clinical developments, and upon the earlier of Genentech&#146;s decision to authorize Phase 3 or the commencement of Phase 3
of clinical developments. In addition, for a second indication, clinical milestone payments would be payable upon commencement of Phase 2 of clinical developments and upon the earlier of Genentech&#146;s decision to authorize Phase 3 or the
commencement of Phase 3 of clinical developments. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Regulatory milestone payments</I> upon making regulatory filings in the U.S. and Europe, respectively, and milestone payments upon obtaining marketing approval in each of the U.S. and Europe. In addition, for a
second indication, additional regulatory and approval milestones would be payable. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Royalties</I> on sales with different royalty rates applicable in the U.S. and Europe. Royalty levels are tied to annual sales volumes. We will receive royalties on sales of crenezumab with the percentage
rates ranging from net high single digits to the mid-teens. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have received total payments of $65 million which
comprise upfront and clinical milestone payments. We received a $25 million upfront payment at the time of signing of the collaboration agreement and have since then obtained three milestone payments totaling $40 million including the Phase 3
milestone payment we received in July 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Genentech bears all the costs of developing crenezumab
through the clinical phases. In addition, Genentech is responsible for the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs, sales and marketing costs. Intellectual property costs related to any
crenezumab-related intellectual property filed solely by us and any costs associated with filing, maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate by its terms on the date on which
all obligations between the parties with respect to the payment of milestones or royalties for licensed products have passed or expired. However, Genentech may terminate the agreement at any time by providing three months&#146; notice to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-tau Antibody Collaboration Agreement of 2012 </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2012, we entered into a second partnership with Genentech to commercialize our anti-tau antibodies for use as immunotherapeutics. The
value of this exclusive, worldwide alliance is potentially greater than $418&nbsp;million and includes upfront and milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at percentage rates ranging from the
mid-single digits to high single digits. The agreement also provides for collaboration on two additional indications built on the same anti-tau antibody program, as well as a potential anti-tau diagnostic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have received payments totaling CHF 45&nbsp;million including a CHF 14&nbsp;million milestone payment associated with the recent
announcement of the commencement of the Phase 1 clinical study of the lead anti-tau antibody candidate and a CHF 14 million milestone payment received in 2015 in connection with the ED-GO decision. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the collaboration agreement is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Preclinical and clinical milestone payments</I> upon selection of a lead candidate, commencement of each of Phase 1, 2 and 3 of clinical development. In addition, for a second indication, clinical milestone payments
would be payable upon commencement of each of Phase 2 and 3 of clinical development. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Regulatory milestones payments</I> upon making regulatory filings in the U.S., Europe, and Japan, respectively. In addition, for a second indication, similar regulatory milestones would be payable.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialization milestones</I> payable upon making a first commercial sale in each of the U.S., Europe and Japan. For a second indication, commercialization milestones exist for each of the U.S., Europe and Japan
which are triggered by the first commercial sale for the second indication in each of those jurisdictions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I></I><I>Royalties</I> on sales with royalty rates differing based on the source of the intellectual property underlying the commercial product. </TD></TR></TABLE>
<P STYLE="margin-top:10pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement, Genentech bears all the costs of developing the anti-tau antibody compound through the clinical phases. In
addition, Genentech is responsible for the costs associated with seeking and obtaining regulatory and marketing approvals, manufacturing costs, sales and marketing costs. Intellectual property costs related to any anti-tau antibody-related
intellectual property filed solely by us and any costs associated with filing, maintaining and protecting intellectual property filed jointly we share with Genentech. The agreement will terminate by its terms on the date on which all obligations
between the parties with respect to the payment of milestones or royalties for licensed products have passed or expired. However, Genentech may terminate the agreement at any time by providing three months&#146; notice to us. </P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Janssen Pharmaceuticals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
December of 2014, we entered into a partnership with Janssen Pharmaceuticals to develop and commercialize therapeutic anti-tau vaccines for the treatment of AD and potentially other tauopathies. The partnership includes a worldwide exclusive license
and research collaboration. We and Janssen will co-develop the lead therapeutic vaccine candidate, ACI-35, through Phase 1b completion. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and
commercialization of ACI-35. <FONT STYLE="white-space:nowrap">ACI-35</FONT> is an active therapeutic vaccine candidate stimulating the patient&#146;s immune system to produce a polyclonal antibody response against phosphorylated tau protein. The
agreement also allows for the collaboration to be expanded to include a second indication based on the same anti-tau vaccine program and intellectual property related to this program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We received an upfront payment of about CHF 25.9&nbsp;million, a research contribution of CHF 1.5&nbsp;million and a CHF 4.9&nbsp;million
clinical milestone payment and we are eligible to receive development, regulatory and commercialization milestone payments potentially totaling up to CHF 500&nbsp;million for AD and a potential second indication outside of AD. Additionally, we will
receive royalties on sales at a percentage rate ranging from the low double digits to mid-teens. We have entered into a three-year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of
tauopathies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the collaboration agreement is as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> upon completion of Phase 1b, commencement of each of Phase 2 and 3 of clinical development. For a second cohort, a milestone payment is payable to us upon commencement of Phase 2
clinical studies. In addition, for a second indication, clinical milestone payments would be payable upon commencement of Phase 3 clinical studies. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Regulatory milestone payments</I> upon making regulatory filings in the U.S., Europe, and Japan, respectively. In addition, for a second indication, similar regulatory milestones would be payable. Also, for a second
indication, additional regulatory milestone payments are payable by Janssen to us upon receipt of each of the regulatory approvals in the U.S., Europe and Japan. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Commercialization milestones</I> payable upon making a first commercial sale in each of the U.S., Europe and Japan, and upon achieving certain commercial milestones. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Royalties</I> on sales with royalty rates differing based on the level of annual sales. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement will terminate by its terms on the date on which all royalty obligations have been
paid thereunder. However, under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the Phase 1b clinical study by providing 90 days&#146; notice to us. </P>
<P STYLE="margin-top:17pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piramal Imaging </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2014, we
entered into our first diagnostic partnership with Piramal Imaging, one of the world leaders in imaging products. The agreement with Piramal is for a compound from the Morphomer chemical library that binds to pathogenic tau for use as a PET tracer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The exclusive, worldwide licensing agreement with Piramal Imaging includes upfront and milestone payments totaling up to
&#128;157&nbsp;million, plus royalties on sales at percentage rates ranging from mid-single digits to low teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The structure of the
collaboration agreement is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>An upfront payment</I> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Clinical milestone payments</I> upon the commencement of Phase 1, 2 and 3 for the lead indication. We would be entitled to further clinical milestone payments for the commencement of Phase 2 and 3 for a second
indication </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Regulatory approval and marketing approval milestones</I> upon filing and approval in each of the U.S. and Europe </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Sales milestones</I> tied to specific total sales amounts </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The agreement will terminate by
its terms on the date of expiration of the last-to-expire royalty term, where each royalty term under the agreement expires on a product-by-product basis and country-by-country basis on the later of (i) ten years after the first commercial sale of
the relevant product in such country or (ii) the date on which the patent covering the sale of such product in such country is no longer valid or enforceable. However, Piramal Imaging may terminate the agreement at any time after the first eighteen
months from the effective date of this agreement by providing three months&#146; notice to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Alpha-synuclein and TDP-43 PET Imaging Tracers
&#150; Collaboration with Biogen </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In April 2016, we entered into a non-exclusive research and development agreement with Biogen
International GmbH, or Biogen.&nbsp;Under the agreement, we and Biogen have agreed to collaborate in the research and early clinical development of our alpha-synuclein PET Tracer program for Parkinson&#146;s disease and other synucleinopathies, and
a second program for the identification, research and development of novel PET ligands against TDP-43, a protein recently linked to neurodegeneration in diseases such as amyotrophic lateral sclerosis. In addition, we have agreed to share the costs
of the collaboration with Biogen, with Biogen primarily funding the majority of research costs, subject to a cap, which includes an upfront technology access fee and funding towards research and development personnel.&nbsp;We will own all
intellectual property rights to any invention relating to alpha-synuclein or TDP-43 PET tracers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless earlier terminated, the agreement
will expire upon the later of three years or the completion of the collaboration, but in no event later than four years, unless we and Biogen mutually agree to extend the term of the agreement.&nbsp;Biogen may terminate the agreement for any reason
upon thirty days&#146; written notice to us.&nbsp;Following the expiration of the agreement, we may be required to negotiate and enter into a supply agreement with Biogen pursuant to which we would supply Biogen with PET tracers created under the
collaboration for Biogen&#146;s continued development activities.&nbsp;Under certain circumstances, including prior to the expiration of the collaboration agreement, we may also be required to grant Biogen a license or other rights to develop and
commercialize such PET tracers outside of the collaboration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>National Institutes of Health/Banner Alzheimer&#146;s Institute </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2013, the NIH and Banner Alzheimer&#146;s Institute selected crenezumab for the first ever AD prevention study before onset of symptoms in
highest-risk individuals. This landmark study is being performed on a family clan in Colombia with Paisa mutation leading to Abeta accumulation and early onset AD. The $100 million multi-year study is being funded with grants from the NIH, Banner
Alzheimer&#146;s Institute and our partner, Genentech. Interim results from this study are expected to be available in 2017. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael J. Fox
Foundation for Parkinson&#146;s Research </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2015, we were awarded an important grant from the Michael J. Fox Foundation for
Parkinson&#146;s Research. The grant is funding the development of a diagnostic imaging agent capable of detecting PD at an early stage. The project focuses on alpha-synuclein PET tracers. We have identified molecules from our Morphomer library that
stain selectively alpha-synuclein pathological structures in human PD brain sections. We are optimizing the potency, selectivity and pharmacokinetics of these tracers and expect to select a lead candidate in the first quarter of 2016. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nestl&#233; Institute of Health Sciences SA </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2015, we entered into a research collaboration agreement with the Nestl&#233; Institute of Health Sciences SA, or NIHS, a
fundamental research institute of the global nutrition, health and wellness company Nestl&#233;, to develop a novel, minimally invasive tau diagnostic assay for the early diagnosis of AD. Under the terms of the agreement, we will provide expertise
in the biology and pathology of tau as well as commit our laboratory capabilities to support the collaborative research program. NIHS will apply its proprietary multiplexed antibody technology platform to the research program with the goal of
identifying and validating a highly sensitive diagnostic assay for the detection of tau in human cerebrospinal fluid and blood plasma. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The biopharmaceuticals industry is highly competitive across all therapeutic fields. In the field of neurodegenerative diseases, there
are many public and private companies or institutions that are actively engaged in the discovery and development of therapeutic and diagnostic products. Some of these products may have a similar target to our product candidates or address similar
markets. The industry is still in its infancy in terms of defining the pathology of neurodegenerative diseases. As disease understanding progresses, the number of novel product candidates may well increase and broaden the therapeutic and diagnostic
options in our product markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Currently, there are no approved disease-modifying products for AD or any other neurodegenerative
disease. Current approved therapies seek to treat the symptoms of AD, such as cognitive decline, but do not slow or stop the progression of the disease. In addition, commonly, there is off-label prescription of antidepressant and antipsychotic
agents for more advanced AD patients who may suffer from agitation, aggressive behaviors, psychosis and depression. No new drugs have been approved for the treatment of AD since 2003. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect there to be several classes of disease-modifying agents that will enter the AD market. One such class is monoclonal antibodies that
target Abeta plaques, the same target as for our candidate product crenezumab. Another target for monoclonal antibodies is tau protein aggregates. Therapeutic vaccines are a second class of disease-modifying therapies, and include our candidate
products ACI-24, that targets Abeta plaque, and ACI-35, that targets aggregated tau protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability of novel diagnostic agents
to visualize the disease development in AD patients is critical for successful clinical development of disease-modifying products in AD. At the forefront of this new diagnostic effort are PET agents for in-life imaging of disease, and in particular,
tau-targeting PET agents which we believe will allow precise assessment of disease AD patients. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Crenezumab:</I></B> If crenezumab is approved, it would compete with other monoclonal antibody products
that target Abeta plaques and act as disease-modifying agents. Currently, no product has been approved </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
that is a disease-modifying agent targeting Abeta plaques; however, a number of such product candidates are in clinical development. These include solanezumab, gantenerumab and aducanumab, each
of which is in Phase 3 clinical study and which are being advanced by Eli Lilly, Roche and Biogen, respectively. Biogen has a second product candidate known as BAN2401, which is currently in Phase 2 clinical study. Aducanumab recently received Fast
Track designation from the FDA as did crenezumab in 2008. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-24 in AD:</I></B> ACI-24, if approved, would compete with other approved anti-Abeta-targeting therapeutic vaccines. Several potential competing product candidates have not continued through the regulatory
approval process, including ACC-001 (Janssen / Pfizer) and AN-1792 (Elan / Janssen), both of which were discontinued after completing Phase 2 studies. Other potential competing product candidates for ACI-24 include ABvac 40 (Araclon Bioscience)
which has completed a Phase 1 study and Affitope-AD-02 (AFFiRiS AG / GlaxoSmithKline) and CAD-106 (Novartis International AG), each of which has completed a Phase 2 study. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-24 in Down syndrome:</I></B> ACI-24 is the first disease-modifying vaccine candidate addressing AD in Down syndrome, with a potential preventive and therapeutic application. While there are symptomatic
treatments of Down syndrome in clinical development, to our knowledge there are no other disease-modifying treatments for AD in Down syndrome. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>ACI-35:</I></B> ACI-35, if approved, would compete with other approved tau-targeting therapeutic vaccines. This includes AADVAC1, an anti-tau vaccine product candidate currently being advanced in the regulatory
approval process by Axon Neurosciences. AADVAC1 entered Phase 1 clinical studies in May 2013. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Anti-tau Antibodies:</I></B> To our knowledge, there are no competing products currently in clinical development for AD. However, the anti-tau monoclonal antibodies BMS-986168 (Bristol-Myers Squibb Company) and
ABBV-812E (AbbVie) are currently in Phase 1 clinical development in the orphan indication PSP, a tau protein-based neurodegenerative disease. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Anti-tau Morphomers:</I></B> A potential competitor to our anti-tau Morphomers is LMTX. LMTX is a methylene blue derivative that is being advanced by TauRx Therapeutics and is intended to target tau protein
aggregation. LMTX entered Phase 3 clinical study in September 2012. No clinical data read-out has been made available. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Diagnostics</I></B><B><I>:</I></B> Currently, there are no approved tau PET imaging products. However, should our tau PET imaging agent be approved, it would compete with other approved tau-PET agents. These
include (i)&nbsp;18F-AV-1451 (previously T807), which is being advanced by Eli Lilly subsidiary, Avid Radiopharmaceuticals, and is currently in Phase 2 clinical studies that began in December 2013, (ii)&nbsp;THK-5117, is being advanced by GE
Healthcare under license from the Tohoku University School of Medicine and is currently in Phase 1/2 studies, (iii)&nbsp;PBB3, a product candidate in Phase 1 studies and being advanced by the National Institute of Radiological Services and
(iv)&nbsp;Roche is evaluating internal tau PET imaging ligands in Phase 1 clinical studies in AD patients. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our
competitors have significantly greater financial, technical and human resources than we have available. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller
number of our competitors. Our commercial opportunity and our success will be based in part on our ability to identify, develop and manage a portfolio of product candidates that are safer and more effective than competing products. However, this
opportunity could be eroded or even eliminated if our competitors develop and/or market products that are novel and have superior safety and efficacy profiles, that may be brought to the market more rapidly due to greater available resources, or
that are less costly than our current or future product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy to date has been to focus on identifying partnerships for our early stage product candidates as both a way to secure non-dilutive
capital to fund our other research and development programs but also as a way to accelerate the development of these partnered products by leveraging our partners&#146; extensive knowledge in clinical studies, drug development, manufacturing and
commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With greater financial resources at our disposal but also given the significant knowledge acquired by our scientists
and scientific leadership, we intend to retain selected promising product candidates in-house for a longer period of time and fund their development from our own resources. This will allow us to generate greater value from these product candidates,
allowing us to demand more significant terms from a prospective partner. For example, our current plan is to retain full control of our two Abeta vaccine programs focused on AD and Down syndrome, meaning that we would fund the planned Phase 2 and
Phase 2/3 studies, respectively, from our financial resources. In the field of diagnostics, the parallel development of therapeutic compounds and companion diagnostics is of growing importance to the pharmaceutical industry. The development
timeframe of a PET diagnostic agent is significantly shorter than for a therapeutic product providing the prospect for potential diagnostic product revenues to be realized quicker than potential therapeutic product revenues. Our Morphomer platform
is particularly well suited to generate molecules for use in the development of companion diagnostics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our current stage of product
development, we currently do not have a commercialization infrastructure. If any of our diagnostic product candidates is granted marketing approval, we intend to focus our initial commercial efforts in the United States and select European markets,
which we believe represent the largest market opportunities for us. In those markets, we expect our commercial operations to include our own specialty sales force that will target neurologists and gerontologists, both in hospitals and in private
practice. In other markets, we expect to seek partnerships that would maximize our products&#146; commercial potential. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect the proprietary technology that we believe is important to our business, including seeking and maintaining U.S. and
foreign patents intended to cover our products and compositions, their methods of use and processes for their manufacture, as well as our proprietary technology platforms, diagnostic candidates, and any other inventions that are commercially
important to the development of our business. We also rely on trade secrets and know-how to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our success will significantly depend on our ability to obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and know-how related to our business, defend and enforce patents, preserve the confidentiality of our trade secrets and operate our business without infringing any patents and other intellectual property or proprietary rights
of third parties. See the section titled &#147;Risk Factors&#151; Risks Related to Intellectual Property&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of August&nbsp;31, 2016, we owned or co-owned approximately 22 issued U.S. patents and 173 issued patents in other jurisdictions, as well
as 18 pending U.S. patent applications and 327 pending foreign patent applications. As of August&nbsp;31, 2016, we licensed approximately 12 issued U.S. patents and 12 pending U.S. patent applications, as well as 110 issued patents in other
jurisdictions and 258 pending foreign patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent portfolios for our three most advanced product candidates as of
August&nbsp;31, 2016 are summarized below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Crenezumab </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio relating to crenezumab includes patents and patent applications with claims directed to composition of matter (including
claims directed to the crenezumab antibody or a fragment thereof, a polynucleotide encoding the crenezumab antibody or a fragment thereof, a cell line used to produce the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
crenezumab antibody as well as pharmaceutical compositions comprising the crenezumab antibody), claims directed to treating certain indications using the crenezumab antibody including AD, claims
directed to a method of manufacturing the crenezumab antibody, and claims directed to diagnostic and prognostic uses of the crenezumab antibody. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio relating to crenezumab includes patents and patent applications that we own or co-own in four different patent families.
As of August&nbsp;31, 2016, we owned or co-owned approximately 20 patents (not including the patents in the individual countries where the issued European patent was validated) and 39 patent applications in 34 countries in our main patent family
directed to the crenezumab antibody and methods of using the crenezumab antibody to treat certain indications, including AD. This patent portfolio includes three issued U.S. patents and two pending U.S. patent applications, which, if the appropriate
maintenance or other governmental fees are paid, are expected to expire in 2027, excluding any additional term for patent term adjustments or patent term extensions. This patent portfolio also includes a PCT patent application which was filed on
July 13, 2007. If the appropriate maintenance, renewal, annuity, or other governmental fees are paid, national stage applications issuing from this PCT patent application, are expected to expire in 2027, excluding any additional term for patent term
adjustments or patent term extensions, as applicable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-24 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for ACI-24 includes composition of matter claims (including claims directed to the ACI-24 antigenic construct) claims
directed to treating certain indications using ACI-24 including AD, and claims directed to using ACI-24 to induce an immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
patent portfolio for ACI-24 consists of approximately 23 issued patents and 11 pending patent applications in 30 countries. With respect to the U.S., we own two issued U.S. patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents in this patent portfolio claim the benefit of a PCT application with a filing date of December&nbsp;8, 2006. The issued patents in
this patent portfolio, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to expire in 2026, excluding any additional term for patent term adjustments or patent term extensions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>ACI-35 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for
ACI-35 includes composition of matter claims (including claims directed to the ACI-35 antigenic peptide and a pharmaceutical composition comprising such an antigenic peptide), claims directed to treating certain indications using ACI-35 including
AD, and claims directed to using ACI-35 to induce an immune response. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our patent portfolio for ACI-35 consists of approximately 14 issued
patents and 16 pending patent applications in 27 countries. With respect to the U.S., we own one issued U.S. patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents in this
patent portfolio claim the benefit of a PCT application with a filing date of April&nbsp;1, 2010. The issued patents in this patent portfolio, if the appropriate maintenance, renewal, annuity or other governmental fees are paid, are expected to
expire in 2030, excluding any additional term for patent term adjustments or patent term extensions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing and Supply </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Background </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The manufacturing and
supply of the clinical study materials are currently done in collaboration with our collaboration partners (<I>e.g.</I>, Genentech in the case of crenezumab and anti-tau antibodies and Piramal Imaging in the case of tau PET imaging) or contract
manufacturing organizations (<I>e.g.</I>, for ACI-35 and ACI-24) for the supply of raw materials, drug substances and drug products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an established standard operating procedure to properly select the contract manufacturing
organization to which the manufacturing tasks will be assigned. In the assessment, we consider the availability of the technical skills necessary to support the project, the business and commercial aspects related to the collaboration and the
compliance of our providers with local and international regulations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Collaboration Partners and Contract Manufacturing Organizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genentech, a leading biotech company with extensive experience in developing, producing and distributing products worldwide from pre-clinical
to commercial stages of development, manufactures and supplies clinical study materials for crenezumab and anti-tau antibodies. Tau-PET imaging compounds are produced in collaboration with Piramal, a well-established Indian company with a strong
chemical background supported by an India based contract manufacturing organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACI-24 and ACI-35 APIs (active pharmaceutical
ingredients) are produced by Bachem AG, an experienced company based in Switzerland. Drug products for the advancement of ACI-24 are manufactured by Polymun, a company based in Austria with significant experience in developing and producing
Liposomal formulations, while drug products for the advancement of ACI-35 are produced by Northern Lipids, a company based in Canada with a strong and long experience in the field of liposomal formulation and production. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compliance with Governing Rules and Quality Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The facilities used by our collaboration partners and contract manufacturing organizations to manufacture our product candidates are
systematically audited by local authorities and occasionally inspected by competent authorities where the clinical studies are ongoing. The facilities where the commercial productions are performed must be approved by the FDA or other relevant
regulatory authorities pursuant to inspections that are conducted after we submit our NDA or comparable marketing applications. We perform periodic quality audits of the manufacturing facilities and contract manufacturing organizations to monitor
their compliance with the regional laws, regulations and applicable cGMP standards and other laws and regulations, such as those related to environmental health and safety matters. The scope of our audits also involves monitoring the ability of our
providers to maintain adequate quality controls and quality assurance systems including personnel qualification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After manufacturing, our
products are submitted to extensive characterization and quality control testing plans performed by using properly developed analytical methods that are qualified or validated; this ensures the accuracy of the results generated and provides evidence
of the quality of our products. In addition, our products are submitted to detailed and standardized stability programs aimed at demonstrating the stability during the storage period; this, while it guarantees the safety of the products, supports
the definition of a suitable supply chain that may encompass the distribution of the products in different continents. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual framework
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have established, with each contract manufacturing organization supplying drug substances or drug products, quality agreements
and master service agreements. Quality agreements define the quality standards required to develop, produce and supply the product. Quality agreements also define the responsibilities related to the collaboration with regards to the quality related
aspects. Master service agreements define the framework under which the quality agreements operate. Any failure to achieve and maintain compliance with the laws, regulations and standards, suspension of the manufacturing of our product candidates or
revoke of cGMP permissions which would adversely affect our business and reputation are defined in the master service agreements and quality agreements. The risk that any third-party providers may breach the agreements they have with us because of
factors beyond our control and the possibility they may also terminate or refuse to renew their agreements because of their own financial difficulties or business priorities, potentially at a time that is costly or otherwise inconvenient for us is
managed by us with constant investments toward maintaining reserve stocks and in-depth process know-how. The latter is supported by continuous in-house process development and production activities of small-scale/research grade materials that may
offer the chance to rapidly identify alternative contract manufacturers to which the manufacturing process could be transferred providing continuity for the clinical study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Interaction with collaboration partners and contract manufacturing organizations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, our partnership with contract manufacturing organizations is managed through an efficient project management platform in which teams
are formed with the representatives of each key function from both parties. Meetings occur either by telephone conferences aimed at updating short term actions or face-to-face when mid-long term development plans are discussed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation and Our Regulatory Department </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department has a strong culture of regulatory compliance, operating under three guiding principles, to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Provide constructive regulatory input for development products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ensure smooth regulatory approvals by anticipating hurdles. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Build confidence with regulators by continuous communication. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department has
conducted four pre-IND meetings with the FDA (ACI-24 for AD and Down&#146;s syndrome, ACI-91 and tau Imaging) and five Scientific Advice meetings, which are the European equivalent of pre-IND meetings (with German BfArM, Swedish Medical Products
Agency; Medicine &amp; Healthcare Products Regulatory Agency (UK), Finnish Medicines Agency, and the European Medicines Agency). Since 2008, our regulatory department has filed a total of six clinical study applications in the EU (Germany, Austria,
Denmark, Sweden, UK and two in Finland) and one IND in the US. Given the seriousness of AD and public pressure for new therapeutics, we consider regulatory agencies to be important stakeholders in our clinical studies. We are committed to working
closely with world regulatory authorities to adhere to and achieve the highest levels of safety in the most timely and efficient manner. The transparency we have achieved and our goal of a close working relationship with the regulatory agencies, in
particular the FDA, are intended to facilitate expeditious execution through the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our regulatory department
contains a quality assurance, or QA, function. As every quality issue ultimately requires regulatory involvement and input, this approach is intended to lead to rapid resolution of issues and ensure full compliance to satisfy both the reviewers and
the inspectors at the government health authorities. The mission of our QA function is to establish, maintain and manage the corporate quality management system. Our regulatory department is charged with keeping our entire organization directly or
indirectly involved in the clinical study application process in a state of &#147;inspection readiness.&#148; To that end, we ensure that the study master file is complete and regularly updated. Our regulatory department is also tasked with
generating our annual quality plan. The personnel tasked with QA have issued a set of approximately 30 standard operating procedures and continuously train the relevant staff. Our QA personnel conduct regular audits, including in-person audits of
the contract manufacturers, contract research organizations and laboratories conducting primary end-point analysis. Other supervision by our QA function involves their service procedures standard operating procedures and periodic communication. In
addition, we have recently added a corporate documentation specialist to ensure good documentation practice. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Product Approval
Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The clinical studies, manufacturing, labeling, storage, distribution, record keeping, advertising, promotion, import,
export and marketing, among other things, of our product candidates are subject to extensive regulation by governmental authorities in the United States and other countries. The U.S. Food and Drug Administration, or FDA, under the Federal Food,
Drug, and Cosmetic Act, or FDCA, regulates pharmaceutical products in the United States. The steps required before a drug may be approved for marketing in the United States generally include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the completion of pre-clinical laboratory tests and animal tests conducted under Good Laboratory Practice, or GLP, regulations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the submission to the FDA of an Investigational New Drug, or IND, application for human clinical testing, which must become effective before human clinical studies commence; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining a positive opinion from the Ethics Committee (Europe) / Institutional Review Board (United States) to commence study on human subjects; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of adequate and well-controlled human clinical studies to establish the safety and efficacy of the product candidate for each proposed indication and conducted in accordance with current Good Clinical
Practice, or cGCP, requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-NDA submission meeting with FDA (highly recommended); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the submission to the FDA of a New Drug Application, or NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the NDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA Pre-Approval Inspection (PAI) of the manufacturing facilities at which the product is made to assess compliance with current Good Manufacturing Practice, or cGMP, requirements;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s review and approval of an NDA prior to any commercial marketing or sale of the drug in the United States; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">having a parallel scientific advice from the European Medicines Agency or Health-Technology-Assessment body where the payors are involved at the outset (Phase 2), which is intended to facilitate the design of clinical
studies to primarily target populations with a high chance of obtaining reimbursement and accelerate the process of time-to-reimbursement. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has various programs, including fast track, priority review, accelerated approval, and breakthrough therapy designation, that are
intended to increase agency interactions, expedite or facilitate the process for reviewing drug candidates, and/or provide for initial approval on the basis of surrogate endpoints. We believe that one or more of our product candidates may qualify
for some of these expedited development and review programs. Even if a drug candidate qualifies for one or more of these programs, the FDA may later decide that the drug candidate no longer meets the conditions for qualification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Fast Track program is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new
drugs are eligible for Fast Track designation if they are designed to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of
the product and the specific indication for which it is being studied. The sponsor of a new drug may request the FDA to designate the drug as a Fast Track product at any time during the clinical development of the product. AD, for example, meets
both pre-requisites&#151;it is life-threatening and constitutes an unmet medical need. Unique to a Fast Track product, the FDA may consider for review sections of the marketing application on a rolling basis before the complete application is
submitted, if the sponsor provides a schedule for the submission of the sections of the application, the FDA agrees to accept sections of the application and determines that the schedule is acceptable, and the sponsor pays any required user fees
upon submission of the first section of the application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any product submitted to the FDA for marketing, including under a Fast Track
program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide safe and effective
therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an
application for a new drug designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Drug candidates studied for their safety and effectiveness in treating serious or
life-threatening illnesses and that provide meaningful therapeutic benefit over </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
existing treatments may receive accelerated approval, which means that they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an
effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity. As a condition of approval, the FDA may require that a sponsor
of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. Failure to conduct required post-approval trials, or the inability to confirm a clinical benefit during post-marketing trials, may allow
the FDA to withdraw the drug from the market on an expedited basis. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial
launch of the product. Fast Track designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Food and Drug Administration Safety and Innovation Act of 2012 also amended the FDCA to require FDA to expedite the development and review
of a breakthrough therapy. A drug can be designated as a breakthrough therapy if it is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that it may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints. A sponsor may request that a drug be designated as a breakthrough therapy at any time during the clinical development of the product. If so designated, FDA shall act to
expedite the development and review of the product&#146;s marketing application, including by meeting with the sponsor throughout the product&#146;s development, providing timely advice to the sponsor to ensure that the development program to gather
nonclinical and clinical data is as efficient as practicable, involving senior managers and experienced review staff in a cross-disciplinary review, assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient
review of the development program and to serve as a scientific liaison between the review team and the sponsor, and taking steps to ensure that the design of the clinical trials is as efficient as practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The testing and approval process requires substantial time, effort and financial resources, and the receipt and timing of any approval is
uncertain. Given this paradigm, AD has been given a Life Threatening Disease status by the FDA and therefore AD therapies are eligible for the expanded access program for investigational drugs and other pathways like Breakthrough Therapy,
Accelerated Approval and Priority Review. Also, a single well-designed, well-conducted pivotal clinical study could be sufficient to trigger market approval pending a successful PAI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pre-clinical studies include laboratory evaluations of the product candidate, as well as animal studies to assess the potential safety and
efficacy of the product candidate. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of the IND, which must become effective before clinical studies may be
commenced. The IND will become effective automatically 30 days after receipt by the FDA, unless the FDA raises concerns or questions about the conduct of the studies as outlined in the IND prior to that time. In this case, the IND sponsor and the
FDA must resolve any outstanding concerns before clinical studies can proceed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies involve the administration of the product
candidates to healthy volunteers or patients with the disease to be treated under the supervision of a qualified principal investigator. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the
parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Further, each clinical study must be
reviewed and approved by an independent institutional review board, or IRB, either centrally or individually at each institution at which the clinical study will be conducted. The IRB will consider, among other things, ethical factors, the safety of
human subjects and the possible liability of the institution. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries. The FDA, the IRB or the clinical study sponsor may suspend
or terminate clinical studies at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Additionally, some clinical studies are overseen by an independent group of qualified
experts organized by the clinical study </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a study may move forward at designated check points based on access to certain
data from the study. We may also suspend or terminate a clinical study based on evolving business objectives and/or competitive climate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies are typically conducted in three sequential phases prior to approval, but the phases may overlap. These phases generally
include the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase 1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase 1 clinical studies represent the initial introduction of a product candidate into human subjects, frequently healthy volunteers. In Phase 1, the product candidate is usually tested for safety, including adverse effects, dosage
tolerance, absorption, distribution, metabolism, excretion and pharmacodynamics.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Phase 2 clinical studies usually involve studies in a limited patient population to (1) evaluate the efficacy of the product candidate for specific indications, (2) determine dosage tolerance and optimal dosage and (3) identify
possible adverse effects and safety risks.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phase&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If a product candidate is found to be potentially effective and to have an acceptable safety profile in Phase 2 studies, the clinical study program will be expanded to Phase 3 clinical studies to further demonstrate clinical
efficacy, optimal dosage and safety within an expanded patient population at geographically dispersed clinical study sites.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 4 clinical studies are conducted after approval to gain additional experience from the treatment of
patients in the intended therapeutic indication and to document a clinical benefit in the case of drugs approved under accelerated approval regulations, or when otherwise requested by the FDA in the form of post-market requirements or commitments.
Failure to promptly conduct any required Phase 4 clinical studies could result in withdrawal of approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The results of pre-clinical
studies and clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information on the manufacture, composition and quality of the product, are submitted to the FDA in the form of an NDA
requesting approval to market the product. The NDA must be accompanied by a significant user fee payment. The FDA has substantial discretion in the approval process and may refuse to accept any application or decide that the data is insufficient for
approval and require additional pre-clinical, clinical or other studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that it generally takes 10 to 15 years, or possibly
longer, to discover, develop and bring to market a new pharmaceutical product in the United States. Several years may be needed to complete each phase, including discovery, preclinical, Phase 1, 2 or 3, or marketing authorization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and
effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. Recently, the Food and Drug
Administration Safety and Innovation Act, or FDASIA, which was signed into law on July&nbsp;9, 2012, amended the FDCA. FDASIA requires that a sponsor who is planning to submit a marketing application for a drug or biological product that includes a
new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or PSP, within sixty days of an end-of-phase 2 meeting or as may be agreed between the sponsor and FDA.
The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such
detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. FDA and the sponsor must reach agreement on the
PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from nonclinical studies, early phase clinical trials, and/or other clinical development
programs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of preparing and submitting an NDA is substantial. Under federal law, NDAs are subject
to substantial application user fees and the sponsor of an approved NDA is also subject to annual product and establishment user fees. Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by a user fee. The
FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s fee schedule, effective through September 30, 2016, the user fee for each NDA application requiring clinical data is $2,374,200. PDUFA also imposes an annual product fee
for drugs ($114,450), and an annual establishment fee ($585,200) on facilities used to manufacture prescription drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first
application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once the NDA submission has been submitted, the FDA has 60 days after submission of the NDA to conduct an initial review to determine whether
it is sufficient to accept for filing. Under the Prescription Drug User Fee Act, or PDUFA, the FDA sets a goal date by which it plans to complete its review. This is typically 12 months from the date of submission of the NDA application. The review
process is often extended by FDA requests for additional information or clarification. Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured and will not approve the product unless the manufacturing
facility complies with cGMPs and may also inspect clinical study sites for integrity of data supporting safety and efficacy. The FDA may also convene an advisory committee of external experts to provide input on certain review issues relating to
risk, benefit and interpretation of clinical study data. The FDA is not bound by the recommendations of an advisory committee, but generally follows such recommendations in making its decisions. The FDA may delay approval of an NDA if applicable
regulatory criteria are not satisfied and/or the FDA requires additional testing or information. The FDA may require post-marketing testing and surveillance to monitor safety or efficacy of a product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities where the drug product and/or its API will be produced,
it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle
of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical study(ies), and/or other significant, expensive and
time-consuming requirements related to clinical studies, pre-clinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could
also approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market
studies or clinical studies. Such post-market testing may include Phase 4 clinical studies and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Special Protocol Assessment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and an IND sponsor may agree in writing on the design and size of clinical studies intended to form the primary basis of a claim of
effectiveness in an NDA. This process is known as a special protocol assessment, or SPA. Upon a specific request for a SPA by an IND sponsor, the FDA will evaluate the protocol. If a SPA agreement is reached, however, it is not a guarantee of
product approval by the FDA or approval of any permissible claims about the product. The FDA retains significant latitude and discretion in interpreting the terms of the SPA agreement and the data and results from any study that is the subject of
the SPA agreement. In particular, the SPA agreement is not binding on the FDA if previously unrecognized public health concerns later come to light, other new scientific concerns regarding product safety or efficacy arise, the IND sponsor fails to
comply with the protocol agreed upon, or the relevant data, assumptions, or information provided by the IND </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sponsor when requesting a SPA agreement change, are found to be false statements or misstatements, or are found to omit relevant facts. A SPA agreement may not be changed by the sponsor or the
FDA after the study begins except with the written agreement of the sponsor and the FDA, or if the FDA determines that a substantial scientific issue essential to determining the safety or effectiveness of the drug was identified after the testing
began. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Orphan Drug Designation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition,
which is a disease or condition that affects fewer than 200,000 individuals in the US, or if it affects more than 200,000 individuals in the US there is no reasonable expectation that the cost of developing and making a drug product available in the
US for this type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting an NDA. After the FDA grants orphan product designation, the identity of the therapeutic agent and
its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven years, except in limited
circumstances, such as a showing of clinical superiority to the product with orphan exclusivity. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical study costs, tax
advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the
orphan product has exclusivity. Orphan product exclusivity also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug or biological product as defined by the FDA or if our drug candidate is
determined to be contained within the competitor&#146;s product for the same indication or disease. If a drug product designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not be
entitled to orphan product exclusivity. Orphan drug status in the European Union has similar but not identical benefits in that jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Disclosure of Clinical Trial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsors of clinical trials (other than Phase 1 trials) of FDA-regulated products, including drugs, are required to register and disclose
certain clinical trial information. Information related to the product, comparator, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is made public as part of the registration.
Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of certain trials may be delayed until the new product or new indication being studied has been approved. However, there are
evolving rules and increasing requirements for publication of trial-related information, and it is possible that data and other information from trials involving drugs that never garner approval could in the future be required to be disclosed. In
addition, publication policies of major medical journals mandate certain registration and disclosures as a pre-condition for potential publication, even when this is not presently mandated as a matter of law. Competitors may use this publicly
available information to gain knowledge regarding the progress of development programs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Post-Approval Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new
indications or other labeling claims are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well
as new application fees for supplemental applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers and other entities involved in
the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP
requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and
documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain
cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards
is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure
to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warning letters or holds on post-approval clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Patent Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of FDA approval of the use of our drug candidates, some of our U.S. patents may be eligible
for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent term to be extended up to five years as compensation for patent
term effectively lost due to the FDA&#146;s pre-market approval requirements. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration
period is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any
time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension. Extensions are not granted as a matter of right and the extension must be applied for prior to expiration
of the patent and within a 60 day period from the date the product is first approved for commercial marketing. The U.S. Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or
restoration. Where a product contains multiple active ingredients, if any one active ingredient has not been previously approved, it can form the basis of an extension of patent term provided the patent claims that ingredient or the combination.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, we may apply for patent term restoration for some of our presently owned patents
to add patent life beyond their current expiration date, depending on the expected length of clinical studies and other factors involved in the submission of the relevant NDA; however, there can be no assurance that any such extension will be
granted to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The
specific scope varies, but fundamentally the FDCA provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity never previously approved by the
FDA either alone or in combination. For a new chemical entity that was issued orphan drug designation, the FDCA provides marketing exclusivity for the &#147;same drug&#148; and &#145;&#145;same indication&#146;&#146; for a period of seven years. A
drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the compound responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept
for review an abbreviated new drug application, or ANDA, or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval.
However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA, or supplement to an existing
NDA if new clinical investigations, other than bioavailability trials, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, for new indications, dosages, or
strengths of an existing drug. This three-year exclusivity covers only the conditions associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and
three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the pre-clinical trials and adequate and
well-controlled clinical trials necessary to demonstrate safety and effectiveness. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Non-U.S. Regulation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical studies, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product,
we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can commence clinical studies or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above
with respect to the United States apply similarly in the context of the European Union, the approval process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods, as
described in greater detail below. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not
ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>European Union Drug Review Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Economic Area, or EEA (which is comprised of the 28 Member States of the European Union plus Norway, Iceland and
Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA. There are two types of marketing authorizations: the Community MA, which is issued by the European Commission through the Centralized
Procedure based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, a body of the EMA, and which is valid throughout the entire territory of the EEA; and the National MA, which is issued by the competent authorities of the
Member States of the EEA and only authorizes marketing in that Member State&#146;s national territory and not the EEA as a whole. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Centralized Procedure is compulsory for human medicines for the treatment of human
immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions, and viral diseases; for veterinary medicines for use as growth or yield enhancers;
for medicines derived from biotechnology processes, such as genetic engineering; for advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-engineered medicines; and for officially designated &#145;orphan medicines&#146;
(medicines used for rare human diseases). The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical
innovation or for products which are in the interest of public health in the European Union. The National MA is for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for
marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be
approved simultaneously in various Member States through the Decentralized Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of
which is selected by the applicant as the Reference Member State, or RMS. If the RMS proposes to authorize the product, and the other Member States do not raise objections, the product is granted a national MA in all the Member States where the
authorization was sought. Before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety
and efficacy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Regulation in the European Union </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product development, the regulatory approval process, and safety monitoring of medicinal products and their manufacturers in the European Union
proceed in much the same manner as they do in the United States. Therefore, many of the issues discussed above apply similarly in the context of the European Union. In addition, drugs are subject to the extensive price and reimbursement regulations
of the various European Union Member States. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Clinical Studies </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case in the United States, the various phases of pre-clinical and clinical research in the European Union are subject to significant
regulatory controls. The Clinical Trials Directive 2001/20/EC, as amended (and which will be replaced from May 2016 or later by Regulation (EU) No 536/2014) provides a system for the approval of clinical studies in the European Union via
implementation through national legislation of the Member States. Under this system, approval must be obtained from the competent national authorities of the European Union Member States in which the clinical trial is to be conducted. Furthermore, a
clinical trial may only be started after a competent ethics committee has issued a favorable opinion on the clinical trial application, which must be supported by an investigational medicinal product dossier with supporting information prescribed by
the Clinical Trials Directive and corresponding national laws of the Member States and further detailed in applicable guidance documents. A clinical trial may only be undertaken if provision has been made for insurance or indemnity to cover the
liability of the investigator or sponsor. In certain countries, the sponsor of a clinical trial has a strict (faultless) liability for any (direct or indirect) damage suffered by trial subjects. The sponsor of a clinical trial, or its legal
representative, must be based in the European Economic Area. European regulators and ethics committees also require the submission of adverse event reports during a study and a copy of the final study report. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Marketing Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Marketing approvals under the European Union regulatory system may be obtained through a centralized or decentralized procedure. The
centralized procedure results in the grant of a single marketing authorization that is valid for all (currently 28) European Union Member States and three EFTA members (Norway, Iceland, Liechtenstein). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Regulation (EC) No.&nbsp;726/2004, as amended, the centralized procedure is mandatory
for drugs developed by means of specified biotechnological processes, advanced therapy medicinal products, drugs for human use containing a new active substance for which the therapeutic indication is the treatment of specified diseases, including
but not limited to acquired immune deficiency syndrome, neurodegenerative disorders, auto-immune diseases and other immune dysfunctions, as well as drugs designated as orphan drugs. The CHMP also has the discretion to permit other products to use
the centralized procedure if it considers them sufficiently innovative or they contain a new active substance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the marketing
authorization application, or MAA, the applicant has to properly and sufficiently demonstrate the quality, safety and efficacy of the drug. Under the centralized approval procedure, the CHMP, possibly in conjunction with other committees, is
responsible for drawing up the opinion of the EMA on any matter concerning the admissibility of the files submitted in accordance with the centralized procedure, such as an opinion on the granting, variation, suspension or revocation of a marketing
authorization, and pharmacovigilance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CHMP and other committees are also responsible for providing guidelines and have published
numerous guidelines that may apply to our product candidates. These guidelines provide additional guidance on the factors that the EMA will consider in relation to the development and evaluation of drug products and may include, among other things,
the pre-clinical studies required in specific cases; and the manufacturing and control information that should be submitted in a MAA; and post-approval measures required to monitor patients and evaluate the long term efficacy and potential adverse
reactions. Although these guidelines are not legally binding, we believe that our compliance with them is likely necessary to gain approval for any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The maximum timeframe for the evaluation of an MAA by the CHMP under the centralized procedure is 210 days after receipt of a valid
application. This period will be suspended until such time as the supplementary information requested by the CHMP, has been provided by the applicant. Likewise, this time-limit will be suspended for the time allowed for the applicant to prepare oral
or written explanations. When an application is submitted for a marketing authorization in respect of a drug which is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation, the
applicant may request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure
if it considers that it is no longer appropriate to conduct an accelerated assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the CHMP concludes that the quality, safety and
efficacy of the product are sufficiently proven, it adopts a positive opinion. This is sent to the European Commission which drafts a decision. After consulting with the Member States, the European Commission adopts a decision and grants a marketing
authorization, which is valid for the whole of the European Economic Area, or EEA. The marketing authorization may be subject to certain conditions, which may include, without limitation, the performance of post-authorization safety and/or efficacy
studies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">European Union legislation also provides for a system of regulatory data and market exclusivity. According to Article 14(11) of
Regulation (EC) No.&nbsp;726/2004, as amended, and Article 10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved on the basis of a complete independent data package benefit from eight years
of data exclusivity and an additional two years of market exclusivity. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#146;s data to assess a generic (abbreviated) application. During the
additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#146;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity.
The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder, or MAH, obtains an authorization for one or more new therapeutic indications which,
during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity and the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version of the drug if such company obtained marketing authorization based on an
MAA with a complete independent data package of pharmaceutical test, pre-clinical tests and clinical studies. However, products designated as orphan medicinal products enjoy, upon receiving marketing authorization, a period of 10 years of orphan
market exclusivity. See also &#147;&#151;Orphan Drug Regulation&#148; below. Depending upon the timing and duration of the EU marketing authorization process, products may be eligible for up to five years&#146; supplementary protection
certification, or SPC, pursuant to Regulation (EC) No.&nbsp;469/2009. Such SPCs extend the rights under the basic patent for the drug. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional rules apply to medicinal products for pediatric use under Regulation (EC) No.&nbsp;1901/2006. Potential incentives include a
six-month extension of any supplementary protection certificate granted pursuant to Regulation (EC) No.&nbsp;469/2009, but not in cases in which the relevant product is designated as orphan medicinal products pursuant to Regulation (EC)
No.&nbsp;141/2000, as amended. Instead, medicinal products designated as orphan medicinal product may enjoy an extension of the ten-year market exclusivity period granted under Regulation (EC) No.&nbsp;141/2000 to twelve years subject to the
conditions applicable to orphan drugs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Orphan Drug Regulation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, Regulation (EC) No.&nbsp;141/2000, as amended, states that a drug will be designated as an orphan drug if its sponsor
can establish: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the Community when the application is
made, or that it is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in
the European Union would generate sufficient return to justify the necessary investment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, that the drug will be of significant
benefit to those affected by that condition. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation (EC) No.&nbsp;847/2000 sets out further provisions for
implementation of the criteria for designation of a drug as an orphan drug. An application for the designation of a drug as an orphan drug must be submitted at any stage of development of the drug before filing of a marketing authorization
application. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a European Union-wide community marketing authorization in respect of an orphan drug is granted or if all the European
Union Member States have granted marketing authorizations in accordance with the procedures for mutual recognition, the European Union and the Member States will not, for a period of 10 years, accept another application for a marketing
authorization, or grant a marketing authorization or accept an application to extend an existing marketing authorization, for the same therapeutic indication, in respect of a similar drug. This period may however be reduced to six years if, at the
end of the fifth year, it is established, with respect to the drug concerned, that the criteria for orphan drug designation are no longer met, in other words, when it is shown on the basis of available evidence that the product is sufficiently
profitable not to justify maintenance of market exclusivity. Notwithstanding the foregoing, a marketing authorization may be granted, for the same therapeutic indication, to a similar drug if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder of the marketing authorization for the original orphan drug has given its consent to the second applicant; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holder of the marketing authorization for the original orphan drug is unable to supply sufficient quantities of the drug; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the second applicant can establish in the application that the second drug, although similar to the orphan drug already authorized, is safer, more effective or otherwise clinically superior. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other incentives available to orphan drugs in the European Union include financial incentives
such as a reduction of fees or fee waivers and protocol assistance. Orphan drug designation does not shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Manufacturing and Manufacturers&#146; License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Directive 2003/94/EC, as transposed into the national laws of the Member States, the manufacturing of investigational medicinal
products and approved drugs is subject to a separate manufacturer&#146;s license and must be conducted in strict compliance with cGMP requirements, which mandate the methods, facilities, and controls used in manufacturing, processing, and packing of
drugs to assure their safety and identity. Manufacturers must have at least one qualified person permanently and continuously at their disposal. The qualified person is ultimately responsible for certifying that each batch of finished product
released onto the market has been manufactured in accordance with cGMP and the specifications set out in the marketing authorization or investigational medicinal product dossier. cGMP requirements are enforced through mandatory registration of
facilities and inspections of those facilities. Failure to comply with these requirements could interrupt supply and result in delays, unanticipated costs and lost revenues, and subject the applicant to potential legal or regulatory action,
including but not limited to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Wholesale Distribution and License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Directive 2001/83/EC, the wholesale distribution of medicinal products is subject to the possession of an authorization to engage
in activity as a wholesaler in medicinal products. Possession of a manufacturing authorization includes authorization to distribute by wholesale the medicinal products covered by that authorization. The distribution of medicinal products must comply
with the principles and guidelines of good distribution practices, or GDP. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Advertising </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, the promotion of prescription medicines is subject to intense regulation and control, including EU and national
legislation as well as self-regulatory codes (industry codes). Advertising legislation inter alia includes a prohibition on direct-to-consumer advertising. All prescription medicines advertising must be consistent with the product&#146;s approved
summary of products characteristics, and must be factual, accurate, balanced and not misleading. Advertising of prescription medicines pre-approval or off-label is not allowed. Some jurisdictions require that all promotional materials for
prescription medicines be subjected to either prior internal or regulatory review and approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Other Regulatory Requirements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A marketing authorization holder, or MAH, for a medicinal product is legally obliged to fulfill a number of obligations by virtue of its status
as an MAH. The MAH can delegate the performance of related tasks to third parties, such as distributors or marketing partners, provided that this delegation is appropriately documented and the MAH maintains legal responsibility and liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The obligations of an MAH include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Manufacturing and batch release</I>&#151;MAHs should guarantee that all manufacturing operations comply with relevant laws and regulations, applicable good manufacturing practices, with the product specifications and
manufacturing conditions set out in the marketing authorization and that each batch of product is subject to appropriate release formalities. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Availability and continuous supply</I>&#151;Pursuant to Directive 2001/83/EC, as transposed into the national
laws of the Member States, the MAH for a medicinal product and the distributors of the said medicinal product actually placed on the market in a Member State shall, within the limits of their
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
responsibilities, ensure appropriate and continued supplies of that medicinal product to pharmacies and persons authorized to supply medicinal products so that the needs of patients in the Member
State in question are covered. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pharmacovigilance</I>&#151;MAHs are obliged to establish and maintain a pharmacovigilance system, including a qualified person responsible for oversight, submit safety reports to the regulators and comply with the
good pharmacovigilance practice guidelines adopted by the EMA. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Advertising and promotion</I>&#151;MAHs remain responsible for all advertising and promotion of its products, including promotional activities by other companies or individuals on their behalf and in some cases must
conduct internal or regulatory pre-approval of promotional materials. Regulation in this area also covers interactions with healthcare practitioners and/or patient groups, and in some jurisdictions legal or self-regulatory obligations to disclose
such interactions exist. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Medical affairs/scientific service</I>&#151;MAHs are required to disseminate scientific and medical information on its medicinal products to healthcare professionals, regulators and patients. Legal representation and
distributor issues. MAHs are responsible for regulatory actions or inactions of their distributors and agents. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Preparation, filing and maintenance of the application and subsequent marketing authorization</I>&#151; MAHs must maintain appropriate records, comply with the marketing authorization&#146;s terms and conditions,
fulfill reporting obligations to regulators, submit renewal applications and pay all appropriate fees to the authorities. We may hold any future marketing authorizations granted for our product candidates in our own name, or appoint an affiliate or
a collaboration partner to hold marketing authorizations on our behalf. Any failure by an MAH to comply with these obligations may result in regulatory action against an MAH and ultimately threaten our ability to commercialize our products.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Price and Reimbursement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the European Union, the pricing and reimbursement mechanisms by private and public health insurers vary largely by country and even within
countries. The public systems reimbursement for standard drugs is determined by guidelines established by the legislator or responsible national authority. The approach taken varies by Member State. Some jurisdictions operate positive and negative
list systems under which products may only be marketed once a reimbursement price has been agreed. Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits and may limit or restrict
reimbursement. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products and some of EU countries require
the completion of studies that compare the cost-effectiveness of a particular product candidate to currently available therapies in order to obtain reimbursement or pricing approval. Special pricing and reimbursement rules may apply to orphan drugs.
Inclusion of orphan drugs in reimbursement systems tend to focus on the medical usefulness, need, quality and economic benefits to patients and the healthcare system as for any drug. Acceptance of any medicinal product for reimbursement may come
with cost, use and often volume restrictions, which again can vary by country. In addition, results based rules of reimbursement may apply. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Other Healthcare Laws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws restrict certain business practices
in the biopharmaceutical industry. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security, and transparency statutes and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration, directly or indirectly, to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare
programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply
to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities
from prosecution, the exceptions and safe harbors are drawn narrowly, and our practices may not in all cases meet all of the criteria for a statutory exception or safe harbor protection. Practices that involve remuneration that may be alleged to be
intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe
harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Several courts
have interpreted the statute&#146;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the statute has been violated. The Patient Protection and
Affordable Care Act as amended by the Health Care and Education Reconciliation Act, or collectively, PPACA, amended the intent requirement under the Anti-Kickback Statute and criminal healthcare fraud statutes (discussed below) such that a person or
entity no longer needs to have actual knowledge of the statute or the specific intent to violate it in order to have committed a violation. In addition, PPACA provides that the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below). Further, the civil monetary penalties statute imposes penalties against any person or entity
that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The federal false claims laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a
false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a
modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or demand&#148; for money or property presented to the U.S. government. Recently, several pharmaceutical and other healthcare companies have been
prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to
be submitted because of the companies&#146; marketing of the product for unapproved, and thus non-covered, uses. The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created new federal criminal statutes that prohibit
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false, fictitious or fraudulent statement in connection with the delivery of, or payment for, healthcare benefits, items or services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our
business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually
identifiable health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to business associates&#151;independent contractors or agents of covered entities that receive or obtain protected
health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates,
and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal civil actions. In addition,
state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, the PPACA also included the federal Physician Payments Sunshine Act, which requires
that certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report information related to certain
payments or other transfers of value made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain
ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, many states have similar healthcare
statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. Certain states require the posting of information relating to clinical studies,
pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual medical or health professionals and track and report gifts and other payments made to physicians and other
healthcare providers. If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or
administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion of products from reimbursement under government programs, contractual damages, reputational harm, administrative burdens, diminished profits and future
earnings and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products will be sold in a foreign country, we may
be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting
of payments or transfers of value to healthcare professionals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pharmaceutical Coverage, Pricing and Reimbursement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In both domestic and foreign markets, our sales of any approved products will depend in part on the availability of coverage and adequate
reimbursement from third-party payors. Third-party payors include government authorities, managed care providers, private health insurers and other organizations. Patients who are prescribed treatments for their conditions and providers performing
the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products, if approved, unless coverage is provided and reimbursement is adequate to cover a
significant portion of the cost of our products. Sales of our products will therefore depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by third-party payors. These third-party payors
are increasingly focused on containing healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, significant uncertainty exists as to the coverage and reimbursement status of newly approved healthcare product candidates. The
market for our product candidates for which we may receive regulatory approval will depend significantly on access to third-party payors&#146; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement.
The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict
patient access to a branded drug when a less costly generic equivalent or other alternative is available. Because each third-party payor individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a
time-consuming, costly and sometimes unpredictable process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval would be obtained, and we may
need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating
results. We cannot be certain that our product candidates will be considered cost-effective. Because coverage and reimbursement determinations are made on a payor-by-payor basis, obtaining acceptable coverage and reimbursement from one payor does
not guarantee the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company will obtain similar acceptable coverage or reimbursement from another payor. If we are unable to obtain coverage of, and adequate reimbursement and payment levels for, our product
candidates from third-party payors, physicians may limit how much or under what circumstances they will prescribe or administer them and patients may decline to purchase them. This in turn could affect our ability to successfully commercialize our
products and impact our profitability, results of operations, financial condition and future success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, in many foreign
countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide
reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company
placing the medicinal product on the market. We may face competition for our product candidates from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of
foreign products that compete with our own products, which could negatively impact our profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Healthcare Reform </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory
changes to the healthcare system that could affect our future results of operations as we begin to directly commercialize our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, there have been and continue to be a number of initiatives at the U.S. federal and state level that seek to reduce healthcare
costs. Initiatives to reduce the federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative
benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other
fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, PPACA was signed into law. PPACA has the potential to substantially change the way healthcare is financed by both governmental
and private insurers. PPACA, among other things, established an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents; revised the methodology by which rebates owed by
manufacturers for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to
utilization of certain injectable outpatient drugs, as well as prescriptions of individuals enrolled in Medicaid managed care organizations; required manufacturers to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs
to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; and implemented payment system reforms including a national pilot program on payment
bundling to encourage hospitals, physicians and other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the future, there may continue to be additional proposals relating to the reform of the United States healthcare system, some of which
could further limit the prices we are able to charge for our products candidates, or the amounts of reimbursement available for our product candidates. If future legislation were to impose direct governmental price controls and access restrictions,
it could have a significant adverse impact on our business. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. Some states have implemented, and other states are considering, price
controls or patient access </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Due to the
volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payor or policy actions, which may include cost containment and healthcare reform measures. Such policy
actions could have a material adverse impact on our profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the recently enacted federal Drug Supply Chain Security Act
imposes new obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new federal legislation, manufacturers will be required to provide certain information
regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. Further, under this new legislation, manufacturers
will have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or
which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Physician Payment Sunshine Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Physician Payment Sunshine Act requires most pharmaceutical manufacturers to report annually to the Secretary of HHS any and all financial
arrangements, payments, or other transfers of value made by that entity to physicians and teaching hospitals. The payment information is made publicly available in a searchable format on a CMS website. Over the next several years, we will need to
dedicate significant resources to establish and maintain systems and processes in order to comply with these regulations. Failure to comply with the reporting requirements can result in significant civil monetary penalties. Similar laws have been
enacted or are under consideration in foreign jurisdictions, including France which has adopted the Loi Bertrand, or French Sunshine Act, which became effective in 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Environmental, Health and Safety Laws and Regulations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations and permitting requirements, including those governing
laboratory procedures, decontamination activities and the handling, transportation, use, remediation, storage, treatment, and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, and the
risk of injury, contamination or noncompliance with environmental, health and safety requirements cannot be eliminated. Although compliance with such laws and regulations and permitting requirements has not had a material effect on our capital
expenditures, earnings or competitive position, environmental, health and safety laws and regulations and permitting requirements have tended to become increasingly stringent and, to the extent legal or regulatory changes occur in the future, they
could result in, among other things, increased costs to us or the impairment of our research, development or production efforts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2016, we employed 62 employees, 9 of whom were part-time employees. 34 of our employees hold Ph.D. degrees and 19 hold
M.Sc. degrees. Our 62 employees are from over 20 countries. We have never had a work stoppage, and none of our employees is represented by a labor organization or under any collective-bargaining arrangements. We consider our employee relations to be
good. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Facilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease
approximately 10,700 square feet of space at the Innovation Park of the EPFL (&Eacute;cole Polytechnique F&eacute;d&eacute;rale Lausanne), Switzerland. This property serves as our corporate headquarters, our research facility and laboratories. We
believe that using the EPFL facilities instead of building our own infrastructure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
helps us to maximize the value of our research and development capital and make efficient use of our funds as we continue to build and develop our pipeline. Due to the expansion of our research
and development team and addition of scientists, we have entered into an agreement with EPFL to lease an additional 240 square meters of space in the Innovation Park. We are planning to occupy this space in November, 2016. We believe that once we
have this additional space, our existing facilities are sufficient to meet our current needs. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time we may become involved in legal proceedings that arise in the ordinary course of business. During the period covered by the
financial statements contained herein, we have not been a party to or paid any damages in connection with litigation that has had a material adverse effect on our financial position. No assurance can be given that future litigation will not have a
material adverse effect on our financial position. When appropriate in management&#146;s estimation, we may record reserves in our financial statements for pending litigation and other claims. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_15"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers, Other Key Employees and Advisors and Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information about our executive officers, other key employees and advisors and directors, including their ages, as
at August&nbsp;31, 2016. The term of each of our directors is one year and, accordingly, will expire at our 2016 annual shareholder meeting to be held in the fourth quarter of 2016. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; font-size:8pt; font-family:Times New Roman"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:27.50pt; font-size:8pt; font-family:Times New Roman"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:13.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Age</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:48.35pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Initial&nbsp;Year&nbsp;of<BR>Appointment</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Executive Officers</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrea Pfeifer, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andreas Muhs, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George Pavey, CFA</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Fabien Monin</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Administrative Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other Key Employees and Advisors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wolfgang Barth, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director of Development</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David A. Lowe, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Innovation Fellow</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joseph Wettstein</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Scientific Officer, Deputy and Head of Non-AD Proteinopathies</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Julian Gray, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Clinical Advisor</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Martin Velasco</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Detlev Riesner, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2004</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mathias Hothum, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Friedrich von Bohlen und Halbach</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Bollmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director </TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current business addresses for our executive officers, other key employees and advisors, directors and
director nominee is AC Immune SA, EPFL Innovation Park, Building B, 1015 Lausanne, Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Andrea Pfeifer, Ph.D., Co-Founder, Chief Executive Officer</B><B> and Director:</B> Dr.&nbsp;Pfeifer co-founded AC Immune in April 2003, and
has served as a director since May 27, 2016. Prior to founding us, Dr.&nbsp;Pfeifer was head of Nestl&eacute;&#146;s Global Research in Lausanne, Switzerland. While at Nestl&eacute;, she led the scientific development of the first Functional Food,
LC1, and one of the first Cosmoceutical products in a joint venture with L&#146;Oreal, Inn&eacute;ov Fermet&eacute;. She also co-founded the Nestl&eacute; Venture Capital Fund, a Life Sciences corporate venture fund. She serves as chairwoman of
Investment Fund BioMedInvest, Basel and AB2 Bio, Lausanne and is a member of the Supervisory Board of Symrise AG, Holzminden. Dr.&nbsp;Pfeifer is a member of the CEOi Initiative on Alzheimer&#146;s Disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Pfeifer holds a Ph.D. in Toxicology, Cancer Research from the University of W&uuml;rzburg, Germany. She continued with post-doctoral
work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch, in Bethesda, Maryland. Dr.&nbsp;Pfeifer is a registered toxicologist and pharmacist. She received her habilitation from the University of Lausanne,
Switzerland and is also an honorary professor at the Ecole Polytechnique F&eacute;d&eacute;rale de Lausanne (EPFL). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Andreas Muhs,
Ph.D., Chief Scientific Officer</B><B>:</B> Dr.&nbsp;Muhs has served as our Chief Scientific Officer since 2005. Prior to joining AC Immune in 2005, he was responsible for the development of the cardiac stem cell-based program to treat myocardial
infarction, including worldwide pre-clinical program collaborations and technology transfers at ViaCell Inc., Cambridge, MA. Prior to ViaCell Inc., he was the Director of Pharmacology and Histology at Cardion AG where he developed research projects
with translation into clinical applications in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the fields of heart and circulation, angiogenesis and immunology and based on gene-, protein- and stem cell therapies. Dr.&nbsp;Muhs holds a Ph.D. in Biology from the University D&uuml;sseldorf,
Germany, where he worked on regulation of endothelial barrier functions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>George Pavey, CFA, Chief Financial Officer</B><B>:</B>
Mr.&nbsp;Pavey has served as our Chief Financial Officer since July 2015. Before joining AC Immune in 2015, Mr.&nbsp;Pavey was an independent financial advisor to a broad range of private and public companies from June 2013 to July 2015. Between
1991 and 2012, Mr.&nbsp;Pavey was an investment banker at various financial institutions including Credit Suisse, UBS and HSBC. His most recent role at Credit Suisse was that of Co-Head of the Global Markets Solutions Group for Asia-Pacific at
Credit Suisse where he was responsible for Credit Suisse&#146;s equity and debt capital markets businesses and structured products business across Asia-Pacific. He has a degree in Bachelor of Arts from the Richard Ivey School of Business, Canada. He
is also a Chartered Financial Analyst. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Jean-Fabien Monin, Chief Administrative Officer</B><B>:</B> Mr.&nbsp;Monin was nominated Chief
Administrative Officer in July 2015 following his role as our Chief Financial Officer from March 2009 to July 2015. Prior to AC Immune, he held several positions during his tenure of 14 years at bioM&eacute;rieux, a leading international <I>in
vitro</I> diagnostics group, culminating in his nomination as Chief Financial Officer. His last position was CFO of bioM&eacute;rieux Central Europe based in Vienna, Austria from December 2006 to March 2009. Mr.&nbsp;Monin holds a Masters in Finance
and International Business from the University of Paris-Dauphine, France. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Key Employees and Advisors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Wolfgang Barth, Ph.D., Director of Development</B><B>:</B> Dr.&nbsp;Barth has served as our Director of Development since June 2010. Prior
to joining AC Immune, he was the Head of Development at TRIN-Pharma. Previous to TRIN-Pharma, Dr.&nbsp;Barth was at Bayer Healthcare, where he was the responsible project leader of numerous preclinical and clinical development projects. The most
important project was the development of the PDE5 inhibitor Levitra which he led from the start of preclinical development until market launch. Wolfgang Barth holds a Ph.D. in Chemistry from the University of Marburg and received a NATO stipend for
a postdoctoral staff position at the Ohio State University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>David A. Lowe, Ph.D., Innovation Fellow</B><B>:</B> Dr.&nbsp;Lowe has
served as our Deputy Chief Scientific Officer and more recently as Innovation Fellow since January 2014. Previously, Dr.&nbsp;Lowe was the Chief Scientific Officer at PsychoGenics Inc., Chief Scientific Officer at Memory Pharmaceuticals (acquired by
Roche), Executive Vice President and Chief Scientific Officer at Fidelity Biosciences Group in Boston, President, CEO and Director of Envivo Pharmaceuticals (now Forum Pharmaceuticals), Vice President and therapeutic area head at Roche Bioscience in
Palo Alto, Vice President and global therapeutic area head at Bayer AG, and head of CNS Biology and deputy head of CNS Research at Sandoz Ltd (now Novartis). Dr.&nbsp;Lowe is also an adjunct professor of Neuroscience at the Icahn School of Medicine
in New York City. He received his Ph.D. in Neurobiology from the University of Leeds, UK. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Joseph G. Wettstein, Ph.D., Chief Scientific
Officer Deputy and Department Head of non-AD Proteinopathies:</B> Dr.&nbsp;Wettstein has served as our Chief Scientific Officer Deputy since February 2016 and leads all of our non-AD programs including our initiatives focused on Parkinson&#146;s
disease, Huntington&#146;s disease and TDP-43 across both therapeutic and diagnostic programs. Prior to AC Immune, Dr.&nbsp;Wettstein was Vice President in Neuroscience with Roche Pharmaceuticals in Basel where he oversaw R&amp;D activities
associated with programs designed to discover drugs for patients covering a range of brain disorders including Parkinson&#146;s, schizophrenia, Huntington&#146;s, Down syndrome, Alzheimer&#146;s, autism, bipolar disorder, depression and Fragile X.
As Head of Systems Pharmacology, CNS Research at Aventis, he played a critical role in the discovery of the immunomodulatory drug teriflunomide (Aubagio<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>) for multiple sclerosis.
Dr.&nbsp;Wettstein holds a Ph.D. from the College of Medicine at the University of Kentucky and was a Postdoctoral Fellow then instructor at Harvard Medical School. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Julian Gray, M.D., Ph.D., Clinical Advisor: </B>Dr. Gray has served as Clinical Advisor to our
programs in neurodegenerative diseases since January 2007 and works in this function exclusively for AC Immune. He has previously held the position of Head of CNS Therapeutics at Eisai Ltd in London leading the global development of early and
late-stage CNS projects in Alzheimer&#146;s disease, Parkinson&#146;s disease and other CNS areas. Prior to this he served as Head of Alzheimer Clinical Research at Hoffmann-La Roche in Basel where he conducted large scale clinical trials in the US
and Europe. After his studies he was Medical Expert at Sandoz Pharmaceuticals in Basel undertaking clinical studies of different compounds in dementia and Parkinson&#146;s disease. Dr Gray holds the title of a Specialist in Pharmaceutical Medicine
(Switzerland). He received his medical degree (MBBS) from the University of London, a BA and Ph.D. from the University of Oxford and an MBA from the Oxford Brookes University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Executive Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Martin
Velasco, Chairman and Director</B><B>:</B> Mr.&nbsp;Velasco has served on our board of directors since December 2003.&nbsp;Martin Velasco is an entrepreneur and Business Angel with extensive experience in the IT, medical and biotech areas.&nbsp;He
serves on the board of directors or advisory board of several other high-tech companies including: as Founder, Chairman and Chief Executive Officer of Anecova, an assisted reproductive technology (ART) company and World Economic Forum Technology
Pioneer 2008, as Founder and Chairman of Sumerian, an Analytics company transforming Big Data into business focused IT intelligence, as Chairman of the Supervisory Board of Cocomore, a digital communications agency&nbsp;and IT services firm, as
Board Member of Aridhia, a Health Informatics company, and as Board Member of Aleva Neurotherapeutics, a Deep Brain Stimulation (DBS) company. Martin is also the Founder and Chairman of Infantia Foundation, a philanthropic organization aiding
children in the developing world. He is a member of the Board of BlueOrchard, the leading private microfinance investment advisory company, member of the Strategic Advisory Board of the EPFL, Vice President of the Board of the Foundation
EPFL<B>+</B> and Vice Chairman of the European Tech Tour Association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Detlev H. Riesner, Ph.D., Director: </B>Prof. Riesner has served
on our board since 2004. He held the Chair of Biophysics at the Heinrich-Heine-University in D&#252;sseldorf, Germany from 1980 to 2007. He has also held the positions of Dean of the Science Faculty and Vice-President of Research. In 2007 he became
member of the university&#146;s Board of Trustees. He worked as a research fellow at Princeton University and held a guest professorship at the department of Neurology at the University of California, San Francisco. Prof. Riesner is a co-founder of
Qiagen N.V., Netherlands, was a member and from 1999 to 2014 chairman of the Supervisory Board. He was also a member of the supervisory boards of NewLab Bioquality AG, Erkrath, Direvo AG, K&#246;ln, and Alantos AG, Heidelberg. Prof. Riesner was a
member of the scientific advisory boards of the Friedrich-L&#246;ffler-Institut, Isle of Riems, and PrioNet and APRI, both Canada. He received the Max-Planck Forschungspreis for International Co-operation and the Bundesverdienstkreuz 1. Klasse from
the Bundespresident of Germany. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Mathias Hothum, Ph.D., Director:</B> Dr.&nbsp;Hothum has served on our board of directors since April
2013. He is managing director of dievini, a life science investment fund. He holds a Ph.D. in Economics from the University of Magdeburg, Germany. Dr.&nbsp;Hothum is a board member of various companies in the dievini portfolio and is the chairman of
the advisory board of joimax GmbH. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Friedrich von Bohlen und Halbach, Ph.D., Director: </B>Dr.&nbsp;von Bohlen<B></B> has served on our
board since October 2015. He is co-founder and managing director of dievini Hopp BioTech holding GmbH &amp; Co. KG. He brings extensive industry experience from Fresenius AG, FAG Kugelfischer, and WASAG-Chemie AG, founded LION bioscience AG in 1997
(now SYGNIS Pharma AG) and served as the company&#146;s CEO. Dr. von Bohlen is a board member of various companies of the dievini portfolio and Chairman of Apogenix AG, CureVac AG and Molecular Health GmbH. He holds a PhD in Neurobiology from the
Swiss Federal Institute of Technology in Zurich, Switzerland. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Peter Bollmann, Ph.D., Director:</B> Dr. Bollmann has joined our board
in December 2015. He has extensive management and finance experience in Switzerland and abroad as CEO, CFO and member of the board. His </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
broad industry experience embraces biotechnology and medical technology firms including previous Board positions with Cytos Biotechnology and Prionics. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board Composition and Election of Directors After This Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is composed of six members. Each director is elected for a one-year term. The current members of our board of directors
were appointed at a shareholders&#146; meeting held on April 14, 2015 to serve until the 2016 shareholders&#146; meeting to be held in the fourth quarter of 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be a foreign private issuer. As a result, in accordance with the NASDAQ stock exchange listing requirements, we will rely on home
country governance requirements and certain exemptions thereunder rather than relying on the stock exchange corporate governance requirements. For an overview of our corporate governance principles, see &#147;Description of Share Capital and
Articles of Association.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Director Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a foreign private issuer, under the listing requirements and rules of NASDAQ, we are not required to have independent directors on our board
of directors, except to the extent that our audit and finance committee is required to comply with independence requirements, subject to certain phase-in schedules. However, our board of directors has determined that, under current listing
requirements and rules of NASDAQ (which we are not subject to) and taking account any applicable committee independence standards, Martin Velasco, Detlev Riesner and Peter Bollmann are &#147;independent directors.&#148; In making such determination,
our board of directors considered the relationships that each non-employee director has with us and all other facts and circumstances our board of directors deemed relevant in determining the director&#146;s independence, including the number of
ordinary shares beneficially owned by the director and his or her affiliated entities, if any. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Committees of the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors will establish two separate committees prior to the consummation of this offering: an audit and finance committee and a
compensation, nomination and governance committee. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Audit and Finance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee, which is expected to consist of Peter Bollmann, Detlev Riesner and Martin Velasco, will assist our board of
directors in overseeing our accounting and financial reporting processes and the audits of our financial statements. In addition, the audit and finance committee will be directly responsible for the appointment, compensation, retention and oversight
of the work of our independent registered public accounting firm. Peter Bollmann will serve as Chairman of the committee. The audit and finance committee will consist exclusively of members of our supervisory board who are financially literate, and
Peter Bollmann is considered an &#147;audit committee financial expert&#148; as defined by the SEC. Our board of directors has determined that Peter Bollmann, Detlev Riesner and Martin Velasco satisfy the &#147;independence&#148; requirements set
forth in Rule 10A-3 under the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee will be governed by a charter that complies with NASDAQ
rules. Upon the completion of this offering, the audit and finance committee has the responsibility to, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and assess the qualifications, independence, performance and effectiveness of the independent auditor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review the scope of the prospective audit by the independent auditor, the estimated fees, and any other matters pertaining to the audit; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approve any audit and non-audit services proposed to be provided by the independent auditor to ensure independent auditor independence; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and assess the independent auditor&#146;s report, management letters and take notice of all comments of the independent auditor on accounting procedures and systems of control, and review the independent
auditor&#146;s reports with management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">be responsible for the resolution of disagreements between the management and the independent auditor; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and evaluate the lead audit partner of the independent audit team and confirm and evaluate their rotation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review, discuss with the chief financial officer and the independent auditor and approve (i)&nbsp;the annual and quarterly financial statements, (ii)&nbsp;reports intended for publication and (iii)&nbsp;any other
financial statements intended for publication to consider significant financial reporting issues and judgments made in connection with the preparation of our financial statements, including any significant changes in our selection or application of
accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review with the management, personnel responsible for the design and implementation of the internal audit function and the independent auditor in separate meetings any analysis or other written communication prepared by
the management and/or the independent auditor setting forth significant financial reporting issues and judgments made in connection with the preparation of the financial statements, including critical accounting policies, the effect of regulatory
and accounting initiatives, as well as off-balance sheet transactions and structures on our financial statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review and approve our quarterly financial statements for the first three quarters of each calendar year and the corresponding financial results releases; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review in cooperation with the independent auditor and the management whether the accounting principles applied are appropriate in view of our size and complexity; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">periodically review our policies and procedures for risk management and assess the effectiveness thereof including discussing with management our major financial risk exposures and the steps that have been taken to
monitor and control such exposures; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discuss with management and external advisors any legal matters that may have a material impact on our financial statements and any material reports or inquiries from regulatory or governmental agencies which could
materially impact our contingent liabilities and risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">review our disclosure controls and procedures and internal control over financial reporting which shall include significant deficiencies and material weaknesses in the design or operation of internal controls over
financial reporting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish procedures for the receipt, retention and treatment of complaints received regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submission by employees of
concerns regarding questionable accounting or auditing matters; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommend to the board whether to approve and ratify any related person transaction in accordance with our related person transaction policy. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit and finance committee will meet as often as it determines is appropriate to carry out its responsibilities, but in any event will
meet at least four times per year. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compensation, Nomination and Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation, nomination and governance committee, which is expected to consist of Detlev Riesner (chair) and Martin Velasco, will assist
our board of directors in overseeing our cash compensation and equity award recommendations for our executive officers along with the rationale for such recommendations, as well as summary information regarding the aggregate compensation provided to
our executive officers. Swiss law </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requires that we adopt a compensation committee, so in accordance with NASDAQ Listing Rule 5615(a)(3), we will follow home country requirements with respect to the compensation, nomination and
governance committee. As a result, our practice will vary from the requirements of NASDAQ Listing Rule 5605(d), which sets forth certain requirements as to the responsibilities, composition and independence of compensation committees, and from the
independent director oversight of director nominations requirements of NASDAQ Listing Rule 5605(e). We will be subject to the Swiss Ordinance Against Executive Compensation (&#147;Say on Pay&#148; Rule). This means that the compensation of our board
of directors and Executive Officers must be presented by the board of directors to our shareholders and our shareholders must vote on the proposed compensation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this committee will also be responsible for director and board committee nominations as well as reviewing and amending, if
required, our corporate governance framework and guidelines. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Code of Business Conduct and Ethics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering, we will adopt a Code of Business Conduct and Ethics, or the Code of Conduct, that is applicable to all of our
employees, executive officers and directors. Following the completion of this offering, the Code of Conduct will be available on our website www.acimmune.com. The audit and finance committee of our board of directors will be responsible for
overseeing the Code of Conduct and will be required to approve any waivers of the Code of Conduct for employees, executive officers and directors. We expect that any amendments to the Code of Conduct, or any waivers of its requirements, will be
disclosed on our website. </P> <P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Compensation of Directors and Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the year ended December&nbsp;31, 2015, the aggregate compensation accrued or paid to the members of our board of directors and our
executive officers for services in all capacities was CHF 1,784,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2015, the total payment made
to directors and executive officers under performance incentive plans was CHF 495,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount set aside or accrued by us to provide
pension, retirement or similar benefits to members of our board of directors or executive officers amounted to a total of CHF 124,000 in the year ended December&nbsp;31, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following the
completion of this offering, we intend to cease issuing new grants under our existing equity incentive plans, which we refer to as the Prior Plans, and to adopt a new omnibus equity incentive plan under which we would have the discretion to grant a
broad range of equity-based awards to eligible participants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Prior Plans </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception in 2003, we have had four separate Prior Plans: Plan A, which was established in 2003/2004 and amended in June 2015; Plan
B, which was established in 2005; Plan C1, which was established in 2006; and Plan C2, which was also established in 2006 but which is intended specifically for members of our board of directors to purchase our common shares. Due to a change in the
taxation of options in 2013, we introduced a new Equity Incentive Plan in 2013. As of August 31, 2016, there were 598,500 and 1,597,750 common shares underlying outstanding unvested options and vested options granted pursuant to our Prior Plans,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The original terms of our Stock Option Plan of 2005 (Plan C) contained a provision that would result in the automatic
acceleration of all unvested options upon the consummation of an initial public offering.&nbsp;Pursuant to a board resolution on October 13, 2015 the Stock Option Plan of 2005 was amended and the automatic acceleration
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
feature was removed.&nbsp;Instead, employees have the right, but not the obligation, to have their unvested options accelerated such that they vest immediately.&nbsp;A total of 1,250 options
could be accelerated in the event this offering is completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Plan Administration</I>. Under each of the Prior Plans, an option, which
can only be granted with the approval of our board of directors, is evidenced by an option agreement signed by the participant to indicate his or her acceptance of the option subject to the terms and conditions of the applicable Prior Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Eligibility</I>. Under Plans A, B and C1, options were granted to our directors, employees, advisors and agents. Under Plan C2, options
were granted only to selected members of our board of directors. Under the Equity Incentive Plan 2013, options were granted to our director, employees, advisors and agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Option Exercise Price</I>. With the exception of Plan A, the exercise price of all options issued under the Prior Plans is CHF 0.14548 per
share. The original exercise price for options issued under Plan A was CHF 0.93186 per share. However, this exercise price was amended in June 2015 with the approval of our board of directors to be CHF 0.14548 per share. As a result, as of August
31, 2016, all options outstanding under our Prior Plans have an exercise price of CHF&nbsp;0.14548 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Vesting Period</I>. The
vesting periods of options issued under our Prior Plans vary. The options granted under Plan A vested immediately but were subject to a four year lockup period. The options granted under Plan B vested over a four year period with 25% of these
options vested after one year of service and thereafter, 6.25% of the options granted vesting each quarter. Under Plan C1, the vesting period for options was four years with 25% of the options vesting each year. Under Plan C2, options were
immediately exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Amendment</I>. Our board of directors has the authority to amend each of the Prior Plans. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Employment Consideration </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
granted our Chief Financial Officer, in the aggregate, options that will give him the right to acquire 196,750 shares. Contingent upon continued employment and approval of our Board of Directors, such options will vest as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">45,000 shares which became purchasable on July 15, 2015, on a four year period at a price of CHF 0.14548 per share with 25% having vested on July 14, 2016 and a further 25% vesting on each of July&nbsp;14, 2017, July
14, 2018 and July 14, 2019; upon consummation of the proposed IPO, the 33,750 unvested options will be accelerated and will vest upon consummation of the IPO; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">98,500 shares which were granted on July 15, 2016 at a price of CHF 0.14548 per share and will vest over a four year period with 25% vesting on each of July 14, 2017, July 14, 2018, July 14, 2019 and July 14, 2020; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">53,250 shares which will be granted on July 15, 2017 at a price to be determined in July 2017 and will vest over a four year period with 25% of the granted options vesting on each of July 14, 2018, July 14, 2019, July
14, 2020 and July 14, 2021. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_16"></A>PRINCIPAL SHAREHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents information relating to the beneficial ownership of our common shares as of August&nbsp;31, 2016, as if the
conversion of our preferred shares into common shares on a one-for-one basis had occurred, by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person, or group of affiliated persons, known by us to own beneficially 5% or more of our outstanding common shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our executive officers and directors; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all executive officers and directors as a group. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, all of our
outstanding preferred shares will be converted into common shares on a one-for-one basis and we will have only one class of shares issued and outstanding. All holders of our common shares will have the same voting rights upon the completion of this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of common shares beneficially owned by each entity, person, executive officer or director is determined in
accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any common shares over which the individual has sole or shared
voting power or investment power as well as any common shares that the individual has the right to acquire within 60 days of August&nbsp;31, 2016 through the exercise of any option, warrant or other right. Except as otherwise indicated, and subject
to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all common shares held by that person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of outstanding common shares is computed on the basis of 49,396,042 common shares outstanding as of August&nbsp;31, 2016
(including the additional common shares issuable upon conversion of all of our preferred shares into common shares on a one-for-one basis upon the closing of this offering). Common shares that a person has the right to acquire within 60&nbsp;days of
August&nbsp;31, 2016 are deemed outstanding for purposes of computing the percentage ownership of the person holding such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with
respect to the percentage ownership of all executive officers and directors as a group. Unless otherwise indicated below, the address for each beneficial owner is AC Immune, EPFL Innovation Park, Building B, Lausanne. As of August&nbsp;31, 2016, a
total of 3,428,409 of our common shares (including the additional common shares issuable upon conversion of all of our preferred shares into common shares on a one-for-one basis upon the closing of this offering) were held by a total of 14 U.S.
record holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing shareholders have agreed to purchase an aggregate of 1.9 million of the common shares being
offered in this offering at the initial public offering price. The underwriters will receive the same underwriting discount on any common shares purchased by these investors as they will on any other common shares sold to the public in this
offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The percentage of common shares beneficially owned before this offering is computed on the basis
of common shares issued and outstanding as of August&nbsp;31, 2016. The percentage of common shares beneficially owned after this offering is based on 55,396,042 common shares that will be issued and outstanding upon the completion of this offering
(including the additional common shares issuable upon conversion of all of our preferred shares, including the preferred shares issued in the Series E Private Placement Extension, on a one-for-one basis upon the closing of this offering). For
purposes of computing percentage ownership after this offering, we have assumed the issuance and sale by us of an aggregate of 6,000,000 common shares in this offering and that the underwriters will not exercise their option to purchase additional
shares from us. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Before&nbsp;This&nbsp;Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent&nbsp;of&nbsp;Shares<BR>Beneficially&nbsp;Owned<BR>After&nbsp;This&nbsp;Offering</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent of Shares<BR>Beneficially Owned<BR>Assuming&nbsp;Full&nbsp;Exercise<BR>of
Underwriters&#146;&nbsp;Over-<BR>Allotment&nbsp;Option</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:78.80pt; font-size:8pt; font-family:Times New Roman"><B>Principal Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>5% Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">dievini Hopp BioTech holding GmbH&nbsp;&amp; Co KG(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,041,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Varuma AG(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman"><B>Executive Officers and Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Andrea Pfeifer(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,083,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Andreas Muhs(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">898,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">George Pavey(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">143,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Jean-Fabien Monin(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Martin Velasco(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">949,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Mathias Hothum(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Detlev Riesner(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">618,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Friedrich von Bohlen und Halbach(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Peter Bollmann</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">All executive officers and directors as a group (9&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,151,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1% of the total issued and outstanding common shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Represents 18,041,000 shares held by dievini Hopp BioTech holding GmbH &amp; Co KG. Dietmar Hopp and Oliver Hopp control the voting and investment decisions of the ultimate parent company of dievini Hopp BioTech holding
GmbH &amp; Co KG. The shares registered in the name of dievini Hopp BioTech holding GmbH &amp; Co KG may also be deemed to be beneficially owned by Friedrich von Bohlen und Halbach and Mathias Hothum, each of whom is a managing director of dievini
Hopp BioTech holding GmbH &amp; Co KG. The address for dievini Hopp BioTech holding GmbH &amp; Co KG, Friedrich von Bohlen und Halbach and Mathias Hothum is Johann-Jakob-Astor Str. 57, 69190 Walldorf, Germany. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The address for Varuma AG is Aeschenvorstadt 55, CH-4051 Basel, Switzerland. Rudolf Maag controls the voting and investment decisions of Varuma AG. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,915,250 of our common shares and options to purchase 168,000 of our common shares exercisable within 60 days of August&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 410,000 of our common shares and options to purchase 488,500 of our common shares exercisable within 60 days of August&nbsp;31,&nbsp;2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Consists of options to purchase 45,000 of our common shares exercisable within 60 days of August&nbsp;31, 2016 and options to purchase 98,500 of our common shares exercisable over a four year period between July 2016
and July 2020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 265,000 of our common shares and options to purchase 62,500 of our common shares exercisable within 60 days of August&nbsp;31,&nbsp;2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 939,500 of our common shares and options to purchase 10,250 of our common shares exercisable within 60 days of August&nbsp;31,&nbsp;2016. Includes shares held through an entity controlled by Mr. Velasco and,
as such, Mr. Velasco has sole voting and dispositive power over such shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Consists of options to purchase 51,250 of our common shares exercisable within 60 days of August&nbsp;31, 2016, and excludes the 18,041,000 shares registered in the name of dievini Hopp BioTech holding CmbH &amp; Co KG
that may also be deemed to be beneficially owned by Friedrich von Bohlen und Halbach. See note&nbsp;(1) above. Mr. Hothum disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 613,750 of our common shares and options to purchase 5,000 of our common shares exercisable within 60 days of August&nbsp;31, 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Consists of 78,750 of our common shares, and excludes the 18,041,000 shares registered in the name of dievini Hopp BioTech holding CmbH &amp; Co KG that may also be beneficially owned by Friedrich von Bohlen und
Halbach. See note (1) above. Mr.&nbsp;von Bohlen und Halbach disclaims beneficial ownership of these shares except to the extent of any pecuniary interest therein. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_17"></A>RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a description of related party transactions we have entered into since January&nbsp;1, 2013 with any of our executive
officers, directors and holders of more than 10% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons, other than the compensation arrangements we describe under &#147;Management.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2013 Series D Preferred Shares Financing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we agreed to the terms of our Series D preferred share financing with certain of our existing shareholders, including dievini
Hopp BioTech holding GmbH&nbsp;&amp; Co GK, Varuma AG, Dr.&nbsp;Riesner and Dr.&nbsp;Andrea Pfeifer. These shareholders agreed to subscribe to a CHF 20&nbsp;million capital increase with an understanding that the capital increase would be executed
via two separate tranches on the same terms. Subsequently, we offered our shareholders the option to subscribe for 4,122,500 Preferred Series D Shares for CHF 4.8516 each (in two tranches), and all shares were subscribed by current shareholders. On
December&nbsp;10, 2013, we entered into agreement with our shareholders and investors pursuant to which we agreed to issue 2,061,250 Series D preferred shares in exchange for a contribution of CHF 10&nbsp;million as a first tranche and an additional
2,061,250 Series D preferred shares in exchange for a contribution of CHF 10 million. The 2,061,250 Series D shares of the first tranche were issued on January&nbsp;7, 2014 for CHF 10&nbsp;million and the 2,061,250 Series D shares of the second
tranche were issued on July&nbsp;7, 2014 for CHF 10 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of our Series D preferred shares
purchased by our executive officers, directors and certain related parties and their affiliates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D&nbsp;Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;D&nbsp;Preferred&nbsp;Shares&nbsp;Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech GmbH &amp; Co KG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,366,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,366,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Varuma AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,433,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Andrea Pfeifer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dr. Riesner(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Riesner acquired a total of 58,000 preferred shares as part of the Series D financing with 2,000 preferred shares being acquired by Dr.&nbsp;Riesner directly, 4,000 shares being acquired by
Dr.&nbsp;Riesner&#146;s wife, Hannelore Riesner, and 52,000 shares being acquired by Riesner Verwaltungs GmbH / Peter Esser. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the number of our Series E preferred shares purchased for $9.6384 per share by our executive officers,
directors and certain related parties and their affiliates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;E<BR>Preferred&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;E<BR>Preferred&nbsp;Shares&nbsp;Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">dievini Hopp BioTech GmbH&nbsp;&amp; Co KG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Varuma AG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and all of our then-existing shareholders entered into a shareholders agreement in November 2013, which replaced a prior shareholders
agreement entered into in November 2008. The agreement entered into in November 2013 provided our shareholders with certain board nomination rights, pre-emptive subscription rights, certain rights of first refusal and tag-along rights. The agreement
was replaced by a shareholders agreement entered into in October 2015 in connection with the Series E Private Placement. However, the October 2015 agreement will terminate in connection with this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a registration rights agreement in connection with the Series E Private Placement with dievini Hopp BioTech holding GmbH &amp;
Co KG, Varuma AG and certain investors in the Series E Private Placement pursuant to which we granted them certain demand and piggyback registration rights for the resale of the common shares held by them, as described below. The shareholders party
to the registration rights agreement hold an aggregate of 33,028,758 of our common shares, representing approximately 59.6% of the voting power of our common shares outstanding upon completion of this offering (assuming no exercise of the
underwriters&#146; over-allotment option). The registration rights described below will expire on the earlier to occur of (i)&nbsp;the fifth anniversary of the completion of the offering contemplated by this prospectus and (ii)&nbsp;the date on
which there are no remaining registrable securities held by the parties to the registration rights agreement. The registration rights agreement provides that we must pay certain registration expenses in connection with any demand, piggyback or shelf
registration. The registration rights agreement contains customary indemnification and contribution provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration
Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the date that is six months after completion
of the offering contemplated by this prospectus, or the trigger date, a shareholder or group of shareholders holding at least 10% of our outstanding common shares may request that we effect a registration under the Securities Act of all or any
portion of such requesting shareholders&#146; registrable securities. At least 10 business days prior to the anticipated filing date of the registration statement relating to such demand registration, we must give all other shareholders party to the
registration rights agreement notice of such requested registration. Within five business days of such notice, any of the other shareholders party to the registration rights agreement may request that we also effect the registration of the
registrable securities held by them. We will not be required to effect a registration of all such registrable securities unless the aggregate proceeds expected to be received from the sale of such registrable securities equals or exceeds
$10&nbsp;million or such lesser amount that constitutes all of the requesting shareholders&#146; registrable securities (<I>provided</I> that such lesser amount is at least $5&nbsp;million). In no event will we be required to effect more than two
demand registrations or underwritten take downs referred to under &#147;&#151;Shelf Registration Rights&#148; below. Depending on certain conditions, we may postpone a demand registration on two occasions during any period of twelve consecutive
months for up to 90 days. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the trigger date, if we propose to register any of our
securities, whether or not for sale for our own account, we must give notice to the shareholders party to the registration rights agreement, and they will be entitled to certain piggyback registration rights allowing them to each their shares in the
registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act, the holders of these shares are entitled to notice of the registration and to request that
we include their shares in the registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Shelf Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the registration rights agreement, at any time after the first anniversary of the completion of the offering
contemplated by this prospectus, if we are eligible to use a shelf registration statement, then a shareholder or group of shareholders holding at least 10% of our outstanding common shares may request that we effect a shelf registration on similar
terms as the demand registrations described above, except that offerings will be conducted as underwritten takedowns. We will only be required to effect one public offering from such shelf registration statement within any six month period, each of
which shall be deemed to constitute a demand registration for purposes of the number of demand registrations we are required to effect as described under &#147;&#151;Demand Registration Rights&#148; above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Related Person Transaction Policy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the consummation of this offering, we intend to adopt a new related person transaction policy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to
enter into indemnification agreements with our executive officers and directors. The indemnification agreements and our Articles of Association require us to indemnify our executive officers and directors to the fullest extent permitted by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employment Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to enter
into employment agreements with certain of our executive officers in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participation in the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing shareholders have agreed to purchase an aggregate of 1.9 million of the common shares being offered in this offering at
the initial public offering price. The underwriters will receive the same underwriting discount on any common shares purchased by these investors as they will on any other common shares sold to the public in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_18"></A>DESCRIPTION OF SHARE CAPITAL AND ARTICLES OF ASSOCIATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Swiss stock
corporation (<I>soci&eacute;t&eacute; anonyme</I>) organized under the laws of Switzerland. We were formed as a Swiss limited liability company (<I>soci&eacute;t&eacute; &agrave; responsabilit&eacute; limit&eacute;e</I>) on February&nbsp;13, 2003
with our registered office and domicile in Basel, Switzerland. We converted to a Swiss stock corporation (<I>soci&eacute;t&eacute; anonyme</I>) under the laws of Switzerland on August&nbsp;25, 2003. Our domicile and registered office is in Ecublens,
near Lausanne, Canton of Vaud, Switzerland. Our head office is currently located at EPFL Innovation Park, Building B, Lausanne, Switzerland. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share
Capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, our share capital is divided into common shares and five categories of preferred shares.
Conditional upon the closing of this offering, all of our preferred shares will be converted into common shares on a one-for-one basis, effective upon the registration of the revised articles of association with the commercial register of the Canton
of Vaud, Switzerland. See &#147;&#151;Articles of Association.&#148; Upon the closing of this offering, giving effect to (i)&nbsp;the issuance of the common shares to be sold in this offering, (ii)&nbsp;the conversion of our preferred shares into
common shares on a one-for-one basis and (iii) any remaining shares from the 5,300,000 common shares issued in the CS AG Issuance, our issued fully paid-in share capital will consist of CHF 152.5 million divided into 55,396,042 common shares with a
nominal value of CHF&nbsp;0.02 each and no preferred shares. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Association </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the closing of this offering, we intend to adopt amended and restated articles of association which will become effective upon the
closing of this offering and the registration of the revised articles of association with the commercial register of the Canton of Vaud, Switzerland. When we refer to our articles of association in this prospectus, we refer to our amended and
restated articles of association as they will be in force upon the closing of this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Ordinary Capital Increase, Authorized
and Conditional Share Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, we may increase our share capital (<I>capital-actions</I>) with a resolution of the
general meeting of shareholders (ordinary capital increase) that must be carried out by the board of directors within three months of the general meeting in order to become effective. Under our articles of association, in the case of subscription
and increase against payment of contributions in cash, a resolution passed by an simple majority of the shares represented at the general meeting of shareholders regardless of abstentions or empty or invalid votes is required. In the case of
subscription and increase against contributions in kind or to fund acquisitions in kind, when shareholders&#146; statutory pre-emptive subscription rights are withdrawn or where transformation of reserves into share capital is involved, a resolution
passed by two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal amount of the shares represented is required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, under the Swiss Code of Obligations, or the CO, our shareholders, by a resolution passed by two-thirds of the shares represented
at a general meeting of shareholders and the absolute majority of the nominal amount of the shares represented, may empower our board of directors to issue shares of a specific aggregate nominal amount up to a maximum of 50% of the share capital in
the form of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditional capital (<I>capital conditionnel</I>) for the purpose of issuing shares in connection with, among other things, (i)&nbsp;option and conversion rights granted in connection with warrants and convertible bonds
of the Company or one of our subsidiaries or (ii)&nbsp;grants of rights to employees, members of our board of directors or consultants or our subsidiaries or other persons providing services to the Company or a subsidiary to subscribe for new shares
(conversion or option rights); or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorized capital (<I>capital-actions autoris&eacute;</I>) to be utilized by the board of directors within a period determined by the shareholders but not exceeding two years from the date of the shareholder approval.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Pre-Emptive Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the CO, shareholders have pre-emptive subscription rights (<I>droits de souscription</I>) to subscribe for new issuances of shares.
With respect to conditional capital in connection with the issuance of conversion rights, convertible bonds or similar debt instruments, shareholders have advance subscription rights (<I>droit de souscrire pr&eacute;alablement</I>) for the
subscription of conversion rights, convertible bonds or similar debt instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A resolution passed at a general meeting of
shareholders by two-thirds of the shares represented and the absolute majority of the nominal value of the shares represented may authorize our board of directors to withdraw or limit pre-emptive subscription rights or advance subscription rights in
certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If pre-emptive subscription rights are granted, but not exercised, the board of directors may allocate the
pre-emptive subscription rights as it elects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to our authorized share capital, the board of directors is authorized by our
articles of association to withdraw or to limit the pre-emptive subscription rights of shareholders, and to allocate them to third parties or to us, in the event that the newly issued shares are used for the following purposes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the issue price of the new registered shares is determined by reference to the market price; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the acquisition of an enterprise, part(s) of an enterprise or participations, or for the financing or refinancing of any of such transactions, or in the event of share placement for the financing or re-financing of
such transactions; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for purposes of broadening the shareholder constituency of the Company in certain financial or investor markets, for purposes of the participation of strategic partners, or in connection with the listing or registration
of new registered shares on domestic or foreign stock exchanges; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for purposes of granting an over-allotment option of up to 20% of the total number of registered shares in a placement or sale of registered shares to the respective initial purchaser(s) or underwriter(s);
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for raising of capital (including private placements) in a fast and flexible manner which probably could not be reached without the exclusion of the statutory pre-emptive right of the existing shareholders;
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">following a shareholder or a group of shareholders acting in concert having accumulated shareholdings in excess of 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the
share capital registered in the commercial register without having submitted to the other shareholders a takeover offer recommended by the board of directors, or for the defense of an actual, threatened or potential takeover bid, in relation to
which the board of directors, upon consultation with an independent financial adviser retained by it, has not recommended to the share-holders acceptance on the basis that the board of directors has not found the takeover bid to be financially fair
to the shareholders; or </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for other valid grounds in the sense of Article 652b para. 2 of the CO. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our Authorized
Share Capital </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our articles of association, our board of directors is authorized at any time until October 20, 2017 to
increase our nominal share capital by a maximum aggregate amount of CHF 426,950 (or CHF 320,950 after giving effect to the CS AG Share Issuance) through the issuance of not more than 21,347,500 shares (or 16,047,500 shares after giving effect to the
CS AG Share Issuance), which would have to be fully paid-in, with a nominal value of CHF 0.02 each. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increases in partial amounts are
permitted. The board of directors has the power to determine the type of contributions, the issue price and the date on which the dividend entitlement starts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is also authorized to withdraw or limit pre-emptive subscription rights as described above. This authorization is
exclusively linked to the particular available authorized share capital set out in the respective article. If the period to increase the share capital lapses without having been used by the board of directors, the authorization to withdraw or to
limit the pre-emptive subscription rights lapses simultaneously with such capital. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares to be sold in this offering have been issued out of our authorized share
capital. Accordingly, upon the consummation of this offering, our authorized but unissued share capital will remain at the amount of CHF &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Our Conditional Share Capital </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital for Warrants and Convertible Bonds </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominal share capital may be increased by a maximum aggregate amount of CHF 91,868 through the issuance of not more than 4,593,375 common
shares, which would have to be fully paid-in, with a nominal value of CHF 0.02 each, by the exercise of option and conversion rights granted in connection with warrants and convertible bonds of the Company or one of our subsidiaries. Shareholders
will not have pre-emptive subscription rights in such circumstances. The holders of convertible bonds are entitled to the new shares upon the occurrence of the applicable conversion feature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When issuing convertible bonds, the board of directors is authorized to withdraw or to limit the advance subscription right of shareholders to
subscribe to the convertible bond issuance: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">for the purpose of financing or refinancing the acquisition of enterprises, divisions thereof, or of participations or of newly planned investments of the Company; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the issuance occurs in domestic or international capital markets, including private placements. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that the advance subscription rights are withdrawn, (i)&nbsp;the convertible bonds are to be issued at market conditions;
(ii)&nbsp;the term to exercise the option or conversion rights may not exceed ten years as of the date of the convertible bond issue and twenty years for conversion rights; and (iii)&nbsp;the exercise price for the new shares must at least
correspond to the market conditions at the time of the convertible bond issuance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Conditional Share Capital for Equity Incentive Plans
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our nominal share capital may, to the exclusion of the pre-emptive subscription rights of shareholders, be increased by a maximum
aggregate amount of CHF 110,241 through the issuance of not more than 5,512,050 common shares, which would have to be fully paid-in, with a nominal value of CHF 0.02 each, by the exercise of option or conversion rights that have been granted to
employees, members of the board of directors or consultants of the Company or of one of our subsidiaries or other persons providing services to the Company or a subsidiary through one or more equity incentive plans created by the board of directors.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Uncertificated Securities </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our shares are uncertificated securities (<I>droits-valeurs</I>, within the meaning of Article 973c of the CO) and, when administered by a
financial intermediary (<I>d&eacute;positaire,</I> within the meaning of the Federal Act on Intermediated Securities, &#147;FISA&#148;), qualify as intermediated securities (<I>titres interm&eacute;di&eacute;s</I>, within the meaning of the FISA).
In accordance with Article 973c of the CO, we will maintain a non-public register of uncertificated securities (<I>registre des droits-valeurs</I>). We may at any time convert uncertificated securities into share certificates (including global
certificates), one kind of certificate into another, or share certificates (including global certificates) into uncertificated securities. Following entry in the share register, a shareholder may at any time request from us a written confirmation in
respect of the shares. Shareholders are not entitled, however, to request the printing and delivery of certificates. We may print and deliver certificates for shares at any time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>General Meeting of Shareholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Ordinary/Extraordinary Meetings, Powers </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The general meeting of shareholders is our supreme corporate body. Under Swiss law, ordinary and extraordinary general meetings of shareholders
may be held. Under Swiss law, an ordinary general meeting of shareholders must be held annually within six months after the end of a corporation&#146;s financial year. In our case, this generally means on or before June&nbsp;30, although in 2016 we
expect to hold our ordinary general meeting in November, which we believe is permissible under Swiss law as the investors acquiring shares in this offering will be permitted to participate in such ordinary general meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following powers are vested exclusively in the general meeting of shareholders: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adopting and amending the articles of association, including change of a company&#146;s purpose or domicile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">electing the members of the board of directors, the chairman of the board of directors, the members of the compensation committee, the auditors and the independent proxy; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the annual report, the annual statutory financial statements and (to the extent required) the financial statements, and deciding on the allocation of profits as shown on the balance sheet, in particular with
regard to dividends; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approving the compensation (basis, bonus and equity) of members of the board of directors and executive management, which under Swiss law is not necessarily limited to the executive officers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discharging the members of the board of directors and executive management from liability with respect to their tenure in the previous financial year; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dissolving a company with or without liquidation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">deciding matters reserved to the general meeting of shareholders by law or the articles of association or presented to it by the board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">An extraordinary general meeting of shareholders may be called by a resolution of the board of directors or, under certain circumstances, by a
company&#146;s auditor, liquidator or the representatives of convertible bond holders, if any. In addition, the board of directors is required to convene an extraordinary general meeting of shareholders if shareholders representing at least 10% of
the share capital request such general meeting of shareholders in writing. Such request must set forth the items to be discussed and the proposals to be acted upon. The board of directors must convene an extraordinary general meeting of shareholders
and propose financial restructuring measures if, based on a company&#146;s stand-alone annual statutory balance sheet, half of the share capital and reserves are not covered by its assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Voting and Quorum Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholder resolutions and elections (including elections of members of the board of directors) require the affirmative vote of the simple
majority of shares represented at the general meeting of shareholders regardless of abstentions or empty or invalid votes, unless otherwise stipulated by law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A resolution of the general meeting of the shareholders passed by two-thirds of the shares represented at the meeting, and the absolute
majority of the nominal value of the shares represented is required for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amending a company&#146;s corporate purpose; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creating or cancelling shares with preference rights or amending rights attached to such shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cancelling or amending the transfer restrictions of shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">creating authorized or conditional share capital; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the share capital out of equity, against contributions in-kind or for the purpose of acquiring specific assets and granting specific benefits; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limiting or suppressing shareholder&#146;s pre-emptive subscription rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changing a company&#146;s domicile; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">alleviating or withdrawing of restrictions upon the transfer of registered shares and the removal of the voting cap of 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>%;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">removing the indemnification provision for the board of directors and executive management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">converting registered shares into bearer shares and vice versa; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dissolving or liquidating a company. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">159 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The same voting requirements apply to resolutions regarding transactions among corporations based
on Switzerland&#146;s Federal Act on Mergers, Demergers, Transformations and the Transfer of Assets, or the Merger Act (including a merger, demerger or conversion of a corporation) see &#147;&#151;Compulsory Acquisitions; Appraisal Rights.&#148;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with Swiss law and generally accepted business practices, our articles of association do not provide quorum requirements
generally applicable to general meetings of shareholders. To this extent, our practice varies from the requirement of NASDAQ Listing Rule 5620(c), which requires an issuer to provide in its bylaws for a generally applicable quorum, and that such
quorum may not be less than one-third of the outstanding voting stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Notice </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General meetings of shareholders must be convened by the board of directors at least 20 days before the date of the meeting. The general
meeting of shareholders is convened by way of a notice appearing in our official publication medium, currently the Swiss Official Gazette of Commerce. Registered shareholders may also be informed by ordinary mail or e-mail. The notice of a general
meeting of shareholders must state the items on the agenda, the proposals to be acted upon and, in case of elections, the names of the nominated candidates. Except in the limited circumstances listed below, a resolution may not be passed at a
general meeting without proper notice. This limitation does not apply to proposals to convene an extraordinary general meeting of shareholders or to initiate a special investigation. No previous notification is required for proposals concerning
items included in the agenda or for debates that do not result in a vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the owners or representatives of our shares may, if no
objection is raised, hold a general meeting of shareholders without complying with the formal requirements for convening general meetings of shareholders (a universal meeting). This universal meeting of shareholders may discuss and pass binding
resolutions on all matters within the purview of the ordinary general meeting of shareholders, provided that the owners or representatives of all the shares are present at the meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Agenda Requests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Swiss law, one or more shareholders, whose combined shareholdings represent the lower of (i)&nbsp;one tenth of the share capital or
(ii)&nbsp;an aggregate nominal value of at least CHF 1,000,000, may request that an item be included in the agenda for an ordinary general meeting of shareholders. To be timely, the shareholder&#146;s request must be received by us generally at
least 120 calendar days in advance of the meeting. The request must be made in writing and contain, for each of the agenda items, the following information: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a brief description of the business desired to be brought before the ordinary general meeting of shareholders and the reasons for conducting such business at the ordinary general meeting of shareholders;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name and address, as they appear in the share register, of the shareholder proposing such business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other information required under the applicable laws and stock exchange rules. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, if the shareholder intends to solicit proxies from the shareholders of a company, such shareholder shall notify the company of this intent in accordance with Securities and Exchange Commission Rule 14a-4 and/or Rule 14a-8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business report, the compensation report and the auditor&#146;s report must be made available for inspection by the shareholders at our
registered office no later than 20 days prior to the general meeting of shareholders. Shareholders of record may be notified of this in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">160 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of our shares entitles a holder to one vote, regardless of its nominal value. The shares are not divisible. The right to vote and the
other rights of share ownership may only be exercised by shareholders (including any nominees) or usufructuaries who are entered in our share register at cut-off date determined by the board of directors. Those entitled to vote in the general
meeting of shareholders may be represented by the independent proxy holder (annually elected by the general meeting of shareholders), another registered shareholder or third person with written authorization to act as proxy or the shareholder&#146;s
legal representative. The chairman has the power to decide whether to recognize a power of attorney. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles contain provisions that
prevent investors from acquiring voting rights exceeding 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding share capital. Specifically, no individual or legal entity may, directly or
indirectly, control voting rights with respect to 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of the registered share capital recorded in the Commercial Register. In the event that a
shareholder should exceed the 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% ownership threshold, the registered shares exceeding the limit of 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB
STYLE="vertical-align:bottom">3</SUB>% shall be entered in our share registered as shares without voting rights. The board of directors may in special cases approve exceptions to the above regulations. Additional voting caps apply to shareholders
acquiring shares for other persons (nominees). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Dividends and Other Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors may propose to shareholders that a dividend or other distribution be paid but cannot itself authorize the distribution.
Dividend payments require a resolution passed by a simple majority of the shares represented at a general meeting of shareholders regardless of abstentions or employ or invalid votes. In addition, our auditors must confirm that the dividend proposal
of our board of directors conforms to Swiss statutory law and our articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Swiss law, we may pay dividends only if
we have sufficient distributable profits brought forward from the previous business years (<I>report des b&eacute;n&eacute;fices</I>), or if we have distributable reserves (<I>r&eacute;serves &agrave; libre disposition</I>), each as evidenced by our
audited stand-alone statutory balance sheet prepared pursuant to Swiss law, and after allocations to reserves required by Swiss law and the articles of association have been deducted. We are not permitted to pay interim dividends out of profit of
the current business year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributable reserves are generally booked either as &#147;free reserves&#148; (<I>r&eacute;serves
libres</I>) or as &#147;reserve from capital contributions&#148; (<I>apports de capital</I>). Under the CO, if our general reserves (<I>r&eacute;serve g&eacute;n&eacute;rale</I>) amount to less than 20% of our share capital recorded in the
commercial register (i.e., 20% of the aggregate nominal value of our issued capital), then at least 5% of our annual profit must be retained as general reserves. The CO permits us to accrue additional general reserves. Further, a purchase of our own
shares (whether by us or a subsidiary) reduces the distributable reserves in an amount corresponding to the purchase price of such own shares. Finally, the CO under certain circumstances requires the creation of revaluation reserves which are not
distributable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distributions out of issued share capital (i.e. the aggregate nominal value of our issued shares) are not allowed and may
be made only by way of a share capital reduction. Such a capital reduction requires a resolution passed by an simple majority of the shares represented at a general meeting of shareholders regardless of abstentions or empty or invalid votes. The
resolution of the shareholders must be recorded in a public deed and a special audit report must confirm that claims of our creditors remain fully covered despite the reduction in the share capital recorded in the commercial register. The share
capital may be reduced below CHF 100,000 only if and to the extent that at the same time the statutory minimum share capital of CHF 100,000 is reestablished by sufficient new fully paid-up capital. Upon approval by the general meeting of
shareholders of the capital reduction, the board of directors must give public notice of the capital reduction resolution in the Swiss Official Gazette of Commerce three times and notify creditors that they may request, within two months of the
third publication, satisfaction of or security for their claims. The reduction of the share capital may be implemented only after expiration of this time limit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">161 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors determines the date on which the dividend entitlement starts. Dividends
are usually due and payable shortly after the shareholders have passed the resolution approving the payment, but shareholders may also resolve at the ordinary general meeting of shareholders to pay dividends in quarterly or other installments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For a discussion of the taxation of dividends, see &#147;Taxation&#151;Swiss Tax Considerations&#151;Taxation of Common Shares&#151;Swiss
Federal Withholding Tax on Dividends and Distributions.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Transfer of Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares in uncertificated form (<I>droits-valeurs</I>) may only be transferred by way of assignment. Shares that constitute intermediated
securities (<I>titres interm&eacute;di&eacute;s) </I>may only be transferred when a credit of the relevant intermediated securities to the acquirer&#146;s securities account is made in accordance with the relevant provisions of the FISA. Article 5
of our articles of association provides that in the case of securities held with an intermediary such as a registrar, transfer agent, trust corporation, bank or similar entity, any transfer, grant of a security interest or usufructary right in such
intermediated securities and the appurtenant rights associated therewith requires the cooperation of the intermediary in order for such transfer, grant of a security interest or usufructary right to be valid against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Voting rights may be exercised only after a shareholder has been entered in our share register (<I>registre des actions</I>) with his or her
name and address (in the case of legal entities, the registered office) as a shareholder with voting rights. Our articles contain provisions that prevent investors from acquiring voting rights exceeding
33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% of the outstanding share capital. Specifically, no individual or legal entity may, directly or indirectly, control voting rights with respect to 33<SUP
STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% or more of the registered share capital recorded in the Commercial Register except if such individual or legal entity has submitted a tender offer to all
shareholders. In the event that a shareholder should exceed the 33<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% ownership threshold, the registered shares exceeding the limit of 33<SUP
STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">3</SUB>% shall be entered in our share registered as shares without voting rights. Additional voting caps apply to shareholders acquiring shares for other persons
(nominees). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Inspection of Books and Records </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the CO, a shareholder has a right to inspect our share register with respect to his own shares and otherwise to the extent necessary to
exercise his shareholder rights. No other person has a right to inspect our share register. Our books and correspondence may be inspected with the express authorization of the general meeting of shareholders or by resolution of the board of
directors and subject to the safeguarding of our business secrets. See &#147;Comparison of Swiss Law and Delaware Law&#151;Inspection of Books and Records.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Special Investigation </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If
the shareholders&#146; inspection rights as outlined above prove to be insufficient in the judgment of the shareholder, any shareholder may propose to the general meeting of shareholders that specific facts be examined by a special commissioner in a
special investigation. If the general meeting of shareholders approves the proposal, we or any shareholder may, within 30 calendar days after the general meeting of shareholders, request a court sitting in Lausanne, Switzerland, our registered
office, to appoint a special commissioner. If the general meeting of shareholders rejects the request, one or more shareholders representing at least 10 percent of the share capital or holders of shares in an aggregate nominal value of at least CHF
2,000,000 may request that the court appoint a special commissioner. The court will issue such an order if the petitioners can demonstrate that the board of directors, any member of the board of directors or our executive management infringed the
law or our articles of association and thereby caused damages to the Company or the shareholders. The costs of the investigation would generally be allocated to us and only in exceptional cases to the petitioners. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Compulsory Acquisitions; Appraisal Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Business combinations and other transactions that are governed by the Swiss Merger Act (i.e. mergers, demergers, transformations and certain
asset transfers) are binding on all shareholders. A statutory merger or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">162 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
demerger requires approval of two-thirds of the shares represented at a general meeting of shareholders and the absolute majority of the nominal value of the shares represented. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a transaction under the Swiss Merger Act receives all of the necessary consents, there are no appraisal rights and all shareholders are
compelled to participate in such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss corporations may be acquired by an acquirer through the direct acquisition of the
share capital of the Swiss corporation. The Swiss Merger Act provides for the possibility of a so-called &#147;cash-out&#148; or &#147;squeeze-out&#148; merger if the acquirer controls 90% of the outstanding shares. In these limited circumstances,
minority shareholders of the corporation being acquired may be compensated in a form other than through shares of the acquiring corporation (for instance, through cash or securities of a parent corporation of the acquiring corporation or of another
corporation). For business combinations effected in the form of a statutory merger or demerger and subject to Swiss law, the Swiss Merger Act provides that if equity rights have not been adequately preserved or compensation payments in the
transaction are unreasonable, a shareholder may request the competent court to determine a reasonable amount of compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition, under Swiss law, the sale of &#147;all or substantially all of our assets&#148; by us may require the approval of two-thirds of the number of shares represented at a general meeting shareholders and the absolute majority of the nominal
value of the shares represented. Whether a shareholder resolution is required depends on the particular transaction, including whether the following test is satisfied: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a core part of our business is sold without which it is economically impracticable or unreasonable to continue to operate the remaining business; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our assets, after the divestment, are not invested in accordance with our statutory business purpose; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proceeds of the divestment are not earmarked for reinvestment in accordance with our business purpose but, instead, are intended for distribution to our shareholders or for financial investments unrelated to our
business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A shareholder of a Swiss corporation participating in certain major corporate transactions may, under certain
circumstances, be entitled to appraisal rights. As a result, such shareholder may, in addition to the consideration (be it in shares or in cash) receive an additional amount to ensure that the shareholder receives the fair value of the shares held
by the shareholder. Following a statutory merger or demerger, pursuant to the Swiss Merger Act, shareholders can file an appraisal action against the surviving company. If the consideration is deemed inadequate, the court will determine an adequate
compensation payment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Board of Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our articles of association provide that the board of directors shall consist of at least three and not more than nine members. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the board of directors and the chairman are elected annually by the general meeting of shareholders for a period until the
completion of the subsequent ordinary general meeting of shareholders and are eligible for re-election. Each member of the board of directors must be elected individually. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Powers </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of
directors has the following non-delegable and inalienable powers and duties: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ultimate direction of the business of the Company and issuing of the relevant directives; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">laying down the organization of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">formulating accounting procedures, financial controls and financial planning; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">nominating and removing persons entrusted with the management and representation of the Company and regulating the power to sign for the Company; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">163 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ultimate supervision of those persons entrusted with management of the Company, with particular regard to adherence to law, our articles of association, and regulations and directives of the Company;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuing the annual report and the compensation report, and preparing for the general meeting of shareholders and carrying out its resolutions; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">informing the court in case of over-indebtedness. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors may, while retaining
such non-delegable and inalienable powers and duties, delegate some of its powers, in particular direct management, to a single or to several of its members, managing directors, committees or to third parties who need be neither members of the board
of directors nor shareholders. Pursuant to Swiss law and Article 25 of our articles of association, details of the delegation and other procedural rules such as quorum requirements must be set in the organizational rules issued by the board of
directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification of Executive Management and Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to Swiss law, Article 29 of our articles of association provides for indemnification of the existing and former members of the board of
directors, executive management and their heirs, executors and administrators, against liabilities arising in connection with the performance of their duties in such capacity, and permits us to advance the expenses of defending any act, suit or
proceeding to our directors and executive management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under general principles of Swiss employment law, an employer may be
required to indemnify an employee against losses and expenses incurred by such employee in the proper execution of their duties under the employment agreement with the employer. See &#147;Comparison of Swiss Law and
Delaware&nbsp;Law&#151;Indemnification of directors and executive management and limitation of liability.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered or will
enter into indemnification agreements with each of the members of our board of directors and executive management. See &#147;Related Party Transactions&#151;Indemnification Agreements.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Conflict of Interest, Management Transactions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss law does not have a general provision regarding conflicts of interest. However, the CO contains a provision that requires our directors
and executive management to safeguard the Company&#146;s interests and imposes a duty of loyalty and duty of care on our directors and executive management. This rule is generally understood to disqualify directors and executive management from
participation in decisions that directly affect them. Our directors and executive officers are personally liable to us for any breach of these provisions. In addition, Swiss law contains provisions under which directors and all persons engaged in
the Company&#146;s management are liable to the Company, each shareholder and the Company&#146;s creditors for damages caused by an intentional or negligent violation of their duties. Furthermore, Swiss law contains a provision under which payments
made to any of the Company&#146;s shareholders or directors or any person associated with any such shareholder or director, other than payments made at arm&#146;s length, must be repaid to the Company if such shareholder or director acted in bad
faith. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the closing of this offering, our board of directors will adopt a Code of Business Conduct and Ethics that will cover a broad
range of matters, including the handling of conflicts of interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Principles of the Compensation of the Board of Directors and the
Executive Management </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Swiss law, beginning at our first annual meeting as a public company in 2016 our shareholders
must annually approve the compensation of the board of directors and the persons whom the board of directors has, fully or partially, entrusted with the management of the Company. The board of directors must issue, on an annual basis, a written
compensation report that must be reviewed together with a report on our business by our auditor. The compensation report must disclose all compensation, loans and other forms of indebtedness granted </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">164 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the Company, directly or indirectly, to current or former members of the board of directors and executive management to the extent related to their former role within the Company or not on
customary market terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure concerning compensation, loans and other forms of indebtedness must include the aggregate amount
for the board of directors and the executive management, as well as the particular amount for each member of the board of directors and executive officer, specifying the name and function of each person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain forms of compensation are prohibited for members of our board of directors and executive management, such as: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">severance payments provided for either contractually or in the articles of association (compensation due until the termination of a contractual relationship does not qualify as severance payment); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advance compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incentive fees for the acquisition or transfer of corporations, or parts thereof, by the Company or by companies being, directly or indirectly, controlled by the us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loans, other forms of indebtedness, pension benefits not based on occupational pension schemes and performance-based compensation not provided for in the articles of association; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">equity securities and conversion and option rights awards not provided for in the articles of association. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation to members of the board of directors and executive management for activities in entities that are, directly or indirectly,
controlled by the Company is prohibited if the compensation (i)&nbsp;would have been prohibited if it was paid directly by the Company, (ii)&nbsp;is not provided for in the articles of association or (iii)&nbsp;has not been approved by the general
meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beginning in 2016, the general meeting of shareholders will annually vote on the proposals of the board of
directors with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maximum aggregate amount of compensation of the board of directors for the subsequent term of office; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the maximum aggregate amount of compensation of the executive management for the subsequent financial year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors may submit for approval at the general meeting of shareholders deviating or additional proposals relating to the same
or different periods. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that, at the general meeting of shareholders, the shareholders do not approve a proposal of the board
of directors, the board of directors must form a new proposal for the maximum aggregate compensation and the particular compensation for each individual, taking into account all relevant factors, and submit the new proposal for approval by the same
general meeting of shareholders, at a subsequent extraordinary general meeting or the next ordinary general meeting of shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
addition to fixed compensation, members of the board of directors and executive management may be paid variable compensation, depending on the achievement of certain performance criteria. The performance criteria may include individual targets,
targets of the Company or parts thereof and targets in relation to the market, other companies or comparable benchmarks, taking into account the position and level of responsibility of the recipient of the variable compensation. The board of
directors or, where delegated to it, the compensation committee shall determine the relative weight of the performance criteria and the respective target values. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compensation may be paid or granted in the form of cash, shares, financial instruments, in kind, or in the form of other types of benefits.
The board of directors or, where delegated to it, the compensation committee shall determine grant, vesting, exercise and forfeiture conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">165 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Borrowing Powers </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither Swiss law nor our articles of association restrict in any way our power to borrow and raise funds. The decision to borrow funds is made
by or under the direction of our board of directors, and no approval by the shareholders is required in relation to any such borrowing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Repurchases of Shares and Purchases of Own Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The CO limits our right to purchase and hold our own shares. We and our subsidiaries may purchase shares only if and to the extent that
(i)&nbsp;we have freely distributable reserves in the amount of the purchase price; and (ii)&nbsp;the aggregate nominal value of all shares held by us does not exceed 10 percent of our share capital. Pursuant to Swiss law, where shares are acquired
in connection with a transfer restriction set out in the articles of association, the foregoing upper limit is 20 percent. We currently do not have any transfer restriction in our articles of association. If we own shares that exceed the threshold
of 10 percent of our share capital, the excess must be sold or cancelled by means of a capital reduction within two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares held by
us or our subsidiaries are not entitled to vote at the general meeting of shareholders but are entitled to the economic benefits applicable to the shares generally, including dividends and pre-emptive subscription rights in the case of share capital
increases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, selective share repurchases are only permitted under certain circumstances. Within these limitations, as is
customary for Swiss corporations, we may purchase and sell our own shares from time to time in order to meet imbalances of supply and demand, to provide liquidity and to even out variances in the market price of shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Notification and Disclosure of Substantial Share Interests </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The disclosure obligations generally applicable to shareholders of Swiss corporations under the Swiss Act on Stock Exchanges and Securities
Trading do not apply to us since our shares are not listed on a Swiss exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Article 663c of the CO, Swiss corporations
whose shares are listed on a stock exchange must disclose their significant shareholders and their shareholdings in the notes to their balance sheet, where this information is known or ought to be known. Significant shareholders are defined as
shareholders and groups of shareholders linked through voting rights who hold more than five percent of all voting rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock Exchange Listing
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares have been approved for listing on the NASDAQ Global Market under the symbol &#147;ACIU.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Depository Trust Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Initial
settlement of the common shares issued in this offering will take place on the consummation date of this offering through The Depository Trust Company, or DTC, in accordance with its customary settlement procedures for equity securities. Each person
owning common shares held through DTC must rely on the procedures thereof and on institutions that have accounts therewith to exercise any rights of a holder of the shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar of Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our share register will initially be kept by Computershare Trust Company, N.A., which acts as transfer agent and registrar. The share register
reflects only record owners of our shares. Swiss law does not recognize fractional share interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">166 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_19"></A>COMPARISON OF SWISS LAW AND DELAWARE LAW </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Swiss laws applicable to Swiss corporations and their shareholders differ from laws applicable to U.S. corporations and their
shareholders. The following table summarizes significant differences in shareholder rights between the provisions of the Swiss Code of Obligations (<I>Code des Obligations Suisse</I>) and the Swiss Ordinance against excessive compensation in listed
stock corporations applicable to our Company, as implemented by the Company in its Articles of Association, and the Delaware General Corporation Law applicable to companies incorporated in Delaware and their shareholders. Please note that this is
only a general summary of certain provisions applicable to companies in Delaware. Certain Delaware companies may be permitted to exclude certain of the provisions summarized below in their charter documents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Mergers and similar arrangements</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, with certain exceptions, a merger, consolidation, sale, lease or transfer of all or substantially all of the assets of a corporation must be approved by the board of directors and a
majority of the outstanding shares entitled to vote thereon. A shareholder of a Delaware corporation participating in certain major corporate transactions may, under certain circumstances, be entitled to appraisal rights pursuant to which such
shareholder may receive cash in the amount of the fair value of the shares held by such shareholder (as determined by a court) in lieu of the consideration such shareholder would otherwise receive in the transaction. The Delaware General Corporation
Law also provides that a parent corporation, by resolution of its board of directors, may merge with any subsidiary, of which it owns at least 90.0% of each class of capital stock without a vote by the shareholders of such subsidiary. Upon any such
merger, dissenting shareholders of the subsidiary would have appraisal rights.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Swiss law, with certain exceptions, a merger or a demerger of the corporation or a sale of all or substantially all of the assets of a corporation must be approved by two-thirds of the voting rights represented at the
respective general meeting of shareholders as well as the absolute majority of the nominal value of shares represented at such shareholders&#146; meeting. A shareholder of a Swiss corporation participating in a statutory merger or demerger pursuant
to the Swiss Merger Act (<I>Loi sur la fusion</I>) can file a lawsuit against the surviving company. If the consideration is deemed &#147;inadequate,&#148; such shareholder may, in addition to the consideration (be it in shares or in cash) receive
an additional amount to ensure that such shareholder receives the fair value of the shares held by such shareholder. Swiss law also provides that if the merger agreement provides only for a compensation payment, at least 90.0% of all members in the
transferring legal entity, who are entitled to vote, shall approve the merger agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholders&#146; suits</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Class actions and derivative actions generally are available to shareholders of a Delaware corporation for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In
such actions, the court has discretion to permit the winning party to recover attorneys&#146; fees incurred in connection with such action.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Class actions and derivative actions as such are not available under Swiss law. Nevertheless, certain actions may have a similar effect. A
shareholder is entitled to bring suit against directors for breach of their duties and claim the payment of the company&#146;s losses or damages both to the corporation and to the individual shareholder and creditors. Likewise, an appraisal lawsuit
won by a shareholder will may indirectly compensate all shareholders. In addition, to the extent that US laws and regulations provide a basis for liability and US courts have jurisdiction, a class action may be available.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Under Swiss law, the winning party is generally entitled to recover or to partially
recover attorneys&#146;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">167 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">fees incurred in connection with such action, <I>provided</I>, <I>however</I>, that the court has broad discretion to permit the shareholder whose claim has been dismissed to recover attorneys&#146; fees incurred to the extent he or
she acted in good faith.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder vote on board and management compensation</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, the board of directors has the authority to fix the compensation of directors, unless otherwise restricted by the certificate of incorporation or bylaws.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Pursuant to the Swiss Ordinance against excessive compensation in listed stock corporations (<I>Ordonnance contre les r&eacute;mun&eacute;rations abusives dans les soci&eacute;t&eacute;s anonymes cot&eacute;es en bourse</I>), the
general meeting of shareholders has the non-transferable right, amongst others, to vote on the fixed and on the variable compensation of the members of the board of directors, of the executive management and of the advisory boards.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Annual vote on board renewal</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless directors are elected by written consent in lieu of an annual meeting, directors are elected in an annual meeting of stockholders on a
date and at a time designated by or in the manner provided in the bylaws. Re-election is possible.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Classified boards are permitted.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The general meeting of shareholders elects annually (i.e. term of office until the end of the following general meeting of shareholders) the members of the board of directors and the members of the compensation committee
individually for a term of office of one year. Re-election is possible.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Indemnification of directors and executive management and limitation of liability</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Delaware General Corporation Law provides that a certificate of incorporation may contain a provision eliminating or limiting the
personal liability of directors (but not other controlling persons) of the corporation for monetary damages for breach of a fiduciary duty as a director, except no provision in the certificate of incorporation may eliminate or limit the liability of
a director for:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any breach of a director&#146;s duty of loyalty to the corporation or
its shareholders;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;acts or omissions not in good faith or which involve intentional
misconduct or a knowing violation of law;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;statutory liability for unlawful payment of dividends or unlawful
stock purchase or redemption; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;any transaction from which the director derived an improper personal
benefit.</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Under Swiss corporate law, an indemnification by the corporation of a director or member of the executive management in relation to potential personal liability is not effective to the extent the director or member of the executive
management intentionally or negligently violated his or her corporate duties towards the corporation (certain views advocate that at least a grossly negligent violation is required to exclude the indemnification). Furthermore, the general meeting of
shareholders may discharge the directors and members of the executive management from liability from actions taken during the past financial year. Such discharge is effective only, however, for disclosed facts and only as against the company and
those shareholders who approved the discharge or who have since acquired their shares in full knowledge of the discharge. Most violations of corporate law are regarded as violations of duties towards the corporation rather than towards the
shareholders. In addition, indemnification of other controlling persons is not permitted under Swiss</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">168 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any proceeding, other than an
action by or on behalf of the corporation, because the person is or was a director or officer, against liability incurred in connection with the proceeding if the director or officer acted in good faith and in a manner reasonably believed to be in,
or not opposed to, the best interests of the corporation; and the director or officer, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless ordered by a court, any foregoing indemnification is subject to a determination
that the director or officer has met the applicable standard of conduct:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by a majority vote of the directors who are not parties to the
proceeding, even though less than a quorum;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by a committee of directors designated by a majority vote of the
eligible directors, even though less than a quorum;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by independent legal counsel in a written opinion if there are no
eligible directors, or if the eligible directors so direct; or</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;by the shareholders.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Moreover, a Delaware corporation may not indemnify a director or officer in connection
with any proceeding in which the director or officer has been adjudged to be liable to the corporation unless and only to the extent that the court determines that, despite the adjudication of liability but in view of all the circumstances of the
case, the director or officer is fairly and reasonably entitled to indemnity for those expenses which the court deems proper.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">corporate law, including shareholders of the corporation.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The articles of association of a Swiss corporation may also set forth that the corporation shall indemnify and hold harmless, to the extent permitted by the
law, the directors and executive managers out of assets of the corporation against threatened, pending or completed actions.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Also, a corporation may enter into and pay for directors&#146; and officers&#146; liability insurance which may cover negligent acts as well.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Directors&#146; fiduciary duties</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the duty of care; and</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the duty of loyalty.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The duty of care requires that a director act in good faith, with the care that an
ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors of a Swiss corporation manages the business of the corporation, unless responsibility for such management has not been
delegated to the executive management (for example by organizational rules and comparable bylaws). However, there are several non-transferable duties of the board of directors:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the overall management of the corporation and the issuing of all
necessary directives;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">169 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">disclose to shareholders, all material information reasonably available regarding a significant transaction.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The duty of loyalty requires that a director act in a manner he or she reasonably
believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and
its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in
good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Should such evidence be presented concerning a transaction by a director, a director must
prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;determination of the corporation&#146;s
organization;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the organization of the accounting, financial control and financial
planning systems as required for management of the corporation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;the appointment and dismissal of persons entrusted with managing and
representing the corporation;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;overall supervision of the persons entrusted with managing the
corporation, in particular with regard to compliance with the law, articles of association, operational regulations and directives;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;compilation of the annual report, preparation for the general meeting,
the compensation report and implementation of its resolutions; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;notification of the court in the event that the company is
overindebted.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The members of the board of directors must perform their duties with
all due diligence and safeguard the interests of the corporation in good faith. They must afford the shareholders equal treatment in equal circumstances.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">The burden of proof for a violation of these duties is with the corporation or with the shareholder bringing a suit against the director.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder action by written consent</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation may, in its certificate of incorporation, eliminate the right of shareholders to act by written consent.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders of a Swiss corporation may only exercise their voting rights in a general meeting of shareholders and may not act by written consents. The articles of association must allow for (independent) proxies to be present at a
general meeting of shareholders. The instruction of such (independent) proxies may occur in writing or electronically.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Shareholder proposals</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A shareholder of a Delaware corporation has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the
board of directors or any</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">At any general meeting of shareholders any shareholder may put proposals to the meeting if the proposal is part of an agenda item. No resolution may be made on proposals relating to the agenda items that were not duly notified.
Unless the articles of</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">170 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">association provide for a lower threshold or for additional shareholders&#146; rights:</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shareholders together representing at least 10% of the share capital
may demand that a general meeting of shareholders be called for specific agenda items and specific proposals; and</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shareholders together representing at shares with a nominal value of
at least CHF 1.0 million may demand that an agenda item including a specific proposal be put on the agenda for a regularly scheduled general meeting of shareholders, provided such request is made with appropriate notice.</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any shareholder can propose candidates for election as directors without prior written
notice.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">In addition, any shareholder is entitled, at a general meeting of
shareholders and without advance notice, to (i) request information from the Board on the affairs of the company (note, however, that the right to obtain such information is limited), (ii) request information from the auditors on the methods and
results of their audit, (iii) request to convene an extraordinary general meeting or (iv) to carry out a special audit and to appoint an auditor at the request of a shareholder.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Cumulative voting</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#146;s certificate of incorporation provides for it.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cumulative voting is not permitted under Swiss corporate law. Pursuant to Swiss law, shareholders can vote for each proposed candidate, but they are not allowed to cumulate their votes for single candidates. An annual individual
election of (i) all members of the board of directors, (ii) the chairman of the board of directors, (iii) the members of the compensation committee, (iv) the election of the independent proxy for a term of office of one year (i.e. until the
following annual general meeting) as well as the vote on the compensation for the members of the board of directors and the executive committee as well as for the members of the advisory board, if applicable, is mandatory for listed companies.
Re-election is permitted.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Removal of directors</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A Swiss corporation may remove, with or without cause, any director at any time with a resolution passed by a simple majority of the shares represented at a general meeting of shareholders concerned.
The</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">171 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">articles of association may require the approval by a qualified majority of the shares represented at a meeting for the removal of a director.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Transactions with interested shareholders</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">The Delaware General Corporation Law generally prohibits a Delaware corporation from engaging in certain business combinations with an &#147;interested shareholder&#148; for three years following the date that such person becomes an
interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15.0% or more of the corporation&#146;s outstanding voting stock within the past three years.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">No such rule applies to a Swiss corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Dissolution; Winding up</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Unless the board of directors of a Delaware corporation approves the proposal to dissolve, dissolution must be approved by shareholders holding 100.0% of the total voting power of the corporation. Only if the dissolution is
initiated by the board of directors may it be approved by a simple majority of the corporation&#146;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in
connection with dissolutions initiated by the board.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">A dissolution of a Swiss corporation requires the approval by two-thirds of the shares represented as well as the absolute majority of the nominal value of the share capital represented at a general meeting of shareholders passing a
resolution on such dissolution. The articles of association may increase the voting thresholds required for such a resolution.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Variation of rights of shares</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general shareholder meeting of a Swiss corporation may resolve that preference shares be issued or that existing shares be converted into
preference shares with a resolution passed by a simple majority of the shares represented at the general meeting of shareholders. Where a company has issued preference shares, further preference shares conferring preferential rights over the
existing preference shares may be issued only with the consent of both a special meeting of the adversely affected holders of the existing preference shares and of a general meeting of all shareholders, unless otherwise provided in the articles of
association.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Shares with preferential voting rights are not regarded a special class
for these purposes.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Amendment of governing documents</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">A Delaware corporation&#146;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">The articles of association of a Swiss corporation may be amended with a resolution passed by a simple majority of the shares represented at such meeting, unless otherwise provided in the articles of association. There are a number
of resolutions, such</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">172 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">as an amendment of the stated purpose of the corporation, the introduction of authorized and conditional capital and the introduction of shares with preferential voting rights that require the approval by two-thirds of the votes and
an absolute majority of the nominal value of the shares represented at a shareholders&#146; meeting. The articles of association may increase the voting thresholds.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Inspection of Books and Records</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Shareholders of a Delaware corporation, upon written demand under oath stating the purpose thereof, have the right during the usual hours for business to inspect for any proper purpose, and to obtain copies of list(s) of
shareholders and other books and records of the corporation and its subsidiaries, if any, to the extent the books and records of such subsidiaries are available to the corporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Shareholders of a Swiss corporation may only inspect books and records if the general meeting of shareholders or the board of directors approved such inspection. The information may be refused where providing it would jeopardize the
corporation&#146;s trade secrets or other interests warranting protection. A shareholder is only entitled to receive information to the extent required to exercise such shareholders&#146; rights, subject to the interests of the corporation. The
right to inspect the share register is limited to the right to inspect that shareholder&#146;s own entry in the share register.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Payment of dividends</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The board of directors may approve a dividend without shareholder approval. Subject to any restrictions contained in its certificate of
incorporation, the board may declare and pay dividends upon the shares of its capital stock either:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;out of its surplus, or</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;in case there is no such surplus, out of its net profits for the
fiscal year in which the dividend is declared and/or the preceding fiscal year.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Stockholder approval is required to authorize capital stock in excess of that provided in the charter. Directors may issue authorized shares without
stockholder approval.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dividend payments are subject to the approval of the general meeting of shareholders. The board of directors may propose to shareholders that
a dividend shall be paid but cannot itself authorize the distribution.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Payments out
of the Company&#146;s share capital (in other words, the aggregate nominal value of the Company&#146;s registered share capital) in the form of dividends are not allowed; however, payments out of share capital may be made by way of a capital
reduction only. Dividends may be paid only from the profits brought forward from the previous business years or if the Company has distributable reserves, each as will be presented on the Company&#146;s audited annual stand-alone balance sheet. The
dividend may be determined only after the allocations to reserves required by the law and the articles of association have been deducted.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><I>Creation and issuance of new shares</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">All creation of shares require the board of directors to adopt a resolution or resolutions, pursuant to authority expressly vested in the board of directors by the provisions of the company&#146;s certificate of incorporation.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">All creation of shares require a shareholders&#146; resolution. An authorized or contingent capital increase requires at least two-thirds of the voting rights represented at the general meeting of shareholders and an absolute
majority of the nominal</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">173 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">DELAWARE CORPORATE LAW</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">SWISS CORPORATE LAW</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">value of shares represented. Authorized shares can be, once created by shareholder resolution, issued by the board of directors (subject to fulfillment of the authorization). Conditional shares are created and issued through the
exercise of options and conversion rights related to debt instruments issued by the board of directors or such rights issued to employees.</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">174 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_20"></A>COMMON SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to this offering, there was no public market for our common shares. Future sales of substantial amounts of our common shares in the
public market could adversely affect market prices prevailing from time to time. Furthermore, because only a limited number of common shares will be available for sale shortly after this offering due to existing contractual and legal restrictions on
resale as described below, there may be sales of substantial amounts of our common shares in the public market after such restrictions lapse. This may adversely affect the prevailing market price and our ability to raise equity capital in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will have 55,396,042&nbsp;common shares outstanding. Of these shares, 6,000,000 common
shares, or 6,900,000 common shares if the underwriters exercise their option in full to purchase additional common shares, will be freely transferable without restriction or registration under the Securities Act, except for any common shares
purchased by one of our existing &#147;affiliates,&#148; as that term is defined in Rule 144 under the Securities Act. The remaining 49,396,042 common shares outstanding are &#147;restricted shares&#148; as defined in Rule 144. Restricted shares may
be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144 or 701 of the Securities Act. After the expiration of the contractual 180-day lock-up period described below, these common shares
may be sold in the public market only if registered or pursuant to an exemption under Rules 144 or 701, which are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, of the options to purchase 2,196,250 common shares outstanding as of August 31, 2016 and assuming no outstanding options are
exercised and no exercise of the underwriters&#146; option to purchase additional shares, options exercisable for 1,597,750 common shares will be vested and eligible for sale 180 days after the date of this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 144 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, a person who has
beneficially owned our common shares that are restricted shares for at least six months would be entitled to sell such securities, provided that (i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time
during the 90 days preceding, the sale and (ii)&nbsp;we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90 days before the sale. If such person has beneficially owned such common
shares for at least one year, then the requirement in clause (ii)&nbsp;will not apply to the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Persons who have beneficially owned
our common shares that are restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject to additional restrictions, by which such person would be entitled to
sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of our common shares then outstanding, which will equal approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; common shares immediately after this offering, assuming no
exercise of the underwriters&#146; over-allotment option; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our common shares on the NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale; </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided</I>, in each case, that we are subject to, and in compliance with certain of, the Exchange Act periodic reporting requirements for at least 90
days before the sale. Such sales must also comply with the manner of sale and notice provisions of Rule 144.<I> </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rule 701 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, under Rule 701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with
a compensatory share or option plan or other written agreement before the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">175 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
effective date of this offering is entitled to resell such shares 90 days after the effective date of this offering in reliance on Rule 144, without having to comply with the holding period
requirements or other restrictions contained in Rule 701. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC has indicated that Rule 701 will apply to typical share options granted
by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after the date of this prospectus. Securities issued in reliance on Rule 701
are restricted securities and, subject to the contractual restrictions described below, beginning 90 days after the date of this prospectus, may be sold by persons other than &#147;affiliates,&#148; as defined in Rule 144, subject only to the manner
of sale provisions of Rule 144 and by &#147;affiliates&#148; under Rule 144 without compliance with the one-year minimum holding period requirement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to file
one or more registration statements on Form&nbsp;S-8 under the Securities Act to register all common shares issued or issuable pursuant to the exercise of outstanding options and reserved for issuance under our new omnibus equity incentive plan. We
expect to file the registration statements, which will become effective immediately upon filing, shortly after the date of this prospectus. Shares covered by these registration statements will then be eligible for sale in the public markets, subject
to vesting restrictions and any applicable holding periods, any applicable lock-up agreements described below and Rule 144 limitations applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regulation S </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulation S provides
generally that sales made in offshore transactions are not subject to the registration or prospectus-delivery requirements of the Securities Act. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We entered into a
registration rights agreement in connection with the Series E Private Placement with certain investors in the Series E Private Placement pursuant to which we agreed under certain circumstances to file a registration statement to register the resale
of the shares held by certain of our existing shareholders, as well as to cooperate in certain public offerings of such shares. Registration of these shares under the Securities Act would result in these shares becoming freely tradable without
restriction under the Securities Act immediately upon the effectiveness of the registration, except for shares purchased by affiliates. See &#147;Related Party Transactions&#151;Registration Rights Agreement.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lock-up Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors
and executive officers and the holders of substantially all of our capital stock have agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of the common shares or such other securities for a period of 180 days after the date of this prospectus without the prior written consent of Credit Suisse Securities (USA) LLC. See &#147;Underwriting.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">176 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_21"></A>TAXATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion is based on the tax laws, regulations and regulatory practices of Switzerland and the U.S. as in effect on the
date hereof, which are subject to change (or subject to changes in interpretation), possibly with retroactive effect. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Current and
prospective shareholders are advised to consult their own tax advisers in light of their particular circumstances as to the Swiss or U.S. tax laws, regulations and regulatory practices that could be relevant for them in connection with this
offering, the acquiring, owning and selling or otherwise disposing of our common shares (such shares for purposes of this &#147;Taxation&#148; section, &#147;Shares&#148;) and receiving dividends and similar cash or in-kind distributions on Shares
(including dividends on liquidation proceeds and stock dividends) or distributions on Shares based upon a capital reduction (remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions) or reserves paid out of capital
contributions (apports de capital) and the consequences thereof under the tax laws, regulations and regulatory practices of Switzerland or the United States. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Swiss Tax Considerations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion
of Vischer Ltd., the following are the material Swiss income tax consequences of owning and disposing our common shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss
federal, cantonal and communal individual income tax and corporate income tax </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Non-Resident Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shareholders who are not resident in Switzerland for tax purposes, and who, during the relevant taxation year, have not engaged in a trade or
business carried on through a permanent establishment or fixed place of business situated in Switzerland for tax purposes (all such shareholders for purposes of this section, &#147;Non-Resident Shareholders&#148;), will not be subject to any Swiss
federal, cantonal and communal income tax on dividends and similar cash or in-kind distributions on Shares (including dividends on liquidation proceeds and stock dividends) (such dividends for the purposes of this, &#147;Dividends&#148;),
distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) on Shares, or capital gains
realized on the sale or other disposition of Shares (see, however, &#147;&#151;S<I>wiss Federal Withholding Tax&#148;</I> below for a summary of Swiss federal withholding tax on Dividends, and &#147;&#151;<I>Foreign final withholding tax&#148;</I>
below for a summary on final withholding taxes in respect of Shares held in Swiss accounts by Non-Resident Shareholders). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Resident
Private Shareholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Swiss resident individuals who hold their Shares as private assets are required to include Dividends, but not
distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>Apports de capital</I>), in their personal income tax
return and are subject to Swiss federal, cantonal and communal income tax on any net taxable income for the relevant taxation period, including the Dividends, but not the distributions based upon a capital reduction (<I>remboursements li&eacute;s
&agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital)</I>. Capital gains resulting from the sale or other disposition of Shares are not subject to Swiss federal,
cantonal and communal income tax, and conversely, capital losses are not tax-deductible for Resident Private Shareholders (the shareholders referred to in this paragraph for the purposes of this section, &#147;Resident Private Shareholders&#148;).
See &#147;&#151;<I>Domestic Commercial Shareholders</I>&#148; below for a summary of the taxation treatment applicable to Swiss resident individuals, who, for income tax purposes, are classified as &#147;professional securities dealers&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">177 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Domestic Commercial Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Corporate and individual shareholders who are resident in Switzerland for tax purposes, and corporate and individual shareholders who are not
resident in Switzerland, and who, in each case, hold their Shares as part of a trade or business carried on in Switzerland, in the case of corporate and individual shareholders not resident in Switzerland, through a permanent establishment or fixed
place of business situated, for tax purposes, in Switzerland, are required to recognize Dividends, distributions based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and
reserves paid out of capital contributions (<I>apports de capital</I>) received on Shares and capital gains or losses realized on the sale or other disposition of Shares in their income statement for the relevant taxation period and are subject to
Swiss federal, cantonal and communal individual or corporate income tax, as the case may be, on any net taxable earnings for such taxation period. The same taxation treatment also applies to Swiss-resident private individuals who, for income tax
purposes, are classified as &#147;professional securities dealers&#148; for reasons of, <I>inter alia</I>, frequent dealing, or leveraged investments, in shares and other securities (the shareholders referred to in this paragraph for purposes of
this section, &#147;Domestic Commercial Shareholders&#148;). Domestic Commercial Shareholders who are corporate taxpayers may be eligible for dividend relief (<I>r&eacute;duction pour participations</I>) in respect of Dividends and distributions
based upon a capital reduction (<I>remboursements li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) if the Shares held by them as part of a
Swiss business have an aggregate market value of at least CHF&nbsp;1 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Swiss cantonal and communal private wealth tax
and capital tax</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Non-Resident Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-Resident Shareholders are not subject to Swiss cantonal and communal private wealth tax or capital tax. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><I>Resident Private Shareholders and Domestic Commercial Shareholders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Resident Private Shareholders and Domestic Commercial Shareholders who are individuals are required to report their Shares as part of private
wealth or their Swiss business assets, as the case may be, and will be subject to Swiss cantonal and communal private wealth tax on any net taxable wealth (including Shares), in the case of Domestic Commercial Shareholders to the extent the
aggregate taxable wealth is allocable to Switzerland. Domestic Commercial Shareholders who are corporate taxpayers are subject to Swiss cantonal and communal capital tax on taxable capital to the extent the aggregate taxable capital is allocable to
Switzerland. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss Federal Withholding Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends that the Company pays on the Shares are subject to Swiss Federal withholding tax <I>(imp&ocirc;t anticip&eacute;)</I> at a rate of
35% on the gross amount of the Dividend. The Company is required to withhold the Swiss federal withholding tax from the Dividend and remit it to the Swiss Federal Tax Administration. Distributions based upon a capital reduction (<I>remboursements
li&eacute;s &agrave; la r&eacute;duction de la valeur nominale des actions</I>) and reserves paid out of capital contributions (<I>apports de capital</I>) are not subject to Swiss federal withholding tax. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Swiss federal withholding tax on a Dividend will be refundable in full to a Resident Private Shareholder and to a Domestic Commercial
Shareholder, who, in each case, <I>inter alia, </I>as a condition to a refund, duly reports the Dividend in his individual income tax return as income or recognizes the Dividend in his income statement as earnings, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Non-Resident Shareholder may be entitled to a partial refund of the Swiss federal withholding tax on a Dividend if the country of his or her
residence for tax purposes has entered into a bilateral treaty for the avoidance of double taxation with Switzerland and the conditions of such treaty are met. Such shareholders should be aware that the procedures for claiming treaty benefits (and
the time required for obtaining a refund) might differ from country to country. For example, a shareholder who is a resident of the U.S. for the purposes of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">178 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the bilateral tax treaty between the U.S. and Switzerland is eligible for a partial refund of the amount of the withholding tax in excess of the 15% treaty rate, provided such shareholder:
(i)&nbsp;qualifies for benefits under this treaty and qualifies as beneficial owner of the Dividends; (ii)&nbsp;holds, directly or indirectly, less than 10% of the voting stock of the Company; (iii)&nbsp;does not qualify as a pension scheme or
retirement arrangement for the purpose of the bilateral treaty; and (iv)&nbsp;does not conduct business through a permanent establishment or fixed base in Switzerland to which the Shares are attributable. Such an eligible U.S. shareholder may apply
for a refund of the amount of the withholding tax in excess of the 15% treaty rate. The applicable refund request form may be filed with the Swiss Federal Tax Administration following receipt of the Dividend and the relevant deduction certificate,
however no later than 31&nbsp;December of the third year following the calendar year in which the Dividend was payable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Swiss
Federal Stamp Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company will be subject to and pay to the Swiss Federal Tax Administration a 1% Swiss federal issuance
stamp tax (<I>taxe sur les &eacute;missions</I>) on the consideration received by it for the issuance of the Shares less certain costs incurred in connection with the issuance. The issuance of the Shares to the initial shareholders at the offering
price is not subject to Swiss federal securities turnover tax (<I>droit de timbre de n&eacute;gociation</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any subsequent dealings in
the Shares, where a bank or another securities dealer in Switzerland, as defined in the Swiss Federal Stamp Tax Act, acts as an intermediary, or is a party, to the transaction, are, subject to certain exemptions provided for in the Swiss Federal
Stamp Tax Act, subject to Swiss securities turnover tax at an aggregate tax rate of up to 0.15% of the consideration paid for such Shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman"><B><I>Foreign Final Withholding Tax </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;1, 2013, treaties on final withholding taxes of Switzerland with the United Kingdom and Austria entered into force (each, a
&#147;Contracting State&#148;). The treaties require a Swiss paying agent, as defined in the treaties, to levy a flat-rate final withholding tax (<I>imp&ocirc;t lib&eacute;ratoire</I>) at rates specified in the treaties on certain capital gains and
income items (interest, dividends, other income items, all as defined in the treaties), deriving from assets, including the Shares, held in accounts or deposits with a Swiss paying agent by (i)&nbsp;an individual resident in a Contracting State or,
(ii)&nbsp;if certain requirements are met, by a domiciliary company (<I>soci&eacute;t&eacute; de domicile</I>), an insurance company in connection with a so-called insurance wrapper (<I>contrat d&#146;assurance vie utilis&eacute; comme
enveloppe</I>) or other individuals if the beneficial owner is an individual resident in a Contracting State. The flat-rate tax withheld substitutes the ordinary income tax on the respective capital gains and income items in the Contracting State
where the individual is tax resident. In order to avoid the withholding of the flat-rate tax by the Swiss paying agent, such individuals may opt for a disclosure of the respective capital gains and income items to the tax authorities of the
Contracting State where they are tax residents. If Swiss federal withholding tax of 35% has been withheld on dividends, the Swiss paying agent will&#151;to the extent provided in the applicable bilateral treaty for the avoidance of double taxation
between Switzerland and the Contracting State&#151;in its own name and on behalf of the relevant shareholder file with the Swiss tax authorities a request for the partial refund of the Swiss federal withholding tax. The Swiss federal withholding
tax, which is not refundable according to the bilateral tax treaty (residual tax), is credited against the flat-rate final withholding tax. Switzerland may conclude similar treaties with other European countries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material U.S. Federal Income Tax Considerations for U.S. Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the opinion of Davis Polk &amp; Wardwell LLP, the following are the material U.S. federal income tax consequences to U.S. Holders, as
defined below, of owning and disposing our common shares. It does not describe all tax considerations that may be relevant to a particular person&#146;s decision to acquire common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">179 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion applies only to a U.S. Holder that holds common shares as capital assets for U.S.
federal income tax purposes. In addition, it does not describe all of the U.S. federal income tax consequences that may be relevant in light of a U.S. Holder&#146;s particular circumstances, including alternative minimum tax consequences, the
potential application of the provisions of the Code known as the Medicare contribution tax and tax consequences applicable to U.S. Holders subject to special rules, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain financial institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">dealers or traders in securities who use a mark-to-market method of tax accounting; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding common shares as part of a hedging transaction, straddle, wash sale, conversion transaction or other integrated transaction or persons entering into a constructive sale with respect to the common shares;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. Holder whose functional currency for U.S. federal income tax purposes is not the U.S. dollar; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entities classified as partnerships for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt entities, including an &#147;individual retirement account&#148; or &#147;Roth IRA&#148;; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own or are deemed to own ten percent or more of our voting shares; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding common shares in connection with a trade or business conducted outside of the United States. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an entity that is classified as a partnership for U.S. federal income tax purposes holds common shares, the U.S. federal income tax
treatment of a partner will generally depend on the status of the partner and the activities of the partnership. Partnerships holding common shares and partners in such partnerships should consult their tax advisers as to the particular U.S. federal
income tax consequences of owning and disposing of the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on the Code, administrative
pronouncements, judicial decisions, final, temporary and proposed Treasury regulations, and the income tax treaty between Switzerland and the United States (the &#147;Treaty&#148;) all as of the date hereof, any of which is subject to change or
differing interpretations, possibly with retroactive effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A &#147;U.S. Holder&#148; is a holder who, for U.S. federal income tax
purposes, is a beneficial owner of common shares, who is eligible for the benefits of the Treaty and who is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a citizen or individual resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of owning and disposing
of common shares in their particular circumstances. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Taxation of Distributions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As discussed above under &#147;Dividend Policy,&#148; we do not currently expect to make distributions on our common shares. In the event that
we do make distributions of cash or other property, subject to the passive foreign investment company rules described below, distributions paid on common shares, other than certain pro rata distributions of common shares, will be treated as
dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax
principles, we expect that distributions will be reported to U.S. Holders as dividends. For so long as our common shares are listed on NASDAQ or we are eligible for benefits under the Treaty, dividends paid to certain non-corporate U.S. Holders
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">180 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be eligible for taxation as &#147;qualified dividend income&#148; and therefore, subject to applicable limitations, will be taxable at rates not in excess of the long-term capital gain rate
applicable to such U.S. Holder. U.S. Holders should consult their tax advisers regarding the availability of the reduced tax rate on dividends in their particular circumstances. The amount of a dividend will include any amounts withheld by us in
respect of Swiss income taxes. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code.
Dividends will be included in a U.S. Holder&#146;s income on the date of the U.S. Holder&#146;s receipt of the dividend. The amount of any dividend income paid in euros will be the U.S. dollar amount calculated by reference to the exchange rate in
effect on the date of actual or constructive receipt, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder should not be required
to recognize foreign currency gain or loss in respect of the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S. dollars after the date of receipt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable limitations, some of which vary depending upon the U.S. Holder&#146;s particular circumstances, Swiss income taxes
withheld from dividends on common shares at a rate not exceeding the rate provided by the Treaty will be creditable against the U.S. Holder&#146;s U.S. federal income tax liability. The rules governing foreign tax credits are complex and U.S.
Holders should consult their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any Swiss income
tax, in computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Sale or Other Disposition of Common Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the passive foreign investment company rules described below, gain or loss realized on the sale or other disposition of common
shares will be capital gain or loss, and will be long-term capital gain or loss if the U.S. Holder held the common shares for more than one year. The amount of the gain or loss will equal the difference between the U.S. Holder&#146;s tax basis in
the common shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. Subject to certain exceptions, this gain or loss will be U.S.-source gain or loss for foreign tax credit purposes. The
deductibility of capital losses is subject to various limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Passive Foreign Investment Company Rules </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Code, we will be a PFIC for any taxable year in which, after the application of certain &#147;look-through&#148; rules with respect
to subsidiaries, either (i)&nbsp;75% or more of our gross income consists of &#147;passive income,&#148; or (ii)&nbsp;50% or more of the average quarterly value of our assets consist of assets that produce, or are held for the production of,
&#147;passive income.&#148; For purposes of the above calculations, we will be treated as if we hold our proportionate share of the assets of, and receive directly our proportionate share of the income of, any other corporation in which we directly
or indirectly own at least 25%, by value, of the shares of such corporation. Passive income generally includes interest, dividends, rents, certain non-active royalties and capital gains. Based on our business plan and certain estimates and
projections, including as to the relative values of our assets, we do not believe that we were a PFIC for our 2015 taxable year and do not expect to be a PFIC in the immediately foreseeable future. However, there can be no assurance that the IRS
will agree with our conclusion. In addition, whether we will be a PFIC in 2016 or any future years is uncertain because, among other things, (i)&nbsp;we currently own, and will own after the completion of this offering, a substantial amount of
passive assets, including cash, and (ii)&nbsp;the valuation of our assets that generate non-passive income for PFIC purposes, including our intangible assets, is uncertain and may vary substantially over time. Accordingly, there can be no assurance
that we will not be a PFIC for any taxable year. If we are a PFIC for any year during which a U.S. Holder holds common shares, we generally would continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding years during which
the U.S. Holder holds common shares, even if we ceased to meet the threshold requirements for PFIC status. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">181 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we were a PFIC for any taxable year during which a U.S. Holder held common shares (assuming
such U.S. Holder has not made a timely mark-to-market election, as described below), gain recognized by a U.S. Holder on a sale or other disposition (including certain pledges) of the common shares would be allocated ratably over the U.S.
Holder&#146;s holding period for the common shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed as ordinary income. The amount allocated to each other taxable year
would be subject to tax at the highest rate in effect for individuals or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the amount allocated to that taxable year. Further, to the extent that any
distribution received by a U.S. Holder on its common shares exceeds 125% of the average of the annual distributions on the common shares received during the preceding three years or the U.S. Holder&#146;s holding period, whichever is shorter, that
distribution would be subject to taxation in the same manner as gain, described immediately above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A U.S. Holder can avoid certain of the
adverse rules described above by making a mark-to-market election with respect to its common shares, provided that the common shares are &#147;marketable.&#148; Common shares will be marketable if they are &#147;regularly traded&#148; on a
&#147;qualified exchange&#148; or other market within the meaning of applicable Treasury regulations. If a U.S. Holder makes the mark-to-market election, it will recognize as ordinary income any excess of the fair market value of the common shares
at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the common shares over their fair market value at the end of the taxable year (but only to the
extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the holder&#146;s tax basis in the common shares will be adjusted to reflect the income or loss amounts
recognized. Any gain recognized on the sale or other disposition of common shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income
previously included as a result of the mark-to-market election). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in order to avoid the application of the foregoing rules, a
United States person that owns stock in a PFIC for U.S. federal income tax purposes may make a &#147;qualified electing fund&#148; election (a &#147;QEF Election&#148;) with respect to such PFIC if the PFIC provides the information necessary for
such election to be made. If a United States person makes a QEF Election with respect to a PFIC, the United States person will be currently taxable on its pro rata share of the PFIC&#146;s ordinary earnings and net capital gain (at ordinary income
and capital gain rates, respectively) for each taxable year that the entity is classified as a PFIC and will not be required to include such amounts in income when actually distributed by the PFIC. We do not intend to provide information necessary
for U.S. Holders to make qualified electing fund elections. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we were a PFIC or, with respect to particular U.S. Holder,
were treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the preferential dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a U.S. Holder owns common shares during any year in which we are a PFIC, the holder must file annual reports containing such information as
the U.S. Treasury may require on IRS Form 8621 (or any successor form) with respect to us, with the holder&#146;s federal income tax return for that year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">U.S. Holders should consult their tax advisers concerning our potential PFIC status and the potential application of the PFIC rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of dividends and sales proceeds that are made within the United States or through certain U.S.-related financial intermediaries are
subject to certain information reporting requirements, and may be subject to backup withholding, unless (i)&nbsp;the U.S. Holder is a corporation or other exempt recipient or (ii)&nbsp;in the case of backup withholding, the U.S. Holder provides a
correct taxpayer identification number and certifies that it is not subject to backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">182 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount of any backup withholding from a payment to a U.S. Holder will be allowed as a credit
against the holder&#146;s U.S. federal income tax liability and may entitle it to a refund, provided that the required information is timely furnished to the IRS. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><B><I>Information With Respect to Foreign Financial Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain U.S. Holders who are individuals (and, under proposed regulations, certain entities) may be required to report information relating to
an interest in our common shares, subject to certain exceptions (including an exception for common shares held in accounts maintained by certain U.S. financial institutions). U.S. Holders should consult their tax advisers regarding the effect, if
any, of this legislation on their ownership and disposition of the common shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">183 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_22"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions contained in an underwriting agreement dated the date of pricing of this offering, we have
agreed to sell to the underwriters named below the following number of common shares: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:46.20pt; font-size:8pt; font-family:Times New Roman"><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Credit Suisse Securities (USA) LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leerink Partners LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriting agreement provides that the underwriters are obligated to purchase all the common shares in
this offering if any are purchased, other than those shares covered by the over-allotment option described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have granted to the
underwriters a 30-day over-allotment option to purchase up to 900,000 additional common shares from us at the initial public offering price less the underwriting discounts and commissions. The option may be exercised only to cover any
over-allotments of common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters proposed to offer the common shares initially at the public offering price on the
cover page of this prospectus and to selling group members at that price less a selling concession not in excess of $0.4620<U></U> per share. The underwriters and selling group members may allow a discount of $0.1540<U></U> per share on sales to
other broker/dealers. After the initial public offering the underwriters may change the initial public offering price and concession and discount to broker/dealers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain of our existing shareholders have agreed to purchase an aggregate of 1.9 million of the common shares being offered in this offering
at the initial public offering price. The underwriters will receive the same underwriting discount on any common shares purchased by these investors as they will on any other common shares sold to the public in this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes the compensation and estimated expenses we will pay: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With<BR>Over-<BR>allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Initial public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">75,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discounts and commissions payable by us</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,620,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,313,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,380,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,587,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate the expenses paid or payable by us in connection with this offering, other than the underwriting
discounts and commissions referred to above, will be approximately $3.6&nbsp;million. We have also agreed to reimburse the underwriters for certain expenses, including an amount not to exceed $30,000 in connection with the clearance of this offering
with the Financial Industry Regulatory Authority, as set forth in the underwriting agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters have informed us that they
do not expect sales to accounts over which they have discretionary authority to exceed 5% of the common shares being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have
agreed that we will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">184 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of 1933, the Securities Act, relating to, any common shares or securities convertible into or exchangeable or exercisable for any common shares, or publicly disclose the intention to make any
offer, sale, pledge, disposition or filing, without the prior written consent of Credit Suisse Securities (USA) LLC for a period of 180 days after the date of this prospectus, except issuances pursuant to the exercise of employee stock options
outstanding on the date hereof or pursuant to our dividend reinvestment plan and in certain other limited circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our officers and
directors and the holders of substantially all of our capital stock have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any common shares or securities convertible into or
exchangeable or exercisable for any common shares, enter into a transaction which would have the same effect, or enter into any swap, hedge or other arrangement that transfers, in whole or in part, any of the economic consequences of ownership of
the common shares, whether any such aforementioned transaction is to be settled by delivery of the common shares or such other securities, in cash or otherwise, or publicly disclose the intention to make any such offer, sale, pledge or disposition,
or to enter into any such transaction, swap, hedge or other arrangement, without, in each case, the prior written consent of Credit Suisse Securities (USA) LLC. In addition, each such person has agreed that, without the prior written consent of
Credit Suisse Securities (USA) LLC, it will not, during the 180-day lock-up period, make any demand for or exercise any right with respect to, the registration of any common shares or any security convertible into or exercisable or exchangeable for
the common shares. Any common shares received upon exercise of options granted to each such person will also be subject to the lock-up agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">However, notwithstanding the immediately preceding paragraph, the restrictions described in the lock-up agreement will not apply in certain
circumstances, including to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transactions relating to common shares or other securities acquired by such person in this offering or in open market transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">(i) the exercise of stock options or other similar awards granted pursuant to our equity incentive plans or the vesting or settlement of awards granted pursuant to our equity incentive plans (including the delivery and
receipt of common shares, other awards or any securities convertible into or exercisable or exchangeable for common shares in connection with such vesting or settlement); <I>provided</I> that, in the case of this clause (i), the foregoing
restrictions shall apply to any of such person&#146;s common shares issued upon such exercise, vesting or settlement; or (ii) the transfer of common shares or any securities convertible into or exercisable or exchangeable for common shares from such
person to us (or the purchase and cancellation of same by us) upon a vesting event of our securities or upon the exercise of options to purchase common shares by such person, in each case on a &#147;cashless&#148; or &#147;net exercise&#148; basis,
or to cover income or withholding and other tax obligations of such person in connection with such vesting or exercise in 2015 and 2016 of options for our common shares, whether by means of a &#147;net settlement&#148; or otherwise;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of common shares or any security convertible into or exercisable or exchangeable for common shares: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift or gifts, including as a result of the operation of law or estate or intestate succession, or pursuant to a will or other testamentary document; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such is a natural person, to a member of the immediate family of such person (for purposes of the lock-up agreement, &#147;immediate family&#148; shall mean any relationship by blood, marriage, domestic partnership
or adoption no more remote than first cousin, and shall include any former spouse); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, to any trust or other like entity for the direct or indirect benefit of such person or the immediate family of such person; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, by operation of law or by order of a court of competent jurisdiction pursuant to a qualified domestic order or in connection with a divorce settlement; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">185 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a natural person, to a corporation, partnership, limited liability company or other entity of which such person and the immediate family of such person are the direct or indirect legal and beneficial
owners of all the outstanding equity securities or similar interests of such corporation, partnership, limited liability company or other entity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any trust or other like entity for the direct or indirect benefit of such person or any affiliate, wholly-owned subsidiary,
limited partner, member or stockholder of such person; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any affiliate thereof; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if such person is a corporation, partnership, limited liability company or other entity, to any investment fund or other entity controlled or managed by such person; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a distribution to any affiliate, wholly-owned subsidiary, limited partner, member or stockholder of such person; </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><I>provided</I> that in the case of any transfer or distribution pursuant to the sub-bullets above of this third bullet, each donee,
distributee or transferee agrees to be bound in writing by the terms of the lock-up agreement prior to such transfer, such transfer shall not involve a disposition for value and no filing by any party (donor, donee, transferor or transferee) under
the Exchange Act shall be required or shall be voluntarily made in connection with such transfer; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment or modification of any contract, instruction or trading plan intended to comply with Rule 10b5-1 under the Exchange Act for the transfer of common shares; <I>provided</I> that (i) such plan does not
provide for the transfer of Securities during the 180-day lock-up period, (ii) the establishment of such plan shall not be voluntarily publicly announced or filed under the Exchange Act and (iii) to the extent a public announcement or filing under
the Exchange Act, if any, is required by or on behalf of the undersigned or us regarding the establishment or modification of such plan, such announcement or filing shall include a statement to the effect that no transfer of common shares may be
made under such plan during the 180-day lock-up period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares to us, pursuant to agreements or rights in existence on the date of this prospectus under which we have the
option to repurchase such shares or a right of first refusal with respect to transfers of such shares or in connection with the termination of such person&#146;s employment with us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares that occurs by any order or settlement resulting from any legal proceeding; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the transfer of common shares or any security convertible into or exercisable or exchangeable for common shares pursuant to a bona fide third-party tender offer, merger, amalgamation, consolidation or other similar
transaction made to all holders of the common shares involving a change of control of us; <I>provided</I> that in the event that the tender offer, merger, amalgamation, consolidation or other such transaction is not completed, the common shares
owned by such person shall remain subject to the restrictions contained in the lock-up agreement; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of any right with respect to, or the taking of any other action in preparation for, a registration by us of common shares or any securities convertible into or exercisable or exchangeable for common shares;
<I>provided</I> that no transfer of such person&#146;s common shares proposed to be registered pursuant to the exercise of such rights under this bullet shall occur, and no registration statement shall be filed, during the 180-day lock-up period.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the above exceptions, dievini Hopp BioTech holding GmbH &amp; Co KG and its representatives who hold our
common shares will be allowed a one-time sale of any or all of the common shares held by them. Any such sale must be a private sale pursuant to an exemption from the Securities Act and the purchaser must agree to be bound in writing by the terms of
the lock-up agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">186 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed to indemnify the underwriters against liabilities under the Securities Act, or
contribute to payments that the underwriters may be required to make in that respect. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>NASDAQ </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common shares have been approved for listing on the NASDAQ Global Market under the symbol &#147;ACIU.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions, penalty bids and passive market making in accordance with Regulation M under the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a
covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short
position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option and/or purchasing shares in the
open market. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Syndicate covering transactions involve purchases of the common shares in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to
close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. If the
underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in this offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the common shares originally sold by the syndicate member are purchased in a stabilizing or syndicate covering
transaction to cover syndicate short positions. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In passive market making, a market maker in the common shares who is an underwriter or prospective underwriter may, subject to limitations, make bids for or purchases of our common shares until the time, if any, at
which a stabilizing bid is made. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of
raising or maintaining the market price of our common shares or preventing or retarding a decline in the market price of the common shares. As a result the price of our common shares may be higher than the price that might otherwise exist in the
open market. These transactions may be effected on the NASDAQ and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Distribution </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus in electronic format will be made available on the web sites maintained by the underwriters, or selling group members, if any,
participating in this offering. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">187 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Investors in the European Economic Area </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In relation to each Member State of the European Economic Area that has implemented the Prospectus Directive, each a Relevant Member State, the
underwriters represent and agree that with effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, or the Relevant Implementation Date, they have not made and will not make an offer of our
common shares to the public in that Relevant Member State prior to the publication of a prospectus in relation to our common shares that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in
another Relevant Member State and notified to the competent authority in that Relevant Member State, all in accordance with the Prospectus Directive, except that they may, with effect from and including the Relevant Implementation Date, make an
offer of our common shares to the public in that Relevant Member State at any time: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive) subject to obtaining the prior consent of the manager for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of our common shares shall require the publication by the issuer or the underwriters of a prospectus
pursuant to Article 3 of the Prospectus Directive. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the
public&#148; in relation to any of our common shares in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an
investor to decide to purchase or subscribe our common shares, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Member State and the expression Prospectus Directive means Directive
2003/71/EC and (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in each Relevant Member State) includes any relevant implementing measure in each Relevant Member State. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Investors in the United Kingdom </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have only communicated or caused to be communicated and will only communicate or cause to be communicated any invitation or inducement to engage in investment activity within the meaning of section 21 of the Financial
Services and Markets Act 2000, or FSMA, in connection with the sale or issue of the common shares in circumstances in which section 21 of FSMA does not apply to the underwriters; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have complied with, and will comply with all applicable provisions of FSMA with respect to anything done by them in relation to the common shares in, from or otherwise involving the United Kingdom. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is directed solely at persons who (i)&nbsp;are outside the United Kingdom, (ii)&nbsp;have professional experience in matters
relating to investments or (iii)&nbsp;are persons falling within Article 49(2)(a) to (d)&nbsp;of The Financial Services and Markets Act (Financial Promotion) Order 2005 (all such persons together being referred to as Relevant Persons). This
prospectus must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this prospectus relates is available only to relevant persons and will be engaged in with Relevant Persons only.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Switzerland </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland.
This document has been prepared without regard to the disclosure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">188 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither this document nor any other offering or marketing material relating to this offering, the Company, or the shares have been or will be
filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of shares has not been
and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or the CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or the
DFSA. This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or
verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this prospectus relates
may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an
authorized financial advisor. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Australia </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission, or the ASIC, in relation to this offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, the Corporations Act, and does not
purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any offer in Australia of the shares may only be made to persons, the Exempt Investors, who are &#147;sophisticated investors&#148; (within
the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations
Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares applied
for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under this offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act
would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must
observe such Australian on-sale restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains general information only and does not take account of the
investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the
information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Hong Kong </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
&#147;professional investors&#148; as defined in the Securities and Futures Ordinance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">189 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies
Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the common shares has been or may be issued or has been or may be in the
possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities
laws of Hong Kong). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in Japan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948,
as amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall
mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Prospective Investors in
Singapore </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this
prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be offered or sold, or be made
the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore,
the SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in
accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where the Non-CIS Securities are subscribed or purchased
under Section&nbsp;275 of the SFA by a relevant person which is: (a)&nbsp;a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital
of which is owned by one or more individuals, each of whom is an accredited investor; or (b)&nbsp;a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that
corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notice to Canadian Residents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Resale Restrictions</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The distribution of the common shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a
private placement basis exempt from the requirement that we prepare and file </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">190 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the common shares in Canada must be made under applicable
securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory
authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Representations of Canadian
Purchasers</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By purchasing the common shares in Canada and accepting delivery of a purchase confirmation, a purchaser is
representing to us and the dealer from whom the purchase confirmation is received that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the common shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148;
as defined under National Instrument 45-106 &#150; <I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument 31-103 - <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Conflicts
of Interest</I></B><I> </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers are hereby notified that the underwriters are relying on the exemption set out in section
3A.3 or 3A.4, if applicable, of National Instrument 33-105 &#150; <I>Underwriting Conflicts </I>from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Statutory Rights of Action</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the
offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities
legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these
rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Enforcement of Legal Rights</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible
for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to
satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Taxation and Eligibility for Investment</I></B><I> </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Canadian purchasers of the ordinary shares offered in this offering should consult their own legal and tax advisors with respect to the tax
consequences of an investment in the ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the purchaser under relevant Canadian legislation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary
course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">191 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments of the issuer or its affiliates. If the underwriters or their affiliates have a lending relationship with us, the underwriters or its affiliates may hedge, their credit exposure to us consistent with their customary risk
management policies. Typically, the underwriters and their affiliates would hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the
securities of our affiliates, including potentially the common shares offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the common shares offered hereby. The underwriters and certain of
their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to
clients that they acquire, long and/or short positions in such securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">192 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_23"></A>EXPENSES OF THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We estimate that our expenses in connection with this offering, other than underwriting discounts and commissions, will be as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:31.55pt; font-size:8pt; font-family:Times New Roman"><B>Expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Securities and Exchange Commission registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,033</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NASDAQ listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,955</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,685,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">285,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,573,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All amounts in the table are estimates except the U.S.
Securities and Exchange Commission registration fee, the NASDAQ listing fee and the FINRA filing fee. The Company will pay all of the expenses of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">193 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the common shares and certain other matters of Swiss law will be passed upon for us by Vischer AG, Zurich, Switzerland.
Certain matters of U.S. federal and New York State law will be passed upon for us by Davis Polk&nbsp;&amp; Wardwell LLP, New York, New York, and for the underwriters by Goodwin Procter LLP, Boston, Massachusetts. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The financial statements of AC Immune SA for the years ended December&nbsp;31, 2015 and 2014 and for each of the years in the two-year period
ended December&nbsp;31, 2015, have been included herein in reliance upon the report of Ernst&nbsp;&amp; Young AG, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting
and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">194 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_26"></A>ENFORCEMENT OF JUDGMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are organized under the laws of Switzerland and our registered office and domicile is located in Ecublens, Switzerland. Moreover, a number
of our directors and executive officers are not residents of the United States, and all or a substantial portion of the assets of such persons are located outside the United States. As a result, it may not be possible for investors to effect service
of process within the United States upon us or upon such persons or to enforce against them judgments obtained in U.S. courts, including judgments in actions predicated upon the civil liability provisions of the federal securities laws of the United
States. We have been advised by our Swiss counsel that there is doubt as to the enforceability in Switzerland of original actions, or in actions for enforcement of judgments of U.S. courts, of civil liabilities to the extent solely predicated upon
the federal and state securities laws of the United States. Original actions against persons in Switzerland based solely upon the U.S. federal or state securities laws are governed, among other things, by the principles set forth in the Swiss
Federal Act on Private International Law. This statute provides that the application of provisions of non-Swiss law by the courts in Switzerland shall be precluded if the result would be incompatible with Swiss public policy. Also, mandatory
provisions of Swiss law may be applicable regardless of any other law that would otherwise apply. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Switzerland and the United States do
not have a treaty providing for reciprocal recognition of and enforcement of judgments in civil and commercial matters. The recognition and enforcement of a judgment of the courts of the United States in Switzerland is governed by the principles set
forth in the Swiss Federal Act on Private International Law. This statute provides in principle that a judgment rendered by a non-Swiss court may be enforced in Switzerland only if: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the non-Swiss court had jurisdiction pursuant to the Swiss Federal Act on Private International Law; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment of such non-Swiss court has become final and non-appealable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment does not contravene Swiss public policy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the court procedures and the service of documents leading to the judgment were in accordance with the due process of law; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">no proceeding involving the same position and the same subject matter was first brought in Switzerland, or adjudicated in Switzerland, or was earlier adjudicated in a third state and this decision is recognizable in
Switzerland. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom16439_27"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the U.S. Securities and Exchange Commission, the SEC, a registration statement (including amendments and exhibits to the
registration statement) on Form F-1 under the Securities Act. This prospectus, which is part of the registration statement, does not contain all of the information set forth in the registration statement and the exhibits and schedules to the
registration statement. For further information, we refer you to the registration statement and the exhibits and schedules filed as part of the registration statement. If a document has been filed as an exhibit to the registration statement, we
refer you to the copy of the document that has been filed. Each statement in this prospectus relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may review a copy of the registration statement, including exhibits and any schedule filed therewith, and obtain copies of such materials
at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet website
that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon completion of this offering, we will become subject to the informational requirements of the Exchange Act. Accordingly, we will be
required to file reports and other information with the SEC, including annual reports on Form 20-F and reports on Form 6-K. Those reports may be inspected without charge at the locations described above. As a foreign private issuer, we are exempt
under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery
provisions contained in Section&nbsp;16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities
are registered under the Exchange Act, although we intend to report our results of operations voluntarily on a quarterly basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">196 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A><A NAME="rom16439_28"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unaudited Interim Condensed Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_1">Balance Sheets as at June&nbsp;30, 2016 and December 31, 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_2">Income Statements and Statements of Comprehensive Income for the Six Months Ended
 June&nbsp;30, 2016&nbsp;and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_3">Statements of Changes in Equity for the Six Months Ended June&nbsp;
30, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_4">Statements of Cash Flows for the Six Months Ended June&nbsp;
30, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_5">Notes to the Interim Condensed Financial Statements for the Six Months Ended June&nbsp;30,
2016 and&nbsp;2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Audited Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_7">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_8">Balance Sheets as of December&nbsp;31, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_9">Income Statements and Statements of Comprehensive Income for the fiscal years ended
 December&nbsp;31, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_10">Statements of Changes in Equity for the fiscal years ended December&nbsp;
31, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_11">Statements of Cash Flows for the fiscal years ended December&nbsp;
31, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin16439_12">Notes to the Financial Statements for the fiscal years ended December&nbsp;
31, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_1"></A>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;June&nbsp;30,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;at&nbsp;December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment &amp; Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>753</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>102,529</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>103,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDERS&#146; EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">123,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,825</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net employee defined benefit liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,196</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,544</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12,740</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,888</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>103,282</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_2"></A>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;Notes&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,451</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,401</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research &amp; development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,018</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,190</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General &amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,750</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13,768</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8,932</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,683</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,469</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>91</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>154</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,774</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,774</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,209,976</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,725,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,101,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,845,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Comprehensive Income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended<BR>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,774</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income not to be reclassified to income or loss in subsequent periods (net
of tax)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Re-measurement losses on defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income, net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,406</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,121</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_3"></A>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Changes in Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January 1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(502</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total comprehensive income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5,121</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>5,121</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June 30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>855</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,077</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(54,928</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,004</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January 1, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>928</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110,496</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(368</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total comprehensive income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,406</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>6,406</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Issue of capital</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>60</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>13,377</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>13,437</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series E extension shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(494</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at June 30, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>988</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>123,379</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(33,825</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>90,542</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_4"></A>Unaudited interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Six Months<BR>Ended June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,774</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile income for the period to net cash flows :</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(154</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,764</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(421</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(155</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(336</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferral of unearned revenue (current)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash (used in) / provided by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,088</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,006</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange differences-gain on payables / receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows (used in) / provided by operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16,063</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(307</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(117</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred Series E shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs of issue of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(472</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost on issue of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from employee loan repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows provided by financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>13,159</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,650</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gain / (loss) on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at June&nbsp;30</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net&nbsp;increase in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,650</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>15,952</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes form an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_5"></A>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Corporate information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune SA (the &#147;Company&#148;) is a clinical stage biopharmaceutical
company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are
generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. Our lead product
candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that the Company developed using our proprietary SupraAntigen platform. Phase 3 clinical studies for crenezumab were commenced in early 2016. The Company
uses two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules); to discover, design and develop medicines and diagnostics to target misfolded proteins. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim condensed financial statements of AC Immune SA for the six months period ended June 30, 2016 were authorized for issue in accordance with a
resolution of the Board of Directors on August 25, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation of these financial statements are
set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation and changes to the Company&#146;s accounting policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going concern
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company&#146;s
cash position of CHF 82.4 million as of June 30, 2016 which includes the $13.5 million (CHF 13.2 million) the Company raised in the Series E Extension financing in April 2016.&nbsp;The Company also received a clinical milestone payment of CHF 14
million in July 2016 related to the collaboration with Genentech on the anti-tau antibody program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has financed its cash
requirements primarily from share issuances and revenues from collaboration agreements. The Company is a clinical stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#146;s business are various
risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The Company&#146;s success may depend in part upon its ability to (i) establish and maintain a strong patent position and protection, (ii)
enter into collaborations with partners in the biotech and pharmaceutical industry, (iii) successfully move its product candidates through clinical development, (iv) attract and retain key personnel, and (v) acquire capital to support its
operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The interim
condensed financial statements for the six-month period ended June 30, 2016, have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim financial statements do not include all the information required in the annual
financial statements, and should be read in conjunction with the Company&#146;s annual financial statements as of December 31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of
measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared under the historical cost convention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(CHF thousands, except share and per share amounts) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical judgments and accounting estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of the Company&#146;s interim condensed financial statements in conformity with IAS 34 requires management to make judgments, estimates and assumptions that affect the amounts reported in the condensed interim financial statements and
accompanying notes and the related application of accounting policies as it relates to the reported amounts of assets, liabilities, income and expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i) revenue recognition on collaboration and licensing agreements,
(ii) clinical development accruals, (iii) pensions, (iv) income taxes, and, (v) share-based compensation. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting
estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income taxes </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As disclosed in Note 5, the Company has tax losses which will expire after the tax holiday period. These tax losses represent potential value to the Company to
the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not recorded any deferred tax assets in relation to these tax losses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant judgment is required in
determining the classification of the Preferred Shares issued by the Company as either equity or liabilities. The preferred shareholders receive certain preference rights that represent a significant proportion of the net assets of the Company in
the case of liquidation or certain exit events, the occurrence of which are outside the control of the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Accounting policies, new standards,
interpretations and amendments adopted by the Company </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accounting policies adopted in the preparation of the interim condensed financial statements
are consistent with those followed in the preparation of the Company&#146;s annual financial statements for the year ended December 31, 2015, except for the adoption of new standards and interpretations effective as of January 1, 2016. The Company
has not early adopted any other standard, interpretation or amendment that has been issued but is not yet effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The nature and the effect of these
changes are immaterial to the Company&#146;s interim condensed financial statements. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenues </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>(all figures in CHF &#145;000)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Licensing and collaboration agreements </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.1 Research collaboration and license revenue </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tau-PET imaging agent in AD &#150; Collaboration agreement of 2014 with Piramal Imaging </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd., entered into an exclusive worldwide license agreement for the research,
development and commercialization of AC Immune&#146;s tau protein positron emission tomography (PET) tracers supporting the diagnosis and clinical management of AD and potential tau-related disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment of EUR 500 thousand received from this collaboration is deferred over a period of 12 months which is the Joint Research Collaboration
period. As such, the residual balance in deferred revenue related to this collaboration at December 31, 2014, was recognized until May 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4.2
Milestones </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tau Vaccine in AD &#150; Collaboration agreement of 2014 with Janssen Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December of 2014, the Company entered into a partnership with Janssen Pharmaceuticals, a Johnson &amp; Johnson company, to develop and commercialize
therapeutic anti-tau vaccines for the treatment of AD and potentially other tauopathies. The partnership includes a worldwide exclusive license and research collaboration. The Company and Janssen will co-develop the lead therapeutic vaccine, ACI-35,
through Phase 1b completion. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. ACI-35 is an active therapeutic vaccine stimulating the patient&#146;s immune
system to produce a polyclonal antibody response against phosphorylated tau protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also allows for the collaboration to be expanded to a
second indication based on the same anti-tau vaccine program and intellectual property related to this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company received an upfront payment
of CHF 25.9 million which it recognized in 2014 and is eligible to receive development, regulatory and commercialization milestone payments for AD and a potential second indication outside of AD. Additionally, the Company will receive royalties on
sales at a percentage rate ranging from the low double digits to mid-teens once product sales commence. The two companies have entered into a three-year joint research collaboration to further characterize and develop novel vaccine therapies for the
treatment of tauopathies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of this agreement, AC Immune has committed to spend CHF 13.8 million in research and </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">development to the end of Phase 1b which is currently anticipated to be completed at the end of 2016. Under the terms of the agreement, Janssen may terminate
the agreement at any time after completion of the Phase 1b clinical study by providing 90 days&#146; notice to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2016, the Company
received payments of CHF 1.5 million for pre-payment of research and external research costs the Company expects to incur during 2016.&nbsp;Pursuant to the terms of the collaboration agreement, there is a performance obligation until the end of the
year.&nbsp;As a result, the Company is recognizing the proceeds from this payment over a 12-month period on a straight-line basis.&nbsp;In June 2016, the Company received a CHF 4.9 million payment for reaching a clinical milestone in the Phase 1b
study.&nbsp;As the Company met all performance obligations on reaching the milestone, it recognized this income as revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-tau antibody in AD &#150; Collaboration agreement of 2012 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2012, the Company entered into an exclusive global license agreement and research collaboration with Genentech, Inc. to commercialize its anti-tau
antibodies for use as immunotherapeutics.&nbsp;The value of this exclusive, worldwide alliance is potentially greater than CHF 400 million and includes upfront and milestone payments. In addition to milestones, the Company will be eligible to
receive royalties on sales at a percentage rate ranging from the mid-single digits to high single digits. The agreement also provides for collaboration on two additional indications built on the same anti-tau antibody program as well as a potential
anti-tau diagnostic product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until June 30, 2016, the Company has received payments totalling CHF 31 million including a CHF 14 million milestone payment
received in 2015.&nbsp;In June 2016, Genentech informed the Company that the first patient had been injected with the anti-tau antibody making the Company eligible for a CHF 14 million milestone payment and which also triggered a small licensing fee
payment from AC Immune to a third party.&nbsp;The Company received the proceeds from this milestone payment in July 2016.&nbsp;Pursuant to the exclusive global license agreement, there is no further performance obligation attached to this payment,
therefore the Company recognized the full amount as collaboration and license revenue in the six month period ended June 30, 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genentech may
terminate the agreement at any time by providing three months&#146; notice to AC Immune. In such event all costs incurred are still refundable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-Abeta antibody in AD &#150; Collaboration agreement of 2006 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2006, AC Immune signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta.
Genentech commenced a Phase 3 clinical study in Q1 2016. If crenezumab receives regulatory approval, the Company will be entitled to receive royalties that are tied to annual sales volumes with different royalty rates applicable in the U.S. and
Europe. These percentage rates range from the high single digits to the mid-teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement with Genentech, the Company may become eligible to
receive payments totaling up to approximately $340 million, excluding royalties. To date, the Company has received payments of $65 million (CHF 70.1 million). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income tax </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The estimated tax expense for the six-month period ended June 30, 2016 is zero.&nbsp;The
estimated tax expense is based on the best estimate of the weighted average annual income tax rate expected for the full financial year ended December 31, 2016. As the Company expects to incur a loss for the full year, it does not anticipate any
income tax expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with IAS 34 and consistent with prior years, the Company has not recognized any deferred tax assets relating to tax
losses available but offset against future profits as the recognition criteria have not been met at the balance sheet date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The major components of income tax expense in the interim condensed statement of income or loss are: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accounting income before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,774</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>5,623</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense calculated at the statutory rate of 22.5%</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,524</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,265</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of expected tax rate for full year (2016)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of unrecognized carry forward tax loss (2015)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax rate benefit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the fact that AC Immune is expected to report a loss for the full year 2016, no tax on income was payable in H1
2016.&nbsp;In H1 2015, no income tax was payable due to the fact that AC Immune could offset taxable income with tax loss carry forwards. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts of financial assets and financial
liabilities which are a reasonable approximation of the fair value of financial assets and financial liabilities: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As at</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial assets</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial liabilities</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables and other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The cash balance as at June 30, 2016 contains restricted cash totaling CHF 106 thousand related to the Credit Suisse AG,
Zurich (&#147;CS&nbsp;AG&#148;) Share Issuance.&nbsp;This cash will remain restricted while CS AG holds shares of AC Immune pursuant to the CS&nbsp;AG Share Issuance agreement.&nbsp;The table above contains assets and liabilities held at
amortization cost. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other current liabilities </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May 25, 2016, AC Immune entered into a subscription agreement, pursuant to
which AC Immune issued 5,300,000 common shares, each with a nominal value of CHF 0.02 to CS AG at a price equal to the CHF 0.02 per share nominal value for an aggregate subscription amount of CHF 106,000 (the &#147;CS AG Share Issuance&#148;).
CS&nbsp;AG will hold these shares as nominee in anticipation of the consummation of AC Immune&#146;s IPO and CS AG has agreed not to exercise any voting rights in respect to these shares.&nbsp;While CS AG owns the shares, it cannot sell any of the
shares without the prior consent of AC Immune and any proceeds CS AG receives above the CHF 0.02 nominal value per share, net of fees, is to be remitted to AC Immune.&nbsp;In connection with the CS AG Share Issuance, AC Immune gave CS AG an option
to put all or part of the shares it acquired back to AC Immune at CHF 0.02 per share at any point in time, for any reason (the &#147;Put Option&#148;).&nbsp;Similarly, CS AG gave AC Immune a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the interim condensed financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(CHF thousands, except share and per share amounts) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
call whereby AC Immune could acquire all or part of the shares it sold to CS AG at CHF 0.02 per share at any point in time, for any reason (the &#147;Call Option&#148;).&nbsp;The CS AG Share
Issuance agreement has a termination date of June 30, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to the existence of the Put Option, the CS AG Share Issuance has resulted in the creation
a contingent liability.&nbsp;CS AG can exercise the Put Option for any reason at any point in time.&nbsp;If the Put Option is exercised, AC Immune will be required to acquire any common shares that CS AG has indicated it wants to sell under the Put
Option, at CHF 0.02 per common share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin16439_7"></A>Report of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Shareholders of AC Immune SA </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
have audited the accompanying balance sheets of AC Immune SA as of December 31, 2015 and 2014, and the related income statements, statements of other comprehensive income<B>,</B> statements of changes in equity and statements of cash flows for each
of the two years in the period ended December 31, 2015. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits
included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of AC Immune SA at December 31,
2015 and 2014, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2015, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards
Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst &amp; Young AG </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young AG </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Geneva, Switzerland </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 21, 2016 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_8"></A>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Balance Sheets </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financial assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>585</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,346</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>29,667</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>SHAREHOLDERS&#146; EQUITY AND LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share premium</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,381</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60,455</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net employee defined benefit liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total non-current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,787</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,410</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables&nbsp;&amp; other payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total current liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,101</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4,419</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>8,888</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>6,829</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total shareholders&#146; equity and liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>79,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,296</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_9"></A>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years<BR>Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Contract revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>39,090</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>30,269</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research&nbsp;&amp; development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,116</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General&nbsp;&amp; administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,417</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,436</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total operating expenses</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(20,466</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(19,552</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating income</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>18,624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,717</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Finance result, net</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,646</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income before tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,412,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,684,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,043,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,552,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Comprehensive Income </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income for the period</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other comprehensive income not to be reclassified to income or loss in subsequent periods (net
of tax)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Re-measurement losses on defined benefit plans</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total comprehensive income, net of tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>19,534</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,426</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_10"></A>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Changes in Equity </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share&nbsp;capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>812</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>73,211</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,092</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,931</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Income for the period in 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive income / (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total comprehensive income</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>9,426</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>9,426</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share capital</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Share<BR>premium</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Accumulated<BR>losses</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>854</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>83,068</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(60,455</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>23,467</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Income for the period in 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Total Comprehensive loss</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><I>&#151;&nbsp;&nbsp;</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>19,534</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" ALIGN="right"><I>19,534</I></TD>
<TD NOWRAP VALIGN="bottom"><I>&nbsp;&nbsp;</I></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issue of capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- preferred Series E shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">-&nbsp;exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">142</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,139</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Balance at December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>928</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>110,496</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(40,381</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,043</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_11"></A>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statements of Cash Flows </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income for the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,270</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Adjustments to reconcile net income for the period to net cash flows :</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of property, plant&nbsp;&amp; equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance result, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,646</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Changes in working capital:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,744</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferral of unearned revenue (current)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,717</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(141</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash provided by/(used in) operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,035</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,641</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Finance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows provided by/(used in) operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>44,084</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(17,624</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property, plant and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(244</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other non-current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows used in investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(244</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(131</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred Series E / D shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transaction costs of issue of shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(200</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cost on issue of shares-option plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from employee loan repayments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>27,778</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>9,801</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase / (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exchange gains on cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase / (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>71,618</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(7,954</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="fin16439_12"></A>Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Notes to the Financial Statements </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>General information </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune SA (the &#147;Company&#148;) is a clinical stage biopharmaceutical
company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. Misfolded proteins are
generally recognized as the leading cause of neurodegenerative diseases, such as Alzheimer&#146;s disease, or AD, and Parkinson&#146;s disease, or PD, with common mechanisms and drug targets, such as Abeta, tau and alpha-synuclein. Our lead product
candidate is crenezumab, a humanized, monoclonal, conformation-specific anti-Abeta antibody that we developed using our proprietary SupraAntigen platform. Crenezumab is expected to enter Phase&nbsp;3 clinical studies in early 2016 and we believe it
has the potential to become a best-in-class disease-modifying treatment for AD. We use our two unique proprietary platform technologies, SupraAntigen (conformation-specific biologics) and Morphomer (conformation-specific small molecules), to
discover, design and develop medicines and diagnostics to target misfolded proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was initially incorporated as a limited liability
company on February&nbsp;13, 2003 in Basel and effective August&nbsp;25, 2003 was transitioned into a stock company. The Company&#146;s corporate headquarters are located at EPFL Innovation Park Building B, Ecublens/Lausanne, Vaud, Switzerland. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to
all the years presented, unless otherwise stated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of preparation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Going concern </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have been prepared on the basis that the Company will continue as a going concern after considering the Company&#146;s cash position
of CHF 76.5&nbsp;million as of December&nbsp;31, 2015 which includes cash related to the Company&#146;s Series E financing totaling CHF 28.9&nbsp;million concluded in October 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Company has financed its cash requirements primarily from share issuances and revenues from collaboration agreements. The Company is a clinical
stage company and is exposed to all the risks inherent to establishing a business. Inherent to the Company&#146;s business are various risks and uncertainties, including the substantial uncertainty as to whether current projects will succeed. The
Company&#146;s success may depend in part upon its ability to (i)&nbsp;establish and maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in the biotech and pharmaceutical industry,
(iii)&nbsp;successfully move its product candidates through clinical development, (iv)&nbsp;attract and retain key personnel, and (v)&nbsp;acquire capital to support its operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Statement of compliance </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements have
been prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). These financial statements have been approved for issue by the Board of Directors on March&nbsp;12,
2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of measurement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements
have been prepared under the historical cost convention. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Functional currency
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The financial statements of the Company are presented in Swiss Francs (CHF), which is also the functional currency of the Company. All financial
information presented in Swiss francs (except for share capital and earnings per share data) has been rounded to the nearest thousand CHF (CHF thousands), unless otherwise indicated. The Company also has transactions denominated in U.S. Dollars
($)&nbsp;and Euros (EUR) that are translated to CHF at the date of transaction or as of the balance sheet date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Summary of significant accounting policies </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal accounting policies adopted in the preparation
of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current vs. non-current classification </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company
presents assets and liabilities in the balance sheet based on current/non-current classification. The Company classifies all amounts to be realized or settled within twelve months after the reporting period to be current and all other amounts to be
non-current. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign currency transactions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Foreign
currency transactions are translated into the functional currency Swiss Francs (CHF) using prevailing exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies are translated into CHF at rates
of exchange prevailing at reporting date. Any gains or losses from these translations are included in the income statement in the period in which they arise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue includes license fees,
milestone payments as well as revenue from research agreements associated with collaborations with third parties and grants from public institutions and foundations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Upfront fees </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from non-refundable, upfront
license fees and performance milestones where the Company has continuing involvement is recognized over the estimated performance or agreement period, depending on the terms of the agreement. The recognition of revenue is prospectively changed for
subsequent changes in the development or agreement period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For collaboration agreements on product candidates that are (i)&nbsp;in clinical development,
(ii)&nbsp;where the upfront payment reflects a payment for past investments the Company has made in the development of the product candidate, access to the product candidate, the associated intellectual property and our knowledge, and,
(iii)&nbsp;where there is no further performance commitment, pursuant to guidelines on revenue recognition as contained in IAS 18, the Company recognizes the fair value of the upfront payment at the time of entering into the collaboration agreement.
For collaboration agreements (i)&nbsp;in clinical development but where conditions (ii)&nbsp;and (iii)&nbsp;are not met, the Company recognizes revenue from upfront payments under our collaboration agreements pro-rata over the term of the estimated
period of performance under each agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For collaboration agreements, in addition to receiving upfront payments, the Company is also entitled to
milestone and other contingent payments upon achieving pre-defined objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Milestone payments </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Revenue from milestones, if they are non-refundable and deemed substantive, are recognized upon successful accomplishment of the milestones. To the extent that
non-substantive milestones are achieved and the Company has remaining performance obligations, milestones are deferred and recognized as revenue over the estimated remaining period of performance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant revenue </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grants provide funding for certain types
of expenditures in connection with research and development activities over a contractually-defined period. Revenue related to grants is recognized in the period during which the related costs are incurred and the related services are rendered,
provided that the applicable performance obligations under the grants have been met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and development expenditure </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the stage of development of the Company&#146;s products, all research expenditure is recognized as expense when incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For external research contracts the &#147;stage of completion&#148; method is used to estimate the amount of accrued expense related to the research projects
for its clinical studies. The Company estimates its accrued expenses as of the balance sheet date in the financial statement based on facts and circumstances known at the time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Registration costs for patents are part of the expenditure for research and development projects. Therefore, registration costs for patents are expensed when
incurred as long as the research and development project concerned does not meet the criteria for capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upfront payments relating to
in-licensing agreements are recognized over an appropriate, project-specific duration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property, plant and equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Equipment is shown at historical acquisition cost, less accumulated depreciation and any accumulated impairment losses. Historical costs include expenditures
that are directly attributable to the acquisition of the items. Depreciation is calculated using a straight-line method to write off the cost of each asset to its residual value over its estimated useful life as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IT equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">3&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Laboratory equipment</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Leaseholds improvements</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">5 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets&#146; residual values and useful lives are reviewed, and adjusted if appropriate, at each balance sheet date. Where
an asset&#146;s carrying amount is greater than its estimated recoverable amount, it is written down immediately to its recoverable amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Profits and
losses on disposals are determined by comparing the disposal proceeds with the carrying amount and are included in the income statement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intangible assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenditure to acquire patents, trademarks and licenses is capitalized and amortized using the straight-line method over their useful lives of five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairment losses at the balance sheet date are charged against the income statement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial assets&nbsp;&amp; liabilities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company&#146;s financial assets and liabilities are only comprised of receivables, cash and cash equivalents and trade payables. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Receivables </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receivables are non-derivative financial assets with fixed payments that are not quoted in an active market. They arise when the Company provides money, goods
or services directly to a debtor with no intention of trading the receivable. They are included in current assets, except for maturities greater than 12 months after the balance sheet date. These are classified as long-term assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receivables are measured at amortized cost. Amortized cost is the amount at which the receivable is measured at initial recognition minus principal
repayments, plus or minus the cumulative amortization using the effective interest method of any difference between that initial amount and the maturity amount. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Cash and cash equivalents </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at
the bank comprise the cash on hand. All cash and cash equivalents are either in cash or in deposits with less than 3 months&#146; duration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Trade
payables </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trade payables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company assesses at each period whether there is objective evidence that those financial assets are impaired. Impairment losses are recognized in the
income statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Share capital </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary (Common)
Shares as well as all Preferred Shares are classified as equity. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expenses directly attributable to the issue of new shares are shown in equity as a
deduction, net of tax, from the proceeds. AC Immune has five classes (Class A, B, C, D and E) of Preferred Shares outstanding. The Preferred Shares are a class of shares that AC Immune SA issued in connection with five separate capital increases and
convey voting rights and certain other rights to their holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of Preferred Shares own 80.1% of the total amount of shares outstanding
(assuming conversion of the Preferred Shares into Common Shares on a one-for-one basis), have been the primary source of equity financing for the Company over the past 13 years and the Company&#146;s Board of Directors consists predominantly of
holders of Preferred Shares. The Preferred Shares do not have mandatory redemption features and the redemption of the Preferred Shares is within the control of the Company&#146;s Board of Directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Shareholders&#146; Agreement allows for the conversion of Preferred Shares into Common Shares under
certain circumstances, all of which are at the discretion of the Board or our Shareholders. The Preferred Shares have to be converted into Common Shares in the event of a change of control or an initial public offering or some other form of
liquidity event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The voting rights associated with Preferred Shares are the same as for Common Shares-each Preferred Share entitles the holder to one
vote. No dividends have been paid on the Preferred Shares and the holders of Preferred Shares are not entitled to any dividends unless dividends are paid on the Common Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Preferred Shares have a liquidation preference wherein, in the event of a change of control or a liquidation of the Company, the holders of Preferred
Shares are entitled to receive, prior and in preference to the holders of Common Shares, the amount corresponding to the price paid for each Preferred Share. Thereafter, all holders of Preferred Shares will participate with the holders of Common
Shares on an as-if-converted basis in any remaining proceeds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2015, AC Immune completed a 250-for-1 stock split.&nbsp;The split
applies to all of AC Immune&#146;s outstanding common shares, preferred shares (Series A, B, C, D and E) and vested and unvested options.&nbsp;The stock split has an impact on the earnings per share (&#147;EPS&#148;).&nbsp;To facilitate a comparison
of EPS figures, the 2015 and 2014 reported EPS figures were adjusted to reflect the stock split.&nbsp;Footnotes 9 (share capital), 16 (share based compensation) and 18 (earnings per share) have all been prepared taking into consideration the
250-for-1 stock split. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employee benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Post-employment benefits </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates the
mandatory pension schemes for its employees in Switzerland. The schemes are generally funded through payments to insurance companies or trustee-administered funds. The Company has a pension plan designed to pay pensions based on accumulated
contributions on individual savings accounts. However, this plan is classified as a defined benefit plan under IAS 19. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net pension liability is the
present value of the defined benefit obligation at the balance sheet date minus the fair value of plan assets. The defined benefit obligation is in all material cases calculated annually by independent actuaries using the projected unit credit
method, which reflects services rendered by employees to the date of valuation, incorporates assumptions concerning employees&#146; projected salaries, pension increases as well as discount rates of highly liquid corporate bonds which have terms to
maturity approximating the terms of the related liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Share-based compensation </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company operates an equity-settled, share-based compensation plan. The fair value of the employee services received in exchange for the grant of options
and shares is recognized as an expense. The total amount to be expensed over the vesting period is determined by reference to the fair value of the instruments granted, excluding the impact of any non-market vesting conditions. Non-market vesting
conditions are included in assumptions about the number of instruments that are expected to become exercisable. At each balance sheet date, the Company revises its estimates of the number of instruments that are expected to become exercisable. It
recognizes the impact of the revision of original estimates, if any, in the income statement, and a corresponding adjustment to equity over the remaining vesting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock options granted under the Company&#146;s stock option plans A, B and C are valued using the
Black-Scholes model (see Note 16). This valuation model as well as parameters such as expected volatility and expected term of the stock options was partially based on management&#146;s estimates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The proceeds received net of any directly attributable transaction costs are credited to share capital (nominal value) and share premium when the options are
exercised. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Provisions are recognized
when the Company has a present legal or constructive obligation as a result of past events where it is more likely than not that an outflow of resources will be required to settle the obligation, and a reliable estimate of the amount can be made.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Taxation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Current income tax assets and liabilities
for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date in
the country where the Company operates and generates taxable income. Taxation is provided for in accordance with the fiscal regulations of the respective country in which the Company operates. Deferred tax is provided using the liability method on
temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is
settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date. If required, deferred taxation is provided in full using the liability method, on all temporary differences at the reporting dates. It
is calculated at the tax rates that are expected to apply to the period when it is anticipated the liabilities will be settled, and it is based on tax rates (and laws) that have been enacted or substantively enacted at the balance sheet date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets are recognized to the extent that it is probable that future taxable profit will be available against which the temporary
differences can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized. Although the Company has substantial tax loss
carryforwards, historically, due to the fact that the Company had limited certainty on key milestones, it has not recognized any deferred tax assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnings per share </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company presents basic earnings
per share for each period in the financial statements. The earnings per share is calculated by dividing the earnings of the period by the weighted average number of shares (common and preferred) outstanding during the period. Diluted earnings per
share reflect the potential dilution that could occur if dilutive securities such as share options were vested or exercised into common shares or resulted in the issuance of common shares that would participate in net income. Anti-dilutive shares
are excluded from basic and dilutive earnings per share calculation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical judgments and accounting estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets, liabilities, income and expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The areas where AC Immune has had to make judgments, estimates and assumptions relate to (i)&nbsp;revenue
recognition on collaboration and licensing agreements, (ii)&nbsp;clinical development accruals, (iii)&nbsp;pensions, (iv)&nbsp;income taxes and (v)&nbsp;stock-based compensation. Actual results may differ from these estimates. Estimates and
underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Income taxes </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As disclosed in Note 14, the Company has
tax losses which will expire after the tax holiday period. These tax losses represent potential value to the Company to the extent that the Company is able to create taxable profits before the expiry period of these tax losses. The Company has not
recorded any deferred tax assets in relation to these tax losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Preferred shares </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Significant judgment is required in determining the classification of the Preferred Shares issued by the Company as either equity or liabilities. The Preferred
shareholders receive certain preference rights that represent a significant proportion of the net assets of the Company in the case of liquidation or certain exit events, the occurrence of which are outside the control of the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment reporting </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has one segment. The
Company currently focuses all of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins which are present in a broad range of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, management considers that there is only one operating segment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standards, amendments and interpretations effective in current reporting period but without impact on the Company financial statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following standards, amendments and interpretation currently are mandatory for accounting periods beginning on or after January&nbsp;1, 2015 but did not
have any effect on the Company financial statements: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amendments to IAS 19: Defined Benefits Plans: Employee Contributions </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual Improvements to IFRSs 2010-2012 Cycle (except for the amendment to IFRS 3 Business combinations </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Annual Improvements to IFRSs 2011-2013 Cycle </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Standards, amendments and interpretations to existing standards not yet effective </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain new standards, amendments and interpretations to existing standards have been published and are mandatory for accounting periods beginning on or after
January&nbsp;1, 2016 or later periods but which the Company has not adopted early: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:152.90pt; font-size:8pt; font-family:Times New Roman"><B>Recently released Standards/ Interpretations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date&nbsp;Issued</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effective date (mostly annual periods<BR>beginning on or after)
Early adoption<BR>is&nbsp;often&nbsp;permitted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Planned&nbsp;application<BR>by AC Immune</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment Entities: Applying the Consolidation</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Exception (Amendments to IFRS 10, IFRS 12 and IAS 28)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dec 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with early application permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Disclosure Initiative (Amendments to IAS 1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Dec 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with early application permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Improvements 2012-2014 Cycle</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sept&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Sept 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Non applicable</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Equity Method in Separate Financial Statements (Amendments to IAS 27)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Aug 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2016, with earlier application being permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IFRS 9 Financial instruments</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Nov&nbsp;2009&nbsp;to</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">July 2014</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective Jan 1, 2018 with early adoption allowed</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Early application of the own credit risk improvements, prior to any other changes in the accounting for financial instruments, is permitted by IFRS 9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Agriculture: Bearer Plants (Amendments to IAS 16 and IAS 41)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">June&nbsp;2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">An entity shall apply those amendments for annual periods beginning on or after January 1, 2016. Earlier application is permitted.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IFRS 15 Revenue from Contracts with Customers</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Annual periods beginning on or after January 1, 2018. Earlier application permitted.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2018</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clarification of Acceptable Methods</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of
Depreciation and Amortization</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amendments to IAS 16 and IAS 38</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">An entity shall apply those amendments prospectively for annual periods beginning on or after January&nbsp;1, 2016. Earlier application is permitted.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2016</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:152.90pt; font-size:8pt; font-family:Times New Roman"><B>Recently released Standards/ Interpretations</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date&nbsp;Issued</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Effective date (mostly annual periods<BR>beginning on or after)
Early adoption<BR>is&nbsp;often&nbsp;permitted</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Planned&nbsp;application<BR>by AC Immune</B></P></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accounting for Acquisitions of</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Interests in
Joint Operations</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amendments to IFRS 11</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">May 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">An entity shall apply those amendments prospectively in annual periods beginning on or after January&nbsp;1, 2016.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IFRS 14 Regulatory Deferral Accounts</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 2014</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Effective for an entity&#146;s first annual IFRS financial statements for a period beginning on or after January 1, 2016. Earlier application is permitted</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Non applicable</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">IFRS 16 Leases</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Effective for annual periods beginning on or after 1 January 2019 (subject to EU endorsement)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Effective for annual period beginning on or after January 1, 2019. Earlier application is
permitted if IFRS 15 has also been applied.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>Jan 1, 2019</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Annual Improvements 2012-2014 Cycle (IAS 12 Income Taxes)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 2016</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Effective for annual period beginning on or after January 1, 2017.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jan 1, 2017</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has not yet evaluated the impact of these revised standards and amendments on its financial statements. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Property, plant and equipment </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Laboratory<BR>Equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>IT<BR>Equipment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Building<BR>and&nbsp;Furniture</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Historical cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,741</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>128</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>136</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,005</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,815</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>172</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,133</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acquisitions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,058</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>172</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>2,376</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accumulated depreciation</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,146</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>72</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>74</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,292</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of January&nbsp;1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,397</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>100</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>92</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,589</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>As of December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,629</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>138</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>109</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,876</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net book value December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>429</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>34</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>37</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>500</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net book value December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">418</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial assets </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="17%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rental deposit (restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Security Deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AC Immune has a two deposits in escrow accounts totaling CHF 85&nbsp;thousand associated with the lease of the Company&#146;s
premises. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Prepaid expenses and accrued income </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">373</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prepaid expenses relate mainly to research contracts with down-payments at contract signature and their related activities
will start or continue in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred offering costs, which consist primarily of direct incremental legal, accounting and printing costs relating to
the Company&#146;s planned initial public offering (&#147;IPO&#148;), are capitalized within prepaid expenses.&nbsp;The deferred offering costs will be offset against IPO proceeds upon the consummation of the IPO. In the event the IPO is terminated,
deferred offering costs will be expenses.&nbsp;As of December&nbsp;31, 2015, CHF 2,169&nbsp;thousand (2014: none) of deferred offering costs were capitalized in prepaid expenses on the balance sheet. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other current receivables </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Swiss VAT</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Withholding tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The maturity of these assets is less than three months. The Company considers the counterparty risk as low and the carrying
amount of these receivables is considered to correspond to the fair value. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Cash and cash equivalents </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>By Currency</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CHF</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">EUR</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">482</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">USD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>76,522</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>3,306</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the balance sheet date, Company funds were held in CHF, EUR and USD bank accounts. Assets in EUR and USD were translated
into CHF at a rate of 1.0916 and 0.9991, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share capital </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, the issued share capital amounting to CHF 928,050 is
comprised of 46,402,500 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes the capital structure: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>CHF</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common shares with a nominal value of CHF 0.02 each</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,227,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,633,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172,660</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series A with a nominal value of CHF 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,538,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,538,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series B with a nominal value of CHF 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,782,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,782,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">335,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series C with a nominal value of CHF 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,619,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,619,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,380</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series D with a nominal value of CHF 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,122,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred shares Series E with a nominal value of CHF 0.02</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,113,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,265</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,402,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">928,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,695,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">853,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Common and Preferred Shares have a nominal value of CHF 0.02 and are fully paid in. In a liquidation or winding up event
(including trade sale), Preferred A, B, C, D and E Shares are senior to common shares in such a way that Preferred shareholders get in advance, prior and in preference to the holders of common shares, the amount corresponding to the price paid for
each Preferred Share. The remaining funds shall be distributed pro-rata to all shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2015, AC Immune completed a 250-for-1
stock split. The split applies to all of AC Immune&#146;s outstanding common shares, preferred shares (Series A, B, C, D and E) and vested and unvested options. The stock split has an impact on the earnings per share (&#147;EPS&#148;). To facilitate
a comparison of EPS figures, the 2015 and 2014 reported EPS figures were adjusted to reflect the stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Increase of Conditional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Extraordinary General Assembly held on November&nbsp;28, 2013, approved an increase of the conditional capital of 727,500 (split-adjusted) registered
Common Shares with a par value of CHF 0.02. These shares are reserved for the Company&#146;s stock option plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance of Preferred Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2015 the Company successfully completed a financing round of USD 30&nbsp;million (CHF 29.4 million). The split-adjusted share price of the
round was USD 9.63624 for each of the 3,113,250 Series E Preferred Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;13, 2013, the Company approved a CHF 20&nbsp;million capital
increase.&nbsp;The capital increase was completed in two stages with 2,061,250 shares issued immediately in December 2013 at CHF 4.8516&nbsp;per share raising gross proceeds of CHF 10&nbsp;million and the second tranche completed in May 2014 with
the Company issuing 2,061,250 shares at CHF 4.8516&nbsp;per share raising gross proceeds of CHF 10 million. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Trade payables and accrued liabilities </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade payables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued R&amp;D costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">712</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred Income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,419</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An accrual of CHF 880&nbsp;thousand and CHF 947&nbsp;thousand was recognized for performance-related remuneration relating to
2015 and 2014, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Current portion of deferred income </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2015 we received a grant from the Michael J. Fox Foundation for developing an alpha-synuclein protein positron emission tomography (PET) imaging agent. The
grant covers an 18 month period. We recognized revenues on a straight line basis over the period of the grant. As of December&nbsp;31, 2015, the remaining CHF 45&nbsp;thousand is recorded as a current liability in deferred income. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, AC Immune SA and Piramal Imaging, a division of Piramal Enterprises Ltd. entered into an exclusive worldwide license agreement for the research,
development and commercialization of AC Immune&#146;s tau tracers supporting the diagnosis and clinical management of AD and potential tau-related disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The upfront payment of EUR 500&nbsp;thousand (CHF 616 thousand) received in May 2014 from this collaboration is deferred over a period of 12 months. No
deferred income was recognized during the year ended on December&nbsp;31, 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Revenues </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Collaboration and license revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,179</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-Abeta antibody in AD&#151;Collaboration agreement of 2006 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2006, AC Immune signed an exclusive, worldwide licensing agreement for crenezumab, our humanized monoclonal antibody targeting misfolded Abeta in
July 2015, Genentech announced it will commence Phase&nbsp;3 clinical studies for crenezumab in 2016. If crenezumab receives regulatory approval, we will be entitled to receive royalties that are tied to annual sales volumes with different royalty
rates applicable in the U.S. and Europe. These percentage rates range from net high single digits to the mid-teens. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the agreement with Genentech,
we may become eligible to receive payments totaling up to approximately $340 million, excluding royalties. As of December&nbsp;31, 2015 we have received total payments of $65 million (CHF 70.1 million): $40 million (CHF 45.8 million) were received
in three milestone payments prior to 2013 and $25 million (CHF 24.3 million) were received in July 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We recognized the Phase 3 payment in our
financials since there is no further performance requirement on our side. The agreement provides for a second therapeutic product based on the same intellectual property and anti-Abeta antibody compound as well as an anti-Abeta diagnostic product.
Genentech may terminate the agreement at any time by providing three months&#146; notice to us. In such event all costs incurred are still refundable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anti-tau antibody in AD &#150; Collaboration agreement of 2012 with Genentech </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2012, we entered into a second partnership with Genentech to commercialize our anti-tau antibodies for use as immunotherapeutics. The value of this
exclusive, worldwide alliance is potentially greater than CHF 400&nbsp;million and includes upfront and milestone payments. In addition to milestones, we will be eligible to receive royalties on sales at a percentage rate ranging from the mid-single
digits to high single digits. The agreement also provides for collaboration on two additional indications built on the same anti-tau antibody program as well as a potential anti-tau diagnostic product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date we have received payments totaling CHF 31&nbsp;million including a CHF 14&nbsp;million milestone payment received in 2015. In June 2015, the Company
recognized as revenue a milestone payment of CHF 14&nbsp;million as there is no further performance obligation. This milestone was due upon the ED-GO decision by Genentech on the anti-tau antibody&#146;s product in AD. At the same time, Genentech
announced that it intends to move the anti-tau antibody program into Phase&nbsp;1 clinical studies in late 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Genentech may terminate the agreement at
any time by providing three months&#146; notice to us. In such event all costs incurred are still refundable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tau Vaccine in AD &#150; Collaboration agreement of 2014 with Janssen Pharmaceuticals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December of 2014, we entered into a partnership with Janssen Pharmaceuticals, a Johnson&nbsp;&amp; Johnson company, to develop and commercialize therapeutic
anti-tau vaccines for the treatment of AD and potentially other tauopathies. The partnership includes a worldwide exclusive license and research collaboration. We and Janssen will co-develop the lead therapeutic vaccine, ACI-35, through Phase 1b
completion. From Phase 2 and onward, Janssen will assume responsibility for the clinical development, manufacturing and commercialization of ACI-35. ACI-35 is an active therapeutic vaccine stimulating the patient&#146;s immune system to produce a
polyclonal antibody response against phosphorylated tau protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement also allows for the collaboration to be expanded to a second indication
based on the same anti-tau vaccine program and intellectual property related to this program. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We received an upfront payment of CHF 25.9&nbsp;million
which we recognized in 2014 and are eligible to receive development, regulatory and commercialization milestone payments for AD and a potential second indication outside of AD. Additionally, we will receive royalties on sales at a percentage rate
ranging from the low double digits to mid-teens. The two companies have entered into a three-year joint research collaboration to further characterize and develop novel vaccine therapies for the treatment of tauopathies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of this agreement, AC Immune has committed to spending CHF 13.8&nbsp;million in research and development to the end of Phase 1b which is currently
anticipated at the end of 2016. Under the terms of the agreement, Janssen may terminate the agreement at any time after completion of the Phase 1b clinical study by providing 90 days&#146; notice to us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The recognition of the upfront payment from Janssen was recorded at the time of receipt as the Company determined that the license granted to Janssen was a
separate, non-contingent deliverable under the agreement. The Company determined the license had stand-alone value based on Janssen&#146;s ability to create value from the license without our R&amp;D support services due their extensive experience
in vaccine development and production which would allow them to complete the phase 1b clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tau-PET imaging agent in AD &#150;
Collaboration agreement of 2014 with Piramal Imaging </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, we entered into our first diagnostic partnership with Piramal Imaging, one of the
world leaders in imaging products. The agreement with Piramal is for a compound from the Morphomer chemical library that binds pathogenic tau aggregates for use as a PET tracer. The exclusive, worldwide licensing agreement with Piramal Imaging
includes upfront and sales milestone payments totaling up to EUR 157&nbsp;million, plus royalties on sales at a percentage rate ranging from mid-single digits to low double digits. We received an upfront payment of EUR 500&nbsp;thousand and are
entitled to further clinical milestones totaling EUR 7&nbsp;million should the compound make it through to Phase 3 clinical studies and are further entitled to regulatory, commercialization and sales based milestones totaling EUR 150 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Piramal may terminate the agreement at any time after the first eighteen months from the effective date of this agreement by providing three months&#146;
notice to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Grant </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2014, we recognized revenue
associated with a research grant given to us by a European Institution in October of 2011 and which had a 3-year duration. We recognized the revenues on a straight line basis over the period of the grant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2015 we received a grant from the Michael J. Fox Foundation for developing an alpha-synuclein PET imaging
agent. The grant covers an 18 month period. We recognized revenues on a straight line basis over the period of the grant. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Expenses by category </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Research and Development </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,669</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation of tangible fixed assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Administration </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,437</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Payroll expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total general and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Related-party transactions </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key management including the Board of Directors (five individuals) and the
Executive Management (four individuals) compensation is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Short-term employee benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Post-employment benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2015, George Pavey joined AC Immune as Chief Financial Officer and a member of Executive Management. At the same time,
Jean-Fabien Monin assumed the role of Chief Administrative Officer. He had previously been Chief Financial Officer since 2009. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Friedrich von Bohlen and
Peter Bollmann joined the Board of Directors of AC Immune in October and December 2015, respectively. Friedrich von Bohlen replaced Christof Hettich who stepped down from the Board in August 2015. Beat Guertler resigned from the board in December
2015. His position was assumed by Peter Bollmann. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Short-term employee benefits comprise of salaries, bonus payments, social security and expenses allowances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">45,000 and 62,500 options were granted in 2015 and 2014, respectively, to the Executive Management of the Company. Zero and 51,250 options were granted
in 2015 and 2014, respectively, to the Directors of the Company. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income taxes </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Income tax recognized in profit or loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The income tax expense for the year can be reconciled to the accounting profit as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Accounting income before income tax</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax expense calculated at the statutory rate of 22.5% (2014: 22.5%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of Swiss Tax Holidays</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,420</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized carry forward tax loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,566</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Effective income tax rate benefit / (expense)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax rate used for the 2015 and 2014 reconciliations above is the corporate tax rate of 22.5% payable by corporate entities
in the Canton of Vaud, Switzerland on taxable profits under tax law in that jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2015, AC Immune was able to avail itself of tax loss
carryforwards to reduce its effective tax rate to zero. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company was granted by the Canton de Vaud, Switzerland, a 10-year tax holiday for all income
and capital taxes on a communal and cantonal level, commencing in the fiscal year 2005 and valid through to December&nbsp;31, 2014. It has also been granted a 9-year tax holiday for direct Swiss Federal tax commencing in the fiscal year 2006 through
to December&nbsp;31, 2014. Consequently, the effective tax rate for 2014 was zero. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Unrecognized deductible temporary differences, unused tax losses and unused tax
credits</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deductible temporary differences, unused tax losses and unused tax credits for which no deferred
tax assets have been recognized are attributable to the following:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Tax Losses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">- Deductible temporary differences related to the retirement benefit plan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,663</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deductible temporary differences related to the retirement benefit plan do not expire. Tax losses expiry
dates are shown in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Tax losses split by expiry date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The tax losses available for future offset against taxable profits have decreased by CHF 20.2&nbsp;million, representing the
amount of tax losses that would have been used as an offset. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Consistent with prior years, the Company has not recorded any deferred tax assets in
relation to the past tax losses available for offset against future profits as the recognition criteria have not been met at the balance sheet date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Retirement benefit plan </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company participates in a collective foundation covering all of its
employees including its executive officers. In addition to retirement benefits, the plan provides death or long-term disability benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contributions
paid to the plan are computed as a percentage of salary, adjusted for the age of the employee and shared approximately 46% and 54% by employee and employer, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This plan is governed by the Swiss Law on Occupational Retirement, Survivors and Disability Pension Plans (BVG), which requires contributions to be made to a
separately administered fund. The fund has the legal form of a foundation and it is governed by the Board of Trustees, which consists of an equal number of employer&#146;s and employee&#146;s representatives. The Board of Trustees is responsible for
the administration of the plan assets and for the definition of the investment strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The collective foundation is governed by a foundation board. The
board is made up of an equal number of employee and employer representatives of the different affiliated companies. The Company has no direct influence on the investment strategy of the foundation board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The assets are invested by the pension plan, to which many companies contribute, in a diversified portfolio that respects the requirements of the Swiss BVG.
Under the Plan, both the Company and the employee share the costs equally. The structure of the plan and the legal provisions of the BVG mean that the employer is exposed to actuarial risks. The main risks are investment risk, interest risk,
disability risk and the life expectancy of pensioners. Through our affiliation with the pension plan, the Company has minimized these risks, since they are shared between a much greater number of participants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pension plan is exposed to Swiss inflation, interest rate risks and changes in the life expectancy for pensioners. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For accounting purposes under IFRS, the plan is treated as a defined benefit plan. Liabilities and assets are
calculated annually by an independent actuary. In accordance with IAS 19, plan assets have been estimated at their fair market value and liabilities have been calculated according to the &#147;Projected Unit Credit&#148; method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the status of the defined benefit pension plan and the amount that should be recognized in the balance sheet: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total Liability</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,787</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,410</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to IAS 19, the following amounts have been recorded as net pension cost in the income statement: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For&nbsp;the&nbsp;Years&nbsp;Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(76</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(118</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact of plan amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(584</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net pension cost</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in defined benefit obligation, fair value of plan assets and unrecognized (gains) / losses are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A. Change in defined benefit obligation </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,044</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Service cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(641</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(521</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest cost</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(101</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in demographic assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in financial assumptions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(591</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other actuarial gains / (losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(176</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan amendment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefit payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(48</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees&#146; contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Defined benefit obligation as of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,439</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,091</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>B. Change in fair value of plan assets </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value of plan assets as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,115</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employees&#146; contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employer&#146;s contributions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">441</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Benefits payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Plan assets Gains / (Losses)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Fair value of plan assets as of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employer&#146;s contribution to the pension plan for the financial year 2016 are estimated to be CHF&nbsp;478 thousand. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>C. Change in net defined benefit liability </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net defined benefit liabilities as of January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net pension cost through Income Statement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Re-measurement through OCI</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Employer&#146;s contribution</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(377</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net defined benefit liabilities as of December&nbsp;31</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the plan assets is the cash surrender value of the insurance with AXA. The investment strategy defined by
the Board of trustees follows a conservative profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The plan assets are primarily held within instruments with quoted market prices in an active
market, with the exception of real estate and mortgages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The actuarial assumptions used for the calculation of the pension cost and the defined benefit
obligation of the defined benefit pension plan for the year 2015 and 2014 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.80</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.25</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of future increase in compensations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Rate of future increase in current pensions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.50</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortality and disability rates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BVG&nbsp;2010G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">BVG&nbsp;2010G</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In defining the benefits, the minimum requirements of the Swiss Law on Occupational Retirement, Survivors and Disability
Pension Plans (BVG) and its implementing provisions must be observed. The BVG defines the minimum pensionable salary and the minimum retirement credits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quantitative sensitivity analysis for significant assumption as of December&nbsp;31, 2015 is as shown
below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Discount rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Future salary increase</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>Future pension cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Assumptions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">+0.5%&nbsp;increase</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">-0.5%&nbsp;decrease</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,502</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,384</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on the net defined benefit obligation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,105</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(55</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(554</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sensitivity analyses above have been determined based on a method that extrapolates the impact on net defined benefit
obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Share-based compensation </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has the following share-based compensation plans outstanding: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.95pt; font-size:8pt; font-family:Times New Roman">PLAN</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number of<BR>instruments&nbsp;awarded</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Vesting conditions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Contractual<BR>life&nbsp;of&nbsp;options</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">362,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">8&nbsp;1/2&nbsp;years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">819,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6 1/2 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock option plan C1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,920,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">4 years&#146; service from grant date</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">6 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number and weighted average exercise prices (in CHF) of options under the share option programs for Plans A, B and C1 are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center"><B>For&nbsp;the&nbsp;Years&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Term&nbsp;(Y)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Term&nbsp;(Y)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at January&nbsp;1</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,768,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.22119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,500</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,000</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(594,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,250</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">283,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.00000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,398,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,006,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.21668</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exerciseable at December&nbsp;31</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,032,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,370,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.23013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise prices for all outstanding options was CHF 0.14548 as of December&nbsp;31, 2015 and 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair values of the options granted in 2015 and 2014 are CHF 1.76848 and CHF 0.77044, respectively. These fair values have been determined using the
Black-Scholes model and an exercise price of CHF 0.14548 (2014: CHF 0.14548), a spot price of CHF 1.9104 (2014: CHF 0.90268), a risk-free interest rate of 0% (2014: 0.232%) and a volatility of 50% (2014: 50%) with an expected duration of 6 years
(2014: 6 years). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exercise price is set by the Board of Directors. The volatility is based on the historical trend of an appropriate sample of
companies operating in the biotech and pharmaceutical industry. The risk-free interest rate is based on the CHF swap rate for the expected life of the option. The weighted average fair value of exercised common share options in 2015 is CHF 1.9104
(2014: CHF 0.90268). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The expense charged against the income statement for the financial year 2015 amounts to CHF 539&nbsp;thousand
(2014: CHF 211 thousand). The expense assumes a departure rate based on the fact that some beneficiaries will not be able to exercise. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Commitments and contingencies </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Within one year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,235</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Between one and five years</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">924</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has research contracts with several external service providers. As of December&nbsp;31, 2015, external research
projects for CHF 5.82&nbsp;million were committed for 2016. Rental contract for laboratory and offices space at the EPFL Innovation Park in Ecublens/Lausanne can be cancelled within a 6 month notice period. As of December&nbsp;31, 2015, rental
contracts for CHF 169&nbsp;thousand were committed for 2016. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Earnings per share </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years<BR>Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands except for share and per share data</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income attributable to owners of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20,270</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>10,744</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings per share (EPS):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted, income for the period attributable to equity holders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,412,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,684,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of shares used to compute EPS fully diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,043,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,552,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2015 and 2014 basic and diluted earnings per share is based on the weighted average
number of shares issued and outstanding. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Sensitivity analysis </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign currency </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company undertakes certain transactions denominated in foreign currencies. Hence, exposure to exchange rate fluctuations arises. Exchange rate exposures
are managed by matching its cash holdings to the currency structure of its expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2015, if the CHF had strengthened/weakened
by 10% against the EUR and the USD with all other variables held constant, the net loss for the period would have been lower/higher by CHF 5,613&nbsp;thousand (2014: CHF 16 thousand), mainly as a result of foreign exchange gains/losses on
transaction of EUR/USD denominated assets and liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Interest rates </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is not materially exposed to any interest rates fluctuations. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial instruments and risk management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s activities expose it to the following
financial risks: market risk (currency risk), credit risk and liquidity risk. The Company&#146;s overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on the
Company&#146;s financial performance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table shows the carrying amounts of financial assets and financial liabilities: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Foreign exchange risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is exposed to foreign
exchange risk arising from currency exposures, primarily with respect to the EUR, USD and to a lesser extent to GBP, DKK and SEK. The currency exposure is not hedged. However, the Company has the policy of matching its cash holdings to the currency
structure of its expenses, which means that the Company holds predominately CHF, EUR and USD (see also Notes 8 and 19). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Credit risk </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The majority of the cash and cash equivalents is held within one bank. However, the credit risk on liquid funds is limited because the counterparties are banks
with high credit-ratings assigned by international credit-rating agencies. The maximum amount of credit risk is the carrying amount of the financial assets. Trade and other receivables are fully performing, not past due and not impaired (see Note
7). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidity risk </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inherent in the Company&#146;s
business are various risks and uncertainties, including its limited operating history and the high uncertainty that new therapeutic concepts will succeed. AC Immune&#146;s success may depend in part upon its ability to (i)&nbsp;establish and
maintain a strong patent position and protection, (ii)&nbsp;enter into collaborations with partners in the biotech and pharmaceutical industry, (iii)&nbsp;acquire and keep key personnel employed, and (iv)&nbsp;acquire additional capital to support
its operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s approach of managing liquidity is to ensure sufficient cash to meet its liabilities when due. Therefore, management
closely monitors the cash position on rolling forecasts based on expected cash flow to enable the Company to finance its operations for at least 24 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the current cash position, the Company is well financed until the end of 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to the Financial Statements (IFRS) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(in CHF thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below shows the maturities of the liquidity relevant financial liabilities as of December&nbsp;31,
2015: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Years Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>in CHF thousands</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial assets</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loans and receivables</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other receivables</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><U>Financial liabilities</U></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Trade and other accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total financial liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,719</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Capital risk management </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s objectives when managing capital are to safeguard the
Company&#146;s ability to continue as a going concern and to preserve the capital on the required statutory level in order to succeed in developing a cure against the AD. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Segment and geographic reporting </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has one Segment. The Company currently focuses all of its
resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins which are present in a broad range of neurodegenerative diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result, management considers that there is only one operating segment under the requirements of IFRS 8, Operating Segments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s geographic information is worldwide. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Post balance sheet events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, 2016, AC Immune entered into an exclusive research
collaboration agreement with Biogen covering the research and early clinical development of our alpha-synuclein PET Tracer program for Parkinson&#146;s disease, and a second discovery collaboration to identify novel PET ligands against the
neurodegeneration-associated protein, TDP-43.&nbsp;Under the agreement, AC Immune is entitled to a technology access fee and will receive significant funding covering its research and development activities on the PET imaging programs. ACI will
retain all intellectual property rights to any PET product developed for further commercialization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;15, 2016, AC Immune completed a private
placement of Series E preferred shares, each with a nominal value of CHF 0.02&nbsp;per share (the &#147;Series E Private Placement Extension&#148;). An aggregate 1,401,792 Series E preferred shares were issued at a price of $9.6384 per preferred
share to certain strategic investors, individuals and existing shareholder in the Series E Private Placement Extension for an aggregate subscription amount of approximately $13.5 million. The Series E preferred shares have substantially the same
terms as the Series A, B, C and D preferred shares and will be as accounted for as equity on AC Immune&#146;s balance sheet. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g16439g27c23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g16439g01b26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g01b26.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[21D4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $ < 5H  QLE1QP"   "   < E  #U)E9VES=&5R960@57-E<AP"!0 8
M0W)E;F5Z=6UA8B!+3R!$87D@4VQI9&5S.$))300E       0>&#Y*/LJ"W&8
M3E(,.,;/5CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70
M   %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT
M   /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M 0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %,
M90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U
M:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M     !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#
M;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O
M;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D
M("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @9&]U
M8D!OX            $)R9%15;G1&(U)L=                $)L9"!5;G1&
M(U)L=                %)S;'15;G1&(U!X;$!LEE8         "G9E8W1O
M<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F
M=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M    #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N
M9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P
M;&]N9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M    #@             _@   .$))300-       $    >#A"24T$&0
M!    !XX0DE- _,       D           $ .$))32<0       *  $
M     3A"24T#]       $@ U     0 M    !@       3A"24T#]P
M'   _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             M8   ++          $                          0
M           "RP   M8                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   M8     4F=H=&QO;F<   ++    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   +6
M     %)G:'1L;VYG   "RP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      :?     $   ">    H    =P
M 2F    :8  8  '_V/_M  Q!9&]B95]#30 !_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ H "> P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M9^A_L+*^LMC_ -@U8]=1N?E&NMC#6;*RX#UF,RFM]]>/:ZKT[+V_T?\ GO\
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M_5%N_&=7=92T7L=3N%9 ]6OUMN^IV_V6_GK0#Y$@$@]PDI6UW[WX!+:[][\
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M.O\ ='W!2224_P#_V3A"24T$(0      50    $!    #P!! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O
M ', : !O '  ( !# %, -@    $ .$))300B      %*34T *@    @ " $2
M  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    0    L(=I  0    !
M    P    .P (N6$   G$  BY80  "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-CHP.3HQ,B Q-#HU-CHS. !296=I<W1E<F5D(%5S97(
M  .@ 0 #     ?__  "@ @ $     0   LN@ P $     0   M8
M!@$#  ,    !  8   $:  4    !   !.@$;  4    !   !0@$H  ,    !
M  (   (!  0    !   !2@("  0    !              !(     0   $@
M   !.$))30/]       (          #_X0%,34T *@    @ " $2  ,    !
M      $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (
M   >    ?@$R  (    4    G $[  (    0    L(=I  0    !    P
M .P   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W
M<RD ,C Q-CHP.3HQ,B Q-#HU-CHS. !296=I<W1E<F5D(%5S97(   .@ 0 #
M     ?__  "@ @ $     0   LN@ P $     0   M8         !@$#  ,
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 3$!+ ,!$0 "$0$#$0'_Q  >  $
M @(" P$             !P@&"04* @,$ ?_$ %D0  $$ @(  00.!P4$!08/
M  4" P0& 0< "!$2$Q56"106(558DY25EI?3U=87&!DX=[;4,5>1TM<B)#=!
M(S)14V$E-5)YM=@F,S8Y2&5G<79XH:6QM[C_Q  4 0$
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ML=\8#=OVJWO\>X#]9CL?\8'=OVK7O\>X#]9?L?\ & W;]JU[_'N _67['?&
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MI-VK.5URLD8[H62,C0[&U'BSZ\A1D;@=.0[Y33P5DTK#T@HR>,[W*6GW-UX
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MVG&59="6;UV3T7VIB]X-7"-C5C2[VX;UJZVZXNVR,%@%3NHW6PRO!"<6R$8
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M%K8W7[18WK;>@;C1P^Q?T.Y2,83!4PPE.8<%YMQ+P3-$[J]@KIV3OVD->]?
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MJRN'D%K*;LJ5"=-T[%$H[3,D_,(DU28M>QAHF0FSYI S,\J>1E/REK<4%@>
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MEV!YB1'8:SP+L<"&>QO[O6^/X,[0_D@YP)FX#@. X#@. X#@. X#@. X#@.
MX#@. X#@. X#@. X#@. X#@. X#@: ?95OWA:;_!FO?SOL3@;_N!5"-WGZAS
M-Y&>MD7L!KM_=]?ME<H1F@-E7,D(%[MM?M%IKU(=(>UO0:K@2 4NS$45ALHL
MXP@4XS+@L29$-B0%K^!CLFWU.'8X%/F6BNQ;:5AOD!=6DFAK%C)#XWE8DSH
M1V2DG,AQ\H7Y^3'BN,M>0KSBT^3GP".^QO[O6^/X,[0_D@YP)FX$<ZOVYK;=
M5<EV[5=Q#7>MP;)9:C++A'U/Q6+%42\D&?&KRM#:_.0Y\1SS3N$9CSX3D0F/
M>E#9T.6^$C<!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P' <!P'
MT ^RK?O"TW^#->_G?8G W_<#JB:PU;1W?9>-@!-CZZ]D+"3XO;8[LZA:ZJ%,
MUF5Z<'6XA\C?*?O^SW@N,%[\#U?.QK3:+F9 1BY&@-W=4::+=GUE4 +$#M=\
M"L%DZ>:&MF_@79@U7#KVUJ^L'(B3HUXN<&MRB-9'E15<+E*7#.LU4F4"#C1&
M+"DRQ3GE)=8<EHDOP![L4/H[9:]HMRT/N0E;*C7;'/!Z;VDL/,,B89"2,6JF
MEWU*@O26G%QE9>88=SEK*<Y<:;5_:G&<!,=DU]5+373U9(C?:P^Q!B@*=(#/
MOA2[$,M"?@27A9D8Y&)"2+3,A:X1(?(CS8,E+<J*\T^TVM(4WUI['%H;1-%*
MT7KV=VSI**5MT"\.DZM?I-EE)L$ ;)%X4X*V=!OE7G"R$9]GTT'( )4$NX.%
MNRVU/#HKC09DJE=JJ)/;]$R-#]@*HC"O.1+H(*Z1V6VC"7,8S[J*B*O^O[#+
MSGS2DM8U]0HCF<.H5*C)6AQH/7'[(4VORY0_=&A-NZ1<@)QF99+#KA=WUEG'
MO^5*;V?JE=YJPP;XISE$NX/U-W"%(]LQ(KRLLI"?*':],;2$)/ZSL^N-A@U^
M'@7I!RNVD;XJQC.$JF@Y<Z.E?AG'BA3F%8_LSC&>!G'N< ? PWYFQ_DX#W.
M/@8;\S8_R<![G 'P,-^9L?Y. ]S@#X&&_,V/\G >YP!\##?F;'^3@/<X ^!A
MOS-C_)P'N< ? PWYFQ_DX#W. /@8;\S8_P G >YP!\##?F;'^3@/<X ^!AOS
M-C_)P'N< ? PWYFQ_DX#W. /@8;\S8_R<![G 'P,-^9L?Y. ]S@#X&&_,V/\
MG >YP!\##?F;'^3@/<X ^!AOS-C_ "<![G 'P,-^9L?Y. ]S@#X&&_,V/\G
M>YP!\##?F;'^3@/<X ^!AOS-C_)P'N< ? PWYFQ_DX#W. /@8;\S8_R<![G
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MYRA7DKQC.,Y2K*4KPE6,?]57D*2KPSX9\E25?V9QG@>7 <!P' <!P' <!P'
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MV!'ZZ;*7G3-E-/5N'?*R2UAL+8P-'HBQ-L [?53A(1;JB4)"XAH*PY-3Y 4
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M#@. X#@. X#@.!B%MHX.Y^A5E7#42972S)H*2 6 U7",*<TG+;B52@LZ$J;
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M1V,YQAY]II;36<XPM2<YX$5]C?W>M\?P9VA_)!S@3-P' <!P' <!P' <!P'
M<!P' <!P' <!P' <!P' <!P' P)%4=KIFZ7(#/LQ<A81K<C-*)V9QRJ/'A<+
M+,.2&;*,3UU225:8B#B/HM]@"O"$DWPKA+,F9(#FJD>E6:O#3<ZMGJA.FM.>
MW:U96H+1H/+8?=C2(DS(R<3&2,)>96J--&D)H^?%4S,AR7H[[:\AD? BS34J
M00H^2<B!(&9+7+9IB/$E*94_@>6V5;2(R0K+#CC?DS1\F+,;QA?E);D(2XE#
MF%H2$I\!P- /LJW[PM-_@S7OYWV)P-X6U*9(V-K#8^O8=B)U"7>Z';Z9%M@5
M>6S%7D6BOD C-B$N)<:4V2"N3DDH*TNMY3*C-*PXC./*P'4MT9ULUOJCMUU9
MUAM#L/['Y-[3A-^]<AX[6?50??+SL+4^A.HVISE6HU+HP016")/4V-T[)NUZ
MNO8\YL@G5*6-%6J0,C3;63(M34!W#N!KCOG2<O=.^--[5>9U@S5JD)ITA[$W
M])$G8IBT5X?=0S;[/M*U#J:'B 1YD=D0O PA%,X)&63P1<@<.(R@L+VRK)H[
MH?<DH7L2XTQ@?IO:2I8VM0M?RH1S&::7<P@HY<*-:R+*4H;7'QD)/#K\U(>R
MI:GTL/,A/GHJ?ZRF_D*Y^7^ ]%3_ %E-_(5S\O\  >BI_K*;^0KGY?X#T5/]
M93?R%<_+_ >BI_K*;^0KGY?X#T5/]93?R%<_+_ >BI_K*;^0KGY?X#T5/]93
M?R%<_+_ >BI_K*;^0KGY?X#T5/\ 64W\A7/R_P !Z*G>LIOY"N?@' >BI_K*
M;^0KGY?X#T5/]93?R%<_+_ >BI_K*;^0KGY?X#T5/]93?R%<_+_ >BI_K*;^
M0KGY?X#T5/\ 64W\A7/R_P !Z*G^LIOY"N?E_@/14_UE-_(5S\O\!Z*G^LIO
MY"N?E_@/14_UE-_(5S\O\!Z*G^LIOY"N?E_@/14[UE-_(5S\ X#T5/\ 64W\
MA7/R_P !Z*G>LIOY"N?X?^8. ]%3O64W\A7/>_\ V#_^> ]%3_64W\A7/R_P
M,1MFL1=UP#4=.654JM&X=B DALP<%*BBL/.<8=BDA(J',3'F1UO0"D!;RX!8
M;(DCR,:3$>6UD/G9D7:+:+)"/JF#Z/!%L%P5ZCF:@ZPXVS&C8,B[,'FUN!/"
M$(DKV[,@S('IL'+",^>GDA))*1SX87UXL(38FG:;;*9?)YJOD8Y-N+.@L@?,
MY>@&B,&8PI$BOXD,O1I<=YEYE]*74+1GQ3Y.4YR$U>BI_K*;^0KGY?X#T5/]
M93?R%<_+_ T'^RF17V.P5/0Z2FS59TY7U8=DMCD.)QF[;"QYO&(8^(UY&,XR
MK&5-J<\5J\5Y3A*4AO=V JJIH=V5>EX:I*:C9%7%S+TV-ANJX#3<V%>9 QQH
MDQA GVVK+P]UN:UX>7$<0^EM6 Z@W0C3H7JMVXZ;;@Z]:K[A=3NG6\W[%I[1
M4'LO3>L^X];W>I]A6JKM?W-P['JG9(_LSI2S;)A:9JI375BWW^F-F)('>YXU
MD!*L+D=0=R?@.!#/8W]WK?'\&=H?R0<X$S<!P' <!P' <!P/Q2DI\,J5A.,Y
MPG&59QCQ4K.$I3CQ_MRK.<8QC^W.<XQCW^!XI<0KPPE:%9SY?AA*L9\?-J\A
M?AX9]_R%_P"RO_T5?[.?#/O<#RRI*?#RLXQXYPG'CG&/%6?[,8\?[<Y_Y8Q[
M^>!Z7949E:&WI##3COO-MNNMMK<]_P /]A*E84OW\XQ_LXS[_O?V\#V-N-NI
M\IIQ#B<*4G*FU)6G"DY\%)\4YSCRDYQG"L?VXSCPS[_ \^ X#@. X#@. X#@
M. X#@. X#@8K>*8"V)4+'1;0U,D5RV")@(W''DR(:7)&$&E,3(S1,3)AD(N)
M#"ELNJC26E.,K<97E33BT*"(NLVKJGK#7"&JJ@TG%K)2+(;49LAVPKD%_-,!
MLR(^39"=B E8\1 :=8@XCLO.,YD/(7(<<=4%A^ X&@'V5;]X6F_P9KW\[[$X
M&\79\6K3=:;#A7EZ1'I,NC6V+<9$3$G,MBK2 !!JP/1<0F9$S,AH2N6MG$2.
M_)RXE.&&77?(0H.HITC/=6>Q_;3IM1>EP_V0+?.C=>%".Z:/L_LWWIF1-%5N
MI=;)M*HA,O2.NDJ7=[V=,TZ3M:F@:[5-B5C3SR6"LI^$M4(1-\D.Y)P*HVWM
M[0J9OP3U\*TS:C]@-3Z,&B7(;469NOFSVP63TX (GF6RV"@U+@JL'R.3T\%'
MJ<MT,6KXFP$;8*(@(H<OVRV)K^F:'W(-N%YIU4(G--[20$@66S!04TPM--+Q
MU(%Q2DV*^04E^0PSE,1M[.'7F6\X\MQ&%!,QO8FOZR.>+V.]4ZOB8ZF4/E#=
MF""AS"Y#J&&$/39\YB,VI]Y:&64K=3EQU:&T84M6,9#!_P!9+KM_?WI;[4J-
M^.\!^LEUV_O[TM]J5&_'> _62Z[?W]Z6^U*C?CO ?K)==O[^]+?:E1OQW@/U
MDNNW]_>EOM2HWX[P'ZR77;^_O2WVI4;\=X#]9+KM_?WI;[4J-^.\"OG:?:.I
M=E:)NX#7&\NO\S9PA59V%JR'8-Q4L2"F;1U3;@.SM=0315@M*>&!R%RJ(6 6
MGMQ9*HHZ3*=S'?2G+*PU7P-,VW617QUIV_TC'JE616!(2/7-]U8#>;.-V-4M
M@77LN1P=9N54?KY"W=LC&O-I3?,6B%B=6*J29PV9\$4BQAS]XK'8:ZDDLO\
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MXXA*EMH=RA2TIRI.,XQG/ R/W2USU@"?2L#[_@/=+7/6 )]*P/O^ ]TM<]8
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M.0IZK.-)8<K3N4]D,9<K[C*4LK#+SD<II*6U1LHQC' Y&L:IV]3#<T[5I>G
M$F97 51;A"-#$!@<97:Z3L9H<+#AX'9^,/&,*+VPZ1FYBL(<G29:%25N)BQ$
M,AGOM?LMZV:N^Q$S_P"]-P(GSH"W9Q6D^Y?KCA%.@8%U5">M*D-@1J)CA%F
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M,&P0]Y]G/^Q)9;<CNXRVZO&0Y[]%]W^,;N;Z#Z]?Z#\!^B^[_&-W-]!]>O\
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M_P#/6U/_ %7?5C_V+NS@:W7_ /YK[HY_^:H3_/);@7GF_O=5W_UG,S__  N
8X&\/@. X#@. X#@. X#@. X#@. X'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g16439g08h09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g08h09.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &* EX# 1$
M A$! Q$!_\0 '@ !  ,  P$! 0$           8'" 0%"0,! @K_Q !.$  !
M! ("  $'!PD$!@H#  ,% P0&!P " 0@5"1,4%U:7UQ$2%C=7=]88(39459:V
MM]49=K74(B,T-76T)"4F,3A3DY6XTC)!83-1<?_$ !<! 0$! 0
M       ! @/_Q  U$0 " 0$' P0" @(" @,! 0$  1$A C%!46&1T1)Q@:&Q
MP? 3X2(R _%"4F*2<H*RHC/2_]H # ,!  (1 Q$ /P#_ '\8 P!@# & , 8
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MWT31013U_-HFEIKIKQ^;77CC*[_"]D17>7[LM#(48 P!@# & , 8 P!@# &
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MP_S;F^5W^%[(BN\OW98V0HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# *]DT7E#Z4 Y1%Y$!"N!8&0 734_%2,D1>(FR,<()N&^
MXZ7Q7=DHTWC_ "GOJIZ=JYU=\<\>C<M_]?4\'IC%TZ/,C6*UPF^-5D?/PRV_
M;6N?=?)OB]BF3W7 KFMGR/#+;]M:Y]U\F^+V*9/=<"N:V?(\,MOVUKGW7R;X
MO8ID]UP*YK9\CPRV_;6N?=?)OB]BF3W7 KFMGR5S;$LMVL8,1F?$@K@WRP*Q
M,;X=S7DF'<*_2>7 HMRMZ7Q:;[YGH7!KT[S?HV_I'HWHWST//>?3J2;B'O\
MHC;2F5M^RQO#+;]M:Y]U\F^+V2F3W7!:YK9\CPRV_;6N?=?)OB]BF3W7 KFM
MGR/#+;]M:Y]U\F^+V*9/=<"N:V?(\,MOVUKGW7R;XO8ID]UP*YK9\CPRV_;6
MN?=?)OB]BF3W7 KFMGR=Q!XX^BT?\*)DVA@@L<EIYZ08"U@S)1S*Y8;E*J+4
M:X*FUVR#/<SRR3\Z4=J+:M^%]M].5?-)G7T]% 5/7U<DNR%& , 8 P!@# &
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MOEA8Z/X3+(R%& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M3U^7GY--->/E_-F31SL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M>8-_E<?CU]/V/R:>OZ']HH#^R61?O,&_RN/QZ^G['Y-/7]&O:-N%C=\)WF3
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MV4KHEO&7MZP9UL#RD=,1RL9O/(<!L*8%HM$Z]G(J,$H!.H9O*X79LA1C,9G
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M'-V_%2B=?OWT@S;MNW%+IO<NN=IU<13(UWE,'KAY/?ZHIM][!7^!J^SE;O\
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M:^40O5E '3H_6,1<3*0RKKS'X(>$1Z:-HFV3OA$ZZWV/0EW(7DS-[1EO']N
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MP_0CZD2/W@R+_#P.<K=_CY9UL7>?A&V<P;& , 8 P!@# & , 8 P!@# & ,
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MJ&:[:;:[:^M@M^?7GC;C\T&K[_\ ?'R\9RMW^/EG6Q=Y^$;RS!L8 P!@# &
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M)J7Q9^,=3741HUYBP^[ZF[54U=_26_ZM739K2^JK187&T/)+3*XD?*^6T7[
MTEVDCG8/L7TMCLXOLI:L*CL<CD.G7K<FY1HK'QK6PI([CO7X+$H]$:*IQWPF
ML?/%H;R\D4< KE'CW*2W'0H=EI6G$8T5]+\7WH?ZYL'$8 P!@# & , KF$?I
M-</WC#/Y25;E=R[?+(KWW^$6-D*, 8 P!@# & , 8 P!@# & , 8 P!@# &
M, KD9];<W^[FK?XFN'+@N[]D3%]E[LL;(48 P!@# & , _R&Q.P>@=J^4WB\
M8ZLHT?54?Z6=A+ON&02#Z?#7O;/OEW'G$;E;*25/3?TND)&PCM6)&R1+B32
MX57B\T-HL(M A*$<&:F4AV?7TUE]22NI9LIT;BY^+JS-"(=$9):MA^6;7D'<
M7JQV2;VSV]Z+W[&[P@EOUY$%ZEA4"*W/ ](I%0,<(34P@]ZPQ"O(@+J8N>,
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M_3/2D%-7J"2;=QKNEKQKFT_ZJ%7-5_LS#7]G+49/_P 4;ZS!L8 P!@# & ,
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M9M)8?*#4/DW+5ZM'QQAN^&2<&:&JO4_F<.%6JCEHX<-5D7"HLNZ7A2=BZ=@
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M(BZ"_ EUJ[065T?:+(;ZN_G\\K<;9M?\4TJI][V8?_)INC7:Y&^<P;& , 8
MP!@# & , 8 P!@# & , 8 P#/7:CZCI5_P 9KS^940RJ_P /V9FW_5^/=$_8
M_6W*?NY@7\361C!=W[(N+[+W98V0HP!@# /,3L?TEL>]KM['6#&[8GU0<S;J
MAUYJFL3D%LR8Q(26L"M[&[:RV4";5C4*+ BYV!N1]K0(2Y7'F!,FU"'IHE"Y
M!&) FB:0&U:25E1,6FVH3HU9S[/Y,X:]/>Q9B_:4LQM1U>U(PK.9]8'H1.$R
M2N2+>#TU":CA\*LRJD9P?#'[<77 2E2<AP$$K%U4]-R>KM!LID/CEDGI5&S
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MMU"+ES)5VSA95!BTYU&9GWW+6P!@# & 8S[ ?4!WL_NS.O\ XYP3-*^QX_\
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M&&;8LR1?-VQ4?MNINP((I+Z:/&2F_*K5QJH@K\BB>W'$*JU.\P!@# & , 8
MP!@# & , 8 P!@# & , 8!CCO/9 >L:3#GCHN2$V"MW=>M=N(R%6..F_(6ZX
M++UN7#1LIJOIJ\8QIX.';:Z;\.SSP2)U^:X)-^>=65+\/V@S:<+RO>?@V&BI
MRJBDKLDHALJGHILBM\SA9'G?7C;E)7A/=1/A1/GGYF_FU%-/G<<_-WWU^3;G
M)H^F , 8 P!@# & , 8 P!@# & , 8 P!@&1>]4[$USU?L>2'&1IV+UXC@]R
MH#&[E%F/)"3B$&[QX@FIHHFQ]*Y0:*.-.%/-KNVW&^G">^ZB>K']EY]C-O\
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M_KD]][%J?C+$O39<"%KN^3*O;Z/_ $$K4&7B$HLH 2<SD:-7>,+:M#591BL
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MW?LEDD=TW2&RD+ VLJNM9<Q@&T^A6L\)L_$1L)VE0+B7$!_+-P1X?,8WR_\
M&7;/D>T=/O24&2B/H;9PZ^?YA%3?4(QP.'+K;JJOUN&\]LVOH0XV]'^:A+IG
M'(VMMZ7JYW:_(D9),M^?2=&;O=O\FO\ KM6KG9/YW""O.H1-QU36]Z/>F-8\
MRN6J79_<>H6T!M;#B+@QL*1";R98GJ,2,;O=AZ4;34D"CWA#EMH$TW*[*<,-
M=G' L/)DD:6+7S\.A(6,[AKT ZC;V9-CC23A'(=Q#QOF^",K0)HOMV2L;8>=
M2]-.IK["VOG4_/ND_GZ_*(3+ & , X.Q,;H20#;D&.AARQ=$VPG9VWU).!K%
MPS:/2"#'E3ATJQ9NB#!LZ=II;-V[A\S154T4<HZ[@<GA='991MJLELX22275
M0X4TY631<;K)H+*)<<_/T26W;.-$E-M>-%-VZVNG.W*6_&H'UP"IY5>%90H[
MI&Y#(':);DD!$N4AT9ED@:"G\F>C1X9$^5CX,H)CNKAV; )N'!YZ.;#=)'&E
MR:S-O(PBK\6']T^_8+ CL@#2R/@Y3'7Z12/R4.-/@R:&JNB) 089HD!KU+1=
M-);1-TS<(KZ:+))JZZ[\:J)Z;\;:\"'<8 P!@&+>]7U21W[QA'\,R_-V+_'R
MC%N[S\,N^(IRE7K]&$H,X!LYLI3@5.'NY.W>O(TUE.\*;:Q]Q(6@U9L1= T"
MW+14LW'N&[U=AJX2:K)+[)[ZY=[[OW-6;EV1X[Q_IS?T2'6*RM6NK$EZ&G;Y
M2](M)>M-D5&1F\LF1_HS!J<DMO2@7V"C@:/%64DL#>;,'C!LI$'0:=FB9-2)
MK5 U;K[PZ-IW7=,5G.ZFG?4W;R)LIG+O)YH]@-(^1*-ZYG<5L]*/LV^L(_*G
M*TI'4&[\6/1028LX\YB@WLE'@/.S=!APA)601+35<LR:K"?]HS])Y@H0YUKD
MS7K$51,=>I,_NSL43MN8V<=I_3KNZM.C9%:45* (Y%XTTMS96KB0*-5;H"ZS
MD2P<HNLP (\R!%1;QB13@2$UHZ*Y.8<=JU=</9'12[JY<D1=5K9,0B+IY8,?
MBE*S2W(PSW;3:LF5@<EZ'ALR#57&7QF*3&>LH0/JE6]=&<WL%Z0;3>H:4TB"
MR^LIFL<,!*]]'%7VQBE(;G T+5_-Z269]J#8ED!@ME&^L76@26'(+)D81$^[
MVM?V\7L1'93E0LB60C\1E'6@<^)<*E$7\:$ 6G*SWECOQR#BG=^;-(]GN9F?
MU]VFW" 4AM>]Z$(2E7MBM"\7<]KXLO;J_9M]"ZE;5S/F\IXNU)PTID.6&VT*
M+Q9_9QJOGTZ-")1ZGT:^0;%M'WY^\%IG9F5_QI&*N[8>3@'>M_>@W&Y<;/3^
M]UK2(0#M\IQS!NQ4CB$*7L=C'X$KU9VBD5%SP''@ 5Q-&\R+C6W D6W=-'.X
M"U.%XCRQCV@39P2BEZEZ\>Q#3,1[17OQ<PZ'B[P/;(77V"BD_?S6U@CVF9'#
M(Y801O 8-6$ )6"X:QB4Q>1B]'VIM*%1=5N"CLV'$)*0&26%#7X2E%W_ !N5
M<&V_KP/BWZ_=ZI0^1<W'Q<$W;QBZ:>L&81P)+EHP$E9R(]M85*-)559=UV]E
M#1M'HI3C:9%D(G&ZZZ_ 7X9]&4BD2*VE%QPH&$K"+FO1K*]YRXS.^J"B?*"G
MEXE'[MG%X-1I.454GV!=QVP"]?MS91EO9"]F2"KIN'[7V3+@<+**K1]#<;5\
M2Z]AU !B'J1ZOH_*8_(!T6!NSA&,>E_\5-,Y+DH&@>S4HEUC#+JDMT14"%.\
MRB!62?F:;^8Z2621WL/6,H:0X4YN:\8R&(!859H*2!+#A0*G( Y(-(<T9]?@
M[X#*1^@C:I$:K;1/#-]S?-/T4+IYZ1<CI$3D&KB$P:OV6Y05&A;Q,#!3MCR9
M@X)\1(-'09 X\,6C(^'Y1F #\O6;84H20('N#)\T(W.F--8X+VP08 P!@%<S
M?])J>^\8G_*2TLJN?;Y1'>N_PRQLA2L*J]+XIBM^6&K?9]Q6$/\ 0M7>RNC3
M9W]%!WHVKK='7=;1ORM\SA;9+3=75/YW*>NVW'''-=[[OW(KEV7L>#E:]..S
M<3C];^EU_=8AC!&W4,3*"XU3JT^N.#NJ4K'ME'38#KF!?%3M.3:J87*+3@00
M-(.P@6>6Z<@TVL8L^E$]F4:@96%PZMJMV.>+5])FF$*4M9WS$Z_FE7U-Y+B#
M6* :QL/5THB4#L2.H/$B@F-F&O6.UZ\JEK*7R14^)>ZZ3=Y%8SQJW.'A&]KF
MXAM'BA/A 04P9QM1CRG]T(7(:EM6MZ[D5G1#JH-L+LE;79Z7'D%!XZI"B/7R
MMPC6SJNIZ=L8U)+#KV/2GF(T&X1;,X %F8W@K:5QS@T2> F<CF)) *.DPDM:
MXM7/'T6.,-DW3,U7\8ILCU_@UH(\Q2L8DM+899[R"2'5NQ@3#K?#6T9)@(B6
M':2.R#HJD:REQV,1VR5*I-CJ'+5Z/' ]+>?$R 3,SGSS2DUG U-1#VUI+?4A
ME$N##HO,G'4"@AET#627.T=&W2I*+8/ 0:39L8/(,C4>CQLL2E -"1&7HT%+
M((@X.FQZ@$LX!W>7':GWP91BU?=KD([5R$]@W=8N&8A8HGV8% NTD=;3>P;N
M2KJ=LCLSIXH.NB.%X=4O%@+@W9..1BPZ]AQ=<E!%@M01F,0^Q.#(4P:TIAM?
MXSEW'71?K7WFD(@&1N2PKZ6GK]=Z%GRD$[(2&%Q1<2.Z,UTB,=1P)!)M%0H7
MTKN8'DA;@['@H"4D';HFT,JZU*97!N0E8>*8SQX\E.S2'=Q[XCO:ZO PR])%
M8C=A.ZHL#8];,:3HM]'Y=Y+*&Z>J*.5^M8:,;93PEVKL.+2W24M8*-Y:>D2)
MZI9^D-W=1=\-?Q479JCG^^?_ ,>_:;I59'7WO5/3MNMYYS;\TC&ML$IRI%HK
M+EHG'YE"(?W1J:S*8'5?(%NWOH4=E\9Z_1@RQ&MXK3M$<+EVQ=K9,DDTUWB4
MK*B2J1EZ]-<,]620+2?E"9%+)",G,TNEB"D-EBF]E.(K-7T'%F86[[>UP:U(
MU=-FG:N9&(>*$]9&5C!EVE35-UZ-*1Z1-VI],S:@D.L,";-(CS6L.^D.N<^$
M7-3]$=ER%]6*C8!NX!=? YE,)M6]BS::*21X"(<SB5QB,Q^+1PK=UO1>0-W]
M&SV6M8Y.PU?41O$TFT)3L^NK,G[(N0:B-J/$-+_2Q2Q?<W!3W7D53Q%FZ93"
M22]$3"MH@(<RMK&])%LH6F!N:3$_(S,6"1EG*CDK+O1#LB:*A-I$[*#BQXX=
M/&905><"-S]VVJ:&P08 P!@%<V3_ +'$?O&@W^.M\$=Z[_#+&P4B-@?H'-O[
MHR3_  9[@%27Y!9E:'4RZ:TKDD@'L*Q.NUC06"%W3I5BV%3*6UJ9 1<DX>H<
M<KLT&)L@Q<JND>.56Z:6RJ?'S].,"RXZ7E#/+$_UYN,U35\PUUUNMA\VM./R
M.#U[+N1/1T5V.A*INBZ_@TC"'VH5$552]23IW'W-7:2,::0L.%QH-HPC:X>O
M=H))X6-RI5>_]H=6\:SZ?._)*,D6M^]-D[.&AE0#BD>P4/-!V'I)2&<=B2H.
MD2,?9"=#/*KAUMM5$8[.C@+XMSLY4C+B0LGBFZI97509P<9KO%?UY@Q%+.IE
ME,*5J.6M*DM/3L5)@=X6]/&],G.N"36$=GKDC\+7BL?G *V6+R)RR$UDQ$H4
MO%Y+') N.CD(@XX.=!RV,REX2"L_U]W+*JI44OFY3EOJR<6YURNZ%3=M;%61
MQ[+9@.90*PIR+<,A,GK]]:)V4;HFT*T@WC->G90$AQ3266Z5#3Z<;KA)>^IT
M[7A%NC#34-=A*B,)\^:.N%%G.9<\:;7M(UN^1"L]0\,LZ1U37 J,\<NV[Z*@
MNYZ'7\@A)GZ#YVB\9% H!F_H"/O"V[=ZP7WBCQ@YT6="R#5(*4QOVG_9FJ:U
M[VP="C*5;0/N\"C2E>6DSJ<+)NU48)S^,=EWL7J1&NK L,XYN<D]+4V-.L)T
MEK$)5-;4@_!M&:%R56NXG):Z'(A3%K##"LX7^%W.1*^NO=1\+FTJ:3:_E+%>
M0CRB\I#CPG8N1A8=S<(?LA&7_D^V(:))V&SC(N*N:<=3+;2)*,V\*+AUT ]Z
MCWY,5&6 U]X$K3_CAA'\L,_.1!A,/[,7B5-DHJ-O [%Q?<>Y$K%)V/:P@W6<
MG TGY5Z NJO;5#""E@O]H?ZI:CJJQF;W8=#X&H\$!'(@CI.2Q:$/-1:+*Y85
MK9>,8MK$CL/Z]]_#@F!/KG4M:8R:"V7UTG4N';2MR" $;;CY^<CY_8<$?[]O
M9\J2KD6C(F)TW#(_%J/@9>&?1_B-TZE,0A>*APFS6$KG$WUIE?Y?<GM 47WS
M+D:B"WG,[[9Q+:>U60OG5"Q"L%?/2\>H3M3O8Y@#- ':^XIDZA$HNI_UX:E(
M[7R=25Z[X9!'<+JB.ADY]H@^_?OH&[.&L8TE1@JQ-:]RSNL77CLU)VDJ#W[+
M+OA>P)N+XC-G&YLB^M$P3FL LZ#VJR"-7=R]@H["#P%=Y7<H:V57SJ$US(S:
M:^E<T/5C-B2\2$;4RDNV"JM%.*SS;/0FH:2%U&L659'7AWTJ-P:$"-G0:,@.
M1D,K]L;5 BUQ\.#QV,KO]#<NESY8F*CH%)4<0$BU!RBX90J3$;^7O]U+MP08
M P!@%<S?])J>^\8G_*2TLJN?;Y1'>N_PRQLA2N:>^J2K?NYA'\,C,KO?=^Y%
M<NR]CS!DM)6=1L:M(#2W5MU.GDP[@2J85W*&ZM83=[44*F?76$0Z<7PUCUL6
MC$=9[/I$9TGT1;CI-)VY8V=E1J53=P0CZI!E*8;E.)>&M:W43PKX@Y%)]<)_
M45]5<YJ:MKUA$(:O:P'3)[;<HZ]32"I4-">F,8J0/&6ZP'5Y;("V0L^AL,$%
M1PHS(12\B8SN6M9H0KR9;A% ;483YG^T]O;L2J1U9*+;#]GZ==QM Q); [I1
MP?:IIUL*;D ?6N3Q"JG#Z0QAR37:OVZ!ZA(YS2XL[$MN2H>=+2 @-YV-10TJ
MV#+1>LOYKVSQN"3]38Q;%VV-I.JY# :;"=:M*/JG:-M8V&<[DKC&3.+WM(!B
M8M-1T*(@ZT'5I7D%(OA[5Q&Q1"PQX/E8/+";?<)A:S+\7>LF?ZIA-S4;:<E(
M3.'-7772R&]BRJWIO9K:/$CD;K+Q'M)84FVEQ0(<CD:!N2<_,Q*TR,2%UDL/
MWV[.67$V6C:.4Z+Y @X:U_UA?=2_#4EK:&]@>>I'1$*9!7B>XCD&@#?LA"ZG
ML7U9WH_T0Z_FQ@%J[F2\_K0MRY V@I%59VS$3L.1)F&Z;PCL3B;22C'H4FU=
MC%)5_9X&?Y?6/E!BH4LRCNO8H#;3U]/=)3.%K]AA"MGM.$ZB?#:OB%? V$M#
M1P5>$:LI6!.I)8(RH($N5)P^V#+V0*12:Q,2>%FSI%,-5+<WJ)I.1\+VK?M!
M0]>7W8$:F_8[Z.!0W:T>)<O^Q,CF9$57:XVOC%'+QC6P)^>U9R]&4IS9&.38
MLFM-AC=\J$E1]*'(A1C,)3:HK[.%^?Q3R=1/*-[RDI46F=8![?C$*;N)0 A8
M^?62A.KXCU&GI]TL,S6#KRI'L-'IJ^-RN0U]V"F(#9KV#%2D963IE%P\WB<H
M6BL68 G9Q]**?Y1AVP^3IM^O?>T4_+R]EZY'DIFE8T%%Y3+>9<[;R)2L*W[3
M]M)07K+F+".Y#"1-IV$JNU*&<-)&POM2<&X:!M)KZWB%GR.3!YP+-FZE[=V+
M5G2Z4\,;BQ&=#]WW=:3TS+9QV.7G+6.TF$KAF(L)Z/Y:QGUORN1V$R/UI$^V
M,=XD,B'5TVKF,3:2;=CN+=*!!!CZ!VV1E$BER$N&96E[]H58SEQ$:&KJ-ZRS
MTU!:VE5PRNPH1.6T@B-HRNO-CD3GK<E9$/BT;KP.1L(Y+6-C\RK72(5Y S8M
MDD=(22$3G8[($;/ETK0CTP"A/RI]:79[8*J-H5E"$*VKV&P)N^4*ZQ..C JQ
M55#AHH6>-&VFC\KLSU6<:,>2;[TA]Z"BNHW9<./16^WF$4\&63K & , Q;WJ
M^J2._>,(_AF7YNQ?X^48MW>?AFD*C^JFL?N]A?\ #8W,N]]W[FE<NR]CSHDU
M^]JU:+NJ3*2JM85=4%[-.*,@T/B$2=SJ'RN23GFM(S4%?['Y4YC9CAFG-+$&
MZ3:S5(XPV3!-CLMXA (4P\$9PW"E9.S.6;>>"N]35,[G]J1>1]?Z7%FX<6M"
M7P.RYK,YH; N@T.+ZTY"8Z-)KM@K8@3=QEI);;L:NR+AJB0+NQ,$;RP>/>;E
M^!YEJ)F^WW9/R8V*WYVD?4G/YS K@B,GTXLZ!5GUOL7BEVC %V.F=EI1.&,V
MX86XESC5K302W#[GEA< I-]H3K47))(Q9RX#&!\\FPL*<;FW54B7O&&>Q+9U
MV$[-TC;+6&VPZ%;024DX&%CU@A(,T-[OA0QQ20B82Z&UO C$[M-^2F<SE\KJ
MY8$?BZR$8LFQ:#;15.41CZ9FG(0FJ7_[QB+J[Z&AX_VA HG^PY$H4;26L*\H
M>HNVT-E<6'\J*$*3M6,6AHW8I-^=D=S9G0U0<]DP]YSPTY=@Y=&1.Z6KD:X=
MNA(=-6UY4<HR:1[]7/%K&D+*;TP00:( (9)(;55=D6%E2B3M9#0%[VYRQW.B
MQ34HN5=.J[#BU@T;BQHLT/C2HR+HSL6_#$C8O2L'G+=,E\_Z+GKGOBZM1R.'
M0FIF!\E'Q;61W5HVM8((9UW'"=IR*K1:H+::1V(F)!)U%XC)Y85@M@ J<E,>
MC@CT,PP;3 Q'8J9$C7M2]Q/U[4(R%\HB8D:]+"0] /=Y%V: 5[/.O[![9H5L
M,.US9D3L"7!#MC%VT;?JUZ>"#8,V=2V,BAD]1;,)..WB9^9EAIP(.%Z;ZT5_
M?3/TU@IU]Y3^3L$"UEFJQ3%5((C >:"@(HPT)6$9X:=)NU/9Z=0^3*O$$H\,
MV8&Z#VC\</Q]^[U>J-V*SYLF/-/N!HO3ZRMK21HI7OMS'C-RQ&PJ=)Q::TC7
M'8*RI2)%S<1)Q#L7158]:+:U'BC^@D1YTA)XQV<C#!?E<8@U 26+R=DFX/!N
M0T@*"1=#OCUE5VU^"!N?*> M#\D9#J'M(M&D)L>J*$RUN(E+0-)+A V&$J+Z
M-R&1$X.RKJ(1,W9A=W&0<T:6%+'/R "SV01:/<JAVI4.FZJNEZ*)[NGV\TIU
MAN"X+35LU"S8.!CBL-N&V(&XV R=N:91_6&*P5.+AFSCPL8[EC:1LCTB-HRE
M<?&W;1F+'LS,8&E"2C(<)3/+#[<:VP08 P!@%<S?])J>^\8G_*2TLJN?;Y1'
M>N_PRQLA2M:CWU2I^L5=MD]-4ZUA>^VZN_":6FND7&[<[*;\_FT3UXX^7??G
M\VNO'///_=E=[[OW(KEV7L>4EA=_[/Z]";VA]MS.JW=EMH34YNAI?)A VNJR
MD9NSX[<Q<].1[]C/92(,]?XLE4I%W D3LM V_,38PE7YMBR>RNM95*,_?O\
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M#AS.H]RR(L1[JQ+W@$E.$V#I)WI$8?)A37=N\,M7[(1*DNY-+>?A,P(=[/\
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MH7(A#$6.D\.0Y=@Y&P:,&QT._00;Z:A+S?W]G<3!OU:M&QCE-R?6*R2P3D.
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M:5PC+9CC6/:MQ^XU1JF[5DB,G9^>%(ZD7^A1AR_4?/\ 302:1V]%!OG!!@#
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M*,(E%GTH-&W1R4EG6@Y)X62CPV+@PLQTA?/Z&"[OS<>?4V[Y=L-I5/*F;U6
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M>?RR?N"P(0'C&WTYE%HS:32I5APA$-=GVC:/!X^$:)C^ E[/A?'<J:,>3JH
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MM!%C<Q/1AC8#TD+G1J0V.]KTL(&FH[GV94U3P[JS-;E=&'I)((O37<*.20L
M1"W0#3)7^_DM5&(19X,!4\2KF9]\;PL+L \MF,,9TP^D1R;=?92(?1M<Q%)@
M28(EXLRK9>$6(*E!%B4^K]W\?;R2M+M?^J2CL_W*._HB#>4\5LH3K94LY QI
M&-)E>#4Q(CIC$DI]1T5E/7/@8?B<.F$=D1B(]HESX7N P8#S@[>.$HL@"DY
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M#;.&4TD[F438L06?6HUL^01E$]+SQP7!#44$D5QZK'@(+$?^XIQA!J3!!@#
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M:0-O7LV%.P[$ZKXTMV*<]@:RY%A)''G<*3<[P+19K+*PB9,+*UPC&H>)/-)
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M</(.5FQ]B3;5])P<'<CM=8Z1GBSB!M!8FYWW>%+[>I (1Y1DK+G$->N^N<D
MQ"6CNJ4GVDB]B1)^Z%0SN-<Q;K_4118"U:\.'1KFQ@A!_(@*#OAL*KSAO(^#
MKB4+;P-$.G58^BE^GF:1B5S,_*42OZ*5"?95@ZK3BU84C=<?\6* I\Z.TR2H
M>_9\@KZ.,<"&L:G V45K$WB@5^Y?C7T9D0_5,QH84DX>(R:K7A\#IOV\RE\_
M<9@<\IY'XN=(@G%4'96@T '5 Q:)RJ/DUSTMB+R"C#L;,<M45(!#23YW,E?"
M0KJRB<N'*@R+.=1.#K\<:Z4=+:6_W'#+M):,?[M2&4RLQ6PV@B3VPJ]>RGUV
M M;,AC(%#H[&Y2 CFI:)2N1I !D[='F4AXD8T651@;1J*"GFT@,!B_$?'2(&
MKJT=W[B;ON,2/JMW8"]IS3YJ"J^P8E&R$-;6/7TQD *1( I;"7AK80S4?OR4
M9"B LJ>-EQ$D:1P.8E[)S&C39VC(=R0X^)$"-1EO=]]_$[>P08 P!@# ,6]Z
MOJDCOWC"/X9E^;L7^/E&+=WGX9I"H_JIK'[O87_#8W,N]]W[FE<NR]BPLA2/
MR6*QR9#FPB4AF)T8SD$3E35D11X7;H2."2H--X>93TYYX^:^CLNCP20"UO\
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MWE]/RZ$GU @Y&!EN# 1\<Y&$'#X2YW'NEQZ*K4$X3\8)YYD4%=.1L:$]FX3
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M4.?[#BLA/"=49WKS$M^YZ%J];JI(QIU'CD98D^2',ZV>%%T&RQM'2U7)E]:
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M([UW^&6-@I$; _0.;?W1DG^#/< [:/?[@!_\'&?\DA@BN79>QW&"C & , 8
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M=B&_4/TVD?9:NI+ZRMI\1:.RLJF4<;5TJ)3@6C5TR*K/4B*I=9HDP$Z5%_\
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MCC7=]P*Y<.(TZ!+^5M1@X67;Q=H9AA7E ^\T;J&+[5B[JT2'A-3]79N7%V=
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MGSENH[6'.TH;2P-58(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M4&M'1!=BI,+"D3^734PT:O7;I 7M))26+2(DQ%:,AJAHJ3):,]'9!XJL!.,
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M9!%EU7V[S1@S#.I37+)]48R%FHIL_FKH*?(QJ+J1M6&RZ2PZ2M%=9"]#6*Q
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MD=O&95*GD)CY'1H6WW)2@=H<7)"DQ^@_DFEN,'QF0FB;ERR19#HX%)25ZY0
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1 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g16439g08u57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g08u57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Z>4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&S(
MH^         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             ">    L8          0
M               !              +&   ">                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   ">     !29VAT;&]N9P   L8
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    #.$))300,     !4=
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P"(  @: <!);;/J=UQS&NBAFX [76.W"?S7;:GMW?U7I_\
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M/I&LT6@ AAEOHN8UM?L:SV?1^@I];<YG1LYS7%CACV[7AYK(.QT.9:SWUO\
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T  C(NP  "<0 ",B[
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C U.C T(# Y
M.C(Q.C,W   #H $  P    '__P  H ( !     $   +&H , !     $   )X
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0              2
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M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $( 2@# 1$  A$! Q$!_\0
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MD/@T 1SD.W/;Q^P>>@!W]H9T#J'(8'@/7T$. ^4,<8'..>-!C(=0R.>_L]7
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M=!8VJN]G%-H1]?C6PQ\M?..O3M[^ !X]W'^A$:@X^ZHP/.,_=!UZ]> XP(]
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M^ .<_J^30 KO8YM9'C^_1VCWY[ YZ!T[^H8\:]U"V'2H<#73W_8TY#CD.<]
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MS21V?_*?#\HZ!YF(D]&K'Z"']F4CH/9_5.G\CH'F8B7/O;,CKG^S21U#H/\
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M.V2P2T\N LXY]+P<P#4;*-5#/O3X*5';B?28E/&,D.5+:_>O,)6="<C!ZO\
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M#LATDTFN8?;K2;;8@1@I<M1JUG G)3=6;[75$D7L0(.=3-(Z:&\[0- T#0-
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M6.QVD_$=],IP/"2&Q&RRAUI:TK$%Y(LN%3<UAQDR"):32MD\45SH6ABSP@K
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MA/,]23ETZC.6RHE@^T[PJ=]Q1>ER&T]ENYU365&624.68R7JHH83Z5'4X4E
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1@:!H&@:!H&@:!H&@:!H/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g16439g10m11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g10m11.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1F.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   *"4@ X0DE-!"4      !"_(.WB
ML4HL'_'/C/[5+RWS.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&HPU0         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/T       2 #4    ! "T    &       !.$))30/W
M       <  #_____________________________ ^@  #A"24T$"
M%0    $   )    "0     $  $T@ 0 X0DE-!!X       0     .$))300:
M      ,U    !@             "A@  !2\          0
M           !              4O   "A@                     !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "A@    !29VAT;&]N9P  !2\    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   H8     4F=H=&QO;F<   4O     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    &.$))300,      _D     0
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MI?374_\ -_ZNG_O&9_X#_P"ETO\ F]]7/_*5G_@/_I=)3PXZ5U1]EC&,]U9
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MED"61+M=6^[VQ[4UA<<S'D1[;.\_N)*?_]'T1CX^L%M8#8=B5O<Z3O$66M:
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MKQJJ]_IC;ZCMS@# G:VOM_)K:I>F/%W^<?[TE(J77'*MWM#&;*RV#.I-F_\
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M %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\
M<P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(
M P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P    $  @
M 3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D    T  ?^)P
M "<0 !_XG   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V
M.C V.C$W(# T.C4R.C Q   #H $  P    '__P  H ( !     $   4OH ,
M!     $   *&          8! P #     0 &   !&@ %     0   1X!&P %
M     0   28!*  #     0 "   " 0 $     0   2X" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!,$U-
M "H    (  <!$@ #     0     !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0
M *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I
M;F1O=W,I #(P,38Z,#8Z,3<@,#0Z-3(Z,#$   .@ 0 #     ?__  "@ @ $
M     0  !2^@ P $     0   H8         !@$#  ,    !  8   $:  4
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $H F # 1$
M A$! Q$!_\0 '@ !  (!!0$!              <(!@$"! 4) PK_Q !U$
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M/EX322<./;XN+GY/+Y,_1T%H=ME2[IMT_A!#6EN.:8^N65O>G5)*;)F[8>Z
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MV1,:*/+UBF.3^8K6<9,ECS9)4 4ZAPRU*AFEH'9,6J"8A)"4J :66(\L(#3
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MN;?;$C-9O<RM>O)#*BE9[6*?.%KM)64B-$O6#6";FUK>I(J2F=SE"8L]K8G
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MT2@H.@VV=L6OZMW2H(\5$W&82&X845+6AFC"$Y8>UJPX5JG:.K1<_G"61YG
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M:=BRV+')6R9O2TH^0KD2E(QIG-(REJB5"DI8J0L!J16%C9LJCT"(XG(T9 3
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M1)J_H1TI1HCBZ4*TN%9 0/#^O5O2MZ)0)7-WR0S-B-,OQGF+',T8S@!8Q5O
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M6X)$*]-A(X#2'*405(6,T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M:SLD^X/>/Z0?G_\ +0.][E*_+;.R3[@]X_I!_1T#O>Y2OYK.R3R?Z!KQ^O\
MZPG\W^W0.][E*_FL[)/N#WCYOJ@_/][0.][E*_+;.R3[@]X_6_U@]!KWO<I5
M\UG9+]P:\?TA/U]?0:=[W*5_-9V2>O\ X![Q_2#T#O>Y2OYK.R3[@]X^+_\
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MS>'.[>.@N]H&@:!H(VN&KH]=E6SRI96H<DD>L"-.49=%C,<E)=41#@3DL*U
M)>D<6XQ2C.P6I+3.C<Y-*O)7575M<&\Y2C/"!*XVNRYALR)6?:U[.]N.E<,\
MD9Z]:B*QK*LFQHS*T21J>'=].A#(F=Y&Z&-*7*$A#AR:8:2-4<Y=Z(G5(R+F
M@)"W(_&=!_I];>ORS0K06"T$6V7<D$J0<7!-CY02*9/&&%B[VJ\L.>X&XYRG
M#S704"BTE#'T?%23_?.09;&WADS/6^!!^2P@?<QOBI_;&!:S29!/9/8ZE.SD
M0>OHU 9EG%ARF3J1(HO#(_8;@PI:L3/[NI+.-/3NTS1"9FI&Y/3L!*W-RH\
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M>5V_$]G(=XXH.<Y=$K=UQ5VN<K6-.3VM:)U9#3HV>$+3?DX]PNY"A9]';OM
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M0S#<C\9T'^GUMZ_+-"M!8+0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M] [^3O4-//:AO]]] [^3O4-//:AO]]] [^3O4-//:AO]]] [^3O4-//:AO\
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M0-H1'%@?'',JC&(Z4\* 8(4)VON,\MZ#(C"E"ESR' M!RRZXBRINBB.5(";
M7PP_KS'(9VA:9 _)7<6!!,?"59K<2G1.PPCR *IL2(.@*YI"4!! 0EX#/-!\
MS3BB"QG'FEDE%AR(9IHPEE@#C''(AC'G 0AQCMSG.<8QC0>=>^W<_0<"VYS^
M<.=GQ=[15E*H05)V6$.K=-I2F=I XGM[*Q"CT?6JUZ5T< 97.1)"XM-_>IG=
MU_PQ" \00GB3V)?LS4(R-OD$KHR&O3&Q/S->5FS$U5$7)N?VXAT3+(M7D)+4
MRJ4!)3*2>>%^D%=ICC,YRD7*2.:<,.D%M8<9]T:G<9==D7"'(ND-@<?<5%,4
MT#(\?LR$Z"URN;GR9,IO'(#&BVIQ9*$TOX09'-$,(@L?"X%!JW8DL7KV&Q:"
MQI"'FHX_#X^U1MF38SX^@;&=(C1EB%GM&().!#%\,+.<YSG099H&@:!H&@:!
MH&@:"%'K]T96GTE+P_'K;WH)KT#0>'W+(2&'/1>W.I6E'6#Y=<MEUHLD:.L/
M=DS[56:O8W+:"M%N?I"_3+P>VW(TBYQ2HA.-8&MT#"(JRXA'WDJ0H<,1S>[!
M?_8%!U=;[.J&A;B>P+'5EB!X7ESC-OCOUG>GQ>_/#F]OY-Q"AE=@GJM_=5JQ
MY=7E-!HHAPZKEJ)O8T"%*G("&%<I&Y-31MI-7.V&ID"59U5A;[7D4^G%6Q;;
M^[G3)N*;;VEM@5TJ;Y3'(S7Z@>%#QC#HS1=_3+<Q2PWMFKI^ECFE"J?)C2-K
M=[.N42C<95>]B0(JW@9RK<]2UYV1=$'CC&9*)QU6E5R.33NRH+"I,4L(6S12
M9!I.&3RYL5(/"*RH&Z*ULL= S>GMT-#6WRC%M2&N[#1R5I8=GU71MV4D,LH0
M=3>B[IM14-$,IV8T!QH@D# /I2 &D9P+FX,R+CC 6>M3?SMFIRUZ=IR:SLE#
M+[K7N#?& !3G!2(#$@2P(SGT:@)!R),].!F&AI-+)/PH<^! \%ASTF@W&;^-
MLQADH0M4S<W9^BPE11["7#IBW*W-0D,P282T*WAB0-2S]GSDG)H5X2@B"(0A
MX+#D>@X!V]J%KF6+.D?8) :K=597?(RN#!*U#K'VT91V33T(8W'7YND"PD\!
M)8R4SFF0]$8-0%Q'@K!1@<11O.BXYHB3I8U>QT;"7T RD&W"S%2)>N.)'@)R
MB5FL^&Q&@3&Y +)I8R\ ,#DM4+!?.'@.83?D:5DRLHV-W](D,HR,K*%R9#(H
M%J*& TK*&/&&GL#JTEC+, $QPROSGI0!/*5D"P/.@Q1UO%K:&:,11-M2LV?,
MD>RG6M W^7U,_J&=<C&86D5#=+"M(YZ5N1(1F"+7Y4JU)1(L!R>' @ T$JE[
MCG129TB>HW5"9@O&!&O,GAY \E\<9"06)H<GH8A@%G.1 %T9&.&<@-'G..(=
M*^[A+>*0Y.C%85FX+<G@P!'(;>?6,&$HN?Q,-4MM52+ %(,8!SDY99I61"%@
M*H6 8R(/NV7G;R]"ERZ16H8VXFAXJRR; F,H2(AA$+B$HP-<1PU>$TL(> NC
M19*&9PR$W!7[*&UTLZZE2-9ECF%!LZX2<86\#S&;-?$Y2KF_"'+!-[DRF')\
MBSGG$$!*-Q@/#!V<BXA#J(]/=PV4IX9=:NW(2L1W]S'16M[41D@2Y ' NF*>
MY2ZB&I"9SA $$8">;S0C+%GCG09.*1S=7D'3;@F)K"#C_P U5H6>([G<./2]
MU4JG .CP'/1]%@/.R//2<[@'08LT%66C<%BAXWGK'QN/";A(V> J&-8D0A'8
M&4/"Y"WA4*,E%8R1D)P>:;@729Q@>,:#*!%EJP  Y;F9T+.1=(>-G86IE&8/
MX;'-*R"-J\)R.<+&>A!@78'&.?PXYT&+&U_&3WX#Z9NZW* P$TDT3$ED["1'
M1="6 KHLH,U@:JZ$W(.F.!EPSD9HABYP2Q8!@,I#&:P-",+G==N/.3,\#!K)
M:\(QB)[,93XRQL+1@LO.,9_9"L%J?AA9PHQGFY"&*OU*;7).:C.?91;"HU!S
MPIA(;YW'1T& F"",03R8O.F0A;CG QP$M*4C!C(P!$$ Q!R$+-D8HM'RB<FL
M;#DXJW)VVB1]H7B<G64NC4K2 LER9L-Y[*O"I1'IRF]K0Y!TQ(Q!5#5*^<)4
MM5&C"_#=/*L:"LD-*YI;"<\WB4WLJM$5GFXP$/$"=M+#GFAX8QQQGAC'#'BT
M'8^%. ^J$G^A.?N+0/"G ?5"3_0G/W%^OULZ#3PIP'U0E?T%T]PZ!X5(#ZH2
MOZ"Z>X= \*<!]4)7]!=,_@0Z#7PIP+U0D_T)S]Q:!X4X#ZH2?Z$Z>X= \*<!
M]4)/]"=/<.@>%. ^J$G^A.?N+0/"G ?5"3_0G/W%H-,VE A8R'$A)XYQG&/[
MB=.''..&.WJ/KZ"L7)J_(_MG'FSMVJP6/7"**MX@Y\_:'.,\,\,XX\,XQGCC
M07>T$>6Q9\(I>MYE:=CN1S5"(0R*GN1+$C2ZOZ[J1/-* D;&!B1.3V_.SBI.
M(;FEC9V]<ZN[DJ2MS>C4JU))(P\S]D[AL6>[B2H]M+M?\PD\&ADT:B(1/#KQ
M6P#:$VG29,T22IU$5LLM(Q4=.G1U9"VYNK1:3B=(HBQ "T-K57HT0UH>N>@:
M!H*^[D?C.@_T^MO7Y9H5H+!:!H&@:!H&@:!H..K5I$"8]8N5)T2-,6(Y2K5G
M%ITR<H&.(S3SSA **+!C'$0S!!"'';G.,:#%5TX:4<G8HF6AD;DY/Z0;B0M:
M8V\KXZ@;0A/R%<\2DI)WNMH3AD9)3)#W/NDJ&:2-.B,('TV X*+%D.ZB:HGP
MJ.Q!H, 8WP5XB[PIDDHP 85A0Y&\I7Z+-\?;%H><A4-[$6GDR,DTH[K[BM*,
M"G"'S+K*-KHZQQZ< %:.&!S[MI72Q$3*^KS'O U8BG89!34A9R%20*Y02@P@
M:D9*!/D!20HD)8. 9')9;%(6V&O,PDT>B;.G#Q.=)(\MK$VDAQY3%KFI2I2\
M8_\ 6-QH*Z#WH4,XJQMM?.\KNESQG( )Z1KZ:V@UB.\A)\RC#(K@#6+/E->I
M6VI@=HC3RPXSG ?)1:VZ*5X!BN=KS?#TIF>:-XW%W!'8@I) +F\U6@B=--5[
M*G3 <9$(2!Y?X:H%G 2Q&DB$(18;,53NGEV>=/MT37"49G 0F;;U3D>C*DL
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MD@@A,4 A,24G(*#@!1)!8"BBP!QP" !9> @ $..S 0XQC&/%C0?70- T&T0
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M5,R/LB/3!("6SQHA"I>U652HA)D:(AR7MB(?5 GY6J.F7$\U(G/&7@TT("3
M\;N3BW:WI9UNR';I8UJ,5LD4[%)"@DSTIK*MXY9Q;PQR!&S-2FQGV#[SKH.)
M>SRC%*9P)44U$2'9P(./R;'CR<M)X>U^@:!H*^[D?C.@_P!/K;U^6:%:"P6@
M:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H&@:!H(4>OW1E:?24O
M#\>MO>@FO0-!Y.[LMDM%6/N]IF[7[<-9%177.BV^,U1736GC$@K.PKKV_P
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MA]&V&_N@F.+;5KBI.9N$LF<7;I+&(RH>Y8)E6.1X(0C1FR"=- # LIR-FW2
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M0O##WZ=P^Z*[XX/#_P#X8^N]=ZWP[_O[]=!T/#^XNJZ""^4?9FA_VZHFQ:V
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MTZI?BI,])XG%)TV1?,54OB:'1J*1FLF"6UX@-<Y(R.=AVI;BN3Q?N=E$0\A
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M1P*CYE*F[9_2F]"-=(Y7!&6BIX]<+?<CF^5,[(&RRI0?8\A@A57($+$Z."Z
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MMR9 W%%(V[#H<F[KO67N5K4"5J;G*0K$+0V)TH6[T#0- T#0- T#0- T#0-
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A\0AF9HVSM24U]#W#T#0- T#0- T#0- T#0- T#0-!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g16439g10y79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g10y79.jpg
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MH$_TP(-U63J,BWXHY4<>AQ:S7_-\O$,NQ9@Q#$DVR5!S&I<Q84FW)#,&H]M
M>@_ ' ' ' /$3JR*]8]YZP-Q:NZ9;%N1DQ4^G[1%HH>*ALS6-*U50;M;KKM>
M%.M6V:[L"*2(WBMDXE8@-S M2#&2CL,/,BK8C.3H3_+2CS<^* N^R_1-]@Z]
MVCN6G0*OJR[UW7NONJZ<')!Y%S&SF=B=+&K6;P;"V-P\@4X48)&VIX,U#J]>
MR'KJ7(/DW8%JD]Z;:)3JD".WCK?ZNM37K8I^^-:+(CP/1GI_>=:U "E62$.>
M/[1WI9*2SE-I)1$V4J0' (<*'9Y:8>0D/,2!-# 8;L\GB8Y==+OV"[;+]$KW
MIK2>?UP2UKJ>5L^K;JW/KPG9VR]DAZMD@-3Z2U;NJ*I'E><+)"#UEA;4AAG9
M9,VL6"@52SVU<,E%82&913SRU^ ;A],O4OMKJ#V[MH3,I=#INJ=9!-1?Q<&R
M5@V+.MFVM':LW&T,<EC%JI*PU63=3(>89&RIV#JVA+PUF-':DRYIJS/EK\ W
MMY . ><_7E;R86[=&].<W5:M$T79F[[E7-CW*IW 51)N0(G1FS+8)AR+,:BR
MQH^.[:@(/_Q+.4R',IBH_P H^CE5_C\H&C-.ZW]S4T7%)-VE&[!M,!>B$1]8
M7J[7^HT*I;NINBMOZ4IVK;G;CV&*S0K"1S%MQ8$/MT$C6A]BE"92(;V)]H60
M9L>G^.=J!EX3Z);L.RU:@#1T+1U,V"=MW4,!NEEW*_L#6>MZ2YH.FT>\+J9^
M!-P0G#KQ;0NPPLQG(*X7FL"@@H^=@%K0_$?!0I%LY;W^ 3)ST0[81#;D:I@:
MWI-ZLO[RU1TYL5Q%ZL!;:ARR;:U36]B#MTU08T)$1S6C0TBUQ?%S'!,(I8Z8
M LMN1. /1$@DH]I^?, 8[=]%&VF1H)"SA=+@AI&M7C2G3=?%'GCSPRF=5=R-
MVR)MZLO,QWQ[A6GZO&U\"R/:\HBBEFL-^K [)8<SEY]PUO999=?K@"9U'KFZ
MJ=O.0!>IM1Z8S8H/2G8>H$V,,VPY9D66S@=G;?U4*I="FTR8^+7"O9?78<P,
M(%2BYE6A%Y0@S#(F6%MPY\^6?-0;>]'?5&YU=U:[;7KH&(*U!BRA*_JLLM<S
M)VU(BT6KE[\2+-/>#$CL ;\;.4*&U%;0[F93B[TS"5NMM-5J/GSR#<+D!HUZ
M)'>;SKCHTVO;M;';%6[I!+:B'AB]2(0Q-E:38]V:YK1.(&)D,X@09I4.7("F
MY4U2(K.)JER%H:PM::K5Y!J92]B]=>C251H1T2DB[U&]1\FAZ0#]4>PP&P+U
MKJE M 678%L*W6XZ.B^1CC$VVT@M(JX%F<2(Q14E0T@8BK>8FQT;+\_OY:"1
MZ#]$GO6S[5L#![110K5!(#8%CK%8U-X%JW5#10=X#-,N!#FOYYV&2L4LDDIF
MT%30,>&$4K(0U72F"4KR81GFHV^8 METZ\-CW ;U,00*]5ZE&4NN[\HU6I]U
MMIRM]6$:YT+IL<V^.O NCI'$@CK34R;C_P!W'UP%"P@J5:LVP@\PBN2)\^?+
M: A^INL7?<BW@-955L#;KGLK:FHM9Q#FVK#89E< *F^AWTWJ,-6&&.KL./.C
M)F6&*1?GA&7W$&"!"=(P2$ND>\0+%/2=X!91'HDFPBLBCWR+6@84EN#0?1JN
M*,MUR*(TMK:Z;UWKNO7)^YV!# ^.1C@16*@QE<W!&+-.>,K5?D2QBFU%%L\W
MM'()SL_T2Z\Z[>U7&')Z<=D39B*4_M1C6=MO5F%.C[EU&$] Q"U)MI,-6*X-
MAIDA"\K(]4G8%C8M(PW69(1%=#,W\TC\[*0;J]$%YMVP=37@U=3Y"R%1W4QU
M65.%.)NX>D1JW3>H;8M8JP=I6$HQB$#KXL>*@M]F<MQ(C*,J5E/A9/\ "]D#
M<3D!X=ZZ)]:&SNK;:)#7MEV\]K_6'7>3I5O,GMDZT3H,;H0!4::7MFMX^K)S
M$[9I"^R6K"ZY7; (A00T"86%ON&T9&$6D6Y>,\;<,K_& B>A/1"-[4?0=+>W
M'(UJ?)V'I=C[DHFP;*1V#.)D#[W4+5-$Q >QX]=KQ:<8(V(G?P,T$U5Q@V-&
MDM(KYHO$'N2;H/-5?E@N)/T6#; >BU.VE-<ZN'QAEJWN#VR809GGVQ(W2^R0
MM+\X&:!5;.;V-7*B4%D9DTS> 0C<@BL'8T(&_!G)*1YN$7>-T#9_377K==J]
M7%CT<K7E9':\B;&W3J\4578$P;]#GZ9$P"2[B0$E2$=1^OW)3CW<Q%>K[9"L
M#3%0-$R9*"8DY@(_&_S9@R4]:-SC?1(JS2#>QHTW3-JZ5]MV^IZQ#@%"8X8S
M4=@]/@-=CM9E\H1?MEGER[3:&!LB/$!"@-<?AC8HQ\D^:,$UWJOS^@;[<@/.
MGT22X[-JFO\ I\':K*['@&[_ -5NLM?%A^I[37*7>K16SM8V'*(5@+9[>_%K
M0A\C*%CW42S,J-!:=B-*>>0G'JU5W]O4&E4O:_7UT]$==1KF?@FCHC1G7WNM
MZA;AMD*S3G-8:LM6G3FKA&Q;+JH:/!6W:H>M$RU?:.A7F0L1JSO3Y4DL\,<'
M3U(?HMG.K0,KRO1/+8[N>FU0!4-7&*);($@;+9DVHU6C]0NK/2I)ZE,#K7=K
M;% 4^-$CJ1" %Y 4(>K( $3@V0Y?!QAR138B*3E.\ QX%]%;VF1H8QB3KV@1
M=MG=LZ_H:HLF%;8]1I8*^ZJO&SAAPR]$.F*Y=6S>=>'0=%)4/:DP=:XSS5AF
MM5K,>."+HON]ZK2V; ;7[DZE1!?H0U_U&;%V/9^FZ#;H&O+&>B:B-5*X7*U$
M#"\*;U)JVY95,"R)%]*X8BAKF+6TJ/7,/EYDH(.25(#E^MN6*RPKZ@V0Z.2.
MQ"W3)I\CM>ZA=A;!EUA;MDM0$]7;5"F/Y+$L0ATFSU)MJLV,[71F(-;LYT&V
MD:6LHDM/C=J)&%9@-F. >/\ UUV#J,,=4FMM0Z));RE.F>ES<M[C5?2VS=;Z
MN=;NX&_:VKM8N5M+;.SY$)5@'FROP28>"P2,RO*D9Z(+EQXDSP*K&\&L<Z4^
M9@A52ZE^KC3>YK%6=KE*1L@<%N_H<^D-IQWYQ>)(&7[J#I=>I]\L^K8HL="!
M01^+^4?MQ)DG&RR<CYQ!'P:]XM#V9XST!9X7HJFT2[>U\UJCZ=M[(VFT;8&J
M# FT$*T..5ZW;Z<T\]#1"V@:H!.\'VAF,FZN*6WJ<E>[#&=J=?'*[\,+R:E^
M;L%\G 'X=]%DO\8+K&16-;4.P%9M#O-ZV2DK/LE!'3)M$W8O3I;754=V NLM
MU&X1)$61)/$+)-M%>!'YH2NPY5B'DVK3Q'I9XJIN!L-Z)SM&Q:NUW&ME$ZB"
M>I+[2JC:MBB*"-L=)KCUU$5DU3<V.W.#+<%GN[3=H8R2Z/'Z8&F:TS?"=SC1
MIYB*]&&2HT!Z>P)C1&#"(,)?0Q.B1YC*)+#L62AJ4RA]M,B,^E#T=]*%XPZP
M\A#K+F%-N)2M.<8 UN?VUOZ-E*9/33%CJ5CM2E_>=$:RK&,]F<IPX/3G..WU
M.W'J=O-1T_=LS,]7V[HZ/3CWM^K@.^GB@?8>(Z?NV8GJ^W='<SMO?LE641^F
MJ(^O&/"REG>E#=5A/K=N4H'JSC';G&.WL[/5XCI^[9B>K[?]D5/IG=1/ZKZ?
MILI'W;Q'3]VS$]7V[HB=A*;:M9>FG[)T>BC)G7IR39J22G;EH[TJLGY@,I6I
M182YD=C,:8^!-EA3CN.W*H9"2UV=CG;Q'3]VS$]7V[HZ)TG9Y2U2;N3Z,P)&
MUS*9,UU,-SMNT*7+ET4@127G5.5X\6XS(!S"2$RY4!YI;+[N/\HE2<Y3E'3]
MVS$]7V[HPJ*Z?:X#I-GUR(]#DUJ/I=R(@"UD!Q=FT)MHB0J3J'ZC(Q+P/\H0
MO,]U&%U!H?+B,U;*G< &QV'G<+4^_9B>K[=T4Q+IPJ)< #JQ'T-O5TFN5K-U
M\A!,[(U\V-&M[&E(GW>*Q$9&MM9@V,BU')SQ[B5PO*<2"18CLSH,-]A"^_9W
M6">K[=T2;.HF57UW:"_0]==N7Y\&Y77[,[LO7CLY\4[6?,IYMY#@I45V8]3,
MYJ#Q5R.HL]5\YK[DU0C.8>4=/W;,3U?;NBY2->%)>H1>A)G0A59FGP:(*0E$
ME[BILH0%6+)Y,BI(A<B&Y.&SA13/?A1"%,8G#7\)5!D,80C"4=/W;,3U?;NB
M'+Z>JTMZJR,>AQ:S9=I FOA*KF+LR@Q$AA]3L4FW5G$=N*.9;=F K/.(GA12
M2A\I"*E2\QB8AXN25*0OOV=]HGJ^W=$P<US.?&P0TGH$HLL0-&;5"PA<W:&O
MI@YD3O$ND]MX;F%*%O1G86PS"$D+1'>;<;)2,84XG&/4XCI^[9B>K[=T62G:
M7AT# [S.]#VH0%0JR1+A"<B;5HRWD6F#5#5%BV!]^1 >>F%FZ?8CE=5-FKD/
MNBRDN,\MQ+G;A3[]F)ZOMW1&Q_3-3!(@P"%>AMZS&"SR +9...VC1X3CB*J>
M59JMB++C0FI@WS8-J[Y6\C9$3('"6XHG,2$TU'0CI^[9B>K[=T7J/H<)$CB8
M<?T.C6S0\&!V#518Q.S-?^28U8VK,FD=AUQ0K(W(Z2!M1 D0G$A$J*^/Q-FR
MI4:.P^^ZXI"^_9W6">K[=T2@!03U4U;<M,57H<K]<UQL&#9X%SKPK<U,939$
M7(/FOV.49GNP7B)0B1"X:%N$9\J3,0/BPH3;R8L**RTCI^[9B>K[=T8\8Z?9
MI4)7F-D]$E>VA<A6NM=ZW,[&L>VZ-$M=K&ZOD0"-3+EGQ,.(U'L \R/;,QBX
MW$2;!FO2FAST,>^J%A'3]VS$]7V[HF(;5QBI BX/7_0Y5]=X)T*X:VC3ZGM#
M6#+P2IWD\7MA\6)'%*\4KZ8,FW'"5H4*G!IP1\Q)=7,&2HKST5U'3]VS$]7V
M[HUAT/T,SM0@MB [7TIB=L,;'1JZ.2CD[AH^B!Q3>G/.9VC$P877M4 ,#+=%
MFV\]-G6V&^P27XZ$/%)#AQL0<BN'_P!V-SO]1/5]NZ,S;!Z=9=TI<JG!>B:O
MZ[S(U0_H5D[2MKT 26&:2,E,R[;KH9F..9C,#+$.G6(?B4^S)DBI=D*FH?A3
MY,K,J1T_=_JQ/5]NZ-L(VQ>H*''CPXG2PQ&BQ66HT:,QNFC-,1X[#:6F6&6D
M#,(;::;2EMM",82A"<)3C&,8QQ'3]VS$]7V[H[O3.ZB?U7T_392/NWB.G[MF
M)ZOMW1%[L8V[LBI6&AWOI %VFG6P7*"62N&-RT>2+,B9J/%RX$Z/D=C#T:0C
M/@N-YSCPL>IQ'3]VS$]7V[HAK=5LS4YDDWT,5/$Z/L0CMIF3G;5$4M&R2]1=
MH1.Y]BARDJ.3J:^]6Y,I:5>-%.KC*1E.<\1T_=LQ/5]NZ,>UCI]KM+3)15/0
MY=; $3)=6FR$C-G4.,E;U'ML:]4Q.,)']C<:IVR%#,UR$UX$,*_#BLCF(\2.
MS'0I]^SOMU$]7V[H2.GVN2I.P)C_ *''K14K:6?"O4A.S* T\;6JSP[NXZAQ
MH<A0AY^ZC1URDO \C795L'P;)(6Z:AQYS:.G[MF)ZOMW1V(T(%:B"H+/H=VO
MV(81C9$49&C[7I,=J-%W *;"[0BY0S#;P_%O0YIMNR1I/CF"+Z<3G6\SNV3Q
M"^_.QB>K[=T7YC568NQ0>VH_H?6OVMD5N$'@!+>C9NO<%H#=>"9K("4VOR7X
MEPL#K:LUX.<?9=-# >?),*>Q _S?B.G[MF)ZOMW1)Z37[?K>36YE$Z'ZS5I5
M0H:=7UA\/MZC1G FOD%63J:C 5@?G+(5)AADCB+CMQWIM+G;VXXCI^[9B>K[
M=T93],[J)_5?3]-E(^[>(Z?NV8GJ^W=#TSNHG]5]/TV4C[MXCI^[9B>K[=T/
M3.ZB?U7T_392/NWB.G[MF)ZOMW0],[J)_5?3]-E(^[>(Z?NV8GJ^W=%L:NF\
M6"TP\QTDBF3I&'"'$#36WM?-EIX\:Y+>'0)A% C$R5#@/3YSL**^\MB*Y,EK
M80VJ0]E:.G[MF)ZOMW1$9$.ZRRQD_*Z$]>23MC1*;L)J1>=2O%CK<X5( SD&
M2+E;5,*(F YDL-*3.>?3(%2I Y["X;[K*D=/W;,3U?;NBM+/;%/S(Q$[T0TD
MT0A!_-V'.+;#U82F1*_F4Q.\A1I4RO//L!^^Q8LSR8TM$+O49B1XCQK+:THZ
M?NV8GJ^W='4=Q?[1%G0;-T.42Q029V/:"4,[?]4EXI"S1(; Z+8IT<A79#,L
M[&'Q8L&.7?0X09AQF(S<A+++:$HZ?NV8GJ^W=$F@W/> R64GC>D@4/G&WXLD
MU-@[=U]$EEY,*#'%PI!22P';>GOQ!D.(.BNRUNN1X,6/$:4B.PTVE'3]VS$]
M7V[HN?IG=1/ZKZ?ILI'W;Q'3]VS$]7V[H>F=U$_JOI^FRD?=O$=/W;,3U?;N
MB*VPGM*^Q(H^]=%M3ND"%)[Y#A6S9>L;'$B3,M+8S+BQC &8S'D^)<<9\>TA
M#OBG%M^%X"E8RCI^[9B>K[=T?CQ/:4B+#A2.BVI/PAP(C5A\1[9>L78L&LEV
MXC):N0XZP*FHH(HS @M$1#"$#YK<*(B3'=3&9PA'3]VS$]7V[HL*Q%J=JP^C
M.=!.M'*2)()+BJ>NYZA75AA5"W74DQ]?56<B81!+C[[B9L:(W)PMYU>'<*<7
MG*.G[MF)ZOMW1?UD]I.6J+>W.BVIN7>".6(A7)>R]8KM4,2XE:5BXMA4!R7C
MCEI<<2N$U,1&4EQ>,M9PI7:CI^[9B>K[=T<9Y#:!0,?KI/HKJ)&OVN=()VD%
M/V3K"6&LI*6N.Y+('QD@"Y",SI+D2*Y(ED6),AY<:.IQQ2F6\I1T_=LQ/5]N
MZ+<0>W"Z"(!J]TI,4*5+IV:*.LM#V]K"O6:L5UM,G(V#62**S(9&1P<F4]/"
MP%1) F#.5E](Y?AN(6CI^[9B>K[=T6W3 [:6A-8U'4>N>E&0/I],@OPQC9#?
M5.)DY<B>0F&#!@N2D#?'$#)TV1(FC$YS",RR<^4_AMI*TMI1T_=_JQ/5]NZ,
MG^F=U$_JOI^FRD?=O$=/W;,3U?;NBV%[IO&PCW1)_I)%'!;[D5Y\:7V]KXD/
M>=@RV)\)UV'-$/1W'(<Z+&FQ5K;RJ/+CL26LH>:;6E'3]VS$]7V[H_9MUWD2
ME"IQ'I*%SYP*6Z0"3)NWM?RI0:>_"DC7YHJ0^(<>'RWATV9 =DQ%LO.0I<F*
MM>6'W6UHZ?NV8GJ^W=%H#%=J5TT?LM?Z+ZH"L5K>;D6D^&V9K(8:LDAG*\M/
MGRL("Q.,/-9<<RVZ1?DK1E:\I5C*E=J.G[MF)ZOMW12RG]CSCY*V3NB.E3+2
M9".UHO996Q-6R#Y6N/L]W? $C+U?61G!'F/\@Z*E278+C/\ DUL91_%XCI^[
M9B>K[=T5$0EM&!-C$H/194H1&%,9(PY\39>L8\V(0C $U2/.C2F0*'V)D>K(
M16F933B7V@"4AD+2.3B-A'3]VS$]7V[HH'$7UT7+!N]#5#<"D 42KSQ#E_U2
ML7-K,"7+(0:[+'JKN8DD%"GSYTV((>:6/C2YDN2S'0](>6M'3]VS$]7V[HHY
M(RW3,@LR^@S6\K-7%X!UG,FZZB?S70J74/I#@O&UE7D@6E]MM[ \?W>)AUM#
MF&?#2G.$=/W;,3U?;NB:"[MO(''=B!>DH6'B/SB!-^*+V]K\?'>)%ICQ$H0=
M9B"&6W)Q(A)D3B$M:<OS)C[TJ0XX^ZM:D=/W;,3U?;NBY>F=U$_JOI^FRD?=
MO$=/W;,3U?;NBV#KIO$.LDL1TDBA:S)-\T86.V]KZ"LJ8DLQX\@L25&$-9G$
MY$>)$8?GRLNRG68L=IQU2&6TI1T_=LQ/5]NZ(Q)1?9@SR)+Z&J'*#9 OU7R1
M)OVJ7QGFQ*G,$Y-<[@[751?(,@E%C$'P_BO)[LZ.Q+<CJD,MN)1T_=LQ/5]N
MZ+<\&M$F,'A2.@?64B'7BBS@"(]<M0.Q@9MQ$5M9@.PY6%-#"BVX,)"R$)#$
MM2(<5.7LXCM80CI^[9B>K[=T2**5VI"M1&]0NB^J1+N7@M#"URB[,UE'M10;
M'PSA@>1L+0)!>;!9Q&CX:B29CL=O##/@-I\4CP4=/W;,3U?;NB[KNN\G"\<^
MYTE"W#L0?+$Q#2]O:_47BBI\B)+G#(Y)0C,QD?-E#X$F7";>3&D2(41YYM;D
M9E2$=/W;,3U?;NBY>F=U$_JOI^FRD?=O$=/W;,3U?;NBV$KIO$SD<HOTDBBJ
M@Y..:$J);>U].R+,0T/-1"P[,H0[F$3BMR)#<>?&\5*80^\AIU*75X4CI^[9
MB>K[=T4Q.T;F-2,2S/1\!+2L"2H'$DGM?7,^1@&>Q&2<"X>E!77,"3.(4/!4
M=A7<R.(D;$QE[##7@(Z?NV8GJ^W=$=;8O+)QNSL]"VOVK(TV,::L+=\U.@XV
MT%'/!P[399-<Q/0V)$2) L8A,C"8 Y]Z#%PU&=6TI'3]VS$]7V[HH60=FCUD
MG2H_0+K%BFFB"2QFI,W#3[59+%4K;<23)@45A(J>02MEE:9LJ*[)PMIM6'.U
MM.<(Z?NV8GJ^W=%^/SMFVL' K%HZ*:?9*T+<B.C*\?V1J\P#'.P(KL&"Y $D
M0$F!#<A0GWH<1<>.VJ/%>=CLY0TXM&4=/W;,3U?;NB[ ;;NNJB(8"K](86M@
MAR74#P@';6NPXB"AY]V4\B&-'AH\.*EV2^](=2PRC#C[SKJ\9<<6K*.G[MF)
MZOMW1>/3.ZB?U7T_392/NWB.G[MF)ZOMW1;5W3>+AABPN=)(M9^*.DAXQQ>W
MM?*,1Q,V3%F3!;!/(C,UD=+EP84J3";?3&?DPXK[K2W8[2D(Z?NV8GJ^W=%M
ME'=MS9<N?-Z-:S+G3R((Q.FRMH:UD2YI>KK;<K127(=!K>D$:ZXTTX"G/+7)
M$K;;5 =CJ0G.$=/W;,3U?;NB,-!;0Q'.Q&>@?63,2T-SV;-&:N6H&X]B:*S8
MY(HT=916,-EVR1&'$GST$$R$S)L6/*D8<?8:<2CI^[9B>K[=T5;D6[.PJF-=
MZ%->N#J#)3,HL!R]:F7"I<M*T.IE5.*JMY8KDE+K;;B7P[<-W"T(7A7A)QG"
M.G[MF)ZOMW1>;(8VO<5AW+=T8U:U.5XDT9 +LFSM9G%@S#'9XDJ'43!2E#"3
M/@X\5.A98E-]F/ =QV8XCI^[9B>K[=T2Z-LOJ#=>0B1TS)C,J\+PW_3GI;W@
M=B%93_DD#L*5X2L)1ZF?XOA>%GU,9XCI^[9B>K[=T?++=;I9MAV@U<K>7F&[
M >G2)Y"?-?<>7EQ]Q3B6&,.*5B/"BI5AB%#9\"/#BMM1X[;;+:$8]J2Z5"L.
M)*JEI39UXKDNW5JL*FUN'*G072\HN!#17)8V+&FD(\/RV4'.D'8<69$=DH@-
MR<M=Y80OL<=0C,?7TIPW6ES=OA"/GC^R#URR'J@<&66L%YX(\&ELSAA89)<B
MS8<IA>%MNM/-92KU\=BVU>$VZWE33J%MK4G-:3HU*!]C-8(R"]:KQ:5X'>B@
M,21D^+3X#?>)L"/)>\6GMSX*/&.J\%/;GL3V8[<]G/ Z-K [JQ>#"74?U/:V
MZ8*[4B]ZB72S']C72%KK6&M=8U(C>]F;*N\T85.^;]/JPSP%R7(%>!'+":*D
MY8H ""B9D\P6A-):\:-)-^EKN7DM6J>L#16U:/7+MFSO:M=LMFL5'CT7>D/T
MGMDP;U4K3!I5DITRF79X82?."K45#A%)#^51\^8;!X%3Y[9D:Y*"'^:5I;<9
M-C[QTK+%FCD3;^KI02MV%51L1B/L"IO"P-K1G.%U@T0;+*B"["G*584%G/,$
MDY3G&8V,XSP2.3]QN[2ZAU&,)V]J]0C9\[R9K4IB_P!4R.V&2\;W?R?1IV"W
M=K;.\?G#/= #I"1XW/B_%^'ZG *%OJ"T*\6.@&MW:A=.U=R0U9@K>RJ8LM77
M8AB+7I39T:DUF8(<C'Y\$'(009CJ9,3(HQS"9LAEA8L/!E?8]W:7IS)&1;MN
MZPJL<02G!BS]COU4!LBS N.&EDQ)%TF6BHA$AT6QUZ3.@R5-2HD<Z&>D--ME
M(2GQ(>!3RM\:-A ;1:INYM41*Q1S**[=+'*V)4(X&H6!Q3*6P5H,.F$#Z^96
MJ1'2@86D1)JE/LX2QG+J/""'@8Y@]8G3Q-W;/T"K9-;@7MFBZFV$#=*'0 ^N
M7H)NLE?AFOXNO#<@LEFZ&BKNM[')R*!-2G\0<CI;&9#4Y.4"PXFZJTCE&SO!
M!P!P!P!P!P!P!P!P!P!P#7UCJ6UP1HYF^@V[)81@;80?6.1HD.G)PG9[(:KP
M>K^28<^9 CRA-G:ME:.@BSDQB'.KIJ"5PM#;F4)L5C*?FA)I/',$WJ&UJQ;8
MEI>6R8J9"C.(3<P5T'>0"];9>&X,Q2$Y*WI ^0'FB\KEQ#8L@0$/=VGQ<3<3
MAA*+$-67S9%XE5RM.%?W/JBS5X/:!6PJBH.<JC%W@NS#XP=(35GHT.4HS-@S
MY,>8.B0T3X;9)<YB/Y-D/HBSN[R,^+Y(?X]1*QM+](V%08C5=D2KQ3XS%P6V
MW4GI%E"LM6EQW+6&D5UQR:E!M;N7V,-I&9E97EYKP<9\8CM0\++<BR1\/NO4
MQV*[,@[#J*6&K>?H?;./#1CCUMK)I5?+A(K)"3&>E3&BF&VHR&$.=_8EP)L'
M,B&0A/R+#P9)6)>\[*UTD3$/9OU*P"(%5 H!K-J!8$S3:7'&5!XA',_N<DJE
MYIUI0]EY<O#C;C>6?"0K&$.R')96)UF]G:[KBS;!J[U:!-K8,I93@MPX.69&
M@0L54PH4D!FI#A3$2%&3XU]U,16$XRA..U2T)5(?X]02"NV 1:P(:S5^<P2!
MGQD(P)GQEI<8ECR$=N5%?;4G.<9PXRXG.<=O:E7:E78I.<8 O/ ' ' ' ' '
M ' ' ,5;UV0]IW2NVMLQQ+1Y_6>N+G?&0;TQ8]DPY4Z\0.(&.ST1Y:X2)RH.
M(RI28LE4?#F7<,/91XM15:6(=$W@?/)_"$+5^JY7_I8(_@'G3^//;]G/^3+?
M]#^$(6K]5RO_ $L$?P#Q_'GM^Q_)EO\ H?PA"U?JN5_Z6"/X!X_CSV_8_DRW
M_0_A"%J_5<K_ -+!'\ \?QY[?L?R9;_H?PA"U?JN5_Z6"/X!X_CSV_8_DRW_
M $/X0A:OU7*_]+!'\ \?QY[?L?R9;_H?PA"U?JN5_P"E@C^ >/X\]OV/Y,M_
MT/X0A:OU7*_]+!'\ \?QY[?L?R9;_H[&O_:$;)C.?'=+ -Q/9ZF&MO3V<XSV
M^OE2]=/XSCL[?4PG&>WU>W^C+^//;]C^3+?]'?\ PA,W^JF*^F67^['C^//;
M]C^3+?\ 0_A"9O\ 53%?3++_ '8\?QY[?L?R9;_H?PA,W^JF*^F67^['C^//
M;]C^3+?]#^$)F_U4Q7TRR_W8\?QY[?L?R9;_ *'\(3-_JIBOIEE_NQX_CSV_
M8_DRW_0_A"9O]5,5],LO]V/'\>>W['\F6_Z'\(3-_JIBOIEE_NQX_CSV_8_D
MRW_1P7_[0D?RG.&^E4.A?J>"I>XIKB<>KCM[4)UJUG/;CMQCL6GLSV9]7L[,
MOX\]OV/Y,M_T4_\ "$+5^JY7_I8(_@'C^//;]C^3+?\ 0_A"%J_5<K_TL$?P
M#Q_'GM^Q_)EO^A_"$+5^JY7_ *6"/X!X_CSV_8_DRW_0_A"%J_5<K_TL$?P#
MQ_'GM^Q_)EO^A_"$+5^JY7_I8(_@'C^//;]C^3+?]#^$(6K]5RO_ $L$?P#Q
M_'GM^Q_)EO\ HJD_^T)'<)3X72H)RKLQX64[DF)3E79ZN4ISK->4XSGU<)RI
M6<8]3*L^OE_'GM^Q_)EO^C]_A"9O]5,5],LO]V/'\>>W['\F6_Z'\(3-_JIB
MOIEE_NQX_CSV_8_DRW_0_A"9O]5,5],LO]V/'\>>W['\F6_Z'\(3-_JIBOIE
ME_NQX_CSV_8_DRW_ $/X0F;_ %4Q7TRR_P!V/'\>>W['\F6_Z.EW_P!H1L>?
M!\3TL!&_7\+QNWYSW;ZW9X/@:Y8\'L]7M[?"[>W'9V=GJOX\]OV/Y,M_T>DW
M1'Z)C2NL883%H"CM>[5 X?E%-=S2SA=4T'A["&+!62RF1*C<!&'&62[.!T::
M&FK2B2PN%)'SYF>KI[?'Y-=/5W>?P>@'G>1]CPO[C_VCF30\[R/L>%_<?^T<
M >=Y'V/"_N/_ &C@#SO(^QX7]Q_[1P#]Q;B.<]GB(7P;_P!HX!\>?/H'G/0S
MIXJKEGT<Y!G@A%BBS;;LANN$YNHDWT+KTH.IE6)F2VP;FNV!UT($<BM"VQKL
M401RVH3/,R$RD1$1.<.MQUTE.$W]7;*L22O=N-OF-*QTFVZ8IYI_>!YY\[F3
M[):'_H/3/^5*[_Z1#YX':_+]SNK%X7L:F=8G35L?<A_IOW+HRWTNI[WZ4]HV
M'8NOF-G"#9K65P&7O6EOU)?Z7<&JU-A6$.DM5+E*EA+0'P1E@C(R(M08E%E2
M$-PVG":=G5$Q;1R:\R>@C=NXMI]-.Y.K/;.LMH7;3E.ZS1Q%RJZXCUT91+#U
M(EM3/ZMQI-B=&G2XZ-#A->SA8>]7";(V 7(RXA]^<W+<=8B!W0FDHE]-\V)S
MA,S9$&E.BO01;UKVFTJGWJZ:3L$6D;*Z#WYJA8K84V%M+5_1ML:Q70DJ^5RQ
M3GJA%L]Z@V*;#%UZ%7"; &1//,&]A6T,4'#P KZ[<YRCNB;/%;)]$6K8GH&N
MQ;*4;6$V9J=ZK%CG54 (4@Y#V($K-#UKU =71+J4KI+7\:ASZ^4S:ZP&)(JI
M>N0#5$'S"P.JFA%V&-5]$2:+WTB+NF<WTI*M/)-;GZ$SU*;%MG7-<;59>D9N
MW]4&!D?7.Q M*OH^U:VJ6N=K4_:NL]6N"X;4$$S6+,=JCAK=EMB9)W>[W(MY
MRRYA&.$!!H(S*A)3"55FU#<^RBGJR43O0E-M[%N-VV#N6YZ(.F[[M/K?VM.K
MXJL68I5Z^6ZK.D?2O3M4H(?%HBRI4M_7AO6),H1/OLP9)@5/BS1HX3.??$00
M[J0E%$K<&WO)8U>@^;<J5<;":ON^@Q0Z4!]#^"V:LSZ0^.'V)729I?<FL=B%
M!5EBU8P;UW:+L>V-6K0"O]+A1+\L55RM4EV("Q9I9)E\_!>Y5E/_ +JSBYLO
MPB3% WT#S>,"A@]9N;-Z<R8HCTQ]+_3':K\8HUR)[)H _06]=B;<*;&T@1>>
M2@)8C0^R@!0P*4G,M,&H$,U+L.&JI!A6(5]:=U[>5>E*+J4TI%3Z9>#F. .
M. . . . . . . 0[80BR6&C6T!3S+-<LQROE X6Q/H=<2 FDXCD)LVTTSC*W
MI8G#ZB$%G/8V],CL-/+0RMQ:2#-3"?2>>JV41]2VMEP&G&C2&*[L0C/DQHYG
MI_V'6;#3VQ\X*)4N"-(4R 3JA1?<Y$IOR94E-)?CQ'DLZG'.S!IZPZXU<LS%
M<J36].5=PJF>Z#KVSP3NQ;Q?B(!^U[%AUH&Z-JK$_P WZ_6JA",,AAS,HME$
M\V0=(V2Q%"!5^&*;<;GPQC(UML9WR;'<E=O)5\5WSYF:V"ND*R,:Z:!$"]53
M;QH_IWB0IPA\V.AE6M L#X[(Z>=CPHYX3#LBQR2T5^#'GKK!Y]@BF&=\F89(
M5]5<J[SS9?&8BVR7EDO/YC,M%CZ1-CEJO,K8ZQ4X9&/@;6T1:9+6_"PUAL>Q
M#U_?DR#\F&0MNPATQ9.#&DCR)RFUN)9(Q6ZM4Z9Y;<J\.KJCYX5E$N*2K2=L
M8>V.5^SJE<2L_P!)YRQPMFCB!"F.,6>G=6-3J\EZ%,E/Q%=1]XKM\&D2K+T'
M"(;M:FP28B>V/?F9G0XPF?'=;=?D0843L\]+_P#FA8MLK^[=?=WG#8O2>?L5
MUM]PKQ.N]ULA.\,1JE,*VBJA8H.^:JT+0ITJ;(J;2I$Z3 (Z:G/RJXEF- L@
M.T.PW#P&8PJ2X3A?U:FW?YMN(U;G[0E&J7I>7M72F^F!F"R9!-N+V78K@\4R
M/GO3W@IGI<.=/T>"\].E3R,J:P1)0S;N2!>=ET9$\0\0DSL)=6GVW[I$8?%$
M):U-H=?ARM>HU0 ',#,& 5;#!R.0STE\6N4,'L0G'(+LR+"E+CNY8\8CQ\5E
MQ.%^"I.?!\+.7\DTOD$OX!A39?4AH3396""VGMZ@4,T0A9*1A%DLHT<2\DX>
MS'49DP77N\P0B9"5,+,S6XXM#J'&U2\+;7A-72W8I(VE:9=%E!AP:/-!2,$N
M'+0HI(45%RX\\:3'3F$284\?.BN.Q9D*9&=;D194=UQB0PXAUIQ:%I5F%*[@
M#@'YC.,^MG&>S.<9[,]O9G'KX_KQ_3C@'XI24)4M><)2A.5*5GU,)2G';G.<
M_P!&,8QG.> 1RG7*J[!K(:Z4BP"K54[#$Q/!V$)+:GBBL/+CC/>84MG*FGVO
M&M.-^&C.<86A2<^JG/#33AT:%M48,ZT8<LAT@]4,"!%D3ITWI_V[%APX;#LF
M7+DOT,ZTQ&C1V4K>??>=4EMIEI"W'%J2A"<JSC'*K5Y7N1V/P_8^#;TJ-I>]
MK?\ YG6+[NYW. ]*C:7O:W_YG6+[NX ]*C:7O:W_ .9UB^[N /2HVE[VM_\
MF=8ON[@#TJ-I>]K?_F=8ON[@#TJ-I>]K?_F=8ON[@#TJ-I>]K?\ YG6+[NX
M]*C:7O:W_P"9UB^[N <T:DVLYG.&]9;"<SC';G"*79%9QC_7G"1N?4X!V>D]
MMOWK=C?,BS?=G 'I/;;]ZW8WS(LWW9P!Z3VV_>MV-\R+-]V< >D]MOWK=C?,
MBS?=G 'I/;;]ZW8WS(LWW9P!Z3VV_>MV-\R+-]V< >D]MOWK=C?,BS?=G .*
MM0;90G*EZOV(E./74JDV5*<>KV>KG(S&,>KZG]? .KTJ-I>]K?\ YG6+[NX
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M5AX/05N*T^E*M;+/58K/ E7@L[8I51BGL56K]U;3/7R5++!YUL>*QXUG@Z\
M.. 2==&G]%].5D8'P\62Z!:K+%*LEFN^8TRU-ID8)@+4@'-:GO3A34A1A6K?
M_MY:=E/[+ZIWKQO)U6O:.U4;#LNP6@>Q16JWTG](1O!(@55469:#.-0KI@4-
ML\NQ(NT3>34_5>2\$"Y7GP+L(HP??;9C<J2HJ31_*1';6VTC;K"=)]:77S/H
M1R-U,[:"U6KQHY:E6D6H94&RNX7*_(AUT0?ET(R8+:_/LV;98:*Y<8)@2,<(
MSYEK@35MG45=ROHN"V7LNU5MI=>ZVV6>A.ZS!W_BV)]?0H[%U-[AI\/8;[\L
M&BW2)R[."IY2JORHH*-%T#IFV1J;'>.W^ADY"3-OLYZ$,'#!)2\V6<'MJ@-4
M\8/-XK)=*<8>]7DU9Z65+-NJPHDX]:YP9PZE.H*WZKK==*TZ*+<+E-?W2]-C
M"X1HG$,S*O!KDR#68<Z1>*?+S-*++R6$BZV*N%IF-H3.B"(D(=->D3I4[;^C
M_ ;A6P_ZSY>!!+UN/=S<5^1@Y5:R G7782(Q2-3#;4FHUC3_ %::UU<N=8"\
MJY9@E1EHUX?/'K%)Q#KT=@; >DP'H\),J6E"P;LOQ3=*:6R.IQ'KM%]TXW$>
MKF[MI!K@?7%F1#<N64IXT+ILE'MQ&QVJ%-VGLZMV4W2C1NUS%"T5NMQ!]LL*
M\"CD"..%-0Y. @N974P["C\W?XIJ?+<8WU$UIX]:S6Z+8KA2^2#>I#8T[(F+
M(M6LXP(E$I<TYMGS)LK=0I%BL54V.9,ZJ,B7;REUNUAS-2JT%;Q ^+)1$W&%
M7"(!BTS@:R$[?/B]YJG-FA.DRK--\?%]2JU?LS95EK%4U7:ILD1,<Z?:SLJP
M[,<2<8,Q*69U, %0B,HY)(^'%V4YMU=O)2)<OQR%5JF2G9@UN>6;EMG";>=F
M<X81N6L+X[/>2,57<VW[%::AMTM7+T,UP9$534YZ.Q)%-48;8;'6HD@E;V@"
M[!BVIM0S>A2#JI4_-84&AUF$0(Y,^HXC-:4-7U>;]8B.VMMNA*_BEGO-NFY)
M^F6Q))D-+XJ%[NEZ;+:(65WHFPWRY;%%@[\F'KQ81<@A;C!]-2N$HG-ND=RK
M!I@MJ8/;*R2(7.0@MZ-.J^D5I2*5UN'3=6:5JW6FEY9HFZ]\!1VSG(4ZMVW&
MO"NW"!"',II>0;:2K?M_I]:@2)#-W'18(6FT6.#OSD-]A$TM3&QD-DD-C3F[
M,NPJ9V5R65[E>;KBS&<7)5]V6TUU9;/& Q,J,S4Y\[$H_+8DQ@,.4'O@$/90
M8M*@9%C:6([TV/"E&XI7TN\;288?'L6@@Y7 OC [Y=*F^[7328RDDO"YS^/Z
MGU+E7]P[]PJPB8%CII9RN;&#U\A*-4$^2GX7L;JZV%IUN$[B!?!B($2D4B$"
MM<*"MI<F0,R+;DS&!DC!!^19FO%G2F[G:)<M?MU=+UYR4%Q$]1^Y5[!KU,+!
M*JTC%KB5*2MP+)&2+]&8W)>];6:TU:-(N<@S"9!5VJP;9(&BJ]<H@E3[SEH,
MA:V5&G8"%'S!/"^RU>HFL1C[O%W*V)]#A5=P[N.&NG_SQ.58' MV-%7BRO!Z
M8: CL1MPZSWZJ5K@@HO<2V%.0;A1ZG"#DW)$:6_8K$%COB5N(B#B2%6VD[-5
MLS$NF#[<;Y_,:U/0/F30X X X X X X X X X!Y![]UKO*H]1G55?JCKF\6\
M)U#]/VO*%2#U!KM+N[$*PTQH]#/TZ^ ;<="I$ [7&*LQ5FD-R8;0^3)D(E,$
M(J&T]$T^GI4_XMN&X3F(KD<VG+>*BBGY9QEI?"T5Z)15,!*N(3L2G%:\SI>)
M3!6L)Y#&LJW3PVM*['OE:@38^Y NM1 UJSM6:$0%F=;6BSSYRXD^O'GXZX*F
M-3T-MTOMM=?#?RZ[,=6#G%85I2GIX@R%>-&]?%9K&B,ZZ);WS@[I;4QGJA9E
M;.MMQ(2]DQ+^ =OK$ >_LP-862RP$@BHF&UG:J?Y5"1I<" 5C.)84F?3/5_C
M$M+Q#B[Q;2<BQU0O\IB7>K?>_&_,J:7H7KH/U[><V\F^H-YX)H789;IF95LF
MU4J:/VLYL"X2J;#?"Q-K64K,(-A4!O)D39EDL\B/7I< 8:FONLNI2;Z5$1:D
MZ)TONC/*ZP)-S,V.%7;V(0+T%UDT,<^( U_?@)4[J7W'>MN2A%DN1\!;JE>!
M$PGK0R##4G<VNS162R?=(^>.:[8Z].CE'PLBTM&X<*/$19Z6_P#MB%%$K+?U
MC:2.K#JO?FR-Z_)63-:Z[ZW8,14+<D7JUM&P9"-"XU'9:GLP4 K=;"#I>%[,
MC;0BXMI^E/376LN)L;%M W(P:&XQ&'$\$7&GX\^G_C"F:5]*5+'5%CU\S-:6
M_*F<^ACIYWAH>=TLP"0O85>JSO3OLZ#O6O&;X5L%6%[/;N=3D:_99K1"QE@P
M&>@$Y9$Q%5&!"@YC>/:G*RYEO&9UOI?=9/=3-/X[<B]*:BV*RL/E-SUH+_S6
M0_X1_P#Z:N<SH8@X X X X X X X X!+J?\ ^-E?\+__ )6^ 9"X X X X X
M X X!9;%_,TW_P K/_<,\ Q3P!P!P!P!P!P#,(K^;!__  47_HHX!7\ < <
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M?6*F/R(+/4E=Z_?H\PJV\I3>%UDG"*#);4%Q22<) J8VJ-(S(C-)L_\ 5_\
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M -O&XO\ ^@'^56KRO<CL?A^Q\ '.YP' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' )#4ZG9;W90=-IP,E9;39244.! AXKDTD5)37,-1HD2,U
MC*UN.+5ZN<]B&T86ZZM#2%K2!]Y70_J?<VE.FW7VO-\7W-^OH:#V.O9\"5BJ
M!W&V?)-%2=\)4BS)K#*51,&Y6<Y7X7D^$MT4/'O.<'$TL.ZF*VFVO(4< < @
MUR]<=_5+_;&X!". . . . . <D?RL?V_LSP#Y'>?0/.>AO3%=Z*&U,7K!W:)
M>LDBA:ZE)(55\#T^OCH<(53X3,M0Z=2CLRP$S48B4?CQ(1N!**LUB2%&M,$E
ML.S.'7TM]<]N%4F_9W>+ZT-)T:\X<?E:GGESN9/LBI#B6J'3G%8<RE-3KN<X
M::=>7GM$P\?Q6F4..+]?U<(0K.,=N<^IC.>>!VOR_<[JQ>%[$6OM2'W6949Z
MG2,9ZMDS'>D)&GX^2E=M%8,U.QA\383#,R ZN,6CF8$V(M$AHN#&H\:RPZ^X
MF?-Q/G1\&/Z/T[:MH)(:7$(MC\\3@>F&N5"S$BMH%U>TTV"V@6"K082REJOV
M\I&=[K!85,E)CE9RI19<Z;-KZF_GK^"*%C7)\%37^GS4=>FLR$B#AJ"P+'BD
M5^RCY)VO*0.IM"H:)3XV<$6F3+?KVLJ4V_F0X[&3-"H(Q8T:7)ENOI?CQZ\L
MLK/_ .7P<IW3WIB?#D-*JLF,6D6R5</.N"$D1+<S.F3WWG1L8^T&Q,9KZ0DA
MRELA$Y[DS2O  MH2TVAU+N?ZN\QOY)1W/3JG6)+(]TT:QDQH.94_8,T^):&#
MQ%P(IR3LHVNAPD^O#*LPLE5I8=X)#%E27B\S@\PLLK-=LCQ5RS(8,-7N?R57
M&C7"N%/^6CLPB(_.)3V3I;U#9WIRYRKXU'(1)8^3"2Y-GLXA$J/3-=ET1I)P
M 7)P2!6L:^J45^R0B$>U0GQTJ0'.C%G;#@L[G$4^-O:7EHA2MM<GA%*&6;-K
MZC6_% \OCS4Q6M;"'LU:6F*:C*\I F/ '))]WA-8)0&IC0\RL<^GN;AH.%)*
M:R^,BY1D2L'3_B^#%(CI@U2 D^4 TF^#B\1498 Q%:\40K;L$W(/P94!2:MB
M,5(M2YQ./.+6V-9"UB'%)H^U3CL;,=$>S\Q^0K+(I I_RNN=U]GO:7J3H#7\
MN(;&OFMI."+1$=3:A+ANQO1K0;?IK>OWK4>DOCG2A$TNJ1X@[,1TAYLI?'BB
MR:\DR)&D(B?[]9\6Y;"CM[M'K19E0<T%JNP0!\"=!LV/([MLEAY3;!!R0,)7
M#9(/:Y$DRB6(E0I$B/<JZ-DPXY"'-&+&IE!B4 B,FRXSJ7[;*/82GCH\9P+7
M+Z?Z,5D5,><6>,U"EBIS8\*2@DY3QTT=V+6]D'Y=GRH6B!)$.&:36VH-=&PA
MP1@7).5] YFN.PA3"<*?U'Y8IGH_.'CQXH5<CI^UNS8G+/4I%UUN2<ESYRFM
M?1?((Q$DN$K=>,N1Q3M8G#X:RPNH5IJ>Y#88><>$1Y3;C4AR2X^G&OF><V*3
M*E?^KX)GG6E&:JM.IXUBR"!5%/"K* >AMFWRB2XR5*EORR1$K!)2#$@ZL@4\
MX99-4J<5<*D)KLM)-Y,YM+KG:)6:\)\$-8Z>]6Q)].GP6K? S3:S0:DPS#21
M9\M!]8J=<I+9B?@-DRV\*=D/YFN@28/SCC.>2K0DT&:CCF4_/-OS04I;3)W8
MT^>&R/ .E?45:CL,"G;VPN(U3(<.0VUW9R,+HL&]B HM+$&KQ(+[3X395R#F
MB,R')/G&"V2!,Q(.QHQ9J]S^>GY2<690*60ZY/\ ")A-T/J<F,6%*!SY$0^T
M*CS!\I!SN\Z((UL7U0S#E99A-.JCR*:<(Q)>&G6G'93J9B7&W6TXY)?SS/N*
M5MKD_&!3A-#:Z"H=RI^[%93P^RBG)I)$I#GDZT@1E;GQ6H8H"+$Q_%"Q,7#4
MB,.9F29RY98M))E)DF8ZE_GU7GR*9V1_B[,*)&0:+4*UKR.9A5]5DS!-%6C#
MD(A$(RV8,Q @8'>\GJ\EMR&F9;0IB7):??DX[Z[(<CY89<3';-S&2@*%C6MC
MX)UY3C?HR'R25^Q<A96>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX
M'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.
M-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C
M(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?)
M)7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[%P)6>CX'E.-^C(?))7[
M%P)6>CX'E.-^C(?))7[%P)6>CX+#:4A#M:/!#(KRN(+B" TH**U^9.&$A\V,
MY&F02,*:/<B2X4N.XXQ*C2FW([[*UMO(4VI6,A*ST?!J1^3ITV_J_:<^AZH?
MAKFOJQ_V7)/IP_U? _)TZ;?U?M.?0]4/PUQ]6/\ LN1].'^KX'Y.G3;^K]IS
MZ'JA^&N/JQ_V7(^G#_5\#\G3IM_5^TY]#U0_#7'U8_[+D?3A_J^!^3ITV_J_
M:<^AZH?AKCZL?]ER/IP_U? _)TZ;?U?M.?0]4/PUQ]6/^RY'TX?ZO@?DZ=-O
MZOVG/H>J'X:X^K'_ &7(^G#_ %? _)TZ;?U?M.?0]4/PUQ]6/^RY'TX?ZO@D
M]7Z<>F9<N1B1T[Z:>3B/VI2K2U2D=BO&H]7P<5=SP?4[<>%V8]?L[?5XGJQ_
MVGV8^G#_ %?!-_R;>EO]6_3'T%U3\)<DO%ZL?3A_J^!^3;TM_JWZ8^@NJ?A+
MB7B]6/IP_P!7P/R;>EO]6_3'T%U3\)<2\7JQ].'^KX'Y-O2W^K?ICZ"ZI^$N
M)>+U8^G#_5\#\FWI;_5OTQ]!=4_"7$O%ZL?3A_J^!^3;TM_JWZ8^@NJ?A+B7
MB]6/IP_U? _)MZ6_U;],?075/PEQ+Q>K'TX?ZO@M)SINZ7TBI:FNG+3+;F$M
M>"O&CZFUE/\ EVL9_P IFIIPGMQVX[?"QV]O9_3Q+Q>H^G#_ %?!C?\ )TZ;
M?U?M.?0]4/PUR_5C_LN1].'^KX'Y.G3;^K]ISZ'JA^&N/JQ_V7(^G#_5\#\G
M3IM_5^TY]#U0_#7'U8_[+D?3A_J^!^3ITV_J_:<^AZH?AKCZL?\ 9<CZ</\
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MK/1\#O;7^S)^)S/J.(>6JY$K/1\')$AM:L)PE_&<^ME<62VGUNWU5K:2A/\
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M&()A^<#-6"LSP<\<U*?C&0M@)C<.P"<%^2P1%D8D9'K-F8G:W(MM?Z@M)V,
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M;6\:B4BW4GLH*#"V.PIFT4W<G7:?>[#7<>))#HK5J$/-%[2*=7/=D1&8,J!
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M7!])O!S' ' ' ' ' ' ' ' -:X?5'1C%!+WZNUZZV*.,V+6-:1*] B5J'8;
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MB;R/GW_.K;R]P>J/D^W_ (PYT[%GMP<^]Y;\C\ZMO+W!ZH^3[?\ C#CL6>W
M[WEOR/SJV\O<'JCY/M_XPX[%GMP.]Y;\C\ZMO+W!ZH^3[?\ C#CL6>W [WEO
MR/SJV\O<'JCY/M_XPX[%GMP.]Y;\C\ZMO+W!ZH^3[?\ C#CL6>W [WEOR/SJ
MV\O<'JCY/M_XPX[%GMP.]Y;\F=>G[T35VW7B/5]W ZI4 QK+,0/:ZZDK%'"2
MBW,I0W96RY4KXL7-\)#22K#K#0IY*5D&EP7WYHZ/HI0JZZU/:*F+2Y+D+0I*
MT+AI6A:,X4E:5.-Y2I*L9SA258SC.,XSG&<9QG&>SG,Z&1. . . . . . .
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MTO']"VW$*0K']&4YYX':_+.ZL7A$>N]M)!2U(JP%J L_>3!:!%DE&I$@>('
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M.,S&83D&5<:JOG@19D6(I1:T6BMQ7]2;#B>(O)'9,:8&NP@"6AW4O *BBAR
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MF_>ZN7Q[7WX[XA8K?@#SG-^]U<OCVOOQWQ"Q6_ 'G.;][JY?'M??COB%BM^
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MLMSF;' ' ' ' ,PBOYL'_P#!1?\ HHX!7\ < < < < @UR]<=_5+_;&X!".
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M,DUX,8+QS,$3($/0Q)-QN<K,"6EFP_C4:S!)6>C]HDYT[?5-OET(4^N=[?S
MG28C):7$)0H!YANBZ]OT<K5WW1N8)D4\(V**0Z_W^*^SE#,UF-*&%1DV0::^
M>> G)T'=\! >QSNO7 I"1@)3BAU5D1(CMAY-M$!T6N3K9'A8R^W:54>1$N;>
M,I7'4"=<>[<+CK3DE.L?OQ-!,3DI_6E;3K"=2>JS%<%'LDCL244CB7DUGS(O
MDNUI\KUYVSL28E7BU==C+ ?),6=*;M@P1)K$AF!+=9*JPP[A#M?QJ+8M$K]7
MZ6[65.AGJ:U4I%QEOS;$V)IQC Y\S!I=QL TJ-30ZGL*3;1;];!%_&4^$#N
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MH>FM[[_ZDJI%O.N!LG2>K>G+=U]T)L@@)+&"L$=M6P.7'5]](U2OU[(K)JM
M4S9\\&2)C!$H.V+U=%M92:]U^)53N)^C!.SK[(I^L.D[8&R11/:VW]*4"WHV
M7KVI#KE?=.Z,%=2)Y3XNPN-F:U57]139I5!PC$?((L$!%;C "#TSOD<3MO\
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MM=)/H=AVB6#7\#5=#53@EZT[JPC%"R[B+GU?8NBP,#6&G1]>L0DK#LM4M5$
M%V*D*M%5+#"*8I$G%)&Y*I)?*[#VGT'=?-M,;76?7&\G%IZ ^F^5IW9NI=;4
M,!J!6P^E>]](D.SU& \Y,JVJKNU<ICT2&+DD$P"LB';;W8;M+FD<J+G[$1G3
M31B2_.??S"RYG.2R:"Z!.C/6NOZ#C7VLZN;98+:9VN,OG?ST\A9+?J2KK%:I
MNL6=,.SW8@>LBBY)^F4X?)11JQ&/$&00&(Q-?PZ'<W?^+;:%98_0\^AC8C X
M'9.GBI%XM"/7QUF-*1;QL:6]MVXXW+L,$:D-E(#6PZ-<KT?7;3U,/O6;7[]A
M?DQW0K<R#)AQ@74[GAZ0H4>%>B9C^G3I-D$)6P1.M0,DD%W)M&\2"PR-:7Y,
M/<-^J3_3WM,X@=$?6KOIBG-R*,5\1!4%B"VG9T-J)AE1)(DD%J?1OT)@9^G]
MRT_3M6@.:[K.OZSK ^+7=L!1H+657)UC64\V 224!,D->5.22#U&\7T.2/5$
M:]E@:?')6SVBMNLNUR_)F")TS]-YWIJ#],</75?G],SU- 5T3K5F68S6)5&@
MR()H*(R]@DDK,"N+C0W7HTH@ZT2B97"(IE09,F,Z)-9FML[R0S=?33T<;YM1
M-.[M;4FY6DA6*?J,M%/J,0'CE0Q?P^Z:34Y<"'.&Q; $;V'KZ):PJEL3XK)>
MN'H#,E"&[*/6*FU8X_KBW%$9(^AJ]#A>E!=?D= 5V370=COEKC+58;RBS$CF
MT8\"%LU^SWEJTHO%SA[#'B PJ\A[=8C@:UB 8$0>@3QH,3%AAW/&T[K_ -!O
M1#:;O)M]TT_6V;MLB]5 TD@/L]UJDDM?==ZNL%,KTH'$K%G#0Q)2/IZ)8*J<
M: QAS=JHT)X+;&C8F$S&:"72ME-Y]Z^:FTFK]94+2^O:AJC5U<A4_7M!"1*W
M3JJ.=EO0  $<GQ<(5!5/DS)>(<)O.&8S3LAWQ#.&V6\I:0VA(CK5VLGG;CL[
M>W'9V]G;V^IV]O9V?U]OJ?U^IP"W#C LOD@D9.C3LBB4@.2[LYAW$,I$0RY*
M@OY3ZB9,=,AGQS?;G+>5X0KL7A2< 7+@#@#@#@&)M[U>Q7;3FR:G4_!<L)^I
M%AHZ&J;Y,254_'SB0"43\)&!J;!$Q("*(Y6A,'$_,I2TI:RK%5&I(YBEII]=
M1%YOMAD9I.GI &G0:77P7B2NJLT&W5:0.V?J S%ID XFZR!EY"YC [6<?<K]
M/57:ZP)AL#+-(61?\IZL5M7-\W.L1*M5K\K!?9=AXI-]]A:4RNI?SOLID>*V
MS$$J$V\H>"3)1\LXT7KV^-4D @P!+*2QU5FRB.HD[(8$C]650/7B MQH23.W
M"S^)DQE+*>?1^JJU,^R@E;J\2O2R<]VY9-G[B.6"P&#POJ!ATB<5V5(UN-HZ
MG %L:L*_2_QKUPU$D.98& Y,)NT/@8>P8RM>CY;QAO9PIB4D3"1*71-)GUG\
M65PO+7.^R,:;?N2TE8/47*02BA']PP;?*S<V-DSWYK_FJUE_;%530)&J$S7'
MP4?,>AY.NQ54^(AA-:1-1LUIVZ9@(S:9-7:.9]8M]*$JU>KM[53"_@NI>L;T
MIC5F(U>5N:TY:)[RKXH3(O,PC(Q2\5ULCKE\7*L[-ECX,Q+'F3D);" D_;93
M3JPTA\M":%BV)*=*75B^DX9Y"M76^E/2[2_&3-73(WL2.,V7%O>;2L8WL-E_
M7;UK;MR9CE-E4"C.R4Q'+^;/WI<%NZ>=R4)MLU@LV]E_#0H0)4,'1XXYLQ>%
M"J:SZ6K.\V;Y"C@#@#@#@#@#@#@#@#@& NJO_P"6/J$__1;9G_\ 3C'*K5Y7
MN1V/P_8^.3G<X#@#@#@#@#@#@#@#@#@#@&2]/5W9=IV73P^GV#+NQW3,5^KO
M 7EQ" \A$7B1@IW]*FT#8@U#:Y<XC)=:APX;3STMQ+"7.'$5L!]D%#BW*#2Z
MO#V&4$F[S&!CF;66 PG!P@@<;C(20E0(;JU+:8<?PK.%81&;>5X3[4$>TXB#
M'\[B:6'H4Q6TEO ' ' ++8OYFF_^5G_N&> 8IX X X X X X!F$5_-@__@HO
M_11P"OX X X X X!!KEZX[^J7^V-P"$< < < < < Y(_E8_M_9G@'@5HRFA+
M]<9=6.!K(7;)UXDV.=JZ1&2 4OAZ%W RZJP6BH@$0F%Y7$>P8,(BOKFLQ6F5
MS9$1QGV];?2I44:MO5ZHG^K;C@E/SEHB]W"MT.Z+AU^5:(K8]L"9"D3L&!7[
M$G$\6/-P"2&0)ZPPHV,YE-2A<N <DJ<C=VE95&D*7'9J?=TUAVIJU4>:]T2S
MY!MCU&G0)W5H>>S(NKD^8>K4P7(N!;<DZ2>&R!EL4_86X-Q4W1(T6=&P&CLS
M0*,R'C8^TQ1+60329CO+_IIKKJE1-4[+:7JN-M;)O-=3HO1UG/&FA[;4W_1"
MJ_\ +8/_ -,B\\[M?E^YU5B\+V,=;5"VN2?UA9*I#CDY5:.6MK,2?F5Y,@$+
M)K^S Z[826(+$N?@?!L$@<%*2(,*5('A+(5**1B)!E9X5_ZQ7XW#W5AK1*Z0
M[>$&CA0:V"-G"2$+6<J^U_;.!0H78;)K#9 R\19495,UZM#K-MCF-A1[00L\
M"R&)DQVIX(/&X,*2PU>[TMB+I7FZD1 C\;1E7U.D7TD7>-<*B<G&:L^%'$P)
M)0>-*AICZ[%#-L7/8DR@4/RAK(B<(4Y^NV>!KE#(JV:JB3*\)S'/@3(!]JJQ
M7=:H_;A*77*;ZV8B/F%O,>]I34'I1V15CVE9LCTKQT/4T?70S$JMNL-D9(BG
MUHE7#[3+LK4[-F[W;91$A9I34._ ZXEPU."$:T8G-2[F<-JMM>5GZ6>MQ(O]
ME2/F<36))WLGI<([#M^TCQ-=.)#[;7MI,5&(;:F3':]:KAJ[0='JUA4VL7(9
M@S !75EEG^4ASCQ ?'+"Y(SPYKDQN&3B/2<X;Y0:F<'/XC2&6^7TI%^^K-BY
M%,@64K;MB'+2>9:FQR=A%VC<E&V-7H!,@P)[V1R'$563"S'FK7%A$Y#6("G(
M[TJ5AW>;%_\ Y:]V5K"W&S^_4BX/I"M3(\0*EQM85R"/@#A%A9K3Q8@SLG#;
M]K<EV:Y19E6#-K-18Q[ \? ?<-MOQRA_#YF-%5!@)O<IF&_-WBTC3:N7C.93
MV\VQ<4$CI$O\JK3*^RQJL$7EU=T=&NHLF==/A(V>G=6G,:P&I32!BE:YDVG"
M[Q(F)GPFF_*,_":&]8DILC\[JY3_ /U,^;OR(I%F=]%"YIFLWD.Y=/*S]^"+
MIM/IX6J:TCZJ2'&%("0M?(DA)C9),W("(A RGB9]4@75DN')1QO=REA-&!;I
M0;+;)$(A.D7N:^BA>'$6T5SL+%5E^;?FZOB8?H^L5:.ZJEUZ=3QHZF5;3(^>
MJ @<-?"V379F:=NI8"G.N2-B+(V=*EJ:L<B#?=<3C*7IV;CFW09>1#=[K<YW
M4*:Q3PR=MEDTGT<N//H1BL]'.Q!Q" 8,HU3,EPI% E*@,.QF('E@'1=]4RT6
MN$X#U!54L%7I&UZL?#8*CS]EGNTB- L-_D/-BS$%W+._W5*MX0_812B2XN=$
MJJ[WO),]T6R8H:1%J4RF46Q/08<&%<:V.?B' :I'3O:-2V$F-DQAT*4J<2N)
MD;:Y6.^15&FQC<XI*26CQ4)G=-NDTMGVH6+;*\1\\E..Z-B\P85A6:)K]<.7
M7]H0A58[1I>O K%;J;0:Y7;$,C ]6:U 09<.=5B,Z=(&TN"0AY<'3&99@LN7
M-1>[S=/A-O%XXBOZETI"5G]&TNF=;D-;,WZ,0BUM*K5?2%R;)@EO=],.&1(9
M!&78F7A [P"Z2T6>CQZ9IC,^)W>>_*C29+T"-EN8\):8!*)\MZF:.0HX X X
M X X X X X X X X X X X X X X X X X!&[B&%V*J60 <@QR@4V$)B2PV6
MCQL4@-(1'8LV%);SV8<8DQG7&749_E-K5C^G@&D_Y(O3-[R=!^1F_P#'S7?U
M8[+@D+!:(?DB],WO)T'Y&;_Q\=_5CLN!"P6B'Y(O3-[R=!^1F_\ 'QW]6.RX
M$+!:(?DB],WO)T'Y&;_Q\=_5CLN!"P6B'Y(O3-[R=!^1F_\ 'QW]6.RX$+!:
M(?DB],WO)T'Y&;_Q\=_5CLN!"P6B'Y(O3-[R=!^1F_\ 'QW]6.RX$+!:(?DB
M],WO)T'Y&;_Q\=_5CLN!"P6B)-5^COI=ERY").C=>O)3'\)*7 C:L85XQ&.W
M'\?U^S.<<=_5CLN"=O2[OQ[$W_(LZ4?>$UQ\A-?X^._JQV7 [.G#=\C\BSI1
M]X37'R$U_CX[^K'9<#LZ<-WR9#UWH33&I2$\MK76E0I90G$1 GD00B/$G2(*
M'</XAJE=BGTQ5/I;>=8;6AIYUEA;R5J89RB-MVLJ25B,N<A1P!P!P"RV+^9I
MO_E9_P"X9X!BG@#@#@#@#@#@&817\V#_ /@HO_11P"OX X X X X!!KEZX[^
MJ7^V-P"$< < < < < Y(_E8_M_9G@'B;TK5RU/6TI<0S9%0NNAY:9C Z+4"#
MIV=EV#+@U[,*YR&P^,N.,(,LS)#+BHTD.QF MLLJ"I/L_P"I$1BUC3.E3SF-
M]\/3G]H6#)"$5&.MQP4=D68CUF')&0HX 8S 'LPJ<E%;ACXD-#+0V,-0E+4%
M+&)/A3,R%JUT*.G&VM:R[:U#^?*&P/4A8S)"EM#F)^M"HADQ5D&BM:L!B9;I
MTYD?:B(=!^JSC!4;4N[R#MG[Y'%^"RN8IJ- =:$QHT%GG_T^E)S66G;#5TM/
MTO\ 6MM;GY;;Z:8Z>W]2::>IM7:>;;=;76P6%MNH2XA6,#(F<84A6,I5V9QC
M..W&?5QC//,[7Y?N=E8O"]C%>Y-\=/?3Y)UC#W/<ZCKU_<VR .HM8I.PGDHM
MNQ[.M38&JP7X@^4Q&FD5H5AI\DY"@-^#G+\MI/J\AI)N84PI?A7C5>]^GO=U
MKV_1]47.I7BU:#NBM=[@#!X3V7Z)=D9FI<KA=V2/CQ7"#*QTYI],!^8TP]$?
M9==0ZC*. TU$WJ5X,V>217M8/^)1OJ^"$!OM[U7J_%,S?B@&LXV%?JWJZF9G
M#U+\OW^WJEHK=9A]UA2/ G%E09>(ZY/B(B<LJ\=(:[4^$%I/O)(KVL'_ !*-
M]7P!Y)%>U@_XE&^KX \DBO:P?\2C?5\ >217M8/^)1OJ^ /)(KVL'_$HWU?
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ML:;\BF_O_BF#U7 KBM'R/$[!]L:;\BF_O_BF#U7 KBM'R/$[!]L:;\BF_O\
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MUO7[,]G^K/%,'JN!7%:/DQ!XJ\>SZI\DE_OKBF#U7 KBM'R/%7CV?5/DDO\
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MT8:4U':[')LYLGJB^]/_ %0W[>NP9=0LLJ@9,5VI+JEI!TC7I2OQ!QF3$K[
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MN\>][#?_ +\7[1P!X][V&_\ WXOVC@#Q[WL-_P#OQ?M' 'CWO8;_ /?B_:.
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M]BW#^K/69\I3AM68L1_SI.,#Y*XX(JU*"@B- OU^ VIP7W)XC.'GXFO3<(?
M88;,)?BDDRH,>8*>'O(?S&4FLHGXA/S7BS6L)R03U"5&PNCUA(Y%4-O80C7%
ML08AR@Q2JF+2!P6J4B1 ?9<Q*CFITP"$RRAYN3!FGFD3TQ90PE":0]I5\Q;4
M3AQ;?4S[R%' ' ' ' ' ' ' ' ' ' +0< !K*.R)/C8I88J8+(+@S6\/1ES
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MY"CRG&_1D/DDK]BX \IQOT9#Y)*_8N /*<;]&0^22OV+@#RG&_1D/DDK]BX
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M\9%3V^MZO9V]G]/KXXB?[2]R3YT;]B%][:_V9/Q.9]1RP\M5R)6>CX'>VO\
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MH:_.7SXB+J3<:&V',FAP!P!P!P"W%_YK(?\ "/\ _35P#$' ' ' ' ' ' '
M' )=3_\ QLK_ (7_ /RM\ R%P!P!P!P!P!P!P"RV+^9IO_E9_P"X9X!BG@#@
M#@#@#@#@&817\V#_ /@HO_11P"OX X X X X!!KEZX[^J7^V-P"$< < < <
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MJ9G:-=&:^J6[U]0@;5M?I6R1EADWS&CRVDF8ADO*WX3THY$=A%&K#8;D$Z=
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M>]C_ '>\4Q>BY%<%J^!V;4]SNO\ Y[V/]WO%,7HN17!:O@=FU/<[K_Y[V/\
M=[Q3%Z+D5P6KX'9M3W.Z_P#GO8_W>\4Q>BY%<%J^!V;4]SNO_GO8_P!WO%,7
MHN17!:O@=FU/<[K_ .>]C_=[Q3%Z+D5P6KX+F+%;9*O.,M ==M9;;\9G+EWL
MN<9QX24]F/!UWG/;VJ[>*8O1<BN"U?!?6]7WRR/L#KA)K@&KJ5EPRU4#QPD;
M.QD]G8#1/F5^N>08$W.>PH1@N2BCD)+L <H;(EI*P[*5E7=*LSM?H*O+P]K$
M;#PH4,;#B#AT2- 'P(S$.#!AL-1HD.)&:2S&BQ8S*4,QX\=E"&F66D(;:;0E
M"$I2G&,9*5/ ' ' ' ' ++8OYFF_^5G_ +AG@&*> . . . . . 9A%?S8/\
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M*8/5<"N*T_9,^X7_ -U-3^8Y;\?<4P>JX%<5H^1W"_\ NIJ?S'+?C[BF#U7
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MMJ#^99/\:<4P>JX%<5H^3FW6=D87C*R@7*?5[<)II).?6SV=F<W)>,>KV?\
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M!EFT6=):XN).%K*C ZO4[6[3AC)R<+C1(LDW:J@1KK-=4ZR^_5+I,GP(\9H
MX+#FU7Q2ZUND93JLQ]5,W6^Q*_.-S:KF38X X X X X X X X X X X X X
MX X X X X X X X X X X X X X X X X X X X X X X X X X X X X X
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M<^;6Z'>*Q29L23BS7Y@QV;@C(DSHF)$7;6?2W;#U3*^ZD>M5-ULY39?>1LG
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MYA]/M-M++*/.9],WU>\68WSEAZDQ&0]MBS-]ES9!VQL,4XA%HR)4RF0XA8U
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MC')!2O@L-QW@_E D2)SAR0$0^0"#X#E@1'!8CMJ'PR:SYF5X(V-F&J(MIB!
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M <4H0CPO 0E'AJRM?@IPGPEJ[/"6KLQCPE9[,=JL]N<]F.W/ .7 ' ' ' '
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M9$LC!\ICXS!&&[(GC?6\H0V6WE.2H/;ZG>V$K8__ .G DNW ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M/Y0DF*NI4F5=1^/569X0Q#QVLA/Y2+X@N.KN@K(FI49^W6>$'NPJ!KC)%ZM
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8%J/JHU7U<X99;EC]^8B<OD7F[_,E/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g16439g11d65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g11d65.jpg
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M5G1VD9FRL]57<8&6EZ'2U-;7*"E(4IA4DJBQT__$ !@! 0$! 0$
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MW%E/W?%R[D%#/EB7M_!I1=]:.8*&OTUXW_5&RVA@4 H!0"@% * 4 H!0"@%
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MW<O3$4&M1DJ'J]6H5J*$K=INS3R6IO4;IJ',4 H!0"@% * 4 H!0"@% * 4
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M='4G*TJH>"BRO.&E"C*#?\ 4FE@$(K<@I$"<2H0-4G@@TMF?'AS6]'IVE!2
M[L&!=AI$/79;TB4ML#B<R.C3@LR&(,MUTNH<SMZ 4 H".9A^*24OR<O?^K).
MA5BMZZE7O# ^37\/OYE'+?T(LBA:^W5XJNK.*VX.B28IVZQ*RDP6^_"#>E1@
M-T"J<B;,CL#@O>YPL<N)&VW;;X(T&1DR6*9)M&.&K)>26JLL;[E.W/():2AO
M#U9*GO+^5/\ D&CK^0]?_CH27K?-CWE_*G_(-'7\AZ__ !T$O6^;.O$\,<?
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MD>"U:WHT;SI>PUGLK6/0C!S<'9NQQ%U.A!N+.,Z;<1$J77"/'=:SGS+D4(*
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M10<38&?7)@/O<(5NJ?ANC0N@XWDV\^#:ZU4G<)D'KN7&#%8Z]E-Q8<3%OO\
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M,GVX:K9;<L+4)33I5*E9^TGKI_VX'R?^Y-Z'_E^-O^-4.OR'WER8_MP/D_\
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MX??S*.6_H19%"U]NKQ5=629"/QR]D_EM8'U7X$H1X+=ZLLW0@H!0"@*Q=?\
MQ)_QP\S?66B.A5CP?1EG:$% 4*[ _7"S?Q,1_GVJNM&''T1RKQX>K*>5LP*
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M$1JH.E&.V)&BIV*.L/5KD!MIIN6T8L3)F1<#3 7^[B<X.MI.;>3?HET35O\
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MKWA@?)K^'W\RCEOZ$610M?;J\575DF0C\<O9/Y;6!]5^!*$>"W>K+-T(* 4
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M;-!+[P,_ ^&[%[D"B'(W.W/$<<C=<(L>< 'PWB&3P5"FPI9)J7BRX<H-=NU
M3%DT*C0M0$$>_>E6)-VE0FW;-.S#/(33?=H_@O8[:_AA,?*WE?L'Q+O^CO\
MZ(QO_IQ==K_]]!IONT?Q1%VWPH>6E3L4--5U+W$L?F\1F\%3<4=\37M=VX I
M)[!V;HWA?=A8MF'W&+;1^1O-+=%L)6V);J<E5LL*LO6^9)6.A1OT5B> !X37
M)[P2KEK5Z>[<<R(4><#6)JVYWS-Q=*.<[4+JV^Z6X04"GGOU)#S:/#UX0^'4
MYZR 8NB6#2"=,M3;]."7K?-B4OR4<:%ZG?6\'#G.UK6^WOWU?]^_<W0WG?\
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M#M* 4 H!0"@% * 4 H"KO3'+B+IL>W11*<^D(;' TCI0+T?/\H_:WT/-$Z]
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M>&65K6H6E2TM;2YL@;1U#.,)RW'$>=C-."VLRIC%29FQYBB207:J;[<=42,
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M(LN9[YDN(5L\%!#>84INME,2']+GDAO:)-?<B"V8M:$?,7'.,S6LHXWZ<;J
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M39NI2^8.1[2_/ ]".6NAPK\MTA6L$=23 XV]C792C%01="1R#52M0VKHG)H
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M5M_.0G:,3,UO-L0_9JO)SO$MI*02CRR<HZ'F8<@NE>82O/'BWY0N2C8]0R*
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$!0'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g16439g14o09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g14o09.jpg
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M 0$! 0'_P  1" $G E\# 1$  A$! Q$!_\0 '@ !  (" P$! 0
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MJ:O'_9D[,.(/2L3#E5R/95NTXTR4)24YDO(F*UY;0QA<9-S'WO':3D(RX?W
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M>E*(Y$-7&]>VBV&-9[$'*@F'C\GP.1)AA>;AD][1@U=,D7H[L;SOE\A5^/\
M*KE&-]G"['>S&;'Z7K['+MMK8K2PY*K),+99T^PGZZU(<E&! ZA0#PH_IO/
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M+\?X"+A<=9MVPR-XA9N+5>A14I%")-'=Q$5+,&J@D?FZ2Q?Z%V/RPDDU$_\
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M5253RWP4343SVVSP4PSVWQSPRVVRQRVWQRVVWVWVU3)\] - - - - - - -
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M;\+W?"Y$$.X?ATXEX]2ZVMXW&6G'ZN+]+N&<#<'G[4?85E$:Y2C#%@G*!VQ
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M?B :-/CT=(.&H\&($(#%:\Q?-+;G. D:E2IK18++KYDCFL.#-_QL?,8Q'*^
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M(9XDU(X_DAP5J(\T\QKDNRC0R- - 09;^_QCW<<?%J0Z G- - - - - - -
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ME"<.'\Y7C9=:JF_R\KO/BO8^"+M?(C$N\94+#>1*NVQ(IWV\%G!8 &#LL-O
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M3Y!XU;J1UZ259*Y-69=HP=[JX8Y3F*8?%^(:B;J.(FN[4T8UHR- - - - -
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M0KYI@ 6X<0.>L6*HEHP1R)H$ILK?=&%TSD-K<L\;]>A65><P;-K@#"XH,$Q
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M(Y/YI8B3VS+:P0HM<2T&8I;R;);:)9MG&>:X[=QN6S7VQR3.)8;;I[S97_\
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MM]-YB- 2>59"-Q'%(<^<%]\;CM"T(- - 09;^_QCW<<?%J0Z G- - - - -
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M;&R816*%V(JGW5H-:LFS38A6A,QNY=0<U*\Y;&8O&)Y().&##B(3,*^"V )
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M;J.FB"+9<@FX?JM&*:[I("SM - - 04=_!Z_NW)OC(6T!.Z : : : : : :
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M7<-ACO-SB<4*()ZRO_9<8QOKFZM=YG%5%8XXX+EA7&G49K1@: : : : : :
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ME>R!I8\M(PS\PV$5PA)PPN.RD*;XNGSXZL^$:Y$\K9U#:DG]>\:H;,(?8?$
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M;06&UQL[;)K*9X#D?%2!1IEV1ELBWZ]HL]ZOM3QRHH!K$+Z/?C "8.&(")2
M&HX TI'_  H*F\K:F&S?CY W%:U>18D,2FZK Z'AZC,81-L]D2,@W!1MP<7?
MKQX3FT%E_/6_Y)J;<%>-<WC\)CF<)<1!E7<&PK>(N:[.%(,3%PUO(*REC 1D
M1C[AHY?8"I/3E;GA3A_FZ<CR<9;+MUL.U/\ %T$O7_>[+9J6AX'33B6%8VK+
MCTJGC@0XF<YL.;RFPYK(4XZT<,8X,<R"6%"CIC'HZV>D? <8#;#(X,>%SI5J
M*3+R X_(B&.\KOR SW_*WQTCFM6/V7/X9FW^KY?*/$?KL<1H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H#N\Z$3\JEW_P"'\>^,>>L6[N?TS=B_E]H]'FN1
MU&@&@&@&@&@&@&@(.,?BU'O<,3_H&^A%<N"^"<T*- - - - - - - - - -
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M T T T T T T T!!1?\ %F.^X0C_ &]OJN]\7\D5RX+X)W4*- - - - - -
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M - - - - - 047_%F.^X0C_;V^J[WQ?R17+@O@G=0HT T T T T T T T T
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MJLV:YX$DXC/ :9EKLEDDR,8OF2#EXBW3>+B/Z710; :$(,M_?XQ[N./BU(=
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M>*F&#PRC&10M,FZPP55QP</<5UL<5%,=L]ML\MMQ);O<F>"! F/B18$"+'!
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M'81&S[7C\7QC<;G=PO9=2E7QVLI?GR4*L:Y@A)S ZR,Q:VX0>W>'TU6 MC(
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M& 3@M)&B$A)2$258.X^D%4?;%4U\LV^^Z;9WF@VEGON=V=PV6_B_'(L"B.(
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M'!4U,L,3C=SGF^S8[IXX9"3\V>E"/PZ/&,8(74CY23F^]S#9 ->J;Q\?WP'
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M3AN^30G!.M47<#2@U@L;<2%O@NU< G'GF=2-*='C5DG\K!&=V1<D[F=WU)R
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M>UHI%+$ECF/,QNTMG(,/)I7N7--&[O$)?FGQ=E@0!D5Q'6ME&@2[*NW=OSF
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M-PV/!91)E"9+<T3S.G1P]L3*9%#.^YDGN\<J[D"^^1-YU[[+=?<)++T T T
MT T!!1?\68[[A"/]O;ZKO?%_)%<N"^"=U"C0#0#0#0#0#0#0#0#0#0&N_*[\
M@,]_RM\=(YK5C]ES^&9M_J^7RCQ'Z['$: : : : : : : : : : : : : :
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M9V<&1Z?PZ!,+#DPZ0#:PAUI32,S^?1B)/$ (V3E1T@DD(A*F+JQ9'.S0,5$
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;A/O^KZM/OU<\,,M6;+33:^,C-JTFFD_G,__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g16439g19n26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g19n26.jpg
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M 0$! 0$! 0'_P  1" #P =P# 1$  A$! Q$!_\0 '@ !  $$ P$!
M      @%!@<) P0* @'_Q !9$  !! (! @,#! D/" D"!P # 0($!0 &!Q$2
M"!,4"14A%B(Q-Q<C)%=T=[.VU1@R-C@Y04)S=7:6LK2UMR4S-4A1B)7'.E)A
M<7*$N,+$>($F-$-$4V*&_\0 & $! 0$! 0                (! P3_Q  U
M$0 " 0(#!P,#! (#  ,!     1$A,0)!46%Q@9&QP? 2H=$RX?$#(D*"<M)2
M8L(3,[*B_]H # ,!  (1 Q$ /P#W\8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!IW\<^VW]ARX[5#V,GY/4%)3%@5+"O9"298
MQEFRYY8Z.099I%,T"'>USV1P"$Q6IW]W7 J3FSEC=8R1"?+(& , 8 P!@# &
M , 8 P!@# & , V=^S]V[8)X]\U&?92IM'41Z2SIXDHQ#-JS2S6$::*#YCG*
M"+*:*.0D9BH%A@J83&$/(<7GC5GYY0Z8'=<39+G,Z# & , 8 P!@# & , 8
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M_P!NL\C';CV9>"_#NC:5G(ZC & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&EGQO1SAYZM2E"08Y>NZ
MW(BO>U6M.!D%8KBB5?@]C9,:0!7)U1"!(SZ6KG;!]*X]3CC^I\.A$7*)& ,
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MM!T-Y8GJITT$JMC1K8\*2;KLI2\7GK[S35BJE1TKK/EXMUV!9!8P!@# & ,
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MTG6A4%0U%'5QHSI/<^/%BUP1QV.\MO5C6HW&YX*#4HXN3(>8:, 8 P!@# &
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MTZRHVU'O"/3QHPK&X44\CK"ZF(:QL2*TDN05S6JFO+<C%-9U:Y>23[S#1@#
M(@[EP]X8.,:C4"[GMT+BF)4,T[7=,O[CEJ3H$L<G0M2WC6-9AU%Y/OZLLNRA
M:SO6VLD!&<YK$,E3V(90XC.RO5B<YRV[35M3T1,)9Q;.+*.ACN3JOL_X,.T=
M]E/B:DH[S2?D'/A1N>*>MHY-$W3(7'J&<+Y7,"6T'IE=!HTLR$(?RXPY[E6U
M[I[M_?%G>_IVS$[ZZ\#(PWG*+\/L2E#Q!QU9<DU_-PQ3+7;&0'K26KMALK&G
MBQK.D%3$E4D)TPU?&BSZ5&C]-!1M.8ASVXX7O:9(L33+B,BH4R9=S#1@# &
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MK8TJ-(UV4Y'S8-K72&R\,3&43:D[LUWV%+$W$YS%ZQ%=T="4624, 8 P!@#
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MWO)CVEC;$ %L+J=4]6-KE16(K<KT8I;E3-:YF>O#$0XW+Y)?5M-1;E>:3RV
M\XWI]'L8VKQ#L$&/&K]]?K5U/LC@[7%]ZFBT%1"$YQE;!C.L0"1?7G<L6E;:
M\)7<N\/9U,AYAHP!@# & , 8 P!@# & , 8 P!@# & , XV%$7N\L@R=B]K^
MQ[7]KO\ 8[M5>U?@OP7HN <F 0'YIY@Y,U;Q\^"?A_7[Q(?&?*>F^)&TY"H_
M<%!-6XGZ/IU39:F9+^;42K^D]WSY)BJ&DMZL-EW^39#FA:P3=R>]=_@S-;4_
M:"?&8:65R./<C:'ML;CWTC=XF4-A U:1/D)&A5]U/ Z'!MI1%1RNCTY3I:%
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MCK%/:. 2*ZRJJ"JKY[HQ7#>6.Z9$B!D* CPB>0*D\M[A#<YJJQJI,EP7/@#
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M0%%^!S?R8\[O^7^7^QS/1MQ']5/&/XO=+_-NMSS.[WOJ=U9;ET,A9AHP!@#
M& , 8 P!@&&_$#SEIOALX@W/FWD"/>RM/T6/52KJ/K4*)8WA!W%]5:Y%2!"G
M6%7%.YL^XBO,A9\=&1FF(U7O8T3]2>)I*[,;A20!C>V2\)\N@+L8J+F=*\36
MN<U^H:RDA4<U7)T&F\N8J]$7KU(F5Z'JO?X)]:T?M\D^_#USMI?B7X?T_FWC
MV/?1-/W9+YU/'V:#$K;P::[LUUJ<_P!="@V%K%#W6=%-?&\J?(\R(X!7^41[
MPCEJ'!2<J3,^8:, LS;-_P!6TQK&W5BU)YQJ6'30ANG7,UG<K$(&O!W%'%4J
M(%]C+]-5QRN8V5- CD7-2;L8\25^69'K8O$%>F*V-30Z750R%<V,6^.RVO93
M%^'VFNBRHE9!F#_>:R7LL=SG)U8O16NM8%F_/-QS>-Y(LF1.Y+V5%),D<L63
M"?!CXM/M>OP#"7Z&-%KE30U,L"I\/,*(Z$;U[RO^<JU^S_KS3ZF?O_[>Y:L^
MJ=K4EAKJ@E:[(EPYTIDZUKT@OE1*\D+U[WS"?/>T#YL)YDD$1SE(TG1RL>K=
ME.T,R&KRB2G"&F['3^\-ELRS:6MO(Z>CU$K5$XY'$"1NS740S5=66YP"2-&@
M@;&FMKR(NR*><R#6Z]SQM-TRS\\[],":KK9=_@UZ^W,_:1Q_QV<:_D]AS,'U
M+CT9N/Z7PZH\Q.^?4B7_ ,+?ZT7/1A_]8>YQ*GIOU7V?X,#^H[&7]?\ V#'O
MAZ_TM8?RC8_VDN8KK>NH-VGL1/VV7B)_$]7?GS69SQVX]F=5=?X+J>G_ #D6
M8)OZB3RUN+Z24IP\9:/,&EPC'O"FZ[F-$*ZI$0:M<2BU83QLLY#">6>^D2JM
MC/7TA9-?2_:I_D[;%\OI6SK+7J>Q>[TW=R].2=*E;IQUL/']';,U,>QU0]9-
M90X;'OK-;G%CP;\%3&8X(8\\NMNL8%,;_,5TXT26X)A1E 3$X<W-:E18A;L/
MAXY_HR4NJ:'R%>'U2CTN^HZ*WA7<K4THX8:KF0>O4*4=-ME+5'G(?<./*H$T
M.N,#&@Z-53(=YK4BMC-6D\-6XF=)TGN[[(9#PO+*U8UW5JLJZE?KO#AS/L&I
M2CW'+NXZ3L\\QQPJJ%N&X3PT5(O(G*^QBK2R6[G="=,+0[;Q]&28"?;6-=]C
MZ'0 V"33R7F:E39-?9;-^RLP5#B[7Q+V[L]ATIO 'B'V.[Y"AKRQL6JU4B[D
MS==V4VR;')L+1LBXY)L*Z3$K*G=35M0&B@;'IE4D=M-0AEQ-4B@;5)-CP]@C
MIPTA)TJN6JV/-W)].*M6M*WOMH7$GA9Y"@ FQ==YCL=?CR"S1Q6P9.Y"?"63
ML?*MW"V)"Q=NAGF7M([D"JEQ:JQ-,U:RL=?[;FME@)!?7O4LU/+9.6<&^EY8
MFE^=NTS[Q9QML6@S]GE76\W.W V$< PXUM8WE@VNLX]YN$^;+A>^;:S9"!,J
M+O7*9(-<R'$"+6 /:'H5C!2W,4M\+\\34FKN>=Z_8S'F%# .(YPQ@FDR3"CQ
MXXB'.<Y&"" (F*0IC%(K6"$)C7/(1[FL8QJN<J(BK@$0;Y9_BEL2:Y3J:IX.
MHK-K[?;/3"2SWJYKWN1D+5'3 %2'50B]R'MT$KBN[AHCVN=&6U^RO\M-+7.?
MUT_BL_/.A)+C_2ZWCO3:#3*E[S0J*"D9))&,&69(*4DJ;-*-BJQA)DT\B2]C
M5<C%*K$<Y&HJRW+;+2A01>^1%O\ JRO>GROF>;]CGY;^3Z ?IO='O_Y'_)#R
M?5]OH_1?=WK_ /.>]?N[TGFY4KT6SCC$R1'[[[;<(Y9DTL@Z# & , 8 P!@#
M & , 8 P!@# & , 8 P!@&IGVN7U4\)?CPA?F1N.7@OP[HY_J9<>QKMYW^H"
MB_ YOY,>=W_+_+_8YGHVXC^JGC'\7NE_FW6YYG=[WU.ZLMRZ&0LPT8 P!@#
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M_$78_GLS*_A_;L0_K6[Y)&9)9T["O@6T&566D.+85TX!(TR#- .3%E1RM5I
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MKC"-0D"#U197P)U550X[^C;BZ$?76V%>_GX)8@ "* ,:,$4:-'$,$>. ; @
M 3$&((1#1HQ"$QK6#&QK6,8U&M1$1$R"SEP!@# & 1S_ -;?_=S_ .9F5_#^
MW8G^?]>Y(S)*& , 8 P!@# & , 8 P!@# & , 8 P!@# -#_ +?;]KUP'_\
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M.Y*UK6L:UC&M8QC4:UK41K6M:G1K6M3HC6M1$1$1$1$3HF26?6 , 8 P!@#
M(Y_ZV_\ NY_\S,K^']NQ/\_Z]R1F24, 8 P!@# & , 8 P",-)S1K>Y;6:GI
M*[=V5DF\VNI@<G'UB:+CFVD:3-F!VRIB[.(I'1X]>*LMJL-I;0:S7K"PK9(Z
M2VG3!1_,KTM7TF)JIL^E.9,S2UU+5'%_:3H[;SSQ1J=8+8F[7!W'5Y>L<@;-
M!GZ%,K=JJACXNK!7.YL'-KK'T3+1(,ZN'#BC.KW2AE:1T-2/*8D]T1L=:"4M
MM[55%)D>]V?3]490CV_D73=6L;UD1XF;/L]70S=@&9P([Q1!6<N,::TTZ3$
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MUPFC<<OD*[VR7G&F9M]N3_-%KY0P]N7%2W-U5;EI5J72^1YW;,UJ]A-7T-M
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M(09W:J,:\A&1_,ZL(]LOJYUI7/R8YTK_ .-.EENY6J<1'$?&LXG8-#;'+=+
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MJ1K7( ;252)T="$9?^M)4DLB)_U4))>4B,3Z48CD8CE<Y$[G.50*K@# & ,
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MJ*6%,$J(J/9U$5J>3)$>.YXG:FU8QI.Y@R%NVZ\&3(NO<LR)6U<=G..'KW+
M0$+-J.]R#BUF_11(4K7IU8(5XSS/4.[7F=)(21[OJ%BM1Z?'GWF7AO5:\KU)
M01)<6?%CSH,F/-A2PCD19<4PY$:3',Q""/'.)SQ&"5CD>,@W.8]JHYJJBHN0
M6=C & , CG_K;_[N?_,S*_A_;L3_ #_KW)&9)0P!@# & , 8 P!@# & , 8
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MW & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!K\\>_(%_K^MZ?I5/,/
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MP;!HE7N4238HI*#5W1.Y6(7M5>B=>G7IGG=&UH>A52>I4L 8 P!@# & , 8
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MO8X@GC([4Y)+.S0>CK2OV&ZE_-FA_NJ+G!W>]]3NK+<NA<V8:, 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8!K!]HA_I+BG\!W#^T:YG3]//AW.6._#NS6[
MG0@G9Y_'>Q<?Z92[CL^KT5"!_%<$C==V'5;8=G';(A0]EDCUM]2'>^/MD@0C
MSY6VW$PDBGM9 I!1)+;,AHV:S13?7A68:T67,JFQ6VZ;)6W5V*+%H>*8\"SH
MRSM#UFRVB#I$;8*>+O@=BUVK\KEJ$)QJW:FS[F0A)6HB2RO60K&:^JC=\N0V
MN$0D6*E[:/2K7IX9BE;*FM)E6=<NY\3M5X K;:*5X=7F@G+Q?&E53=[(R%4E
MN]KW2FWB0Q]1O6Q%;[JHZZAM2H7:+6-6%E1+"07W;-]";)Q=<KVC);<OD0J5
MTFJVS9O19YG$#C_@LM/K@*VXUF39R[>''/<[)ND"MK$,NP7D:ZB;&.-N]?;1
MJ6OUV+$GULVLU6L2;,2O4>S6++GT<79<O38F]SM'O'*J%"[Q[UE+@#:!PO/V
M&9Y)--H:6MW-0GC/Y7IK!9&EOT^6Z!8!F!VJ>*7+L-JC,))@5$VQG4OJH\&>
M3TC72B):2NWNA3.=)7LFD'$Z*5G+CWXW@XH.O^'U[ZVNDQ=;3S9VB5$RX=OM
MB,C0;)Q:78=FO7#]^)"$;6]SC"IV]0I60I<L]9;1I$ET4,97_P#66CHN*Z4%
M.GNJ\G]Y*_I^N<-Z\+1[5;71GWA*VY@V[B[G"2!:1MBX1W [W6K9NTSS5IP;
M?Z.D]2_7M.+66DD< <&>1]=92L;=;^^35J9J7F$ELYZINLZ.%E4C+RI5ZO4[
M)#C:M[L$,NMZ_+O*^DN_E)25&S28#"7574WB3;1+&'&.K7(1+6T:$Y3Q$L)"
M1^Y*4Q75\48_/M5ENZ1^S34/YT4'][1,TPE[X_\ ZXM9_%I3_G3N.1@MQ[(O
M'?AW9!K+(+FU/4+S=;,M10!ADEQZZPMY+[&UJZ6#$K*J.Z7839=E<S(-?%CQ
M(S'&*0\D;6C:YWT(O18%^>NYAXM9+U&#:65;#L:[Y1>5K]C6W]:6LM8CH;[^
MFN:4UK#CBG0V.AR;6FGA>40?2R3]0(-F4=;Y?9BWV?='0UG:.4$O*EU+<3(=
MA9P:/3H$JR=6PJDM?6LA.H:^3*NQCI!AK61H$J#+FO:Z$H03F21/:TV(7GGY
M!27;KR((0Y*W5^,;J^)0BF_;6/="!L7RWA0Q3D&A%(W8W>_P%8;U2RE0[2J/
MHF;3SE]A7SG]RY$Y=YBC2[%/E!;BD6"5U991'5%>T17 DV%C7Q"USZSTPY!)
MMC8ST:V,P\R7)D3"J<ZJ1,A:6$G43DGEP,"J EWL X%<VN=5N] -@V-I:^='
MK'-D>B1TE*VJE3@1'&(;TU=U$-6Q8XVB0M!+U.A5[YR;5^0:JN+V,E?!HV">
M"*CF K=<#,-2-?UBN8Z%"C6<US4-W /%F%23YP"=,VCV@K N5N9(Y9OD;!?Q
MR0P0G2V!KHX/=@:^+)C59T$.O8VJ6MAS#AJY(6Q25X"(V$0#6#[,A=OG[BO3
M[?8L#8]7OM4G>[[^O+!E.!!E-57C. HK*MA6\5PI<=Y8QGN@6,,Q1C,XD=QD
M%(:,S7L;H+?P"YM*_9EJ7\YJ'^]8N >CK/.>@8 P#6_[0_\ T5Q7_*&W?V;7
MLZ?IY\.YS_4RX]C65 @S+2=#K*Z,:;86,J/!@PXPW%D2YDLS 1HP!,17$,<Q
M&"$-J*Y[W-:B=5SH<S,-U4<O: NGV)K$:?)Z5/UO6":UL.N;*.AM?/DV-IKY
MP:Y.LQPK8IK24>;!L1>HF)(*UWJ!C>T>)I_C7?<UIJ_5,I+>3>7!A@!;L&Q-
M%K$JOEQON5O=7R];A&JX)9A5B>84E96V3ZQWO%YD;7'! D(Z(R.%B%H9/GMT
M*I/WOF_6;:9ZZWV*KM%H=>+*9Z6,U(=&L1]EK$H0@Q71JKT,6[*M3+C,BS*A
M)IH<<L1_FQVH6FOP_OJ:Y\Y]RC&Y*Y5+%K8IKR[6.Q&0Z_N@A:20]=;DZJQG
MJ$A(>PE/U:W+3^:8LB42MD1A*1S PU$A:>3/42]6<E1R/RW4]0U%WL$=83*6
M!V"@L,^!\FXJU%.$2$A%=!D084Q:M'B\F2:+*6%)>81U$]"T,*=7[OR2(D E
M9:WGF0R:K*KW1HOF*,FC19U9JA@]L9_?[CC&L(L1>CF]%.TWFO&JM4V?GY%?
M-GP52'R;R\!E7 @WVP#6JAP)56./!'ZL,*MJ9U+636&9"]684*ELYM;"F%(7
MR*\Z1@E: 06C0M!+U*'O#-ZFFI]BW194I;NAJY=/.=Z58:4:^JB5<:..O1L*
ML&Q($KRJQHHI1HQYW1D\[S";2L<=XK2>&XL/ /1UI7[#=2_FS0_W5%S@[O>^
MIW5EN70N;,-& , 8 P!@# & , 8 P!@# & , 8 P!@# & , U@^T0_TEQ3^
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MJ='-<B*B_!4SJ<CCP!@# & , 8 P!@$AO#GP]M7)?(>LR857-%J])=UUO?[
M6.4=;'AUDL4PD(,M[4$>RG^2D2+& I3,>;U11MB@.1F8G"Z&X5+ZDN_'3Q!M
M.Q3M>Y,UNLF7<6JH_DYL,.O 25,KHL6PG6<"S2(%KS%AN?9SPSC#8J0_*C$,
MGDD>048&K%XT[FK]45JJUR*US55'-5%145%Z*BHOQ147X*B_%%SH<S\P!@#
M& , 8 P!@# & 2"\._#^U\F<@ZT:!5S1:Q375=:[!L)(Y1UL6%6RQ3"Q!2WM
M0)K*:@?20XH7%,A"^I*-L0$@HYQ.%MR*PJ7LS-[V<3L, 8!#;QH\3['R1H=+
M:ZI"/;6^EV,V:2FBL<6;/J;*,$4]U>!B*^5-B%APC,AC:II$?U2 0DAH0&O
MTG7,C&I4Z3Y[&FZ1'D1#EC2P&BR0/49H\@3PG"1J]',*(C6D&]J_!6O:CD7X
M*F=3D<. , 8 P!@# & , R)QKQ=N'*NQ0=>U6JE2O421#GVOIRK54L1SVH>?
M9S$:@0!CB5Q$$I$D2GHV/%&:040W8VE<U)NQZ#JR *JK:^K KG K8,2 %S_B
@]PH<<<<:O5/AW*P:*[I^_P!<X'=4H=[ & , 8 P#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g16439g24u20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g24u20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( -T!_0,!$0 "$0$#$0'_Q  >  $
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M .LKE_ I3@0/N*'W:>>/]\,P_5-)ZJ.E+]M\O%1>R)[F0F) NX=05455 !^
MJF4#Y^R'3SULK3*GPZ>-YQ;(Q\:UK'YKL^1[&UCMK7<IW:#P"CN4'+=/<0VZ
M%,=(J)Q^8G ?\0;[ZRDVA;?GS.,AZL2SY-1THO?N7EKD0R1_"EXHR1@$ ,JT
M5 ?AS @Y%,  .X@#HY]OLD-MUWTZ.>37O3N:L6JZ=J7K]:F=QLS&2R8*,'2:
MP[;F2'F37('F)T% (J ;].;EY!_=,(:DJ>NA=-#1H!H!H!H!H!H!H!H!H!H!
MH!H!H!H"%<F\0V(L1E42N5O8HRY"<Q:Y%[R]A4$2@=,IXQEXBC$JQ1W1<2AV
M#13KLXU2PMV5-<B7B2^C1"]?21.^99#'..T4$@$00E;J]4775*/8PU^$6;E0
M, >T GL*I1W^QL4>;HO\6KRR_54]4O<EXWDNIJ_8N-OB-L J$3NA*\W4WV0@
M(2#9 GS=?V;E=@\DR[!T#FD##L #ON(CJ_\ 7ANE-''Y3:Y7YQ6?5B>?0C!?
MB)SVX6YU<OY&Z_:\"VS#,@_Y4F;M!$NWERIE^>XZWT*/Z]MEE&LSIE:N2]7U
M9YH\17$"P-XC+,>0C"/42OK))212B'4 *627=D'?S]@-^W;6>A1;#1[3&<JN
M>TZK(2]7U9)M6XYN)2OF(1U;HFTI)B E:V:O12GB &WL&>1*$._/S>8G?<_N
M. ]\?^/!S?%1?;*F5=#?5BU[(VFH?TEC111%GE#'*S PCRKR],D"N4P$=@YP
M@9P[90B11W$XDL#I?E^PW4$/:E_XO^KGR4];;<RE_DU7G#\F_P!C;-F+\MM
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M;J/0- ?@F*7;F, <P\I=Q .8P[B!0W[B( ([!UZ#H#]W#?;?KWV\]O?MH#\
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M^?@95 '$?*1C@CEJX3$1*8 .4=TUDC@9)PW5*FX;+$.@X2363.0O$ZE^T T
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M$R3!B0V_*4.AW;PY? 9-]U51,84DE:PX7B<+]&-I(X'Y?S/?,XV52QW%_P"
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M7<A.40]CJTDOBM](SWRS:=3E=Y<X\\H9&V;%  $";!T$ '<YAWZB*@C]I00
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M:FI<TX3VKSY0E8UO$E#6M\_%*E/,L;V.(<I@ -A$!VZ=^X;#\>FVVVPAU'S
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M*0O3L'7;H =@DIS1*[S^=>^>;@S!LV*4H  ; '<0#;?X![@#\OGH:E'R]2O
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M59"MRS.50:O" !E&3X&JJBC!\D4Q3*LGI$':0&**B)0,&YIJZ-E,S42@/EK
M>LZ8& 0#\!ZAH"S/&X&*([=N@ATW^(#[^GOW[>[6UHNGXT(Q0GMB33TG)D7V
M%@!B* (=-A -NX#L(@(=^O<!_P"FNN%RIR^<^]==\CFZ<5>>W;A2"AQ99AK=
MZ:-'(\C.S&+#N#= (+WKZN5-OMS*>D\B/,(CRIOE# 7<3B+&I7"OV;@</C0W
M4UQ.PT T T T T!:YJ13B8M[(*"4 ;(&,3F^R*IMDT2C_A%4Q -[B[CY:)31
M&-PI-?87QWJIG*@F$7*RBIQ-U,<.83"<X[=144.<5/[PAS#N.VKQ0DDN=5W^
M+4.2_EB[^5^ZQD3/$- *FF40V#8!-\?,0Z=.O3_W??J"X]6*ME,<:><NN6$#
M8OS_ %_S^_0L\] :[SW%MPRUBT.J98,Z8TBK''OBQ<FQ=6F-*E#R9E/"".FY
M$JIHN%?E5_9G9RKUFY3.(%43*80 =]+T9DK7SQFP39RW>-T';-=%TT=(I.&K
MILJ1=NY;KD*HBN@LD8R:R*R9BJ)*IF,10ABG(82B ZPT]V@(<S+EO^RN,K2$
M35I&^WR_V9&FX\HD4^9Q;FQV \9)3CL[Z8?@=G UZ"@8>5G+%/.47*<;&L3^
M"T>OEV;)SJ4[:LQN-WDB%9S/^;,/EB;!Q"XEH$/CJ8G(2 <V_$^4I&Z/Z;(6
M22;Q$,E8JK;*)09*;:JR+QLW=/*4K.R"!14<)P#ALFHJGJ2=G71KYE]S):JU
MT?Q],W-U)1%N9X*\V;'4Y7\>6UK0Y^77A6+RYKKJ-G5:J:TY'!>)6"<$:/2-
M[0WIP3@5=RY23:-9\T>Z=.FB*)W">J$ZU,<M4HSG!9J/P_S7I]9X-ZOD2^9T
MCCF9M\W8[R==VE;I%C2 H#,Y-S=/S$W5;:1%8#KSE)2:9$E)LI7,<XJZ/C N
MWM3_ ,H2BS2E[)1]11DTMAJYNFZ;MY]=5*.JE7;3[.LUUG:Y)G,VEK!1#:RS
M$<S]71\M/H1[=*9DF,>)CBQ9OI$KETV9B<_HR"I$.8W)N/-[6+6]RM=I<Q1V
M[E_,!V^7;H/X^770QJ4T1K8F0&*8P%\A';K\A ?N_736KSBK?1,RJJSC%PUS
MM1TT(2>/G%=EF<RW*(JQ3HKDNWLB=$3<JZ)C=.5)9(5$C@.WLK#U*4Q]=?[+
MCYEO['.SX>^GZZFWK)XA(,VC]J?Q&SUL@[;J!^^BX2*LD;_U$.4=<3NJU*K0
M#0#0#0#0$>Y7OS'%V.+C?I#PQ1K,&[?H(JFY2.Y(Q0;1+$1YBB'I\HNS9@(#
MS *^X;B&VM2EI&-PFSYC)*;E;%*2<[+.57<E.R#V7DG*H[JNG3UTHZ7<*B'[
MZSA998X;  B<![" AZJ1*I$)0K4BM%V?(X%2T*'* >0C[^X[^[X;[_?\];56
MO3#,:4ONZ<N!BMKOQJ7]/W!T#;H'N[ &_P =M8U_%4SA/55]V:5Z6_Y!O^N^
MH!5)^8_K]==7B_XI:4YV]@590Z 'R_$?^>I=_;@K=@09DZVOB2$O M)65@:_
M5*TSM%VEZ^1(;,_&:>O(VLU"M++E,G'R$VYCWAG$B0OI*) 9-V:S15V=VA@(
M4M"N4L9A!3=5JSF#?3CQ=LW:RN5++D2#D3MXB2EU(FXQ4XB06T_)-HY<D%(5
M6731-,^''/) &;CQ% ,N?93S)$IQLGR4.3H\H:H>#?GM>G81(!N38B[#T2N$
MMC]S,,&IW<8A)23*1248'=J@$:]*Q>J( 3A6+G,+6!Q2;K$LH>U)1IYJ.<1#
MQ5] 66%1<)-'3Z*5<HMWK-U'N7#9&2B7Z0KM_26[ALY?-E163 D8X;AOYA_#
M0%$J7O\ ^[^._P#/58:-;SA\TN@4A]A#8?CM^ORU+HVM 6ET3KN >\-A#S#J
M'Q]X!\/?J\-97/E9SM[ZJ$3B4I]N.JSGF61<.@AW#W?=]_7;?;XZIU2FE_I\
MK/A)2JD]2X46[2V-;O5[S#")9*JS+.3;AS"0'"2*P>D1ZY@_^D?M3NF#H [M
MW*I.QMPC$EBIRRK5VWS4U?&Y.')]0-9L,9;:[!6F&6](B;%#QTW&K=-U&,HT
M1>MC& !'E/X*Q 4(([D.!B&ZE$->5TH>A.5)J]ER9&4OZ<<41%I7VZ+8Q0'<
MAWBZ!7JIMO[Q".DDA'WD,&WL[ZZX%_'C^OLY8W6-#R@T!Y2=AYB\W3IN!NGP
MZ% -@WV  'H&MQ.$VK_7U,\"?;M7]=B16B8 4NP=^H?>/_,/EMKB_)+PUQ/_
M ,:>^R]N&1=2%\OQ']?EH="$LZ7^T5*-IU1QTE&J9-RS;4Z-2G$P@H\AZ]R0
M\K9+/=9ABDLW6D(^H56#EI1.-(NCZUEPB(E19!)^=9.DE5NRO\(EMT2N[?+-
M!59Z:=0EER+ VCC#N5%J3F34L.?H',5/9@8(11QZ[N=:X=3^#6IG'4<NU<NV
MZ(5--U,0;5=U!Q4VR!L^>7%8:PIO+T]IM/*Y-;IXFE%?4O\ X_#-\>&_)4WD
MFA2!K2\BY2VT>X6#'UEG8-L+*$L[J",T>0]NBF1CJ"Q;6VJ2U>LAV!3"E'NI
M1PR;B9LW1.:,2A]R\+E>+SRA/VI-&@,>MT\6K52SV<Z NB5RO34\9L4W*9R6
M(C7,@9 IMAY16!N*8&V'83;[#HJM+4.B;T.4]5GI:"FL5U8;K-42U9KK&*LB
M9PS95(*HS&1;7?\ /[BW!0:='2][8S$-5L;U@](EH1 S.(F%FA%*;7X&+9+2
M,N^5ZZTF'"64*FE]$]<HKSM#F)B71NM=536BYY9OCB7L=8XQV=9?SS*USI9V
MXXINM]CX:)KSO)5<1Q) YCJ;J^1%=;M*ZXR!C*74<UI>P1K".\>%MC=!1BR,
M[,V#&IP3:SCMM=9:1%G).,47RGO[_,S2.H6N9T&@*-P3N.WZ]_\ $/PVT)Q_
MU?GGF1@4XWW(;[^WEUZC^(?H._5.O&&N?Q.R?<YWKM&=UVF/)(&LJ@M!373,
M*2[5T1XBH3H9-5!1-1-4H]P,4R9]P#H/*F'V=PU9)T"KTLE/04/-(B IRL:R
M?  ?N&<MTU3IB'D9(YC)F*/4IBB ]0UYW1M:'=52>Q>-#1H!H!H!H"'\N2AD
MF,5#I"('D'"KI?8=MF[/PDP*;X*JNB[!Y@D<1VY=7@59T(QND%FKJ(&\,2AR
M@'(0 V\BEW_/8/(.@[:S%?F]/W28KIR68*)M^:DQ1Z?*3\"A]_7^&VI*PVG-
MUZU+OH48Y<&R3VI6EFO/.ZL@[KDVV6L[!9%N^KB2\8Z24GF3ARFJW0=Q!##(
M-UETE$4EFY#JIG(4Q1(,T*Q??T[GB^)Q3P6XFA)O%$3%!55,SY=8_5_%+\&R
M1&<K*,J:F@E?,M3,HJF[=2KE>(JM?FI195RZMRA7"AC4[SB=;PK]<N]"$YIA
M4JS;^KN>53;; F(6F"L6UW&;.>>V-.$4EWBLFZ9M(IL+R>F7\Z^:P4!' $;6
M:RQ>2*[2N5F.YF<%#HM(Y)5P*!G"N-RY*2A03%K#2 >(Z2S;"T)O*\/]#K-\
MR&WG6B)$;&M'%6KT \9OV\W8ZZPEIVI1T[8&B1D6S2">7&JM9!)XX!>6\-(S
M-WJC.WOM0QS%%+]MS4/ ]APA;<YQ=:S!)YHN'%G$Q[FRPT+Q!5$(IO4&R#85
MWLGC:ITL9?#=,131)_JTNQDWUI=I@"8663$YA/3F*1Z=OF:LE1,.9WZTR7D'
M3K4%F Y0QG3\QT&S8SO\>XE:?;F)(^;8-9*1B%W#=)TW?(^%(13EF^0,D[:M
MUMDUP36!,4'*:[559!0G%4&IHSFQAF5RG!<2YN'[%V5K-4,78L><LUCOB.BJ
MF[MEZJ<8Y11>/,$Q\!1JQ87%'!$XHLKM,WR63167:NC5QRBFLBYZ.JEJ7JLN
M/FQS5'"<+1Y\/-SK+KF=#TJAN&WO 0_7XZ PR;1YTS>_80#Y&+UZ^77^&A'_
M ":U4_&9 5I2*!'!3E 2G3$H^R ]QZ@(>>Y0,(!_>*7R#IUP9TS\KT\M#6^2
M[\M9<]:WES"TP64I2#05/$6@WCJ)4YA]L$R"5RVWWZB4J+DJ)#= $$1#N4=1
MC48N-3I@_KP_?R2UJ2AH!H!H!H#F/])Q?5(C'%(QZT7%->YV-Q,R1"#[2D/5
M$FX%;JAUV3<2\S'.D]P#G/&'Y1$$U UT_P :JW:*3I+O=>,YXW9:^<CCBF/-
MS&*'*!C<@!VV(4=P(/F._LB.W;8 V  UWI72L4IG5<IO6E'IS+^T* &3 >O(
M4W,7WG 3" ?Y=]@_'16NYO/&^\M3QA1D99?'#?[+N0>4=Q'?W_?Y?=Y;ZK^R
M:M:)]]%HXL:7!$V^WX?=MOOKD"O2#M\1W_#_ *:IW6V%>U^K!6D#N/Z_7]=2
M#7;+,*E'2LU,RB[IC3;U68JLV2?:)>DFI-AK,H\E:9;7B @;_N8CJ2<-I-P;
ME;,UVT:J\,DT6<N$0->L@XYR9ZFBG;6SPM4K42[DIIO(.,GI,,;>L)=D\!"6
MJ(IQC6RPSU=1XZ<14.]D)>&:+/ET&3E)F/.<"/JVQQQ$._K;-N[8K5H8S",C
M&1[HSB+75RM6I&P*5U9VN"MVBCF;F4;2E)M+:31;[)!7$2> 00.AV/JMC^/C
MVUGI48GM8HYLY+8'HRCV>DH]P4CE KV4L"CB>,D81(J+5VN4"* !C(E.4-@)
M%'KTT!2JA^0[?=_SZ:U9]5QD%N4[??\ UUN*\ZPP6QP(B4?+N;_V]?U[];@5
MWP76ACLXX]"SK (_?WZ;^_?I\-]_X:V5+5[YQDJ/.G&,WJ,-E/'J6%Z)0*J!
MP 0,4"@(^X!'F =N_?F 0VZ$ NX /3(AQKTKE6&K6<\'9Z=W?H]KX:W\/S*$
M<+F5>T"?E*P/B&YE?5JW@SD681W'=)).56CT Z<B<>"8 !2%W\^-5G6OP=<#
MI&GGV6Z2=&?6FR/3#S>D6*551-YBDLY4.4NXB/LH(@FB7L(%, >8:Z*RX(YM
MRY),A"[) (C^Z4-_<4=Q#;[OZ=?*,;R\<<]]/8W#=<=*^>QG[4  "^?L!U^8
M;CKF7@K+U?GN7(G8?GH6:L\2:J=1GL$9DD WJ^-<DNXJ]+B(E3AZAE2K3&.U
M;.NH4!.DTKUEF:P\E%P "M80TJ\5.FBV.<+PUE9N(6L9<R<5T^*F8B5?S.#1
M5/$V7\1Q-NQ&T8Y;:P=DIL-C*:D<9XCA,H1^4Z+68^0JM4FZK<'%OK[7#E]>
M4!TUJ5R3OL/+P;:1C4K+!KJ%6!8U3A<.E*U;36O?ZW)AJE='"F5KM1_9T+X9
M<93>,\>R"=HCV<)9[M<)V^35;CWY95C4BRB<?$UZHH2I !.54J].@JW!OY-$
M/1G\HQ?.FAC-%4##&)R^"B==RL*A=^&W(V(U)0T!3/6;619NX]\@FZ9/VR[-
MXV6+S).&KI(Z#A!4O[R:R)SIG+YE,(: YB0."4KDFZP9+3L1!Y<P/6RT"/\
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M4F3X"^8%*8[5RH(=DVQA'IN(7@=>)&-4G0UQHDX"B2>RFX@!1 -]PV'8/SW
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M28R@@,W(B_O[N+<,Z@$@JZ4300B&\^XCW<TY4$WHT0@]7(BN=,J"@'"M'/\
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M!(F<0C$X7E^O6QJ4N#ZAB$(F0B:9"IIIE*0A"% I"$* %*0A2@!2E*4  I0
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M&P6$B8'V.&_4.G7[@#MM[QV#<0#;RU6'#/ S$X4+1:JG;R91KY;[<1 BH^(
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M//%CR7"?/<Z8<&;Z?9O@  4 *4 *4H !2@     ;   '0  .@ '0 US.A^Z
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M<O076:,UWSU9JW.F@J[<'(98_([%TT T T T T T T!^" & 2F #%, @8H@
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MS$BXD(U-FJ5N"&>IN=_;3@:DE&WDLV#UAHT T T T T T T T T T T T T
MT T T T T T T T T T T T T T T T T T T T T T T T T T T T T T
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M@]]9!!EDP2],+$^L ![ZO!8&HNP*X%+Q2@8!L?1>M - - - - - - - - -
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ME:Q*PEC;.G<9+QKAQDI)V48-1*!B7+AS7H=E&L(=&.: ;5: : : : : : :
M: : : : : : : : : : : : : : U'><17"YFBCYPK$UF2KU>'QU.7;'69$9
M/)<5C>R4,]5ODSC9_*SSM&QQTM5JY.6FOOV-=F995A%VMD8K8$WK-\X8J@:"
M2W"C]'!CE/++2PY!0R#37U1QM4F."*GEZ;FG>-:3F;$U<X.HBW_5&$R&X?OG
MUTIN5)&.B\KR,6RDHBKY%DDH"24;!%N"A7SJ9H\'Z+/B#RG;FS;)%8DK+Q%D
MB)J3DXG+\K4ZM=KWB3)%*@(WZLHFM$4U-E2,LV&*288V!C@<6*L0*,L9K+05
MGE7<\!.%#X8> _#3VJYJI]DAJS"X1B*I<&4V[X@K$ZQK7V[O%=IQG3LD6]I,
MWIU3Y"4E<1WR7K<-?+4FZ>2]:<1JK:4= R9.B 1_;L6?1VLK"PFCVM.X34MF
MBD3KNG4/.EBLJ9YOBTSQ0[Y526RC5Z\F06P[=LZR-9RRQAYM@XI19"4FI:%9
M'@;).Q<N'[Z+X7LC=_#O$;AK.L)397'E[KTA*7?&-1S#&T5U,P[?(T=CZ\1D
M;+5VPV"CDD%YZ%8O&\O'I>E.VA68.G";<CI0YR<P$X: : : : : : : : :
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8>3JT)5P\]Z=^.]YWPT T T T T T!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g16439g27c23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g27c23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1+.4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #-0    8
M (\   +^          $                          0             "
M_@   (\                      0                         0
M 0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   (\     4F=H=&QO;F<   +^    !G-L:6-E<U9L3',    !3V)J8P
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M;VYG   "_@    -U<FQ415A4     0       &YU;&Q415A4     0
M $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L;%1E
M>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L
M:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T
M06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G
M0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M"71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG          QB
M;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"
M24T$*       #     (_\        #A"24T$$0       0$ .$))3004
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MY?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$
M A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R
M@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9V
MAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]3LL;6V3K.@ Y)\
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M    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M 0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0   1H !0    $
M  !B 1L !0    $   !J 2@  P    $  @   3$  @   !X   !R 3(  @
M !0   "0AVD !     $   "D    T  \1;   "<0 #Q%L   )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C T.C(W(#$U.C(S.C4V   #
MH $  P    '__P  H ( !     $   +^H , !     $   "/          8!
M P #     0 &   !&@ %     0   1X!&P %     0   28!*  #     0 "
M   " 0 $     0   2X" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!,$U- "H    (  <!$@ #     0
M   !&@ %     0   &(!&P %     0   &H!*  #     0 "   !,0 "
M'@   '(!,@ "    %    )"':0 $     0   *0   #0   #P     $   /
M     4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#0Z,C<@
M,34Z,C,Z-38   .@ 0 #     ?__  "@ @ $     0   OZ@ P $     0
M (\         !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !
M)@$H  ,    !  (   (!  0    !   !+@("  0    !              /
M     0   \     !_^%+P&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M!08'  @1$A,4"14A,187(B,R021">!@F,S0X46&!ML;_Q  = 0$  04! 0$
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MHC/=GC9Y]3T3J4^RO\D_^0H?:3\_M7WV-?\ #[N_]<7/W_Y/J%?#_"*)]_\
M$:5;D::TS4/UCX<<U]8Z#(X"]9!5M49HI>CX&EEV=Z/'!Z$ALC0F$V)QT2-(
ME*A^;(]TZ+(L_N?F?ORJ#\?R^HY_U\ZFGCC2]P[^"<1Q_1]E/'=[Q:7QA09V
MN#7N2S#*F_QYV:%%CDF!_=L^-T-W6S_)*:]TCY7ERR2RR2O=(X0,G*N>? T&
M<8V\OS%5^4';!]6C*45+ELU>T]7G,U4UU!GZQ.5PG)74E,'#750*.CFAC<@@
M T Z.9#$Q4C\MC8WPU*]R/!/Z&HPKP5_W"K*MMG"\EIK"ND9)%"TF0NJG1',
M;,!)*YXDL+T7^N)/$,JM7S&1$]/QX15XN\5]#7+AMKV]61YEZ/%1.>N&GIB0
MIM,JSR'UO6Z3'=3@%R.C$:1V9RS-COMC&P$Y;MDQNX0FG00I6P-OH.#M=2D!
MQ*AX*/K)SU0H>=8@G1: V#XIE]=%B^GTJ,5:'$#JW^S5AEG?&Y$_1$5J^$_"
M>$ZMN?K?6MUA?AUTUAJFY6_9V9@3]0W>9#4C]U463,<84D= %(.!R&!RKZ$0
MX;:^T;BQFW.N]##25@^2DH"AYX/,\SSKR]M1_M/56><]N:;[]7'4ZQ#Q/FG>
MEB+*(Y(8HT5\DJ-E56,8BN5R)XZMZ+#E7&0S A1I$R7,6(\:)$9<DRI#KN4I
M9CQVDK=>=7G"&VT*4H] :]6WW%5HGP;J@I"[;,BST%:MB-T1]M].]9Y)25(
M)/N-:O\ WH[#;8_<:?@*VHK7)%9.R8'K(K,:0,J\F8D)E>\%DB(K\U/$\>S
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MQ6<X>XLHN%>+,1Q)FCK:RS^#SHF:JC[V4.>Y*"#:YL<UA-7A5P4A3D>OK<,
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MK=;%QN#TN:TPM1R8S3Z(_3#0 &,;W"X3);JT2)#CC:%J"6^2&Q@X![- 2@J
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B.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*.E*__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g16439g31v36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g31v36.jpg
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M&B(C05>7UQ@D,3)",U$E-$-2<39A8G.A_\0 & $! 0$! 0
M  (! P3_Q  S$0 " 0(#!@4$ @,!  ,      1$"(3%!41)A<8&1\ .AL<'1
M$R(RX5+Q0G*"8B-#XO_:  P# 0 "$0,1 #\ ]_& , 8!J&^)9Z-N]+*5OC%&
M,D*TT8KB;5;C B2["*3X4\B1%# +$^.IN3#A_,3.E%4QG$+GMOPHJW4Q4S(\
MKOX-"<U.\.$M^OF<ZWEU-<"2?2_-9CFMZI/34R"%VJZ;RV_7)I-\*^PW:K%7
M'P9Z.0;BL6!/Y-<D?J3,N#N+IYQ;+"GMQFISG:U::=.#B^.":>[$C"'S/2IR
M2^M]1YC1.AMQ=0=V^KB3;\%*E+1"FRXK:I\-MQ7]IQF+.U(CLNJ^2G6FT.*T
MG:MZUXZELU-:-H[)RDR1,PT8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#6Q[Y\
MBVCNB0'1N:M1Y]XK E8 E79$F/!<L5>1+DD8/Z9,EN,PFR@J;.(J_&F/L-$(
MLY>FY3<F%'C3>WA>(J93P=YT?P152W=&NNM^0O5'7B-#IEBH,RD5ZBB':LQ9
M;-$;$PQ@&59SUIF2'&W)6YEBG:)6,G^*V*87IUO<1AUR-';<FIZOQ**4VG+;
MF%K"7HNV0J6X41Q1Z#J%31//*55**#TY^D5$ +K\!;WT[D/L"X;474J3M.M)
M5*EJ;5)DK3K25R'7%:UK6_EKRMRVWBW)U2A09;F&C & , 8 P!@# *O=,]6\
M^H1&77PR'[S9!R9KA:*$>2@.!9%+_P#C#IDVVS.WK](0B3HQH*.-_MMYG7[O
MW6X3FI^M5+>BTG/@8W&_AWTUR+!52QP;A5ZW;1C<ED;:0 >QCVIJ&FYC4$V.
MC$XC<MMAZ0RB2AB4VE]#,A]I+NEI;>=1K2U8:=_@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# (%]-^C>>>3>)
M7+O74DV!^GTQRM0GAM3%(-V@\>NEM!42G5JNBWI@Z)),66WV8$"@;($A@J,^
M03++$QHQB7.CC4FW"[S?D1'SKW?R"Q47I5Z[0$N_C*+R"S!JMT*![";I/(F
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M-Q"QPWG.!^A^5&=]+?DV'55"<JM@>FV&W7AG]G4LF1/52M7$3/J-L/KA K8
MFBK6*CL'0LV4.<+IGB&WE38$EI R//2_?;,](=$Y^(FC1I:]4X81,O!XX> 0
MLP2%-+2+#N7H P-BR9S3\YXYN!.T':BMNK)[A2]0DO[CO?0!F. , 8 P!@#
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MZR_3':Z[L;H-MS*A<-(V8X1SWEC(?@WF,;R7U/Q]*Z%V@K2NTP+L.Z/?I]M
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M+$:F,;L]L,.PE2(SDMJ(XS'D2Y2FOO*&-MN7N\E!8;!@P!@# & , 8 P!@#
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MS-2I(X'&EM!12MQHBG!P^*I \>C:83'%W>AU1.F , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , K;ZHF?1S&*)5OZ46"Y5B&M>O\ N3^B2G;J
MUI'_ /:_56F'/G_]%US_ !^651^2Y^C)J_%F->2AOTA>@'7D_*3+ML$"PI.O
MDE0@)6A!2+]6O_)[1:T'M+<UOZ=L_CMZ3I32E+VO\N"_8H_'C_1;?(*& , 8
M P!@# & , 8 P!@# & , 8 P!@# & 819N9<WNA&&7N//J1;"P^$^-@%+-4P
M)XC!'27D2),"'-*0)4F-"D2&VWWXK+J&'7FT.N-J6E*M 4']:<\YO1"5'FUR
MJQ*; _:O3BYF+S_<BDM$_P!"?H#L=R9%JLH&Q/E1F9L]$)<K2]M_ER$Z<1IU
M6]]*&VW+Y=]W(KPE)2WHF8IYFX5 N!.1$MQ6W34U.BA6S4I-YMCZ"%O/24-Q
MBL3\PBY%DZAHK5DW)BRAS4#:38]?Z<O:6T0E3:A3>+]LRE)RXMEEZ<B3^\\$
MJ=)J8TH.M-T?GS+A6(P^"1D59P2ZX.G_ +HE(F)C52*36E0RO3VX_P",1CK3
M+7&<=6MA#S:U-3;2;]-!52DFTO744#S:5N-6:MT>[0P#UCFSYFQTNHOFDQFX
M#^P,529+-J"*=3+AB(\[>ML(VTN4ME*G$-I6HZVFTH\PJ$TFY\CMI_E/H##;
MK$6W4JS,R$[2ZW/$&Z>VE&]_S:=9;EWU$U._^NU*W$UK?\OM;_ZX^IN\_P!#
M8W^7[+BT"L/4RFUZKR)VB+P8>B(N2VTIB-K?W''=11\92W%1!4!+FH F'MQ?
MX@R-$C:5O36LYLZ(S# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# (9[ES8KTVICAH*? A&@-BC6,:@JN2R*(/-"S 1^ 0E0XTV7"9<@G);[,M
MB#.4S,CQ=KB/,[<3FIPTS&I4'9\8H4_FW/A58,3() WJ<=,&)8Y+_P"&J:>.
M$"Z84=Z4AJ3-CA8<R(!BD'XT%R?%%L2]CAOWM0(QN7(2A)$IYAHP!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@&AOXL_Q(_0?CGUI\,GSQP"'SLBCU[V231.GL7>MDSY&. G
M](XE2*^]6'AMB!?I$YU-VN&U293))AQ^)!7N/I$1UM\=**54JV_\5*XP_*QO
MDP<Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , \B'KA_P#XM_XH;Q7Q@5O\
M^M>,>7ANA7C3>_OM@[6'#V_N46:_I._I:W-EF^*A]:W\E-2I++BU;^>FTCLK
M>#4_Y.%Y?OH>N_!Q& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!@W3NCT_CO.
M+[UGH)=D!1.:4ZR7RX&I&]?:%UJJ")9PU-VG:D_<4P/A/K;93OZWW-(9;UMQ
M:=;!7LL6>5_^&^HMO]-=V]__ !<>IB7H1OT9T\_S3EC4OYK6+JKAZ)>;N-'/
M.I^J4#"-,\JHH2<QOZ-*I)N XZZ['>2V.WBN%30O\5+X]SU/6S@XC & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MRPE*M+E-SI5:(F@\,E- 29K+;3,N0'DR71STIIIIN0Y&4ZAM"5Z3K2&99@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , H7\0OXBGGGX;G#2'8NY'4OEI[<X?S'E@>7%_?75K7'82XV#KD)
MW:MQ1L1;T9VS6J8U^C5@>^T_,6^0F"110532ZW"YO0\\GPX_!_H3XLGI<=\6
M[XH893/-8[\,CY'\Q%(LINK.5L?,61J)N76R?S7'Y0$><28 P2;&R/8K(Z[=
M;)IVHN18]T'2NI4+8H_Z?[]=,#V'X.)6[O'IRI>?IXB'9J?T&S,2^>]1ZY82
ME+@5>6-HO+>,2^?1ND7BTKL=MK$M^#7V^E5Z<@)4H=IN!B$R64"K9*1 W&=&
MI3Y+FYCTX%;(GQ+^0A(X>'T4*<$V @!Z&=D,5B?2K RPJA .LW=89JMN7.'T
MU<\O2.1'B XRNA(I$@W(@5O5M08D_B-C=E^FN<<LR517N+F<@G;@%DI?4*!9
MJ':^=4RW5VVC*6[-#&>G]$H/-*WM<^IWNTU^; 0:Z16R) @,-38S8%4R?#7.
M>8:AR!FR\<KWX)OCEH18&^*/YU/U05=!8B]R*X9*UJ-#,*G\?9!M +B (6.K
MVDI:W>MHIP)TW"%SHT+F!VPCN]**M-BG.1MS9<)F2-V7WCT]\-YLBP2, 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P#2'\4SXW_GKX>$.1RRG,L>@O89Y$<=3^"5"8Y/U72YC
M3;86?U8B(3+D5Z.^Y)BOC:;!;>O5J_(@LCAHT41W9H Z4>&ZKX4YOXU]#S5O
M#^3<V[*Q\0[^(AZW+Z9Z4+#AUMX7\-:JCH]GM]=KBUNE*6CI_.T3H]5Y;2HW
MUK(5OEER,U^$7?W(*=&)V.R2K+5I@Z8K9\)0LZ\//'IR4&U_P]_%&>5^RVSN
MJ_7$RI^/>?@9//X'G6LIK_6.H6FSC'6[DF]$KE9J%1RU;@NPOQ*3H8&:!UUD
M<F?/C,$+0EIR=#$U>#4HC[M7;TQ^3:$%^._\(X^I"8/M[F#&U_+2?UH-T.MI
MU\__ +U6*EBDM_\ 7^>W-IUK_'Y?+>"/IU_Q9Q+7[$^$#Z6Z'SN^6GW-Y:/2
MZ!4>BTP/43'HVC4L&?'=./<J/G8]G"$[-79MK@_?Y*"AJJ1A4ZIEX4\FW8JZ
M86V,<'!LUK_%Y93PA\^)86K\T^'?UH@F;1R'!^CJG+*O;%4[JPZTUPE,L53/
MT$Z4?J0&XS:R2-6"A6D]131M\1(+F*42<J1";)KS4<<R)^Y:K+T?DTC.*SX:
M\ZUPS,.OU,E9B#G2(G41\BU6NU')$*QCI'/3(C]3F33+DV\,!+IS2N="!.]$
MD6V:%O"'[",EQ9JFUMC=IZY1ZKT<6R.^_P"#+S/^BZKNN70DADI5"U!18KBA
MO]LK%Z!*YUMQ%BT^KD.P>M!?Z&5.[Y1H/K0O5-U!_N,&2^_7COQWEG\&# /F
M\\U':=??=;889;6Z\\\M+;333:=K<==<7M*&VT(UM2UKWI*4ZVI6]:UO> 8I
M4[]3;ULYJH6,98/VV8> G/TY_3WZ>68::?7%>_EKZM;:>;<:D-?<C/IVK[#S
MFVW-(UIJ)42I7!YB4S^7&_TSGT85,NMD%UN*;+L 1;Y21IAN85D1Y,M$5M7R
MW]/T1(4N9(?<^B/$B1GY4IYF.TMQ.)-X!M+$RMEYF2TW(CNM/L/(2XR\RXAU
MIUM>OJ0XVXC:D+0K6];2I*MI5K?SUO>L ^N , 8 P!@# & , 8 P!@# & ,
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MFVT6P8%AP"DV+;#XMF:[, "ILD7^AZ&'@@EU)*6C;)B4ZB/ (5%FYPW6Y/\
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M8B;95'*RE?-$2+.@QF);VVXD66].?CQ7:J\*JE3BEC&7(Q5IXVY_T7XSD6,
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M;2GZ$HIU-KE80E'R^7TI2$&P4Z3\OY?3K7R^7\OE@DD# & , 8 P!@# & ,
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M9N1VQ3>$-1P<VWO?QF<MDV"1@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & =6@
M(%;B$8#8@6W!+N372T) ^(F(3=))V@BX1C):TS-<GH5M$U<E#JI2=[2_M>M[
MU@'G*^ D2(V/J7Q%MV&?-/;Y/W&+QWEGZS*?*?T:<B%&KQ(&<LY_^<X_^S><
M#GQ\!Z!1ZY^FUF&]"B.1Q;:XS*D#I7^-&]2][G%ZO>>DG!S& , 8 P!@# &
L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g16439g34u48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g34u48.jpg
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M*5S@%R /^VB^4)_^K3TXM'T9GJPZE>QSCA>2$H,<M8V<F.(%*FG=ZWVAC#X
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MCKW$[.6RVS]^2E.*NS.:E=9VES^/F]KJ(X<P>G'S=;JD\4JD777;].5%H:+
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M<JVFU'4\[AH&!AYV4=3IB)-W+MPYDXDD,Z;,$#B7_P"TYV4Z4?UQ,5DLJ/\
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M+VX\-JW,>I]M5QY9@?\ ZPT&_,1"7;DYC!W8Q]@7 @;AWB/,8RB0[<RB?,W
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M3!SHI QCCF439I*J>C#A6%+5WWJU2=,ESUCAB<OV-=@.=PJ(F,(%\Q 1\-_
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MJ15-^T'M%51'^T<0#DW'H/*!"E^!Q.  .NC\GSS8Y$G1R)0*F0 V#H ^'78
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M!TZ;,6SEZ]<(-&;-!9T[=N52(-FK9NF95=PX75,5)%!%(AU%55#%(FF4QSF
MH".@-)8SBUR1D)LI9\%<*>2<HXR%18(G(4K<,?XQ;W%HW4,09BC5VYRR$_-P
M3PA#*1,I(-8-"4()#-P!,X*:KTI7Q0](DGU-V3?;H3EA7/E/S<UL2$/'6>HW
M.D/FD7?\:WV&/7KU29"005<QI9F*%9RW7CIAL@NY@YV)>R,),MT%SL7RJC9T
MDAC4?:L:FGQT=R;]8:- :5V?'V8\]Y9O\99+[E+".#<>.(.!IT=C*71I=JRY
M..X1C.6*X2EU;MWDVTI\2M))UB(AX)>/]H/V$J\D'2:S8K752DE1-YS7L3#;
M=6DK13SS>8-J=LF\<\1M*Q5P^9SR/Q,0#^:%CG2C7V8+D^,PW7#(N1-<29L%
M)%U6IY@Y;E:-\;S4G875A%1RD5K$NB,W&MNI:6'2*3RSX_DRSA-O57[Y<#J-
MJ"RSV%@PE8"<C)5=9K%R4/)L))RW='8KMV#QDNW>+H/4C%59K)-U%%$W29BG
M;G*58A@,0!T#.>&+>(&0NU-A<5< N+6,]CW'T8PI#',^57[JJXLA6T*W+'I+
M1,$B0V1LD/=FJQG:S>+KS)W(BHNYG!%910;:BN)WK"O^"$\L*MF_/*3<V6P=
MP_N,93ENR1>[[,97S3D1I$1]QO<DQ:0,6A"P)WBL+4Z;4HPQXZLU>)6D'BZ+
M<5Y"3?.W"SV2DW*AR$1EN=DK(I*+N6[FR AN AK#2V.T^8NX!UVV^>W7;ZPW
M#_AH9B4KVXD=3[4! X@'^,!VZ!X[[?7[W3R^&M5_.7<E.56ZH_KFJ5NR#["R
M/^N[,/>V,H7R#W2F$ ^(B&PA_9,GS>6P]<+E)ZWRVYN4<WSI36U^"Z\38?%]
MA&QTZ-<*GYWC#GB'PC^UV[#E(F8__P!XJT,V64'8 [10^VX  CSQ*&^J.N%R
MNQ(6I*&@&@&@&@&@&@/S7\3N4#Y=SE=K0BX%>"C9!:MUSE'G1]CP1EF#)9$-
MQY4WZR3B84+S"!5WRNW0Y2AZ<*].&)6;WF+RJZT<'!N7)"2!>42 /4Q@*.W0
M=A, #L/H.VWQZ^6JO,Q%J3:76%1I1/*\DYKGIM77."_M?$.7J(!UZ>NX"/\
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M^0^8?GXZD%I<$WZ^8A]X;?P'SU>&(:UI-,^/#\&.JI=57(LZQ1Z]!WZ[?#S
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M.GPV9QH!H"%>(R\*8YP;DZWMU>P?1U5?M8I??849J;[.!A%@Z@(]E+2;-3E
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M!+4GUMQ:E<_LQW_2E9O_ .UF/_,Z1_E;IZ,.G=_9OK>W?['^E*S?_P!K,?\
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MY@K!(2]03D).:5LLS:K) 04T@SUI5?9-6UYOCLAZG%\JN',YKBE7+<Z63[H
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M9CXR4;&$-B<QBJMW($'H'/WQ@JJIMN8"J$ 0$#!J<']>'[*Q_P!GR+'5),1
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M8.;QZ+J6"J?2^*+ODR6_"Z!8LYB@JYK5O.>0;D$P<QTV$I#)MGIP+ORI'DV
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M7:&3ZAS  F#KYD*.X?(?$/E\0TY>: A+C XETN&K#,E;V'=EKG//$ZK0F+H
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M55J#KVFF1),B29"D33(5-,A0 "D(0 *0A0#H!2E    Z  ;:X'<^] - - -
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MR/V2T8=J5JDV>IK]+SF;Z4_V_.1KS8^ R0?3V0UZIEQQ3:E=ZZ6L!5VL1<9
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M!.%9F@*JFIN E !$Q=]@$!(/-ML =/+IX!MX#H#1'C1HU4SKE6LX^OELD:?
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M,55VK,RCI'?4DE*F+6S:\WS1D5C0K87ASA+K6JU+URSMF$:VA[_8+5;I-%5
MC^(@[_7Z5758^!>OFQ&CITXL3#MFSB1:IHM^]+*NE723=JZ>OTTB]$M+NKZ_
M UV_18W7#1*QZ3Q=S>*CW-E57]K<3""SEU7@CX[/9,"K.$IAN11)>--)'_2I
M.411.D> +L5$SDP%UGJM2J=-Z>K:-EN;'M/>,BS?H,ZQ7DZQ4M204F&BT!&3
MC*8!@5DQEVBCE9)K)Q"J#^482D2Y[5;N4O&R+QD]2)[JB:Z2[="L+EZ4LVX;
MM;AD]E)+I6)CSW@SQ)7P^W?;[/Y[;>NM:GCE72Z>K5IVKOI;)VL0-G(S)-L$
MGG<7!'+8QQ,0Q3%,43I"<@E,=LX H%<-SB*2H 41+SD3,7F#)4^1,A$R$*0B
M92D(0A2E(0A0 I2E*4 *4I0  *4 V    VT!]=H'I]_Y_/GI+U!YF7V_(?CZ
M_5]^B3=@6]5QX]=MO/\ /Y]1Z#KHL*2F_3LL]%-[K(%K6<@.X<VP!O\  1_E
M]OS]-:]E,WNZ:NO"-*U!:E%A-T >GJ/G\@\@UCQ).JVZ;IU?M::LEMNB:5)E
MWZ?>M+%L=.@*40YO(=_^0> CX 'CZ^(!K&UE>F\<\_:+&I-7<OS+(PR1?% #
M  [%Y=Q'?J/P ?N^ =-95U\^L^>]32[XUILUD>[0%*@&W>9JSRC"'CTQ PI$
M.]<!VKESR@(D9LFZ:CMZJ(<B+5)=4W1,^V-PM(GBNW#>@/U<8_I41CFDU:BP
M1!+%5:%8P[4QBE*JY[HB4J[YP!?=%U(.>V?.S!T.Y<*G_K:\S<N3T)0H,PT!
MHUQ<8A6D4F^5ZXB4)&(039VM GN&>Q:8\C.3Y@#E!9@!Q:NE5?<%F+1151%O
M'J&'I_C?^KL_/SUU.>-9]?OX-1JM/F!NH0XF(NV,!SEZARE,)4C@=(WOIB8P
MEY@'< $P@(;!S:Z',Y_?2?1UL2H%/RO47\@S8Q:<GC?(J<>JH1-_2[G)UV:C
MD98"B"8PZ%NJL611-3W!DY"*-U%,@@!R]9<4^?&KV;DH[+E^9O+.G!$L+A.P
MOP<R8UJ!_1:$,Y<&5,N<S&MB:!*J!P.O#G-'.3+-#BF*%HNV94QTX>;<N!0C
MQ YC)&1$&;)-L5AHBKR=/C8YS**+H-JK-1(P,A7!!8#F<PJD,/LMNP<F60CV
M!4FC C5%%(I$+0R5RRX.=]^&N]Z#B8SDC,LK(CE:ZDFH^!=UMO+C,KFD@A)
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M'33D65W)%( CON/4 \O7H >7X^?3QTB77^3T67%VUH;#S<)\=K*[\J89)S(
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MOF2K'M=$G;9;X288K5>D6R*&6=MU"GPTY8QU,A) B:I=PH;B 8)UW?<T6+!
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MATB=:]MGK^H;JI?JU\WU19W,P4H&'M!'TZ]=_+8/(//X^GCHERI9)*OFK:?
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M)D2<B)N\,C*BD8546RQ@*4RS5JJ)VZ7-T;6A7JFREY[<RY/9T@ /((;!OU\
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M - - - - - - - - - :/\1?#@ZFG#G(F,VQ4["7G<6*M-RE3)/DZF6D(T@
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M+(SBQ117*PX9X>YTX9,F<:S;1\>V19L62";9HT;)E20;MT2 1)%),@ 4A"$
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MDW#J/43K.G2QMU7;YXL8[EZ\7,==RX4455.)C:X-MN75L[6HC+M - - - -
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MH" AN._3<!, C\/0-##$'=V64*;LQ$QQYMA 1#8H!N8QOVA "AU$0$-MO(=
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MBH@B1W%'>1<RV3,F9+VF\DX$4["Z8QR9"<S9@#QUR"4J**2(*KHYT7GE7U!
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M@H&':D9QD3&-DVC)FV3WV3102*4H<QA,HJ<=U%E3G65.=50YS<;U9UM1%YT
MT T T T T T T!#.4,"8URTW4_2:$(A+&*((V*)!%G-(G @$(=18454'W9E*
M4I"2+=T4B8"1/LP$=4L35NCL2\*>SU\N:!W+@OR=3A4<4EW'W^(3.H=)LEW:
M LS9+]H *V>+>S'9R![IA1DBE<&#G]E@;E)KHL>%WH^VWYXSE7F\#6_FAK'/
M0UCK;H[2QQ<Y6GP&$!;SL&^B51,&X""/>4$6KDFX#RJM'!T% ]Y,"AMO<S^+
M.OFK<5),>]JN4!_52*9P*7F4YR]@*6WFH!G F(00_9.)0*/38=.G&W'):]M
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M]&YB6FGSC!LB([2;!B>=@A+X<Y9:'!^1LF.P&*G)BW4'?]A  Y2VFG9_'O\
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MPD3O.),;.810YA.)X.VVQN0HC_V+1Y,/F#<OH5NT2*'IJO\ J8IF9XHST83
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ML@_W8IO[]S?^76E-7T7V*Z+J_H=^R#_=BF_OW-_Y=:4U?1?8KHNK^AW[(/\
M=BF_OW-_Y=:4U?1?8KHNK^AW[(/]V*;^_<W_ )=:4U?1?8KHNK^AW[(/]V*;
M^_<W_EUI35]%]BNBZOZ'?L@_W8IO[]S?^76E-7T7V*Z+J_H=^R#_ '8IO[]S
M?^76E-7T7V*Z+J_H=^R#_=BF_OW-_P"76E-7T7V*Z+J_H=^R#_=BF_OW-_Y=
M:4U?1?8KHNK^AW[(/]V*;^_<W_EUI35]/R*Z+K^"^P4G[:A(:9[#NWM:*CY/
MNW:=MW?O[1%UV';=FEVO9=KV?:=DGVG+S=F3?E#'2AJJD]2ZZ : : : : :
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MM[K6W;L=*-24- - - - - - - - - - - - - - - - - - - - - - - -
M- - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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.. : : : : : : : __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g16439g41y22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g41y22.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[25N4&AO=&]S:&]P(#,N,  X0DE-! 0
M     /<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #
M&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!
M6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE
M1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H
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M<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F
M"7!R;V]F0TU92P X0DE-!#L      BT    0     0      $G!R:6YT3W5T
M<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B;V]L      !2
M9W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O
M;       3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;
M0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M      !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M    4G-L=%5N=$8C4'AL0'P@           *=F5C=&]R1&%T86)O;VP!
M %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'1 0H
M!         !4;W @56YT1B-2;'1 3+___         !38VP@56YT1B-0<F-
M60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1"
M;W1T;VUL;VYG   "4P    QC<F]P4F5C=$QE9G1L;VYG          UC<F]P
M4F5C=%)I9VAT;&]N9P   TH    +8W)O<%)E8W14;W!L;VYG       X0DE-
M ^T      ! #P     $  @/      0 ".$))300F       .   _ XXY/TQQ
MQS^    X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M    "0           0 X0DE-)Q        H  0         ".$))30/T
M   2 #4    ! "T    &       !.$))30/W       <  #_____________
M________________ ^@  #A"24T$"       C0    $   )    "0    !D
M   (    $@L    800   "I#    ,'D   !"?    $BR    6K0   !@Z@
M '+L    >2(   "+)0   )%;    HUX   "IE    +N6    P<P   #3S@
M -H$    [ <   #R/0   00_   !"G4   $<>     20 0 X0DE-!!X
M  0     .$))300:      +V    "    !     !        ;G5L;     ,
M   (8F%S94YA;65415A4    !0!5 ', 90!R       &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   &.0    !29VAT;&]N9P  ".0    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P  !CD     4F=H=&QO;F<   CD     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P     X0DE-!"@       P    "/_         X0DE-!!$
M  $! #A"24T$%       !   !L,X0DE-! P     #"P    !    H    '
M  '@  #2    #!  &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D@
M  '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.
M#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,
M#/_  !$( '  H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0
M   #  $"! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q
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M_P DEO=^X[_H_P#DDE,TE#>[]QW_ $?_ "26]W[CO^C_ .224S24-[OW'?\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  ( !# %,
M-@    $ .$))300B      %V34T *@    @ #0$   ,    !%-8   $!  ,
M   !#04   $"  ,    !  @   $#  ,    !  4   $&  ,    !  $   $2
M  ,    !  $   $5  ,    !  $   $:  4    !    J@$;  4    !
ML@$H  ,    !  (   $Q  (    >    N@$R  (    4    V(=I  0    !
M    [    1@ 1*H@   G$ !$JB   "<0061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-CHP-CHQ-R P-#HU,3HU-@   Z !  ,    !__\  * "
M  0    !   (Y* #  0    !   &.0         & 0,  P    $ !@   1H
M!0    $   %F 1L !0    $   %N 2@  P    $  @   @$ !     $   %V
M @( !     $              $@    !    2     $X0DE-#Z      !A9M
M;W!T     P    $         !P    $!      $  /__________    9
M  '_____                     0    #_____      3_____     /__
M__\     _____P    #_____          #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M_P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
M    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P   /\
M  #_    _P   /\   #_    _P   /\   #_    _P   /\   #_    _P
M /\   #_    _P   /\   #_    _P   /\   #_    _P   /\   #_
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M<D%M;W5N=&1O=6(               ]E;6)E9$E#0U!R;V9I;&5B;V]L
M  IF:6QE1F]R;6%T96YU;0    I&:6QE1F]R;6%T     $I014<    ,;F]-
M871T94-O;&]R8F]O;      +<')O9W)E<W-I=F5B;V]L      QZ;VYE9%%U
M86QI='E/8FIC     0      "5IO;F5D26YF;P    0    )8VAA;FYE;$E$
M;&]N9_____\    -96UP:&%S:7IE5&5X=&)O;VP     $&5M<&AA<VEZ959E
M8W1O<G-B;V]L      5F;&]O<FQO;F<     .$))30^A      ;U;7-E=
M !     !       $;G5L;     0    62%1-3$)A8VMG<F]U;F13971T:6YG
M<T]B:F,    !       $;G5L;     8    30F%C:V=R;W5N9$-O;&]R0FQU
M96QO;F<   #_    %$)A8VMG<F]U;F1#;VQO<D=R965N;&]N9P   /\    2
M0F%C:V=R;W5N9$-O;&]R4F5D;&]N9P   /\    40F%C:V=R;W5N9$-O;&]R
M4W1A=&5L;VYG     0   !-"86-K9W)O=6YD26UA9V50871H5$585    #<
M+P!5 ', 90!R ', +P!T &T <  O $0 90!S &L = !O '  +P!N &4 =P!S
M &P 90!T '0 90!R "\ 4 !3 "\ : !T &T ;  W "\ :0!M &$ 9P!E ',
M+P!B &L 9P S "X 9P!I &8      !15<V5);6%G94%S0F%C:V=R;W5N9&)O
M;VP     #$A434Q3971T:6YG<T]B:F,    !       $;G5L;    !8    5
M06QW87ES061D06QT071T<FEB=71E8F]O;      -071T<FEB=71E0V%S96QO
M;F<    #    #$-L;W-E06QL5&%G<V)O;VP!    "$5N8V]D:6YG;&]N9P
M       21FEL95-A=FEN9U-E='1I;F=S3V)J8P    $       1N=6QL
M"@    Y#;W!Y0F%C:V=R;W5N9&)O;VP!    &41U<&QI8V%T949I;&5.86UE
M0F5H879I;W)L;VYG     0   !9(=&UL1FEL94YA;65#;VUP;VYE;G1S5FQ,
M<P    9L;VYG     FQO;F<    8;&]N9P   !AL;VYG    &&QO;F<    8
M;&]N9P   !8    226UA9V53=6)F;VQD97).86UE5$585     < :0!M &$
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M3F%M94-O;7!O;F5N='-6;$QS    !FQO;F<     ;&]N9P   !-L;VYG
M'&QO;F<    8;&]N9P   !AL;VYG    &    !%5<V5);6%G95-U8F9O;&1E
M<F)O;VP!    $55S94QO;F=%>'1E;G-I;VYS8F]O;      01V],:79E0V]M
M<&%T:6)L96)O;VP     $$EM86=E36%P3&]C871I;VYL;VYG     @    Q)
M;6%G94UA<%1Y<&5L;VYG          ]);F-L=61E0V]M;65N='-B;V]L
M !));F-L=61E6F5R;TUA<F=I;G-B;V]L 0    9);F1E;G1L;VYG_____P
M  M,:6YE16YD:6YG<VQO;F<    #    "T]U='!U=%A(5$U,8F]O;      2
M475O=&5!;&Q!='1R:6)U=&5S8F]O; $    14W!A8V5R<T5M<'1Y0V5L;'-L
M;VYG     @   !%3<&%C97)S2&]R:7IO;G1A;&QO;F<    "    #U-P86-E
M<G-697)T:6-A;&QO;F<    "    #%-T>6QE<T9O<FUA=&QO;F<
M#51$5VED=&A(96EG:'1L;VYG          =486=#87-E;&]N9P    ,    &
M57-E0U-38F]O;      457-E3&]N9TA434Q%>'1E;G-I;VYB;V]L 0   !9-
M971A9&%T84]U='!U=%-E='1I;F=S3V)J8P    $       1N=6QL    "
M  M!9&1#=7-T;VU)4F)O;VP     !T%D9$58249B;V]L 0    9!9&1835!B
M;V]L     !-!9&1835!3;W5R8V5&:6QE55))8F]O;      +0V]L;W)0;VQI
M8WEL;VYG     0    Y-971A9&%T85!O;&EC>6QO;F<         #U=R:71E
M36EN:6UA;%A-4&)O;VP     %E=R:71E6$U05&]3:61E8V%R1FEL97-B;V]L
M      =697)S:6]N;&]N9P      .$))30^B       (;7,T=P    (X0DE-
M!] C5')A8XX@9&4@;&$@9F]R;64@4F5C=&%N9VQE(#$@8V]P:64   "V  8
M                                "
M          0  0 !                          ( 3W8C '"4# !/=B,
M<)0, $]V(P!PE P  @!/=B, ?A]A $]V(P!^'V$ 3W8C 'X?80 " %32GP!^
M'V$ 5-*? 'X?80!4TI\ ?A]A  ( 5-*? '"4# !4TI\ <)0, %32GP!PE PX
M0DE- _T       @          /_A 7A-30 J    "  - 0   P    $4U@
M 0$  P    $-!0   0(  P    $ "    0,  P    $ !0   08  P    $
M 0   1(  P    $      14  P    $  0   1H !0    $   "J 1L !0
M  $   "R 2@  P    $  @   3$  @   !X   "Z 3(  @   !0   #8AVD
M!     $   #L   !&    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$V.C V.C$W(# T.C4Q.C4V   #H $  P    '_
M_P  H ( !     $   CDH , !     $   8Y          8! P #     0 &
M   !&@ %     0   68!&P %     0   6X!*  #     0 "   " 0 $
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M)#,X05C8,C=1<G5W>)BRMM<E0E=A<;?P)B@T8I&AN,'10T93<X&4L\33_\0
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MKCT .%2Y.2@46Q-UP9&A820#>.=';=("&;9BI)A+CKR71QSG%:3)(;;#;_\
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M3@A _#=:.;DZ/73V'&'.1YT576)?)\%Y+;K54C5]M5-A3&^N9=VFT2#21=Q
MVPV4P& P-".@W1X00;E_D9D,?<E8^4+7 1QG82IP6M0YR"6@QE[UVF629 QU
M926]IT3L$';NE>$9[ ;[X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# C=BM,5666=F[)+/-4IN
M*@XL=9\Y,$)ZNMF-CFM]X[I':2HDMW;,?'L[V5(F!B(<?0%;O4&<Y(*'D.5=
MLL5D8AHR,XICB=%0[KP[NW!3+])MZ;3;"D;TV[JN,H14@GM;02BRK:'D$!=:
M4I2G24ZTE*=:2E*=:TE*=:ZM:UK7HUK6O1K6O1K7HU@?N P(Q=K*)3*=:;:<
MK21*U7Y><?WO>M=I$8 ^7W:>O>NMQU36FFT]?6IQ:4Z].]8'GET9B^>>!./&
M#[SQN98.+[$4NW./UTIJ0O=-;F6F7B9*1JVNHV3C"$(9/+"#4]*Q25D$$M=?
M?"LAZ-UZQ0ELA(VQUN3$F8.7%;,CI(%U+PQ0[G[E(5KTI4A6E-NM+TEUEU"V
M7D(=0M&@S. P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P&!5 /.G#QPAIVN1ZE'B1]LF:.0]/3 M;2NTP#H3,G$A^7UQN
MY!QORE&O#D :)$/$DHXT @D0\1YX.\?R_P :!0XDZU=*[+QI\Q6H$%ZOS$;.
M*,DK:?# PC(J(THC9&B=3\7(K6UV]-0Y.I97\1UWVP_7.7^,D.*[-YJKX0^K
M%J3F1K##/P<$[5$Q:YT6?EFSMA0Q8"9@!3XY[K+K6GD[>2WK:>T$5<Z1W$;$
M+3K _8#TP][!FY:OR M9LTN%N&KDU$U^9G9<Z#B),&O0 4I/0S#L[/$QT3IN
M2&(V9ICO'&PF;'*_%I3RAQN2:"0^D:3-4RQ<:Z\ZD.$'47,EJ;;D5+2-$"H4
M3)O[UIH =*GBE--IVK0<[7)O&S\?N69Y"H[T5I.E[DFK9 N1^D*& -2O9B#]
MC=E0<K%EZ5WG5L:2 ?UONC!UN!Q#\J\7E^&\+R10B?&S3%;#\/<*\]XNQ%(2
MX- B]W(J\1-$-K0XQ%M=LYU"DJ;85K>MX& L_.O%53A@K ?;&92&/D92*9/I
MT9-7]ILR#AB[#-),31HZPNQ[$/" E2<H6<V.* (UMTIYK2V^T&:URWQ5LA(?
MZS./]&+,.CT";N5=T6J0BQFS),#0VY'3_CHX1YHD\3N_$!CNMO$MMMK2K88T
M#F[BF8C(:5@KW6I]FP"5N2B1(>7 ,EBXJUV*-JD1+>1M$)E&8[<]+"1Q9#XC
M?@B^^$(2@QE8^@Y0KOQ@D*2N5>L%?L[;]A@:I(S%9E@;23Y=L4M#Q$'7W303
M#=B:4=/Q*F8Q;XXH(YZ#]LL,.K?4$8D>DKPQ%AER!%L)?!CIZWUR5+BZK<)I
MB&D*$T&3;R9I<1 ':B(*#!D0),NS2/AJXJ(,&EF)1V->05L.] ](#BZS3C%=
MAIF4?DR+$_6&TFU:T08KL@PY<15$!G3T/%ARL0J5H=E@FYJ'>D8M4Z*/%^*T
M2>$E\)W=+@%2(9,R>#)232SPHYL2)2"HQP@YWNFMZ\I'QHB6T=6UNJ66A6D:
MWV$N+WI.PK;]?41\BKQ_[*9^,L"E^6N8HSD1$;Q6)5+<V%+G14SR EU-5V[J
MA1LDV25%,J8M3K+9EI/$8AVT%$A[W%;FBV%/*#[E87-OGR":3I3M.NK#".SV
MW5(J"FV6];UI3BD,V]QW:&T_M;2TVXYM.MZ0A2NI.PZ,E#[X6M!EV@&%-<7V
M@KO>1J\*CJ#ITT\K6D\E1(B=Z;$B25=3%]$%;0TTA35L4C7A)IUT-@FG6GVF
MWV'&WF7FT.LO-+2XTZTXG2D.-N(WM"VUIWI2%IWM*D[UO6]ZW@<F P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!\.)VMM:
M$N+:4M"DI=;TC;C6U)WK3B-.H<;VM&]]I.G&W$=K6NVA2>M.PU/C>ACQ#$,>
M$ *NR EQ \<2&98VY=HLYM%48,L;[DU'2)29R6#I-: /V,0Q$)"C6QX^( 3O
M>!\A]$RK,V<Z35,28T,Q!0L=7F 5B[F1YB/Y0URR199$@H!Z%>D$3@T7!1Z&
MX-2TU<)R/.+,T0VD4/T+H<<; "!#CV.^I(AQX0.O2"CJLHJ !JAM.D*:&(SY
MHZC9%NJET>%="?L0$V;+I4:S;"K$.\TTP$_B>CKQL WQVU)@/6Y'&41:HNN(
MMPT%+LJ?MUCKEH.G#!4P@H>IT"4K .X<R.'CFH]D@U&AG''&'1@@<ET-N)Y1
MF/&(+M.AX^C>8:&M/UI[;H;*+JB/G._+JY)(5CC=\@6;;1L2]'!GMF[$G(^5
M 62(2'/:.C=QYLFQ7J^\AV]T#3+-DMAUAD*!#5QMZ C*FQ(6F8>$I<0)'-*@
M>/X >8UX@.O#@ EEMQX1)1ABPYY#HFT&5F92;*LM[[4U,V"3/C!3:N%!;C+9
M,UVPV:M!1 =38"B8Z?F:K!24M-Q#8-Z--$>->MZC)&3(,":?!ZXS?K/'5/F(
M=-DK?&A$@7#1%C%AY<"4?DHB7AB%V((B*\');[B:,)1W0XG6;IIYWO4:<:=#
M".]&3C]<K"2K4A9Q51-FG+04$.5":#GRIGE[7.+04OMV =-8 A;^V,7%^03(
M20=BQ6(>;/F =.-N!&Z[T/N-JX3&$LSETD7(ICCQH;<H]477.^XP/IC]6,T4
M+3PS1GTQ-!K%9DVH\H,&4APGB2PU6$PJ=="50G1UK%0JBJQ4)>8!_P"5N(95
M!\KX"2<;5P_NGC1*=,BAQ;*GI:*J PTF^YI:=F&$&L,MMI;#2&!J_0_X7JQT
M62B,EK$#&,,J\@W0]BX09TXB&C8$FUG"3P)KV[ ?&0T,.0H0D2)93%AICHD%
M"74.A*HGH^TNL^0DU882*V-R.5R):Y-R+CG+#<27#+I/1\9)30;$<]X:&M-N
M1(QJR&C=CQD>[%:;VY(D2&@GG(M0+NM?;B 9$:,*9EHV3;)+$=-'WX![;BF5
ML,E".?PJ%*2E:7M=A75O:5ZZ]8%&S7$EIA8F1E7;+ D) $>)2*Q7Y'Q!;K:-
M[9#'TN>2G9);O8&'3M6M*>=;3U^G QE9Z.=NB&##3;76WI^=(U)3QGD*3=VX
M7MM+; +#OEIO_DV(&TB.CFTMM)[AG9*VO%E%..*P2-S@NTD-J8>M<!IEW]AW
M;4!(]YII6]:7W>USFTZ<[/7V=JUM.E=6]Z5KKU@;.*2E:5(6E*T+3M*DJUI2
M5)5KJ4E2=]>E)5K>];UO6];UOJW@5E T.0I$IU4V7[%++>VLFB2^G2 (-;KG
M6\12I-*EEP8:>TISS7(:/@=;2D>&37&=KVH+/P& P& P& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P-=.F!_-,Z3_\
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M8$QP& P& P& P& P& P& P& P& P-=.F!_-,Z3_^CUS/_P!W-CP-B&_Y-O\
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M4:Q7SBQVQ2S82 BHDLD5I6EM#$$ "#O/#MKUI;;+BU-H5K2DIUO77@2? 8#
M8# 8# Z.XN,5)HFMQP.YAL%R+;EMB#[DVXUXAHIZ.0?MOQ2072F&"7!$NZ'6
M0RT\IO;C:%:#0C])[_-"N/\ 1_Y6<<?[[0W_ (ZOZ<#^>^QZ_P#.%XXZOW^;
M0G_;_<17_P __G@;$=&[HI<O\R6#F^\TB/A"H'SBE*?WA\X+'D^64P$06I.Q
MGM=KPVFCQOX?2NKKVO6D[[/I#TOX6_1=\:Q'#=/K/)DI>AKBTD&5M0L!9Z^]
M$M3H)CKS3<<0JJ.K4#W>F.VG;BUJWM>M/?NW@>KNM=6M:U^[6NK_ -F!^X#
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MBP]F!!L$>%4XRRM0_>=RI;3:MHWM"=Z"68# 8# 8# 8# 8# 8# 8# 8# 8#
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M)D2UVH6V*-KTG=JQ$6&)@1XR (&7+0T=)R0MT&G3*Q.5'N6#]1[FR4('#?[
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M<["U=AUM;:NI:%:T'?P& P&!KWTD_B-%?2P'ZGG<"T^._B#2/HE7?J@3 F.
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MKUO>NTA:5(5K]Z5)VG?5O6]8'U@,#7OI)_$:*^E@/U/.X%I\=_$&D?1*N_5
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MYBK<IR05RO:P[*Q-69XNI-1YII(8,1Y5L! ZFA#V&U0R]P9M<AWXH%2(QI^
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M^._B#2/HE7?J@3 F. P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW
M?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]
MP'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^
M_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E
M_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>S
MY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7
ML^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZ
ME[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJ
MNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]
MZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R
M_>JZE[/E_OW ?"<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"
M<OWJNI>SY?[]P'PG+]ZKJ7L^7^_<!\)R_>JZE[/E_OW ?"<OWJNI>SY?[]P'
MPG+]ZKJ7L^7^_<"'7;F6TWV*'AYD*"'%&D&I)M<:*>R_M]D8L5*5J)DRT;:V
2V8[M2=-I7M:4;TO6M*2H/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g16439g47w32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g47w32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E\4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   H)2' )0  ,-(" <
M @4  PT@(  X0DE-!"4      !"7(C2Y[HK=2'K@+5*?]Y8T.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'8&O'         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #P     $  @/      0 ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/T       2
M #4    ! "T    &       !.$))30/W       <  #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             $*   "+@
M         0                         !              BX   $*
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $*
M  !29VAT;&]N9P  "+@    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    #
M.$))300,      ^T     0   *    !,   !X   CH    ^8 !@  ?_8_^T
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M<ZQSVL+'.J=M> ^2TPU^U_Z/VNVO1TDE/__9.$))300A      !5     0$
M   / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B
M &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M 3I-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0    $
M  !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @
M  0*("  AVD !     $   "P    W  UQG(  "<0 #7&<@  )Q!!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C V.C$W(# X.C$P.C$W   #
MH $  P    '__P  H ( !     $   BXH , !     $   0H          8!
M P #     0 &   !&@ %     0   2H!&P %     0   3(!*  #     0 "
M   " 0 $     0   3H" @ $     0              2     $   !(
M 3A"24T#_0      "           _^$!/$U- "H    (  @!$@ #     0
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    ! H@( "':0 $     0   +    #<
M   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,38Z,#8Z,3<@,#@Z,3 Z,3<   .@ 0 #     ?__  "@ @ $     0
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M 0$! 0$! ?_  !$( 2("8 ,!$0 "$0$#$0'_Q  >  $  00# 0$
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M  =/7X  <\(=G9V=W#LX!WZ#Q/&&?X]LY," <>Z3>>4?B7X\/)V]@<>';WB
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M"OC#/B AUY+\>/<$F\#R<?L_;V]GE^+AH 6"?].3 ]G?UD] !X]H"/\ ;^T
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M2Z;GF0$K15\(-&9G1D'HM DLVSK+I*<-I%UC_KLM%#*!\4EOL .7DL=C$EL
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M ]O  X!Y!X=V@>8. #Q[^';_ -^SAY?/V\>T KW=G#AP[O+V^0> "/;^A\G
M>WXM 'M#X^P?B[NT./'LXAV_SCVAH'=V<.WB'9Q'CQX]G;W#Y_V>/9WZ"GG[
M^'=YN_B(>0.'9Q_=\W$-!] 'D'CV]OE^/@ =@!V<>/\ U>8*#Y@XC_.';Y.
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M;7+.I^U3TS99Q\8IGTS8)-[,RSP2@"9#.Y&1<.7;@2$ I""LL<0(4"A]:7@
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MA)=I886_72(GH^)"!83<7:9QA+L80H"!85K)-'R3QO$E 1*$<@N1H #P!'M
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M,?U6G4+)=JE:M;D\>.F=M</<?Y*R&WN]VL5*KD8^>'G22B<TF&[30- T#0-
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M &NZ&\%UC=K"UJOVS</NKR=#T&>VZO\ &<9?\@4E[%8\K.V++-:S%CJBPD-
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MQ$2-@L=CGI!K$P<#!0[-:0EIF8E'RJ#*-BXQ@W7>/WSM9%LT:HJKKJD23,8
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MK*NJJB22D(Y[)M"&Y)4UD&"[5!PF0YC@8[@HNR*E1(0PB@FNJ(@5(V@]C0-
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M)DZMDOA#(?(X;V;H'5LE\(9#Y'#>S= ZMDOA#(?(X;V;H'5LE\(9#Y'#>S=
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MT>OD.A$2LK\E06CD[D[40:KIO(G):5YK3I1ZNYZE27 #B$?M;AOUP73I2U9
M9T#-E<KTF9N^B+"J%;R.>$$[-!K.Q^0<35)]5+("JCD2KL9C .,D(H&SM_.6
M5K$$-))!*,?OKQM%MXQ3,=(R=M\)*LF+YA8<J1%?1Q5(MI$B2C)Q&YSJUFLN
M&E$GJ:[=9BVDKO$S*Z+A(RD.@J"R*(7#<+6QGLX;:YF$0-+Q4IX^N8F1BY6L
MR+"6;*8_LYRN(U\RGEV;Q 4P,J"J2XD,F43$,;AH,HNLWOP>F/P\![<T#K-[
M\'IC\/ >W- ZS>_!Z8_#P'MS0.LWOP>F/P\![<T#K-[\'IC\/ >W- ZS>_!Z
M8_#P'MS0.LWOP>F/P\![<T#K-[\'IC\/ >W- ZS>_!Z8_#P'MS0.LWOP>F/P
M\![<T#K-[\'IC\/ >W- ZS>_!Z8_#P'MS0.LWOP>F/P\![<T#K-[\'IC\/ >
MW-!^8I_NOS,E/;@<R1^^;(,UFW$/A9&VU3&6S!O)X&0HU@Q//[G*%CP^%;#C
M9"!')%LM<_B^VV6TP.3T)P):H,X.*E6;Y.%K-R<309CJ/-]W]D8<Q0\,][FO
MNUF,5HG#^ )]P#Q'\>A$&Y'2CW^R9]Q[J'^UE<'5]W7Q*X*&4\?^)M!@EC2P
M4!3 FS"K12-94WL1OAR\ER5YC(Y]3%,T)78-Z^X%]N9=SK!M+#<D6CO:R>V%
MEG\FU3B5<5K5H3._%Q2 6$,[O"0V21M^ZGP<4+CR]8^PK=XVS;K;E5,^YDBJ
MAD[#,0[J&-H:@V[$JN.7&0:-%VS+%O1O+F4JZB>4Z%8J9#XUR(\9'GVO7];=
MAJ1<W'*%K\&)";98_;9N!R+M/IU6W_3N>\T;?4,=3^-<_9(QYN!SJQJD55UE
M+O0%*GM;N60F<QGRR0]<C)./:X[BZ)@R$/>J/)W&3?AF3NZQ]4=Q/@'\.91R
M!CS,M==X7VG8FG:31;5:1JE?&WQ[+%U=ALA7.@U.^.H"\JQK>!6L.*%;:G-M
MZ^RM0V1O"1=G6;+0P;ZMQ<@[4P5E8AH*41*>DSA3+*K0@II +0P"HH",PLJ)
M"A]<8$DE#\ 'DD,;@ AI[\.QE7(6(D-I=JJFX6CXK@8_(<G,S>,K3O"9;,WF
M4WU8N6(+$,D2YOR)M+[6:W0X_(U/L5 ?/4F"3_*5<NQXZ<>5-BP$-EW@\,I1
M.5MGF#))#<9C;=1;*M0:O1LI9BQ9>8O(E<G\H5ROQ:-N37L\:)#2$LDZ726>
M.Y-G&RTJ1RWG'L<T-*%)H,UM T$1X3_2;,_?<W ?Z^,D:"7- T#0- T#0- T
M%HW>NRECI]M@*U8%*5/V.$D8QC;F4>D^>P;]ZQ,Q0FD6AEVA7;V/()%&G.N4
M^0HBC]>!4P#08M[7L-Y PIB>A5^IVJDSE8E9-C;9B'E:M.0CB*@[/#UQ>29U
MN7;VJP+*RJ$BE.SZRU@;22<U(S/0DEZY'-$0 ,IFMK,O;92IKUFU1_5\>E)M
M;,[BTC5&:;&!J5=*.G&3QXFA(,UW7,+1<TC$R2_1W3M@T>1R!GF@]B&G(6Q1
MZ$O7Y>+G8IT!A;2<-(-)./< 41*84'K)5=LL!3 )3<VH;@(" ]N@]30- T#0
M-!PK-T''(YY)-44C\XD8Y0$Z*O(,GSJ)_P!$DJ!#G*55,2J% Q@*8.(Z#!G!
M&S+:Q3JUF:DP>$:,M3;9FB3LL_6; R7N,#*V&*8-$V%@6C+<ZG683:2<B[(>
M7123?N2J%!RX6!%#F@DP^RG:4(<&VWC%$4(<>"D!4(NNK /'B!@7@D8Y8#$'
MCS1P/RDN4?FA)SA^4'5'91MN(/%G2[%$=W M>RQF"MID !$2E33@+[&IIE(
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M%T:-E7"@G?)&6;$.Q:,G#]$QTRF$Q5FJ8HB D6!,_P!;H(HP+<:Y(T![(LY
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M?04U$S3)-4R"CR)D6<BU(N0"B=$[AFLLD54H&*)DS' Y0,41 .(:#U@$!#B
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M4%ZWC_I&@IXTUCO\8X'A_P#U>/\ I&@KXT5GX107K>/^D:!XTUGX1P7K>/\
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M#QGK7PA@_6S#Z1H'C/6OA#!^MF'TC0/&>M?"&#];,/I&@>,]:^$,'ZV8?2-
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M/0.8L?I2$]1/_P H] YBQ^E(3U"__*/0.8L?I2$]1/\ \H] YBQ^E(3U$_\
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MX3[FN19F^3ECI(OFM6LMN44>F4H*1DFHQE6D4B*(D<*B]5:)"B5%15P@'O\
MC#E_[651_A2=?F[T#QAR_P#:RJ/\*3K\W>@>,.7_ +651_A2=?F[T#QAR_\
M:RJ/\*3K\W>@>,.7_M95'^%)U^;O01_DMEFR[5R-AF&.Z.T799 Q-;E%7F4I
M#FCLL?Y4IM\DFQ.9QNJ?I3V.K;IFQXE!+IJ[?I"B*'.*D"0/&'+_ -K*H_PI
M.OS=Z!XPY?\ M95'^%)U^;O06Q;<FY.IL<PE)3%E=6;R%GI]31*QR:HJJ62N
MUJAZA$JJE7H;8A6:,G-M%GZA3G619$750;N5B$;JA<_C#E_[651_A2=?F[T#
MQAR_]K*H_P *3K\W>@>,.7_M95'^%)U^;O0/&'+_ -K*H_PI.OS=Z!XPY?\
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M)Y3ON8]W<Y9*%(56V-LK0V5K->E&A^IH>46OD*R/3;$^J,4E%65H$20/@?\
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MSZ$1+.6B:2TC%HSJ"$TE'O#K-$Y9%*2(D#Q,BP!^E;0- T#0- T#0- T#0-
&T#0-!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g16439g50q80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g50q80.jpg
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M=I?2(C$V-[6VMR0U05$C,CA"=7?5&3-A<9*T)BAD<H&BX?_$ !<! 0$! 0
M               ! @/_Q  V$0 " 0,#! $# P0" 00# 0   1$"$E$AH=$Q
M06&1<8&Q\ ,BP1-"X?$R4F)R@J+"0Y*RD__:  P# 0 "$0,1 #\ _P!_% *
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M-@<?\8,CV)IOBP03_&GB?MT>AA^Q*IL?E$0[1Y(S(F>2O&;80OM])N,B8$&
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M .G5"D_H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M!N^31R822"2<A&.7D<Y:NUK5U?R2GHO@LS4** 4 H!0"@% * 4 H!0"@% *
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M(\H^2FF3LUY::+T 6BN[=&\"Y V<#&]M[AFK\R-\WU*-[+UTR=#L%,/I4/M
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MY?\ KIZ[&S=K_P!UNROW ,?\NR-#+Z/X?V)_0HH!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% :]]6 KBJ\507,F7G\E*2SAO&[
M*V/%L?2$S(NI:37;QT<5M6#/%U(O73K)!FV0;IJ+9V223PZ,; ?KU:#G:6P/
MXL[4^,J U#Q^&D#30VDS$F(-@RA(6:EUR2D$EEM'9+7*0FYP/AY.5?7:L2ML
MR;7=OG2Z]T&;9NU1NIY-N@DECAAC7U?RR+HOA&U'VIA&39/(V0<G3QA(-7#%
M\T<;6VDH@Z9NTLT'+9=/(ROBHBNBIFDIAE;HRPRRQO\ )>H4V50%,^=G,T:X
M+:&F]WD6N=B[2]'N4&;$5U[ 23^_CYWMF[ERTI2CG@_KX2BFEE%WY.4KM6BK
MJ[*"AT98CEHF(>C5--S27?/YK]#4\EX20"PYYJ<$A\.;3Y5!20N/')$YVYJ4
M5((4A,-8NMN1UA/4123Q>P=FC4$'9CKDW(0]FZ7'713'HM(6<2C2%>("W]MT
M[/XZQ&KF/AGSV]X1X4UCSHUWP7CP>'(C R&]8D\P436ZM7ZWQA&NSBP['V,2
M-!IM)QY/L\HBHD DRAX,@R,A+KL)"%9-FV3^4:)J@J9IN^5TGHIZ]NO<P?$'
MPFD'R_>A$&*:?FA\E*"DEPG(MP7,IEH$ZR&]+:KVK)'$[*M()JG8G'RW=^M=
M G&M+MT)$4W9CL@9PG)EEK*;E7(.FWO_ +EK^&T\1DO4:[:C1#8>L]:)Q;R:
M(]AQ^PBE5NP\OFO :]UA$Q*A<99,6K-\]F<&968ZU"V\)&(Y2;R5/XQ=OCFW
M9.[4)'?X7U?XW]"G,]X14=B-/1^V7>M'H&A,\C#GCPV;[[.!W28T*/PB&.B'
M(PVV;2K>>8:OB"9@!N(D:B):/?D"IN4A01,L(69F']H86W6,)/37K'3I/7[O
MH3":YVP4;JA_MJ.TYMF?91?%76?*&0"(V$POL6.:[?;%#P' 9>#RO>(@)A%L
M#&:AN0SQ%&# -C"IJR[_ #;2"#C$+=8E=6O&GG[9/N3<VF<"21+1KK*4E@F+
MA^-<GMLTQ)HUFIKM?E68J ^MF42/*QZBYKZ D[-)O9;CTB-8C0?*QDQ )F,I
MF_'X\2.OUVU?^/X(6->$-BYH;D"^0U/+14'*:&.N56L&[4PB)TF.>/6J2\6'
M-E$4L-Q\=9P&; AXDR&R. UTLYG$R*\TS&ERN$)61+'#HMOGND_#<\?X+6[*
MY'Z9U$@+.3LQR8(&4+-%$"I"CA8964#AG" S*#V4L%P1#D.Z[%L2L7N4;"(K
M104-]8X*TW.L+RS"RXD/'3[X^?'4A!-S8XP!LD91A/M-I#9@2TFT(9)V,&W5
MO*2@28=#"6$'2U(:4%C0B$BPM'!TS' R8GYT.EY5!D41\2M@OBD$/'YKV^C/
M9$<Q^-\S,^@D]D)Q+O&)=RJ[PL%3@('V2D6"8;0G!J2*S(:@AB+V ,:YR4."
M[6<C,-=B" LSDILF%XEA%22[4(?YKX^YA\^<?&1.%8369[-VSEBM@$PPOZJ]
MO7V/.$DN%3VQX-E!:JL!WV9-MB$"%B4P&Y:*$GD,1CT#+RD'(/VL>Z42"UXW
M4=8Z].NA_-[<MP_5/'(;Y%A$4\W*/[$F](C^KD!!N5/XTO=;_.@X& )=S)B
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MSCB(.9E$QVD@V=EIBK!KPC >&O1N0:R<C^-EM@,-@%C2)*8P1N?]Z?1=O/\
M!%Y?P?\ )7DMDR AON;$,MI+<CX AO;7XY/.&VL>3QPVV:;#D4K(R&+= T%3
MM<HD->'3ED[B8V'*%X4O C?.*BI)N+/C'M=-NJ.@HV/Q@F.P(M"(YMX8:A8L
M?B&ZBJBZB$9#,4(Y@CFNKEDJMFDU;)89*J99**98WSSROE>]Z&3-4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M"C9XS=(*:XR36;N6ZJB*R6=KX*)YY896O:][4GPM^1'E[<$6UOHIKJ4$%=;
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M:UK6M:UNBUK6^2UK6M\EK6M_5:@/[0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MZW::3I3*:^>FI8O9'A!.90OPTG^60,QXC[!9 ^U(@"+XYT&\M-9IKM#8OTN
MAO5Z'VJ+!92K(QL]L:;E"J0=1]QYU"-X5J//',PA-MT0M5UKGW2\OM/@Z+[(
MY,/>+FFM7EO)^']/[&/MB"FGDA[C@,DAA'SVS3Z0EVX9""$01.&1!DTE<&#9
MDJ\EU4DF<DOFJ[5;1=LW: S$MQTZZZ?/Y_)7B2\+MQ78BT81LX#?)%((#FX3
M+: ,-:@F9@_X_!W'XY7UKN@GWB-HN\<Q*.U^;,WT&_;1;DBF)K./?OA*,(8Q
MHN]P"Q]-.T:]94J/E??4RK?PIO',S-=Y:OU0Z(BLLTQKD[-7Y;Z!;OM<6<!^
MLX_9V"<E:)GE#^.A)""FHM>()9<.@A,P4\\BPLHFI9+!OD%KT\Q]X_CRUW17
M@$\+E(G1-'B*>HW0_9 W\'B&JGLE'3C@0/77-@9'B=TV#F&#AI*"\BBW)&:(
M%@4NG[)RU;/)<I=QR:?F&(MGGM6X[JW\]&]W_A>^';$+C3>TGL%XSDM< )_C
M#M W&Q!'RNT-R36@@/5$VQ=RS5O![9GMHBAQ W&99ZTCH=L!F,T03T3"PV;]
M02RJ8_-%+?PE#^J+G\<>1.M.4^IH3<FIWTB[%9>4*1URSFF-HN?'BH&)Y8,,
MA<@CL5W2+68'2>#E(MUDS>/XQ[9NG)0\E)Q#QC(.1&FG#-YT(* @&M?[.R/[
M_P"U_P#5(QH1=/J_NRB?-CG@YXEDTLB]MJZ&%P70\]R E\-E$4A"$^[&@X0.
M8R:U#H%LVS0:O]DQ$1'Y3$FN[3(L&KTJUW#JC:;$F?DL"-JF<]4M.WS_ !KG
M!8T(W@<DW*3<6BI_6R0@(Z^U;J_8(:6/"..E9\^Q."W:0O*R.<)#*O6(V.-5
M]?(X0",C)9$TA=9^[F8>!3\Q:K"0H3[N9\1!M_:_]UNROW ,?\NR-#+Z/X?V
M)_0HH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4!6+?G#WC_ ,H2W4I-O\"A]L1FF7!M
M(BFN3R+A2S54A.'$(T'79$6 )%%2<(3S<#$MW2 B[DTE,!U:7E7S)'SY=%RV
M%534PXG&C*QM_!&\.(^$V6*0D 9#89LO6/)+3:P0.$R$*'@VMN59R$[(VJ):
MS'V,0DP"H7KB"QTL)1D<GE'"OI.<9QK3%B]0;LQ;ZNO>:7.73,3GK]2!<R/!
M9"W(X---:ASR$'Q?D1R+TWNCDF1ETD3R!<RB-2!>O]8.(W2C>!]'L(>:/-3
MCC5Y$H1/58M*#,BB3LW?.'.,=D%-4-/":7UEZ_5SZ+#;.\'5QZV>8%VQEUMB
M ^QB0RTWL&$.];&:H@1ZU,=%@93K %F-<JM6"\?#)W 38J%B"&E(^<'Y^)F7
M+=]$Y8X-_(@JFOC51X9 '/@F.'[@02#L(?8;1NAJW#6;>?:[$G+&*+U/D WY
M36VOB5K>7F5-PY;^;X;)5,EW*J2\MFLS7B5(97.-N%[F=.L]/$1'2(T-N!G
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MXJ_]F#CC_P"1&H_\@#]5]7\O[D71?"^QONH44 H!0"@% * 4 H!0"@% * 4
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MVFUS$>(,D=><?H]@9YO=O*Z':L+!0U'!4M(I&ZNW)_E%,#>.(^^02E,Y>:T
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M&J.\6S><C&TC@U?.QR8A)C)HBVE&WC$T]4*J72XJ4/\ /MT?E,WE5,B@% *
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M>KP:^@==[5I?5G9<"Q>=N!ZO!KZ!UWM6E]6=EP+%YVX'J\&OH'7>U:7U9V7
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M60XV:96(I61?:A&Q,\QP61D!U!$T:ZWD( @2>19MLQV4PXZ12JOT]*6FDO\
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M;LX,ZT9K.)8G#R,0?P[^8,Q"ZUGDU(WDQ&HE==$_*U7/3X.H5#(H!0"@% *
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M279J2^$A-LV,$/M):2FHM%P;A++[3'W"IEM)RE.J3<J8T777MN:Q7\("%1Q
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M[IT4,"M_M:$Q@AW39R9Q$*.:P9!_'_6?'_DIK>#06BKE1%-$&U34CY!NE'Q
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MUG91RHP'XMK$L\W&=K6MFOFW:)Y+9VM:V2E\KVM;IZ*VM$E@YO5MY)+0"@%
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MF-IV329R(DUQNXZ"3)HQ0U&);Q\)?G =2=SUEI4J=7":;;<*7I"_P7EK1@4
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M1T?9DS2FIO.8%1F"G).:(7\@K(R;QR]B<8Z(=-8] 9<:1A>XDM;0@H!0"@%
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B"Q_XHI8_&_ O7G;DXM^NL5[/(.ZQW_JM+'XWX%Z\[<G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g16439g55g60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g55g60.jpg
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M2QX= %477I%@BFTY,"YFSP57*Q(*B\?.PT6(83R-<$/OS&GC Q1^^G*./KZ
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M[\J0(4+>FYK?I$+/J6?>]L_"+O;:[9:1H@2<GZSV\TW+6W$V[:N4-"Y=JK,
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MV+7M H=62TG3E:_%*O+8P\P.*6C5L<Z:=3&1:^K+EXG>;1-%%=\ST_(24?\
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MK#-<NZ]E.W;G5VNQJR]TS7B')/R9KLXJS;.<]2PE&_:JTUEO,3ZWV\<&2Y*
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ME"T1)>IZ6.=N:6M#AQ<SRMR"QQT)<*4-*-MMV36XH+2A->M^53<RKFL7(,9
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M>3M)&+<6)#2LZX405]CDDV,SR\B"$ IMYE[A84(C"2$(XQ@"@+;VQP-*GL[
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M10E+,1PQ@#UPOKR"2=9"YMH5U<[\SKZ^%BY%)"Q\<Y^8)JX-@"KOC*6?=@'
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M);;:?9.Z\RPZXT69V6VS$898,3/F(8YS2F4Q9RSF4R$G*<LY\<YSGH"GZ =
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M@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T
MZ = .@'0#H!T!TD^Y0=Y7Y(:C^GNN_:>L[>'7L_!K8Q:=UY'W*#O*_)#4?T]
MUW[3TV\.O9^!L8M.Z\C[E!WE?DAJ/Z>Z[]IZ;>'7L_ V,6G=>1]R@[ROR0U'
M]/==^T]-O#KV?@;&+3NO(^Y0=Y7Y(:C^GNN_:>FWAU[/P-C%IW7D?<H.\K\D
M-1_3W7?M/3;PZ]GX&QBT[KR/N4'>5^2&H_I[KOVGIMX=>S\#8Q:=UY'W*#O*
M_)#4?T]UW[3TV\.O9^!L8M.Z\C[E!WE?DAJ/Z>Z[]IZ;>'7L_ V,6G=>1]R@
M[ROR0U']/==^T]-O#KV?@;&+3NO(^Y0=Y7Y(:C^GNN_:>FWAU[/P-C%IW7D?
M<H.\K\D-1_3W7?M/3;PZ]GX&QBT[KR/N4'>5^2&H_I[KOVGIMX=>S\#8Q:=U
MY'W*#O*_)#4?T]UW[3TV\.O9^!L8M.Z\C[E!WE?DAJ/Z>Z[]IZ;>'7L_ V,6
MG=>1]R@[ROR0U']/==^T]-O#KV?@;&+3NO(^Y0=Y7Y(:C^GNN_:>FWAU[/P-
MC%IW7D?<H.\K\D-1_3W7?M/3;PZ]GX&QBT[KR/N4'>5^2&H_I[KOVGIMX=>S
M\#8Q:=UY'W*#O*_)#4?T]UW[3TV\.O9^!L8M.Z\C[E!WE?DAJ/Z>Z[]IZ;>'
M7L_ V,6G=>1]R@[ROR0U']/==^T]-O#KV?@;&+3NO(^Y0=Y7Y(:C^GNN_:>F
MWAU[/P-C%IW7D?<H.\K\D-1_3W7?M/3;PZ]GX&QBT[KR/N4'>5^2&H_I[KOV
MGIMX=>S\#8Q:=UY'W*#O*_)#4?T]UW[3TV\.O9^!L8M.Z\C[E!WE?DAJ/Z>Z
M[]IZ;>'7L_ V,6G=>1]R@[ROR0U']/==^T]-O#KV?@;&+3NO(^Y0=Y7Y(:C^
MGNN_:>FWAU[/P-C%IW7D?<H.\K\D-1_3W7?M/3;PZ]GX&QBT[KR/N4'>5^2&
MH_I[KOVGIMX=>S\#8Q:=UY'W*#O*_)#4?T]UW[3TV\.O9^!L8M.Z\C[E!WE?
MDAJ/Z>Z[]IZ;>'7L_ V,6G=>1]R@[ROR0U']/==^T]-O#KV?@;&+3NO(^Y0=
MY7Y(:C^GNN_:>FWAU[/P-C%IW7D?<H.\K\D-1_3W7?M/3;PZ]GX&QBT[KR=K
M/AN=O/)O;7PIMVD\JUM;5W]ORE;;2D"LMTKH$Z=O4],J0&FRC,@AED[2OPR"
M6<$C <"9QY2PSGGC:;IH=,":5=3H1UDT.@/GM[U/AZ]SG-7<YRCR=H.L:\_J
M.TLZP6G;=V^BK&C0J])UJD<R5%MD; /)85C8X8)#&20A$L?&$XYSTPXDDDW\
MZG)X<4NF>XU:^Y1=YGY&:I^GVL_;.M;>'7L_!-C%IW7D?<HN\S\C-4_3[6?M
MG3;PZ]GX&QBT[KR/N47>9^1FJ?I]K/VSIMX=>S\#8Q:=UY'W*+O,_(S5/T^U
MG[9TV\.O9^!L8M.Z\C[E%WF?D9JGZ?:S]LZ;>'7L_ V,6G=>1]RB[S/R,U3]
M/M9^V=-O#KV?@;&+3NO(^Y1=YGY&:I^GVL_;.FWAU[/P-C%IW7D?<HN\S\C-
M4_3[6?MG3;PZ]GX&QBT[KR/N47>9^1FJ?I]K/VSIMX=>S\#8Q:=UY'W*+O,_
M(S5/T^UG[9TV\.O9^!L8M.Z\C[E%WF?D9JGZ?:S]LZ;>'7L_ V,6G=>1]RB[
MS/R,U3]/M9^V=-O#KV?@;&+3NO(^Y1=YGY&:I^GVL_;.FWAU[/P-C%IW7D?<
MHN\S\C-4_3[6?MG3;PZ]GX&QBT[KR/N47>9^1FJ?I]K/VSIMX=>S\#8Q:=UY
M'W*+O,_(S5/T^UG[9TV\.O9^!L8M.Z\C[E%WF?D9JGZ?:S]LZ;>'7L_ V,6G
M=>1]RB[S/R,U3]/M9^V=-O#KV?@;&+3NO(^Y1=YGY&:I^GVL_;.FWAU[/P-C
M%IW7D?<HN\S\C-4_3[6?MG3;PZ]GX&QBT[KR/N47>9^1FJ?I]K/VSIMX=>S\
M#8Q:=UY'W*+O,_(S5/T^UG[9TV\.O9^!L8M.Z\C[E%WF?D9JGZ?:S]LZ;>'7
ML_ V,6G=>1]RB[S/R,U3]/M9^V=-O#KV?@;&+3NO(^Y1=YGY&:I^GVL_;.FW
MAU[/P-C%IW7D?<HN\S\C-4_3[6?MG3;PZ]GX&QBT[KR/N47>9^1FJ?I]K/VS
MIMX=>S\#8Q:=UY'W*+O,_(S5/T^UG[9TV\.O9^!L8M.Z\C[E%WF?D9JGZ?:S
M]LZ;>'7L_ V,6G=>1]RB[S/R,U3]/M9^V=-O#KV?@;&+3NO(^Y1=YGY&:I^G
MVL_;.FWAU[/P-C%IW7D?<HN\S\C-4_3[6?MG3;PZ]GX&QBT[KR/N47>9^1FJ
M?I]K/VSIMX=>S\#8Q:=UY'W*+O,_(S5/T^UG[9TV\.O9^!L8M.Z\C[E%WF?D
M9JGZ?:S]LZ;>'7L_ V,6G=>1]RB[S/R,U3]/M9^V=-O#KV?@;&+3NO)]6_7$
M[#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z = .@'0#H!T Z
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MYS#V^=RNB\A\H=P'*VU=L^G4]BSBW3V@;&O9D>GL$VA<@T-5>TJ<Z.N=;A9
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M1548_6:PY$L0>0#H!V]V#;T-GPVP%G(AZ_D>188G (RJ-1R )BS*'"XS!*+
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M6LNJAH3M:^(#)E"D4;#*0CC@RN8.9CE*.9CEC&<^'CU@W<G^@'0#H!T Z =
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M2LT6VEY3&+(X 9=5ZIRI.34?@LI/T1Y-,\C".9Q4TQY:+ 2Y9@5]*:I4\P/
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M,HLA"_%<(#$F4&9K ]$D\Q2AY3Q+-DBWB..)>N:,1^4> (^3;*9<, 6K2,@
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M59=5YC>QMZI&[2]\D[4O8K;%8;:IG:FV72M:LV0DCZZ5FDFZF;!%G%P,B**
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MG,@DA+.<]"ERXQC&,8QCPQCZL8Q]6,8Q^#&,= .@(PW[<5_\G6O^\4_0$GT
MZ = 437^/K?XZ3^KG^@*WH!T Z = .@'0%F[B:2XJTGD\P/=&BU*11K"$O[4
MLS$F[.4<J$P*!(KDQG&,FE&'G"3(CBJSO;+WVYG%EI/T\_>*,=7=5A=$CK"\
M'F_8NQQ#./.8:LJ[)@JP@(_E*'&!'/Z#(29C!<T,$%$?GL*KKBN%[OU&7UHY
MF*4FCH[Y-962.=DW?6 N9?S9QZD'"3*+,<DF#THKS@($U\LJYGDD,2%&6&)*
MKQ +TQS@7L<RA#-7&9Q V<JP9Q @00XBQ)<L%<PE' E@S(:/JY-(V<ESC#;2
MX?$+"\2@5N%TV9^?)61XR-?.,8@M"&<1QYQY@5>NE+!)2S(4AGC@$/7+A660
MP$>($1<7RVN*9/D/AA0:OC)=;R,>9B<XC&4X(276$:,?2 $T\B'@:P9$&6"P
MQEW![DB#P9@D9Y'%@$&58 ('+3T"CQC#1ESP'%:$0 BO* \Y$0BS9%O3RJ8A
M0)<8<D--O,&,!G[I;()Q^]B$?@:$8P$2131Q&7FC"(_!@DH2-G(IY2$!3^!!
M%D?[_P ' 2R1;S'%&4P$\RZY'"1/CRPRP?(5!QF<8/,.,,*A+ZP'LFQ.$<"R
M.QPMXB\Q9Y*:$82B3/\ V)#/+T6O1&*,BY#Y<9R.$5XDCF0'@LQ& C>XBG&+
M40QQ-PT9"A+SP"!,(L/,9GEB)9'\IL8D8TO3QB$HC),#]KX07E81(L#UF\&-
MZ^)A4<D,\8ACC(B2BO*&(!9GD.?)D,@9R,)B$F.8'@!NJ: )L03'B()!!@O#
M%AD; !1R&4(HX.4@E\3@9/#!Y3SD.2X%X3)*(%,^1)6,#$$ "<YLE-B!#9P0
M>"@-B<!0@P9X6(%4@NC*:X9X!^R!) $9, ;+\2Z,)C7:S9WFH#'FWQ98KSH(
MM_,9%4)"IP?"V18:P!Y4;Q8+"9*_&(HB )6.2-8Q8HIKR[^QO-+#-?><2[Y7
M?<W#TAX;T&9@&?VLE*\BYF%'%"YAYG%?;L1>7 QEI>*D(GB7]D#CTPY&.,(2
M)S?OS3=7AINWA43%G&7'C\SK4OWJ&QT Z = 6/N]7OEI#6<:+M57JTDMMIG]
MIS9T,+WY[IZ\R_.J!#,V08J;%^$A>WM?39D# ICB,<C88"49^O(CFD<^!3<L
M,%4XQY"8"@W:3%I6T3]@@L)UQK$:-_.0K)GE@+AB>'E&F7$QMSSA8D?(64HU
M77%?(=GP9\Y7$&S:OJNJ:!R%5\Z\;Z_H;VG%V/<:[3JQ O(VU<AVJY]DV]"W
M*)9^PK%%G8,K#3QA=9!.J3KH5\2X"T/N<##W<%WZ:KN5994O&R9,7&YA)4DN
M(4)U7"5JC335:GC86CIV9".%52$VLC7S1J9/9R,Q9R3>&!R^L;^R)99L'+5F
M<WKBNLKUVR?*18J0[<B/N(3&*Q,:O$JU)MHR ;ET1FF91$>*9B-BV]]^>!L$
M[J!X0T;98[$Y0CS'5XI4W(>*60S-L5]1GR55=LYZH;]#EN<S-H1F&:5':4UC
MB<:-M0U@DG?WUE^Z%O5WK&DVM1L=$PMN,J;:JC5&2ITE!77;-E.NOQV"6Q40
MZ:^V.WL/D]/J-%F+Y<R4L$GUT\U:2WB]3+UWKWQ3>;LZM=WM<GJ-O?<:8UPC
M5L/DKD/0*$EKF-/JD]@K,K5+ZA&:^H/::]7:E6>M4765HZ^@/7% ^YNWP+9>
M^V]T)[\&7&+BSUC?JO&]/:7HE)NY$*_0[BKW H'Y:J^&-YM2R>CM6>)4%=*\
M:<UK;;NJI4 IJT]T28#UMEL%L[+\GXC.*7_*+^_>=/Q4UVH>!]#VO5B[;KMC
M\NU_;@;:PC=V^Q!UQ7"A,[949K*-[Y$*[7=UV5Y7NT%K955ZK<4>Q$R3<77F
ME&JZZZ^W'OZZJG<N39X;)6:S;0U^REM08RG=/JZW7:TOLVTPJ'83E/7=J5W<
M=3<:[<WY[A6RUVMU;8([2T"M$_7LM!9HGQ#M[V'H@2X JY++WJHG;RU>&.\L
MZVXD1=@:4DF:VQJBG4;K&$/:S$2;+KL3^Y ]8/-!(Q/CC_T=<%N9N9UDV.@'
M0#H!T Z = .@'0%E2Y&T>.Y0X]^DU7/=9"]7.NB+(U@*/L)VF(LQ%"8U2YK8
M>_B!D@CR3(!B(\B8!,EAQ.1)4QF7KU"CH"%V3_N[?_R+:?[B?JJZXHCL^#.-
M7#G!4=P[<]CY-/?4JUB@4K%5*Q/NE3BJ#5S6VO(D6JC>4ZHMALA+?-$UAF@)
M@\B*E6\C,9#;Z/%&*(?*'--+]^QR6&5=7BKMP=ODTH[67MCXG^(DK=Z+Q$';
MJGD33]@/;7:UJ:88(9K\7G(&UZE9&LDZ-,RUXLI76=5<YL28CGP4^72O$LPN
M)2M!A;55TG3\:_)]-&KW1MCU^IO3535+FV2"^.N=.DRT!=J&#+9,6O8:4S,H
M)C+F CD]/S^2><3C+&.+4.#JG*3U,%[MS5>7&SVO$W;_ %-5N_)=2426Z;7<
MY;GQ+PD1I<30R<B6=8PJWL>YQKV 6M5PUJ;X=PM@-4S&UV_&>H[#7[W :C-_
MGW*?DFN%.%J'CE4^UOV=IOO*NVUB =UY5VSVQ]HO%5,S82UZK"J$%7INA4IS
MG)KV@:HI6:W6L,/7+*MEM5SL.QW(B=%DH5#/'0#H!T!'5?\ DYOY1MOZT;Z$
M5N;^62/0HZ = 1J/^57/\I"_J>JZKLN'VR*[X_2)+J%'0#H"/%^VKO\ )]9_
MO-OT)F^"^R0Z%'0#H",-^W%?_)UK_O%/T!)] .@'0%$U_CZW^.D_JY_H-"MZ
M = .@'0#H!T!:NS-C4E3^I$Q<LV.%@K (L/)SY%-B.9X9EB)! $N8Y("Q(V(
M#E.'A&$\](ONJ1Y?4:/6GO)P1#I!0:D0:8% LLSE)>4CLB($8H2S(V<>))8<
M',,Q8'*91P]*0B9"7&1)I[*I?^T3ZCFI;048M;6"JRB8 V#WK5R6&!A!@%BR
ME/&88@3QQ".99P,A/V*9\R\\C@Q$_H.);L%CUYAKC*,PO 3*?C-D1SP<,9F>
M'F9&]LY B^!^A$LEHS'Y8F)F0I2B![!G)[B4Q27('P+-PAB$$0>($\D8"7'D
M_M_2 PN*+"S$"YC& QPE+UCA A=E2C:5AJLQHXBZ2<,%9]5=**^,8#()F2+C
M<_9SSD47[D&5\-QC,ZY@3 H]!3>K:=1*[?'8/)X+7#F&.)D9&%B4DO4)%-"0
MVXD%G+,O3FL64AEB4Z['JR N*#)(NK'$N1G+[+2KLY16DTACP+.4)?X2J/ ,
M$)%>!%F'F/ B><*>)HL8 JF BSA:,LQS!3&#Q7P,!AM8R?&5EI0]4OI>UF<6
M<_L8\8QY?V?,Q2P4"BLH392D8LBB:*H8!<D&H9V)AY((AHD*0ZQ,)%G[0/J(
MR7:]'&,Y9# ?F _%H0S@D5<P#F(@Q%'S8RU&368J1)XY;B60AE\F8%$/!2@P
M;,HR+Z.,@>QB1Q8\)FQA(0IRFL"&8%F:<0F_8X,SP=LK(8L"A*?D7++R2B..
M2DG #P9G'TU\0R3.7(EPX*7E+DHQB6,ME++8205.,<73Q L#S@(:## /5^^B
M!Z!G$!>)\6J6:^3F;)T]F6"JU;72A8D7B?Q%E:(AR(T=C,,C&N& "-9]6!,P
M WLXRK*RBTJD>J]C?MD[0*-A)J=C%5(BQ1KP8!5>W0-@ZDFF<&AX-J2/ HX8
M*V&1,$Y8FVXBUNV^*\#HDHE-[^4N%OIK:N9G;3U5E';B$,3PP:*3A!S9<8B
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M2].Z_AM7_1C?_-NGOM![[4>G=?PVK_HQO_FW2G/C]1]BO+A]S]#T[K^&U?\
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M04P*]I<+.4I&*.,!#FWG.#!D-B.)9SF=@3Q)DRT2,RP4C \P(3&,$G'!/39
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MA<N8R]OC.9R(L7$A^B7 I <&8Y(-Q-F4S3PN/IZ@>A',\>1<L&)+%39R*S#
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MNBC/VVOUS;"UO8K6F,F%.+3U8.WQ"-@592H*P#'I-2I/?>Y?K*>5WU 8&HI
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M&2C $?F4+"/G*6480\TY1C'S2QXREB./KSC'4#L^#-#N/]DL^+^0-DU'4WZ
M=5S%3\(\OZJ>Q19NZHMO=7&G\)<QHH#KKRE\':V4=#VR>(.DA\QV1R3"\_6+
M*'1J:Z/$NDM<H,8:6B'LOK"??]:=#18)@8\&G AL0A@LQ#D$<R8CC$YC%,II
M"A*7CF Y&-*$<XCDI,XS//,Z$=2?M16_Q,'_ +,="*RX+X)3H4= 6KN^\Z;Q
MIJ=[OG(.T46EZ9K"$[/8=HV6S5J*2H1A. _</6#I1+AP0Q!+@A*?J,M& JO
MK!A#F!8_#'-7%G-E)>6W%^YUFUKZ]LEE2[$JN-VONM;MS$^;KUNR:[<J5U_K
M[K=185]NBM<5B17JI]*R4B9%H!R E'5_+,Q= .@(6YV37M=S61O[RHI9W=A.
MHI!VEBHB6ZMQU=E=SJ:@+)1EM+3%-37%M\N1@PYFMJK%W <K),D$! Z/NFI;
MP*]LM0V.FV-->RIHN$J'UW"5QKO1-.W&I5M5Q3RS5/6&I[-KFR+(6(5724=]
M3VF >SLDS&NG"O5_0K7MPA?<E\=0$%KNS4&VUQ;?6K52ZK V^P4)'D29*MBX
MU2^LM7V)&)?#$2&J-@I[.I;R/,AQ<18'&<O)X] >C<-RU+C[6;G=-[V:@TW4
M-=3E87VS[1;(T5!3(PG >6K.VLSK(I ]4@Q1(P>&)F(,4/,0D(R L?C[F7B?
ME&P$QQQR+I^\K7&KPOJEO5KY"Z3LZJFV>^U:]9KVT#&6<EKNS+DU_95ERD:U
MRYFO67@*]QM4)@K.ZGW]09<Z = .@(PW[<5_\G6O^\4_0$GT Z = 437^/K?
MXZ3^KG^@*WH!T Z = .@'0&L'=+C&=6U*.2X#Y]O%"$\C]3.#DI[6 LPQY<^
M)(>:10PQ*&9F@/QS(>"0SO!?E]HQCLN)SLWG>T=(TP6.0;UVJH5W1%1&*;N$
M6L61ATZHH"K?19RTV0B>(L "*:T?78]Q@)H98Z^^WWY<CD8]T);EG6WLTEI0
MZH:JLSOGL-QUZU<-)>SEY%* C];:X@]M3*H5@X=O6;G)[%XTYLH0(68E ,H-
M1]P"2+9"3;*/S,"6*>4/&O;BVN;#@O'UCE](#4)R(O'(G(1Q+$23%E\@]I M
MS:!D1Q!QZWE/(><FC,;!#89KB>09QJ0.7T0R%@@; X1QB6<O9R](#S"&623+
MEAA9D*I@%&!QH4H"L/*9@1D"'86&9HE3,:=@2.7$U1Y@/THN,P8 EA0<@L&.
M9OS]M"?OO01"/#,0>V8%[D <G!++*DX":+ 0P0&WB$!>'JR@![!F7.*7B/TW
M"EB9::X2&Q-K!%Y1-*$"8"N.4?" R87BNI*>8!%ZLL@&!$9\WB$K8Q#"HJ,;
M,X89RNP%B40C]I$)9>B."X\..9%.$S2AF,L^83$>@/PH6O<9@O' L'8AF68@
M%B0C&&B3!%6#2B$$0Q]0F!3*0I",2B"0I%Q@;W@#W'#.;"F!L8');RB+D4&)
MJLE(P8Q<B)ZDYYL9I!D/,38S'U5V"'\<3('(%W:9KSFW7V* 'MF86\2R=]RM
M)$L%<P1P-@1YHS75*?VKB6$P*$+,Q%6!F],GJ8C<*?>@2FB-[*/6Z[6'I*4R
M2H4&EO0?B%93$O?*'1 "NL7R3F9P9 -'/@(DY%G*'K9>BE@0!\FVU6],]SRM
MQ\R=$H:TUI>;/G:]<VB:L+IQ:JL7D:M-IL69P#5!9 N.T8RL2(0V5A$V5U08
MF*(_4\"G)ZL%IB#+SP/*3>G#]YSNSJ67#<)NB><VX*J=%5N=T$BX8<488K!8
MR7(UX>W("#0@^)I>J+T\%0) 66)3&(X3YRB8*9?2D&.! <?WV]XBL))7R<N%
MXZQ2E:3.IG&T[=LK-+D6R1064PL@:DFSB!6">H0##$898"T!B,(DG',"1ECT
M\^(HO?>#DJJV\ON7^]\\B]NH:'0'YG.(XS*6?#$<9SG.?P8QC'CG.?\ RQT!
MXC\/3AY?-Y<QCG'FAD<O#.,9^^'F,,PE^^CF$,QSXXS&.<>& /+.,9QG&<8S
MC.,XSC./'&<9^K.,XS]6<9Q^''0'[T!ZYXEF,\1G@>90\L)^&,Y@27CC$OOO
M&,O#.8>6.8Y\<XSC/CXXQT!\B_Q,*'2G\]S,6[A;5=,XTYDXMV31MM2:%:VT
M-^W/41H<E:S6,5EHZU[:P'1(-%5E\E96L*ZPG\K71:"8O?#7"F_?5#]1QB,4
M*L6]W&\/;USOP=S+Q'Q]7;/L-'#8;'5ZS4&*K9Q#.SLR"GMD502$[!F#I&2C
M7]6!BF+%B,FI3'F?WE?N7Q8R:']U_;^'A[<*S;-%L5-.J(W-=-*J?29;1;M$
M CDMGW.:\"Z_H#&0::0SX6#"KBHG/U9@"6Z^^^K.&-:N3]E&YM=:WRQ2Z#J%
M^HC+81/#I+"5(.3+M-3,R7U97YK=G^4DU:P#.O!?UV+#!T[T\A-63^"2WNO7
M6OT6_3XZ</++\XKX<U*%9])-RNA;BW'6<7EEKM3%)9"V-4OV%*0]?N+]@.F<
M#8TR0U[U#:*U*JGL$BKM8K8UZE?(0S5Q+<;YMM=5:AK9.*J&LVH;=?L>S[LQ
MY[V0_E!B>;1ISN++-O2QJ;A->EK:XJ>+9',4ME 6O<:9FX>1[[R.B'!?'S=#
M6CV6DO\ 5+JHUM&\0('3]M?M:4<G'*5JX;D$*3#-#:7B5FRTXW"^P0ED2W?N
MX;(JE0FUZ-Y;XMN=_GIDY+I\SW7QGGI"F=8XPY1OMAT78]ZX==MKZNM;M'CB
MS4OT@5EB\I3L!K[VWK;EZP63KK'5_F3:#;->).K.M5.)YL2D:2IIM*MJ7OPY
M^V$-QOM[[)VY4,1E5=@JITBG (I$V<@DPK,D,2DN?*QF%\E%G.8$R$Y19E'/
MD)./AG/$[E1T!^>/UYQX9\/#&?'ZO#/CX_5CZ_'QQX8SGQQC'UX\,YSX^ '[
MT Z = .@'0#H!T!H#K ;U;N6HM;ELEO=:E5[UR1N:&O+YUX2NHW>RU/(LC3O
MTB<4:]NHOF.+BZ93*QM]M3%%;43DK6P7L]>]_K_C-)=,ZI1:L:9:Z&%7$M%/
M5MWM'ZJ;O;8]<UFJ[+9:Y71M]AK]?N7J&IGYO):7*E<R>KKI>24)>5UX8%I>
M6<)>!<^$HY\,XRC;LS5,O,'(#&JU%>%;;$-I#</8V5\&G/WMSG6Y:%L]AKVR
M5VO3T&D;1J+KDFL0TO$+34?=X(K;C78.KE;88:A:]TLU*N\G-#$MJS7*:0XZ
MO]HE^ZOERWXA[0^1N2[O4+"^OEN.@)VVMT><Q]G<;8LIK[[!6/3=RM3T#MN5
MZP9R-CTJ](LLYS_C,,*G$HUGH5O^O&E-_N? C.Q'D<_(W:/P3L -/NM?&KH=
M3J^$[0JT",YTP>=4E;IR+E>9ZRYE3YLZ\V0PQ)9F$<9)Y/5FQ?Z?7K487.%=
M.AMBQ(K89KMT>65R8Q@@&"5Y@DQC.)8Q,1"RA/&)8Q+&)1SX9QC/X<8ZR:.8
M'Q+N3L=O6J< <V5.B6#]AQ]S-6#RI7251I&]5L 2O-BUVYL$Q-QJ!7EGK.NM
M5K4D6(QN*I4N0ER/(R;P5VEJO?>!C'-(]M3>=%] W=K?=%TW=QZK<T4-OU>B
MV:%+<$3!:U,;RL6LHUUB&18R&XGAGT&(YA#."0E]['_LXPZ4-JJDFZ5IS%37
M8Q6&EC"@/#.&4\8SCR8^OPR?&<>/^O'CT=V167!?!)^[=_%1_P Y2_7]"CW;
MOXJ/^<I?K^@-7.[KCKD#E+C#7 Z!K2>P[1QUS3P7S6CI5U>5U-5[\'ASE75N
M0']/);,981K+:R1HV&-/L+07R='>$=9;N&$:P+=@J*K]5U4&I7(>D]P?-.QT
M_(VY=I<X\2UV^G%LO;XIOW%E3SYRC5(Z1R)4T6T<H;12\KCX;V.ET+D#;%F=
M&XR/R>XM1)QM.3XW#V[*ZSIM4&&%G676'"_M-,^--RI4Q%QKV$<YO67&EGW#
MK6W(MW7<S\1YY&MC\T[):HWG!NK?#^J^,=OU<\3;'5L;+3W7<]65]AMJEK4+
M6/*1J.IW?=*QX8%XJ2NOZCS4NUIRHJ?VGXZ5@PWPOV_=V=G:W^E@UW?J7N!X
MFVKM7UV7=#L',*U_JO'*6F]EW 0N6-*SKSVZ-7VZGY&M6;&OM7Z;4]CUW<;?
M8"[+NFPI7W']%-JEE7RAJ.;:X9;R9XP[&^Y5"/%5UO'&FV63/'G*W!&SV5#?
M\D\>,&8W?5^*.XG0^1^<==@ER1LP;5A_:N3>+MAV#>]IW*KY2Y/I-&(Y;<4T
MNRZS6I;R)*KSBF]>-%#*[BOLPYTX_*^7D#@'8.7M;L=BXWV+E/0=9YATRFL.
M3MQ!V&]M'#%=M3MS><D:LM<V'%',_&_,5K:K[%:UHLCY2UKD_16-KV_4E*JG
M!M.U(F]KMVAY-=&C?'LC[>^:>'\<F;/W V%CO/,.P*\(:NKR ??+':DK>ETG
MM([:=$WNQJZJULX*4OTCY\TCE'8[-J='3WVTD,E>7D2C/70 &)IQ"A*>^)M5
MNZ-7WFF/%W:MS/N?$?&5Y\BOP[WQ#VI]DO$&HF+R&[KT]9[FNV_G/E4'=1L0
MZL=[7I%N+*"]<G].7T3RWK7["UK$W7Z2_MU7P;KQ;?+$E%)YWH;6RXQ[Q:6.
MP7&YT]7W T:;^J7=/Q;L/,.D;!AM[7.4M(VQ>]U=&][<N**"MY'TJIH[':N*
M['8M]7HT>2*;51VK]6J4FV4(E,F^D7X/KN,0]M/$/,.B]P/$XMDUS;ZY].X[
MP^8+]G=;S2]EY)0XLYFV/3<4&H\R[;QXVWQ\]O>Y<E@^E=+7:M8/4@=2XM4J
M5K*S=TMQPP/CDEN<36RB_-MG8#W;OXJ/^<I?K^A![MW\5'_.4OU_0#W;OXJ/
M^<I?K^@(TK3GS=#/RPWCBOM,8C[E/QSC+%1XYQGUO#[WPQX^.<9SYL>'CX9\
M )+W;OXJ/^<I?K^@'NW?Q4?\Y2_7] /=N_BH_P"<I?K^@/00[)&JV)42KQ]X
M7/J3,M/'CBN?\(^419R^O_/X>&/W<] 3'0#H!T Z = .@,!=P2#5CK^NKJ.0
MKB_2.,\6!E1NJ)R^5V, E<6,(@S@DQ,0\#G(&<&F$P2S9"!9C6"[C3Q8QCLN
M/N:-<=JX;U';:9!;;!*6E?7P!6CK7ZBK,630ZO%DJPNGE'((,": 20DE8Q$S
M$L92F#RR++HFYB,FUUC?DYW9(YQOW.EJ?-UREM'!W?2=S>V]R%9LFKZ==EXZ
MXSY'5UJGT9/8J[.MRHIVMC78Y MJS-DI,%0BFTRR.EDDQ 28JAE(<8K*6!M>
M^^UZD.JU>Z9L,,^NB4X&\#]18!I1*#$LA*,&,M!S)P*RPO+!<;,Y0'"9LC"(
M<R >I?T\F:\@RQ3>#B7N,A,'#8"M^[,7)W!O^R>C*,HN>U,M/,HMR6QF."Y
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M"\?+0HV%;36ED1ZR40L=C=AI0O.A7*TFODNKFR3J6@TE7>6)&F:<7W\OOO\
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M$[ZL9^AA3]DADF7R#S,WMA-PR1(OH-RD=,\X>GJF-Y&W,I<X>L1N>L2W"R+
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MJZQQ=QII)%S:=Q]I6JF5 TJN?7=7I*8XEWC+,/"B>O27+Y'6$U#MXS//N3+
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MPLO3"R$L_+BN?\<^2$Y2\,>./'/AX8_=Z0U=,2M>A,=0HZ = .@'0#H!T Z
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MH!T!JOW.<K;EH&.,=6XZ;\FY\B;/>J@03U6FVK8'M=U73KO9+XNOBV_?>,=
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MLN[;L)IAKDSVC01P.^92O6716*W,LP)@"L*40BA"($AT Z = .@'0#H!T Z
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M\_AE.<LYE.6?&4I9SG.<YSU7?DOA!6YOY9F?J%'0#H!T Z = .@'0#H!T Z
)= .@'0#H#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g16439g55x10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g55x10.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[0\&4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "O*( .$))300E       0IJ5YC4=@,/637BQ#
MZ;<04#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          CA"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              K0
M  .:          $                          0             #F@
M K0                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M K0     4F=H=&QO;F<   .:    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (    #@
M 0,  0   ",%   ! 0,  0   -L#   " 0,  P   +8    # 0,  0    $
M   & 0,  0    (    2 0,  0    $    5 0,  0    ,    : 04  0
M +P    ; 04  0   ,0    < 0,  0    $    H 0,  0    (    Q 0(
M'@   ,P    R 0( %    .H   !IAP0  0     !   L 0  "  (  @ P,8M
M ! G  # QBT $"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P
M,38Z,#8Z,30@,3$Z,C@Z,3@    #  &@ P !    __\   *@!  !    F@,
M  .@!  !    M (           8  P$#  $    &    &@$%  $   !Z 0
M&P$%  $   "" 0  * $#  $    "     0($  $   "* 0   @($  $
M         $@    !    2     $    X0DE- _T       @          /_A
M 8Q)22H "     X   $#  $    C!0   0$#  $   #; P   @$#  ,   "V
M     P$#  $    !    !@$#  $    "    $@$#  $         %0$#  $
M   #    &@$%  $   "\    &P$%  $   #$    ' $#  $    !    * $#
M  $    "    ,0$" !X   #,    ,@$" !0   #J    :8<$  $      0
M+ $   @ "  ( , #   !    P ,   $   !!9&]B92!0:&]T;W-H;W @0U,V
M("A7:6YD;W=S*0 R,#$V.C V.C$T(#$Q.C(X.C$X     P !H ,  0   /__
M   "H 0  0   )H#   #H 0  0   +0"           &  ,! P !    !@
M !H!!0 !    >@$  !L!!0 !    @@$  "@! P !     @    $"!  !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@
MW0$G P$1  (1 0,1 ?_$ !X  0$!  (# 0$!          $  @,$!0<("08*
M_\0 .Q   @$"! 0$!0,$ @(" P$! 1$A,4$  E%A P1Q@042D:$&!['!\!,B
MT0@RX?$40A52(X()8G(DDO_$ !0! 0                    #_Q  4$0$
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MFRU*6P]H];_7 <4 G8295=B]JMMO :.E*P([P#(;IO9X#)#)T,T^X!"[[G3
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M)DD3+FCU760OH27,OS#3\H#@,@4!<RH_B+Q:TM!I08F8A-F9N+DUP!0JBC:
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M8!!^J[0!2TN4)&V ?U,YR9>$2N&,WFRY5_VO-:G4@'7 #(T8:K2HKK>4 (I
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MZQ/7<::TP$$RU,UZ]#$]*6P$1,5-]"*:J-MKX"L-5"GK0'6DC <W"XOZ?E!
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M3Q;D1PN(.6YO@\3AY>+Q,N3]3,'H+C9/T<V;*1^X7KZ4CKIM@.!PC4*L#2A
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ML">GYM9S[&4'@)&&(;U1]!K65M7 1<@".A]/>$@ ], "O_\ SOJ>Z(+1#F^
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M9P<@*RK*A*O-Y/95!6 X@3T<:'16K7^$& ON49F-:CO[R :3;63>+&WN83P
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MFNG2&8MT!"]K,FM=;N8#O<H&P0F#%J1Z(;UHT$+.Y< BH]^ZANAP$30D*7>
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M#P (1M*ZZ#0)F@W(: 3,CJH4UU,U3$I@X!.I$1%_;=>]L  *5!*=WTH$'U6
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M>3N*X"!LOK9+K8$.N  S[2%H\VL/U,8"E&5J$.D2-"6;#8X!U==:6ZF@9/J
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?2F-^[B+V5,! U&BR]652T>O; 01)!&W8'\][0 __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g16439g57z32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g57z32.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1B&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   *"4@ X0DE-!"4      !"_(.WB
ML4HL'_'/C/[5+RWS.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&8^3>         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/T       2 #4    ! "T    &       !.$))30/W
M       <  #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@             !JP  !&<          0
M   !              1G   !JP                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !JP    !29VAT;&]N9P  !&<    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   :L     4F=H=&QO;F<   1G     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    '.$))300,      [B     0   *     ]
M   !X   <F    [& !@  ?_8_^T #$%D;V)E7T--  /_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1"  ] * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(      2Y-30 J
M"  ' 1(  P    $  0   1H !0    $   !B 1L !0    $   !J 2@  P
M  $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
MT  ;)PX  "<0 !LG#@  )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$V.C W.C W(#$V.C(V.C(U   #H $  P    '__P  H ( !     $
M  1GH , !     $   &K          8! P #     0 &   !&@ %     0
M 1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
M 0              2     $   !(     3A"24T#_0      "
M_^$!,$U- "H    (  <!$@ #     0     !&@ %     0   &(!&P %
M 0   &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
M     0   *0   #0   #P     $   /      4%D;V)E(%!H;W1O<VAO<"!#
M4S8@*%=I;F1O=W,I #(P,38Z,#<Z,#<@,38Z,C8Z,C4   .@ 0 #     ?__
M  "@ @ $     0  !&>@ P $     0   :L         !@$#  ,    !  8
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MM,$9&BA%1W64T=37X4-$4F9G<GF%A_%38F1HB):ET__$ !4! 0$
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MPKJ@AHJREAP32Z5YK2,D'EID/!ERZY'"VG 42U#)+50RAL-2*FP3*8>Q[F.
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M]]O/>^W+^,-?3OFCH]-^4>?1_7^[.G[KVZ.B]O:WOTT&GIX33;?]=Z4=[?\
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M\U7Y^F_*'3;?^O\ =EK<^5[?VVZN7X>OF"\WS3TVF"4=N?\ C^[.71Y5:_\
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M Y<=]ND4$< 9P)X8@(P0BK<,0,7#++ 0+/&^&>&78Y6OC?:X8TEWZZ\G<_\
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MJ48LZ1] 30:QR1UE7B%->B*MN%_MUI-SO^57E<F?2322E-)SKI!#*DRI?O<
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MC*A]),Y!;]KN.G&A28U\.N^&0@.=\;].U\;VZJ"Q>&]'C+/Z7)GF.539P&0
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M. XY=GCGC8,%P[JN.PMIN>4=,=:>[5EA7FQB2.A.-OB DT/%!:Z0<**"6L'
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M3%$R.37P')#!&3"[J-J)0@"C'<WD\+KZ5="-%U0T<-X@DKV#/7.D$RX)FW8
M6,A_T6@F2;U-DHVMH;U!)Z(4>;71]/3@TXR6RP5*Q$P)9LB*C;<28,:##'LF
M'E%"<".Z$>Y@M<,UMAAE>X-\S&(896)\TTQ5$4PQ]II;\NJ2[/6*2BNMS2X&
MTDT)E,9+5PUN[::Y%K**Q==-*!C'N0VL*@J5>Q8,(4,I8;"V%PSPY.(A'KYF
M>5TY^)LFNK2E+T<MMHGF0?Q2Q'.RW,W&JFD2+T9:*.Y1T)-4"Z^6/#"!DUU.
MLI%SH9Y0OD:*!DLPA="\TLB,(QU7,$^ YU(S,S%1&@QCY5,3< 0AD=W8+/=C
MG#$6[9I08Z=AC;L$RZ[F&;OD!^J"P[IN',I/7B*!H:TW1H8'+B.5SR3*4R&2
M&(V&1M);(O<C';PIL''?("R\92E<Z2L+MD*5)ACX6RP&M>P0=Y\NOJVOT]//
M?KMO?E;HY?QA^K_JN7M^3IM?].6W1?GTT&GGORO]NW/;;KOMT;\^GHY=5P=%
M]MKWMMU>WTV]OET7V\WD!Y^CKMSZN7DRMOS\MKWOO;>@R%$?UUHP\OIA,OIV
M_L?1*F<OP7VZ;;\O)0)<WO*\G7ZK2&]+7\]O1(I^WY;VWOM;HH,>;[>U:_1O
M;^/IVZ^5NGGU4&M_XNCGMOSVOUWY;[;\[6VH%[=7GMOSY7Z=O+?JZ[V\W.]!
M9TW]5;99*)H2F<(J1>+PTZ)LD1>\8WQ7PF\K&TS 8^:9:T :$3E<P EJ"&ZA
M0<U )*/E\%5$.D<^T"#A4&$7).&F2ZBGNB/=,;P9CX37HW7>77E34 >=J=_4
MERDEU53\D$:.4D+*ZL5+F4\$U<W?O;F9P.8ES=R]BPH<YD[5AIZ?DE')I2M,
M+J;<KGI(;DD&'"//AM;1KJ*2Z4IP*I3%M91LFE\ E<D0-)@.=C78IHAO _8
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M%-4"8P)HD=*#BES)<4,4$3/#/'*X?;\&33;ZWN#_ ()V%\P4#P9--OK>X/\
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M^"=A?,% \&33;ZWN#_@G87S!0/!DTV^M[@_X)V%\P4#P9--OK>X/^"=A?,%
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MRO:]KT']%! OBA>+[U7^Y*L?ZT1H)W@?L /[T'_(M0;M H% H% H% H% H%
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M-_+5:3@I[Q80AY*(J,_.V843460TX!/MK+Z9@S"4&+<-'Q5E.0TU.%;YLPM
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M6@K)XPGB_9?^RZ /RAXKH,5F/VP8V_\ QQOYS*@V:!00TXAWJ(-37N8GK?\
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MVVRZG>IDE:'5[) 9387WFZ#:8VINCIPK@R2UVLG*[A6AB"*F'U 0DD)AT[F
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M0JE%Y^0DW)>E*2HV:"]%,B!CJS6@V*))8!N032ZY2K;:RFIF"KH,LUOK"NM
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M'$.:4"@4$*.)-XO;6][U*>_DQ<M!).(?K31?[G;*_%I,H,B4"@4"@4'X$R[
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L*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g16439g61l28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g61l28.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1I*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   H)2' )0  ,-(" <
M @4  PT@(  X0DE-!"4      !"7(C2Y[HK=2'K@+5*?]Y8T.$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #P     $  @/      0 ".$))300F       .             #^
M   X0DE-! T       0   !X.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/T       2
M #4    ! "T    &       !.$))30/W       <  #_________________
M____________ ^@  #A"24T$"       $     $   )    "0      X0DE-
M!!X       0     .$))300:      ,U    !@             #IP  !VP
M         0                         !              =L   #IP
M                   !                         !     !
M;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #IP
M  !29VAT;&]N9P  !VP    &<VQI8V5S5FQ,<P    %/8FIC     0
M!7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M        !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE
M<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
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M='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M   ,     C_P        .$))3001       ! 0 X0DE-!!0       0    #
M.$))300,     !""     0   *    !/   !X   E"   !!F !@  ?_8_^T
M#$%D;V)E7T--  /_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*
M"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,
M# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,
M# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !/ * # 2(  A$! Q$!
M_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$!
M 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#
M!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#
M)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A,1($
M05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$
MDU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#0^LKJ6U?5T7$MI^R,]4-,'T_U
M;U=D?G>G]%4GCZK^I#,N_P!,$:D.EP ]_P"8=FY_T/\ ,_PGJU]]DXN$W(P\
M+['3?6RAXJ;8UKG-;6['J:VMUWYK66[W_P#%H=F'TJM];'X- -UCJV;<7U -
MKMFZU]<MJ:[]^S8DI\^(Z*R]H;E6W4!I-CS^C).YK6MK;MW?S>^W_P #_KO/
M0AMBZPG: [<7!NX;O4M]K=VU_LV4_P#@B](/1L ?]I,4_P#H.W_R2'=TOIM-
M-EUF'C;*FE[MN,'NAHW'977OL>[^0QJ2GS@GI9N(;=%/IMVN<ZP$V$@.W;:[
M/H_2?[?H?S7Z5)IZ1%A?<[Z3_1 <Z8 _1>I[-KF?NO\ 99_IO27H&-3T7*O-
M%6'3OV"V7X3F-VD[?IVM8W=_P?\ .*U^QL#_ +AXO_L.S_R22GRNQ]8L>*[-
MS XACIY:#[2F]0?O_BO2,D=#Q7VLMPZRZC;ZFS >\>\ MV/K8YEOTO\ !_\
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MSZA-53&L=NW,K?Z=;/29^C6;U(=3-S3A9+ZJAN+VM:';B+; ]FYX]GM=_P"
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MZ C;VUC7\$E-3[1D;]L MW1O#V?1_?V$!_\ 84K,BQD%CA8)&XRUD#\YWO\
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M &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P "  0P!3 #8    ! #A"24T$(@     !.DU- "H    (  @!$@ #
M 0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    '@   'X!,@ "    %    )P!.P "    ! H@( "':0 $     0   +
M  #< "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O
M=W,I #(P,38Z,#8Z,3<@,#<Z-3@Z-38   .@ 0 #     ?__  "@ @ $
M 0  !VR@ P $     0   Z<         !@$#  ,    !  8   $:  4    !
M   !*@$;  4    !   !,@$H  ,    !  (   (!  0    !   !.@("  0
M   !              !(     0   $@    !.$))30/]       (
M  #_X0$\34T *@    @ " $2  ,    !      $:  4    !    ;@$;  4
M   !    =@$H  ,    !  (   $Q  (    >    ?@$R  (    4    G $[
M  (    $"B @ (=I  0    !    L    -P   /      0   \     !061O
M8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP-CHQ-R P-SHU.#HU
M-@   Z !  ,    !__\  * "  0    !   ';* #  0    !   #IP
M   & 0,  P    $ !@   1H !0    $   $J 1L !0    $   $R 2@  P
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M4F)C='5VHPH91YBWV.%D:'*&HO_$ !4! 0$                    !_\0
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MZ=[Z;\9J6ZW"/$ D7GW0G:'/_#XAX\??#0?T$-!XQ^Z=\/;U[@/_ (Q30X\
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MBV5SCEC&E*JL:F )E.GC@TYD"Y2C)$1XBSA!G*E#<Z7E FI/D1X\HB@ &'_
M?%U<!#@' .T>'CX\>OC^C]&@IY!$ X?"(]7 ?$(^/AU?[^O0!]_@' >KAU=?
M5_1U#U\>/O=0Z"O .O@(?F >H>/5PZ^KC_QU:"G'M#LZ^/CX]GE[?TAV<1][
M05 . ]O#Q=0]8B''JZQX>3Q>/AXQT%/Z!\O$?A .WLX=O^CCV@[1#W^KR>\
M\>'O<>'7PX:!XN/'MXCP[/%PX\.KCU<>L/'Y=!0?]'9XA[>KR]@\>H.'9VZ
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MP:"G:'P?G\0CV\/Z!X_T#H/T/7U=O5_4/B 0X!V<./C][CH/SQX#P#JZ_?\
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MPJ$:&X/ <CF.8PQC68W!Q-/@,U2U3BY3(]?H))1.I5^R2*7?CF!B.F9*8D5
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MCFO4^I8]HE4QZ#,M!K--K%>HY8]\,HP+3X6$8QM:!C)BNY&19A"MF0-GPN'
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M18,H-*9<0D0]L QQIU_',WTBX0(&4;V091J15W[I%HB90$BJ+G A#*&*8Q2
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MV1ZW&(9+1X;3YNBUFQ6:DV^68&<S^/'<X^J;PKITB6-<V.#<UR7.9LBLFV>
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M8XEB@O6:J-M>J.BHK, FV$#WNV%)4YG??4B0Z*O)5(DCS! !0>>YP!Y*9M!
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MV44'A^R%"#O6&H>,ZQZ^2M<4N1Q O+4ZSZ#YR;DLB1BBB=RV=[DX!-$.)I2
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M-2ME4B5L4W@U53;#<'4&:3G%6IF#YJ]F.B(E_5RG>I.&8P%EG$^]"RI(66B
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ML\9B"Z/[=^V$XRL[GZ,>,N[U(EE;L/8OVDU-'>5E',U:R?D&$8T?<%5:KC:
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M)?ZLN@Y] T#0- T#0- T#0- T'Y.0JA3$.4IR'*)#D. &*<I@$#%,40$#%,
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M Z2I"*I&(J0ARA:XM[357U$K]4@6,Q06S(T#.NY*S21[97D63-).#E$5ID)
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M"^K&?S.@>"=7_!Z%]6,_F= \$ZO^#T+ZL9_,Z!X)U?\ !Z%]6,_F= \$ZO\
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MG\SH(OJ4<PC<\Y51CF35BD?%F$%#I-$$VZ9E!M&=RB<Q$BE*)A*4H"80X\
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M>33T9'Y&@=X,?O)IZ,C\C01+A0A$XF^$3(5,A<QY6 I"% I2_P#AC(CU%*
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MW&T7CZL[DK8NE1AGS)86PG-V]ONFJ,/(M(U8ZMVL$1/X<<4>,457G7"SBQ]
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M/74A\_\ ]_CT%.@$/.,[ZZD/G]!7H%#SC.>NI#Y_0.@4/.,YZZD/GM!&6#T
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M!0Y1 +LZ9W"?BXPU_/7=_L!T#IG<)^+C#7\]=W^P'0.F=PGXN,-?SUW?[ =
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MSDY(*Y$AN.T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0- T#0-
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M=!19)0(*M/<\]FUL)N-/-8/A3N]Q]QQMD++TM&6*[P$]/7K$$%%16,;= V&
ML\9.8\L5(:Q3-2 EL<2%2>LI ',N58TL_?O7(6F/<P=CG2&()4,*N"R>-(]M
M$PD@3*>9DWMBBV5PD,FM8W+#DF0RK9T8H9#EI6Z$:9K/D! +))/Y84Q>.W"J
M@23AG9#M=P7DUGE?$V+$*7D#HG,$ YL4?;;XY5E(;+N7I'-M\CIQA)VA]%3[
M>1RE-3-NB"S;&0&GNY:394TT!$OW<>J&9F@:!H&@:!H&@:!H&@:!H&@:!H/_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g16439g64u74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g64u74.jpg
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M8N1)F?X/*)D*-B=TZ H;S"'B2N[]"I"4[QIS<7 QM X*AFI;+A;O-23)P9&
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M.91#J5F:7EBZHA50837BV&R*PCV";2ILEQ<K?#D<EN0B(MZ )[,S3Y,Y$C3
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M#,,&$ =[T!PR#VI6%G:>-UM8\#L+4=5)4,@W!Y?'I9IB6KDH5R)(\;87%?\
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M4%*T2Y$K* >E6(U1 S"%*52086<G4$F#*.*& PL8@"UO8'M8 P!@# & 8CZ
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MW8(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M4DZ]Y]<V%VK)$?EE<^8HO3O>'3/.L!J=OYNY-EZ=J@53RA$ABZGX_/8J7*7
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MY!N-\&JL*/E?UU$Y<&1@& [H_P 8<S_;X9^!EWX*L'P^Z,^8(, 8 P!@# &
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MV>#<SEICP+U,&!@%.?=7UH?A)^TKNG\HKY@W3W>TX4_4BXS!@8 P!@# & ,
M8 P!@# ((<S?M;>2+[9>?_RC4O@KP7#[LG?@@P!@# & , 8 P""'%'^-^_\
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M8<S_ &^&?@9=^"K!\/NC/F"# & , 8 P!@# & , 8 P!@# & , 8 P#5WO\
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MK@[ V\'0.1)QN["K=%,?7H&]4T&EB!1L5P[PI48?$LYN;-V#F, 8 P!@# &
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M@RBC5#5=8#S2RQ"V !AX$R<!PPZT(P)!(1[%HH&@CS]O^7]WV-U+!YQ@# &
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M_P!GE(?S)8F#S]O^3]WV-[_!YS =T?XPYG^WPS\#+OP58/A]T9\P08 P!@#
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M .B"WXBPI;'X8M^ --?60SER8M#$G*0_'6=[;8TR/I@T.C!K94I3CG&%VL/
MA_T9U;3UV>8SQ,T]"G.3GV12MB=C;LQI=JYL>+LC2HDO'L@/0%,,QE<49(I-
MR1;3GZ&KAKP^IB@!*.-- 2I3C-&DFJ*WDU3FOU+Q7B;#V#F=5+\H6^N+[2_Z
M@J7\OU38/9V7].GQ^IE,.#H;/GR2[ZS6?_=!M+\3J1P<>W[B^9>C-Y3M7N=C
MXT44:P[I&Z.@)_T-.9! JXKND&V(.,F<'2+Q!RFSV>>&8RV(H0)TK&UJ5 0D
M*U!YFBCA;+  KTC'GIIVINDE=MX8QO*F>PNBKMZ>25B<B\6'E8BCY";-KMT>
M%<:GZ6JT3Q5*.=1]YM>)&H:GZ?CZ)U>);$&Q>Q-+@\(AJVX]4'2)[9"S#501
MI4I?GHP>_)QC3J9_E?EY<^:JM32>TO&)Y%JPIRO$4/C;O/)RV5*_)HVSJW1D
MA#$LD+\Z7P]29\5&KW)J1J'1T6.;R[+E.E+BM4K%!ZD9VN38G\]#>B;Z%Y^#
M P!@'3^>4_ZR_P @'WR>D?Q<EF#V]GW*>! K!LW)OD=W^>';'V4U-_-\IP<.
MWPIXOT+_ +R14O#>F?(_XQ^?+673T^I9A6/=LEDT6A5GV)6&GIZAD=HM?&5R
MYUK>319X/,:%*E2),$:_9>BU2HD0!$J3@#'*EM4UM8S3DGKK)DQ7X(/&\O,0
M'+J^NY::UK=.38:KZ_ZS4F-SCI*J0Z7H!G7.,2-;I$N6H]*D^RS])5BI/[3V
M2@T Q/Q*]5_C3T(.^0#QO\P\80+GR\.=R;NAED(>X.-XN0\N/3_1TS1B899>
MT3:9 W*&":6B_L"LEQ;C#$INU+::,!8Q^R$#8M[V-4U.K:3B-BK\M*RW(V:L
M'(8 P#IA>K_VI>E/M^N/\1)'@]ZP7!>A@'!3>>^1P?X3\@/_ %%S3_XV\L'G
M[?\ )^[[%NG7=%1_K3R^4_SY:4XNEIJ=L\=-FV\1%ZKNJRJC(.G[3T?7\01O
MRXVOI&PF+CM1^1.* T"K9H3B](]F>MM"F]F.:<4-PIVDKI/)ZIF65'@PX?6.
M+:[JWWK=4[,P5H&AT4=G])'N+4!S+*)<@-JTVPQ*4(7 H@@I:%*:5I6624 _
M1@2P:T,[;_M_PI_^2)?1'$=7\.=+>,::4'8?3")TLKN^)59-D,YZ>N^R(\_0
M=UJ6VGYP95L<F<T=V8XI4XQ]L$<,Q&(8R2C$XM[)/-"(:I<JM-4]V;4TK-:)
M&R#@YC & :Z-W4YUE'K?LRZGRJ+(:IP1UA'WJK.MG?R%):ZJ"#T0.YH>T0ZO
MCN=7&RVBOCXY(:[T="7J%/<,5N4ZEDO6*%&ELE=$!I+WR.B:B)M&&S-XQGCF
MFK&Q=@YG&9K#(I8T/E%?SN/M<LA,VC[O%);%WQ*6N9I%&W] >UO3*ZHC=;*5
MMSFW*E"-8G,UL!R<XPL6O0+> 5-=I?6V>%'_ )^1[\L\7P;I[O:<*?J1<7@P
M=3+YR_K:.X_M@U_*49P>SLOZ=/C]3*H<'0VO/DAG[??0OW/Y)^-%*X./;]Q?
M,O1G8>8/*1\F?[2E#?9Q?_\ KZ6P7)\5Z,D'@@P!@# .GN\GWUDWD!^^GU!^
M-<UP>ZCN4_+3Z(@Q@T;G/R.G_-CN?[/*0_F2Q,'G[?\ )^[[&]_@\Y5AWGSG
M1UI]&^/!YL*LXS+'2:=0R>KY8L=4IIALBKUEXB[>LUJA[O[(\H*YC06!&V"7
M)D1X1@+?&=O6Z_XB8KU1NEN*N$^.U2O0M-  !8 %EA" !80@  .M:"$ =:"$
M(=:^C00ZUK6M:^C6M>C!@_6 , 8 P!@# & , 8 P!@# & , 8 P!@&NCTC3G
M63/:]WW8YU19*28(N@&-_H[K)P\A26IZ?JJG4,H@S7%H@LY^766Q5\=&'-K2
MO+/+HS)H>N56 \3!RVYB7N3BA]W'1-0ES6S+;S<X\-.:-B1<A1.:)6VN21*X
M-S@E4(5Z!<G*5HEJ)64,A4D5I3P&$*4JD@PPE0G.+&4<4,99@! %O6QS(]Q;
MD'F"$0UZKR)476\>@\DADRKR0Q=KCB-,SOD(L+W?4UC+ND 'U'%JD9*1&C<4
MZOVOKMR%"VEB+0(DJ8H67KIY8%?G<A)2;R>^$-.06$H@BQ>Y222@:]4!117(
M3T LL =?0$( !T$.M?W:UK6#5/=[3A3]2+D<&#JI?E"WUQ?:7_4%2_E^J;![
M.R_IT^/U,IAP=#9\^27?6:S_ .Z#:7XG4C@X]OW%\R]&;@/D#_;Q\,WWG>@O
MRIV3@X4]WM.%/U(M[P8*@_//]4]U=_\ #I'\QU09'@^#]#5'>7CZ,M\RF1@#
M .G\\I_UE_D ^^3TC^+DLP>WL^Y3P(%8-FY-\CN_SP[8^RFIOYOE.#AV^%/%
M^ALK]1_7#^*/[%/(I_*-"X.*[E?&C_T6]X,%0GFF_9HHC[__  I^8>'X-T8U
M?)5Z%O># P!@'3"]7_M2]*?;]<?XB2/![U@N"]# ."F\]\C@_P )^0'_ *BY
MI_\ &WE@\_;_ )/W?8O?D'U\M8?]IZW_ ,VM18.7_&_G7TLM[P8*@_*/_G1X
MC/\ N90+\#+UP;HPK^1^M);Y@P, 8!KR6I(.F3^A)^AT]>0(73A75T>1TA6D
M9K>1N?C\>.7BK*B8&ATF4D*@BRCAQX^GOC+Q9\AF,_;KHCEE[<4L1+2+&^*-
MB@=$E'Y8B[GXIC)3,SA:-<S8;P<Q@%.G:7UMOA2_Y^1[\L\7P;I[O:<*?J1<
M7@P=3+YR_K:.X_M@U_*49P>SLOZ=/C]3*H<'0VO/DAG[??0OW/Y)^-%*X./;
M]Q?,O1G8>8/*1;O?I7E#GR80A=?]JP*MIDK:WI'!#9<XGH5ZELD*YJ3/*=J
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MHVZM?)=#XJKY/KX?UR@Q4MXV9EBH[8=FJ55O]"*%!NPA" .S#C;:&8/80!"
M/K"WZ A"'7T:UK$+?S?4OXE?ZF>O_N]7AU_<MCW\6.@/ZL8A;^;ZC\2O]3/.
M3\GX\1*#1YK/R U-"XU,<G+6H;@Z%3G%^TUK>O2(FVRQ&%A,"68(H0O4'LL/
MK:^C6](X\WU&W6\:F80Y9^3O<)0:@*HBG4U.,-V]!1=E5E6#:C+:_0C,UR1_
M4NKH<6X,[<DL2.D-Q1#*J0-.Q)F1JVHTC&:8F"(X>Q(X\WU*^TJEM-I/*Q(K
M]0SXH?W5=_QSZ2_K#B%OYOJ9VZM?)=#P*? ?XF%I TRSDTE6F-]7VB=3=O1Q
MY!GJ#"8#URC;?&6/U# !&'U@[]480BUZ!:UO2%OYOJ-NK7T//^H9\4/[JN_X
MY])?UAQ"W\WU&W5KY+H/U#/BA_=5W_'/I+^L.(6_F^HVZM?)=!^H9\4/[JN_
MXY])?UAQ"W\WU&W5KY+H?".^3X^'M2<:H4<9L9Z@\P9IQYUN=!&G'&F"V,PT
MTT=LB&88,6]B&,8MB$+>]BWO>\0M_-]2_B5_J9XO]WJ\.O[EL>_BQT!_5C$+
M?S?4?B5_J9\"8_)[?%F;!9TU5CRZS02=/</D35$I45;708B&"4+&=<FC;XL2
M!M0XI>F97@Y(XF)%"944> @90TYP1B+$CCS?4?B56ES&L''Z(^3W>.N+4S3C
M#>U M%EWC%:UB+)9UD-=O]$-Z&66"FCS<DG$D94I%F,H&YMD#\G6+B$R9H9R
MO=C" [:T6@A2DHX\WU#[2IMPX3>%O S#^H9\4/[JN_XY])?UAQ"W\WU)MU:^
M2Z'@4>!#Q,*P!+5<FDJ2P&E'@ HNWHXX #B1Z,)."$RWQ!":4/6AE&:UH98]
M:$'>MZUO&RM_-]1MU:^2//\ J&?%#^ZKO^.?27]8<0M_-]1MU:^2Z#]0SXH?
MW5=_QSZ2_K#B%OYOJ-NK7R70?J&?%#^ZKO\ CGTE_6'$+?S?4;=6ODNAQ\?R
M>[P\&C&89Q@P&&&"$,PP=M= C&,8][$(8Q"MC8A"$+>Q"$+>][WO>][WO>(6
M_F^I?Q*_U,_/^[U>'7]RV/?Q8Z _JQB%OYOJ/Q*_U,Q)T#\G;\>,@H6W8ES'
M04;IB\9+"7AOK&Q%MJ] JF:+38:8S3 ]/+<*Q7Q.M0HU(MZ/">Q/.BB333 -
MJL0?8&(X\WU"[2J4VVTFF9;C?@$\6"!ECP9'S E>Y8@CK8U/<D+N;HM*:Z.!
M*1-IV5E!+MPO:5*XN1)B[2(H)9!8A@T$H/J!UI"W\WU)MU:VTL<B_4,^*']U
M7?\ '/I+^L.(6_F^HVZM?)=#P'> _P 3"D1 U')I)XTIVE"81UV]'&B3J-!$
M#1Y AV^+9)V@#&#1I>PCT$8@Z%Z!;UM"W\WU&W5KZ'G_ %#/BA_=5W_'/I+^
ML.(6_F^HVZM?)="9O+'$/+_%+5,&3F6L?T:-D]<&IUEB;YZV',_BJ]C3+$C6
M?[:P)9*U"#W5.O5E^R;349)_M?74%G#+*$"^\9]2-MXDKL$& , 8 P!@# &
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M1ATFBK'.=.8I?4<C$0Z(IM 4NGYR)BRU:@9E E5.RD]=UN=U.$K(M!P9& ,
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MMZ^G6  @ $0QA $(S-ZV8((=:$/80Z"'8Q:UZ1;"'6@ZV+>_0'6M:^C6 ?K
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M@<7<@EJ&%4'EWG[V\6;Y:TQT>ZA@0O@S7/%DC<)HW-X!,.P)T,I7S&7K'Q*
M.B7%3+)0>I 89('<2P7:>KYOWDC+M;U=6].Q1)!JH@<2KB&H52]<DB\)8&R-
M,9*YU5FKW1>%M:4R5*)<Y+CSEC@L&6)2L5&C/4FF&BV+8DSC<YW@# & , 8!
M^0@ #6] "$&MB$/>@AT'6QC%L0Q;UK6O2(8M[$(6_I$+>][WO>]X!_!E@- (
MLP # "UZ! &'0P"U_?Z!!%K>MZ]/T_3K /[H  B&,( Z&9ZOKCT'6A#]36]
M]<6M>D7JZWO0?3O?JZWO6O1@'ZP!@# & , ])R;D#PWKVET1IW!L=$2IN<4"
MLH!Z1<@6D#3+$:H@S0@')U*<TPDXH>M@,+&( M;UO>L QA3M$5-03(\1ZI(>
MEB3;(7HJ0OX@N+V^.;V\IV)EBR):[/LD<GA\<1-D7C<?C302L<3D[/'F-I9&
MLE(V-Z5*4*VWB9;WK6];UO6MZWKT;UOZ=;UO^_6]?^NMX(?@))(-@V HL&RB
J_8E["6$.RR?[._9 WK6M@+]( ?\ ##Z _P!@/T?V=>@#R8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g16439g68g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g68g01.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2+:4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "O*( .$))300E       0IJ5YC4=@,/637BQ#
MZ;<04#A"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24T$"@       0  .$))32<0       *  $          CA"24T#]
M    $@ U     0 M    !@       3A"24T#]P      '   ____________
M_________________P/H   X0DE-! @      !     !   "0    D
M.$))300>       $     #A"24T$&@     #-0    8              K0
M  .<          $                          0             #G
M K0                      0                         0     0
M     &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M K0     4F=H=&QO;F<   .<    !G-L:6-E<U9L3',    !3V)J8P    $
M      5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L
M;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O
M1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$
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M&]G;O;L/]96!0:@ZJ]I9LL]KA&YQ!V/JD)*0MJ?5>:[&N9?4_:61#@\&-O\
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MY%?3;NG"NLXV4:K"7MW/8^G<UMM#_P#!/>QWI6_\$H5,]+&(-0==<0&V:[V
M ^QM<C;ZNYN^QS?^+24SQ\^SIME-^#8:\S%L#VN #V[P(]4"S<QSF3^ZJ=UU
MM]UE][S9=:YS[+'&7.<X[GO<?WG.16U.8V]EC ;2  "8+2'#<Z!_5V(!KL&A
M:?N*2DE%OI/:7#?7(WUS (!_>_-_KJ64QE=KV,<7-#SM<>2#JU,S&NLW;=OZ
M-N]Q+@/:"!INC?\ 3^@U%O\ 2<6/<X"S9MNY<UQC]&_=[=N_Z#_=^9ZB2F&"
MV@Y=1RK/1Q]X]2WT_6B/=_,;J_6_J>HH9+J77/\ L^X4$_HP^ Z/Y36^U1M(
MW!@X9I([_P O^TGIJ-UK:@X-<_1I<8$_FM+OS=R2F ) ,=^R)5D6U56UUF!>
MW99H#+9;9MEP]GO8WZ"-7TW.=CG(&):^DVC';:&.V^L=10UX&UUW_!JWT7$Z
M&[,:.NWY&-AMD7.IK!<'Q9LKY>_Z;/\ 0_\ I1)2.J\NI>^YK!NC:1&FUNP;
M*OI;_P"4K6!UAW1VBS$NNJS2T[;JH!8T\,_3;OYSZ5GM0L'!NRV/?M:RC':;
M2'-,N:7,I8/;_.;GO9^Y_A$#*QG5YEYMK=5562_9S )_1B7;/;N_/24NV^S)
MR"S(L,V.>YMCX<\OULV[OS?5M_ZM1R,J_P!.G&R:@PX^[V$;'[GN+G.L,;W?
MR/40\>IV7> P!KG/8VL3M&YQVM!>?:S]][TLEIHR7XV6W?;0?3L=6\<L]D;V
M^I6_;^^DILUTT$>H'S61I.D'\YCOZO\ TU+$OM9?-4.+#(!X)5+%ULU(:QHW
M/&L$#\W^TB_:*!5:&-(M?[=W@V==G]9)38S,LY5I-Q94^U@&X@^U@^BS</S;
M/ZJJL.7CO<^C(87!KV$UN&HL:ZF[VO#?IUNVJ!9ZP8 3($$C72='%OTE 4%K
M]020Z !X@_1U24Q%-KW$NU(]QDB2!S_62<7L!#3#3RWLIV%S'R=I?).T<C5"
M-MA.IXTB.!^ZDI__T^%Q'^F^JRBO[194)<*C[VUEK?4=[B[W.KWMV[/35#-R
M&V^FQC0VJMNQI@!Q&YSF^KM^DYK7;5$6"MC;Z[2V]K@&L:"V &C])O'[SD2W
MJ65>\/N(L<&AI+@"3'YQ<X?224U=6\:=E)C[@UP8YX;$/ )B">'*V_\ 9C[&
MAA<V9]1SM&S#2/2 #MGNW?3_ ,Q2'3\QM>]F/ZM!@>JUX<V3ZCF--E9V5V.]
M*QWIV?I/T:2FDP/W-.OT@!XRK-YKOM]&MK:ZZVEK7<2YNYS[+7:N<]WN4:VA
MMC;MWI$G< 3&TMUW:_NN^A^^K&,RIN77D^H*6-L-A+';GP/?L:UP_G/;^>DI
MHV;=E?M(?M)<?$$^Q6L/$QK,876WMIL;D,K@L?836X?IKMK-U>S&^FZMW\Y_
M@T+(/J6OOL'\YJ&C0-\&^P?18WZ+$$G<0 (T#8&I/_G22F_BXSG/K9D7/907
MF8W&&N+?5M;4#[G.8S=Z?^$4FXL.LR2PMPVN(IRB-NYK3L_1L>[\]G^C]_J?
MX3Z:6QPHW7D@&& ,<T.W&-S7[MSF5^G^?^^JV59=DV@,GTP VNN8 #1 ]OT=
MR2DS,_(98XU7_9Q:UX+J'N#MKN:;;&_SC+?SMRNY=3.H8=N5/H.JI;8QUQ<?
M5;6?2?CU;19^E8Y_^$^FLS&P<WUG%N+9;]G;ZUS"PD"L;7;[6Z?HO?7_ )Z+
MCU75D[ 0QPAX!,0?I5N=[?[22F(:*^ENOW2;[?3%8B&[6ZOC]_WJK70ZP.VQ
M(_-F.?SM?S&PM@=2R[&C#L,XQVM%-;&#1I.SW>F7_1>]K]OOO_PRS^HWUW9+
MS30S%J'M%-8+1ISNWOM=]+]ZQ)3.H4UX%[FEMEAV,>8)VRXN_1/CVO=LV_U$
M.I^.P'>WVV-+'N.I83^>W]YS/IH#22VQH<0(!+>Q(,#3^TD^176)'=VGF8U_
MS4E-O[/9AEYNN%5[/3- ;#]PL:+A9N83LVU^B[8__2*MFV569=ME%(QJW.EM
M&YS]O\GU+/TC_P"TC7&]_3\5K@?2K]1U<<:N:QWM_-=[57N:YMA#AM> -T^,
M)*8O:Z=Y$!VH*=P:3+M# F-9/BH=Y224_P#_U/-ZZJ@QQ>QVTL!#VNT!_><W
M;[_W$,8YVFQ_LJDAKW: ENTEC2 [=9M>B8^5Z+/3M MI/N#-"02.0?S=WYZ/
M8^JH5U6ZV4M_1UN) :7>X.<W^;;_ ,)^^DI55-56<SU6U/;5ML=07$M<SZ3F
M&RMWYS?Y7J_]<_1H+\K':^]M%5C<>UTM8^P[A <&"TUM97;LWN_P:ED8N1C<
MTO#@ ^XO!+VD$']*-OZ'Z3'_ /",LK_2*M8&$>HP_2)W,/(_\Z24VW9[LNX;
M_P!$"0&55?0'&[:QY=[OS_\ 1J8-9!]Q]-KBT:Z!H$>[Z+K'?X3V*B',.T/]
MI;W'?XJU@5NWD.:U])U=NU;IK[6_O?FI*6LQM[C72]KF EY>2!N$?2[.?_)J
M5O%Z?>-H:V+S7N8Q@#K8=OW/=7^;MK9O].O]+^>FR7MEA96&PW:7#O*ADV78
M-]8Q,E];O29:^RLN!:ZP;G-8[]YK-E;GM_XM)3"_,QX94+7Y+:@W;ZC6[8'^
M <-+'5U_0^G_ ,6B59%A8UK**JL=TN>]X%=;P'>IJ7>^QC7-]E>^Q=!]5/JM
MD_6;%(=G-Q\.FT 5V5BP[R=&,:7UV>__  C_ %/Y"YCJ]F[+]#TZZ_L8.,34
MYSA8ZMS@_(>][GM?9:[_ $7IU;-GZ-)22[-I:*'TY&1=D !US[# ;:UT4_9W
M[B]U+*&U?397^D6SUOZXU]88S]09BW; VZUADV$#^<=HU<JI,< X$^*2G1QP
MWU YQ( [C0RGZCCC(?ZV.?4>[6QI :XNY<\?F.W)&VG9N[-'W^:EAY+*[@;
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MDE/_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !BDE)*@ (    #@   0,  0   'H%
M   ! 0,  0   !H$   " 0,  P   +8    # 0,  0    $    & 0,  0
M  (    2 0,  0    $    5 0,  0    ,    : 04  0   +P    ; 04
M 0   ,0    < 0,  0    $    H 0,  0    (    Q 0( '@   ,P    R
M 0( %    .H   !IAP0  0     !   L 0  "  (  @ P,8M ! G  # QBT
M$"<  $%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#8Z,30@
M,3$Z,C<Z-#     #  &@ P !    __\   *@!  !    G ,   .@!  !
MM (           8  P$#  $    &    &@$%  $   !Z 0  &P$%  $   ""
M 0  * $#  $    "     0($  $   "* 0   @($  $              $@
M   !    2     $    X0DE- _T       @          /_A 8Q)22H "
M  X   $#  $   !Z!0   0$#  $    :!    @$#  ,   "V     P$#  $
M   !    !@$#  $    "    $@$#  $         %0$#  $    #    &@$%
M  $   "\    &P$%  $   #$    ' $#  $    !    * $#  $    "
M,0$" !X   #,    ,@$" !0   #J    :8<$  $      0  + $   @ "  (
M , #   !    P ,   $   !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$V.C V.C$T(#$Q.C(W.C0P     P !H ,  0   /__   "H 0  0
M )P#   #H 0  0   +0"           &  ,! P !    !@   !H!!0 !
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MP? S4M'A\0H90U/_Q  4 0$                     _\0 %!$!
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M8"M>]CW-Z-.W]3'Z#MR#QS7WEK4WN(5,G'\<O0N>4MC,6:@9:$ZGM=T?Q&]
MSA5$<C>L;FE:CANZO 9O&-IQIA?(.!U&0@NKO'UR$,3/)U.=M=-D54YRPI+*
M!9B>G'E1V/\ 6::4Y!$*)HU1&KU^ HO/.$_W-Y!NXD591:>68EA2R);@//(K
M3F>V,0Q(SGQB%(UO47T'.&C]]&F*S8!CI<[I[Z15_"IV1=+V^57OK7W[Z1?
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M,V\1U"YP3,Z7#ZM/1$1'KT*J_P KNR*!>D1X=/3@;98^7&J$*,-6DE#<R\O
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M>CQ3ZQQ:]S'.ZE3H<QC=JC!M1-> )/E[\G_-7F5Y(Q?C'BS%RY)E.5S&0*V
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M32(IXHCADT09B7,&&^5+%#]Z40$<I7E9U#$]_@!U.#99S>228Y5NA5<&/(+
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M(UCCA@^@X,BT%+$)L83_ %D<$T<AN@PWHB,<K? 8>89O=5.9 L)^4W&=9%0
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M9]E!II>0TQ_U$Q4(PHK@XWL@%](CA&:Y IV*S[*CRH]LE),G0"P'U7L+&LA
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MP^FM4)X<03Y:,DDL"3I@$8*,K@I%KRMQRVX<#&:(M?CE43UZYST#'RR\5D0
M14U];QT&)]4R8PTM$&%AO0*T!'E]/3@KE-Y@N7J $R)1W4ZG*K5+%-7/8">%
MY5>U\F-+&-LA3N"5P'$&5'>EU+V5RN0 '-M+HUD2RFRYIY\LY))Y4@YSR3&=
MM7D,8A'F>]RJKGJ][U5RJJ[3L@5WP'=/A/WWW^KO]OMV7NO_ .+KP'?6O^_V
MVO[K\_/QWTB=D3XV'O$F2H;B^V(HU,QPB=*(NV.VCF]T7M\?=/LGSX G\;<1
MY5R7.D Q]D0<6N)6I=W5E*'#K*,-M/%7@F3S(I#^B,SU>=L4$DXP#*;T'-&Y
M4#:I5TN7AP67QSB\?(I6*$H#Y3B. S+#&2/D8_C]6KK[+K48Z^+>6'J302[^
M&R.\:!KBC U7@#-(\ >7.N3.7)=?15V1YS279ZUD;,,MO+*0"ER.C@0P41JV
M++CQ$?55]-CPZZM+%"5XI4-CFF&P;6,\ F7*;;RAS>TKXF4UF0UM5-]A"N,9
M(8-)+!&8-C#1A.%%>]HU;Z3C%"A)!0J5ZKM'* DDJ\D@SBN17(JE<7X4RNTY
MRJJ]U3JWO>T5=]^_@,(8W2#M:/6WJB*G;2(GY5%[)VUM%1?OK?;P!:Y0QBIQ
M2KP>'!R:JR*998Y&N;056Z2JT4R8\R.II[3-:U)T=K&D)Z6Q=)6IM'(J> $8
M7L:]5>SU$Z7(U-_';LNE_P"^M(GW\!F(A61E5R(Y3=D:Y55=+]^_?7WTFOZZ
M\!AL8J.Z7*C>R[WOI1432=^_U:_=/Z??P'D[OM>Z_P W=%[+I=(J[[_?_+]O
M@)RB$AY@AK+6&K516R>M6>F[6VJCVN:J?.D5%37;7[@S?&>=CB%/B&4K/R6M
MMQMKTC#MW5P[D3Y GNI+:P<I2BK#]"2!O&QZ1IX(IGJS37(&%YB.**G$9]/D
M.)4UG48O>UH'$C3G23!@W@!(VUAPITAQVRH@CO&C'K)(Y'.*U7]'I.< \X:&
M >4R?=PH]H)M/8F6KD!,=)OMHQ9) L$%KGHY@ADDN>J*P(AD*]4:Q7(%'L9\
M>?9%D0X(:YKS/4<:.CFL"B]2L;WTJHUO?J1.ER(BIOLO@-Q^+Y)&3@&AXSS1
MF !Q65G&(9I973>.:F;RA*QAM:PEVRIY!3T+1V.C>-12\<]=D=T\89#G*C"J
MT %D,\7$_)%'#RS$9L3B'-(MR;IK9<>5"R*LER908\_&]3#1JN*PL> YJ,*-
MYAHY\@BDVB@):KCREQZ1/S/$YUH;,@9=70<9P!L=@FS*VS',D>ZES2R_=.Z3
MB#$'7L@'%+9(0WN&C:U'!<)&;9&3CS)LVY+Q2OO8?ZU44.))=5,"I9&G15-/
MR4%2&# A/DJQ[ZJ',L^H\ZN@FC4\8\0<U2#!6[[FK,[2R/)KY$7&H3HWL(57
MC\.-7PJV FMQX;6L+($YSVM(^2LDTIST<]\GJUH*KD?)&>9G/L;3*LNR+([2
MXD'DVUE=V<RSG6,B2K'2#RI,LQ2G)(48W$<5RJ56-5_4K45 @*VJMK*5'@0(
M<R;*FE8&'$C@*21)(5R-8*.,;5>YSW=OH3NY57OW5 <>JQ>SQVSQG"*'"K*5
M,!''=Y2W*:X[AP[.'&-9$":.QX/1KV1XI7$ XPS2F+TB>A.A%!W?[/3SLY)Y
M/<^N\TQZAQW+"MPNZQPD:WJPO;;2+^/)&QKI,M),F+'AR))G^M%>Q2?4%_N1
M%=U D7)^29;EW(V32:JK%C35LYUO0U,49J5(LR5*28?V"N3WCNA%=[;U3B&B
MIU"0:+](5^]Y)SJNI7X[5&L!6=E=%FY!>7$^5+F -<5]<T=='C3YEC75)F2!
M$L&WL*,*[/(-]$T"-:K@/&$8U&B6].7*.68=U?XPS')!R2:W$R843%KIS&Y!
M4VN53IGZC)MV^\<)8Y:,\ZN>$\TLD;@A<H!3)^7Z"ZS!\(./8O25]-9CAGE0
MYEM*).CQ#SP,D1"GM)$7I]:8*6B18L<#VQ1+':-BD80 ARE9W8J/$<;N["+8
M'KWW%G&E1G!*\<2Q=$ .,^8%-%'J%[@8'JKH[I!=]R*B@#^VT5/SKLJ)I.R=
M_NOW72]ONOW\!8(5U-$%@4=U^EOTBN1%(/>T5K7KMS=M56]U7:+^-HH6*FP3
M)LH<R;3PI<B(Y#.)-E.%%C#(!4=(&*1,(&.4@T5$4#"/*O6B(U?CP \U^-K_
M (?^?_.]?X!V1.E=_C_I_3_[^Z;3P'=@R%5&B&][G+TM1B;<Y47LC6HG4Y?R
MUJ;TFFHNE3P#[^73R>P>6.*<LY;RS-8>)8UBUH&KFHT#Y-A!0AH$:+8S8:N&
M98]S96$>BI& 172;5_\ O)0A&]? '/E_B3&^%<!Q!_',":>WN<?#-SJN.;U3
MSJN"P\I]\*97R3QUKSQA$D[]*&2$X+8J!*BH8H*]RQS#S#%MJ6\LK7]#L(>/
M2J6FDUL$M#++B]I6BKEANC-;'D+ /"84:^LOIN4YD:Q6OVH0DSG[D?+>*:C'
MI>07<TG%AK8E$WWP00:6ARZR',O&1X8O2ZY%I;N8>QD%;)*?8AO>P06Z +5J
M6.6.#"@5Y)]R=[VBAPQ.-,GE>]7.:(3=J\KN[D1B)U(GT_?P%7LWJ&04,V(6
M++ CHA(Y&*PH7">K',*SY:1KDZ2-5$5%3OW3P%]XOXVN.1;D591EA!()/5*:
M9*CQ #8G5OU3'>QB-[:ZG*B(O?YUX"(Y,XZY X[NA0\_Q>^QB39Q VE0R\KY
M->ZSII;5)76L%DD;''KIP%:>))&BAD!<T@W*U4V%!4;AM&9[509%^AVMM7\_
M"_C:JG95;V3Y\!DD0C4$XO5T.5O0Y&HY$:G_ #(W[KM.S?YOLO@,209YG]3E
MZFM[,5$:WLFU3::W\;WO:[3Y\!T;_*Y=[_;7RO=?A/C[_GM^W;P$_-QRP@^T
M(,L::DB RP7V,A)#HP'?*2D8JJ![%73F/5')V14^? 7/#95QA6:4UA,JG,N:
MV1$G0*>Y@N5'2#16S:P\RLL1M&>))":/*8(PWBEQ3A*UKPO8Y0=_CGEO"N1,
MQOJOS8%R(55>5,Y^+"P+",:&#&,D]03HFJYT_&Z\6*^V66^:.$^78$(@6C$9
MS&=0&3D;B_R9\$LX)Y$P'+;W.<HN'GN<UQNY;,@XO32Z>1+CR\,N(=7%G3I
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M%':N,-(4!HD<V0%R;(]SMHJ=.T5JM5?A45J^ ]QXE,> !/<! IB/&7W1&QF
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MDBK&*.,Y!JB@/N;?+.W(J7BJ%+7)L$9 *.'ER^@DZDMKU$C1K#):;]3MJJ'
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MU3%K8UO'IR-+%G/E@-.!)DVL,I6/E!E/$]CFH]CGM5K 9;^U._MC\^_M&*7
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M^1+D1:_&::0RN@6TZ-!%33)1)D6'8N-,GMZ71Z85@&1--'%). QXZ.Z!M*Y
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MD,0D,K'%$)R/:4TIR(]0#5-R3G54(0S8B&[QR+$/ +66M5-)7R:DDE)ZQ3.
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MC%#*O9Y'/"']+IEA.BPUF/E++M"UH8CA!V1LN5)!'>7Z5.TB[0&TXOY0\N7
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MFCT1RHJ*B:5/  C2(U4(BHY==_Y51$7\*FUWI?M]NW@"'A^(UN2P[1223AL
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M@Q*0AH;AR3.>YCVR O8C0)*"0X%\!-\0LYCY+R"YY;PX]YFTBJ RSY)R"EC
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M]$[(F_ 50$R<\;7!,DWWA/2A6%2-BB*5Q7KTM>CD(OTLZGL5B.&J="HG4CD
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M_P"-Z_P^R?\ 3P#%>67B:UYPY8Q[!X610\3 Y)=K.R2Q%/?7TL2KC$FO(?\
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M39K#XY!8&HK#+*K*K*KDTLXT:0*+%)6S'-=)AN4+6&( CQL<[ZM/Z=]6E5/
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MS7QKP'Y3?. +,:%X\_S^@Q>CP#+F,C.L<>@RK!6Y"E*.6J*&;)"(*+* -\H
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M98JQ1="N63)]5K&L85BM>QZ_2X2M?\*FP]L5\K6:9,ZX(R9708E%%678FF3
M"00D17OZ?K_B.Z$=V1-]N_@(PE3Q!B\:TCV9R9%: >D%C(9F@$TK6(]9;']_
M5&C_ .$NE5%<J?C?@(&'C1>3K.GHL16)^I.:04*K>9@'/5NU1Y#$Z1]3TVU&
MJ[;E8O?OX"#R'B#+<>NX]"<,>18R ^KZ,4S9#A/1RL<!_IN=HC7[16[1==]_
M.@9B?Y1\9IN!L+Y;M^3J>+D]UEEA37_'A&JVXIZF$B/2W5R_0K2OT)K'*KGH
M]BM^%V%$E<<<+4KVOM\P?*B3I3@PF5KP%D1&I'&1A9/5M4:0CE1R(GT=/U)]
MU#V/R+B/%&Z/!:#&;B6*>DEV67$5EQ9'@2XC!OAA%*:L*,P?=ZJT"D:1>Q51
M/ -1@W%,#D+RV9YS7,K*LM?5Y+54C9DV[9&D@-8CDL9#BT#&?QVEE^DYLD35
M0+&*U5Z'JG@-7E@&537$Z&YBQE9+*,@GHJ:"I--UM&HJ=*IK2K^^_ =[VE=5
M+#*THY$>QCMDC4:HJL<JZ5FD7;5VJII4WKOW\! :ZNK[:3XZ=_=?C[_E5TG;
M2_.O ,AY:87OLV=7W&0WV,8=;1#Q,EG4C(ZRY<)0&>.&($Y60I)#&:SI&9S5
M376U45.P>F3<XV5?D,:!C0V)C.)D/64<&SCAD'-$]<A2K/<[J1ZG*1[GQFO<
M!N_H5$1-@9_+#.P/DC/+A_),GC&@QK'Z&_Y(O8&>FF4M/F*8K#).3!JZPIQ%
MGQ[G(E_W>I#&422)+& <5J=.P)K_ "Y^7'S!5^4VGEZR6ZQ>WQ41LBOZK)F+
M+I:VFED%T/'._ARXD"++DMKA'*DF0KVB:5SG/ZO )1F7!68XYD$BA@!9DKX_
MU$DTB^_CN:WLA&D'UN<W2Z5&(JK^/MX"/I.&\EFS# MB1<>;%KS6;2VY4AB.
MR/W0(NZO605R()@U8CGO5&:ZETH1EYG>1RH9<:Z$8!BQPJK!N]1&16>DP8FI
MV:(J=+E[(I'+U.VJJBADX5;2HD>[I+=[TBSZL_1'DM5Y4<+94:#K_E?U-ZD:
M/OK]O #BP8C#O;$&](ZKL:N8J*YO5W<O;79=HJ]D1>WQX R!PNG9@YL@D>YE
M6?I13@*XJ,8%7R7#*BLZ7*3K1K51RN;TJG9%\ /;K(+:Q$%A9LAK(4=@Q-:5
M_P#(Q%Z4VJ]M=M:3MK[^ KHW/F_PI!'DTBD1[EZGHJ)\;7Y^?G[:_P @FY3W
MTT(08;W,=)VXI47I>YK](K%U\I]/SO2[_E[)X"MO17[*]>ISW?4JIM5^=?LF
MD:B:1._SX#P1_9>W9/A-_OK7^O@)JBBLF6=9%*JHV3.CL>]O9R->]$5$[Z[=
ME1>WQV_/@-K'EIHA\S\GO\J^1%9'P2_I9UY,M8\4)<C"?&:.?>1V09Q=>W]=
M\+VSB.0OIC,YR,?KH4 =S_DF-57+^,4-#@-#38KB&&U-)#Q^,\JAGRF#>67?
MVDA!L67=6+C)[N2H6M?Z0],1K>GP"W<O!B$OHLZ)$#7H>#')Z$;?IL5Z_;>D
M77V7I3X1?MW I<%\HY8/+FP;"P-9TT#'[Q&U17H$)4?7/8[K(-BO158U&;TO
MTZ3Y3?@%^M"EO[T#C%>%9ENV./H<KO:C*9K&H/:MWZ35TW^7>DWKP#<^:?RN
MP>&\2Q'+ 9G.R(U_5UQGQI=0*$Z/[B/ZNO=ML9;SJ/?2CE$/;43Z4\ AD9CG
MFZ$>K=N:O4F]HJ=T5.Z:TNOO]O .'QUE%K9CQJIGR3RH]*HH4?U3.?NOG3$]
MQ#8U[7H)CE.9[7HKW,>_;432)X ES_,#F/)G,,>BRL,.31QI<>@B0(_7'='#
M4(VM@R1RE]0J''' SJ&U&QG.5ZH!JN16@>?-5E^86UV1X,EL:NTL<9K:"XL8
M/HB2Q@Q(HHT=JQ C P"MB((+U0A'$<-2.?MZM0%/P'#"6M%=P#Y!;M,4A!EF
ML.1'D&P:]3""0S6O:]-II7:;O[^ 5',J$>-7)ZT$A\@;'$:A'L1C_P#U$3;M
M/?MW;NJKW_":1? 5D$N7!.(\206/(9I1G"]XBC<J(G4U['(Y')^>K7[)X"<I
MKRY9;!GLLYC98-D&?UWN(C]HNT<J[^>_=5[Z_'<)G(<\RV[ 2MM+F3,BH=3J
MPW2Y5(BM[JY$3_!/M^^DT% <J[[JJK_-M55=?2J=ONF_RB]OMV3P'L/J>5NW
M*KG.:Q7+]2Z5$:GRN^R*FTWM=?*;\!M*\O\ PC$R+C HC95=QH,A8EK)K0JJ
MPCRF2A#&YP$DL8BL0BZ?I7:VB*G4J^ !>=X!49GF^0P7=-2S'[>+4B)$ UY9
M0W!C#4IG.>Q$?MRO1.ER(O;?W\ /[?BFJJX)0K/DRO;Y8VB8\@VM<D?K7^(U
M/4?T.76U:WLJ]^I$[> P9M!C^!6YI'Z/&OF0&JYL:P4C E<Y%1/40;G+I%3>
MD72IV[)X"2XTMI/)V;UV&3 PZ&DGRR$]&CC>V<%[0O03NOKZR>DGQM[=[7X\
M +>7<6A8=F4ZH@$*8#$:5'E_G5[G/157;G[558JJN^_5K[(O@!FKG(ND<NG:
M[=M;14[JBHJ+^W;:?GYV$O"N;>H!-2LLYT%MA%]I.2)*-'65&5S#>@=0O9ZH
M/4"PGHD1[/4:A-=2)X P<.\VY=QWEU-:QTBWL>-80O=55RCS0[".V0CWQC.8
MK2L81K5;U,=U-VCD^-*&USSRLQ',N/,9YUBX=!QFXS;&TKSX]3G&.DK$KPA*
M \-K(("/,XZ(0I"[(3NCG[57> UT<><?T1,'?R'9-+9306@HB0"N],#FO]9Z
M.4K>IVVN%O2C7?5\IKN%\SB'BTZN#.3%XL>T8>(W]0#**Q[HRQ>AX'"8-C.I
MR*O\9JHY/_;ONH7+&,1XTY'Y@;@']P(&.5E1@[9!9%993CR+*T:*&9;"6DM7
1HWJ4KOX G-;M5<I%336A_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g16439g73o56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g73o56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1C64&AO=&]S:&]P(#,N,  X0DE-! 0
M     "<< 5H  QLE1QP!6@ #&R5'' (   *"4AP"4  ##2 @' (%  ,-("
M.$))300E       03=VKSF[#&+J2[J"OVK7T0#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \
M   !  (#P     $  CA"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          .0   ';          !                          $
M        !VP   .0                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   .0     %)G:'1L;VYG   ';     9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #D
M  !29VAT;&]N9P  !VP    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M2PN89^D=0!MVSNV_2=ZB],9TKI;P2.F8NA@S4!_U5 4OV/TS_P K<3_MMO\
MZ024^5;F^(^]+<WQ'WKU,=+Z47[/V9B[M?\  B- '?2^S[?SE+]C],_\K<3_
M +;;_P"D$E/E6YOB/O2W-\1]Z]3?TOI3(W=,Q3,_1I#N!/YF.Y3KZ1TASW,=
MT[%:6@'2IAYW>-;?W4E/_]#U'(8ZRBRMD;GL<UL\21&JJU6#&IJ:\/><>DL?
MMK<22STF.].MC/?N_,]-JGG9KL1V*T5^I]IO;03)&T.:]_J:-?N_F]NU$%U;
M\@!IU:+&F01J#7N^D/-)2WVRN8#+3_UMX_ZIH3_:CVIM/]D#_JG!&W#Q4=M<
MS GQA)2*C,KL.QTLLW/ 8X02&N<SV?2:_P"CN]G_ $$?<//[BJXIJ;7Z5C0^
MISB2''=!<XOF73^<[_K:6V^G^:=ZU8_P=A]P_J7'Z7_7O^WDE-C<//[BEN'G
M]Q0!G8^[:]XJ<!+FV$,<-8^B[\W^6WV(&:.F9S*Z[LE@;58+8;8T26@@-<?I
M;?=^8DIJUYOU@WGU:,:&.#75MLASB2Y[JZW%^W>S'_3_ *3_ -4ZCG W5P9C
M=/W!9GV#H36AK'UN8;&N],V!S27?H-FTD[FN]7_MQ7,;"Q<*S;C-+1:]]K]S
MG.)>0QKG387?N)*5U*I]C*2T BJ^NQY) #6,.Y[]2WZ+4[LC!#MUUM6USP:B
M]S8+@QMLU[OSO3_2?U%(Y](SW8)#A8RD9#GF S87.K^E.[=[/W46IP<ZQS2"
MTD$$:B"UJ2F+<O%?]"ZMWP<#_%2>^AU;]Y:ZO:=X^D-L>Z6I.II=]*MKOB 4
M*_ QK:+*Q6UI>QS):&R-P+?;N!;^<DI)75CU%QK:QA?&\M !,#:W=_5:B;F^
M(5;9?0?T3MS3Q6\^W_K=FKJOZCO4K_T?I(M6178[9JRT"34_1T?O?NO;_+K]
MB2E"K&%IN#&"T\O@;M0UOTOZK&(/4+\FFEEN,&. >/6+X %<.W.:Y]E+-S7[
M/SO_ $HRU(^[E4+^AX&1;?=<'O?D.#B=Q&W:UE0],-AO^#_/WI*1XUEN275=
M7JQCM:W:06N&Y[6MOH=6]SW;F>HQG_">JQ7V$>N^.S&<?&Q4+OJ]TJ[).1:Q
MQM>X.^F1):[UVZ3^;;OL_M_\'3Z6@W^D/_J,_+8DI__1]!ZX=MG3'>FZX_;:
MVAK7[(EMOZ5VGZ7T6_I/2_\ .%>]6IU[0U[7;6O:X @P0:]S3_55+K I=D],
M;<\,'VL.K!;N#GM99L;S[?SMJO>TWMB/HOF/&:TE)-S?$);F^(3I)*6):1!(
M(*@'!A )EIT!)X/@41,0""")!T(*2F/L]3=N$Q$?-2W-\0A O9<6[2YFP0^9
M/+O:6_2]O[Z(U[7<'7PX/W)*4Z'"-T:@_<94'$&ZN#^]_!$)@3Y@?>84'_SU
M?]K^"2G.W5_\YG5.+B]^""UFP>GM%K@_==N+O4W/;^B]/Z"T*F,:ZP!H D0
M .&M"HMJ]3ZP7O<YI9]C96ZK<)ULL=NLJG\[\SV?Y^_]%=IKK87L8(:"  /
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M '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8
M   ! #A"24T$(@     !.DU- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    ! H@( "':0 $     0   +    #< "W&P   )Q
M+<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#8Z
M,3<@,#0Z-3(Z,38   .@ 0 #     ?__  "@ @ $     0  !VR@ P $
M 0   Y          !@$#  ,    !  8   $:  4    !   !*@$;  4    !
M   !,@$H  ,    !  (   (!  0    !   !.@("  0    !
M  !(     0   $@    !.$))30/]       (          #_X0$\34T *@
M  @ " $2  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    $"B @ (=I
M  0    !    L    -P   /      0   \     !061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-CHP-CHQ-R P-#HU,CHQ-@   Z !  ,    !
M__\  * "  0    !   ';* #  0    !   #D          & 0,  P    $
M!@   1H !0    $   $J 1L !0    $   $R 2@  P    $  @   @$ !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!) )@ P$1  (1 0,1 ?_$ !X
M 0 " @(# 0             '" $&!0D"! H#_\0 <Q    4# @$% Q0,"0@&
M!@<) @,$!08  0<($2$2$Q4Q010640D7&!E4559787&!DY25EI?1T]76(CA2
M4UAWD9*AMM37(S(V-W:QM+?P,T*EP=+8X?$D)B<T9'(U14=B9H8*)2AE@H.U
M1$9UA)BBIKC&_\0 %0$! 0                    '_Q  <$0$! 0$  @,
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M4\%Z!SAF^UAB_*+?K]?_ )VX7WO0.69UV&+;U1W_ $WWZ^/5?AP[:#%ACO\
MYX_8$+KZ^'K6X;;V]2_&@SRS.OEF>M85]NOAZG5ZG'A?C:] L,SM&.W5;B(7
M;PZKW]>_K^M>@<L?#^$'QMV"%>_7?\NW5O;U^KA08N89O>W+%MV?97[+_P"+
M;^'MH'+,X?9CX==^4+CQOVW\&_;M0.<,^Z%OO]T/P^OMMOPVZ^SU:#['_$JK
MWOH0P?>]][W%D?C?M_[5IO0=(/BS0AVUD6M80K6\:B#< BV__;)'X+^OU[?D
MM>@ZGN6.U[_9"VM?JY5[;6W\&]O5\/9;;JH,\X/?^./C;PBM:W&UONK^K[-
MY9F_\<>W'CRA7_JO^3_7:@QS@]_\H/;A_G"W]>W&_J^QU\=J#%S#-_XX^/\
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M$-TB=D-RK.*BQ-PB-;DC35.3-/$5R<L=U<;8-*BO$L@E+,V27I'$&5#9S.I
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M_&_"@SMZOK=?A]F]N/9M>^^_9QH'@VXWWMQXWZMNOA^FW9U[]=!C;CQM??\
M+;;AM;M];Y;\*#G!R1],CJ:(B=EMXPC>EDA3L03A!;0OBY&C;U3L),'DEFN
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M<J!Y6)H5VV\8%HV_ICDCZY4#RL30KZ0+3\,<D_7*@>5B:%?2!:/ACDCMW_\
MC+U;T#RL30KZ0+1\,<D=G5O_ -<N.W9O0/*P]"GI -'A_ECDCZY4#RL/0KZ0
M+1\,<D_7+P\?7XT#RL/0K?CXP+1O_3')/URH'E8>A7J\8%H^&.2?KE0/*P]"
MGI -'9_^^.2.S_YRH,>5AZ%/2 :/ACDGZY4&?*P]"GI -'PQR3]<O5H/('B8
MVA8L81@P$T!& 01!OWX9(X"!>UPWMO,MM[7M:@OE0*!04+TM:I,IYPROF+'\
MWA6+8XUXI?\ (,8"[P'(#M,%;T\1#)CK"@DJVI_CD.>X_9N2-)Y+J-:Q'I'9
MX$)6PKN@PH5#J%]*"%L@27(0,@0;'^/W&&,BB21'(LO<GB8QA[EA)9,)>,:,
MZ=M0MK+,H4,DU<.?FJCERAP5 * V%D 1BNI$>2'Y=#:D/3'PC\2L\_?[0.AM
M2'ICX1^)6>?O]H'0VI#TQ\(_$K//W^T#H;4AZ8^$?B5GG[_:!T-J0],?"/Q*
MSS]_M Z&U(>F/A'XE9Y^_P!H'0VI#TQ\(_$K//W^T#H;4AZ8^$?B5GG[_:!T
M-J0],?"/Q*SS]_M Z&U(>F/A'XE9Y^_V@=#:D/3'PC\2L\_?[0.AM2'ICX1^
M)6>?O]H'0VI#TQ\(_$K//W^T#H;4AZ8^$?B5GG[_ &@=#:D/3'PC\2L\_?[0
M.AM2'ICX1^)6>?O]H'0VI#TQ\(_$K//W^T#H;4AZ8^$?B5GG[_:!T-J0],?"
M/Q*SS]_M Z&U(>F/A'XE9Y^_V@=#:D/3'PC\2L\_?[0.AM2'ICX1^)6>?O\
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M6:<:8$SDG / 7<%N;O>X2K0*!0*!0*!0*!0*!0*!05IU(Z4\::GT>/S)DYY
MADTQ)+5$XQ/E;$<W=\=Y/QS)%[$YQ5Z41V3- A@/:Y)&'ETC\FC,@;WN+2%M
M5! [,JL]&WGI @%9XE]IA-QU"86TGY?B\TQ]ER3Y]C>HF.9=EZ34M;-<[9U<
M:G^1WW+RM6N>)6Z3N*+38A*624IGB&KX@F9HP5&4S)&HTA9PFK&&CW%6&L&Y
M#P7CEUR0PI,KJ9\^Y%RHHGSU(<Y2Z?9+;NC)7E)ZR?)A/+RMR(<E+0DM#X<
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MAS?F(E*58DN\.P\.X;"&+[(1^3+7O]F(5^-@V[=N'503C0*!0*!0*!00F_\
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M%!UJ>*LXEROFO3-!8+A8<U03H>L?0M(RI3CUL;WB58]CT1U<8?DLOR>WH'A
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MKVWO0<2K@\37RIKG"ID2&2UF1FMS<_!YXE>2@."J"-"8,DTL"I)_TU4,M.K
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MOT!0.B5WHF?/:8[] 4#HE=Z)GSVF._0% Z)7>B9\]ICOT!0.B5WHF?/:8[]
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M *PP#!>X1!O80;WM>UZ#]*!0*!0*!0*!0*!0*#Q  !8 EEA"   A    V"
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MI0B5W,L8SNZYG.'N2287S9QR PXG8?*YDPOG @,Y0 AS7?&T>:#O<+A^R_\
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M=L=2&)PD[,QNJLU.%:B&I?F]F3IP7CK*B!SR14'J#R(DC3#%5V4RF_'[S)'
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MK)U2I$0K0$W5W#DF"21Z5MA+U%WYFDC.HN*R=U871$\-I]P;<L)2YO/4)C!
MWMRK -O<.]M[6H.:H% H% H-/R&H/20"<JDIYR94FA\F4)E*<P9)Z<\EE6F$
MGD'%B"84<48$)A9A8@C ,(1!%85K7H-PH% H*]:2_M8< ?BB@7ZN(*"PM!7_
M %78,+U.:9L^:=C)4M@X,VXDGF,+R] FLN41R\SCB]B"[7;A*48'1,D$LL8M
M:AK$@'1%90WC5)P*;F@"@N =)>L)SU&X S'JA:]%&-X[I-QY/,=8L;-(C'D,
M#_D-KFT;01(EKE:N<,D;28WQ7'D"4Q_:\.QN\S;;2\E@=N^4L$<3 5!V]4"@
MAK)O\N].OXVY!_<)FJ@F6@4"@4"@4"@4"@4"@4"@4"@4"@4&IL3:M1R";K5)
M-RTSL[M*EO-Y98NZ"$T99D!P[! ,0R^0K2GD\DT(!7N7RPAN6( Q!ME H,7#
M85MA6L*W"^U[6O;A?>W"_@O:U[>"]MZ#4B88V)9BNG"5?(RG5S:2VA>VCD[^
MHB:@"<1%TB\,04.)L=1.Z8!'<_2S8WH7!2F--)6J%0>;YH-<M+9-"H>X/V5&
M](K/:W2R8:G%S++Y5W:RGG)B4KZ;%4[6X2)L,*$<:8[MB R3E-B1,)<%V5$B
M- F"2TZ@I400I(%<9*DDI02(0!EB$4<"QA8KEFA :7<016O<!@ C#?[$80BM
M>U@_:@4$>XT_]!//XPLH_P!XTHH)"H%!"\5_GTS#_0O#G]HR;0310*!04A\4
MABF19KHAU"Q[%9Y!$Q41! O ,<DBT+7#C+%*&%^GJ>.S>;C)B4%F:J!MDD30
M:<R!6W-L-F)K')CW9HZ+LYI ZO\ Q-&^H)YUPY"E.0LE3*[C)<49@GF?,$RW
M5K"LW)L+IYUFB()-#6*TF)(KDR;$0*<P+3;#'^29-GC,R,\?F;KE9$$V4SAT
MYU2UA]#U!4_3)K'Q;JO69&28U9I^V^-BXM+3(#9K'$[!83BZ=*EF-@4Q+LY.
M#2^,RME7I'Z,2I''I0U_] 7G,UV=X:')<&UN\CCRO4EC-*E?F92J08=SZ2N3
M)W1"<>B.#.-.A8BE9)9XC$YEC"C2[@." 5AEC#>W* *U@GCI)N\WHO=1'SE
MZ2;O-Z+W41\Y0.DF[S>B]U$?.4#I)N\WHO=1'SE Z2;O-Z+W41\Y0.DF[S>B
M]U$?.4#I)N\WHO=1'SE Z2;O-Z+W41\Y0.DF[S>B]U$?.4#I)N\WHO=1'SE
MZ2;O-Z+W41\Y0.DF[S>B]U$?.4#I)N\WHO=1'SE Z2;O-Z+W41\Y0.DF[S>B
M]U$?.4#I)N\WHO=1'SE Z2;O-Z+W41\Y0.DF[S>B]U$?.4$=XK<6\,.+M=<C
MM?OEGM]KJB+7XSR2WMUCZKVO:]O4VI.02)TDW>;T7NHCYR@TEYB4,=6!UCR%
M:.($/"\MW5N$"?#(2]7=RSDQ]G3I2.GH%)RLT:-,6MLKNI3NB4ON!T3K4!AJ
M8895FRE(ZQ0#')HDLBZ-/=%+$\C)5&2IQY!)8$SNU/S:Y$-92P(BQ77-RR.#
M(7#/$<0X-MB;$&AY),B-HW64MSNUNT80Q8@*X4G?SF$J+/37S1IISDT.Z!\<
M @)1@)-NN3/1+.Y)  L><B"F,+.&'/,DOB<E:T;Y')/'G]E<"^>0.[*]-SHV
M+2N4(%S$BY$I/2J 6&$0+B*-':PPB#>_*M>U@Y7I)N\WHO=1'SE Z2;O-Z+W
M41\Y0:5DIQ;[XYG]K+T=[WA4JM:UE1%[WO=B7[6M;E\;WH-UZ2;O-Z+W41\Y
M0.DF[S>B]U$?.4#I)N\WHO=1'SE! VDJ]KZ8-/\ >U[7M?$,!O:]K[VO:\<;
M[VO:]N%[7MU7H+#4%(O%+FM2^>)X:XF9%)V6%+772CGMN1R^1N]F!AC*I9C.
M2)T[X[O7(-NV(&PXP"M0L"4:8265<191IG)+$'7AH5U$25ZU6QW"LR\4\S1J
M.=$^-4SP?AZ>:%L?X&A;@_/>+XGDU+#KY<9,811>ERY!(!-HO/9'B8QY32]L
M8W'G9(R$V0NQ"(.^R@4$-9-_EWIV_&W(/[A,U4$RT"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@U-R@\8=I.Q3-8W"M*(V4I3-;PC7N3<ILA6%'EJ&QP"W*
MTI+TT#$H,4A:7DI>VE+PDN)24M>G3J2PXQ.9.HZ3-G1^/23EO(.5NT.9(HP%
MLTJ"WV"I/[V51CO)[L;VY%WL0F;'3GXV2JL*X5Y!1@;JC YQBE#:^M;(YV+<
M&4Q_3C/0LTF0*8](0B(M>ZI,H9'0"=>4J2V#<1Y=BAAL5R5!8S$QA1PPU[&)
MA9C"]W+&$=@Y$RH6*X!6'R3"\D2@(P"N&]]A %:X1!OQ#>VU[;VH)$H%!"\5
M_GTS#_0O#G]HR;0310*!04+\4_C,(EN@G4JUY'R UXQAB2$H9,\RY]ACKDB/
M%VADJC\P;X]),;L2I&^9&C<W=&)#"9#C]E4EN\U9I"MC+9RUSH06(.HCQ(^'
ML0M7ZB4SLF;8SU&!PAJ3R7.X7D_1_D'2[,LW/NJ#4G"9Y.9_%ETPD,D0O^#L
M#,\.P_AK&D(L[N4PAI;@K<94%H+>F=ON'TUT&AQ#'K/"W_)TB;%KPJ696FZ*
M>OY#FL*4HFYV0X^@V."D; 26F($@:3&: -*\Y(<8K,&]K7=;90$I66F3A%+G
M"H:VZEL<KVZ)1E N=\/Y_4NJU$PM256YJ!SK3L>,]P4D)"SEIPSSCCA&J1F#
M$:::9<5QF#O<)_Z%9O.EL]P)?FJ!T*S>=+9[@2_-4#H5F\Z6SW E^:H'0K-Y
MTMGN!+\U0.A6;SI;/<"7YJ@="L_G2V>X$OS5 Z%9O.EL]P)?FJ!T*S^=+9[@
M2_-4#H5F\Z6SW E^:H'0K-YTMGN!+\U0.A6;SI;/<"7YJ@="LWG2V>X$OS5
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M'G$J\0$N$93:7,WJXTO8\032+3%M)4)G-@.LK?'DYKD"!<[J4URB&YS9$12
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M&4$O3Q)\ W-B1^!9,XO*(T.(:=.6I<#W#%,A:L[R5B9YYC*7V:Y0GU/2$R&
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MV-98Q-'X^R(D[:S,;)IW/:FAI;DA824J!M;4.82$:%&F*"$M.F3$E$E #8
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M?W=6E>B O2E C:>59P&LN@*,2-95DY1;<G/3HN>**N<>!-W2;8:@T>X4-?\
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M 4#HA=Z)GSVF._0% Z)7>B9\]ICOT!0.B5WHF?/:8[] 4#HE=Z)GSVF._0%
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MD85(F0!PR+/K.<4XM UJ0P)UPDQE28<9\B8BEN,28HRL<B0969USHR<TT)G
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M33#S'&,V8H&QMYF9WIS7KLM1-W4GOTU6IY0^O#TZJW\X9CE(Y,[O#J>8<86
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?+'QMT?.;V-L#ZAJ!0*!0*!0*!0*!0*!0*!0*!0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g16439g79m98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g79m98.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1Y 4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    N %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0
M #$ ,  N &8 :0!N &, ;P!A &0 +@!C &\ ;0!< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             "U    QP          0
M               !              ,<   "U                      !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "U     !29VAT;&]N9P   QP
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    $.$))300,     !0*
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
M# ,!  (1 Q$ /P#U.NME;&UUM#&, :QC1  &C6M:/HM:I)))*4DDDDI2SLC
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MM8ZFU_H?H_3]Z2GHDEFC&NP62W(>\WY@M<#J +3MLH'J^K9Z6X^JW])^C?\
MS7IXWZNM))2D.ZYM+0YP>X$Q#&.>?\VL.<B(=UCJVAS:GW$F-K-LC^5^D?6U
M)2']H4_Z._\ [9M_])I?M"G_ $=__;-O_I-/]KN_[AW??5_Z66=U#'S\W,HN
M;]JQJ<=I(KJ=6"^POJM8^S].&;*O0]/9[_5JR<FI)3H?M"G_ $=__;-O_I-+
M]H4_Z.__ +9M_P#2:Q!@]?\ 6R++'W6^MC>D'BP52\AG%%=WIX?INKN=]IQG
M?:?U_P#[HT^HV-T_KC'$V>N!NH< W(-GMJMKN^S?I;6^RBBNW%]?^<ZO]H]3
M/_FTE-G/KR,K/&35DY.-734!0QE-Y'K;GN?9D4M%==U7\PWTW?39ZW\Q_.*K
M91U5S,P>K<]][:P'3E,]386NL8!70&]*WUM?B^O@_I'^O]KL_2T+>^UW?]P[
MOOJ_]+(M-CK&ESJG5$&-K]LG^5^C=8U)3C](.7B6Y+LVR_)%PJV.++W'<Q@K
MM+*G4LKQJO:W]$SU'V6>KD66_I?9I?M"G_1W_P#;-O\ Z35I5+>J8%.:S MM
MVY-C=S6EKH@BU[=UNWTF.<S&R',8]_\ @+4E+_M"G_1W_P#;-O\ Z32_:%/^
MCO\ ^V;?_2:$>N]*%=UOKAS,9S6V%K7.U?HST@QKG7LW;V>I1ZE?J57U_P"
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M$_!.F=P?@DI\=Q"?LM&I_FV?]2$63XE"Q/Z+1_Q;/^I"*DI[;_%__P F9O\
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M !;/^I"*A8G]%H_XMG_4A%24]M_B^_Y,S?\ PX?_ #SBKJ%R_P#B^_Y,S?\
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M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      8I)22H "     X   $#  $   !M!0   0$#  $
M  !O P   @$#  ,   "V     P$#  $    !    !@$#  $    "    $@$#
M  $    !    %0$#  $    #    &@$%  $   "\    &P$%  $   #$
M' $#  $    !    * $#  $    "    ,0$" !X   #,    ,@$" !0   #J
M    :8<$  $      0  + $   @ "  ( ,#&+0 0)P  P,8M ! G  !!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C V.C$U(#$R.C0S.C4S
M     P !H ,  0   /__   "H 0  0   !P#   #H 0  0   -0"
M   &  ,! P !    !@   !H!!0 !    >@$  !L!!0 !    @@$  "@! P !
M     @    $"!  !    B@$   ("!  !              !(     0   $@
M   !    .$))30/]       (      $   #_X0&,24DJ  @    .   ! P !
M    ;04   $! P !    ;P,   (! P #    M@    ,! P !     0    8!
M P !     @   !(! P !         !4! P !     P   !H!!0 !    O
M !L!!0 !    Q    !P! P !     0   "@! P !     @   #$! @ >
MS    #(! @ 4    Z@   &F'!  !      $  "P!   (  @ " #  P   0
M , #   !    061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP
M-CHQ-2 Q,CHT,SHU,P    ,  : #  $   #__P   J $  $    < P   Z $
M  $   #4 @          !@ # 0,  0    8    : 04  0   'H!   ; 04
M 0   ((!   H 0,  0    (    ! @0  0   (H!   " @0  0
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MH1HC-D)$2&1VB)'!T?'_Q  4 0$                     _\0 %!$!
M                 /_:  P# 0 "$0,1 #\ W^*!0*!0*!0*!08I=QY[9RZ,
MVA(ADADP77D,G'.0PG+6VZ-P!VFKPAT>,=GS;7200@TU1.8\1=72'RY[++J6
M#-##R1$AQ$2#=IY![S[LO=EI?MD!G%8Y%!42/*B'!N11IN22TZ&0W5%-;MYM
M/FD?VZ\,R4$8@IPML]#V5!ZC30&B<7@MW)(CB3DXX*3A/7.QH;#CB)R2 I0_
M/27:!#7)\L%EF:<W+9=N;,@)89%VA$\^?IQ:,ZN]K) !'<'[F\1CRHQ=0DZ
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M*!0*!0*!0*!0*!0*#7K\<3;&G\,=0ZW.[,T4C,8WC,9,[U_(-D<'17< 4W)
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M&;=')5*RF&*ED\[Y8VSQQS\GG6M>P;J5 H% H% H% H% H% H% H% H% H%
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M!%5)US(BJL"F>S)7*0:JR"O0&*K=PH)+,LW#97'%1LODHAG^J3O>X4C^EO\
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M_P"1]%=;$8J:U+J'7<\EL[&01>=M=&RB9D(Z<>,Y/LD8<?&&C5 ;=H'M;/\
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M-.IUN+F9;:15#I7V'B6THM$^H(Y-MP3S6CN&3-KLB")DM,,I)''XFZFKR9
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g16439g80t23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g80t23.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1*X4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M   ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    !
M "T    &       !.$))30/X      !P  #_________________________
M____ ^@     _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M #A"24T$"       $     $   )    "0      X0DE-!!X       0
M.$))300:      -9    !@              K0   YT    2 $$ 0P @ $D
M;0!M '4 ;@!E "T 3 !O &< ;P M %( 1P!"     0
M       !              .=    K0                     !
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M;&]N9P   *T     4F=H=&QO;F<   .=     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
M  =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L
M;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U
M='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT
M3W5T<V5T;&]N9P      .$))300H       ,     C_P        .$))3004
M       $    "#A"24T$#      (EP    $   "@    '@   >   #A    (
M>P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(
M" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1
M$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ '@"@
M P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'
M" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&
M" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3
M\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2E
MM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%
M-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&
M%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]3LL;6V3K.@
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MSS[#]F].OZ>_U5U:22G_V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU- "H    (
M  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!*  #
M 0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0
M "W&P   )Q  +<;    G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,34Z,#@Z,C0@,3@Z-#(Z-38   .@ 0 #     ?__  "@ @ $     0
M YV@ P $     0   *T         !@$#  ,    !  8   $:  4    !   !
M'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;  4    !
M    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0
M   !    I    -    /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-3HP.#HR-" Q.#HT,CHU-@   Z !  ,    !__\
M * "  0    !   #G: #  0    !    K0         & 0,  P    $ !@
M 1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $
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M"?/ JCD7\AB(KXL9ZI]V&B.17JJ.8YJM(1KW/$,7C6_R6>]*'4&2T]IW(WV
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M\L,B1>_PR:T/>FOP[L] <<LO-BX$ML5K7'VNL[:WAC6.&VN\C/=V>9BC50%
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M<,]5S<^N8>L,%L,'L-%P]E46,W.*TMO4X=DLBTP84PV+0[*')!2@,:PN#C!
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M2>YZ?#V=_*H<  $#;K[!3>X.G-15E2M#6ZLUS HU"L=U/#PC&8U6X"IV4+H
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M;^^20(B_-A4+Y?M\DL1:_%V&BB(U1EM3I[<IS514<D(**JQ^Z?FR".]]$5?
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M<4I!?4-4)ZF_7EAO3_C[GVO2UT?3R9%OC(XZJZBRK8LN0,<G *^:#R%-EJ*
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M0<6!50I6?ADV,R0]?$46(,Q7_/BQ41>U?%D]OW#]*GE7V?>?UJ7M@T!:#)[
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/'%*.*4<4HXI1Q2CBE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g16439g81p33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g81p33.jpg
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MQ  8 0$! 0$!                 @$#!/_$ #$1  (  P8$!@(# 0$! 0
M   ! A$A,4%187'P@9&AT0,2,K'!X2+Q0E)B(X*2TO_:  P# 0 "$0,1 #\
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M%O(YZ>W!!A9#!7W5$73_  JW#<C5<@YS6)#/(I414)*>HTHYS5'O?>IAT@=
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M\<JY*/'J&EE(<7+3TU75R%/7EY,E># (\AR\-Y=,Z%9'+VMY5R^R?31A%9T
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M)&46$)A,;7=KI!Q9+-L\S&N16N=&QS4<G"KSI-X+_P"5V'EAPZON5'[N5O\
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M%[0+IA\_#.7)$CCK,MZQM541[W+RJN55N.W5$06:,V"Z@L: : : : : : :
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M)8+DA]U\:_9ZD_=0/^!H)+!<D/NOC7[/4G[J!_P-!)8+DA]U\:_9ZD_=0/\
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M\.#];W_3O]7Y/G]W'\KS.?Z]<IW7%R6"*KH:- - - - - - - - - - - -
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MB-\RZLEM2/*<OU>V.A:QZM7Y62\._P"(FJ\2Q+.9D%KI*DJ\OA^QU/ZY'0:
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MW/%H1D_6Z-OP29\:KQSYKE3V5%68[=%U-@5)XOIN9M@U!8T T T T T T T
MT T T T T T T!#/Q"]K6;P]%_4-A:#^H,_T=W&2UC&L[YOB.'-9E0[!TX55
MG);42!,1OS/0ET:>[]5"Y1+ES)B4TS6A]GEO8SNE;=&@5[%,QO>(J(B+E/,C
MB-QRH\A7ISRC7/#(:SGA%6.3CZ+JO$NW\?)D%_.^_7>;)7^,]D,&/>'7OHLK
MT;+<2X%2"(J\*\DO/<<G[6)^;O3B$.X3W[6N7\M3!ZM)V\OGM4V*S7?2WWH6
MGX)&U";;]"V'7<XZ16.YN07^82R.;VRNKX"4Q^OBD14Y[62U!Y$2KSRTON1>
MUR:WQ'66"Z[D9 J3QWW-O&H+&@&@&@&@&@&@&@&@&@&@&@&@&@&@.?O[0KM;
M]X>FG;7=@4;O-VUW%^%%S,;\[*K+Z]TGF2K[*L,%ACXT3%_D2G\(GXBZZ>&[
M5HUE*GS]XQ'<]5\KJMVFT+P_;^')^BGIFNH'-<PG:7%X%5BHJ>=7C+6D)RGM
MW).)(CT^J/1R+[HNIB]3W<;!Z5Q]V:5OM$)?QNTZ-]O1D20VXO=R#5B9\TRQ
M3S8"!#\B?/VNDBE[%XX>YKD1>6KJO#OX?),=J[;5QT)[$;?0[4;+[6;<0PM@
M7#,#QFA*C8B(U;$*J&;:R\-]N9[)2YW<?RI%]U^NH;FVRTI)(RQK#1H!H!H!
MH!H!H!H!H!H!H!H!H!H!H# O5'DHF)].F]5L5<B4$C]M<PJJRS,9'-%#>WE$
M;3T36BR/C0R:6V-$CB$1RN(>Y(T:[E4UL-8EJC(J)Z&E[P*,(3!3.I46N,LY
M:2Z.PZQ; 4D;1_7#/OH/4+'&G$,\D<TRL1J]KHGO8KI%@16]/$E):[^"()S>
MGZWV)*^-OB;\TZ1<>HW2G1A+O/B%A91AN[8R1 *'+ID@*YY1['3^2L+'(YOG
MM8_M58T5)@M>G8V.Q:_#)#>&3D%98](6W6- V\%F3@+KG%RX4CB&.KH/C!UK
M4BGB1O=V/CJ[$:&(CM8PMD"R)W2-F72-/S3QJ('30V :@L: : : : : : :
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MB1SNDB?"]RRP2,?!+Q+&]$Y-2;1T3FDRZ]8:- - - - - - - - - - - -
M- - 8%ZA>G;!^I7#@,+SNSS&HKZN[AR  W"[_P"!6,-E &8!&^7U =E6'0H.
M<1VP6-:6R.16S0I'(G<NIM6&-)VEF=,O1[MATJQY1]P;;-K\S+?AC;*RS:VJ
M;$N(>K@5K!@XZ*AQP".,HZ4VW,DF"G)DL; M8YX1%B$BUQ-VF*%*R9>G45TZ
MX'U-X#'M[N 5D5?6#7@&0@V>*V =?<@V ,)8CEADLJVXK98#:VPL*PV VL*:
M\0V98?();"1%B;ALTJ:U.C+*Z;NCS;3I?*R,_!,@W&OC<I%##LY<VR8:U@2$
M&9\\#AJVIJ*&IC)1\C^XV0&8WL?)$TAL<TS9-<3BM,4*5DR5VI*&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@(8]1W0QM%U/935Y?G>0;ETMM65(%"L6'Y. #4V%/7
MV)UDP$ZHO*'(0$81-8EQF3 P@E$1/C[I_-@@ECI1-45A+A3K[&=-C]F<3V"V
MWH=L,,)NSZ:B0F3XGDAT%A>VIQLSB#;*S(##K0/5%S.5\D==6UX3%_X(D7+N
M[&VW-FI)*2,']2/0YM'U/Y;CF:YO=[@X_?8W228]%/A-W35\-E6>J--#BLA[
MS',BC62N(L[5PDP" /D99%PG*9#Y$<.J)JBL,<*=IFS8[97$]@-OP=N,+/R>
MRHP#3CXRLMNY+VV>38/9(3R2L HPPZO8CV!@!AA1R/EE8.DT\TDF-MN;-224
MD9>UAHT T T T T T T T T T T T!%[)=Z+?'3\RIV6>/,LZW<MU+&^^"L"
M1<7PY=KALLKK2RK*!L%L8)D.6C)A=18.F1S[[**\<)+NP' QFT Q_DO4CNKC
MV+BWUG@-1C1N5&9/7XU59%$7 N,V.,VN9@BUN865C>X[1G$92S':N04J"WQJ
MOI!+$RW83DPPH@IX%\8%O3N#G&1CUP^/XXVBDS^;'I[L>139(L8KP]TRF9!$
M#69%:RH'F0F#X;=XA=7"T5=/3;CC3@#9,-4 6.5 649U [@T-C8T,%+%;S"Y
M+N&";8Y#60TXU%6@;@9BM/>R61.3T@]A1"XE4"T=2EC78MBEOD2C@V&[500'
M?I6@5BBW>W7N28/1"AESW%VX,(,S#+:G@Q.COK;99E'89C2I:V5R5;!8_FF2
M7HPT.18T$7"$>$=WH(VWJ /)C'4KF=\7N)#]T*B>WP7:(K-X]N B%9G5SE8^
MW^W69P4E1!/<.N+(&>RS&QQ.Q<F$@K0W0=,,38&&748<8%A9/N=OY)=T.>U:
M_&,2K:X(LG#\1I9SJS)6@!=39#[9F0X]G5Q7PP'2X+ME9W5+#8Y++7K(+CHA
M9[[8@?(0,B)OCN-9U)DZ3X+B1U;DF"A0QEU9.3IDV#VVXF)U-[NQ7$TN:+15
M^%1XK:VHYXT%WD,>,7@!SSLQF'#%6P F5H!H!H!H!H!H!H!H!H!H# F]65[G
MXK8X(1MS2DY)#,1DK,AQX:K0Y]NXFIBI<5B<<K6_!PZ[++JJOKHY3 HV8U3W
MCY)E;%P@&',,WNWE)I\2Q^PH@+7,2<9VO"NR;7'+D&VK+7(H-DPKS<3**FJ^
M'5/P,XW<3,R@<;I_@:QEX#9UT=I$P;+DV_ N:'>_<<_;2_S5F$R,N*>XI4AQ
M>K<+/=!S3QN*N\(R6N&GRHX:TQ]S( ;6PF%QJUL&'I+#CN,2CM=.!4DW+WLC
MMY*"?&,8>07>,HP;L>ARWX371I9[9>?>G#/LE?8BMJMQ;**&NAL*ELI^W]J6
M^ZB&NYP\2 L]_4+O$ W'XC]J1B;*T<AL@0;IJJ"Q9+BVS^3KAM&;D]O3O(RX
M:/<;+ @9APK,G)2]M;*,?$J=#K=V(@4VOWTW%$DR:U*,&OZTNWN(,=N:7$R?
MN&$Z+%>G*42O7[P6^,DD(+>9;N+5QG'Y]0(;D@-S3K43Y##7XG3@57"]_-TK
M>\Q:JN<7J!9LJR-TA-8>&N/&8Q1GDX5*'BI1=OD8TYV5UF,9/8Y>R>&@>9DX
M-.@-?BX([[:_H +4W0W/WZRT#,JW!(DP(C$\LW!JXI!J1V1Y&4+CF![_ +L?
M6QJZO+([  3(;7!]O<SQJS. I8[F/+:FFBJKBKA]=E(%^XEOAGME?!XS;4E'
MAE8VV/IER#)FFVQ0EI27DM&+MY:5H.5F6'WURZM8-DN.7]O9 16HJV$5;CV2
M#0U=_?@9YV=O[_*=J]OLBRLNN,RFYQ*D/R62JK)J8.'(9P8770"5)%A:$5I-
M79>IK3P9S9)ACQ"898A7L<) !DC0#0#0#0#0#0#0#0#0#0#0$+NN3_LQQ#_Y
MAN__ )IN5H"36V?_ &;[??\ P1BG_P"A T!>^@&@-?.TG_KN[O\ _@>XO_WZ
M<- ;!M - - - - - - - - - - - - - - - - - - - - - - - - - ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g16439g82t66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g82t66.jpg
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MR==L<6^A)Z%>+QTM$2;95G(1S]L<4W#1XU6*15NX14 2*)*%*<A@$! !P*G
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M*_6$\N?&E.'TZHX:]C:4IU-@$=@&JYK!'[+VA..&\_3U+(52"D.'JQUZI ]
M\'*-'T<KL1Q&(H1:YEB-I Q)-PU0;)G>DF:__P">?7CLB,=?'#=VK";ITW+,
M331+-JJG[>F-,Z=:S%SLVHTI*M$L-<O%W4VI &K\10)B,2LUBI:E&30DHRN"
MQDVT6I$IS+!TLHL2*3UI7/CA'7.O"J:_433+K/*GUQ<^V;OGAALE:W.XAUZ3
M,25HL&]G4DE.0DFTG[E*6N456U9:JXX5U+-R8'@F1V QYG.P:"2N/XMZM(1,
M@C*F%Q$1:K&5(VQC&/$IF8XY\=\)PGS&#S-Q2WK4%LH>MV&LYREO+)"N44=L
MGKVOWU07O-S)2:HR]<&'=N8UNEV* +*1@30G,K:P6-"5LW8V=.R \;S%:S6O
M3C'#I_5X<.2LTX4[\/KC_=9YO#F608# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# _7SP
M:_\ LK:#_P#IE6?[D7,)QG[GRWC"/J/#"Y[%S*?C&ZG_ #.<^;FM[\;6C&D9
MQOZ/8N93\8W4_P"9SGS<7OQM:%(SC?T>Q<RGXQNI_P SG/FXO?C:T*1G&_H]
MBYE/QC=3_F<Y\W%[\;6A2,XW]'L7,I^,;J?\SG/FXO?C:T*1G&_H]BYE/QC=
M3_F<Y\W%[\;6A2,XW]'L7,I^,;J?\SG/FXO?C:T*1G&_H]BYE/QC=3_F<Y\W
M%[\;6A2,XW]'L7,I^,;J?\SG/FXO?C:T*1G&_H]BYE/QC=3_ )G.?-Q>_&UH
M4C.-_1[%S*?C&ZG_ #.<^;B]^-K0I&<;^CV+F4_&-U/^9SGS<7OQM:%(SC?T
M>Q<RGXQNI_S.<^;B]^-K0I&<;^CV+F4_&-U/^9SGS<7OQM:%(SC?T>Q<RGXQ
MNI_S.<^;B]^-K0I&<;^CV+F4_&-U/^9SGS<7OQM:%(SC?T>Q<RGXQNI_S.<^
M;B]^-K0I&<;^CV+F4_&-U/\ F<Y\W%[\;6A2,XW]'L7,I^,;J?\ ,YSYN+WX
MVM"D9QOZ/8N93\8W4_YG.?-Q>_&UH4C.-_1[%S*?C&ZG_,YSYN+WXVM"D9QO
MZ/8N93\8W4_YG.?-Q>_&UH4C.-_1[%S*?C&ZG_,YSYN+WXVM"D9QOZ/8N93\
M8W4_YG.?-Q>_&UH4C.-_343U+>74.5,G$7J@QSF*0A2LYT1,8P@4I0#F]L1$
M0  _CQ>_&UH4ZQOZ<S]ASVA[\-"\S6'YN1?CKM[6N3TW]'L.>T/?AH7F:P_-
MQ?CKM[+D]-_1[#GM#WX:%YFL/S<7XZ[>RY/3?T>PY[0]^&A>9K#\W%^.NWLN
M3TW]'L.>T/?AH7F:P_-Q?CKM[+D]-_32/J.NSB]H=Q4$!_L:P_,Q?CKM[+D]
M-_3Y[#OLWWXZ#YFL/S,7XZ[>RY/3?T>P[[-]^.@^9K#\S%^.NWLN3TW]'L.^
MS??CH/F:P_,Q?CKM[+D]-_1[#OLWWXZ#YFL/S,7XZ[>RY/3?T^#ZCQLLH")M
MR4  #NB,-8>0/_T8OQUV]ER>F_IM^P^[']^C7WFBP?-Q?CKM[+D]-_1[#[L?
MWZ-?>:+!\W%^.NWLN3TW]'L/NQ_?HU]YHL'S<7XZ[>RY/3?T>P^[']^C7WFB
MP?-Q?CKM[+D]-_1[#[L?WZ-?>:+!\W%^.NWLN3TW]-DWJ0NP2B)3;LUV AVA
M 8FP<H#_ +N+\==O9<GIOZ?/8A[_ ._;KOS38/F8OQUV]ER>F_H'U(>_@ B.
M[==@ =L1ZTV#N!^1B_'7;V7)Z;^FW[$9>_?PUSYJL'S<7XZ[>RY/3?T>Q&7O
MW\-<^:K!\W%^.NWLN3TW]-)O4CKR7MFWEK@ _IBK!\W%^)PB=/\ :)LS&,QO
MZ:?8D;M[^FM_-=@^;DWOQM:(I&<;^CV)&[>_IK?S78/FXO?C:T*1G&_IMF]2
M7N1!YIM[ZU ?XAB[!]_\C(OQE.G^TQ8F>,3&_II]B9N'O\:U\UV#YF+\==O:
M;D]-_1[$S</?XUKYKL'S,7XZ[>RY/3?TV_8G[7[_ 'K/S98/F9-[\;6B+OY6
M=7P?4H+4':'?NL@'^F-GP_PXO?C:T13K&\^(:1]2CM!0Y1W]K$ _LZ?^;B]^
M-K0IUC?TT^Q2V;W_ /6'FZ?^9B]^-K0I&<;^FCV*FQ_C ZO\W3_S,7OQM:)N
M_E9U:3>I6V H\AN(/5P#W>08^?[G^YB]^-K0N_E9U:!]2PG0#E'B%U: ?V?/
M_,Q>_&UH7?RLZM/L64W^,/JSS?/_ #,7OQM:%W\K.K;'U+>7#M#Q%:JY0_\
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M"FP& P& P./.?W0KY8X&Q@:%/!J>0;T1P*K 8$5UWA?*_4.7L8]OW"EO#O\
MJ4'-61@5#OPYO$7T0S&W\I[>(;6/C'?S*-E5C I\Z'.B+=_\ 8$5;O/A# B8
M$ >Z/C'Y<"O=>$#R ](V!"5\&;X/2# AX%2?OS>4;Y1P(#OND\0_*&!7K^"/
MXOUA@5F!5*>$4\LWI#@0'?\ !_E_X<"O5\&?R1P*O RIZ0_>HI7]E'_OKO,;
M?RGMXAM8^,=_,L>=JM=?I-?F+19Y)&*A(&)E9N3=J%56.G'0L<ZEI)5NS;)K
M/7RS>/9.G(-&+=R\6*B8J""A^0H[,724-7^&C8]@F=FI:XH$E8FZ=8&0O]HU
MBSBY&11G(&"M=;=-;+9Z^R6F2=;)&&,5XS=NACGR(0[E5M)1JS)L'-EM0Z-1
ME+0^<:RU6G,;";*%N;IQ3JF$A=69GK9RN6R**Q_3V!JI) S<KA(B[24?@V75
M SGHCX$JPZOTW>PF8VTZ^UK;^ODC'V*P,IRK5F</+RT0S"OQ<[,(O6+D[^0C
M8YF$&QDWA57+1@VZUH+$;)"@4-+C76EWJI+,ZHNL7:T;&1%?)/N*S55SL(>J
MR[&8@(4LFHR.+6-K<]&1LI#QP+$;0TM'LGK)%L\:H*$"# PNFZKL>U.*Y2:O
M6K].UMI<K?<8FC-X49^&DY9^V37F+\UB&T=,/E)*+<O'D8XFG,FD3J:6>M"(
M.VKI8.VD5DG"2:Z"J:Z"Q"JHK(G*HDJF<H&(HFH03$.0Y1 Q3E$2F*(" B X
M&Y@,!@,#KS:^S*]IW7MFV3:DI)Q"5=FW<+LH5J1],23I^_:1,5$Q315=JBO(
MRTL_8QK(CATU;=4NDQ<N6Z *+$#QY7.,"Y2>W']*M%&=T&-:[71HR=9F*VWE
M[TG&)<-[W<<@G+2$!L=_76\B>98.#0TI MK*SDH$\?&FB6[]\K-L N*YQ^ZU
MM49*GA*-L"2M36WZ\I,-18M[K*;F[+.[086:6JS1E+0.Q)2GQ3A&,IMG=V9C
M9;+"OZMUH<MY=LBZ%-$X0Y/CQUN[A'CWUG=P3Z4/6=D7NT0ZD'K\KRJ5C3MX
M6I%YF)QM+WYLU!:&E6QW39A&K2,D[0%($&Y70+(H!V0/&#0#7%& :U:_/:D:
M_5K5#K:K6+A34=CLVW0T7-P-.7:GL!+LJZ<HS<1'KR;2HN89G,R;*-</R'5,
MHF'5;#CAHVSZJC/4RN2#(K+9FF:Z52UQU(N &9[*V*UI1!5B*EL\\A2[0V*9
MT99A;SQ5AK9'+*64JL^ETL6J'=.E^*NB[QO%QHU6A+$P>4\TZ#E[+O*8;I^Q
MVRFJLBF]@(:VR]PJ;I:1*+J*97:N5QU+0YBR;-(Z?/3('IW 8# 8# 8$V-^Z
M+#^NM?TZ>!DSSG=!@,!@,"*OWX>2'RC@;. P& P-ASX!3Q!Z08%-@,!@,!@<
M><_NA7RQP-C T*>#4\@WHC@56 P(KKO"^5^H<O8Q[?N%+>'?]2@YJR,"H=^'
M-XB^B&8V_E/;Q#:Q\8[^91LJL8%/G0YT1;O_ ( P(JW>?"&!$P( ]T?&/RX%
M>Z\('D!Z1L"$KX,WP>D&!#P*D_?F\HWRC@0'?=)XA^4,"O7\$?Q?K# K,"J4
M\(IY9O2' @._X/\ +_PX%>KX,_DC@5>!E3TA^]12O[*/_?7>8V_E/;Q#:Q\8
M[^98&.+GAPNVX[:SGX&GZ]V3%K:5V5J]C!;$GG4(VUS<[<ZB7L/MFM]'7+(1
MU,,48Y2,7ZC)#S2()QXL)ALBH[50V8NC['P9;GD(UW#C&Z[G8>7NFOIB282,
MC#.'":%7X7ZQJ$'[7LRU[?:LAU'<HN15=J.*A+3G8\HF^K+J(FS%40#SK?M(
M7BGOJ;K>?I,/L?9;RG<&M:@K$:+V')6/7A]86:*CKK':XG@U\]J,M5IULVD)
MZT/C7>K%A(\THI98U=R6#06#TZ' Q?D8MNI6G%-H]ZG(SC,B+G?85RY0FI%K
MNN=>R&J$I&191B$G+L8-NHVZN;J+<ZN*&<K0I5W9S*JA32'!=LN7JUQ*RUMK
M76\?*SFDGL;I^@7:/&O'D=6Q=M93NP%5+%JN8H<I.V5S/PZ(UVSTF0CYB*KZ
M3RQ286%*-<M0WGO!=N>4I3:(GVE"D7B.B]4T%Q$UNP)59B>8H.^+MLOJ%@D\
MHE@J9D6E9F8!N#66ICNE3,XVD&!ZY%P1VAVH>Y>%K75TU5IF!I-\3K+>;CI:
MUO$F54;,&L8PB9FS2DQ%,UTX:&KE?&62:/B&ES5RN04!UP.N6+C4FQ2JK!Z'
MP& P&!PW85 JVTJ78=?W2/-)UFSL>H)1HDZ<L7'-(LDZ:NF;YDJB[8OV#UNV
M?L'C95-=J];(.$S =,,#HEIP<Z837>/)1*Z6B2DYJ1L$S+6N\V.=EYJ5E]92
M6HI%>2DGCP7BI'%'EGL:F@DLB@R4,@M'IM :-4T0Z^MG!)5FE/<1^KY!ZA;C
M26JG;:?O]MV!(.X]OJ%.PL:@-7GZM8H&:I$U#P]GEHN/E8@KR-%DNNA*UV44
M>KNBA9ZGX*Z13]?/ZW>'CNTV.ST3;FNK;+1TG/-&*U2W-=GMVLT+'#*R4I,J
MK-'+ELQ:V26D7<^[!H=^Z<%7>*I$#L'[$W3@6]I;@868O4L[!6Y2J)W&Q)41
M_>*S!M*Y!7J1J*3XD2YMD=$Q\>DG*="0%73!G)N$%I1LD\*%1$\&>DXI\YDU
M&]QFY1>0H3Q"4LMWL$])L&VM+:C=ZA#MI"1=K/%8MA8D$73@)!9](2"22;5]
M(+MTTTRAS&B<-VM->[ ?;,A2VF0M3F)F*^P<V:VSEE1K\%/S+6?EXB#3EW;E
M5!D[DV+)4@/%WRS%NU281RS./Y[4X=]X# 8# 8# FQOW18?UUK^G3P,F><[H
M,!@,!@15^_#R0^4<#9P& P&!L.? *>(/2# IL!@,!@,#CSG]T*^6.!L8&A3P
M:GD&]$<"JP&!%==X7ROU#E[&/;]PI;P[_J4'-61@5#OPYO$7T0S&W\I[>(;6
M/C'?S*-E5C I\Z'.B+=_\ 8$5;O/A# B8$ >Z/C'Y<"O=>$#R ](V!"5\&;X
M/2# AX%2?OS>4;Y1P(#OND\0_*&!7K^"/XOUA@5F!5*>$4\LWI#@0'?\'^7_
M (<"O5\&?R1P*O RIZ0_>HI7]E'_ +Z[S&W\I[>(;6/C'?S+$38^+KACJ%AE
MZI:-Y:X@+) /UXR:AI6QLV3Z-D&QA(X:.T5C%%)9$X<TY!'VH]W-F* GQG\)
M:O>\1NG0_P!I?:^C^F>DP+!/B]X5%>]XD=&A_M-I4M']-,IX&/GANX_G]PXE
MMFU':VZ-71VHHAK?%*;*24I1JU%NU8VYQ+"L@TLZCADG*BXKR[Y=N0KU<9!
MAWQ05*B*I0R2I\2O#FMX+?VE%>7N='M2BGY?]V>' GI\0&AUO [LU&K_ +/9
M%-/W?)F1P)Z6Z]-K>!VUK)7E_DKY55/1E1P)Z>U=7+<G0[(H*O+W.CN%>/R\
MO<Y.;(CW<"P3V!0UN3H;M45>7N='9(8_+]_M<UZ/+VNW@3T[75EO V2 5Y?Y
M.8CC^BY' GIRL6MX&2CU?]F\;G]%0?XPP)Q3D.'*0Y3A_&4P&#_O 1# U8#
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MK'/62S-N9JU54;-Q21(**"AT4Q*F<Q1#- KPZ</JWAM%:;5Y?Y76-)4]*#'
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M!S5D8%0[\.;Q%]$,QM_*>WB&UCXQW\RC958P*?.ASHBW?_ &!%6[SX0P(F!
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MD&!#P*D_?F\HWRC@0'?=)XA^4,"O7\$?Q?K# K,"J4\(IY9O2' @._X/\O\
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M@5>!E3TA^]12O[*/_?7>8V_E/;Q#:Q\8[^9>%,V8F P& P& P& P& P& P&
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M+66\>T-QK"]'. E@C"'- /NA$AV^41^^_#^/%^SGM/HN6LMX]HJFJ[Z8@@$
M81'D_P#M&(_C#_YAB_9SVGT7+66\>T;UJ-@?@^;SE#_6&+]G/:?1<M9;Q[5Y
MM0[%$QA"N&Y!,(A_K2%^^/\ :6+]G/:?2+LY3HAN-.[(.)>;6SCR /+_ *TA
M/K+%^SGM/I-VUE^O*O<Z4V.X;JH*57IDU2"F=)22@3IJ$-VC$.0\D)#%,7E
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MT^FP'7V$]V8KS@T^FP'7V$]V8KS@T^FP/H3D*80*68BQ$1   )!H(B(]H
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M5F8H\NLW82Q#<UQ+M&:K!86ZJ)&PD<'*"QUDS)@'#X;B2.N^B59F!.C6!U]
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MG^49_P#:./'A'&-<_P#Q5T"?XG[/'5.)=7/:3>$G]QZ[A)BPEJ$HWM\# O\
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M]\J__'&Q?6.*1E&D%9SG63UU]I>^5?\ XXV+ZQQ2,HT@K.<ZR>NOM+WRK_\
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..S&$<QG&?N6T81]0__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g16439g84j07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g84j07.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2.<4&AO=&]S:&]P(#,N,  X0DE-! 0
M     "<< 5H  QLE1QP!6@ #&R5'' (   *"4AP"4  ##2 @' (%  ,-(" !
M.$))300E       03=VKSF[#&+J2[J"OVK7T0#A"24T$.@      Y0   !
M   !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E
M96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;
M   +<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B
M:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M   !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L
M.$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,
M   7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B
M;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M 0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O
M=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L
M=                $)L9"!5;G1&(U)L=                %)S;'15;G1&
M(U!X;$!RP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M  !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P
M(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D            0
M8W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M       ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO
M;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \
M   !  (#P     $  CA"24T$)@      #@             _@   .$))30/R
M       *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0
M   >.$))30/S       )           ! #A"24TG$       "@ !
M  (X0DE- _0      !( -0    $ +0    8       $X0DE- _<      !P
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          .+   #HP         !                          $
M         Z,   .+                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   .+     %)G:'1L;VYG   #HP    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #BP
M  !29VAT;&]N9P   Z,    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M       ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M       X0DE-!"@       P    "/_         X0DE-!!$       $! #A"
M24T$%       !     (X0DE-! P     &<8    !    H    )P   '@  $D
M@   &:H &  !_]C_[0 ,061O8F5?0TT  __N  Y!9&]B90!D@     '_VP"$
M  P(" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,
M# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$(
M )P H ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"
M! 4&!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($
M @4'!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&
M!P<&!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ *5[&5W6
M,8T,8QQ#6M$  '1K6A7/V%U+V^UD/PSU .W&/1$:3L_G_=_-?^"*IEB<FX?R
MW?E6D/K'>,08GHC8&>GNWZ[/LO[.]/\ F_H>IMS=O^D_1?\ "I*:5G3,UFW;
M6;G/L-+*Z0YSR\55YIVU;&/V^A<Q2/2NH?M!W3&U;\QK0]U;9T'IMR-9#?\
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M.;)+=KO3V^HV/T__ )\M75;6^ ^Y+:WP'W)*>/LZ%TIC+,>NHWU4E@IFRB;
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M](*+CEM+1]DI.XP2+# T<[<[]!_)V)*;BKXG-_\ QSOR-48R_P#N-1_VX?\
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MDDI22222G__9.$))300A      !5     0$    / $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H
M &\ <  @ $, 4P V     0 X0DE-!"(      3I-30 J    "  ( 1(  P
M  $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    0*("  AVD !     $   "P
M    W  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$V.C V.C$W(# T.C4R.C$Q   #H $  P    '__P  H ( !
M  $   .CH , !     $   .+          8! P #     0 &   !&@ %
M 0   2H!&P %     0   3(!*  #     0 "   " 0 $     0   3H" @ $
M     0              2     $   !(     3A"24T#_0      "
M    _^$!/$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %
M     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!
M.P "    ! H@( "':0 $     0   +    #<   #P     $   /      4%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#8Z,3<@,#0Z-3(Z
M,3$   .@ 0 #     ?__  "@ @ $     0   Z.@ P $     0   XL
M    !@$#  ,    !  8   $:  4    !   !*@$;  4    !   !,@$H  ,
M   !  (   (!  0    !   !.@("  0    !              /      0
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M&B8G-$9C<\/B_\0 % $!                     /_$ !01 0
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MCV5T'%%%./7??3\]W;^3E4IV]7Y>JM.W0.7?6G\N_L[>7=U=G'CUU_Q6GB[
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ME9V9;?7-T7E39=YBK.IH I(EFY-P'2:1JZZQ,P;<,) N*)J*H-$$VM7-U$-
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MD0+1@8B$D I#K9:-H/0Y]JU*7CU6"Y"VYVDK5!LU0)!@,O[QH+ WN H'@T/
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MR\.(<>]Q_+3AX^OJ\O\ 17MK^<+S1*E/!2,==/P>"^7VM;>]H*/N*5YY;_\
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M>>?D,^5 /Z=H'JCX\\_(9\J ?T[0/5'QYY^0SY4 _IV@>J/CSS\AGRH!_3M
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M-_B4_P"'0.B-?8S?XE/^'0.B-?8S?XE/^'0.B-?8S?XE/^'0.B-?8S?XE/\
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M]%0)5-E?1P*6I%6MJX(0_:W\XT[\AQ"+Z]@Z61>6D+$FB: =L*<5,1\0TR(
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M&]RHV_E@]XAPE2E?O4<AX0Q-(4.3PX4HI6"L,6.KZ^.MU'=G'Q4MT':\'MZ
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MM=R$NI2E*=M:U^YGZJ4T&@1ONK<HEZE$HYB#")*]5L/?,^3N7F+6TJ-+JND
MYD%>]VQMDY "+K,7J(D\$N(!B:K1RDQ?.%&ZUM@2!ZX-FWW..*O^\A+_ /TS
MZ!ZX-FWW..*O^\A+_P#TSZ"')IW7R80"3N(O)=NT$;+C049DQ\NVSI/7L>C
M&82,M$P!60E6^V2],>Q=' 9-!TZJFH@(:MKRAA0>+I<\H%-XYO>V[[A,UGG0
M;:KBR692DN1\?[ASRZFYK+2#%U.,,8H@H2''5++MNZ86K$'C_+$2;K@6J5P(
ML1D#IX^8/C#0JY;!K0G=OMUAJ8HN VHQVYCC:&6'VQ\5N5SJ5;AX"SBP.:@
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MZZ@< NZ?SZ3#FY4'A/"KYDYL,WIW?=,RULO9X.%'0.1)NF3S;,W?,EX\;9/
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MGL"\D=,GM<!L):J7'VXS(K)L<;,\-NV^-V-LB=K2 <3"B2;^%T$+D'H=()A
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M- T#0- T$/82_!>3_##G3^V*;:"8= T#0- T#0- T#0- T#0- T#0- T#0-
MT#0- T#0- T#0- T$&Y8_&!MB^&R1?LWY_T$Y:!H&@:"JF]Z8EH#M7S!*P4R
M(8_,#@HA =+!BP9BY&.2TI A[$E#<A.1D-%!Y3OA406FY"0AD8**?O9C0BU4
M!V*VAV=E\AETLVS8ODD[F#:=RHRSD+XI(V1^'2QDISLOD'0Q+*4P*22Z,25G
M&F%&L;:GFA]X]+H"4WYM(><7(C6@6BT%5,8YDQ5%1LR R/($6"&6.8<W=,&$
M2[5L\;=(RU,72'/(*7TOLYULNBNGQI]\FI9=3JK2N@DC[H7!W\ZD(]/,OG-
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M5OHBV;9H313Y:E]ZE_(LMY5]]U]>-UU:U#N^K++_ '->>/C<'_WV:!ZLLO\
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M?,S+ $$-N\AO4(:*B=SPBZ9HK/Y:1--H\+'(KT>$WY%!BRL4<KIV5#O8^R+
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g16439g87q91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g87q91.jpg
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M\T__  =%_P#L@OW]7[GZ._/,=1X \ > / '@#P!X \ > / '@#P!X \ > /
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MZ%= NL+_ %X5EQ8;6;E5IXV)"AMWAWK&E_.YYR?T86C%3[SV$J.JE11I%.=
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M710( 89+EE "MBVO&'KIN9GUJPEJR!IUD)%%07+@ 8WVV<$"%'Y71#!T._X
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MC9SLZ_JG'J<B2+U[-RS6(T:PUV^>,!5"-(LI_(9-VIUG*0UX-'SCR=]]G?\
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M<6P]I2QW\%]]A.5RQ1'M6B:IX_BM20:.J*;2S6Z_.5-K?OR<3B.DQ6-.7\3
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M.!63%<>W(S\74KFM*@<TF\B3BV5Y>]9'#N[16JM!LLI6")5:U,OK^T I7AK
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MRB\XTBV4[2#CTZE:<81;.=MY)-MULI3G*7>.)1B<6.V%RD;;>9-#P!X \ >
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MT"NZ=%D#/MFIA*ROR)&"S)IOY?/GC5556W^#I@=+>GNT>@G]8VY_^@'V=_\
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MX!57MO3MT25.FS1$0M1N7U.53-)4U$Q15R7,G;W0_CWQLHN(3YQ,UO4UE4W
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M(^; #I8+A.S'LA.LB [-0S&NHOK%-'MK@EJDM=2PG6$^A97D*/ '@#P!X \
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MN:SI[/YS_BJEC<';51='BB:LBOLF'2Q1EDUW<E>&7,PY3MHB#8KX0'F89I]
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M%M-]-D+:;JK(\E"RJVOLH65SCWDH3A+L91[SO.]YWS)HP>EUN9QJ_C75/E:
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MZ($NF^@I/GA=&Q'JB.Q*%&5,E9QKAU:2[SNDLM_<<4V4O-6CK['$5\0M6=C
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M(CR"8]%8BN)YU5HRC[F'ATH];^IE(S3^I!C]6_D<I5Z]FJ-UPJN?ZEA,/IC
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M\\A1X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \ > / '@#P!X \
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MH6TGR'L8#@E60H_-%C8(1;.$![K>V5_6AZ;ZW'$M3N@>YO4K7](_3?96(/\
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0 > / '@#P!X \ > / /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g16439g92q71.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g92q71.jpg
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M 0$! 0$! 0$! ?_  !$( ,X"3 ,!$0 "$0$#$0'_Q  >  $  P # 0$! 0
M        !@<(! 4) PH" ?_$ $@0  $$ @(   H&!P<"!00#  4  P0& @<!
M" D2$Q08&5B6E]81%1875-4A-U=WE-?8,39VF+6VTB*X(R0R.$$F459XA[?3
M_\0 & $! 0$! 0                $" P3_Q  R$0$  0$%!P0" @(" P$
M     1$A,5%AD0(207&AT?"!L<'A$_$B,G*R0E(#DJ+"_]H # ,!  (1 Q$
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M(L)WAAW!S%K$>,99\FP-@-1TS,W\_A8B(NA]".CM3%!])&2J,&;AZW<DYT7
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M^S5:+KT,>F6&P7$KM:=.+MTN8X9FG#+&M:6\(XYS1ZP(R(" @(" @(" @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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M)FE)Z=VZN<L>.<<><L>,LOI\7'GGCCG+Q>/IY\7C^WGZ./T\_1_9Q_:LM/\
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M#FQVI45_#Z>,O$>COX.-.X^-CCEXN>&7'T\<<_1]/'"#E(" @(" @(" @("
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MHB" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M@(""*WK^Y%Q_PK8?](F((UI']3&HOW84'_:@E%F^><^ZST00$! 0$! 0$! 0
M$! 0$! 0$! 0?-UII]IQA]MMYEYO-IYEW#%QIUIS'G!QMQO/CG#-O/#GG'/#
M+CG'+'GG'+CGCGGA!D6XZ?U+0-J=73-#U=KJDF)&[+,-D%:C2:U6R3XY[K1V
M&DO#WIP89"E.PG9,.)(=BYNY,./Q8SN3?+C#66-K,WS)$1;9%V&<-?* @("
M@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(,J,=K1<FXW?7C6F-Y_
M;FM58)>:=6G:_2(\O<E-/GR-9A6'7TV1L)H,#CQRXUQLR-W*3U.>K\.3"*G1
M(X7*PF(4\P\HMK3&VZWO/6X#9M5@6 0+-R+",D@K8,;#VBMV.GV8S2[C5K".
M8ED(;!JKVZO'*^2R&DB@E^8->DB"I,8]$GR!,44A.[K:MK)?8PC9%<V5JIRA
M5VCV\5)N];&9M[1J^R[G+US09^M8-1L%K-S3-JOT>)3Q>OK6*J&T.3INOQ)-
M(C\&(CF8IZ^>9-3UXOF?"##68R:&Y)Q&IF(PC)"3)L5M[CQFL7Y=;+GP4CEQ
MOG![!T89(1<VW,.<)&7/C8XAW* @(" @(./'F1)?,CB+*CR>8DC.'*XCOM/<
MQI;6.&;D61PWEEY&0W@XWEFPYXKN&+F&66/'&>//(<A 0$$5O7]R+C_A6P_Z
M1,01K2/ZF-1?NPH/^U!*+-\\Y]UGHC_.>>,>.<LN>.....>>>>>?HXXXX_3S
MSSSS^CCCCC]////]B"I=7[WU'NB1;XNK[T#N+]%.NUVS-BG\L\H,]OCGQ'VN
M'<&_/Q$O)N0T..P/.0Q-V)-P'SI/,1_Q+,3%\)$Q-:<%MJ*(" @(" @XD6?!
MG<RN(4V),Y@RW8$WB+(9D<PYS.+>;T*5PSGGS'EM8.M9NQW?$>;Q<;RRPXXS
MQYY#EH" @(" @(" @(*&V_\ K!ZK_OYL/_;#V.18NGE\POE$$! 0$! 0$! 0
M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!!BS'6G;-DKM^T0[?UZA7&\0H@.
MH6;"G7Z26KU:$VE^76@9)^597(,F+5:L9MW(]J():CD-A65^WD&.134BK3S7
M\;+\[L.":T3K^2@4ZL"K;;C%;, A_(KD-I&WW^DZ]CPHLZ7F.RB""UC-EYQ:
M1#=9?LAXP2E$K ;<GDY>?&4CZ.#,^547=>J>XMN$CI?:QO1927'VCJ79U3^K
M*=;9$@E%TGL]NZT;6MSE'CI =Q38M<FV\-B^*K[S\*[W*?LIH;)D1':T5-5B
M,>-;N,4L\C!ISKEI=C0FM'*#&F1'V)6Q-Q;#9'"H^42OU5O;FV;IM/"CU:)S
MBWPQ6:3C<.*L$YPBCF94(4W.9#@V96 : 29K.D:11>R((" @("##UD\')U!N
M5VOFQ+;K$D>M^R+5)N-J*N['V:*PE&9(T8*SRC#:]< PJ%&PA"(6&#,>#CSX
M^+CCF;F;G/*+6<K,HYX.L]61TB_8U,^*VZ/YBH5G+2.QZLCI%^QJ9\5MT?S%
M0K.6D=CU9'2+]C4SXK;H_F*A6<M([(W<_!G])XM/M<EC3DS!^/6SK[.?WJ;F
MS\1UD7*<;R\3/8>6&7BYX\<^+GCECE]'T98\\<\\(5G+2.R/Z@\&KTL)ZFU>
M2G:>F/32&NZ3.EO<;3W(UP[*EUH8_(<X:9V$VRWY1US/+R;3;;6'T^*WACCQ
MQCP69MFZ^>$=EB>K(Z1?L:F?%;='\Q42LY:1V?5GP9W2B,[@_'T[,:>:R\=I
MS[T]R.>)GQ_Z<^&W]@NLY\X\_IXQ=;SPYY_]6&7'T\(DS6*66Y1'M"G=2^"3
MZX4?.[XW_P"O]JQ#YSRM7C3SMDJ'V7K,?+EZ ,D/TL\$D&S/E7<\21>2\S"E
M-1X?F089GYYS*UM;4SYQ9V=G=FM:^BW?5D=(OV-3/BMNC^8JRW6<M(['JR.D
M7[&IGQ6W1_,5"LY:1V/5D=(OV-3/BMNC^8J%9RTCL>K(Z1?L:F?%;='\Q4*S
MEI'8]61TB_8U,^*VZ/YBH5G+2.QZLCI%^QJ9\5MT?S%0K.6D=CU9'2+]C4SX
MK;H_F*A6<M([+[Z]]:]1=7*K9:3I@#/KE7M5\/;&)#)]@-V3G"RV2()A%'8I
M"PSB13"&XR%@^2BOSI'#.6+G.&?T.<\<"9F;U\H@@(" @(" @("#SB\)'V&(
M=7ZIUKVR,K$.W2AW9;D/B%GDGQ4=W WUN['1,W^9D>+,<QRC\?\ 7CAPQSPY
MS_T\Y8_VK6S&]-+B9I&U.4?[0P!Z[JZ>S_5_?LM\N+7X\^GVY_DRZ_1Z[JZ>
MS_5_?LM\N)^//I]GY,NOT>NZNGL_U?W[+?+B?CSZ?9^3+K]'KNKI[/\ 5_?L
MM\N)^//I]GY,NOT>NZNGL_U?W[+?+B?CSZ?9^3+K]'KNKI[/]7]^RWRXGX\^
MGV?DRZ_1Z[JZ>S_5_?LM\N)^//I]GY,NOT>NZNGL_P!7]^RWRXGX\^GV?DRZ
M_1Z[JZ>S_5_?LM\N)^//I]GY,NOT>NZNGL_U?W[+?+B?CSZ?9^3+K]'KNKI[
M/]7]^RWRXGX\^GV?DRZ_1Z[JZ>S_ %?W[+?+B?CSZ?9^3+K]'KNKI[/]7]^R
MWRXGX\^GV?DRZ_2\NM7A7+3OK>6O=13M-5^N1+L4F#GC<2WD2$@?C%#$BG#K
M4-X)%:?RSR@8L\XYOM\<8N<Y\<\\X\8\R=BD5KT^R-NLQ%+\_IZ>7KL/JO6U
MZINO;@4L(TW>SX*IA"D>A7TM1XMJM3ST6I5BS['#UJ?0:;8+7,9Q@5L1:[&'
MG&)\T-!AL.2K  :)X=$=@=M^OQ$7D9BWWC,>\,H1L&[]G;5D_= 6T[9.HVMC
M>O8#81PAL 9>;8/D!ZQ(IT4UR6R=&3XN&8DZ!GDRTGS7IQ6?0=H4[9K9=^G2
MRTU@&Z'CDGB=7M%9X9DG:^,M0V+@U9PX:0_(=KAL(8=P89<\VAF!V4CEMR1P
MWP18* @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @((K>O[D7'_"MA
M_P!(F((UI']3&HOW84'_ &H)19OGG/NL]$$! 0$! 0$! 0$! 0$! 0$! 0$!
M!XL^'&:<>Z\]?,&F\W<^>UP7GQ&\,L\OHXZ]=COIY\7'CGGZ./\ Y_1^A;V+
M_3YA-K^NURC_ &V7YR/,)WX*7_#/?\%U<#S"=^"E_P ,]_P0/,)WX*7_  SW
M_! \PG?@I?\ #/?\$#S"=^"E_P ,]_P0/,)WX*7_  SW_! \PG?@I?\ #/?\
M$#S"=^"E_P ,]_P0/,)WX*7_  SW_! \PG?@I?\ #/?\$#S"=^"E_P ,]_P0
M/,)WX*7_  SW_! \PG?@I?\ #/?\$&TO!W0Y;?=#0N;D62WAC9BW.6>;#N..
M/_TE8>/TY98\<<?IYXX_3S_:L[?]9]/>%V;XYP_3!NJG[HONQM?"!NN]1VK2
M( O7;28)6C<=QI]S@W.$4E-LV")0Q&D+D#MC6OH&<>VTH9,V/4N2M^8%S)9"
MLY5L68=X^WF7R]'KT^:LS:EZ*G:N+U SL2-6+3*ZQ=1M6]<M1MA+C;JLY:KI
MJDDQ/'[-)GJ\/$FJ V28J%&9B0@[QZ8)Y/;!#ROK<,S ?L99VIMSF9X<;^R_
M>MW7W9&FK1=9%LOF%GK<XB0<JL48<L,(3B.*@M?9R6W=:91H].JTYJ\"-BV/
M(C!FV<P_&NL, /- J: "4P22;?/-;&QT00$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$$5O7]R+C_ (5L/^D3$$:TC^IC47[L*#_M02BS?/.?=9Z(
M(" @(" @(" @(" @(" @(" @(""AMO\ ZP>J_P"_FP_]L/8Y%BZ>7S"^400$
M! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'GV4VIL_2.Q=L'+]
MMZ/>]1OUJBB0#]QK=0J]<H._K)9+*P3J%8/4ROAS#FK*]4L 9^X\;"(7BX@N
M<AT +<;+8"TJM1"V<M?/.#G=3^X-7V-UNTI>+W<25PNUKHHDG:;!4=8W4@#G
M6#/-^*4Y8YIE5* !V;<V.ZVX+9F9.0/%Q;?^GGGAUP3$UGA3A6+,E4[;VYVD
MTE9+]C6;HWNH/?;-UQU+07[;5:*  ZMWIMW;).H[ AU1ZKP*A-L>OM?:_G +
M(S7]B'K-8G;L_7:8]M&;(-V)JLEBD^D3,VVSK6-.'#';?7;:,7;NL8]D::N$
M<F"N.R]96N+?&:LU:(MWU'L6T:QNL>:]1V(U/(1,+/5"F08M7(\<:5"Y#Y^,
M:(_(?B,$F_SC;Q7BB" @(" @(" @HKL7O)CKOK7C9,C7>Q]IM\7C6=+^Q^IZ
M]G:[Q)SV1L&MT%LJ,K[;K+I*-7G+'B>+L,N8O?5(Z;DS]+F./')8BLX7S;E%
M66KEWQ@2*?:V..HW?!GE^MG6>'9'6.QM,->4%RL/*/NY%/H:9P\;QG'.?T88
M<99<_HX0IG'7LC^H>]D&!J;5\'GJ5WKE\PM=TF)S+@=9K'*@RN8U:&,\R(4G
M$IQC(B/^)Y2,_CQQB\SE@YQQQQDBS%LVQ?./98GI[P/9"[[?Y7[+^:HE(QCK
MV/3W@>R%WV_ROV7\U0I&,=>QZ>\#V0N^W^5^R_FJ%(QCKV/3W@>R%WV_ROV7
M\U0I&,=>S[1^^,&0^RQQU&[WL\O.MM</2>LMACQFN7,N,?*2'W"O#;+.'T^,
MZ[GSQ@WAQSGESQQQRA2,8Z]F9>OWA33FS36THEDZX;?L$2NEVI=8AZ.HI?8Y
M\/7Y<CD='$WL8U)C.1C3<B.]+Y*Q?(0YG.4^'B,A<"L7YVMK9W:6N>QM;TTF
MSC7RK2GI[P/9"[[?Y7[+^:K+I2,8Z]CT]X'LA=]O\K]E_-4*1C'7L>GO ]D+
MOM_E?LOYJA2,8Z]CT]X'LA=]O\K]E_-4*1C'7L>GO ]D+OM_E?LOYJA2,8Z]
MCT]X'LA=]O\ *_9?S5"D8QU[(W;/"+CJN$<,9=/.]CW&! $/^B=UR-AH#/)P
MZ-!XS)Y683RC0($#(CQ-FR7<<L6XL=WGCCG+Z$*9QU^8>C2((" @(" @(*&V
M_P#K!ZK_ +^;#_VP]CD6+IY?,+Y1! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$
M! 0$! 0$! 0$! 04W0.O>E-66<_=->ZVK-5MEH^M/M#81D3/$L6^O#&-@-<S
M)CSKSKF1<[A@7*9<98Y3R.&$N5RZ]ACGP%CUBL5VEU\35*D%'5VM 830X*#$
M16H0P7 8XYX9B0HC..+3$=OCGGC!MO'C''Z?T<(*7#]3^N%?>LTD-IVEP)EP
MD-SK%/9'Y\D2!)FU0KU'+\$7'LYT(U$NXT9<H1H?(BE85K%C+%%F,F!T*8P*
M^=/9=%:K%?IX=@!6!,,*(CR"4W&'";\3%TB:)S#9PK+=RYS?G%SILB1-G2TU
MV02-&B$\L3E2R$V3)=#O4! 0$! 0$! 0$$5O7]R+C_A6P_Z1,01K2/ZF-1?N
MPH/^U!*+-\\Y]UGH@@(" @C8"G5.JR;#,K-;!@)=L-.V.SR XR&.>/GI##$9
M\P6<BLM93B+[,=G%Z7(YS>=YQYS<SR<S<RR)$1%<[TD11 0$! 0$! 0$! 0$
M! 0>7OA3][W?KCKOKAL_7K81RRP.SK(IC"PP'R0WF*8ZX]CHLOER+'FP',G>
M&_TM9\2<>,,OT\XY\?H6MF*S2<$F9C9VIC"/]H>5OKA^VWX/4ON:6^:EO<C/
MIV<M_:QZ1V/7#]MOP>I?<TM\U)N1GT[&_M8](['KA^VWX/4ON:6^:DW(SZ=C
M?VL>D=CUP_;;\'J7W-+?-2;D9].QO[6/2.QZX?MM^#U+[FEOFI-R,^G8W]K'
MI'8]</VV_!ZE]S2WS4FY&?3L;^UCTCL>N'[;?@]2^YI;YJ3<C/IV-_:QZ1V/
M7#]MOP>I?<TM\U)N1GT[&_M8](['KA^VWX/4ON:6^:DW(SZ=C?VL>D=CUP_;
M;\'J7W-+?-2;D9].QO[6/2.QZX?MM^#U+[FEOFI-R,^G8W]K'I'8]</VV_!Z
ME]S2WS4FY&?3L;^UCTCL>N'[;?@]2^YI;YJ3<C/IV-_:QZ1V/7#]MOP>I?<T
MM\U)N1GT[&_M8](['KA^VWX/4ON:6^:DW(SZ=C?VL>D=CUP_;;\'J7W-+?-2
M;D9].QO[6/2.QZX?MM^#U+[FEOFI-R,^G8W]K'I'8]</VV_!ZE]S2WS4FY&?
M3L;^UCTCL>N'[;?@]2^YI;YJ3<C/IV-_:QZ1V/7#]MOP>I?<TM\U)N1GT[&_
MM8](['KA^VWX/4ON:6^:DW(SZ=C?VL>D=CUP_;;\'J7W-+?-2;D9].QO[6/2
M.QZX?MM^#U+[FEOFI-R,^G8W]K'I'8]</VV_!ZE]S2WS4FY&?3L;^UCTCL>N
M'[;?@]2^YI;YJ3<C/IV-_:QZ1V/7#]MOP>I?<TM\U)N1GT[&_M8](['KA^VW
MX/4ON:6^:DW(SZ=C?VL>D=CUP_;;\'J7W-+?-2;D9].QO[6/2.QZX?MM^#U+
M[FEOFI-R,^G8W]K'I'8]</VV_!ZE]S2WS4FY&?3L;^UCTCL>N'[;?@]2^YI;
MYJ3<C/IV-_:QZ1V>VO13L9;NP'7-W;NUWZP*)0[-;()*:*C9 @,$+7FH<CSR
M5Y^0FXQL([#LAZ9+>EXL8--\N9\-X89<K&U%)I&#IL3,Q;;->SB$O" :BB"]
M//CJY;BEDWIM;;^H]>4 F?TUK*YE3>D-G&]37H@U W7MG6, GA'LX=ET?3ZV
M2/;4(BRT67%UZYF-LC /+=+\(B)F;>-UT3RPKQ6;%[44XK:&ZS7:=?[&W,V?
M8-1B+&.BU!@">ME'LS52V7R%9*W$=9IHK69J-:F+>0XKF''#6OKW) -'8X')
MV0*>>>6PTZB" @(" @(" @(" @(" @((K>O[D7'_  K8?](F((UI']3&HOW8
M4'_:@E%F^><^ZST00$! 0$! 0$! 0$! 0$! 0$! 0$'C]X9JD7/86D>O%;H=
M3LEUL3_:@9*9!50(2L)AV-$Z[]CG)4AH:)C2YF;,9O\ \1]W%GG!K#_J<RQQ
M_2M;$Q$VX)/]=KE'^VR\&_1+[3^S=O?X2WS\A76L8QK#C2<)TD]$OM/[-V]_
MA+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2
ML8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G
M"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^
MT_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_
MA+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2
ML8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G
M"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^
MT_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_
MA+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2
ML8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G
M"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_A+?/R%*QC&L%)PG23T2^
MT_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2L8QK!2<)TD]$OM/[-V]_
MA+?/R%*QC&L%)PG23T2^T_LW;W^$M\_(4K&,:P4G"=)/1+[3^S=O?X2WS\A2
ML8QK!2<)TE^A/P?^AK#+Z3R]3;9!;(UC.*;&,%9,/)LWKZYQXPXY6CPR1'RG
M1(T]H>0EA\(TMMV,[!,#,IXR4W(ARI#67/;FLV8=W38BD6X]ECA>D)L9I2W]
M;C&S(%]U-LB][VOEN*7JMES>S Q7;>\SVW@DNB6%ZW9A1)BG1#SS$$[+ 2)[
M&RXS.UX/,?+-RF\X=:VUY77613S*Q8.V>H878]U"6T/.J-/A![8'MA&J1Z#&
MDU[8,[B79C5LYV;'#&:M*N'V@M4VD6AOZQF.9QIU%F0I#LT5L&XPI1*^9819
M-./.K65="QJU7P5=ANOOPP <8%BO2N6\I+T85"8@L.R,F6V6LGW&F,<WN6F6
MF^7.<N<&\,?HQX([A 0$! 0$! 0$! 0$! 0$$5O7]R+C_A6P_P"D3$$:TC^I
MC47[L*#_ +4$HLWSSGW6>B" @(" @(" @(" @(" @(" @(" @H;;_P"L'JO^
M_FP_]L/8Y%BZ>7S"^400$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0
M$! 0$! 0$! 0$!!0.P VS;1M6I@:WL786M:,UKZY%SA6D5[6I%DE;&K'2(=>
M'E"NQ];[ CQ'6@\JR280\5]5/3<//),OSW""QYJ.&=GS7X?3[G]A>U3OKW=Z
MP?TX('W/["]JG?7N[U@_IP0/N?V%[5.^O=WK!_3@@?<_L+VJ=]>[O6#^G! ^
MY_87M4[Z]W>L']."!]S^PO:IWU[N]8/Z<$$>MVF=D2*I9X\?L_OR<^_7C3+$
M+&M]9<\ICSHV3@W%QPC]<L)&>4C/+%KC%C/![+G/Z&LL<^<>> Z'5&E-FP-6
MZU@S^RV_0LZ%0*=$F!G:SUJ8<$RX]=',R!CC,_KH].9S@/89Q<VIKSLMO)KG
M"2XX]QGER6;YYRG_ -S^PO:IWU[N]8/Z<$0^Y_87M4[Z]W>L']."!]S^PO:I
MWU[N]8/Z<$#[G]A>U3OKW=ZP?TX('W/["]JG?7N[U@_IP0/N?V%[5.^O=WK!
M_3@@?<_L+VJ=]>[O6#^G! ^Y_87M4[Z]W>L']."!]S^PO:IWU[N]8/Z<$#[G
M]A>U3OKW=ZP?TX('W/["]JG?7N[U@_IP0/N?V%[5.^O=WK!_3@@?<_L+VJ=]
M>[O6#^G!!#KO0]S5*!6SM7[!;NN<UC:&F89:M$:EU[FC2E+,;=I ;8>!/"M:
M#"'HPV-02%EF$"@HP*F!H<=\NT0A\P>9#8:K0$! 0$! 04+N_3X?<!71\2ST
MZIWBHTG;9"ZV@)<A(@Z*X'Y:4W'2A\UL0;BS(<Z:Q9+F"P9QQ8R?CM//S,,L
M<(SG*+''E\P_ST5.KWLW:$^#VO/EU$/14ZO>S=H3X/:\^74#T5.KWLW:$^#V
MO/EU ]%3J][-VA/@]KSY=0/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU!6=\
MZ:Z$,6G2Q$#UUT.T+JFS"I^Z-X:MU]#QDUF3IS;-7BL.Q\0&/!7#&XV2IR>(
M&>+F+;D=LIQAQF-Q<P"S/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU ]%3J]
M[-VA/@]KSY=0/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU ]%3J][-VA/@]K
MSY=05GL/IKH0X5U5)KW770[,2N;,BG[5CAJW7\+B16FZ9=13K&;>(#'@CAR9
M+!7?,,N,\<LFL97B>-$QRQ+CG'S$K,]%3J][-VA/@]KSY=1#T5.KWLW:$^#V
MO/EU ]%3J][-VA/@]KSY=0/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU ]%3
MJ][-VA/@]KSY=05EM/IKH2Q"JK&JW770[$L=LS6E@*98:MU^/Y<K("YARME8
MR<Q 8<R,'PL68UG YYYQGXY<Q<L,\7><>0LWT5.KWLW:$^#VO/EU ]%3J][-
MVA/@]KSY=0/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU ]%3J][-VA/@]KSY
M=0/14ZO>S=H3X/:\^74%9[9Z:Z$LE6%#JGUUT/'*1MF:6/RG&]6Z^&Y95FJ;
MCH=HNC',C$!ARYA)IP<]&=@<Y<XE6W<Q>>#F$S)O(+,]%3J][-VA/@]KSY=0
M/14ZO>S=H3X/:\^74#T5.KWLW:$^#VO/EU ]%3J][-VA/@]KSY=0/14ZO>S=
MH3X/:\^74#T5.KWLW:$^#VO/EU!!M@=3M-9C*S-UIHG3-;N%>VQHZXPCH/7=
M(K9<8+I&YZ%;[/)'&8 6+-BRL:L$-8M-QGVW9O.7F&///G7BY%CXGVEK1$$!
M 0$! 0$%'[IV_,U++TVQ'K4:PL;5W54=12WWCCHAVN-VH>>GX6"-%P#%,#F<
M7('S&R%.RPF.7$OB5P1YYC>:2"Q;I/2U>"((" @(""E]\;?8TK2A-CX$XGC%
MIV9J/4M5#N3,AT65:]Q[,JVL@4DE/PBS7(@4)+M'%B/.QX<J;]1B". Z+*(9
MQ8SP^^EK^=&[?;W "N<A\5@$L.N=K;&U!;AL>7G.A<'M?6*0+;*#9;D>*[D.
MLP%P':HD5YGS@4T<X#2GY<D<]+?$^>>8KJ0$! 0$! 0$! 0$! 09_P"R>R]F
MZCU;;-A:TH5-O<BD56UWJPP[UL$AKL-B IH9TY-&02H>DW\B]8CC+#L4/P\"
M8!P^&9DXN69S8@"S B_R5T5XH\<  S<@41 R# <84?!EV\&2P9XA"8ENBBC3
M6;K;1$=F]E#FMMN.88267<<,\\>.,N0[A 0$! 0$&>]F]F=::GLA6M6;,T\_
M5:K3+WL$D*API G6U(V%>9^O:=;+D]+)094<,:L(*W9-NAH9J1"$TBV%R4:%
M!&8.R0T(@(" @("#.EF[0ZRJ13;(8SC8V2.H"VG:X9C8B6?&L=IWV9A5?5%9
MI^3L]G$F6MEM*":M$Y(<B!S1@K"\Y(-#N7R# IYAS]^2Q]:[.K>TQ)PE7\2$
M.35;E:=?VH&89BQS5;MU0)9CBX@FU!F$8/.6>'FA8;+@SYL$H"*"BT&2]$GL
M9\A8B @(" @R)<NYNN-=7>Q4B_U#:-0='U"S7*F6(O6P^5=V[#I^P*!JFP"M
M<YCK+/-_:!C9&U-<U,2,O8.C\VQ^XAS=.>L%5SDGXQ:65URO^(GY7KKC:%<V
M='MOU(T2'%J#=2VO+O7#34-DU5[8)A"C/(PEP-GE!CG!*M6"MVH3*'$YT6;7
M[$(F<.MNONQF"3%%C(" @("#,6P.UE&U79K4 V%5=BU@97-:77:0VZ3 0B55
MKJ$UZ?H]4M(BJ-C+%.M6%G:LNQZ<&KXBU5>K\7J06\YH4FSC84^=&+3SSWNC
MC1:FNMI5[93MZ'BHQ418=8W3+7]_JYUL?@9J]HSJE5O@^#-<#DC(:6V7HUYI
MUL&RQ)<A&=%6*#@^[')-3Q\,DQ19* @(" @SMM7M+I[2]IGU._FB N8&TCM7
ML)8)\<3*(":_K;3TBHQ[5,)R(G#C_)B3S<A[@ "/BSB9=J$2Y;8:R;A83A2O
MMJG&N=LU_9!"] 88XY7+9K0Z(KUXJ%G:%-' 4X_4@%W!NYN RYX*0'%:[9!T
MB*1$EY\3B<T5#ONLEPQ6#$"T4! 0$!!E"X=R=/4G:>Q=7%I,Q]S3&LR6VMWW
M" :UZ[7]-TX;5B%SSG7RO2+S%VHSA)KD2&1AS@&N#X1[$X):R+MN_66 TM)U
MFGG#JXLKO!UVK9$A7]HW)O2UM&_5#LBG;2R'!K#E!.5P+9AI2.T')GQTH>]#
M-MP7'F".><4T.,B)33,P9(PX(UR@(" @(.A*6JL Y&$0U8P(>4XSC(;C%# \
M?(SCYYN-XOX,RY#+F3.3C3K>+N./.'.;;F/&7.6&7' =Q&DQYD=B7$?9E193
M+<B-)C.X/QY$=[#AQE]AYK+)MUEUO+'-MUO++#/#+C+'+G'GCE!GH]U;U).&
MZ["U$'$U$"UON(+O(:"U)7:-3@QR[A84^!AG9!N-2G1)<,E'(98EGQS8HY,\
MVA<<&FL(_&&1:^>9-%H@@(" @(*WVKJZN;?J;52LSA"(Q!ME"O@,L(=BLEP%
MSUC=Z_L6D6 ;G.AD(&<@-;*P'G.0R,"<+*16I(DO!G"ITR&^+G\ZLU97=2@3
M(4 ^1(/V6[778MG.&7(CI<_;[]8I]E/DYN4"&/A-MX29V(P3#B0H\86!'"A3
M&'+4'#/(3-?,%E(" @(" @(" @(" @(*!W[1(FP!=5&2]^W71' FQ-V1F52\
M]*9YVF4*:^F##-#]W:OVF")#P9!^&=A-01$.1$/1!!3.3D_!@^2>M/,STKK\
M3"WZKS%XK@1F'9'KBS#&Q!W-IE2Q4Z<??&LX09)4C*!1!X9TG-DQW7R7(L>/
M@XSLY&$6!"9QPC-!WZ @(" @(,/;^ZA/;CMFX2L&R0103L;I+4&@-NQYL>4X
M1@T?3^S=G7F%.IW,?_R[ANP@MV[/J<OZR<BL"I<JK65IPEB"F5\P:B:13"LQ
MSF*3[1Y-FX49$! 0$!!A/8G4@[L*Y;WL\FRA!V.P+[T^VE0,<&B$ET/;^H.P
M:_M&NQ;0UY&-@^#MEEK X<6^K)&4N"#DSN8_EIO+&;98FFDQK%/FQ?.BM0O:
MHA[-G$R$4C9]O;ANFXK5R.X?X$CB-F;$A0X(5G)P:DRX]>IM8JX245?CP<SQ
M6 0/<"PS9/ /!$S7TBB\T00$! 08!VUUEW/O$]?_ +<633\,!((54GJ<R,K]
MQ(W6G?=;M2B;CUR"F^>FH0)L(:OVNZS8-K.BH^)2W<#!@;"4T/ 5;, 6L4LK
M7SG7C'#W:)TEJ*3K*=NJTEYT.9:]\[DG[BMD<7E(<#!YN&OM=:FKP,3(EL19
M<UD90=4T]@B2D0X&10[];D6APZ-*8@QQ,UIE%/GWF5ZH@@(" @P!O_I@[V0L
M=CM-HDTZ@VN)3+;1*==Z5%*33=I#2;;1=@:S;VQ E8!<"P76UTHT4UC4VS!=
M@K/G3)X W1^)A8>6+7]:QY/26A],ZBFZ]LN^+^=FP9%L[ ;5&[,L X0Y)DA:
MTW7=2:PTQ7ZZ)GS(P^85:PKNK!ITB3E#!KKYX\788ALCHT##$3-:1A%(UF<9
MXROA$$! 0$'FMO\ \'CGO*Z6P\YO_98:O7C4/9S7ANL38%#-08!S?S&J6 Y@
M8_A31EBF J/SK$3(9!FK5,GR&J_2P4 Z+K8LF**FJW673$Z5LZ\*:M5:AU$6
MIE[W;M:V3A4BY[M/4><1&5_*:\!K837VOPE*#!X4XBQ#F%GY9*+9+1*(OCAN
M4?"R1J]C'F85_$V6,K_0$! 0$&$>S?3ECMSE8*]M'&FUZO-5?<U&J%ZI<.;G
MM*11]Z]>KOHVW5&R2"49J+%#PI>PBEXXB#3,X58#U4UW+E!Q$ZMYS)AJ-K=N
MRZ3$Q[4_=&?=Z^"?UUV[V,1W%V6LY#.^R1-:K4"+K20X-KT"OUROC8>6+F1J
M(],F3BMHRL]C\;R,9L4.-C:WQD4<!N'S C:F+I]KWK@C(@(" @\/_"&Z@W%L
MSPBO@\B^I*L78QK6E^\]=LFVR6D;ELO5M"*;&I^L!E"&W:Q"8&%6K,ZS2@MG
M@5Z=82DJ. F<Y&YE<-1,FQ18WLTW-JO&=FRMME>%_E[K!VR^W@7N<$ZIZ?!;
MEU3U5$67;^B@-DPZN8PM=:AIE9Z>:^-:(L= MY&A6^HVBKU_;@^P1:_<K)L-
MH;8B,\SK6T:J$CJ[3CIYYYYQ*12MDS9-^<UKQK\6Q-J+S]Q^%;#=?]#G[B'O
MP?8!JF=H0FZ9%*U/3+Q9PVWM%Z"-5K2DH74@FM2\>-3NRG8"K6?9 Q_ZEE0G
MAA/55'%D:['M+X0L(W:SZ4BO"9MK.,19J^@6^^%5NO':FQE;U>=-W#6,'JG$
MU-JTQUN'&=(6VV[8TAI.7O,6.V (TI;=D6FJZXW>3V6!POE*-7F)KV!Q./7$
M7;*[7X\3 G\;,)KQMOF^VD64^'KIU4N6Q]@]>]873;M3MU%V18PDHC:ZA>L@
MKEGKY#,R3P;'3Y%?JU'&38[4)N+R)(XTRJ320;(?/+UP,7DSA\<DWM!H@@(/
M/?MQ;@=0[.>#REV*VP:H D[BW9C9G2MD;KP*:'A]8MLSQ>-DQDSH8R>,A7>-
M4YPS$OB_%AVMJORH?#1?$>XBQ=/+YAG+>NX Y+L70MQZYV&!WGK,I;>MNHS>
MGJ[=+'3]MT<Y#["EX0G>G6^4+E\@]LT&UGCW /L13LQD<5>=6:M>)1KX2!UW
M.KDBQ=,<8K-UEW'"G"<9X7KR[>=JMNZ3V/+K5"F:KC @NJ]?;'(,W:J6(X7(
M/V/L53-2&Q[) 5L:I1!L+&L6684@2,Q$YZ$5'^<RN9\#+.&R(BL9VTCE%?55
MU([R;IM.T8.H9I+KO7CXC:%KK>1JX-7VL1]ZU^C]J=EZCNU=TH %3;I)RVC4
M-/U*H76:!<,6+B6?V/53#L,91\R3L1YYYH4XV^]+*Q7RRDH13_"+;2V65UR
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M<B" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
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MRGV)[&/'>SYEL5NX#R%/LDB%S)9KUM@S*P9<@G8K\!LBST! 0$! 0$! 0$!
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F 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$'_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g16439g93d53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g93d53.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1RD4&AO=&]S:&]P(#,N,  X0DE-!"4
M     !                      .$))300Z      $_    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    N %P 7 !0 $@ 6 !& $( 50 M $T 5P!% "T 1@!0
M #$ ,  N &8 :0!N &, ;P!A &0 +@!C &\ ;0!< $$ 6@ P #$ -0 Q "T
M6 !% %( 3P!8 "T ,0 X       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+
M           *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/
M     0 !.$))300F       .             #^    X0DE-! T       0
M   >.$))3009       $    'CA"24T#\P      "0           0 X0DE-
M)Q        H  0         !.$))30/T       2 #4    ! "T    &
M   !.$))30/W       <  #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!!X       0     .$))
M300:      ,U    !@             "J@   QP          0
M               !              ,<   "J@                     !
M                         !     !        ;G5L;     (    &8F]U
M;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M3&5F=&QO;F<          $)T;VUL;VYG   "J@    !29VAT;&]N9P   QP
M   &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S
M;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N
M=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N
M=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
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M;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M"W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M.$))3001       ! 0 X0DE-!!0       0    ".$))300,     !)N
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MTW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H
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M*W!Z@&WEUX=;9Z>QYDCV/<]SO3V[:M[';/38M%))3G,PNHM(:<DN9[?<7'<
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MW^=_L(1Z _8]@NVAVW;!>?3+'-M8^CU'V;7^M55=^D]7?97_ */]&M#9U/\
MTM'_ &V__P!+(M(RAN^T/8_C;L:6_P!;=N?8DIH872;<!]C\5U3/5#&N!:X@
M-K&VL#]('.^D[])<ZV[_ (3TF55UVMO4_P#24?YC_P#TJK222FKMZG_I*/\
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M_*S?_"]W_5XRZ))2DDDDE*0Z+Z\BOU*]VW<YON:6F6.=4_VO#7?38B*MT_\
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MGZM>5Z/H?]IO5_3(?U.KLKP\EMC*F'[08=2W:' M8\.?#WML^E_.U5X^,_\
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M_;KO_2"ECLN:;7W0'6/W!K7%P #65_2<UG[F[Z*,DDI__]DX0DE-!"$
M %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3
M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"
M24T$(@     !BDE)*@ (    #@   0,  0   &L%   ! 0,  0   %D#   "
M 0,  P   +8    # 0,  0    $    & 0,  0    (    2 0,  0    $
M   5 0,  0    ,    : 04  0   +P    ; 04  0   ,0    < 0,  0
M  $    H 0,  0    (    Q 0( '@   ,P    R 0( %    .H   !IAP0
M 0     !   L 0  "  (  @ P,8M ! G  # QBT $"<  $%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,38Z,#8Z,34@,3(Z-#8Z-#4    #  &@
M P !    __\   *@!  !    ' ,   .@!  !    J@(           8  P$#
M  $    &    &@$%  $   !Z 0  &P$%  $   "" 0  * $#  $    "
M 0($  $   "* 0   @($  $              $@    !    2     $    X
M0DE- _T       @      0   /_A 8Q)22H "     X   $#  $   !K!0
M 0$#  $   !9 P   @$#  ,   "V     P$#  $    !    !@$#  $    "
M    $@$#  $         %0$#  $    #    &@$%  $   "\    &P$%  $
M  #$    ' $#  $    !    * $#  $    "    ,0$" !X   #,    ,@$"
M !0   #J    :8<$  $      0  + $   @ "  ( , #   !    P ,   $
M  !!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C V.C$U(#$R
M.C0V.C0U     P !H ,  0   /__   "H 0  0   !P#   #H 0  0   *H"
M           &  ,! P !    !@   !H!!0 !    >@$  !L!!0 !    @@$
M "@! P !     @    $"!  !    B@$   ("!  !              #  P
M 0   , #   !    _^% ;6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M&"$Q-;:WU-8R-C<X05%6=7BTN"(C)''7&31%88&1H>$F=O'_Q  4 0$
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M59?>? ?#0X>^=;QM]N59?>? ?#/X>^=;QM]N-9?>? ?#/X>^=;QM]N-9?>?
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M+$2$PUF"E6A0(_V1F&O2ZS.ZTG>&F.+Q.R9S5;I'H^RSESY 16H+634C8;C
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M 03P&:VM,++&KWK9XP $9L.@K>!C=QI^:KC_ (D;Q^F:K R1P& P& P& P&
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M&BG2\P*@YM94R-J2" 2,M/HM$E)+V D)@@[-&8,0978# 8# 8# 8# 8# 8#
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M!555N4\25W*V:_F-'4MO0ITE<LC+:M"GB4*GZ)D9I(+;MMNG$1+1N WT-O\
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M 8# 8# 8# 8',Y$OP9KZ9;\^O"PL"5X# H3S_O\ 7?IQX]?7M76!TJX# 8#
M8# 8&,W$7\B@/2WR1_J/M? R9P& P&!IUM>'TL]\^$B$=^V:*0J;7X^61-ZF
MB?&>:V<FCUJ5['"$=5H!\GHY!7UJH.,/,47D+9I 'J0-I+A%)O,G!2LC\?MR
M1'O(7*Y37JVR.W&2EA\4>6=E/E 6+3M_D2:O*HI>70M^)1FNRZ/'1=VL&W(N
MM+[9T0O#,N>VQI2/D<>F5065LD)R)2L#.FXZOCU^4Q8=22Y"26PVG GZ)N1+
MPT-KT)IW(F@]*G<#&A;M2VJG./+3T[HC+&8,HIT;TYI*@(BBSPA9;CSQ&9N/
MU@VE.VB4@6EV9'J_CZM@98PEAZ Q3!D[V49-I68WNB[QQLE\+>BF55,C2&A4
M1#HW$8QWJI"Q <5(5+B''4$2AEH1QL4OJQ T\BKS3IE4GD\DFC^< 4Y7G[$Y
MRF8.SY)GD_0SA! I=W9<H+("2E+, F3D$EAE=@,!@,!@,!@,!@,!@<SD2_!F
MOIEOSZ\+#P)7@,"A//SA7?IQX]?7M76!TJX# 8# 8&DZ[^3?* GD9R'A$(MY
M%!H;5]@1.&1ME2UQ"W\X2-RHFG+(7KG%UD2)>N5+E#_8#R6'0!D)26\AO3EI
MM&%''J M[\(_F/YQ^O\ +J?JWW'@0Z"6MRIKF.ZB\:Y&JP-6GV72+05U45:K
M4>$IO+GR;/F^[>+Y7]P)\D+CM(5VO^'2;(3]L9LKN@@D3KR:YE(&MQ6E\C0#
M-1H5:HL(Z?J[M!#((,-"$>@LFA;!L0=:%VH@BZ.GH%K?QX&\.J)*XS.K:UF#
MQI.%VED ATE=-)"A$I-.+['6YT6Z2DB&:(I/I2J-T24(TP19?:AV,>]=ML)_
M@,#1G*HR5'>R.M*Q;SOKF#SJ5O\ 2\DL_C_&(_RHCJ"<NC2U1.%-:)U$S<L-
M46R2"9HA1)C9VJ8U\].JU(_05O>VR5@>HWX4#&GLD\SOZ&\A;$C,?O&/V<HL
M-0T[I#CK!N<7)&E;AB\I45XRLE=H@\?^+?%NVYBO31BPT$WLG4K?+-C$2M#4
MK0L-D(0,E=QL2<.@^E'&V76KX@NO&*1.$VB:V[#*8Y")\Z6;'D9Y*@XE$>GF
M;Q6E0+G-:XMI:-R=R!5ZPIVIV5K6A%X21H2'5:%T\#&[C3\U7'_$C>/TS58&
M2. P& P& P& P& P&!S.1+\&:^F6_/KPL/ E> P*$\_[_7?IQX]?7M76!TJX
M# 8# 8'/9;_YV/,STXP?^DKC'@1K 8%&D7XOOG[H<?Y,[ WY<>_R!T?Z(*T^
MAC+@7?P&!S4\G9=7S9V9.L6)XKJ/M<PW.:&TG)>KBG\:;KC;9>Z4XDC\[30)
MMG;'7[],XC(X6I?DNWN*R#9 ^(\#CSVD72*T:=6QD,MNR#1WBU7]G-EA"K7D
M@U7^@C3UR<E5I\1W2!L+C#H91I#1&UEW7+";3G<9J*Z#(4@?T3(RMKW7]P67
MX%)/;8I'PHT980AM:EMGU_5U6NMLV5.V.+US$8F&52FPI4K2,3(@84R$I2>^
MN9Y@4R5&!0 0# IRRBQ#4'EHTB<1QA) @I-=WS4-LO\ +XO7,[9Y6_0,IA42
MIN;@K0F-::3$K#656$U6D3)W!(K,;71 8K;#EJ9$\M#PQ+S4KTTN*!,$*XT_
M-5Q_Q(WC],U6!DC@,!@,!@,!@,!@,!@<SD2_!FOIEOSZ\+#P)7@,"A//SA7?
MIQX]?7M76!TJX# 8# 8'/9;_ .=CS,].,'_I*XQX$:P&!1I%^+[Y^Z''^3.P
M-^7'O\@='^B"M/H8RX%W\!@<VG(Z54DV]F#A4)4(Y.PSV06+1,G=S RRHB)5
M/'I,Y<<VM("NX%)8"Z66Y5N4:U4FY2^6Q6?L1B:.5/R;;V9J+1-\\'( _7LH
M!L4G7(^1,UINW*=7%JJJ!YGC+%8QV.V@^2D-@[ P)F!7/+FKNR+%CTA?D'>Q
MKDT(G)2)"/N,@:SDZ':TAC$C1AOZDL+CEMTZ^5^\+'-7%;'KE?%%[F6:BT]F
MLDJC9C6:YD*=IE3>6\Z2+MK4RK20]*2X!+/ 086#0-A9R@^'55<<YG8TW@JV
M7+'.R&N/LJU+(7-N5H&!K8W.3R)0DCW@]G:UQ6I!+IG*)6\G.RYW4:='7:1I
M.:F)"VM",'$*-MD0A=H1IF&[&-;1R*O-.C&^R&02QW$6.<KU MKY'*W1ZD+L
M;W0X>@J'1T6'@)T6G 8%.2246&5^ P& P& P& P& P&!S.1/\&:^F6_/KPL+
M E> P*$\_.%=^G'CU]>U=8'2K@,!@,!@<]EO_G8\S/3C!_Z2N,>!&L!@4:1?
MB^^?NAQ_DSL#?EQ[_('1_H@K3Z&,N!=_ 8&C6U91*X=V2?866?<@FAUDUS<<
MFM!4 &>M7N'3^M))!&V/678M=R"3<0;#D$2KR(K$#.ALF.M').NEKF<S6L_I
M3(S(!0M'801+LQT6M2>6GQNB]74$T7LJ#$[>4.[,Q1?<VG*H+HRA:XM'+"8$
MEH5L<'C:^6(&$]8A4I\*UH_J$Q+=,W&-%HT.WP-\S0%4!I:PKDB1O6A;D05B
M! /NB!$JTF*TH2(A]S*[=(F-T,E,/N1?;$@!ON8.GM=!4<#&[C3\U7'_ !(W
MC],U6!DC@,!@,!@,!@,!@,!@<SD2_!FOIEOSZ\+#P)7@,"A//SA7?IQX]?7M
M76!TJX# 8# 8'/9;_P"=CS,].,'_ *2N,>!&L!@4:1?B^^?NAQ_DSL#?EQ[_
M "!T?Z(*T^AC+@7?P&!H7#7]I2[LABJ[S^&[KN-2ZTJL.'-KYX44194YK-#7
MS(Q0P]XK7D@DY^$2>N8HKVQCFC/MEH=Z.C#PZN;\1$7=]<W;;B%H>SO4Y&;"
MF-%2&63B 18AIK2UV:--RZ34A#)^Z2!Y?8.W"4^,]QQ.0IV:O8]IT;Y>^O07
M.-Q5N5Q8+7)UYCC)HJ)*'13%T1[=&HZWJ@I0JD#$THE(41YZI$$]*@3D'!2*
M57^*4)=& %I.>I_OSBNT,._O!"P+2PKD?55@W;;_ !]BSV-?9-%DQ8VQFP0$
MQ!329,&!GE#,G3Z,5Z7K^V8W]G5J5R=O$TD'+M-WA$3FF6HDP47C3\U7'_$C
M>/\ YF2G?_O_ "W@9(X# 8# 8# 8# 8# 8',Y$OP9KZ9;\^O"P\"5X# H3S\
MX5WZ<>/7U[5U@=*N P& P&!SV6_^=ES-].,'_I*XQX$:P&!1I%^+[Y^Z''^3
M.P-^7'O\@='^B"M/H8RX%W\!@,#G^[+REDC_ '96$"AUBSFKU5A\9[OBL^=X
M"BMF8JI36[K+J^:'.&/T&HWC_=TX0(UAKNH4M<]=#8VUM@PNS*Q*PNKJX;,#
M=C3$(55S6$/AJR<3*QCV=K"#QMGVV3QH<"E1IJTA.N!'HM"FLE.U$*"VEK3%
MQEK4)FM$C3KBS5I:@\T/A:Z.@#7<$DO0)#\X6')8L"%&K7J4R%Y:&.+#/9E;
MBR12.N+BH9(P@?%\=8W-[3LZ%*6X.;:6O,#I2H7&*@MEQ'C<=A\/M*,Q-B9X
MQ'&CD7>:9I88^VHV=F;$XYPN4#(0-C>2G1(RAJ#CCQEIR2PC..--%K9A@Q;#
M*O 8# 8# 8# 8# 8# YG(E^#-?3+?GUX6'@2O 8%">?G"N_3CQZ^O:NL#I5P
M& P& P.>RW_SL>9GIQ@_])7&/ C6 P*-(OQ??/W0X_R9V!ORX]_D#H_T05I]
M#&7 N_@,!@:'>R_P:=OE@4U*89&;?"X,%6VL5&Y13A?*MX<YC.!2" J8[0TS
M*XS\BZ%!6, L!6 A8]7'/1.L>85C6V$G/T6VF+ ^!O092SRF=I*5)A(E1;:@
M+4HQKSG0:0\"4H)R8;FH$)0XB(,T(H2\\0CEFP;4&BV,P6\"I8&-W&GYJN/^
M)&\?IFJP,D<!@,"/R261:&-VG>826/Q1I$H*2!=)(\MS$W;5G!,&2ETM=%*5
M-M0: HT11.C>Z&!+,$$.] %O05TLPLXL!I0P&E&@"8686((RS"QAT( P##O8
M1@&'>A!$'>PB#O6];WK>![X# 8# 8# YG(E^#-?3+?GUX6'@2O 8%">?G"N_
M3CQZ^O:NL#I5P& P& P.>RW_ ,['F9Z<8/\ TE<8\"-8# HTB_%]\_=#C_)G
M8&_+CW^0.C_1!6GT,9<"[^ P&!JU[(I4?'Z9)F*=W#R.DU$-SK$YUQHEP8S#
M(-:)4[KBRRF:;3J#J(W,*SM-1$'$IN@J23*I_&VMF61EE;C'B0K3&UN:U36&
MSAF+;R6=J):5&E;44VH2VU5I8-QTI;P)2@HU&G PT\Q=HY-HLS2P9QPU/;=V
M$:8(>Q["Q4+Y0U-/;WM/CI'W%U'8]0I4JJ4EJVHQ*QJ=C9X6^.R9B=Q&B YJ
M8PWV- A2(.R4Y2,^6-J9,<L/)<P-X6NXXW%425LM\*JTZX3"-Y&7:H*"?.(R
M2(P@Z8JA%' T8Z!V,DT/]HLP/2 8?C"+>L#(KKLIGRN5CZ^Q7WM@.NRF?*Y6
M/K[%?>V Z[*9\KE8^OL5][8&-W*ZT:-D%2)$"ZQ*G>RM7%QQ4=Y*Y=#W(O02
M>0U7[4'][G.!P>@I%M3LXSM/["79^QBT5LS R/#=5+@"$ +:J\  !T$(0SR*
M!"$(== 0A#IUUH(0ZUK6M:UK6M:Z-8'MUV4SY7*Q]?8K[VP'793/E<K'U]BO
MO; ==E,^5RL?7V*^]L!UUTUT=/6W6/1OY-^/L5Z-]'R_\5_1TX#KLIGRN5CZ
M^Q7WM@.NRF?*Y6/K[%?>V!S<1.QJ]T"9;\>X;T&7#?!Q>_&ADZ!E'798!Q)H
M-]_= BS2A@-*'KI"86,(P;V$6M["5=8]>?MY#/6AC^W8#K'KS]O(9ZT,?V[
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6GHUK]'R_+_SP& P& P& P& P&!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g16439g98s75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g16439g98s75.jpg
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MU?*SS96O5M7='3'#V;49B*!M2',R@9QQ=&7ZN'IS)3*E<)?#2-^-UQ:7(:&
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & 8VY2^.-"L:%Q<RTRHL(!C)$0J,V$)@=
M#!OKBB# ?A!WK?1H6]Z_[]&\L-X)DE9QU(6,A/&HY Y-I\0ABE&[);#0. %4
M>/5&*$%MN#<[6D@[94(S512"Q75H;'.:HB3BTLF<$1"QX*5J0]DVAY/1BTOJ
M6N6!Y,7JOB?"FEM8(K7=>LD?9F2%QMGCZ**;"PM4?K>4:FM>,S:RC0C:T+;
MY=K<DAJ1,D*)C#R(Q>RA1*##!B0\GHRVE]6?'/'7B>.DH[A\W2)XF#/7,)8)
M@_RUUGSQ,(VTNT;EJV=/K6%B?)F.3L06]]+E3VP U'GB0$N!;JZ1W8V!<K4-
M!AB(2'D]&+2N^)787HXSZ&X8*'5(^;J.KB'=OK4JF4#BAA@6U4BJ$E06K!5R
M0UO0)MIZ]VM*+7&0XKK(\<N#I:<WF*ND[:R\GH2TOJ6>)G+E$N-[P=5)[E$8
M4K-HM42MIL9D9%KP8*T['WL$J(0$M  ,=-+C6S(Z$3;I/O3$>J:/_P O5J4Y
MJ'D]&+2S6I#R_B=U/UT72YR<..]$K%\_+GA,W5'UBUC-EB:T) SRNQ$D@%MG
M_P#BB*:29A:GV1(E>C4KFZIS%J@D9ZM:-0AY/1EM_=AA\65RX\$0S>W 'AA=
M\ECLH,;6V%K6=QLY_=28@FEL3W)9E:S?6S/(+)='ZO7R!S8^Q4#)5D88VEV6
M2M?'5#2#:>41*3'-$24QI#R>C"KCBN&,/!S&KDM%5E4\9*==SY9#6!A+L1VC
MT<C\OM1Q9Q+++L(4:C[1&4\AGTMTUDKI-+G5J86@N125;KNF_";T/=$XXI"A
M*3(>3T8=2?%=)5W[+U>9/'A"AWELKWJO^JXAY/1DE9K5#PA0[RV5[U7_ %7$
M/)Z,2LUJAX0H=Y;*]ZK_ *KB'D]&)6:U0\(4.\ME>]5_U7$/)Z,2LUJAX0H=
MY;*]ZK_JN(>3T8E9K5#PA0[RV5[U7_5<0\GHQ*S6J/->;9KV/M#J_/$D(1-+
M(VKG=T6"1.AH4C<VI35BU2(LA":>8$A,2:;L!)1AH] ZTLL8]Z#M#R>@E9K4
M_K1;%?/S2UOC3(R%C4]-R)V;%843H4%4WN*8I8B4A+/0E'%A/3'%FZ <66:#
M0NM,  >MATAY/02LUJ>CX0H=Y;*]ZK_JN(>3T8E9K5#PA0[RV5[U7_5<0\GH
MQ*S6J'A"AWELKWJO^JXAY/1B5FM4/"%#O+97O5?]5Q#R>C$K-:H>$*'>6RO>
MJ_ZKB'D]&)6:U0\(4.\ME>]5_P!5Q#R>C$K-:H>$*'>6RO>J_P"JXAY/1B5F
MM4/"%#O+97O5?]5Q#R>C$K-:H>$*'>6RO>J_ZKB'D]&)6:U0\(4.\ME>]5_U
M7$/)Z,2LUJAX0H=Y;*]ZK_JN(>3T8E9K5#PA0[RV5[U7_5<0\GHQ*S6J'A"A
MWELKWJO^JXAY/1B5FM4/"%#O+97O5?\ 5<0\GHQ*S6J'A"AWELKWJO\ JN(>
M3T8E9K5#PA0[RV5[U7_5<0\GHQ*S6J'A"AWELKWJO^JXAY/1B5FM4/"%#O+9
M7O5?]5Q#R>C$K-:H>$*'>6RO>J_ZKB'D]&)6:U1D;8Z('A*%:VJ JDHAC+":
M$!I>MC+WT##UIH"Q_@[];IZWHW_VWO(69P/0P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!6"S_9>M_1D/[J7G6C#
MS_".5>/E^60XNF$2;.Z_=*41UO[@#;"W[MY[;$G<0QZV$+.!W[.I+[FC=A#!
MIL"L[#M?L8=)=&[%KIW*SPQ,0\L<#TTSJV+6Q.]HW% K9E: IT2NZ98G/;%+
M8>G"K)<4Z\HP:4Y <E$%24K+-$G,3B"< S9>]"P#%&:T*TD45!.X_8D%?80:
MJ$A+F3-+6!SBIBT*\+4)&"0HG ]H&J"YB"W"3A6;.TO$%'L';&]%Y)6,J"P\
M(<Y09R$6A:T(.]""+6A!$'>MZ%K>NG6];UZV];UZ^MZ];>LI#^X P!@# & ,
M 8 P!@# (QNS\C-N?JQGO\*NV1X/H_0JQ75>IR4Q^1ZJ/U:P7^%VO"P71>@>
M+ZOU)*RD& >!J51H4E'#0OS3N6%M(7X<<TO3=V@LHU.T@73;=V3MK2':K78.
MV.Q]CT9L(=BUUP>D#W\ 8 P!@# & , 8 P!@# & , 8 P!@%FZM]B1'Z:M_U
M-9QK^9^7HCK1AY_A$BYDV, 8 P!@# & , 8!1#CQ;M5Q)TY*LDNL^OHR\D<J
M+9-,:)'-8XRN9*<\F-F)S!H'-S3*BR3B]]>2,16@& WUQ>]AWTY8>3T)*6+1
M9'Q@J$\]]0^DJ&?;6(>3T8E9K5#Q@J$\]]0^DJ&?;6(>3T8E9K5#Q@J$\]]0
M^DJ&?;6(>3T8E9K5#Q@J$\]]0^DJ&?;6(>3T8E9K5#Q@J$\]]0^DJ&?;6(>3
MT8E9K5#Q@J$\]]0^DJ&?;6(>3T8E9K5'JLERU!)G1(QQNUJVD#VX", @9V2<
MQAU=%HRB3%!H$C>@=%"M2(M.2:>8$DD>P$E&&BUH !"TAY/02LUJ?;/<-22%
M5/D3!:5<OBVJE)B.T$C/-XRYJJW5E%*SS4L^3HG,\V'J2B$"XXPB0@;C0%(U
M9@@Z G.V"%/8<+ @;23'U#I-HBVD2PG2B+'N$D9D9,E3[)2J-'Q\Q0M+ \D[
M(6HC]&MPE(-DJTIFA=8H*$,#W6AW:7]K;WMB=&YZ979&G<&IW:%J9R:W- K+
M"<E7-[@C-.2+4:DD8#4ZE,:82<6((RQB"+6]@>C@# & , 8 P!@# & , 8 P
M!@# & , K!9_LO6_HR']U+SK1AY_A'*O'R_+-/MOU'8DCLV_E\8:9K#N[UI<
M6I%%;;B;)IP>X2;"8V]I9#8<6C"Q"M;+&/95RE-&'Z+.;8\MZ]CD;LX*V9\1
MM9R!1&G+NXTP\N?/H6EI)3#NJ33XS@IX9R3353)>,4X_0Y@E\#K83''J[1MD
MH@#6V3!VDTB;6MKVG>T;>R.3VZDF/,U3DJ5J6,OS\[&HUCT!BD3XYJ$Z]R45
M6HP41A#G3-D=EU.]S.-R7_2PGS2X%/W^J[6DDU6W)!(;=E7.3LEY+V7II30^
M& TV<NI+6W'^O**?$$.D:25H5S VU97,RA+K/WMI96=7+9/*7)V5,3?.%R1G
MS?DUBU"_NX790L8QDW*P;3P4R_DEVK^;<\7"4&W^.;?=QYAW*0MX)-MF:]R(
M#3LW;4%]VA(V[A;-G[V?MO"X=L:1[.WLW:;1?9-]?TYU.)[. , 8 P!@# &
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M# & , 8 P!@# +-U;[$B/TU;_J:SC7\S\O1'6C#S_")%S)L8 P!@# & , 8
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M01LS1I!GX!H "]; *_6?[+UOZ,A_=2\ZT8>?X1RKQ\ORR/LV8& , 8 P!@#
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M9G*9& , 8 P!@# & , 8!9NK?8D1^FK?]36<:_F?EZ(ZT8>?X1(N9-C & ,
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M5U%DV/%4S:+3&V!C@"%MF[8896$(@_,:$UY%E"YL5&#=XX5S7(:;)<W.5 *
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MYJ23L_+V3\VWJ?BC[.JC!Q4AN65@1+VSO#(:4,2:JU2M#>WP].F/5!V<O?G
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M!@# & , 8 P"S=6^Q(C]-6_ZFLXU_,_+T1UHP\_PB1<R;& , 8 P!@# & ,
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M3!9/&"AG]]=+/=K'G%(5RO?9P1Q\MES:%$\?(6U;>)"<>PURDA9B?4D/5+U
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M?.(WOQ+H<*[,6V;3$;>#T[FH1K&=#*$DD>Y>Z2Q^>Q3=Q?9$,$E3NY1ZV"R
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M5"A8(@D9RA0K6JA]<>L<%ZHPY:O5""$LD)ZL\T924E.D*V!,G(*+ S[ & ,
M8 P#R7YA8I4QO,8E#*TR2-2-J<6&0QY^;D;PQOS&[I#F]V9GEI<"5"!T:G1
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MT+B<T+52%6F1NR<A*J4-:H\@PI.XD)EY*A"H.1'" I*(6)STIPR@EJ"321#
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M'M8MUL1@A#%O6C-=&NN%O>_6_P"WKYRJ^9^7H=*'*OS[$A9DV, 8 P!@# &
M, 8!5NG+W;7];=+=/YS#F]P@]\3^"LB%:[,3(L2Q=B+93&<I2F-5)SSS>M6G
MBVM/!LU2$0=B&+0=;RPW@F24L6B:?"E67G%@GQNC_P!H8AY/1B5FM4/"E67G
M%@GQNC_VAB'D]&)6:U0\*59><6"?&Z/_ &AB'D]&)6:U0\*59><6"?&Z/_:&
M(>3T8E9K5&5-CNTO:(IR9G1N=VX\0P$.#8M3+T1PBS1$&!*5)332#!%G!$2/
M0#-[ :$18M:'K>LA3O\ 7!Z[0.N#U^P[%H'3KKMA#O6A"T'\>PZV(.M[Z.C6
MQ:UOU]ZP!UP>NT#K@]?L.Q:#TZZ[80[#H0M!_'L(=B#K>]:Z-;$'6_QZP#ZP
M!@# & , 8 P!@# & , 8 P!@# & , 8 P"L%G^R];^C(?W4O.M&'G^$<J\?+
M\LTSW#7L_=;4Y%J82RSJ&N3U;G$F016TFJMWJ4,3&Y1*-NP769K(CW)[5N&.
M-BL"*)RQA9U U38%^3R ;U&38V"1,\:O=SQIO2Y.7S*G<IA_#4H;\XGARTXD
MYU)NW(_QMA,<F=&1!-#&.KT++,8_J?V4YSA:Q-C+VE)M-%8MM'NSXN5OB0A>
MLC5?Z>"7P](O;8TL2LCF(]J0539B.&$N=EL1PZ_FOG&%&4RW'GYE)%< D1CX
M?.J.BMOUW!U!G)&\6ZO$W&J;Q>)L'+)/ >/46H)@5U'8]9M:]RBZB%P^QGY\
ME#,P-,04W)*)6Y,5@-$U61]4AD/FL7"I=SX*]1M=?!N5$.'\M,VE+IEMX-QP
M6,Q'.=TT</>U4>85,F0I6R2*&9K/D#:@/[:0M[V<A(,=4*-3L0^V4J1>)00G
M/Z\79B2P&=<+KNG?1<\3B^6![. , 8 P!@# & 4DYG1Z^7]SXC[X^*D#7*6;
ME+IWD;[(XM*YG 6&&ZXV<D6M6X6-'8?+(.Z+HP=(72--2+9TI:42>9.444&C
M4GEID*G-4W1C/?$W19BNU]-T1,VZ<)Y3Y2?7>UU1SSU<)ODP7K_5WCX_MW']
M/*O6GL.]KJCGGJX3?)@O7^KO'Q_;N/Z>5>M/8CRW8YU0T%3V>)SN7AB>VAKR
M:B<2$'&B\$BXY#J-N>U92)4HY9+4Z968GT8!.H/1JR23M@,-3'@"(H<=J'\N
M#S*O#E75XKC3_J<E3QOJAPJLK039<O#$AM%7\-$WDK^-%X*EQ*'<=;=I"EBI
M/RS1D*519'8P*#R$B4DX[0S"TQ !!*"5J%\N"S#\.7=7B^-/8D9+&^J)!4IQ
M+;EX7'H@GDB5DI.-%XI%1R71@=J"DRH[EBN)3*#"NO 2H-1+"B3-A,,2J AV
M4._%]NY'8X*N>$M=C6(W0;F!KF ,C2MR!<P7+NPMEAPCAQ 41$=I/MV-."2%
M&;7YJ,.D!+4!.'?2 #"2WE/90416C!LZ41OJB@CSQ);GX6%)=G&;3%J.,MY'
MGED;&+9(#SR^6J<LXX!?6A,-+3D ,'H0PDE!WH <_%]NYO\ IY5ZKL</>UU1
MSSU<)ODP7K_5WCX_MW']/*O6GL.]KJCGGJX3?)@O7^KO'Q_;N/Z>5>M/8=[7
M5'//5PF^3!>O]7>/C^W<?T\J]:>QPJ(SU1S:<_6KIX4BWLDW6M%\8;UT9O>P
M"Z- WXW6^@>_Q!WT;Z-]'K;_ !8=O[?*0O#RK\VNQGO"!HFL?X9<3F*R4,B;
M+#9N.%*-<Z;I<6O*E2"7H*YCB61HY*4Z_P#Q,M^3.Y2LEV X_P#C0+P'A5?]
M?0\JP71$KBU5&%IQTEP6BRF1@# & , 8 P!@# & , LW5OL2(_35O^IK.-?S
M/R]$=:,//\(D7,FQ@# & , 8 P!@# /QD\HJVL62\ON7;K'(#-) UF<@9,46
MY,D6?'5 8:3'XJ XL"Q A/3C,*'KK#0!,V(L7X(M:WZV=:6K*O7'CS.5>/E^
M60QX%[B\T]E_$24_96:E9K5&!X%[B\T]E_$24_96)6:U0'@7N+S3V7\1)3]E
M8E9K5 >!>XO-/9?Q$E/V5B5FM4#>S0T*E:+A[P,;UT$F&WR-\SF)^=T0(7(E
MKI&(^5-++&X/[VG3-1ZN.L!296C$M>W,*%K+*5)>V%80GD]?RJ^9^7H=Z/E\
MG_\ M)*[]4G(FX>3EPL<[BKQ6D;LOC:ZPDJTV&6+)3%&EA0W%VZR0Q @1)(N
M8G.E$/).239L12AHE:KOBD;XW.K,E,8D['DUPQXX1O.A(?&!KL*.7A+PE5,T
MPN#R5MC;@C?O!>]Q=0Y0IW\+,H:T3&I1*4$6A2%AD*AF=%L.D0)+9:8^S3(2
M_%HVNK621OP/]PRU>4X778FRK!!@# & , 8 P!@# & , 8 P!@# & , K#S0
M<[09N+5UNM,KI,V64@AIZF-.$-5UXV2E((M<AV[',+W;0PUE&G(#%W3[7ED[
MT=&(F+_^)'=*K2-1B4X58J=Y_%^A37J2T[LVR:TL^6SR;WS8C,KEC,CB$HO*
M\>)5]FJ2T#<M*?4<1EO#30JM1MB)<(@#DU.QYTT)<AC-<]%M!C$'8M6/#RM?
M_P!7_@N39_LO6_HR']U+SK1AY_A'"O'R_+(^S9@8 P!@# & , 8 P!@# & ,
M 8!&-V?D9MS]6,]_A5VR/!]'Z%6*ZKU.2F/R/51^K6"_PNUX6"Z+T#Q?5^I)
M64A\]8#K]F]8'LFPZ!LSK==?L =[$$&Q]'7;#H0A"T'IZ-;%O>M=.]X!]8 P
M!@# & , 8 P!@# & , 8 P!@# & 6;JWV)$?IJW_ %-9QK^9^7HCK1AY_A$B
MYDV, 8 P!@# & , 8!5'BK^/DE_ZKK?_ /9&\ M=@# & , 8 P!@# & , 8
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M<438!8H5K MZ58YG$(@JE:I2%,65H]0<;H1@JKTGR,U**FLFUHR8<I!@# &
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M^^!*V:9&_M8+6-><)>ARFW,3P2BXMJFQ4E2J6W3Q;F)SN-A&:.8P!@# & ,
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MH(\*#==UF2V0Q+<G;%;,W( 6O.F2%G2-_:I+9AL3GES;&V/9I%>RIG"5'/\
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MCRXGI\4(ER53M\QLWEJAH^/7/8IL=1*H;Q^+DJV$Q:)0].Z C:1XF$P+3/\
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M ])FYZ+&8<,#LA)6@3.(!FFB"L*."(P>];%OHL%T.34-K)P9KE(, 8 P!@#
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M?,*%F=!0:;1"^'=\(ETLI"<!FSE#&N"*&$IO55U+YF],(X\8\KE*CLIK.D=
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M+V'6_7P9.]@# & , Z+FH6)&UP5-R#;JX)D*M0A:PJ240G)82088F0!6*?\
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M<>%.6?WR'WD#YV+"Y[=A;?+?N/"G+/[Y#[R!\[%A<]NPMOEOW'A3EG]\A]Y
M^=BPN>W86WRW[CPIRS^^0^\@?.Q87/;L+;Y;]QX4Y9_?(?>0/G8L+GMV%M\M
M^X\*<L_OD/O('SL6%SV["V^6_<>%.6?WR'WD#YV+"Y[=A;?+?N/"G+/[Y#[R
M!\[%A<]NPMOEOW'A3EG]\A]Y ^=BPN>W86WRW[CPIRS^^0^\@?.Q87/;L+;Y
M;]QX4Y9_?(?>0/G8L+GMV%M\M^X\*<L_OD/O('SL6%SV["V^6_<FJ#O*Y^8"
MG%P$6)2-2I*WLHO10.L*'H(.@&M[UT]'X]_]\YU*&T;I<J7F9AD-# & , 8
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M"8;V)(G!V14L4)DA!YY=E/!HD-8ID3\?><%67&QNATI<V&KI.RJ#!+F63R)
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MM5R \UM.^]IK_-V6PN>W8S;?+?N/5JN0'FMIWWM-?YNQ87/;L+;Y;]QZM5R
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M/X-<%J45QNEC\Z<<T\%-N:-Q9[<;1#!T\,I2%758%6L#4EG4.@%ERRTYBED
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MO5E:&(O9B98D,-3G@"8 98A%&"UH8! WO0@[UH#T< 8 P!@# & , 8 P!@#
M& , 8 P"S=6^Q(C]-6_ZFLXU_,_+T1UHP\_PB1<R;& , 8 P!@# & , UM4E
MR?X]U=).3,1L.WH/#Y,EY36JK4,;Z\DHG E,N3QH]&>80/77!+4$[T84+_\
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M." 81")-V66=HLW0=[V69LDTHW0!] MEFECZ.M&'>P.3 & , 8 P!@# & ,
M8!I/ZJU.#XA<G"-M8VNB; GDYE%CQ2!TQ=MK,],M=C.KT&"189!DH<:'ME6_
M-:-SED=**B31-*N<E$M615>W); =$R J'C5*E.9242TIC'&]:WFP'A!:,2M?
MBY33Q$IFP6""-P&'0.1R^(P:2US"GZ7Q&)L;;(G>!Q641F)+$D!>%FN[,&5-
MK*3'7"*.#.MCIZIG.2'"$>+E1R9I@ZG[0D4K[FJ59_8^*S0ME%J\CHG&W%FX
MOS2KN2%CJ%</!:BE[)M:4W%+GRR8.LC,W2+39D^UM%DTQ&P'.2M<SN8X\WRD
M:=4J/BX?W)TSQNBZ^6H>'(W7V?[+UOZ,A_=2\ZT8>?X1YZ\?+\LU#.Z6@$]O
M6C8I_'ZUEY\3ACG!7:+H.)][GM5KJS+.8WY;-)8[AJI8S7,:FFQ;4Y0<UF,G
M[TS-:B>V3HA<E=%)['+OI=UR48\WZ7Z7FOBA*U3??+J5UV"ONNQPX*;B4Z/9
MI#!Z':(;"ZR:G&FD:"7F'AEY]Q5+.NY4@?G]^FC1&J"<:%5S.-1YG<G=]8:M
MA!BXAT/AK?%TK4("94W'CTDU3$2HS:?.Z)Z&6YJEN'=A#7*^U#Y\Y*6**]6O
M4SW/*;B5T5/7KL]6[;[E!VSC'-(FT1_D0R5-4L*XYIG2J+$JM$3,&U/'(79$
MEETE9XJ;&4-JO,.0-4XW(&&*2,O'DUCPNRI36'_>FYA0VF_A7S*8ENJ&N<<4
M[LL=QT%5RM?"8<OG;8A99PMBL>5S)F:S^V6QIE:EI2'2%L;E/9E';"% [C6)
M4A_;!_94Y19G9C>NZ\75<\3BXEQAPZ&58 P!@# & , 8 P"D/,J+7S)I)P\-
MX_+FMEDL=Y..CY)9+*8?)YY7\;B ^+G)5B/<;!BT2F]<NCDP*Y"]1QC;-[F3
M.F23-WBRTW:X2<MN5XJF:8_,><?L'2BS%=K+E./">)V.]/JC'G^X4_)#O3^M
M[']3.C2KN3^GE7K3V(\MV*]4*!4]GC<[XX:*6T%>343@G0<3+N1+CT(8VY[5
MDHUBCFFO3I%9J?1@$ZD]"M)(.$ TU(I  1(X[<.71$7PGW*O#E75XKC3_J?=
M317JA0ZLK0;;?'#-.W"K^&B;TZ[B9=RQ:0B%'&W:4E8L3\TT!"M441LL"A22
MA1E'FA&:6D3@$$D!>)"OHP7!]P_#EW5XOBNQ('>GU1CS_<*?DAWI_6]E_J9T
M:5=R?T\J]:>P[T^J,>?[A3\D.]/ZWL?U,Z-*NX_IY5ZT]B([Z@O/]RI^9(7B
MSZ-FR4TA.)>PTA2UB55,7!@+ J[N(2G*7WU<13P2I*$F$<RM2!@<ER0A6D*<
M' *K;.MJM?W6>4)KU;([/]MKS:_"1!W""%\R UT_N%6S*O(!#'1P*,CX+KKN
M6V4QKUI1PRWEPC,9BUEU.\-Y0^QA3*74<HVU*U98P%L[@J(/5HJYCX8GGAL1
M1/Q3'*$]TRYO>GU1CS_<*?DAWI_6]F?ZF=&E7<U_3RKUI[#O3ZHQY_N%/R0[
MT_K>Q_4SHTJ[C^GE7K3V'>GU1CS_ '"GY(=Z?UO8_J9T:5=Q_3RKUI[#O3ZH
MQY_N%/R0[T_K>Q_4SHTJ[C^GE7K3V'>GU1CS_<*?DAWI_6]C^IG1I5W']/*O
M6GL895<-Y9-O,X$DO>45].(;XL,A8V=^I^J)_5L(;I,=:L07A:'Y-,KDN$AV
ME2EJ3K%K<>C7,IJ=H(6EB2*0#V< K5KXHPQ2<8\YO*W18BF9M<6G=#PA(V$Y
MLYC & , 8 P!@# & 6;JWV)$?IJW_4UG&OYGY>B.M&'G^$2+F38P!@# & ,
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M^R%Q*4,7G5>43'(^>6J+,5G.<!7W$HD0%*,/_52E$ES1CVF.,_!5;-4:+_\
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M&XG,.]"UH6NGH%K6]=<'8=]&]=/KA%K0@[_M"+6MZWZV]:WE,G]P!@# & ,
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M-,AH8 P!@# & , 8 P"J/%7\?)+_ -5UO_\ LC> 6NP!@# & , 8 P!@# &
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M,D3&:@"[C;E6VN2[24-8Y9>9;-*HJ=JFIITI1:NF9^:FG'S-@6:.8P!@# &
M, 8 P!@# & , 8!:RO/8:R_FU?\ N"O.#Q?5^IVH^5>?JS-,AH8 P!@# & ,
M 8 P#\GUS<VN3]'\G.6E?U=:!T6B*'D3,%Z5H!$H&[A*5N;)%E2X[MU_B[JX
MC[.>+9G6&+!EE]/6E +!^#G2FE-)M>N9SKJ:=SX&%>J;\X_/FH]']5?R-FK%
M.6[[F;=6>R[&^^Z)5R$C\TXLV.B>G(SC\N>:<AMIM<%E$789TMGEQ3B-PJ/O
MTFB\FI^8)II6*60OD2;W]NA-DU%*(\S/<QD>A2Q.VM[4CY/%]6=J8=-^,3RP
M_/GP1&<<OF[X/9==Q.['F?.TM,C\JG=G5[!FZGU\=2.;/'Y(_/+(RO) 6LQ!
M5D*:9!$SD9[Q.D]HK!H:C-DD97'7 [#+A8NGAZ^4]=\C:G@@P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P#1CU8JRW* R7CBC;;'FU8C>F.XE(G9JZI#674Z
M(:Z@:E]5E";7F33Z$SA394F3[="U,>8VU*UE,34.2N!RE8-8$M)(G/6/0U3@
MW$X?VSG?BH]T;#*\AE7SK@Y341FYQ\8JQ=05)&+#&:\I ,3*RL\6ASPSE)N0
M,2?XV^25&D/;FX@V>H'Y&7.4(35BP:EO?%28^DX^WXP-+O#!*8R]4V:255=,
M\2%+U/(60,ZQ1R%ZHE;4W4H6<$A:9&7)83<L39>*D+>F23'=PYD1#EFMQ5],
M0LD 3JX;*(\^/(TW\,3A"B*?57O"[/,W:V![,'O\^1^YIL[4?*O/U9YJ_F?E
MZ(K@V<?*$97R3R=FI"H6F2S8M:3,I"V5K#$#Y+2G-V2OSD5)W9*RE+WXMP?$
M2)Y6@=5"L*MV2)7$_1BQ.4<"PLEH2U5]3NYLD=$P,+8S%QUM9&AOCY24U"4Q
M(FU&D9BT)^C-'(RVL@DM$!*=HTW1J<)&B3-&&:&#>ABZ;'#@2>/$C".\<N/4
M0;%[)$J'IF+LSHX(G9S:([5\(9&QQ=&U,N1-SDO0-K&F2JW! C='-(B6*"C%
M"5,XKB"#"RE:@!DA9+0MJIXMOS9,"=.G2)R$B0@E*E2DE)TR9.4 E.G3D@"6
M20026$)91)180EE%%A" L 0A"'0=:UE(<V , 8 P!@'FJ&5G6.;8]*VEM5/+
M*4X$,[LH0)3W-I(=@I@.I+8O-*$J0%.8$:0#@6E-* L"E3!4Z,T05H('I8 P
M!@# (QNS\C-N?JQGO\*NV1X/H_0JQ75>I@4!JFNYK ^/<PE42:'N2P>OX2LC
M#LM3[&H;CC(JV]&MZT()2PI.>+2Y$0N+4DH'(LIQ1 (6EA/PL%T7H'B^K]2Q
M>4@P!@# & >:<RLZAW02 ]I;3WYK;W-J;'LY E,=VYK>SVM4\MJ!R&4)8C;W
M=2QLBES1ISBTZ\]G:SE19IC>D$2!Z6 , 8 P!@# & , 8 P!@# & 6LKSV&L
MOYM7_N"O.#Q?5^IVH^5>?JS-,AH8 P!@# & , 8 P#6K2G%OCS:DEY-3"Q:B
MADPDZKE+:B-0]O3;VRO.3(4\:(1DC-[('I+3DZT65KH_!#K6LLO-ZDA/%(GG
MQ%.('N>JV^!?_P#MB7F]6(62T1.:>JJQ2RQ-/2*[A!<[2,C3&TTVU%F3<O)C
M["%T QLH),)%M[[ELX7MZ"V(=KMIT.GEV[6++[I+.S0IZ2N P5>XIWA?"XFM
M=TCWN3)'59'6A2Y)9'M"WMFW],N/1C5$/6VUI:F[NJ4:%=VBV-Z3L_:Z),66
M!EF , 8 P!@# & , 8 P!@# & , 8 P!@# & , T;=5R8I4Y61QM7UZV\AW&
M:)83>"01-#\<^%=V!'&%3[3!SB;*7KFDX(8W'!)'5*S 9&N#EJWQTTO=U;J-
M&@;R KANEQ/RK#%U+2S?U+'W=6T^M3J4:.NH9$Y)++#>^-5*%MD93M$(C\S.
M>6=M@+RJ.119MG5>5JDES+IL4NZ"'))VQP)0^MQ$;+6J(V?VJJ?M_L3^Z_/K
MQUVGDRE?4\X_=+'=--AL&(=6&CC9J.R%(I#S6N#CY*J"3N 8$]F%)$\:KA<J
MGILHULDS4;$]M;0B1D@<37$92X*-$I&JHC__ #_^*=K'G<O7<VOV![,'O\^1
M^YIL[4?*O/U9Y:_F?EZ(ILJY+)DL]?*UW3-U'2PB*N$S@:,MI@1:>W8\RR5H
MBC\MA"U58B9,P]PW20Q\UP*MT=8#$V/2%T0Z6HMJ#4ZUR?+GV[7EL73*B8JQ
M^'K=?Y3?<2%6EOQ^T:M1VLS,\K:VPXJ4EN$9?&8.IHQO<'?'N+RZ+.#,RJWI
M.K?V.2QUY8S"F!Q>FYS6(]&L+DZH%2)8HLW3POV(Z6JK-W"_A?@\^.1#B#F3
M7@G-;$I/$Y_ +.26475Y-5S ,!!*G)W-A3)8P'UO>X]/Y#6PX@&$O[:\*7]1
M/4Q*!:I1Q)>2EG#JR1ESEI+''+]NW+8=S3334RISC!I/'ES+;@V(0 B$#98A
M!#L0!;#O8!;UK>P;V#8@[V'?K;V$6P[WKIUO>NC>:,'U@# & 8*KLB((;+CU
M0J7(PN>RB"S&R&5HT@7C)51"!/\ !HQ*'(3F!.)L3F('FQX@E+0*%92]:%R,
M4(TYZ= O-3R5,<2PXGA,>>)G64@P!@# & ?S>]!UL0MZUK6M[WO>^C6M:]?>
M][WZVM:UZ^][_%@% K"YF4I, 7;3C2^=*\BL9PC99.8,@,8E#^",/8%["S+]
M&;[*H(Z"0-RHP(4;XITJ3MAINP-XW2/!]'Z%6*ZKU+:4Q^1ZJ/U:P7^%VO"P
M71>@>+ZOU)*RD& , 8!@MF63#Z@@DELJ?.1C/#XDA"Y/SD2@7NAB1(-20C"8
M! UIE:]3O:A22#L:9,:9K0MBV'K0BWHW%[*DVTEBS.L$& , 8 P!@# & , 8
M P!@# & 6LKSV&LOYM7_ +@KS@\7U?J=J/E7GZLS3(:& , K5(.5%<QIQM9G
M=&^6%NE3V'3M5+D($#0(V6SN^CX>AK%DAHA/H"5.WQUG4=:U*Z0FQQO9S5"I
M>[*D;(WK74D6/SMCM>8RFYI50O7',[:US%=(&99,4<\8M)XHWGU?WD6>54+H
MIL!V>I<V1AJ2N,T-&"-&-[\["DC"C<I4T%JHZV+W).$?B_JI1[-P<L8-1U(1
MF]Y[$K%11R4*8ZE3QE.SL.YNV'2=O6.C<4]M*R3HFU >4E1C[H)=/1RM">8!
M*<1H\"@LBI3<C+=G'I<4N]6?XM>TB]_BM OO,S5A\M^QFVN>W<>K/\6O:1>_
MQ6@7WF8L/EOV%M<]NX]6?XM>TB]_BM OO,Q8?+?L+:Y[=R>NIYVI';NK2X[5
MB:1X0QV:<G+B=&I)($Z-(\$)RU3*A$!>G;U[HC*.[,D-%H*=P5 V7L NR:%L
M0 Y:AP;QOS+\Y , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&@CJU-
M0F61+.,STW5''[T<HTR6ZT*(&\<&+,YT&-+9*W:J3]SC48AEDUK'ZZ3-)D:-
M;C7EX=5TDE87,UMBK(ZE,CX)O&Z7$WM=*E3GR<_LFU>L(C*57#BJH35\^8:^
ME?B]UK'X;8S#6QZB-1I:F@3"C;I"QU1-E#8L3LI!903VF&2H]*N;$8D[8\:"
MJ2GE[&>-^=]_Y_)17B_P1L6F>4##>/(Z?W]RON8V/K&%BY"2BWDBNMX1W59I
MWNP&]IH-K2P"*5+')N65" ,48BD#G>V%W1C KM<T*U0D=A75*:25*R2TOQ>R
M+MV![,'O\^1^YIL[4?*O/U9YZ_F?EZ(HPOK+DP;([+DS79%(M[O*4.V.&/1M
M5318_1&,I)"6J9F-4L%:9;<X$H&)7(#E9Z%H:CG:<N:*1JQ:869)#]R*K[U?
M@[YC+EWU+-'PW578J5#<8X9YS=<9%$:'<&:(MI+K)5*6:LZ 1#8FKZ6W'!ZE
M2'-NADQLH->:M%W&<CT00@-E@E;PI5RIT,>756<4<ZC++67&,/@DW'[F+2G"
M5FTF_P +H5_<N'%@3%>3*;-DU*S&8[B%UP-U,*JV0(V.3-E^1Z!LTQE,E2OL
M[E:E=*F@VKJ_11TA&-M:4U?LKA6R/3.VN;:[QR6:GC''/CVNCV-6Z5\MI8<4
MXLX)88RYY^9>J"Q8N#0B'0DES<GLJ'Q6/18IY>3^V7AW+C[0C:0.;LIZ-=L.
M2\*32M<?T:[*J--,Z/PLZ*Y)9'-N6WFY,JP08 P"GUX\-:VY$7?65I6JG)DL
M:K:J[6@"2#F&/[4-6^61+JAD265AD,>D3,I) PH*T<V@;,<D6$.(I,!=M0D,
M:"RU>73+3>$8&E6U2Z5QJ3GHFLN9X_J='#3S,$?'JS?YTQ8IRW?<6ZL]EV'J
M='#3S,$?'JS?YTQ8IRW?<6ZL]EV'J='#3S,$?'JS?YTQ8IRW?<6ZL]EV'J='
M#3S,$?'JS?YTQ8IRW?<6ZL]EV'J='#3S,$?'JS?YTQ8IRW?<6ZL]EV.PEZGE
MP\0J25B2GB2%28P)R<X,XLD8BC0;Z0&!";,3"Q;"+HWK0P##TZ]<.]>MBS3E
MNQ:JSV78I'+>IME1=QMR2NDG[>JB,P&62:)I"S1%R=T<B&%W5HF)Z&6462F2
MLIZ8HQ>YI1:&\IQ)2TA* Y2M[F5X/HR+%=465JCJ>_#YTJVM7-?3Q*A<XP"'
M+EA^YO9)>SE:N.MRA0;LLJ8EE [(<8,?6%  6'IZT  AUK6LJFF%=P7%FG75
M+OXO@L^AG_J='#3S,$?'JS?YTRV*<MWW);JSV78>IT<-/,P1\>K-_G3%BG+=
M]Q;JSV78>IT<-/,P1\>K-_G3%BG+=]Q;JSV78>IT<-/,P1\>K-_G3%BG+=]Q
M;JSV78C:W^I<\79[6\IB4)A2:OI8\)$H&&:#?;!DP8\X)7%$O*7[87"<D(G/
MHTE$5VLI-"5O9O7BZ[K.MW'0HN5_5FJ?^1IIMRER1LBS9S& , 8 P!@# & ,
M 8 P!@# & 6LKSV&LOYM7_N"O.#Q?5^IVH^5>?JS-,AH8!&LPJQAF[F2[.C]
M936H(0E-X$\/MBR8*V"))/4J G'-$/E+(V*%PAJC &N)R0Q<<06F3&J!D)$Q
M90L]-$_4K#+.(+E*Y3=,F/E[:F.G-V<7;T@0=H7!8=')%QA-KQ4VL\E4'K=#
M>VV;F0 2!X7).U%[4UR-?I*%:Y($S@>$W:[J#[(X6L@XE*4*MQCI$]LBU+1L
MN<V&GB+<O?D*.QGI[D:>#114ZZ.$&.LZ@,*C#Z4ZEFH9U$F:5)G!E:#ILH U
MA/I'OK+63Z$37?P0F,UXD,O'N$2R(]]".8PF4N\DDNI&V-CNHC$(30]U=ERL
M )M)'63R<]O)DD@>WM4X.+[(7-Z=')Q$I4])FJ7#EY&:TZM=%?<:U_46>2OG
M&HWX<GWW=YNVN>W<YV'RW[#U%GDKYQJ-^')]]W>+:Y[=Q8?+?L/46>2OG&HW
MX<GWW=XMKGMW%A\M^QL\ZEE5+]1]!6+5$G7-#F_PKDC<K6YKF$U8>T*3S')K
M7:&A.<$+:M,)T4K+!O:A"F'V0(]:!UN@B%SJ<MLZ*Y)<C95D*, 8 P!@# &
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M & , 8 P!@# & 51XJ_CY)?^JZW_ /V1O +78 P!@# & , 8 P!@# & , 8
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M3L[>H[.J[.A;'LQ<B2'=LJ.RIR"Q]G.Z[L@NJYXG)Q+B]3<\T9G@@P!@# &
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M*=C *NW^_MJ*+S\J[:?;IY0S>W,II#<TADUIO]BOJU>U(TD5D%(,E=N1:R/
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M23VN>L[H"[(E!V4LGL0>M.'UV^@"7L 8 P!@# & , 8 P!@# & , 8 P!@#
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MJ1."< %W:O9-F V(DR.J[!^:N*J)<6J>.#R4FS;-F!@# & , 8 P!@# & ,
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M$E@WL.Q;UUPM[WSJ4-HZK!=$;0,A1@# & , 8 P!@# & , 8 P!@# & , 8
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MJ5;&F&H*]?78%"XE4!Z5T%EDTK;!118"BBJNG991180@+++!$W4("RP!UH(
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MG:CY5Y^K/-7\S\O1%&Y)R[BT,GPJ[F%;6K&7EYTQ[K-6Z-T-$W6WW<LJ*52
M$1"@FZYV9#VZ3SB**G-)9#5!5A$9=A2(E,H0M3[W+6KXA\N?#R\RV&U*:>,W
MX0IRONRDFN 6E'+%B+I+V4AV((8)%/(C(694ATH?V>45M*'N'RUD-;V<YUTN
M5I'M@7@;Q-!S@0^(AH'!G-6I'%&:=9E-Y3=QN,M--+-)KH\/UD J.:U=L*]]
MCEAQ">U=.VJ<QB"-<"FYU<E.\M63"+NLU9'J/O\ '[#D$ +8 1:.REW?%C_,
MF-1&RXNZDO21(>J8 /<M+CCE=Q\XW-6'P::B94PKXOE)Z)X]8N F-&<G(.,
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M@L.9XA'9V[PBOWVP4XF%K);6V4*7IVB2IN62@DX@MWVI4LHVD3KKK^X^D/\
MX'%E1$><*2.IMS.+F):72Y_F>9XC3Q$1( L:MTO&Z);)8TWS9C89?(B*5(?6
M^-V4@*3V QFDQ*FHHPO.I8\(F29/#](65XE:R81UG<E3\>A[J-3HL\WMQQX8
MM<2V_M262M<+UBWAEA!9>%Q%@K^'1.!11%W-B\(C3%$8VW=F.4=H,$;:TK,S
MHNV% S#S^U6Y$G([,>88<;V/KS!B&(0MZ5UQEN6V\6YU,EP08 P!@# & , 8
M P!@$8W9^1FW/U8SW^%7;(\'T?H58KJO4ABA^/U9HFI+:RMD(D$GM:LJ/*D
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M^P\/GM[CP0/WE)H_;6?4\>)RW]AX?/;W'@@?O*31^VL^IX\3EO[#P^>WN/!
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MW>V[3B<J9U"9(54N%A$SYP2JATTIMJ74U":>"I>*;7' N5FC P!@# & , 8
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MBF=XL.9+2E"=&2M4#?#BUBE20F0E)47SQP++B.$S'-POPC,,$& , 8 P!@#
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M[#+W-QDDQ2P)+5E=;7IF6"D%F XN_?VZ[RGB72P08 P!@# & , 8 P!@# &
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M%T7H'B^K]22LI!@# & , 8 P!@# & , 8 P!@# & , 8 P"UE>>PUE_-J_\
M<%><'B^K]3M1\J\_5F:9#0P!@# & , 8 P!@%4>*OX^27_JNM_\ ]D;P"UV
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MY&VG#V:<WC=&].N$B--V41LPQ)L_9 Q[()V,1>Q;*+Z>LT,GNX P!@# & ,
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MKP$%ZUH>@];TAWO>&H<'17I/,V%Y , 8 P!@# & , 8 P!@# & , 8 P!@#
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M7_W1C/Z,5O\ /./$Y;^P\/GM[CU$%_\ =&,_HQ6_SSCQ.6_L/#Y[>X]1!?\
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MBUQ\3B$:C1ZTDL11*PYB9D368J**&(0RBU THC0%C$(0 CT$0M[UO> 9?@#
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MYT="&-LLPQQ>39"Y1<]K0P:QU:]H=65!7KP]&21*GB!AT5966/VM7\I>)-)
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M2UJN5$\=KUO!H8T,G<:;J&QK53QIR<5#.BD.J\B3M+CV,YV2H7,]KV[)V<U
M4X@;7#M(Y06I&B5 *$08*E+2S:6K*54%U2F$V%4T#N^T5=<P^O+#BM?D-A]?
MO\TM&1-5W22BBN2,QI%9&V"!C<G=U@]2*>[YK\P%K JE++*&AU9HZZM25$Y
MU%WMQB<?6"PT?YY\2Y2Y+&MAN! N.05_5]LJ%G>M.TK'NKKDB<CG5>6*GDBR
M+IX\M@[O$HA*7QRE*-S4,D31QYX[[UK"<@4E%A#RQN\UPW,2<^J4\+6A@;)&
MKM]<-(]22#Q%H;&ZJKF>):Y2&S:L<+KK= B@K17BZ:J-3^L6EVD\+6%Q\2"4
M!:G-I9%2Y^;U;62%EY=L8QPQ)NJ/DY2=[.;LTU3+ELL5L&U93X,N&3MG;F=P
M;DD67.3"YO$@C+2T(I2V)II'1.<34KBY*W&K%*9:U$*6EX*0"$]X P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
B8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
